<SEC-DOCUMENT>0001493152-23-027603.txt : 20230810
<SEC-HEADER>0001493152-23-027603.hdr.sgml : 20230810
<ACCEPTANCE-DATETIME>20230810165024
ACCESSION NUMBER:		0001493152-23-027603
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230810
DATE AS OF CHANGE:		20230810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oncocyte Corp
		CENTRAL INDEX KEY:			0001642380
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				271041563
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37648
		FILM NUMBER:		231160362

	BUSINESS ADDRESS:	
		STREET 1:		15 CUSHING
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
		BUSINESS PHONE:		949-409-7600

	MAIL ADDRESS:	
		STREET 1:		15 CUSHING
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OncoCyte Corp
		DATE OF NAME CHANGE:	20200213

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oncocyte Corp
		DATE OF NAME CHANGE:	20200205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OncoCyte Corp
		DATE OF NAME CHANGE:	20150513
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:OCX="http://oncocyte.com/20230630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_OCX_oncocyte.com_20230630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20230101_20230630 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001642380 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_070_XDX_form10%2Dq.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Number_0_Number -->
<!-- Field: Set; Name: xdx; ID: xdx_069_euro_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityCentralIndexKey">0001642380</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0064" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2023-06-30" id="xdx2ixbrl0066" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-06-30" id="xdx2ixbrl0135" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-06-30" id="xdx2ixbrl0164" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0165" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0259" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0265" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0373" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0378" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0386" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0526" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0539" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0542" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0556" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0598" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0600" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0604" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0605" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0607" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0613" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards" contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards" contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0618" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards" contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0619" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0622" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0624" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0625" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0632" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0633" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0636" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0637" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0638" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0639" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0645" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0646" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0648" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0654" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0668" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0674" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0684" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0685" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0690" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0691" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0693" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0696" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0699" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0702" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0704" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0705" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" id="xdx2ixbrl0710" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0711" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0712" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0713" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0714" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0719" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0720" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0721" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0722" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0727" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0728" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0769" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0775" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0779" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0782" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0785" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0799" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAssetsHeldForSale" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0806" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0815" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0817" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0832" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl0836" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0838" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0841" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:PaymentForFinancingCostsForAtthemarketSales" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0844" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0847" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl0868" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member_custom_MarketableEquitySecuritiesMember" id="xdx2ixbrl0957" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_MarketableEquitySecuritiesMember" id="xdx2ixbrl0958" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0961" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0962" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member_custom_ContingentConsiderationLiabilitiesMember" id="xdx2ixbrl0964" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member_custom_ContingentConsiderationLiabilitiesMember" id="xdx2ixbrl0965" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0968" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0969" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_custom_MarketableEquitySecuritiesMember" id="xdx2ixbrl0973" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MarketableEquitySecuritiesMember" id="xdx2ixbrl0974" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0977" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0978" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_custom_ContingentConsiderationLiabilitiesMember" id="xdx2ixbrl0980" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_custom_ContingentConsiderationLiabilitiesMember" id="xdx2ixbrl0981" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0984" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0985" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" contextRef="AsOf2023-06-30" id="xdx2ixbrl0998" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DeemedDividendOnPreferredStock" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl1064" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DeemedDividendOnPreferredStock" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl1066" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1126" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1128" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2022-12-31_custom_TwoThousandTenPlanActivityMember" id="xdx2ixbrl1400" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember" id="xdx2ixbrl1406" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember" id="xdx2ixbrl1408" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember" id="xdx2ixbrl1410" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember" id="xdx2ixbrl1412" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember" id="xdx2ixbrl1416" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-06-30_custom_TwoThousandTenPlanActivityMember" id="xdx2ixbrl1418" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" id="xdx2ixbrl1440" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" id="xdx2ixbrl1442" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" id="xdx2ixbrl1446" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" id="xdx2ixbrl1450" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" id="xdx2ixbrl1454" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" id="xdx2ixbrl1460" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" id="xdx2ixbrl1468" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" id="xdx2ixbrl1470" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" id="xdx2ixbrl1474" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" id="xdx2ixbrl1478" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" id="xdx2ixbrl1482" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" id="xdx2ixbrl1486" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember" id="xdx2ixbrl1503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember" id="xdx2ixbrl1505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember" id="xdx2ixbrl1513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember" id="xdx2ixbrl1522" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" id="xdx2ixbrl1564" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" id="xdx2ixbrl1568" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2023-06-30" id="xdx2ixbrl1653" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">http://oncocyte.com/20230630#MachineryAndEquipmentNetAndConstructionInProgress</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2022-12-31" id="xdx2ixbrl1654" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">http://oncocyte.com/20230630#MachineryAndEquipmentNetAndConstructionInProgress</ix:nonNumeric>
  <ix:nonFraction name="OCX:RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations" contextRef="AsOf2023-06-30" id="xdx2ixbrl1671" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" id="xdx2ixbrl1751" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-06-30" id="xdx2ixbrl1779" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-06-30" id="xdx2ixbrl1783" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-06-30" id="xdx2ixbrl1787" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-06-30" id="xdx2ixbrl1791" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl2050" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl2055" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl2060" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl2065" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl2070" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl2075" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" contextRef="From2022-04-012022-06-30" id="xdx2ixbrl2076" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" contextRef="From2022-01-012022-06-30" id="xdx2ixbrl2078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl2080" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember" id="xdx2ixbrl2093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember" id="xdx2ixbrl2096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember" id="xdx2ixbrl2099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember" id="xdx2ixbrl2102" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales" contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember" id="xdx2ixbrl2105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember" id="xdx2ixbrl2108" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationAccruedCompensation" contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember" id="xdx2ixbrl2117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember" id="xdx2ixbrl2120" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="From2023-01-01to2023-06-30" id="xdx2ixbrl2138" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ocx-20230630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-23_custom_RazorGenomicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorGenomicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-152022-12-15_custom_RazorStockPurchaseAgreementMember_custom_DragonScientificLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:DragonScientificLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-15</xbrli:startDate>
        <xbrli:endDate>2022-12-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-15_custom_RazorStockPurchaseAgreementMember_custom_DragonScientificLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:DragonScientificLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_custom_RazorMember_us-gaap_CommonStockMember_custom_DragonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:DragonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-152023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-15</xbrli:startDate>
        <xbrli:endDate>2023-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_custom_RazorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-232023-07-24_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-23</xbrli:startDate>
        <xbrli:endDate>2023-07-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-24_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-102021-06-11_custom_AtTheMarketSalesAgreementMember_custom_BTIGLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BTIGLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-10</xbrli:startDate>
        <xbrli:endDate>2021-06-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012023-06-30_custom_BTIGLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BTIGLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_BTIGLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BTIGLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012022-06-01_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012022-06-01_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-12_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwriterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-12_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwriterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-12_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwriterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-182022-04-19_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwriterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-18</xbrli:startDate>
        <xbrli:endDate>2022-04-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_custom_BoardMembersMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:BoardMembersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-03_custom_RegisteredDirectOfferingMember_custom_BoardMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:BoardMembersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-03_custom_RegisteredDirectOfferingMember_custom_OtherInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:OtherInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_MarketableEquitySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member_custom_MarketableEquitySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member_custom_MarketableEquitySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_MarketableEquitySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_ContingentConsiderationLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member_custom_ContingentConsiderationLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member_custom_ContingentConsiderationLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_ContingentConsiderationLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MarketableEquitySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_custom_MarketableEquitySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_custom_MarketableEquitySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MarketableEquitySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ContingentConsiderationLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_custom_ContingentConsiderationLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_custom_ContingentConsiderationLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_ContingentConsiderationLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_VariousAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:VariousAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_PharmaServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:PharmaServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PharmaServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:PharmaServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LineageAndAgeXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">OCX:LineageAndAgeXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LineageAndAgeXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">OCX:LineageAndAgeXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_InsightMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_ChronixMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_MilestoneOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:MilestoneOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_MilestoneTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:MilestoneTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_MilestoneThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:MilestoneThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_RoyaltyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:RoyaltyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_RoyaltyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:RoyaltyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-15_custom_RazorGenomicsIncMember_custom_OncocyteCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:RazorGenomicsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DevelopmentAgreementMember_custom_OncocyteCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:DevelopmentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_DevelopmentAgreementMember_custom_RazorGenomicsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:DevelopmentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:RazorGenomicsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SublicenseAgreementMember_custom_OncocyteCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SublicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-142021-04-15_srt_MaximumMember_custom_MergerAgreementMember_custom_ChronixBiomedicalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:ChronixBiomedicalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-14</xbrli:startDate>
        <xbrli:endDate>2021-04-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-072023-02-08_custom_MergerAgreementMember_custom_ChronixEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:ChronixEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-07</xbrli:startDate>
        <xbrli:endDate>2023-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-072023-02-08_custom_MergerAgreementMember_custom_ChronixMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MergerAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:ChronixMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-07</xbrli:startDate>
        <xbrli:endDate>2023-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_ChronixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:ChronixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_ChronixBiomedicalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixBiomedicalIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_DetermaIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermaIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DetermaIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermaIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_DetermaCNIAndVitaGraftMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermaCNIAndVitaGraftMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_DetermaCNIAndVitaGraftMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermaCNIAndVitaGraftMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_SeriesAPreferredStockMember_custom_OncocyteCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-142022-07-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-14</xbrli:startDate>
        <xbrli:endDate>2022-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_PreferredStockMember_custom_InterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:InterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_PreferredStockMember_custom_OncocyteCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_PreferredStockMember_custom_SecurityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:SecurityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-042023-04-05_custom_RegisteredDirectOfferingMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-04</xbrli:startDate>
        <xbrli:endDate>2023-04-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_TwoThousandTenStockOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandTenStockOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_MonteCarloValuationTechniqueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MonteCarloValuationTechniqueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_PerformanceBasedOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:PerformanceBasedOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-05-31_us-gaap_PerformanceSharesMember_custom_ExecutiveOfficersAndEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-05-31_custom_MarketBasedAwardsMember_custom_ExecutiveOfficersAndEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">OCX:MarketBasedAwardsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-05-31_custom_VitaGraftMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:VitaGraftMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-05-31_custom_DetermalOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermalOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-012022-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-01</xbrli:startDate>
        <xbrli:endDate>2022-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-07-31_us-gaap_PerformanceSharesMember_custom_ExecutiveOfficersAndEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-07-31_custom_VitaGraftMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:VitaGraftMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-07-31_custom_DetermalOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermalOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-142022-12-16_custom_DetermaCNIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermaCNIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-14</xbrli:startDate>
        <xbrli:endDate>2022-12-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_TwoThousandEighteenIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandEighteenIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandTenPlanActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_MarketBasedAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">OCX:MarketBasedAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandTenPlanActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandTenPlanActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_TwoThousandTenPlanActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandTenPlanActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandEighteenPalnActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandEighteenPalnActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandEighteenPalnActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandEighteenPalnActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:CostOfRevenuesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:CostOfRevenuesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:CostOfRevenuesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:CostOfRevenuesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:OutsideUnitedStatesPharmaServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:OutsideUnitedStatesPharmaServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:OutsideUnitedStatesPharmaServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:OutsideUnitedStatesPharmaServicesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460937">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460953">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460953">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460968">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsOutsideUnitedStatesLicensingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsOutsideUnitedStatesLicensingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsOutsideUnitedStatesLicensingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsOutsideUnitedStatesLicensingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461031">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461031">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461046">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-23_custom_OfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:OfficeLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-222019-12-23_custom_OfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:OfficeLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-22</xbrli:startDate>
        <xbrli:endDate>2019-12-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-222019-12-23_custom_MonthlyRentMember_custom_OfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">OCX:MonthlyRentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:OfficeLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-22</xbrli:startDate>
        <xbrli:endDate>2019-12-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-222019-12-23_custom_FirstTenCalendarMember_custom_OfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">OCX:FirstTenCalendarMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:OfficeLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-22</xbrli:startDate>
        <xbrli:endDate>2019-12-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_LandlordMember_custom_OfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:LandlordMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:OfficeLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-27_custom_LeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:LeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LaboratoryEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">OCX:LaboratoryEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_ExecutiveOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:ExecutiveOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">OCX:OperatingAndFinancingLeasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">OCX:OperatingAndFinancingLeasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-12_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_BroadwoodCapitalLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodCapitalLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-132022-04-13_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_BroadwoodCapitalLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodCapitalLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-13</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_BroadwoodCapitalLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodCapitalLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_BroadwoodCapitalLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodCapitalLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_PuraVidaInvestmentsLLCMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:PuraVidaInvestmentsLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_UnderwritersMember_custom_BroadwoodCapitalLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwritersMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodCapitalLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_PuraVidaInvestmentsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:PuraVidaInvestmentsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_PuraVidaInvestmentsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:PuraVidaInvestmentsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_custom_BroadwoodCapitalLPMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodCapitalLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_custom_PuraVidaInvestmentsLLCMember_custom_UnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:PuraVidaInvestmentsLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_HalleSpecialSituationsFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:HalleSpecialSituationsFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:HalleSpecialSituationsFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:HalleSpecialSituationsFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember_custom_UnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:HalleSpecialSituationsFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_BroadwoodPartnersLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodPartnersLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_PuraVidaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:PuraVidaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_AVMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:AVMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_ArnoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">OCX:ArnoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_MrGutfreundMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">OCX:MrGutfreundMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-052022-04-05_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-05</xbrli:startDate>
        <xbrli:endDate>2022-04-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_ArnoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">OCX:ArnoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-162019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-16</xbrli:startDate>
        <xbrli:endDate>2019-10-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-17_custom_AmendedLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-04-02_custom_LoanDeferralAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:LoanDeferralAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-31_custom_BankWarrantMember_custom_AmendedLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">OCX:BankWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-23_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-17_custom_BankWarrantMember_custom_AmendedLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">OCX:BankWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-162019-10-17_custom_BankWarrantMember_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">OCX:BankWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-16</xbrli:startDate>
        <xbrli:endDate>2019-10-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_LifeTechnologiesCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:LifeTechnologiesCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember_custom_TwoEqualTranchesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">OCX:TwoEqualTranchesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012022-06-01_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-142022-07-15_us-gaap_SeriesAPreferredStockMember_custom_OncocyteCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-14</xbrli:startDate>
        <xbrli:endDate>2022-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember_custom_OncocyteCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember_custom_SecurityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:SecurityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_us-gaap_OverAllotmentOptionMember_custom_AprilTwoThousandTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">OCX:AprilTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_us-gaap_IPOMember_custom_AprilTwoThousandTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">OCX:AprilTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_us-gaap_IPOMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_us-gaap_IPOMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_custom_UnderwritingAgreementMember_custom_AprilTwoThousandTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">OCX:AprilTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_UnderwritingAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_custom_UnderwritingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-122022-04-13_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-12</xbrli:startDate>
        <xbrli:endDate>2022-04-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-182022-04-19_us-gaap_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-18</xbrli:startDate>
        <xbrli:endDate>2022-04-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-03</xbrli:startDate>
        <xbrli:endDate>2023-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-142022-12-15_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_DragonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:DragonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-14</xbrli:startDate>
        <xbrli:endDate>2022-12-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-15_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember_custom_DragonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:DragonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-162023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-16</xbrli:startDate>
        <xbrli:endDate>2023-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-162023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember26469671">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:RazorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-16</xbrli:startDate>
        <xbrli:endDate>2023-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-312023-01-31_custom_LaboratoryEquipmentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:LaboratoryEquipmentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-31</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LaboratoryEquipmentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:LaboratoryEquipmentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-03-31_custom_AuctionEquipmentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AuctionEquipmentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-312023-03-31_custom_LaboratoryEquipmentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:LaboratoryEquipmentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-31</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001642380</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Number">
      <xbrli:measure>OCX:Number</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="euro">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001176" toRefs="Footnote001187"></ix:relationship>
  <ix:relationship fromRefs="Fact001178" toRefs="Footnote001187"></ix:relationship>
  <ix:relationship fromRefs="Fact001180" toRefs="Footnote001188"></ix:relationship>
  <ix:relationship fromRefs="Fact001182" toRefs="Footnote001188"></ix:relationship>
  <ix:relationship fromRefs="Fact001252" toRefs="Footnote001275"></ix:relationship>
  <ix:relationship fromRefs="Fact001254" toRefs="Footnote001275"></ix:relationship>
  <ix:relationship fromRefs="Fact001256" toRefs="Footnote001276"></ix:relationship>
  <ix:relationship fromRefs="Fact001258" toRefs="Footnote001276"></ix:relationship>
  <ix:relationship fromRefs="Fact001268" toRefs="Footnote001277"></ix:relationship>
  <ix:relationship fromRefs="Fact001270" toRefs="Footnote001277"></ix:relationship>
  <ix:relationship fromRefs="Fact001556" toRefs="Footnote001577"></ix:relationship>
  <ix:relationship fromRefs="Fact001560" toRefs="Footnote001577"></ix:relationship>
  <ix:relationship fromRefs="Fact001562" toRefs="Footnote001577"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1564" toRefs="Footnote001577"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl1568" toRefs="Footnote001577"></ix:relationship>
  <ix:relationship fromRefs="Fact001570" toRefs="Footnote001577"></ix:relationship>
  <ix:relationship fromRefs="Fact001651" toRefs="Footnote001676"></ix:relationship>
  <ix:relationship fromRefs="Fact001652" toRefs="Footnote001676"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20230101__20230630_zkcLiJRES8Kk"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--DocumentQuarterlyReport_c20230101__20230630_zDGqGBKfhCxk"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUARTERLY
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the quarterly period ended <span id="xdx_90C_edei--DocumentPeriodEndDate_c20230101__20230630_za2A2yLTi0gh"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, <span id="xdx_90F_edei--DocumentFiscalYearFocus_c20230101__20230630_zhl2fcq1jKR5"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OR</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--DocumentTransitionReport_c20230101__20230630_zZONzxpXNFkl"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from ___________ to __________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number <span id="xdx_90E_edei--EntityFileNumber_c20230101__20230630_zcJbNirlWQ95"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityFileNumber">1-37648</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_905_edei--EntityRegistrantName_c20230101__20230630_zptsSG5UeJWf"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityRegistrantName">Oncocyte
Corporation</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20230101__20230630_zOR69aiZPy84"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">California</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20230101__20230630_zq7ZNYJUkKB6"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityTaxIdentificationNumber">27-1041563</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20230101__20230630_zmowTqda62qk"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityAddressAddressLine1">15
Cushing</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressCityOrTown_c20230101__20230630_zY33wch0KX9k"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityAddressCityOrTown">Irvine</ix:nonNumeric></span>,
<span id="xdx_908_edei--EntityAddressStateOrProvince_c20230101__20230630_zN51a0wURnq9"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20230101__20230630_zkbLPOVcGbR4"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityAddressPostalZipCode">92618</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--CityAreaCode_c20230101__20230630_zDE0WqLxRkK4"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:CityAreaCode">(949)</ix:nonNumeric></span>
<span id="xdx_90E_edei--LocalPhoneNumber_c20230101__20230630_zhB7mN6Pmkxg"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:LocalPhoneNumber">409-7600</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--Security12bTitle_c20230101__20230630_zNLFv2KkAnxb"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:Security12bTitle">Common
    Stock, no par value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--TradingSymbol_c20230101__20230630_zxxdW3Xdesz7"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:TradingSymbol">OCX</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_90C_edei--SecurityExchangeName_c20230101__20230630_zU8aJe0ocFK7"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. &#9746; <span id="xdx_906_edei--EntityCurrentReportingStatus_c20230101__20230630_zq59WUp3dpg4"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9744; No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). &#9746; <span id="xdx_907_edei--EntityInteractiveDataCurrent_c20230101__20230630_z4KpB7LwQWp6"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9744; No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityFilerCategory_c20230101__20230630_zdEWrMlB0wca"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_90E_edei--EntitySmallBusiness_c20230101__20230630_zb0fJ8hTaSb6"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20230101__20230630_zmoA2uoprvGe"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#9744; Yes &#9746; <span id="xdx_90C_edei--EntityShellCompany_c20230101__20230630_z94zEutHdjId"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock outstanding as of August 3, 2023 was <span id="xdx_900_edei--EntityCommonStockSharesOutstanding_iI_c20230803_ztALBM21vxPh"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-08-03" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,240,928</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>
<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#s_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#s_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART 1&#8212;FINANCIAL INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#s_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><a href="#s_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED BALANCE SHEETS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><a href="#s_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><a href="#s_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><a href="#s_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><a href="#s_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt"><a href="#s_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#rs_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#rs_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#rs_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4. Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#rs_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II - OTHER INFORMATION</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#rs_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. Legal Proceedings</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#rs_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A. Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#rs_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#rs_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. Default Upon Senior Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#rs_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4. Mine Safety Disclosures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#rs_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5. Other Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span>4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#rs_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6. Exhibits</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#rs_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td></tr>
  </table>
<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_001"></span>CAUTIONARY
NOTE REGARDING FORWARD LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
Report on Form 10-Q (&#8220;Report&#8221;) contains forward-looking statements that involve risks and uncertainties. We make such forward-looking
statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities
laws. All statements other than statements of historical facts contained in this Report are forward-looking statements. In some cases,
you can identify forward-looking statements by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221;
&#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221;
&#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221;
&#8220;will,&#8221; &#8220;would,&#8221; or the negative of these words or other comparable terminology.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Any
forward-looking statements in this Report reflect our current views with respect to future events or to our future financial
performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or
achievements to be materially different from any future results, performance or achievements expressed or implied by these
forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among
other things, those discussed in this Report under Item 1 of the Notes to Condensed Consolidated Interim Financial Statements, under
Risk Factors in this Report and those Risk Factors in Part I, Item 1A of our most recent Annual Report on Form 10-K as filed with
the Securities and Exchange Commission (&#8220;SEC&#8221;). Given these uncertainties, you should not place undue reliance on these forward-looking
statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason,
even if new information becomes available in the future.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
forward-looking statements in this Report also include, among other things, statements about:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and potential achievement of future milestones;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and our ability to obtain and maintain coverage and reimbursements from the Centers for Medicare and Medicaid Services and
    other third-party payers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    plans to pursue research and development of diagnostic tests;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential commercialization of our diagnostic tests currently in development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and success of future clinical trials and the period during which the results of the clinical trials will become available;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential receipt of revenue from future sales of our diagnostic tests or diagnostic tests in development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    assumptions regarding obtaining reimbursement and reimbursement rates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding future orders of tests and our ability to perform a projected number of tests;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates and assumptions around patient populations, market size and price points for reimbursement for our diagnostic tests;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding future revenues and operating expenses, and future capital requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    intellectual property position;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of government laws and regulations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitive position.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unless
the context otherwise requires, all references to &#8220;Oncocyte,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221;
&#8220;our,&#8221; or similar words refer to Oncocyte Corporation, together with our consolidated subsidiaries.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
description or discussion, in Report, of any contract or agreement is a summary only and is qualified in all respects by reference to
the full text of the applicable contract or agreement.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>DetermaIO&#8482;,
DetermaCNI&#8482;, and VitaGraft&#8482; are trademarks of Oncocyte Corporation, regardless of whether the &#8220;<sup>&#8482;</sup>&#8221;
symbol accompanies the use of or reference to the applicable trademark in this Report.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_002"></span>PART
1&#8212;FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_003"></span>Item
1. Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_004"></span>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED
CONSOLIDATED BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_111_pn3n3_z8QIahCwiOc2" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230630_zQDc3Lpu6Ju" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zk4ghgBM0F0j" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsAbstract_iB_zbxiFKfXhUP5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrentAbstract_i01B_zyPV8lXrFQIf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pn3n3_maACzGmF_z2sy2XeFL616" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,368</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,993</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsReceivableNetCurrent_i02I_pn3n3_maACzGmF_zFNdG9ACTr0a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net of allowance of $<span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20230630_zsQqhLKbjNre" title="Accounts receivable, allowance for credit loss"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">178</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20221231_z3ovRKM0vDxl" title="Accounts receivable, allowance for credit loss"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154</ix:nonFraction></span>, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,012</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EquitySecuritiesFvNi_i02I_pn3n3_maACzGmF_zdqOBX7or5ua" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Marketable equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">433</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pn3n3_maACzGmF_zPKF8aLOdqM3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,179</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">977</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroupCurrent_i02I_pn3n3_maACzGmF_zE07dZipuAea" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Assets held for sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">191</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0064">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_pn3n3_maACzGmF_zm8dRswoAlmb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Current assets of discontinuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0066">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrent_i02TI_pn3n3_mtACzGmF_maAzqUh_z58Sq6M74Ss" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,984</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,536</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NONCURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseRightOfUseAsset_i02I_pn3n3_maAzqUh_zaAkwTss8hCg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Right-of-use and financing lease assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,891</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--MachineryAndEquipmentNetAndConstructionInProgress_i02I_pn3n3_maAzqUh_zcNGrEYbTj5b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Machinery and equipment, net, and construction in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:MachineryAndEquipmentNetAndConstructionInProgress" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,997</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:MachineryAndEquipmentNetAndConstructionInProgress" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,763</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_pn3n3_maAzqUh_zhEJTMPconPd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56,639</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61,633</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RestrictedCashNoncurrent_i02I_pn3n3_maAzqUh_zXYKvNTT7Utk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAssetsNoncurrent_i02I_pn3n3_maAzqUh_zwRuRE6CMlS5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Other noncurrent assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">329</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">371</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Assets_i01TI_pn3n3_mtAzqUh_zTaxdyEDL5gg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87,540</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,091</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_i02I_pn3n3_maLCznfx_zTPuRNYBklof" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,253</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrent_i02I_pn3n3_maLCznfx_zSwWsWiqRD9g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,771</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_i02I_pn3n3_maLCznfx_zo1ei2qJRMr3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,839</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedSeveranceFromAcquisitionCurrent_i02I_pn3n3_maLCznfx_z4EFtenw1805" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued severance from acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:AccruedSeveranceFromAcquisitionCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,314</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:AccruedSeveranceFromAcquisitionCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,314</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiabilityCurrent_i02I_pn3n3_maLCznfx_zngWVOn8LjGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued liabilities from acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--RightOfUseAndFinancingLeaseLiabilitiesCurrent_i02I_pn3n3_maLCznfx_zcz53MJ5Xwrh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Right-of-use and financing lease liabilities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:RightOfUseAndFinancingLeaseLiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">737</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:RightOfUseAndFinancingLeaseLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">815</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_pn3n3_maLCznfx_zPr3U4P1hcll" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Current liabilities of discontinuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,005</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCznfx_maLzqB0_z08msSBxOzAc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,106</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NONCURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--RightOfUseAndFinancingLeaseLiabilitiesNoncurrent_i02I_pn3n3_maLzqB0_zuOIRqyBL452" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Right-of-use and financing lease liabilities, noncurrent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:RightOfUseAndFinancingLeaseLiabilitiesNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:RightOfUseAndFinancingLeaseLiabilitiesNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,729</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_i02I_pn3n3_maLzqB0_zLCH1zStIgcg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Contingent consideration liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,662</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Liabilities_i01TI_pn3n3_mtLzqB0_maLASEzgs8_zVwLW6GB2mq9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">TOTAL LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60,497</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommitmentsAndContingencies_i01I_pn3n3_maLASEzgs8_ziNTHLKUNcfk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0135">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0136">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_i01I_pn3n3_maLASEzgs8_zqVfLn0N90L8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series A Redeemable Convertible Preferred Stock, <span id="xdx_904_ecustom--TemporaryEquityNoParValue_iI_do_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_ziU0Cxp1mdQa" title="Temporary equity, no par value"><span id="xdx_905_ecustom--TemporaryEquityNoParValue_iI_do_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zqNmhT8efmA6" title="Temporary equity, no par value"><ix:nonFraction name="OCX:TemporaryEquityNoParValue" contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USDPShares"><ix:nonFraction name="OCX:TemporaryEquityNoParValue" contextRef="AsOf2022-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value; stated value $<span id="xdx_907_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z2cvKyeVvMHc" title="Temporary equity, stated par value"><span id="xdx_906_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z6q5bcA3oNj4" title="Temporary equity, stated par value"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USDPShares"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USDPShares">1,000</ix:nonFraction></ix:nonFraction></span></span> per share; <span id="xdx_900_eus-gaap--TemporaryEquitySharesIssued_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_za6yyho2XoEk" title="Temporary equity, shares issued"><span id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zZnIuy0Cfiv3" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5</ix:nonFraction></ix:nonFraction></span> </span>and <span id="xdx_90D_eus-gaap--TemporaryEquitySharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z8GVH1uzTir1" title="Temporary equity, shares issued"><span id="xdx_90F_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z5vTfReVVCKa" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2022-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">6</ix:nonFraction></ix:nonFraction></span> </span>shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $<span id="xdx_90C_eus-gaap--TemporaryEquityLiquidationPreference_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zYU0ux2Ud2oh" title="Temporary equity, liquidation preference"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,140</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--TemporaryEquityLiquidationPreference_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z3SlrXUPMXs3" title="Temporary equity, liquidation preference"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="AsOf2022-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,091</ix:nonFraction></span> as of June 30, 2023 and December 31, 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,725</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,302</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PreferredStockValue_i02I_pn3n3_maSEzVMU_zNZNdvcUhfF7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Preferred stock, <span id="xdx_908_eus-gaap--PreferredStockNoParValue_iI_do_c20230630_z0jZcHec0R9" title="Preferred stock no par value"><span id="xdx_907_eus-gaap--PreferredStockNoParValue_iI_do_c20221231_z41kxkxYfBd7" title="Preferred stock, no par value"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2023-06-30" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20230630_znvaE5o5Mmqi" title="Preferred stock, shares authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zvglhB60p9qg" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20230630_zYpQDYUaHxZ7" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20230630_zIKVEemz4CBd" title="Preferred stock, shares outstanding"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_do_c20221231_zGsgoovYsSEj" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_zugjetAKtHFc" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-06-30" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-06-30" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span> </span>shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0164">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0165">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_pn3n3_maSEzVMU_ztqHlmGvEqjd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock, <span id="xdx_906_eus-gaap--CommonStockNoParValue_iI_do_c20230630_zu15EPAbe3U7" title="Common stock, no par value"><span id="xdx_902_eus-gaap--CommonStockNoParValue_iI_do_c20221231_z1pr0riBdA4c" title="Common stock, no par value"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2023-06-30" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20230630_z9ZwawK3kCOk" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zgkAA3qVLID6" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">230,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20230630_zLGB1HdnYbl3" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20230630_z5uaZFlFhJ4d" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">8,241</ix:nonFraction></ix:nonFraction></span></span> and<span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20221231_zzDCfQlXrdb6" title="Common stock, shares issued"> <span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zHTkYpLiaZO3" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,932</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">309,535</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">294,929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_pn3n3_maSEzVMU_zA25129LfGO5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_maSEzVMU_zkZaoyELFe02" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">265,976</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">260,676</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquity_i02TI_pn3n3_mtSEzVMU_maLASEzgs8_zENU57QfIoQh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,600</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,292</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEzgs8_zTbOZdh2YN2h" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87,540</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100,091</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_005"></span>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands, except per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_113_pn3n3_z6WPjk2QvBl4" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230401__20230630_zqx19U2xmmDi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220401__20220630_zwpnPerQJZtk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20230630_z1wKTipuOp03" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20220101__20220630_zSJl6c8EjXha" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Three Months Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Six Months Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>June 30,</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzNzz_zwDc0HPrPEZb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-weight: bold; text-align: left">Net revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">463</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">237</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">760</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">617</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CostOfRevenue_msGPzNzz_zXdv7VZw4xw3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">288</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--CostOfRevenuesAmortizationOfAcquiredIntangibles_msGPzNzz_zE9kvq2DTCka" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Cost of revenues &#8211; amortization of acquired intangibles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OCX:CostOfRevenuesAmortizationOfAcquiredIntangibles" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OCX:CostOfRevenuesAmortizationOfAcquiredIntangibles" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OCX:CostOfRevenuesAmortizationOfAcquiredIntangibles" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OCX:CostOfRevenuesAmortizationOfAcquiredIntangibles" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_iT_pn3n3_mtGPzNzz_maOILzgch_zc4NMswtVKVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Gross profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">272</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">282</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">278</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEztUZ_zHVjiW37NHC9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,435</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,444</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,451</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SellingAndMarketingExpense_i01_pn3n3_maOEztUZ_zeV8UUaCH2F4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">805</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">393</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01_pn3n3_maOEztUZ_z80nUZKTlKJ5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,531</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,445</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,092</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_i01_pn3n3_maOEztUZ_zc1EEvfoP3zc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,795</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,359</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,512</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,015</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_i01_pn3n3_maOEztUZ_z5xzrlpAZWb9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Impairment loss from intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0259">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GainLossOnSaleOfOtherAssets_i01N_pn3n3_di_msOEztUZ_zRGdFoKLZ4Rc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Loss on disposal and held for sale assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0265">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,283</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingExpenses_i01T_pn3n3_msOILzgch_mtOEztUZ_ztB1Z4XG0KT4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,566</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,657</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,726</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,921</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_iT_pn3n3_mtOILzgch_maILFCOztW4_zrG495EfNTbh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,294</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,626</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,444</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,643</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">OTHER INCOME (EXPENSES), NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InterestIncomeExpenseNet_i01_pn3n3_maNIEzJN4_ziJjAhtWSG1l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest income (expenses), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">21</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">51</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i01_pn3n3_maNIEzJN4_z5xuXLqyuopi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Unrealized gain (loss) on marketable equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">325</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpense_i01_pn3n3_maNIEzJN4_z3JZ0kDpt2vb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Other income (expenses), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">278</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">242</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpense_i01T_pn3n3_mtNIEzJN4_maILFCOztW4_z3s8TtV5Nvg1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Total other income (expenses), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">39</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">262</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">134</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_mtILFCOztW4_maILFCOz4Eq_zdaVcDoT3O71" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LOSS BEFORE INCOME TAXES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,333</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,364</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,374</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,777</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_iT_maNILziQi_mtILFCOz4Eq_zHCbqylJ6lwf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Loss from continuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,374</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,777</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_maNILziQi_zGX9Ls4JB12b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Loss from discontinuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,936</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,926</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,814</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILziQi_maNILATzG1f_zszi8dlGfjUa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,300</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,300</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,591</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock_maNILATzG1f_ztG8TFNJ28We" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; padding-bottom: 2.5pt; font-weight: bold; text-align: left">LESS: DIVIDENDS AND ACCRETION OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="OCX:DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">311</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">$</p></td><td style="padding-bottom: 2.5pt; text-align: right">(<ix:nonFraction name="OCX:DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">(<ix:nonFraction name="OCX:DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">541</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">(<ix:nonFraction name="OCX:DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_mtNILATzG1f_zEzN6SCDe9L3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS: BASIC AND DILUTED</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230401__20230630_z93jxhxJI5Y4" title="NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS BASIC" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20230401__20230630_zzPNP7SUg5r9" title="NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS DILUTED" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,644</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></p></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20220401__20220630_zmgMEEFOZAvl" title="NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS BASIC" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20220401__20220630_zkb11eQ4NJDl" title="NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS DILUTED" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,372</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20230101__20230630_zBIL6KNGhWsg" title="NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS BASIC" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_904_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20230101__20230630_zgwx2SnAIwsh" title="NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS DILUTED" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,841</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20220101__20220630_z7tnBL0EB2U3" title="NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS BASIC" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20220101__20220630_zW04TY264lSa" title="NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS DILUTED" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,663</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_mtNILATzG1f_zZWC0nltxt5f" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS: BASIC</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,644</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,372</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,841</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,663</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_z08nm1PSm4ci" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss from continuing operations per share: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20230401__20230630_zLGO2qTLhCje" title="Net loss from continuing operations per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.03</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20220401__20220630_z95SVLads4u1" title="Net loss from continuing operations per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.24</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20230101__20230630_zo1pJlwUgzBe" title="Net loss from continuing operations per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.34</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20220101__20220630_zfoJuWOlqeGb" title="Net loss from continuing operations per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.93</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_z79eCukZtCp4" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss from continuing operations per share: basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.03</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.24</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.34</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.93</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_pid_zzVhldbCR538" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss from discontinuing operations per share: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_pid_c20230401__20230630_zu9zuOKk3Qci" title="Net loss from discontinuing operations per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span style="-sec-ix-hidden: xdx2ixbrl0373"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_pid_c20220401__20220630_zRxUseeHBY01" title="Net loss from discontinuing operations per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.23</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_pid_c20230101__20230630_zm9wBzZabUR4" title="Net loss from discontinuing operations per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.42</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_pid_c20220101__20220630_z4kvSEPCJS1b" title="Net loss from discontinuing operations per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.69</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_pid_zYbGggnY38yd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss from discontinuing operations per share: basic </td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.23</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.42</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.69</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_pid_zzGyFALF23U5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss per share: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--EarningsPerShareDiluted_pid_c20230401__20230630_z0JcE2FGqvkj" title="Net loss per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.07</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--EarningsPerShareDiluted_pid_c20220401__20220630_z5EbiTK90Cic" title="Net loss per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.48</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230630_zGr7rjBcFzCl" title="Net loss per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.83</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220630_zZ9nc8gg7THj" title="Net loss per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA" style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.63</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--EarningsPerShareBasic_pid_zo0PhlB8AsYk" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss per share: basic</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.07</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.48</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.83</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.63</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average shares outstanding: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230401__20230630_zrg4cEZNUt4b" title="Weighted average shares outstanding: basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230401__20230630_zq8W6WX9ID23" title="Weighted average shares outstanding: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,090</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220401__20220630_zqFn2W6cjmCe" title="Weighted average shares outstanding: basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220401__20220630_zEMdxLGvWWc9" title="Weighted average shares outstanding: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,652</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230630_zAtpfdnlgpxg" title="Weighted average shares outstanding: basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230630_zKBYSEWNydIb" title="Weighted average shares outstanding: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,030</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220630_zSgLvjXtkqyf" title="Weighted average shares outstanding: basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220630_z3v6XSPe19jk" title="Weighted average shares outstanding: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgKFVuYXVkaXRlZCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,135</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_006"></span>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_113_pn3n3_ziIg8RPXdCt4" summary="xdx: Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230401__20230630_z9keI6s7tDOk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20220401__20220630_zZ3JX73ECcf8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230630_zayDc2px1hqi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220630_zdr730Q4QeC2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_maCINOTzUO7_zkdUDWwvccPc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; font-weight: bold; text-align: left">NET LOSS</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,333</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,300</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,300</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,591</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_maCINOTzUO7_zzDIPMetDnt3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Foreign currency translation adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCINOTzUO7_zjGEFBSrHG2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">COMPREHENSIVE LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,335</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,307</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,298</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,597</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_007"></span>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_pn3n3_z7l6rBd6G6J2" summary="xdx: Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesARedeemableConvertiblePreferredStockMember_zYvXC50OHHVl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zqyuaxd8BtZ1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zhEVRxsIgKGk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Comprehensive Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zm32x6gnpHz1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_z8MIwmqD7F0i" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A Redeemable Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total<br /> Shareholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Comprehensive Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_437_c20230401__20230630_eus-gaap--StockholdersEquity_iS_zM0YH0gsGY42" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; font-weight: bold">Balance at March 31, 2023</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_ztg0Ab9cdW1" title="Balance, shares" style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,882</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,532</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaslkqUTVN" title="Balance, shares" style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,964</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295,533</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">257,643</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,933</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zu5hnxXFVWWh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,333</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,333</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zC5F7KhALX8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_zAnZIVlLr8yg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">834</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">834</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueVestingOfBonusAwards_zGHxar4i08N" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vesting of bonus awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueOther_zStouT7xBY9b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sale of common shares, net of financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0474">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWHt5JsZlSTd" title="Sale of common shares, net of financing costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,266</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,421</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,421</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeemedDividendOnSeriesRedeemableConvertiblePreferredStock_zk1fSVwuO5jg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deemed dividend on Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">118</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">118</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_z0sUaXoDR872" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Redemption of Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zEaK9hvWmmPd" title="Redemption of SeriesA redeemable convertible preferred stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">1,064</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">)</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ziNIGQBAvWlk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued upon vesting of RSU</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z483cHWwevM5" title="Shares issued upon vesting of RSU, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0499">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue_zqabgdOZxb1h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accretion of Series A convertible preferred stock to redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">193</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">193</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">193</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_435_c20230401__20230630_eus-gaap--StockholdersEquity_iE_zp7VW5VmtGe4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at June 30, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z4YLrCFaK29" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,818</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,725</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLN78YZBhvch" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">8,241</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">309,535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">265,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A Redeemable Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total<br /> Shareholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Comprehensive Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43D_c20220401__20220630_eus-gaap--StockholdersEquity_iS_zyfUkpvZ7D2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; font-weight: bold">Balance at March 31, 2022</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zwipm3zfb0qa" title="Balance, shares" style="width: 5%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">-</span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">-</span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwejba1RRwFj" title="Balance, shares" style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,612</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">254,994</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">198,065</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56,967</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zzbGKMICMkj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,300</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,300</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zUPU6zGoq7rd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0536">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_zmAH0427yhG6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,232</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,232</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zpSnfYCc5486" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbR293ftgxfe" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,423</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,423</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zUyG6ng60Mjl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued upon vesting of RSU, net of shares retired to pay employees&#8217; taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIUKZmImyQec" title="Shares issued upon vesting of RSU, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zAAlMJoc1OS" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Series A redeemable convertible preferred stock, net of financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zUSsYIXGSM7a" title="Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">11,765</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,782</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue_zXFayXNCJJg5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accretion of Series A convertible preferred stock to redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">72</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">72</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_433_c20220401__20220630_eus-gaap--StockholdersEquity_iE_z7LY3NPOZjM5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at June 30, 2022</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zAtGEETwiMz6" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">11,765</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,854</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQcVqF3EhmMc" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,930</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">289,649</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">206,437</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83,243</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A Redeemable Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total<br /> Shareholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Comprehensive Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_431_c20230101__20230630_eus-gaap--StockholdersEquity_iS_z8SfVnomTzB3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; font-weight: bold">Balance at December 31, 2022</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zIW0gymNtzhi" title="Balance, shares" style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,882</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,302</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpCKw41lWi2k" title="Balance, shares" style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,932</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">294,929</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">260,676</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,292</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zFblPdvmz9N" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0598">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0600">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,300</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,300</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zf68qU3UMp9f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0604">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0605">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0607">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_zEoCv4G4jErd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,668</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0612">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0613">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,668</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueVestingOfBonusAwards_zlRVQUVRwrN4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vesting of bonus awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0618">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueOther_zUt1U0s9SDn7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sale of common shares, net of financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYB1PsexurLg" title="Sale of common shares, net of financing costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,266</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,421</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0624">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,421</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeemedDividendOnSeriesRedeemableConvertiblePreferredStock_zqdtAkdXoBF4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deemed dividend on Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">118</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">118</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zntyyJn2EzU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued upon vesting of RSU</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0636">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zA8ke1IF5vud" title="Shares issued upon vesting of RSU, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0637">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0638">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0640">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_zh8mSsaGSL78" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Redemption of Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zH9F2mcXmz86" title="Redemption of SeriesA redeemable convertible preferred stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">1,064</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">)</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0648">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue_z3gznTYA5uNe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accretion of Series A convertible preferred stock to redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">423</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">423</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">423</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20230101__20230630_eus-gaap--StockholdersEquity_iE_z7PcP8wZlM8e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at June 30, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zUhEU5sugxb7" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,818</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,725</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4rJh9Zz6Pxg" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">8,241</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">309,535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">265,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="26" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A Redeemable Convertible Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total<br /> Shareholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Comprehensive Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43A_c20220101__20220630_eus-gaap--StockholdersEquity_iS_zvjtD7jpr5F5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; font-weight: bold">Balance at December 31, 2021</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zpkdypNtjUpb" title="Balance, shares" style="width: 5%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0668">-</span></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwE8RZqA8plh" title="Balance, shares" style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4,612</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">252,954</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">187,774</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65,217</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20220101__20220630_eus-gaap--StockholdersEquity_iS_ze8ZW9j0YXGe" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Balance</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0678">-</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4,612</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">252,954</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">187,774</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65,217</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLoss_zZagg65EImHh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net Loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,591</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,591</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zDBODTDXL327" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0693">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_z8hpQ47vsOm7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,242</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0699">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,242</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zgKQrVDjXmU2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbJGbORmlBM2" title="Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,314</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0704">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,453</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zo8DPHAHZBy4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued upon vesting of RSU, net of shares retired to pay employees&#8217; taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za16KjKjz7e1" title="Shares issued upon vesting of RSU, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0712">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0713">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0714">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_z9hjldVSoHTf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Series A redeemable convertible preferred stock, net of financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zotjVNv30dG6" title="Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">11,765</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,782</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0719">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0720">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0721">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0722">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue_zTxstCnhNiVi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accretion of Series A convertible preferred stock to redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0728">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">72</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">72</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20220101__20220630_eus-gaap--StockholdersEquity_iE_zOLlmySKsGii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at June 30, 2022</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zFp8g1BFyHs6" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">11,765</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,854</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_c20220101__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfsX4W42wiTg" title="Balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,930</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">289,649</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">206,437</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83,243</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_43C_c20220101__20220630_eus-gaap--StockholdersEquity_iE_zWWlW3oHWsda" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">11,765</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,854</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">5,930</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">289,649</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">206,437</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83,243</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_008"></span>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_pn3n3_zxm4O3Mn6yFd" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20230630_zxhbw2IkrNFd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220630_zuKSIeH8dW4g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zJwtFQVh3ev1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_i01_pn3n3_maNCPBUzES5_zabLlbcAA9rb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,300</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,591</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zDMMLtiHdfFg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Depreciation_i02_pn3n3_maNCPBUzES5_z2NLC2Wjy1m" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">885</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">671</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AmortizationOfIntangibleAssets_i02_pn3n3_maNCPBUzES5_zUJcSVR851si" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,904</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_i02_pn3n3_maNCPBUzES5_zTSi12k78HOa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,668</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,242</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i02N_pn3n3_di_msNCPBUzES5_zDbRqhSUkw21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Unrealized (gain) loss on marketable equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">325</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfFinancingCosts_i02_pn3n3_maNCPBUzES5_za2ZytNKWJK9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0769">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_i02_pn3n3_maNCPBUzES5_zXo1NzcfFwCh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,512</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,015</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation_i02_pn3n3_maNCPBUzES5_zVOOvkU1qJsg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of Series A redeemable convertible preferred stock second tranche obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0775">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OCX:ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">305</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_i01_pn3n3_maNCPBUzES5_zsQjJiY7Hirb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Impairment loss from intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0779">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_i01N_pn3n3_di_msNCPBUzES5_zmYHzxdUoRsa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Loss on disposal of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">149</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GainLossOnDispositionOfAssets1_i01N_pn3n3_di_msNCPBUzES5_zomxgfisQXb4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Loss on disposal and held for sale assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,283</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0785">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_pn3n3_di_msNCPBUzES5_z84vGbhRJXXd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">296</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">365</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_pn3n3_di_msNCPBUzES5_z2rO2PDQoSrk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">773</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_pn3n3_maNCPBUzES5_zdVcR4uh67m3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accounts payable and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,319</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">239</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition_i03_pn3n3_maNCPBUzES5_zy9qnSwbRHu2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accrued severance and liabilities from Chronix Biomedical acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0799">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OCX:AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">817</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_pn3n3_maNCPBUzES5_z4yvhJ80w9e4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">118</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInAssetsHeldForSale_i03N_pn3n3_di_msNCPBUzES5_z08TK7WxLWn1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Assets held for sale</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAssetsHeldForSale" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">191</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0806">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pn3n3_maCCERCzKpW_mtNCPBUzES5_zwceuFCnDnK2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,504</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">24,524</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromSaleOfMachineryAndEquipment_i01_pn3n3_maNCPBUzLWU_zSHnBrfliITi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0815">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pn3n3_di_msNCPBUzLWU_zo30O55z8BU1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Construction in progress and purchases of furniture and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0817">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,679</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pn3n3_mtNCPBUzLWU_maCCERCzKpW_zRluuZYsbc13" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,679</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zx7HuUWCZtWj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pn3n3_maNCPBUzs5D_z5Z4ViGcZMaf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of common shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,848</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,812</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_pn3n3_di_msNCPBUzs5D_zNf2sHJ5qH8l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Financing costs to issue common shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">427</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">389</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_i01_pn3n3_maNCPBUzs5D_zdZKZo6LBP7b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of redeemable convertible Series A preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_i01N_pn3n3_di_msNCPBUzs5D_zlQKUFq7BQOh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Redemption of redeemable convertible Series A preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,118</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares_i01N_pn3n3_di_msNCPBUzs5D_zjbWDMzmuSta" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Financing costs to issue redeemable convertible Series A preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OCX:FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions_i01_pn3n3_maNCPBUzs5D_zly4gWUo6Ped" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of common shares under at-the-market transactions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0841">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PaymentForFinancingCostsForAtthemarketSales_i01N_pn3n3_di_msNCPBUzs5D_zBeU0Aw61Jo2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Financing costs for at-the-market sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OCX:PaymentForFinancingCostsForAtthemarketSales" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--RepaymentsOfDebt_i01N_pn3n3_di_msNCPBUzs5D_zkJ7CfH8xWb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Repayment of loan payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--RepaymentOfFinancingLeaseObligations_i01N_pn3n3_di_msNCPBUzs5D_z6fIJl2ChPH7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Repayment of financing lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:RepaymentOfFinancingLeaseObligations" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:RepaymentOfFinancingLeaseObligations" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pn3n3_mtNCPBUzs5D_maCCERCzKpW_zFQZVtudfQNl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,246</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36,434</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pn3n3_mtCCERCzKpW_zcSxvc8q5Fui" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,135</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,231</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,305</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,068</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,536</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z7H8Hlur7s7a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPaidNet_i01_zTg8fMrWrnFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cash paid for interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zTxCQxV52SH9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability_i01_zYJoYtX9GJ0d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="OCX:ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="OCX:ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,331</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_009"></span>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(UNAUDITED)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zmQ7sEi77j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82F_zrJiSVKexLfd">Organization, Description of the Business and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
Corporation (&#8220;Oncocyte,&#8221; the &#8220;Company,&#8221; &#8220;we&#8221; or &#8220;us&#8221;), incorporated in 2009 in the state of California, is a precision diagnostics
company focused on developing and commercializing proprietary tests in three areas: DetermaIO is a gene expression test that assesses
the tumor microenvironment to predict response to immunotherapies, VitaGraft is a blood-based solid organ transplantation monitoring
test, and DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte&#8217;s
first product for commercial release was a proprietary treatment stratification test called DetermaRx that identifies which patients
with early-stage non-small cell lung cancer may benefit from chemotherapy, resulting in a significantly higher, five-year survival rate.
Beginning in September 2019 through February 23, 2021, Oncocyte held a <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210223__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorGenomicsIncMember_ztWDR584VUid" title="Equity ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-02-23_custom_RazorGenomicsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% equity interest in Razor Genomics, Inc. (&#8220;Razor&#8221;),
a privately held company, that has developed and licensed to Oncocyte the lung cancer treatment stratification laboratory test that Oncocyte
is commercializing as DetermaRx. On February 24, 2021, Oncocyte completed the purchase of all the remaining issued and outstanding shares
of common stock of Razor. As a result of the purchase of the Razor common stock, Oncocyte became the sole shareholder of Razor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
December 15, 2022, the Company, entered into a Stock Purchase Agreement (the &#8220;Razor Stock Purchase Agreement&#8221;) with Dragon
Scientific, LLC, a Delaware limited liability company (&#8220;Dragon&#8221;) and Razor. Pursuant to the Razor Stock Purchase Agreement,
Oncocyte agreed to sell to Dragon, <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221215__20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DragonScientificLLCMember_zGR6pcci908j" title="Number of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-12-152022-12-15_custom_RazorStockPurchaseAgreementMember_custom_DragonScientificLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,188,181</ix:nonFraction></span> shares of common stock of Razor, which constitutes approximately <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DragonScientificLLCMember_zCIY2Et1gq3f" title="Equity ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-15_custom_RazorStockPurchaseAgreementMember_custom_DragonScientificLLCMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>% of the issued and outstanding
equity interests of Razor on a fully-diluted basis, and transfer to Razor all of the assets and liabilities related to DetermaRx (the
&#8220;Razor Sale Transaction&#8221;). </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of Razor in order to conform
to the current period presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
a result of the divestiture of Razor, the Company has retrospectively revised the condensed consolidated statements of operations for
the periods ended June 30, 2022, to reflect the operations and cash flows of Razor as discontinued operations and the related assets
and liabilities disposed. See Note 16 for additional information about assets held for sale and discontinued operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2023, Oncocyte completed the Razor Sale Transaction (the &#8220;Razor Closing&#8221;). In connection with the Razor Closing,
Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. While no monetary consideration was received for
the sale of <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DragonMember_z8kqT2L6gt5c" title="Equity ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_custom_RazorMember_us-gaap_CommonStockMember_custom_DragonMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>% of the equity interests of Razor, the transaction allowed the Company to eliminate all development and commercialization
costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to own <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230215__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8ByWFZO8lCk" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-152023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,366,364</ix:nonFraction></span> shares of common stock of Razor, which
constitutes approximately <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zUCufJrESbp2" title="Equity interest"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_custom_RazorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></span>% of the issued and outstanding equity interests of Razor on a fully-diluted basis. <span style="background-color: white">See
Note 16 for a full discussion of the Razor Sale Transaction.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2023, the Company implemented a <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20230723__20230724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6McoWJBE5Qk" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-07-232023-07-24_us-gaap_SubsequentEventMember" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-20 reverse stock split</ix:nonNumeric></span> of the outstanding shares of its common stock. The par value per
share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split.
All common stock share and per-share amounts for all periods presented in these condensed financial statements have been adjusted to
reflect the reverse stock split. The number of authorized shares of common stock remains at <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20230724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqma1QdPTce" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-07-24_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="Shares">230</ix:nonFraction></span> million shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230630_zRCntyEOk3uk" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">266.0</ix:nonFraction></span> million as of June 30,
2023. Oncocyte expects to continue to incur operating losses and negative cash flows for the foreseeable future. Since its formation,
Oncocyte has financed its operations primarily through the sale of shares of its common stock, convertible preferred stock and warrants
to acquire common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, Oncocyte had $<span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20230630_zlK5HQqKluE8" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">17.4</ix:nonFraction></span> million of cash and cash equivalents and held shares of Lineage Cell Therapeutics, Inc. (&#8220;Lineage&#8221;)
and AgeX Therapeutics, Inc. (&#8220;AgeX&#8221;) common stock as marketable equity securities with a combined fair market value of $<span id="xdx_907_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20230630_zTuLBRCkxT4c" title="Marketable equity securities fair value"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 11, 2021, Oncocyte entered into an at-the-market sales agreement with BTIG, LLC as sales agent and/or principal (the &#8220;Agent&#8221;
or &#8220;BTIG&#8221;) pursuant to which Oncocyte may sell up to an aggregate of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20210610__20210611__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--BTIGLLCMember_zjadrUkvWD6k" title="Fair value of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2021-06-102021-06-11_custom_AtTheMarketSalesAgreementMember_custom_BTIGLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> of shares of Oncocyte common stock from
time to time through the Agent (the &#8220;ATM Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
July 1, 2021 and June 30, 2023, Oncocyte sold <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210701__20230630__dei--LegalEntityAxis__custom--BTIGLLCMember_zZnINzCZmY95" title="Fair value of common stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-07-012023-06-30_custom_BTIGLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,167</ix:nonFraction> </span>shares
of common stock at an average offering price of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230630__dei--LegalEntityAxis__custom--BTIGLLCMember_ziMRQ2HM90I6" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-06-30_custom_BTIGLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">111.60</ix:nonFraction></span>
per share, for gross proceeds of approximately $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn4n6_c20210701__20230630__dei--LegalEntityAxis__custom--BTIGLLCMember_zBMWnzPVy9Ja" title="Gross proceeds from offering"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2021-07-012023-06-30_custom_BTIGLLCMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">6.27</ix:nonFraction></span>
million through the ATM Offering. The most recent sale of common stock through the ATM Offering took place in January 2022. Oncocyte
will need to raise additional capital to finance its operations, including the development and commercialization of its cancer
diagnostic and other tests, until such time as it is able to generate sufficient revenues from the commercialization of one or more
of its laboratory tests and other tests, and performing Pharma Services to cover its operating expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 13, 2022, Oncocyte entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with
institutional accredited investors (the &#8220;Investors&#8221;), including Broadwood Partners, L.P. (&#8220;Broadwood&#8221;),
Oncocyte&#8217;s largest shareholder, in a registered direct offering of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znckcjBsFEUc"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,765</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Series A Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;), which are convertible into a total of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zROBhDIdg7Rk" title="Convertible preferred shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">384,477</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of common stock, at a conversion price of $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYlfgKahIF2c" title="Conversion price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.60</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
&#8220;Series A Preferred Stock Offering&#8221;). The purchase price of each share of Series A Preferred Stock was $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zVA3C6kJwBBi" title="Net proceeds"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">850</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which included an original issue discount to the stated value of $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zS4ZRvMHMi4e" title="Preferred stock stated value per share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. The Securities Purchase Agreement provides that the closing of the Series A Preferred Stock Offering will occur, subject to
the satisfaction of certain closing conditions, in two equal tranches of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zo5NZcmzcnNh" title="Net proceeds"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
for aggregate gross proceeds from both closings of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220601__20220601__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zvNv0qK2Tmo7" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-06-012022-06-01_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220601__20220601__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zvp1lPe40oHk" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-06-012022-06-01_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.9</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
from the Series A Preferred Stock issued from the first tranche. The second closing would occur, subject to the satisfaction of
certain closing conditions (including but not limited to a requirement that the Company has not received, in the 12 months preceding
the second closing, a notice from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that the Company is not in compliance with the
listing and maintenance and listing requirements of Nasdaq), on the earlier of (a) the second trading day following the date that
Oncocyte receives notice from an Investor to accelerate the second closing and (b) a date selected by Oncocyte on or after October
8, 2022 and on or prior to March 8, 2023. On August 9, 2022, Oncocyte received a letter from Nasdaq indicating that the Company no
longer met the minimum bid price requirement of the Nasdaq continued listing requirements. Accordingly as of June 30, 2023, no
additional proceeds are expected from the second closing of the Securities Purchase Agreement. On August 8, 2023, the Company
received a letter from Nasdaq indicating that the Company had regained compliance with the minimum bid price requirement of the Nasdaq continued listing requirements. See Note 15 for additional information about the Series A Preferred Stock Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, on April 13, 2022, Oncocyte
entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with BTIG, LLC, as representative of the underwriters
named therein (the &#8220;Underwriters&#8221;), pursuant to which Oncocyte issued and sold to the Underwriters an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220412__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_znOvFlImpvwl" title="Number of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-122022-04-12_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,313,320</ix:nonFraction></span>
shares of common stock, and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220412__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zC1OHcE1BEBb" title="Purchase of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-12_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,313,320</ix:nonFraction></span> warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220412__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__srt--RangeAxis__srt--MinimumMember_zyAPMpdP2pdb" title="Purchase of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-12_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">656,660</ix:nonFraction></span> shares of common stock (&#8220;April 2022 Warrants&#8221;) (the
&#8220;Underwritten Offering,&#8221; and collectively with the Series A Preferred Stock Offering, the &#8220;April 2022 Offerings&#8221;).
The Underwritten Offering closed on April 19, 2022, and Oncocyte received net proceeds of approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220418__20220419__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdHdcmedVVrg" title="Net proceeds"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-182022-04-19_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">32.8</ix:nonFraction></span> million from the Underwritten
Offering. See Note 15 for additional information about the Underwritten Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 3, 2023, Oncocyte entered into an agreement with certain members of the Company&#8217;s board of directors,
and several institutional and accredited investors, including Broadwood, the Company&#8217;s largest shareholder, relating to their purchase
of an aggregate of up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--BoardMembersMember__srt--RangeAxis__srt--MaximumMember_z595chI480fb" title="Purchase of warrant"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_custom_BoardMembersMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,278,121</ix:nonFraction></span> shares of its common stock at an offering price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--BoardMembersMember_zXgMKP3e90xb" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-04-03_custom_RegisteredDirectOfferingMember_custom_BoardMembersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.08</ix:nonFraction></span> per share to board members and $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--OtherInvestorsMember_zlOFqicx7tSl" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-04-03_custom_RegisteredDirectOfferingMember_custom_OtherInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.03</ix:nonFraction></span> per share
to the other investors participating in the offering. The offering was intended to be priced at-the-market for purposes of complying with
applicable Nasdaq Listing Rules. The aggregate gross proceeds from the offering were approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember_z4ThkXHnQ9z9" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.9</ix:nonFraction></span> million. The Company used approximately
$<span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwE95qVzgSE4" title="Net proceeds to immediately redeem"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million of the net proceeds to immediately redeem an aggregate of <span id="xdx_902_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaTI3UioATvh" title="Number of stock redeem"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,064</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its Series A Preferred Stock and may thereafter elect
to redeem additional shares.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, Oncocyte is completing clinical development and planning commercialization of DetermaIO, although DetermaIO is currently
available for biopharma diagnostic development and research use only as a companion test in immunotherapy drug development to select
patients for clinical trials; and the clinical launch of VitaGraft. While Oncocyte plans to primarily market its laboratory tests in
the United States through its own sales force, it is also beginning to make marketing arrangements with distributors in other countries.
In order to reduce capital needs and to expedite the commercialization of any new laboratory tests that may become available for clinical
use, Oncocyte may also pursue marketing arrangements with other diagnostic companies through which Oncocyte might receive licensing fees
and royalty on sales, or through which it might form a joint venture to market its tests and share in net revenues, in the United States
or abroad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, Going Concern, we evaluated whether there are
conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern
within one year after the date that the unaudited condensed consolidated interim financial statements included in this Report are
issued. This evaluation initially does not take into consideration the potential mitigating effect of our plans that have not been
fully implemented as of the date the unaudited condensed consolidated interim financial statements included in this Report are
issued. When substantial doubt exists under this methodology, we evaluate whether the mitigating effect of its plans sufficiently
alleviates substantial doubt about our ability to continue as a going concern. The mitigating effect of our plans, however, is only
considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that such
financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or
events that raise substantial doubt about our ability to continue as a going concern within one year after the date that such
financial statements are issued. In performing this analysis, we excluded certain elements of our operating plan that cannot be
considered probable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to
support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year
after the date that the financial statements are issued. Management intends to complete additional equity financings and reduce
spending in the remainder of fiscal 2023 and in 2024. However, due to several factors, including those outside management&#8217;s
control, there can be no assurance that we will be able to complete additional equity financings. If we are unable to complete
additional financings, management&#8217;s plans include further reducing or delaying operating expenses. We have concluded the
likelihood that our plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce
expenditures, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about
our ability to continue as a going concern for a period of at least twelve months from the date of issuance of these unaudited
condensed consolidated interim financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction
of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability
and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the
uncertainties described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to general economic and capital market trends and conditions, Oncocyte&#8217;s ability to raise sufficient additional capital
to finance its operations from time to time will depend on a number of factors specific to Oncocyte&#8217;s operations such as operating
revenues and expenses, progress in development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future
laboratory tests that Oncocyte may develop or acquire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unavailability or inadequacy of financing or revenues to meet future capital needs could force Oncocyte to modify, curtail, delay, or
suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests
of its shareholders. Oncocyte cannot assure that adequate financing will be available on favorable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_zHZOs2dGQqB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_824_znUtGPNE8S4i">Basis of Presentation and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNUiTmKaFlFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zkS5tceeAXY1">Basis
of presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance
with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with the instructions to
Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures
normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance
sheets as of December 31, 2022 was derived from the audited consolidated financial statements at that date. These unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included
in Oncocyte&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated interim financial
statements presented herein as of June 30, 2023 is not representative of the full fiscal year or any future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zBEPow0Ifnt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zrKXO5Nmd15e">Principles
of consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 31, 2020, with the
acquisition of Insight Genetics, Inc. (&#8220;Insight&#8221;) through a merger with a newly incorporated wholly owned subsidiary of Oncocyte
(the &#8220;Insight Merger&#8221;) under the terms of an Agreement and Plan of Merger (the &#8220;Insight Merger Agreement&#8221;), Insight
became a wholly owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight&#8217;s operations and results with
Oncocyte&#8217;s operations and results (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 24, 2021, with the
acquisition of the remaining equity interests in Razor, Razor became a wholly owned subsidiary of Oncocyte, and on that date Oncocyte
began consolidating Razor&#8217;s results with Oncocyte&#8217;s operations and results (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (&#8220;Chronix&#8221;) pursuant to an Agreement
and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated,
the &#8220;Chronix Merger Agreement&#8221;), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary
of Oncocyte (&#8220;Merger Sub&#8221;), Chronix became a wholly owned subsidiary of Oncocyte (the &#8220;Chronix Merger&#8221;), and on
that date Oncocyte began consolidating Chronix&#8217;s operations and results with Oncocyte&#8217;s operations and results (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have reflected the operations of Razor as discontinued operations for all periods presented. See Note 16 for further information. Unless
otherwise noted, amounts and disclosures throughout these Notes to unaudited condensed consolidated interim financial statements relate
solely to continuing operations and exclude all discontinued operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting
only of normal recurring adjustments, necessary for a fair presentation of Oncocyte&#8217;s financial condition and results of operations.
The unaudited condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other
interim period or for the entire year. All material intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_842_eus-gaap--UseOfEstimates_z9HUDZz4sJRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zwTeAy75rgGb">Use
of estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and contingent assets and liabilities, at the date of the unaudited condensed consolidated financial
statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates
estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the
use of judgment to prepare financial projections, timing of potential commercialization of acquired in-process intangible assets, applicable
discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable
companies or transactions, determination of fair value of the assets acquired and liabilities assumed including those relating to contingent
consideration, assumptions related to going concern assessments, allocation of direct and indirect expenses, useful lives associated
with long-lived intangible assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies,
valuation allowances related to deferred income taxes, and assumptions used to value debt and stock-based awards and other equity instruments.
Actual results may differ materially from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
Oncocyte assessed certain accounting matters that generally require consideration of forecasted financial information. The accounting
matters assessed included, but were not limited to, Oncocyte&#8217;s equity investments, the carrying value of goodwill, going concern
assessment, acquired in-process intangible assets and other long-lived assets. Those assessments as well as other estimates referenced
above were made in the context of information reasonably available to Oncocyte.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="OCX:BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock"><p id="xdx_84B_ecustom--BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock_zm0JZ0NZggYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zVjdQpE4iuY4">Business
combinations and fair value measurements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at
fair value on the acquisition date in accordance with ASC 820, <i>Fair Value Measurement</i>. ASC 820 establishes a single authoritative
definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement.
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered
observable and the last unobservable, that may be used to measure fair value, which are the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<i>Level 1 </i>&#8211; Quoted prices in active markets for identical assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<i>Level 2 </i>&#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for
similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated
by observable market data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<i>Level 3 </i>&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable
to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted
on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets
and identifiable intangible assets acquired, including in-process research and development, and liabilities assumed, including any contingent
consideration, as of the acquisition date. Goodwill is recognized as any amount of the fair value of the tangible and identifiable intangible
assets acquired and liabilities assumed in excess of the consideration transferred. ASC 805 precludes the recognition of an assembled
workforce as an asset, effectively subsuming any assembled workforce value into goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented,
Oncocyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for money market funds and marketable
equity securities of Lineage and AgeX common stock held by Oncocyte described below. These assets are measured at fair value using the
period-end quoted market prices as a Level 1 input. Oncocyte also has certain contingent consideration liabilities which are carried
at fair value based on Level 3 inputs (see Note 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3RKpaWznMh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of June 30, 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zmTaNgYcWYHf" style="display: none">Schedule of Fair
Value Measurement of Financial Assets and Liabilities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total carrying and estimated fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left; padding-bottom: 1.5pt">Marketable equity securities</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zrte2Oe4Xsje" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-06-30_custom_MarketableEquitySecuritiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">530</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zmlsnasuFB8l" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member_custom_MarketableEquitySecuritiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">530</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zLhWjk5r3sIa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zJWYuvYPxmpa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zn3zRaxWFSh9" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">530</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJ3K5CDPnLqg" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">530</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zqMfCKTnq4B7" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV4fpBbD8sD8" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent consideration liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zhUYvCFL4uY8" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-06-30_custom_ContingentConsiderationLiabilitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zFvKQVbzLoxe" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zDj19v3hYJN1" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zjKMlaBqLsR3" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_ContingentConsiderationLiabilitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630_ztZ3r8fTeEY8" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,150</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuX5gETrWj07" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRbVr03xVsNj" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh2pOmfCD0gh" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,150</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total carrying and estimated fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left; padding-bottom: 1.5pt">Marketable equity securities</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_z4Tev33z1EWi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_custom_MarketableEquitySecuritiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">433</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zdTflE7GPOx2" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_custom_MarketableEquitySecuritiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">433</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zzdrgphbJ4M3" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zeuvjS5nU5Gi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zBQNHaivDNA1" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">433</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zezVqYduTUk5" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">433</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMgrynHvJ4Be" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYOxUVrvdDij" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent consideration liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zzdaxrShvpDh" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_custom_ContingentConsiderationLiabilitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,662</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zIc6J1GvURw2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zfUTVBs0Ucrc" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zVAT8i4bZSM8" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_ContingentConsiderationLiabilitiesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,662</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231_zyECdBhHNRMf" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,662</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGDRKTs94eGk" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDefP5WOZrh9" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0985">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zigpHVQl2mfd" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45,662</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zKaCNtGVNq65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate
fair values because of the short-term nature of these items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zlIkj3sDupkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zGQbyBZFOfBi">Cash,
cash equivalents, and restricted cash</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s reconciliation of cash and cash equivalents, and restricted cash reported within the unaudited condensed consolidated
balance sheets that sum to the total of the same amounts shown in the unaudited condensed consolidated statements of cash flows were
as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zdytl4la5juf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B2_zJpqATCenCh1">Schedule
of Cash and Cash Equivalents and Restricted Cash</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20230630_zJ6xNQ6lEwZd" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zbOy4sanmZce" style="text-align: center; font-weight: bold">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_maCCERCzBSt_zf6VijB9xmCh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,368</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,993</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RestrictedCash_iI_maCCERCzBSt_zgED1GuzIi3k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_iI_maCCERCzBSt_zl8as0JpcIH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash from discontinuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0998">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,510</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_mtCCERCzBSt_zusozGCYoAfl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash shown in the statements of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,068</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,203</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_8AF_z1Pt03fS2p2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:DiscontinuedOperationsPolicyTextBlock"><p id="xdx_841_eus-gaap--DiscontinuedOperationsPolicyTextBlock_z6jQVYPfHbq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zX7Hlyt3Qfbj">Assets
Held for Sale and Discontinued Operations</span></i></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, the Company classified laboratory equipment previously presented in machinery and equipment as held for sale in current
assets, in the unaudited condensed consolidated balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment
(&#8220;ASC 360-10&#8221;) have been met and the transaction was qualified as assets held for sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, the Company entered into various agreements to sell laboratory equipment for an aggregate amount of
$<span id="xdx_905_eus-gaap--IncreaseDecreaseInAssetsHeldForSale_pn5n6_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--VariousAgreementsMember_zba3kXUdbysg" title="Increase (decrease) in asset, held-for-sale"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAssetsHeldForSale" contextRef="From2023-01-012023-06-30_custom_VariousAgreementsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million. As a result, the Company classified the equipment as held for sale as current assets, in the unaudited condensed consolidated
balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment (&#8220;ASC 360-10&#8221;) have been met and
the transaction was qualified as assets held for sale. The equipment was written down to its fair value, less cost to sell, to $<span id="xdx_90C_eus-gaap--InventoryWriteDown_pn5n6_c20230101__20230630_zm94u4G9nNs8" title="Inventory write down"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million
in the unaudited condensed consolidated balance sheet. As a result of the sale, the Company recorded an impairment loss of $<span id="xdx_90B_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20230630_zpYCbYN0Vjz7" title="Asset impairment charges"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million
on held-for-sale assets, in the unaudited condensed consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management,
having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in
their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate
a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable
and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation
to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the
plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified
as held for sale in the unaudited condensed consolidated balance sheet. Assets classified as held for sale are reported at the lower
of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for
sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discontinued
operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business
that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a
major effect on the Company&#8217;s operations and financial results according to Accounting Standard Codification (&#8220;ASC&#8221;)
Topic 205, <i>Presentation of Financial Statements</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
details surrounding the Company&#8217;s assets and liabilities held for sale and discontinued operations are included in Note 16.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zdALh9iWRtf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_z9k4q47cS8wj">Goodwill
and intangible assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 350, <i>Intangibles &#8211; Goodwill and Other</i>, in-process research and development (&#8220;IPR&amp;D&#8221;)
projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived
intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the
project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts
are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&amp;D assets, including the
current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability
to obtain local determination coverage (&#8220;LCD&#8221;) from the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) for
Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement
of competitors&#8217; diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the
eventual realized value of the IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges
may occur in future periods. During the period between completion or abandonment, the IPR&amp;D assets will not be amortized but will
be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in
circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts (see
Notes 3 and 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&amp;D,
is not amortized but is tested for impairment at least annually, or if circumstances indicate its value may no longer be recoverable.
Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant
events and factors affecting Oncocyte&#8217;s business. Based on the qualitative assessment, if it is determined that the fair value
of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared
with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte
continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at
the enterprise level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D discussed in Notes 3 and
4. As of June 30, 2023, goodwill has been fully impaired and acquired IPR&amp;D has been partially impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_847_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z43I1D7VHtqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zpKA0ODzalm9">Long-lived
intangible assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
intangible assets, consisting primarily of acquired customer relationships, are stated at acquired cost, less accumulated amortization.
Amortization expense is computed using the straight-line method over the estimated useful life of <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230630_zgG4WqZN1Jhc" title="Long-lived intangible assets, useful life"><ix:nonNumeric contextRef="AsOf2023-06-30" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">5</ix:nonNumeric></span> years (see Notes 3 and 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ContingentLiabilityReserveEstimatePolicy"><p id="xdx_841_eus-gaap--ContingentLiabilityReserveEstimatePolicy_zrQpGIlIQKhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zYjoCbRT84U6">Contingent
consideration liabilities</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of Oncocyte&#8217;s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former
selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones,
from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable
agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and
timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows (see Notes 3 and 4). These obligations
are referred to as contingent consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration
transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling
shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones.
Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings,
such as &#8220;earn-out&#8221; provisions or percentage of future revenues, including royalties paid to the selling shareholders based
on a percentage of certain revenues generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions
occur, with the subsequent change in fair value recorded in the condensed consolidated statements of operations. Changes in key assumptions
can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that
Oncocyte records in its unaudited condensed consolidated interim financial statements. See Notes 3 and 4 for a full discussion of these
liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:EquityMethodInvestmentsPolicy"><p id="xdx_84C_eus-gaap--EquityMethodInvestmentsPolicy_zZ7s92dN3mxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zB5wx3auyJye">Investments
in capital stock of privately held companies</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable
interest entity (&#8220;VIE&#8221;) model, and then under the voting interest model in accordance with accounting guidance for consolidations
under Accounting Standards Codification (&#8220;ASC&#8221;) 810-10. If consolidation of the entity is not required under either the VIE
model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with
ASC 323, <i>Investments &#8211; Equity Method and Joint Ventures</i>. The equity method applies to investments in common stock or in-substance
common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically
represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment
balance based on Oncocyte&#8217;s pro rata share of earnings or losses from the investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
February 24, 2021, the date of Oncocyte&#8217;s acquisition of the remaining interests in Razor, through February 16, 2023 the date of
its disposition, Razor entity&#8217;s financial statements have been consolidated with Oncocyte. See Notes 3, 4, and 16 for additional
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zoQTYhsYePXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_z5dg3AsKZ7gi">Impairment
of long-lived assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired
and the carrying value may not be recoverable. Oncocyte&#8217;s long-lived assets consist primarily of intangible assets, right-of-use
assets for operating leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are
less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair
value, is recorded. See Notes 3, 4, and 16 for additional information with respect to impairments of long-lived assets. See Note 16 for
disclosure of machinery and equipment impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zsk7ub5YDnIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zYx3gprohqnj">Revenue
recognition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to ASC 606, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration
Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
identifying the contract with a customer,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
identifying the performance obligations in the contract,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
determining the transaction price,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
allocating the transaction price to the performance obligations, and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
recognizing revenue when, or as, an entity satisfies a performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services
in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable
consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal
in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently
resolved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">DetermaRx
testing revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received
from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria (i) through (v)
above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered
complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no
shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered
and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx.
Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the
transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires
significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving
payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual
reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient
history to reliably estimate payment patterns or has had contractual reimbursement arrangements, or both, in place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, Oncocyte had accounts receivable of $<span id="xdx_904_eus-gaap--AccountsReceivableSale_pn5n6_c20230101__20230630__srt--ProductOrServiceAxis__custom--MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember_zbTDkx4S4eEk" title="Accounts receivable"><ix:nonFraction name="us-gaap:AccountsReceivableSale" contextRef="From2023-01-012023-06-30_custom_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million from Medicare and Medicare Advantage covered DetermaRx tests (see
Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain an allowance for expected credit losses at an amount we estimate to be sufficient to provide adequate protection against losses
resulting from extending credit to our customers. We base this allowance, in the aggregate, on historical collection experience, age
of receivables and general economic conditions. Our bad debts have not been material and have been within management expectations. During
the first quarter of 2023, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, <i>Financial Instruments-Credit
Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> and subsequent amendments to the initial guidance under
ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial
assets, including trade and other receivables. Adoption of this standard did not have a material impact on the Company&#8217;s consolidated
financial statements and related disclosures. As of June 30, 2023 and December 31, 2022, we had a credit loss reserve of $<span id="xdx_90F_eus-gaap--ProvisionForDoubtfulAccounts_pn5n6_c20230101__20230630_zK53gXfBx3ri" title="Provision for doubtful accounts"><span id="xdx_904_eus-gaap--ProvisionForDoubtfulAccounts_pn5n6_c20220101__20221231_zYX0GVuuq9Bf" title="Provision for doubtful accounts"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></ix:nonFraction></span></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Pharma
services revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
recognized include Pharma Services performed by Oncocyte&#8217;s Insight and Chronix subsidiaries for its pharmaceutical customers, including
testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These
Pharma Services are generally performed under individual scope of work (&#8220;SOW&#8221;) arrangements or license agreements (together
with SOW the &#8220;Pharma Services Agreements&#8221;) with specific deliverables defined by the customer. Pharma Services are performed
on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with
a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable
basis) and recognizes Pharma Service revenue at that time. Insight identifies each sale of its Pharma Service offering as a single performance
obligation. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license
agreements with customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
of the service and satisfaction of the performance obligation is typically evidenced by access to the report or test made available to
the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs
under which work is performed pursuant to the customer&#8217;s highly customized specifications, Oncocyte has the enforceable right to
bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period
during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage
of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements,
any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed
to the customer as of the date of Oncocyte&#8217;s condensed consolidated financial statements are recorded as contract assets and are
included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified
to accounts receivable in Oncocyte&#8217;s condensed consolidated financial statements when the customer is invoiced according to the
billing schedule in the contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
establishes credit loss reserve accounts based on the evaluation of the collectability of its Pharma Services accounts receivables after
considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer&#8217;s
ability to pay, such as a bankruptcy filing or deterioration in the customer&#8217;s operating results or financial position, reasonable
and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to
customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections
and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its
historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are
written off against the credit loss reserve accounts. As of June 30, 2023, Oncocyte has not recorded any losses or credit loss reserve
accounts on its account receivables from Pharma Services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, Oncocyte had accounts receivable from Pharma Services customers of $<span id="xdx_901_eus-gaap--AccountsReceivableSale_pn5n6_c20230101__20230630__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_zjG4mfP83gx6" title="Accounts receivable"><ix:nonFraction name="us-gaap:AccountsReceivableSale" contextRef="From2023-01-012023-06-30_custom_PharmaServicesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million, as compared to $<span id="xdx_90A_eus-gaap--AccountsReceivableSale_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_z02GYWvfQmt2" title="Accounts receivable"><ix:nonFraction name="us-gaap:AccountsReceivableSale" contextRef="From2022-01-012022-12-31_custom_PharmaServicesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million as of
December 31, 2022 (see Note 7). As of June 30, 2023 and December 31, 2022, we have not reserved a credit loss reserve for Pharma Services
accounts receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Licensing
revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte&#8217;s proprietary
testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose
of marketing Oncocyte&#8217;s tests within a defined geographic territory. A license agreement may specify milestone deliverables or
performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte&#8217;s performance
obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing
fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and
ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p id="xdx_84E_eus-gaap--CostOfSalesPolicyTextBlock_zxfsZ5sugvq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zgAik2cMrqKd">Cost
of revenues</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and
infrastructure expenses, clinical sample related costs associated with performing DetermaRx tests and Pharma Services, providing deliverables
according to our licensing agreements, license fees due to third parties, and amortization of acquired intangible assets such as the
Razor asset and customer relationship intangible assets. Infrastructure expenses include depreciation of laboratory equipment, allocated
rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte&#8217;s CLIA laboratories in
California and Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless
of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues
generated using the associated technology are recorded as expenses at the time the related revenues are recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_z9VYzThSZKkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zmAQLAXY8zZk">Research
and development expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based
compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure
expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development
expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications,
property taxes, and insurance. Research and development costs are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="OCX:SalesAndMarketingExpensesPolicyTextBlock"><p id="xdx_84C_ecustom--SalesAndMarketingExpensesPolicyTextBlock_zSZzKJiXdkvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zhPOYeNSdVCh">Sales
and marketing expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses,
branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead
allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property
taxes, and insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z9lDskHkVHDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z3870c4zEFu7">General
and administrative expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive
and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property
taxes, and insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zmvDJyck8SM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z6KeBeISQsx6">Net
loss per common share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and
accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. Diluted loss
per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion
of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that
would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted
method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the
computation if their effect is antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zpRphtLnuNF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents
the calculation of basic and diluted loss per share of common stock (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zQpZ5bBe8SVf">Schedule
of Common Stock Computation of Diluted Net Loss Per Share of Common Stock</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230401__20230630_zi6VhUSRhcLf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220401__20220630_z250A9VByK31" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20230630_zZLffxMsbPOe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20220630_zGHbu2Vm7Qw6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossIncludingPortionAttributableToNoncontrollingInterest_zjjvwqg2rtfd" style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Net loss attributable to Oncocyte Corporation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,333</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,300</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,300</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,591</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--DividendOnPreferredStock_zyO5mNeeH4A2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend on Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OCX:DividendOnPreferredStock" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">76</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OCX:DividendOnPreferredStock" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OCX:DividendOnPreferredStock" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">166</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OCX:DividendOnPreferredStock" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--RedeemablePreferredStockDividends_iN_pn3n3_di_zI6LFGQVusXe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RedeemablePreferredStockDividends" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RedeemablePreferredStockDividends" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RedeemablePreferredStockDividends" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">257</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RedeemablePreferredStockDividends" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--DeemedDividendOnPreferredStock_iN_pn3n3_di_zB0jDxh8Nn73" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deemed dividend on Series A redeemable convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:DeemedDividendOnPreferredStock" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:DeemedDividendOnPreferredStock" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_z9ehePWv2Rxk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230401__20230630_zYnUNlYpzbi3" title="Net income (loss) attributable to common stockholders - diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,644</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220401__20220630_z4N0PXtRYJFf" title="Net income (loss) attributable to common stockholders - diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,372</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230630_zllfG01ZWKT6" title="Net income (loss) attributable to common stockholders - diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,841</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220630_zC6uczPfyZx6" title="Net income (loss) attributable to common stockholders - diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,663</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zR1QiUYWycd4" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders - Basic </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,644</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,372</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,841</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,663</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average shares used in computing net loss per share attributable to common stockholders - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230401__20230630_zRFBQSfPOkbi" title="Weighted average number of shares outstanding, basic" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230401__20230630_zsUr2lKy1a2k" title="Weighted average number of shares outstanding, diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,090</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220401__20220630_zLJZeVYaGELj" title="Weighted average number of shares outstanding, basic" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220401__20220630_zSirTTGqB954" title="Weighted average number of shares outstanding, diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,652</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230630_zrwt9ABffUmi" title="Weighted average number of shares outstanding, basic" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230630_zQW8KDSFUm3" title="Weighted average number of shares outstanding, diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,030</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220630_z7b2pwLFNBO9" title="Weighted average number of shares outstanding, basic" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220630_z4eHT6aWOVzk" title="Weighted average number of shares outstanding, diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,135</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EarningsPerShareBasic_pid_z2zA7tJPerI4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--EarningsPerShareDiluted_pid_c20230401__20230630_zjxqFaYQCnb1" title="Earnings Per Share, diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.07</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220401__20220630_z3A48JpK1jNi" title="Earnings Per Share, diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.48</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230630_zsjAZl3ZjXgf" title="Earnings Per Share, diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.83</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220630_z8t0RQsbemKa" title="Earnings Per Share, diluted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.63</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pid_zlGdnrGr1wy3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic  net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.07</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.48</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.83</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.63</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgjK9PEZ67Uf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">483</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">731</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">549</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">657</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zaYmmxPLXS79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfRcuUjnwSP3" style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">820</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012022-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">845</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">820</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zmgQqoSMUupa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Series A redeemable convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012022-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zjFch4FZu3ad" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,315</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,582</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,384</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,508</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zd9x3szxLcDa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,315</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,582</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,384</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,508</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br /></span></p>

</ix:nonNumeric><p id="xdx_8A5_z7z5mTtaPrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zAR2qsO6DnPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_867_z57se08r5Vei">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
accounts for leases in accordance with ASC 842, <i>Leases</i>. Oncocyte determines if an arrangement is a lease at inception. Leases
are classified as either financing or operating, with classification affecting the pattern of expense recognition in the condensed consolidated
statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease
components as a single lease component. Oncocyte recognizes right-of-use (&#8220;ROU&#8221;) assets and lease liabilities for leases
with terms greater than twelve months in the condensed consolidated balance sheet. ROU assets represent the right to use an underlying
asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease
ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most
leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate
the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a
straight-line basis over the lease term. Operating leases are included as right-of-use assets in machinery and equipment, and ROU lease
liabilities, current and long-term, in the condensed consolidated balance sheets. Financing leases are included in machinery and equipment,
and in financing lease liabilities, current and long-term, in the condensed consolidated balance sheets. Oncocyte discloses the amortization
of our ROU assets and operating lease payments as a net amount, &#8220;Amortization of right-of-use assets and liabilities&#8221;, on
the condensed consolidated statements of cash flows. Based on the available practical expedients under the standard, Oncocyte elected
not to capitalize leases that have terms of twelve months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
prior years, Oncocyte entered into various operating leases and an embedded operating lease in accordance with ASC 842 discussed in Note
10. Oncocyte&#8217;s accounting for financing leases remained substantially unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="OCX:AccountingForSharesOfCommonStockPolicyTextBlock"><p id="xdx_84E_ecustom--AccountingForSharesOfCommonStockPolicyTextBlock_zpQoUHH9QS8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_863_zGtUX57eq779">Accounting
for Lineage and AgeX shares of common stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
accounts for the shares of Lineage and AgeX common stock it holds as marketable equity securities in accordance with ASC 320-10-25, <i>Investments
&#8211; Debt and Equity Securities</i>, as amended by Accounting Standards Update (&#8220;ASU&#8221;) 2016-01, <i>Financial Instruments&#8211;Overall:
Recognition and Measurement of Financial Assets and Financial Liabilities</i>, as the shares have a readily determinable fair value quoted
on the NYSE American and are held principally to meet future working capital purposes, as necessary. The securities are measured at fair
value, with related gains and losses in the value of such securities recorded in the condensed consolidated statements of operations
in other income (expense), and are reported as current assets on the condensed consolidated balance sheets based on the closing trading
price of the security as of the date being presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023 and December 31, 2022, Oncocyte held <span id="xdx_903_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20230630__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zEZd0tzlxVGj" title="Common stock, shares held as available for sale securities"><ix:nonFraction name="OCX:CommonStockSharesHeldAsAvailableForSaleSecurities" contextRef="AsOf2023-06-30_custom_LineageAndAgeXMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">353,264</ix:nonFraction></span> and <span id="xdx_90E_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zImG2PjERDme" title="Common stock, shares held as available for sale securities"><ix:nonFraction name="OCX:CommonStockSharesHeldAsAvailableForSaleSecurities" contextRef="AsOf2022-12-31_custom_LineageAndAgeXMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,326</ix:nonFraction></span> shares of common stock of Lineage and AgeX, respectively, as
marketable equity securities had a combined fair market value of $<span id="xdx_904_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20230630__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zLN7EUyPGDPl" title="Fair value of equity securities"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="AsOf2023-06-30_custom_LineageAndAgeXMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.5</ix:nonFraction></span> million and $<span id="xdx_901_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zztEm86lPzuh" title="Fair value of equity securities"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="AsOf2022-12-31_custom_LineageAndAgeXMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zj4d3sWVNN3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_867_zX90kLV5ULI3">Recent
accounting pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13,
<i>Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> and subsequent amendments
to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit
losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a
valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets,
which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent
changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Previously, U.S. GAAP
required entities to write down credit losses only when losses are probable and loss reversals are not permitted. The Company adopted
this ASU in the first quarter of 2023. Adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial
statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): <i>Accounting for Contract Assets and Contract Liabilities
from Contracts with Customers,</i> to provide specific guidance to eliminate diversity in practice on how to recognize and measure acquired
contract assets and contract liabilities from revenue contracts from customers in a business combination consistent with revenue contracts
with customers not acquired in an acquisition. The amendments in this update provide that the acquirer should consider the terms of the
acquired contracts, such as timing of payment, identify each performance obligation in the contracts, and allocate the total transaction
price to each identified performance obligation on a relative standalone selling price basis as of contract inception (that is, the date
the acquiree entered into the contracts) or contract modification to determine what should be recorded at the acquisition date. These
amendments are effective for the Company beginning with fiscal year 2023. The impact of the adoption of the amendments in this update
will depend on the magnitude of any customer contracts assumed in a business combination in 2023 and beyond.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_804_eus-gaap--BusinessCombinationDisclosureTextBlock_zT8FqY89fnt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>3.
<span id="xdx_82A_z2eG6KiFBee2">Business Combinations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Acquisition
of Insight Genetics, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
January 31, 2020 (the &#8220;Insight Merger Date&#8221;), Oncocyte completed its acquisition of Insight pursuant to the Insight Merger
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Contingent
consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future
if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration
also includes additional future payments to selling shareholders based on achievement of components of earnings, such as &#8220;earn-out&#8221;
provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of revenues generated
from DetermaIO and Insight Pharma Services over their respective useful life. Accordingly, Oncocyte determined there are two types
of contingent consideration in connection with the Insight Merger, the Milestone Contingent Consideration and the Royalty Contingent
Consideration discussed below, which are collectively referred to as the &#8220;Contingent Consideration&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">There
are three milestones comprising the Milestone Contingent Consideration, collectively referred to as the Milestones, in connection with
the Insight Merger which Oncocyte valued and recorded as part of Contingent Consideration as of the Insight Merger Date (see table below),
which consist of (i) a payment for clinical trial completion and related data publication (&#8220;Milestone 1&#8221;), (ii) a payment
for an affirmative final local coverage determination from CMS for a specified lung cancer test (&#8220;Milestone 2&#8221;), and (iii)
a payment for achieving specified CMS reimbursement milestones (&#8220;Milestone 3&#8221;). If achieved, any respective Milestone will
be paid at the contractual value shown below, with the payment made either in cash or in shares of Oncocyte common stock as determined
by Oncocyte. There can be no assurance that any of the Milestones will be achieved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zr62CmVli4Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective
Contingent Consideration liability (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zXLzQ9fEPZy1" style="display: none">Schedule
of Fair Value of Contingent Consideration Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Fair</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Contractual</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Value on the</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Merger Date</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black">Milestone 1</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_988_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_zW5aIZGI60W8" title="Contractual Value" style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="OCX:ContingentConsiderationLiabilityContractualValue" contextRef="AsOf2023-06-30_custom_MilestoneOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_z6iz8Hc5EKF7" title="Fair Value on the Merger Date" style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-06-30_custom_MilestoneOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,340</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Milestone 2</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_z8AAqFL8bsy" title="Contractual Value" style="color: Black; text-align: right"><ix:nonFraction name="OCX:ContingentConsiderationLiabilityContractualValue" contextRef="AsOf2023-06-30_custom_MilestoneTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_zGhydEVa15pg" title="Fair Value on the Merger Date" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-06-30_custom_MilestoneTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,830</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Milestone 3 <sup id="xdx_F45_zVGjZGh31Un2">(a)</sup></span></td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_zpWwOxo6gMld" title="Contractual Value" style="color: Black; text-align: right"><ix:nonFraction name="OCX:ContingentConsiderationLiabilityContractualValue" contextRef="AsOf2023-06-30_custom_MilestoneThreeMember" id="Fact001176" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_z2cZ4qX0fw0e" title="Fair Value on the Merger Date" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-06-30_custom_MilestoneThreeMember" id="Fact001178" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">770</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Royalty 1 <sup id="xdx_F44_zb4wasIRrhe5">(b)</sup></span></td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See(b) </span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyOneMember_fKGIp_zVn3EkJpMAO8" title="Fair Value on the Merger Date" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-06-30_custom_RoyaltyOneMember" id="Fact001180" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,980</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Royalty 2 <sup id="xdx_F4D_zwRw9dSDKHw7">(b)</sup></span></td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See(b) </span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyTwoMember_fKGIp_zhj5TRoXpMWk" title="Fair Value on the Merger Date" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-06-30_custom_RoyaltyTwoMember" id="Fact001182" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630_zDaGfAJD9Rda" title="Contractual Value" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="OCX:ContingentConsiderationLiabilityContractualValue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630_zwyBT5L1AwFi" title="Fair Value on the Merger Date" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,130</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><sup id="xdx_F01_zb2eceMRkTc3">(a)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_znT1wWChX9nd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><ix:footnote id="Footnote001187" xml:lang="en-US">Indicates
    the maximum payable if the Milestone is achieved.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><sup id="xdx_F04_zTzRw6bHRPqj">(b)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zcX7SCTMlHB4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><ix:footnote id="Footnote001188" xml:lang="en-US">As
    defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful
    life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_z3k9HRBwMhfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of the Contingent Consideration after the Insight Merger Date is reassessed by Oncocyte as changes in circumstances and conditions
occur, with the subsequent change in fair value recorded in Oncocyte&#8217;s condensed consolidated statements of operations. As of June
30, 2023, based on Oncocyte&#8217;s reassessment of the significant assumptions noted above, there was a decrease of approximately $<span id="xdx_905_ecustom--FairValueOfContingentConsideration_pn5n6_c20230101__20230630_zhtxecgaS3I1" title="Fair value of contingent consideration"><ix:nonFraction name="OCX:FairValueOfContingentConsideration" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span>
million to the fair value of the Contingent Consideration primarily attributable to revised estimates of the timing of the possible future
payouts and, accordingly, this decrease was recorded as change in fair value of contingent consideration in the unaudited condensed consolidated
statements of operations for the six months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-06-30_custom_InsightMergerMember" escape="true" name="OCX:ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zNbFLAlRDEJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following tables reflect the activity for Oncocyte&#8217;s Contingent Consideration for the six months ended June 30, 2023 and 2022,
measured at fair value using Level 3 inputs (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_zWcmSODB5ZF3" style="display: none">Schedule
of Contingent Consideration, Measured at Fair Value</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; color: Black">Balance at December 31, 2021</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zHLOuhwRwX1l" title="Beginning balance" style="width: 16%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,060</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zkpPhq7UfiGc" title="Change in estimated fair value" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="OCX:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" contextRef="From2022-01-012022-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 2.5pt">Balance at June 30, 2022</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zR1ZhP0Pwvu6" title="Beginning balance" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2022-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,460</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; color: Black">Balance at December 31, 2022</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_z7klqkL6XAlf" title="Beginning balance" style="width: 16%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,370</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zhgZfEG7nRY6" title="Change in estimated fair value" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="OCX:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" contextRef="From2023-01-012023-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 2.5pt">Balance at June 30, 2023</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zhyHgOLlU4r9" title="Beginning balance" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,870</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zqVr8LkLaasi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Contingent
consideration is not deductible for tax purposes, even if paid; therefore, no deferred tax assets related to the Contingent Consideration
were recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Asset
acquisition of Razor Genomics, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
February 24, 2021, Oncocyte completed the purchase of all the issued and outstanding shares of common stock of Razor. As a result of
Oncocyte is the sole shareholder of Razor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
December 15, 2022, the Company entered into a Stock Purchase Agreement in which the Company agreed to sell approximately <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221215__dei--LegalEntityAxis__custom--RazorGenomicsIncMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zsP8901u4iSa" title="Outstanding equity"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-15_custom_RazorGenomicsIncMember_custom_OncocyteCorpMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>% of the issued
and outstanding equity interest of Razor on a fully-diluted basis. On February 16, 2023, the sale of Razor was completed. <span style="background-color: white">See
Note 16 for additional information.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span style="text-decoration: underline">Development
Agreement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On December 31, 2019, in connection with Oncocyte&#8217;s purchase <span style="background-color: white">of&#160;<span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20191231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_z7YXMzqjlYsl" title="Outstanding equity"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2019-12-31_custom_DevelopmentAgreementMember_custom_OncocyteCorpMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%
of the outstanding equity of Razor,</span> Oncocyte entered into a Development Agreement with Razor and Encore Clinical, Inc. (&#8220;Encore&#8221;),
a former stockholder of Razor (the &#8220;Development Agreement&#8221;). Under
the Development Agreement, Razor reserved as a &#8220;Clinical Trial Expense Reserve&#8221; $<span id="xdx_908_ecustom--ClinicalTrialExpenseReserveAmount_iI_pn5n6_c20230630__us-gaap--TypeOfArrangementAxis__custom--DevelopmentAgreementMember__dei--LegalEntityAxis__custom--RazorGenomicsIncMember_z46ZfEP6wgPf" title="Clinical trial expense reserve amount"><ix:nonFraction name="OCX:ClinicalTrialExpenseReserveAmount" contextRef="AsOf2023-06-30_custom_DevelopmentAgreementMember_custom_RazorGenomicsIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span> million of the proceeds it received
at the Initial Closing from the sale of the Razor Preferred Stock to Oncocyte, to fund Razor&#8217;s share of costs incurred in connection
with a clinical trial of DetermaRx for purposes of promoting commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The
Development Agreement was terminated on February 16, 2023 in connection with the Razor Stock Purchase Agreement. See Note 16 for more
details regarding the Razor Stock Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span style="text-decoration: underline">Sublicense
Agreement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On December 31, 2019, in connection with Oncocyte&#8217;s purchase <span style="background-color: white">of&#160;<span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20191231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zW1qK9xIv1H1" title="Outstanding equity"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2019-12-31_custom_SublicenseAgreementMember_custom_OncocyteCorpMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%
of the outstanding equity of Razor,</span> Oncocyte entered into a Sublicense and Distribution Agreement with Razor and Encore Clinical,
Inc. (&#8220;Encore&#8221;), a former stockholder of Razor (the &#8220;Sublicense Agreement&#8221;). Under
the Sublicense Agreement, Razor granted to Oncocyte an exclusive worldwide sublicense under certain patent rights applicable to DetermaRx
in the field of use covered by the applicable license held by Razor for purposes of commercialization and development of DetermaRx.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Sublicense Agreement was terminated on February 16, 2023 in connection with the Razor Stock Purchase Agreement. See Notes 16 for more
details regarding the Razor Stock Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Acquisition
of Chronix Biomedical, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 15, 2021 (the &#8220;Chronix Merger Date&#8221;), Oncocyte completed its acquisition of Chronix pursuant the Chronix Merger Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span style="text-decoration: underline">Contingent
Consideration</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
additional consideration for holders of certain classes and series of Chronix capital stock, the Chronix Merger Agreement originally
required Oncocyte to pay &#8220;Chronix Contingent Consideration&#8221; consisting of (i) &#8220;Chronix Milestone Payments&#8221; of
up to $<span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferred1_pn6n6_c20210414__20210415__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixBiomedicalIncMember_zO1hMYSvrZ25" title="Business combination consideration transferred"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2021-04-142021-04-15_srt_MaximumMember_custom_MergerAgreementMember_custom_ChronixBiomedicalIncMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">14</ix:nonFraction></span> million in any combination of cash or Oncocyte common stock if certain milestones specified in the Chronix Merger Agreement
are achieved, (ii) &#8220;Royalty Payments&#8221; of up to <span id="xdx_906_ecustom--EarnoutPercentageOnCollectionsForSales_pid_dp_uPure_c20210414__20210415__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixBiomedicalIncMember_zOT7846rt91k" title="Earnout percentage on collections for sales"><ix:nonFraction name="OCX:EarnoutPercentageOnCollectionsForSales" contextRef="From2021-04-142021-04-15_srt_MaximumMember_custom_MergerAgreementMember_custom_ChronixBiomedicalIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% of net collections for sales of specified tests and products during the
five-to-ten year earnout periods, and (iii) &#8220;Transplant Sale Payments&#8221; of up to <span id="xdx_905_ecustom--EarnoutPercentageOnCollectionsForSaleOrLicense_pid_dp_uPure_c20210414__20210415__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixBiomedicalIncMember_z5bWiy7suAq1" title="Earnout percentage on collections for sale or license"><ix:nonFraction name="OCX:EarnoutPercentageOnCollectionsForSaleOrLicense" contextRef="From2021-04-142021-04-15_srt_MaximumMember_custom_MergerAgreementMember_custom_ChronixBiomedicalIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span>% of net collections from the sale or license
to a third party of Chronix&#8217;s patents for use in transplantation medicine during a seven-year earnout period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
February 8, 2023, the Company and equity holder representative entered into Amendment No. 1 to the Merger Agreement (the
&#8220;Chronix Amendment&#8221;), pursuant to which the parties agreed that (i) Chronix&#8217;s equity holders will be paid earnout
consideration of <span id="xdx_90D_ecustom--EarnoutPercentageOnCollectionsForSales_pid_dp_uPure_c20230207__20230208__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixEquityMember_zA8dt6e3Sn08" title="Earnout percentage on collections for sales"><ix:nonFraction name="OCX:EarnoutPercentageOnCollectionsForSales" contextRef="From2023-02-072023-02-08_custom_MergerAgreementMember_custom_ChronixEquityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
of net collections for sales of specified tests and products, until the expiration of intellectual property related to such tests
and products, (ii) Chronix&#8217;s equity holders will be paid <span id="xdx_90C_ecustom--EarnoutPercentageOnCollectionsForSale_pid_dp_uPure_c20230207__20230208__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixEquityMember_z4BAgvEqkP82" title="Gross proceeds percentage"><ix:nonFraction name="OCX:EarnoutPercentageOnCollectionsForSale" contextRef="From2023-02-072023-02-08_custom_MergerAgreementMember_custom_ChronixEquityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%
of the gross proceeds received from any sale of all or substantially all of the rights, titles, and interests in and to
Chronix&#8217;s patents for use in transplantation medicine to such third party, and (iii) the Chronix Milestone Payments, <span id="xdx_901_ecustom--RoyaltyPaymentsPercentage_pid_dp_uPure_c20230207__20230208__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixMilestoneMember_zAkyMSYsWqmj" title="Royalty payments"><ix:nonFraction name="OCX:RoyaltyPaymentsPercentage" contextRef="From2023-02-072023-02-08_custom_MergerAgreementMember_custom_ChronixMilestoneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>%
Royalty Payments and Transplant Sale Payment obligations were eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of the Chronix Contingent Consideration after the Chronix Merger Date is reassessed by Oncocyte as changes in circumstances
and conditions occur, with the subsequent change in fair value recorded in Oncocyte&#8217;s condensed consolidated statements of operations.
As of June 30, 2023, based on Oncocyte&#8217;s reassessment of the significant assumptions noted above, there was a decrease of approximately
$<span id="xdx_908_ecustom--FairValueOfContingentConsideration_pn5n6_c20230101__20230630__dei--LegalEntityAxis__custom--ChronixMember_z85PzHMf9Se6" title="Fair value"><ix:nonFraction name="OCX:FairValueOfContingentConsideration" contextRef="From2023-01-012023-06-30_custom_ChronixMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">14.0</ix:nonFraction></span> million to the fair value of the Contingent Consideration primarily attributable to revised estimates of the timing of the possible
future payouts and, accordingly, this decrease was recorded as a change in fair value of contingent consideration in the unaudited condensed
consolidated statements of operations for the six months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-06-30_custom_ChronixMergerMember" escape="true" name="OCX:ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zVFsHijgf9R1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following tables reflect the activity for Oncocyte&#8217;s Contingent Consideration for the six months ended June 30, 2023 and June 30,
2022, measured at fair value using Level 3 inputs (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zryJ7Rbu1YH5" style="display: none">Schedule
of Contingent Consideration, Measured at Fair Value</span><span style="color: Black">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; color: Black">Balance at December 31, 2021</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_z5g0QnsIAr39" title="Beginning balance" style="width: 16%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69,621</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_989_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_znlqDc29oDY2" title="Change in estimated fair value" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="OCX:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" contextRef="From2022-01-012022-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,415</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 2.5pt">Balance at June 30, 2022</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zePuBAVIo0X9" title="Ending balance" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2022-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,206</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Fair
    Value</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Balance
    at December 31, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</span></td>
    <td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zq0O6vjV7D09" title="Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,292</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Change
    in estimated fair value</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td id="xdx_988_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_z7lb0Qit2Vxh" title="Change in estimated fair value" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(<ix:nonFraction name="OCX:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" contextRef="From2023-01-012023-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,012</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Balance
    at June 30, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</span></td>
    <td id="xdx_983_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zAxmVVnZ6Z6a" title="Ending balance" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,280</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_zvgtJJ4Jw9Hb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Goodwill
</i>- Goodwill is calculated as the difference between the acquisition date fair value of the Aggregate Chronix Merger Consideration
transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill also includes the $<span id="xdx_90B_eus-gaap--DeferredTaxLiabilities_iI_pn5n6_c20230630__us-gaap--BusinessAcquisitionAxis__custom--ChronixBiomedicalIncMember_zVzw2sOKdUF9" title="Net deferred tax liabilities"><ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2023-06-30_custom_ChronixBiomedicalIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.2</ix:nonFraction></span> million of net deferred
tax liabilities recorded principally related to the VitaGraft discussed above. Oncocyte recognized approximately $<span id="xdx_902_eus-gaap--Goodwill_iI_pn5n6_c20230630__us-gaap--BusinessAcquisitionAxis__custom--ChronixBiomedicalIncMember_zPFqHQEpzNo5" title="Goodwill"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-06-30_custom_ChronixBiomedicalIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.5</ix:nonFraction></span> million of goodwill
related to the Chronix acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">None
of the goodwill recognized is expected to be deductible for income tax purposes. Goodwill is not amortized but is tested for impairment
at least annually, or more frequently if circumstances indicate potential impairment. During 2022, the Company identified circumstances
that could indicate a potential impairment and after a valuation of the Company&#8217;s assets and liabilities was performed, management
concluded that goodwill was impaired as of December 31, 2022. (see Notes 2 and 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_zggyCJUTfJp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>4.
<span id="xdx_825_zq1y9iRbkQpd">Intangible Assets, net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
part of the Insight and Chronix acquisitions, which were accounted for as business combinations under ASC 805, completed
on January 31, 2020, and April 15, 2021, respectively, the Company has acquired in process research and development (&#8220;IPR&amp;D&#8221;)
and customer relationships.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the first quarter of 2023, due to changes in management and the economic condition of the Company, management shifted the Company&#8217;s
business strategy to direct efforts on fewer studies and to transition from test that are laboratory developed tests (&#8220;LDT&#8221;)
to research use only (&#8220;RUO&#8221;) sales. Due to the change in strategy, the Company&#8217;s long range plan forecasts were updated
and anticipated future benefits derived from the Company&#8217;s assets. The change in strategy represent a significant indicator for
change in value of the Company&#8217;s long lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
original IPR&amp;D balance was reassessed based on the updated long range plan (&#8220;LRP&#8221;), using the multiple period excess
earnings method (&#8220;MPEEM&#8221;) approach, the results of the valuation noted that the carrying value of the DetermaIO related IPR&amp;D
intangible assets was greater than the fair market value, whereas the CNI and VitaGraft related IPR&amp;D intangible assets carrying
value was lower than the fair market value. Accordingly, the Company recorded an impairment of approximately $<span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn5n6_c20230101__20230630_zY7zfMhJclk5" title="Impairment of intangible"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zkuWtg5fnVwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">At
June 30, 2023 and December 31, 2022, intangible assets, net, consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BF_z1ntElUJtXUf" style="display: none">Schedule
of Goodwill and Intangible Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Intangible assets:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Acquired IPR&amp;D - DetermaIO <sup id="xdx_F45_z50d1JgML9p8">(1)</sup></span></td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230630__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zd0UJXxJJbn6" title="Intangible assets acquired IPR&amp;D" style="width: 16%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" contextRef="From2023-01-012023-06-30_custom_DetermaIOMember" id="Fact001252" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,700</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zX4pGhgdrW7e" title="Intangible assets acquired IPR&amp;D" style="width: 16%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" contextRef="From2022-01-012022-12-31_custom_DetermaIOMember" id="Fact001254" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,650</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Acquired IPR&amp;D - DetermaCNI and VitaGraft <sup id="xdx_F4B_zbFL00dbpQ5">(2)</sup></span></td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230630__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zCGNkZococe" title="Intangible assets acquired IPR&amp;D" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" contextRef="From2023-01-012023-06-30_custom_DetermaCNIAndVitaGraftMember" id="Fact001256" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,800</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zOz5SV12oK97" title="Intangible assets acquired IPR&amp;D" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" contextRef="From2022-01-012022-12-31_custom_DetermaCNIAndVitaGraftMember" id="Fact001258" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46,800</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Intangible assets subject to amortization:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Acquired intangible assets - customer relationship</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpvNVGqMyt49" title="Acquired intangible assets" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue" contextRef="AsOf2023-06-30_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z00ckkSXCPCf" title="Acquired intangible assets" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue" contextRef="AsOf2022-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Total intangible assets</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20230630_zJ75ddvYgyFg" title="Total intangible assets" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56,940</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20221231_z8PLkXFu9Whe" title="Total intangible assets" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61,890</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accumulated amortization - customer relationship<sup id="xdx_F41_zz21ALezTe4j">(3)</sup></span></td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zwOyH1flKbod" title="Finite-lived intangible assets, accumulated amortization" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-06-30_us-gaap_CustomerRelationshipsMember" id="Fact001268" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">301</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zBfDr8zMLMJe" title="Finite-lived intangible assets, accumulated amortization" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31_us-gaap_CustomerRelationshipsMember" id="Fact001270" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">257</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20230630_zXvCCFA7Cwjb" title="Intangible assets, net" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">56,639</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20221231_zAFMNxxZ9SLk" title="Intangible assets, net" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61,633</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zb3i25T8jMbd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zM4dTMPHLKd2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><ix:footnote id="Footnote001275" xml:lang="en-US">See
    Note 3 for information on the Insight Merger.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0A_zf1xpeCdv4Nh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_z4MzpgPX1bUl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><ix:footnote id="Footnote001276" xml:lang="en-US">See
    Note 3 for information on the Chronix Merger.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0E_z4YcBThmyYY4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zrznRYC4dSy1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><ix:footnote id="Footnote001277" xml:lang="en-US">Amortization
    of intangible assets is included in &#8220;Cost of revenues &#8211; amortization of acquired intangibles&#8221; on the condensed
    consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired
    intangibles.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A7_zYTeDvFxU5vj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zlmAtQRW29pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Future
amortization expense of intangible assets subject to amortization is expected to be the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zNjId23XsWCd" style="display: none">Schedule
of Intangible Assets Future Amortization Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230630_zy6ik692tCF7" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Amortization</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Year ending December 31,</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzyWn_z0zj0iJZHfg7" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; color: Black; text-align: left">2023</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 16%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzyWn_zc1zdTU4h8Q6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">2024</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">88</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzyWn_zoSArfeed3Wk" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">2025</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzyWn_z2O6eEIFz0Hc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zx5jEpHcdZF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwdQQ4cBeOQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>5.
<span id="xdx_824_zvW4mSQ9OOqb">Shareholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Series
A Redeemable Convertible Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 13, 2022, the Company entered into the Securities Purchase Agreement with the Investors in a registered direct offering of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_z2KvzPhwOX69" title="Offering shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,765</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">shares of the Company&#8217;s Series
A Preferred Stock, which shares of Series A Preferred Stock are convertible into a total of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znxyqV2Hvvf5" title="Convertible preferred shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">384,477</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">shares of common stock, at a conversion
price of $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTzhSUeLZoW8" title="Conversion price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.60</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.
The purchase price of each share of Series A Preferred Stock was $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zn4bkusr0hO" title="Preferred stock offering"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">850</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">,
which included an original issue discount to the stated value of $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDOVOEDpAFr6" title="Stated value per share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">per share. The rights, preferences
and privileges of the Series A Preferred Stock are set forth in the Company&#8217;s Certificate of Determination, which the Company filed
with the Secretary of State of the State of California. The Securities Purchase Agreement provides that the closing of the Series A Preferred
Stock Offering will occur, subject to the satisfaction of certain closing conditions, in two equal tranches of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zaTYO1W8Drqb" title="Preferred stock offering"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">each for aggregate gross proceeds
from both closings of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zozNK6Oxl05j" title="Gross proceeds, closing"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.
The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zj8MiLmaxZ9h" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.9</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">million from the Series A Preferred
Stock issued from the first tranche. The second closing would occur, subject to the satisfaction of certain closing conditions (including
but not limited to a requirement that the Company has not received, in the 12 months preceding the second closing, a notice from Nasdaq
that the Company is not in compliance with the listing and maintenance and listing requirements of Nasdaq), on the earlier of (a) the
second trading day following the date that Oncocyte receives notice from an Investor to accelerate the second closing and (b) a date
selected by Oncocyte on or after October 8, 2022 and on or prior to March 8, 2023. On August 9, 2022, Oncocyte received a letter from
Nasdaq indicating that the Company no longer met the minimum bid price requirement of the Nasdaq continued
listing requirements. Accordingly, the second closing did not occur and no additional proceed</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s
were received under the Securities Purchase Agreement. On August 8, 2023, the Company received a letter from Nasdaq indicating that
the Company had regained compliance with the minimum bid price requirement of the Nasdaq continued listing requirements. See Note 15 for additional
information about the Series A Preferred Stock Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Series A Preferred Stock is convertible into shares of the Company&#8217;s common stock at any time at the holder&#8217;s option. The
conversion price will be subject to customary anti-dilution adjustments for matters such as stock splits, stock dividends and other distributions
on our common stock, and recapitalizations. <span id="xdx_90C_eus-gaap--ConversionOfStockDescription_c20230101__20230630_zRjjaUnk7bPi" title="Conversion of stock, description"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" name="us-gaap:ConversionOfStockDescription">A holder is prohibited from converting shares of Series A Preferred Stock into shares of
common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of
our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership
limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to
the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect
to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer
apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)</ix:nonNumeric></span>. On July
15, 2022, the Company received such shareholder approval to remove the beneficial ownership limitation with respect to the Series A Preferred
Stock held by Broadwood. The Company may force the conversion of up to one-third of the shares of Series A Preferred Stock
originally issued, subject to customary equity conditions, <span id="xdx_905_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_z9KKBKFKc825" title="Equity method investment, description of principal activities"><ix:nonNumeric contextRef="From2023-01-012023-06-30_us-gaap_SeriesAPreferredStockMember_custom_OncocyteCorpMember" name="us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities">if the daily volume weighted average price of our common stock for 20 out
of 30 trading days exceeds <span id="xdx_90E_ecustom--ConversionPricePercentage_dp_uPure_c20220714__20220715_zxCCzDgJI6El"><ix:nonFraction name="OCX:ConversionPricePercentage" contextRef="From2022-07-142022-07-15" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">140</ix:nonFraction></span>% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or
exceeds 20,000 shares of our common stock</ix:nonNumeric></span>. The Company may only effect one forced conversion during any 30-trading day period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
the event of the Company&#8217;s liquidation, dissolution, or winding up, holders of Series A Preferred Stock will receive a payment
equal to the stated value of the Series A Preferred Stock plus accrued but unpaid dividends and any other amounts that may have become
payable on the Series A Preferred Stock due to any failure or delay that may have occurred in issuing shares of common stock upon conversion
of a portion of the Series A Preferred Stock, before any distribution or payment to the holders of common stock or any of our other junior
equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
of Series A Preferred Stock generally have no voting rights, except as required by law and except that the consent of holders of
a majority of the outstanding Series A Preferred Stock will be required to amend any provision of our certificate of incorporation that
would have a materially adverse effect on the rights of the holders of the Series A Preferred Stock. Additionally, as long as any shares
of Series A Preferred Stock remain outstanding, unless the holders of at least <span id="xdx_90D_ecustom--PreferredStockRemainsOutstandingPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_za9Qp0Q7e1k9" title="Preferred stock outstanding percentage"><ix:nonFraction name="OCX:PreferredStockRemainsOutstandingPercentage" contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">51</ix:nonFraction></span>% of the then outstanding shares of Series A Preferred
Stock shall have otherwise given prior written consent, we, on a consolidated basis with our subsidiaries, are not permitted to (1) have
less than $<span id="xdx_900_eus-gaap--Cash_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z6Hicb4W9sEe" title="Cash in hand"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">8</ix:nonFraction></span> million of unrestricted, unencumbered cash on hand (&#8220;Cash Minimum Requirement&#8221;); (2) other than certain permitted
indebtedness, incur indebtedness to the extent that our aggregate indebtedness exceeds $<span id="xdx_90B_ecustom--IndebtednessExpenses_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zcU48xM07Lgf" title="Indebtedness expenses"><ix:nonFraction name="OCX:IndebtednessExpenses" contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">15</ix:nonFraction></span> million; (3) enter into any agreement (including
any indenture, credit agreement or other debt instrument) that by its terms prohibits, prevents, or otherwise limits our ability to pay
dividends on, or redeem, the Series A Preferred Stock in accordance with the terms of the Certificate of Determination; or (4) authorize
or issue any class or series of preferred stock or other capital stock of the Company that ranks senior or pari passu with the Series
A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
of Series A Preferred Stock are entitled to receive cumulative dividends at a rate per share (as a percentage of stated value) of
<span id="xdx_907_ecustom--DividendsRatePerPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zixFccYnMMWg" title="Dividends rate"><ix:nonFraction name="OCX:DividendsRatePerPercentage" contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% per annum, payable quarterly in cash or, at our option, by accreting such dividends to the stated value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company is required to redeem, for cash, the shares of Series A Preferred Stock on the earlier to occur of (1) April 8, 2024, (2) the
commencement of certain a voluntary or involuntary bankruptcy, receivership, or similar proceedings against the Company or its assets,
(3) a Change of Control Transaction (as defined herein) and (4) at the election and upon notice of <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InterestMember_zPuZLzD3uCua" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_PreferredStockMember_custom_InterestMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">51</ix:nonFraction></span>% in interest of the holders, if
the Company fails to meet the Cash Minimum Requirement. A &#8220;Change of Control Transaction&#8221; means the occurrence of any of
(a) an acquisition by an individual or legal entity or &#8220;group&#8221; (as described in Rule 13d-5(b)(1) promulgated under the Exchange
Act) of effective control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of
in excess of <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_z8VqlYAtzo6l" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_PreferredStockMember_custom_OncocyteCorpMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the voting securities of the Company (other than by means of conversion of Series A Preferred Stock), (b) the Company
merges into or consolidates with any other person, or any person merges into or consolidates with the Company and, after giving effect
to such transaction, the stockholders of the Company immediately prior to such transaction own less than <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SecurityMember_zhOynCNCprej" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_PreferredStockMember_custom_SecurityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the aggregate voting
power of the Company or the successor entity of such transaction, or (c) the Company sells or transfers all or substantially all of its
assets to another person. Additionally, the Company has the right to redeem the Series A Preferred Stock for cash upon 30 days prior
notice to the holders; provided if the Company undertakes a capital raise in connection with such redemption, the Investors will have
the right to participate in such financing. On April 5, 2023, the Company redeemed <span id="xdx_901_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230404__20230405__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7yo2bp0iT44" title="Number of stock redeem"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2023-04-042023-04-05_custom_RegisteredDirectOfferingMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,064</ix:nonFraction></span> shares of the Series A Preferred Stock for approximately
$<span id="xdx_908_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230404__20230405__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkkVV88XsEX1" title="Number of stock redeem value"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-042023-04-05_custom_RegisteredDirectOfferingMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023, Oncocyte had <span id="xdx_901_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z4mv9Ns6Z9Di" title="Temporary equity, shares issued"><span id="xdx_90D_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zujHw6qI6Ae3" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,818</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding. The future right or obligation associated with the Series A Preferred
Stock to be issued in the second closing was written off in the prior year since the second closing was not completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Common
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023 and December 31, 2022, Oncocyte has <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3pP1GE86ex9" title="Common stock, shares authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zple5sn9d7X" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">230,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock, <span id="xdx_908_eus-gaap--PreferredStockNoParValue_iI_pid_do_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPVLfI1kcjD4" title="Preferred stock no par value"><span id="xdx_90D_eus-gaap--PreferredStockNoParValue_iI_pid_do_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQB8MzRWlm77" title="Preferred stock no par value"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="USDPShares">no</ix:nonFraction></ix:nonFraction></span></span>-par value, authorized. As of June 30, 2023
and December 31, 2022, Oncocyte had <span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230630_zB17FF9GO6rd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,240,928</ix:nonFraction></span> and <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zogPhqe0kEjb" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,932,191</ix:nonFraction></span> shares of common stock issued and outstanding, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Common
Stock Purchase Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023, Oncocyte had an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630_zswm8m17NPy7" title="Number of common stock purchase warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">819,767</ix:nonFraction></span> common stock purchase warrants issued and outstanding with exercise prices ranging
from $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__srt--RangeAxis__srt--MinimumMember_zJkBB6TPrWg9" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.60</ix:nonFraction></span> to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__srt--RangeAxis__srt--MaximumMember_zEGob5kqrAzd" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">109.20</ix:nonFraction></span> per warrant. The warrants will expire on various dates ranging from February 2024 to October 2029. Certain warrants
have &#8220;cashless exercise&#8221; provisions meaning that the value of a portion of warrant shares may be used to pay the exercise
price rather than payment in cash, which may be exercised under any circumstances in the case of the 2017 Bank Warrants and 2019 Bank
Warrants or, in the case of certain other warrants, only if a registration statement for the warrants and underlying shares of common
stock is not effective under the Securities Act or a prospectus in the registration statement is not available for the issuance of shares
upon the exercise of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
has considered the guidance in ASC 815-40, <i>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in,
a Company&#8217;s Own Stock, </i>which states that contracts that require or may require the issuer to settle the contract for cash are
liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement
feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement
for transactions outside of the company&#8217;s control and, in which the form of consideration to the warrant holder may not be the
same as to all other shareholders in connection with the transaction. However, if a transaction is not within the company&#8217;s control
but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders
in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification
criteria are met. Based on the above guidance and, among other factors, the fact that the warrants cannot be cash settled under any circumstance
but require share settlement, all of the outstanding warrants meet the equity classification criteria and have been classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zJsOujnmJlCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>6.
<span id="xdx_82B_ztPRACyljOu8">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
had a 2010 Stock Option Plan (the &#8220;2010 Plan&#8221;) under which <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenStockOptionPlanMember_zRifiA3HRJE8" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2023-06-30_custom_TwoThousandTenStockOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">260,000</ix:nonFraction></span> shares of common stock were authorized for the grant of
stock options or the sale of restricted stock. On August 27, 2018, Oncocyte shareholders approved a new Equity Incentive Plan (the &#8220;2018
Incentive Plan&#8221;) to replace the 2010 Plan. In adopting the 2018 Incentive Plan, Oncocyte terminated the 2010 Plan and will not
grant any additional stock options or sell any stock under restricted stock purchase agreements under the 2010 Plan; however, stock options
issued under the 2010 Plan will continue in effect in accordance with their terms and the terms of the 2010 Plan until the exercise or
expiration of the individual options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2022, the Company awarded executive share-based payment awards under the 2018 Plan to certain executive officers
and employees with time-based, market-based and performance-based vesting conditions (&#8220;2022 equity awards&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of the 2022 equity awards with performance-based vesting condition was estimated using the Black-Scholes option-pricing model
assuming that performance goals will be achieved. If such performance conditions are not met, no compensation cost is recognized and
any recognized compensation cost is reversed. The probability of 2022 equity awards performance-based vesting conditions will be evaluated
each reporting period and the Company will true-up the amount of cumulative cost recognized for the 2022 performance-based awards at
each reporting period based on the most up-to-date probability estimates. The Company will recognize the compensation expense for 2022
performance-based awards expected to vest on a straight-line basis over the respective service period for each separately vesting tranche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of the 2022 equity awards with market-based vesting condition was estimated using the Monte Carlo simulation model. Assumptions
and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated
period to achievement of the performance and market conditions, which are subject to the achievement of the market-based goals established
by the Company and the continued employment of the participant. These awards vest only to the extent that the market-based conditions
are satisfied as specified in the vesting conditions. Unlike the performance-based awards, the grant date fair value and associated compensation
cost of the market-based awards reflect the probability of the market condition being achieved, and the Company will recognize this compensation
cost regardless of the actual achievement of the market condition. Assumptions utilized in connection with the Monte Carlo valuation
technique included: estimated risk-free interest rate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zPyhBbWkC0E1" title="Risk-free interest rates"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-06-30_custom_MonteCarloValuationTechniqueMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.0</ix:nonFraction></span> percent; term of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zV8FMPrYlugj" title="Expected life (in years)"><ix:nonNumeric contextRef="From2023-01-012023-06-30_custom_MonteCarloValuationTechniqueMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.8</ix:nonNumeric></span> years; expected volatility of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zLCKwsPZeEv6" title="Expected Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-06-30_custom_MonteCarloValuationTechniqueMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span> percent; and expected
dividend yield of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_z1ALEfkqpaB4" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-06-30_custom_MonteCarloValuationTechniqueMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span> percent. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues.
The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations
regarding dividend payments. The total grant date fair value of the market-based awards was $<span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_c20230101__20230630__us-gaap--PlanNameAxis__custom--PerformanceBasedOptionsMember_zr7yY7AG4PM7" title="Grant date fair value"><ix:nonFraction name="OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" contextRef="From2023-01-012023-06-30_custom_PerformanceBasedOptionsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,625</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
May 2022, the Company approved amendments to vesting conditions of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220501__20220531__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndEmployeesMember_zeZmunvDFnRf" title="Share based awards vesting"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-05-012022-05-31_us-gaap_PerformanceSharesMember_custom_ExecutiveOfficersAndEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">61,875</ix:nonFraction></span> performance-based and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220501__20220531__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndEmployeesMember_zfLSqOEYlmQi" title="Share based awards vesting"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-05-012022-05-31_custom_MarketBasedAwardsMember_custom_ExecutiveOfficersAndEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></span> market-based awards of certain
executive officers and employees. The performance-based awards were modified such that the stock awards will be eligible to vest as follows:
(i) <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220501__20220531__dei--LegalEntityAxis__custom--VitaGraftMember_zZTF9LXezoq9"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2022-05-012022-05-31_custom_VitaGraftMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% will vest on December 31, 2023 if the Company achieves LCD reimbursement for VitaGraft (formerly TheraSure<sup> </sup>Transplant
Monitor) for one organ no later than December 31, 2022 and (ii) <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220501__20220531__dei--LegalEntityAxis__custom--DetermalOMember_zPUwwusTQ5Ij"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2022-05-012022-05-31_custom_DetermalOMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% will vest on December 31, 2023 if DetermaIO or DetermaCNI (formerly
TheraSure - CNI Monitor) submission for LCD is completed no later than December 31, 2022. Additional performance-based restricted stock
unit (&#8220;RSU&#8221;) awards were modified to be eligible to vest upon the achievement by <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220501__20220531_z7iY7vXqNkTe" title="Share based payment award description"><ix:nonNumeric contextRef="From2022-05-012022-05-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the Company of average market capitalization
minimum, target, and maximum goals of (i) $300 million; (ii) $400 million; and (iii) $500 million, respectively, during the period beginning
on January 1, 2022 and ending on December 31, 2024</ix:nonNumeric></span>. The market-based RSU awards were modified such that the awards will be eligible to
vest upon the achievement of product commercial launch minimum, target, and maximum goals as follows: (i) one laboratory test product in
the US; (ii) two laboratory test products in US, and (iii) three laboratory test products in the US, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
accordance with ASC 718, the Company calculated the fair value of the market-based awards on the date of modification, noting an increase
in the fair value of approximately $<span id="xdx_90B_eus-gaap--IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_c20230101__20230630_zJLiRFx1D9f5" title="Increase in fair value"><ix:nonFraction name="us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,500</ix:nonFraction></span> on the date of modification, with the incremental increase in fair value representing additional
unrecognized stock-based compensation expense. The following assumptions were used in calculating the fair value of the market-based
options on the date of modification:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_znVbihcDDGN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_zbFjVRKNuywk" style="display: none">Schedule
of Assumptions Used to Calculate Fair Value of Stock Options</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; color: Black; text-align: left">Risk-free interest rates</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zS6GXqshyhFl" title="Risk-free interest rates" style="width: 16%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-06-30_custom_MarketBasedAwardsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.72</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Expected term (in years)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zScan6519KL9" title="Expected term (in years)"><ix:nonNumeric contextRef="From2023-01-012023-06-30_custom_MarketBasedAwardsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.6</ix:nonNumeric></span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Volatility</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zfqfI8JqNsMc" title="Volatility" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-06-30_custom_MarketBasedAwardsMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.0</ix:nonFraction></td><td style="color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Grant date fair value of awards granted during the period</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zqwwvt1LEdea" title="Grant date fair value of awards granted during the period" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-06-30_custom_MarketBasedAwardsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.60</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_z1uHSVncfNq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
July 2022, the Company approved amendments to vesting conditions of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220701__20220731__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndEmployeesMember_zlX8RTBUmRle" title="Share based awards vesting"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-012022-07-31_us-gaap_PerformanceSharesMember_custom_ExecutiveOfficersAndEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,750</ix:nonFraction></span> performance-based awards of certain executive officers and
employees. Certain performance-based awards were modified such that the stock awards will be eligible to vest as follows: (i) fifty percent
(<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20220701__20220731__dei--LegalEntityAxis__custom--VitaGraftMember_zayDBC727wxk" title="Vested percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2022-07-012022-07-31_custom_VitaGraftMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%) of the options will vest on December 31, 2023 (the &#8220;Vesting Date&#8221;), subject to Continuous Service through the Vesting
Date, if local coverage determination is issued and priced for VitaGraft (Transplant) with respect to one organ no later than December
31, 2022; and (ii) fifty percent (<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220701__20220731__dei--LegalEntityAxis__custom--DetermalOMember_zNaIcQEEHDp8" title="Vested percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2022-07-012022-07-31_custom_DetermalOMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%) of the options will vest on the Vesting Date, subject to Continuous Service through the Vesting
Date, if the Company submits a local coverage determination request for DetermaIO or DetermaCNI no later than December 31, 2022. Additional
performance-based stock awards were modified to be eligible to vest upon <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220701__20220731_zTHL6RUiECM1" title="Share based payment award description"><ix:nonNumeric contextRef="From2022-07-012022-07-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the achievement of performance minimum, target, and maximum
goals of (i) 90% of revenue goal; (ii) 100% of revenue goal; and (iii) exceed revenue goal by up to 150%, respectively, during fiscal
year 2022</ix:nonNumeric></span>. These same awards contained budget performance goals which were modified to be eligible to vest upon the achievement of performance
minimum, target, and maximum goals of (i) complete fiscal year 2022 with sufficient cash to continue operations for 12 months; (ii) complete
fiscal year 2022 with sufficient cash to continue operations for 15 months; and (iii) complete fiscal year 2022 with sufficient cash
to continue operations for 16 months, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of December 31, 2022, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zC92BXiduMbk" title="Share based payment award description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">50</ix:nonNumeric></span>% of the performance-based were forfeited since the Company did not achieve LCD reimbursement for VitaGraft.
<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221214__20221216__dei--LegalEntityAxis__custom--DetermaCNIMember_zADgkkHvn5P3" title="Share based payment award vesting rights description"><ix:nonNumeric contextRef="From2022-12-142022-12-16_custom_DetermaCNIMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">The remaining 50% is eligible to vest on December 31, 2023, since the Company completed the LCD submission for DetermaCNI on December
16, 2022</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2022, the Company accelerated the vesting of certain equity awards in accordance with the 2018 Incentive
Plan after the departure of officers of the Company and the adoption of the workforce reduction plan. Due to the acceleration of such
awards all associated unrecognized compensation was accelerated and recognized in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zUo4G291Qxh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A
summary of Oncocyte&#8217;s 2010 Plan activity and related information follows (in thousands except weighted average exercise price):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B3_zUVPAoU1vP1i" style="display: none">Summary
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 75%; margin-left: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Shares</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Number</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Weighted</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Available</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">of Options</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Average</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold">Options</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">for Grant</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; color: Black">Balance at December 31, 2022</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_z3bPk7Z2hlC3" title="Shares available for grant options, beginning of period" style="width: 14%; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zFOGPbH0leT7" title="Number of options outstanding, beginning of period" style="width: 12%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_TwoThousandTenPlanActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">30</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zADSJFwO0K48" title="Weighted average exercise price, options outstanding, beginning of period" style="width: 16%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_TwoThousandTenPlanActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">80.78</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Options exercised</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zqOvjuGnwdt6" title="Shares available for grant options exercised" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1406">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zjUVWaMiQIF5" title="Number of options outstanding, option exercised" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1408">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zhTpksbXooPj" title="Weighted average exercise price, options exercised" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1410">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Options forfeited, cancelled and expired</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zM59qaMLhB44" title="Shares available for grant options forfeited, cancelled and expired" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1412">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zv8eGHd0dz36" title="Number of options outstanding, options forfeited, cancelled and expired" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zJLp9a92ow0b" title="Weighted average exercise price, options forfeited, cancelled and expired" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1416">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; padding-bottom: 2.5pt">Balance at June 30, 2023</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zeAulXHuE4Wk" title="Shares available for grant outstanding, end of period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zdkmWa1lVQB7" title="Number of options outstanding, end of period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_custom_TwoThousandTenPlanActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">29</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zoLDCyCZx97e" title="Weighted average exercise price, outstanding end of period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_custom_TwoThousandTenPlanActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">80.58</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 1.5pt">Exercisable at June 30, 2023</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_z9qBjbwvr848" title="Number of options outstanding, exercisable, end of period" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-06-30_custom_TwoThousandTenPlanActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zy6hs1gHwlV8" title="Weighted average exercise price, exercisable, end of period" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2023-06-30_custom_TwoThousandTenPlanActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">80.58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z67g7wUSLcXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenIncentivePlanMember_zIDoKr6cCvIl" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2023-06-30_custom_TwoThousandEighteenIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,050,000</ix:nonFraction></span> shares of common stock were reserved under the 2018 Incentive Plan for the grant of stock options or the
sale of restricted stock or for the settlement of RSUs. Oncocyte may also grant stock appreciation rights under the 2018 Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z5LNGTnwPm19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A
summary of Oncocyte&#8217;s 2018 Incentive Plan activity and related information follows (in thousands except weighted average exercise
price):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B8_z1p5ZtaNnrsl" style="display: none">Summary
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Shares</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Number</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Number</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Weighted</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Available</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">of Options</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">of RSUs</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Average</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">for Grant</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Outstanding</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Outstanding</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Exercise Price</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black">Balance at December 31, 2022</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zWpYo9KcyF76" title="Shares available for grant options, beginning of period" style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2022-12-31_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">442</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zZpp1RzLqs2f" title="Number of options outstanding, beginning of period" style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">428</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z3AMQbzxUvv7" title="Number of RSUs Outstanding, beginning of period" style="width: 8%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">22</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zXNv18lN5Ei6" title="Weighted average exercise price, options outstanding, beginning of period" style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">59.23</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">RSUs vested</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zYb3QJGBQePf" title="Shares available for grant options RSUs vested" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1440">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zbAJWodSEFh8" title="Number of options outstanding, option RSUs vested" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1442">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zkdiDQKHUL8k" title="Number of RSUs Outstanding, option RSUs vested" style="color: Black; text-align: right">(<ix:nonFraction name="OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">11</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zJ6XNesZvlwd" title="Weighted average exercise price, options exercised" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1446">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">RSUs granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zbYCBYIRLTL8" title="Shares available for grant options RSUs granted" style="color: Black; text-align: right">(<ix:nonFraction name="OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">10</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zuWhw0y11dIa" title="Number of options outstanding, option RSUs granted" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1450">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zLrAvC8ibjQ7" title="Number of RSUs Outstanding, option RSUs granted" style="color: Black; text-align: right"><ix:nonFraction name="OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zM3rSyS54Dbh" title="Weighted average exercise price, option RSUs granted" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1454">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Options granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z2ZDnY6hiFm7" title="Shares available for grant options granted" style="color: Black; text-align: right">(<ix:nonFraction name="OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="Shares">178</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z8lyqrBOxt6c" title="Number of options outstanding, option granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">178</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zSWQasQEY5H9" title="Number of RSUs Outstanding, option granted" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1460">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zc2i2Yt6Wre8" title="Weighted average exercise price, option granted" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.72</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Options forfeited/cancelled</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z88uUJWhN4Ze" title="Shares available for grant options forfeited, cancelled and expired" style="color: Black; text-align: right"><ix:nonFraction name="OCX:StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">150</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zxTQetor3MVa" title="Number of options outstanding, options forfeited, cancelled and expired" style="color: Black; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">150</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z6iEOpEvAp2h" title="Number of RSUs Outstanding, options exercised" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1468">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zjfFUTP8YKsj" title="Weighted average exercise price, options forfeited, cancelled and expired" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1470">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">RSUs forfeited/cancelled</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zSFd1P701Tf3" title="Shares available for grant RSUs, cancelled and expired" style="color: Black; text-align: right"><ix:nonFraction name="OCX:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zOIAXOfygFyh" title="Number of options outstanding, options forfeited, RSUs cancelled and expired" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1474">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zynL5Qcb5eJ5" title="Number of RSUs Outstanding, options forfeited, canceled and expired" style="color: Black; text-align: right">(<ix:nonFraction name="OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zry2kFdeHEq7" title="Weighted average exercise price, options forfeited, RSUs cancelled and expired" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1478">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Performance RSUs forfeited/cancelled</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zq93vvRHWQr2" title="Shares available for grant performance RSUs, cancelled and expired" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="OCX:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">15</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zb3PM74cW644" title="Number of options outstanding, options forfeited, performance RSUs cancelled and expired" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1482">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zcD410D3Owf5" title="Number of Performance RSUs Outstanding, options forfeited, canceled and expired" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">8</ix:nonFraction></td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zXdTYCrQ4ho3" title="Weighted average exercise price, options forfeited, performance RSUs cancelled and expired" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1486">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Balance at June 30, 2023</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zBE452ssKTMk" title="Shares available for grant outstanding, end of period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">421</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zb1bjooPGIp6" title="Number of options outstanding, end of period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">456</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zOqu6EdR1Py3" title="Number of RSUs Outstanding, end of period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">7</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z58qbI1LVeLj" title="Weighted average exercise price, outstanding end of period" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">38.33</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Options exercisable at June 30, 2023</td><td style="color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zQPjFDJSbtw5" title="Number of options outstanding, exercisable, end of period" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">199</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zIOpWwt77GY4" title="Weighted average exercise price, exercisable, end of period" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">89.54</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zXqrjqkuAcmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zumb57BYa663" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations
for the three and six months ended June 30, 2023 and 2022 (unaudited and in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B8_zjSkLQRZWvOg" style="display: none">Summary
of Stock-based Compensation Expense</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230401__20230630_z4wQRtx3Fgn1" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220401__20220630_zumjx50dv8Ik" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230630_zpEcUDfgDAqf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20220630_z10e4bZGfdug" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Three Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfRevenuesMember_zCkPYa49noYi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black">Cost of revenues</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 11%; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 11%; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1505">-</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpey2jkfKDj8" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Research and development</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">309</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">201</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">632</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">381</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zoISYlpmpp86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Sales and marketing</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1513">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zBWFQgwYRVy6" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">General and administrative</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">461</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,283</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">867</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,463</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--DiscontinuedOperationsMember_zT9Otyru4NB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Discontinuing operations</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1522">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">748</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,369</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zEDH6FLrnMz6" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">834</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,232</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,668</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,242</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zLds1KQEk77a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zQGSpIbAmENg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
assumptions that were used to calculate the grant date fair value of Oncocyte&#8217;s employee and non-employee stock option grants for
the six months ended June 30, 2023 and 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z4UZFSnKmyK7" style="display: none">Schedule
of Assumptions Used to Calculate Fair Value of Stock Options</span><span style="color: Black">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 60%; margin-left: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; color: Black; text-align: left">Expected life (in years)</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630_zeUtM678C3X5" title="Expected life (in years)"><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630_zFHUw2fgj3Zf" title="Expected life (in years)"><ix:nonNumeric contextRef="From2022-01-012022-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.01</ix:nonNumeric></span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Risk-free interest rates</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630_zm4Uj6iHd28e" title="Risk-free interest rates" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.76</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630_zVCdVzMVxWr7" title="Risk-free interest rates" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.24</ix:nonFraction></td><td style="color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Volatility</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630_z80XuOQGEzJ4" title="Volatility" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105.99</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630_zZREqp28xlml" title="Volatility" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">106.98</ix:nonFraction></td><td style="color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Dividend yield</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230101__20230630_z0ANCgUDMkf7" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Pure">0</ix:nonFraction></span></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d0_c20220101__20220630_zQb5GWKZB7Uk" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Pure">0</ix:nonFraction></span></td><td style="color: Black; text-align: left">%</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A5_zlmvJy65BHZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and
assumptions requiring the use of judgment. If Oncocyte had made different assumptions, its stock-based compensation expense and net loss
for the three and six months ended June 30, 2023, and 2022 may have been significantly different.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified
disposition has occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_z6chgspCk2Pb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>7.
<span id="xdx_82D_zTvKItJCUZbj">Disaggregation of Revenues and Concentration Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zqy0QgGJbp92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents the percentage of consolidated revenues generated by unaffiliated customers that individually represent greater
than ten percent of consolidated revenues:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z3jVQvNEEGnl" style="display: none">Schedule
of Consolidated Revenues Generated by Unaffiliated Customers</span><span style="color: Black">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Three Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black; text-align: left">Pharma services - Company A</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zxfp3alJLkY2" title="Concentration risk, percentage" style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">68</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zJCpZ7jkoO6h" title="Concentration risk, percentage" style="width: 11%; color: Black; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" id="Fact001556" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Pure">-</ix:nonFraction></span><span id="xdx_F2F_z7vMN5d4eRS3" style="color: Black">*</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zlLKyU3olChk" title="Concentration risk, percentage" style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">27</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zdjux8jRKO21" title="Concentration risk, percentage" style="width: 11%; color: Black; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" id="Fact001560" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Pure">-</ix:nonFraction></span><span id="xdx_F20_zGRwEbtdpCja">*</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Pharma services - Company B</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zElYATED5ts8" title="Concentration risk, percentage" style="color: Black; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" id="Fact001562" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Pure">-</ix:nonFraction></span><span id="xdx_F25_zyjuziASFAL3" style="color: Black">*</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____z79HgCpzdRdj" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1564">-</span></span></span><span id="xdx_F2F_zu6qsSTvG9V7" style="color: Black">*</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z8V8EfpYmt53" title="Concentration risk, percentage" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zuO8xPUMUUCh" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1568">-</span></span></span><span id="xdx_F2A_zTHi7s59lrpk">*</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Discontinuing operations</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____z9kJz2RKVz3h" title="Concentration risk, percentage" style="color: Black; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" id="Fact001570" format="ixt:zerodash" decimals="INF" scale="-2" sign="-" unitRef="Pure">-</ix:nonFraction></span><span id="xdx_F2C_zqqmO4eaVu6a" style="color: Black">*</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zzpR3hpLL0fd" title="Concentration risk, percentage" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">89</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_ztNbN4TIqCR6" title="Concentration risk, percentage" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">38</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z1s74MtfTMa7" title="Concentration risk, percentage" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82</ix:nonFraction></td><td style="color: Black; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F02_zNlR4QJccOi" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i id="xdx_F14_z8ncoxfAiM4c"><ix:footnote id="Footnote001577" xml:lang="en-US">Less
    than 10%</ix:footnote></i></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zEayKbcQkpRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="OCX:ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock_z2uDC0RRZNUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents the percentage of consolidated revenues by products or services classes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_z2Hu4PVXQd88" style="display: none">Schedule
of Consolidated Revenues Attributable to Products or Services</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; color: Black">&#160;</td><td style="text-align: center; color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Three Months Ended</td><td style="text-align: center; color: Black; font-weight: bold">&#160;</td><td style="text-align: center; color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="text-align: center; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; color: Black">&#160;</td><td style="text-align: center; color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="text-align: center; color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black; text-align: left">Pharma Services</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9Xjrdg7WES3" title="Concentration risk, percentage" style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">94</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zvZ9H0lKKCqe" title="Concentration risk, percentage" style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmc4BTMqLoLd" title="Concentration risk, percentage" style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">62</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zzN1D0DgLeBa" title="Concentration risk, percentage" style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">DetermaRx&#8482;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zTYfckakGv1e" title="Concentration risk, percentage" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zEqjMu4engE6" title="Concentration risk, percentage" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zJh79XNBWHk8" title="Concentration risk, percentage" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zZ6NDbOs1tHa" title="Concentration risk, percentage" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Discontinuing operations</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zrPabShcwCIl" title="Concentration risk, percentage" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zThxy0Kpeh4" title="Concentration risk, percentage" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">89</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHggRznVbJZ1" title="Concentration risk, percentage" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmfTXAdFMYzg" title="Concentration risk, percentage" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zan6Cbz7T2pc" title="Concentration risk, percentage" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zExgskS5WBt4" title="Concentration risk, percentage" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHHBSHiQqXQ3" title="Concentration risk, percentage" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHsgQISwGKG2" title="Concentration risk, percentage" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_z0kS2WzHsYj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zfyWsQxLnOp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents the percentage of consolidated revenues attributable to geographical locations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B4_z0uLsoGhqduh" style="display: none">Schedule
of Percentage of Consolidated Revenues Attributable to Geographical Locations</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20230630_zdDOIsZiUdE8" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220401__20220630_zdI6I9JfrP6h" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230630_z6XgtebHtHSc" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20220630_zh59t8KWLAvf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Three Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zip8EzMyc6vj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black; text-align: left">United States &#8211; Pharma Services</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">74</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 11%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">65</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--OutsideUnitedStatesPharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zBgnqatcKvq1" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Outside of the United States &#8211; Pharma Services</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></td><td style="color: Black; text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zbOL5HCtHxZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">DetermaRx&#8482;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460937" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460953" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460953" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460968" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="color: Black; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DiscontinuedOperationsOutsideUnitedStatesLicensingMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zW4KqOI5Va0b" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Discontinuing operations &#8211; Outside of the United States &#8211; Licensing</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">48</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></td><td style="color: Black; text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zS9pnQ5RHtt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Discontinuing operations &#8211; United States &#8211; DetermaRx&#8482;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461015" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461031" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461031" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461046" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zyh8OVaiiftb" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-04-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-04-012022-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zRFBErKJTnfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_z7AEZ80Y4uBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>8.
<span id="xdx_82C_zPrpK9h5Mrwa">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270,
<i>Income Taxes, Interim Reporting</i>. The effective tax rate may be subject to fluctuations during the year as new information is obtained,
which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against
deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or
the interpretation of tax laws in jurisdictions where Oncocyte conducts business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
did not record any provision or benefit for income taxes for the six months ended June 30, 2023 and 2022, as Oncocyte had a full valuation
allowance for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A
valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Oncocyte
established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net
operating loss carry-forwards and other deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zlI40JiDP3m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>9.
<span id="xdx_82F_z0gDgBo9MBVb">Right-of-use assets, machinery and equipment, net, and construction in progress</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zvPDTIkyIMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023 and December 31, 2022, right-of-use assets, machinery and equipment, net, and construction in progress were as follows
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_z0BVyoOH8m5b" style="display: none">Schedule
of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230630_zUpRJVoNE2Lg" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30, 2023<br /> (unaudited)</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zuM7ETkm63H3" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_z5jNeFxA5Ht5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20230630_zIG0BrdyttC9" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230630%23MachineryAndEquipmentNetAndConstructionInProgress"><span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20221231_z6b6xO9VJ40a" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230630%23MachineryAndEquipmentNetAndConstructionInProgress"><span style="-sec-ix-hidden: xdx2ixbrl1653"><span style="-sec-ix-hidden: xdx2ixbrl1654">Right-of-use assets</span></span></span></span> <sup id="xdx_F40_zN6xqg4WcXQc">(1)</sup></span></td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-06-30" id="Fact001651" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,036</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" id="Fact001652" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,499</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_zQRBYqk1aqEl" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Machinery and equipment</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,644</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,408</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_zwtKrC6CA9ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,310</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,196</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_z0d4N7kgAzAd" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Right-of-use assets, machinery and equipment, net</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,370</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,711</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ConstructionInProgressGross_iI_pn3n3_zMVwAzmE96Bf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConstructionInProgressGross" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">518</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:ConstructionInProgressGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RightofuseAssetsMachineryAndEquipmentContinuingOperations_iI_pn3n3_ztd6090Il5Mk" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Right-of-use assets, machinery and equipment, net, and construction in progress</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="OCX:RightofuseAssetsMachineryAndEquipmentContinuingOperations" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,888</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="OCX:RightofuseAssetsMachineryAndEquipmentContinuingOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,851</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations_iI_pn3n3_zuglr7g44059" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Right-of-use assets, machinery and equipment, net, and construction in progress from discontinuing operations</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1671">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="OCX:RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">211</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RightofuseAssetsMachineryAndEquipmentNet_iI_pn3n3_zGONvbakKhIe" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Right-of-use assets, machinery and equipment, net, and construction in progress</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="OCX:RightofuseAssetsMachineryAndEquipmentNet" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,888</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="OCX:RightofuseAssetsMachineryAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,062</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F05_z31mCAvn6Jb4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zmttJPpFz7y8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><ix:footnote id="Footnote001676" xml:lang="en-US">Oncocyte
    recorded certain right-of-use assets and liabilities for operating leases in accordance with ASC 842 (see Note 10).</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A0_zbULD6GkgIkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Depreciation
expense amounted to $<span id="xdx_90E_eus-gaap--DepreciationAndAmortization_c20230401__20230630_zinxV2FPFZVd" title="Depreciation expense"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">435,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--DepreciationAndAmortization_c20220401__20220630_zFRCuEwx0HL3" title="Depreciation expense"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">384,000</ix:nonFraction></span> for the three months ended June 30, 2023 and 2022, respectively, and $<span id="xdx_904_eus-gaap--DepreciationAndAmortization_c20230101__20230630_zUnvH1sL4YDd" title="Depreciation expense"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--DepreciationAndAmortization_c20220101__20220630_zq7x7D4Uga01" title="Depreciation expense"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671,000</ix:nonFraction></span>
for the six months ended June 30, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zNVv5lHb1z2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>10.
<span id="xdx_82D_zZqPae8kp7b8">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
has certain commitments other than discussed in Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Office
Lease Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
December 23, 2019, Oncocyte entered into an Office Lease Agreement (the &#8220;Irvine Lease&#8221;) of a building containing approximately
<span id="xdx_90B_eus-gaap--AreaOfLand_iI_usqft_c20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_ziN80D2S9sK8" title="Area of Land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2019-12-23_custom_OfficeLeaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">26,800</ix:nonFraction></span> square feet of rentable space located at 15 Cushing in Irvine, California (the &#8220;Premises&#8221;) that will serve as Oncocyte&#8217;s
new principal executive and administrative offices and laboratory facility. Oncocyte completed the relocation of its offices to the Premises
in January 2020 and subsequently constructed a laboratory at the Irvine facility to perform cancer diagnostic tests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Irvine Lease has an initial term of 89 calendar months (the &#8220;Term&#8221;), which commenced on June 1, 2020 (the &#8220;Commencement
Date&#8221;). Oncocyte has an option to extend the Term for a period of five years (the &#8220;Extended Term&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
agreed to pay base monthly rent in the amount of $<span id="xdx_904_eus-gaap--PaymentsForRent_c20191222__20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zYJA6vXGAFEe" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2019-12-222019-12-23_custom_OfficeLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,640</ix:nonFraction></span> during the first 12 months of the Term. Base monthly rent increases annually,
over the base monthly rent then in effect, by <span id="xdx_90E_ecustom--CapitalLeaseAgreementImputedAnnualInterestRate_pid_dp_uPure_c20191222__20191223__srt--StatementScenarioAxis__custom--MonthlyRentMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zyODDrbEVAub" title="Interest rate on lease agreement"><ix:nonFraction name="OCX:CapitalLeaseAgreementImputedAnnualInterestRate" contextRef="From2019-12-222019-12-23_custom_MonthlyRentMember_custom_OfficeLeaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.5</ix:nonFraction></span>%. Oncocyte was entitled to an abatement of <span id="xdx_905_ecustom--CapitalLeaseAgreementImputedAnnualInterestRate_pid_dp_uPure_c20191222__20191223__srt--StatementScenarioAxis__custom--FirstTenCalendarMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_z5kdl1ffgeic" title="Interest rate on lease agreement"><ix:nonFraction name="OCX:CapitalLeaseAgreementImputedAnnualInterestRate" contextRef="From2019-12-222019-12-23_custom_FirstTenCalendarMember_custom_OfficeLeaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the base monthly rent during the
first ten calendar months of the Term. If the Irvine Lease is terminated based on the occurrence of an &#8220;event of default,&#8221;
Oncocyte will be obligated to pay the abated rent to the lessor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
Oncocyte exercises its option to extend the Term, the initial base monthly rent during the Extended Term will be the greater of the base
monthly rent in effect during the last year of the Term or the prevailing market rate. The prevailing market rate will be determined
based on annual rental rates per square foot for comparable space in the area where the Premises are located. If Oncocyte does not agree
with the prevailing market rate proposed by the lessor, the rate may be determined through an appraisal process. The base monthly rent
during the Extended Term shall be subject to the same annual rent adjustment as applicable for base monthly rent during the Term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
addition to base monthly rent, Oncocyte agreed to pay in monthly installments (a) all costs and expenses, other than certain excluded expenses,
incurred by the lessor in each calendar year in connection with operating, maintaining, repairing (including replacements if repairs
are not feasible or would not be effective) and managing the Premises and the building in which the Premises are located (&#8220;Expenses&#8221;),
and (b) all real estate taxes and assessments on the Premises and the building in which the Premises are located, all personal property
taxes for property that is owned by lessor and used in connection with the operation, maintenance and repair of the Premises, and costs
and fees incurred in connection with seeking reductions in such tax liabilities (&#8220;Taxes&#8221;). Subject to certain exceptions,
Expenses shall not be increased by more than 4% annually on a cumulative, compounded basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
was entitled to an abatement of its obligations to pay Expenses and Taxes while constructing improvements to the Premises constituting
&#8220;Tenant&#8217;s Work&#8221; under the Irvine Lease prior to the Commencement Date, except that Oncocyte was obligated to pay <span id="xdx_905_ecustom--ObligatedToPayExpensesAndTaxesPercentage_pid_dp_uPure_c20191222__20191223__srt--StatementScenarioAxis__custom--MonthlyRentMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_z4B2cdxoccS8" title="Obligated to pay expenses and taxes percentage"><ix:nonFraction name="OCX:ObligatedToPayExpensesAndTaxesPercentage" contextRef="From2019-12-222019-12-23_custom_MonthlyRentMember_custom_OfficeLeaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">43.7</ix:nonFraction></span>%
of Expenses and Taxes during the period prior to the Commencement Date for its use of the second floor of the Premises, which was already
built out as office space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
lessor provided Oncocyte with a &#8220;Tenant Improvement Allowance&#8221; in the amount of $<span id="xdx_905_eus-gaap--PaymentsForProceedsFromTenantAllowance_pn5n6_c20191222__20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zo841TY6aBSe" title="Payments for (Proceeds from) Tenant Allowance"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromTenantAllowance" contextRef="From2019-12-222019-12-23_custom_OfficeLeaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million to pay for the plan, design,
permitting, and construction of the improvements constituting Tenant&#8217;s Work. The lessor retained <span id="xdx_908_ecustom--PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment_pid_dp_uPure_c20191222__20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zKZSftwiIE15" title="Percentage of administrative fee paid on original cost of equipment"><ix:nonFraction name="OCX:PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment" contextRef="From2019-12-222019-12-23_custom_OfficeLeaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.5</ix:nonFraction></span>% of the Tenant Improvement
Allowance as an administrative fee as provided in the Irvine Lease. As of June 30, 2023, the lessor had provided $<span id="xdx_903_eus-gaap--PaymentsForProceedsFromTenantAllowance_pn5n6_c20230101__20230630__srt--TitleOfIndividualAxis__custom--LandlordMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_z6ZKTr3IFFd3" title="Total tenant improvement allowance"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromTenantAllowance" contextRef="From2023-01-012023-06-30_custom_LandlordMember_custom_OfficeLeaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million of the
total Tenant Improvement Allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
has provided the lessor with a security deposit in the amount of $<span id="xdx_905_eus-gaap--SecurityDeposit_iI_c20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zM9p05LQ7st8" title="Security Deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2019-12-23_custom_OfficeLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> and a letter of credit in the amount of $<span id="xdx_90D_eus-gaap--LinesOfCreditCurrent_iI_pn5n6_c20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zMUZco8xWw55" title="Line of Credit, Current"><ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2019-12-23_custom_OfficeLeaseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million. The lessor
may apply the security deposit, in whole or in part, for the payment of rent and any other amount that Oncocyte is or becomes obligated
to pay under the Irvine Lease but fails to pay when due and beyond any cure period. The lessor may draw on the letter of credit from
time to time to pay any amount that is unpaid and due, or if the original issuing bank notifies the lessor that the letter of credit
will not be renewed or extended for the period required under the Irvine Lease and Oncocyte fails to timely provide a replacement letter
of credit, or an event of default under the Irvine Lease occurs and continues beyond the applicable cure period, or if certain insolvency
or bankruptcy or insolvency with respect to Oncocyte occur. Oncocyte is required to restore any portion of the security deposit that
is applied by the lessor to payments due under the Irvine Lease, and Oncocyte is required to restore the amount available under the letter
of credit to the required amount if any portion of the letter of credit is drawn by the lessor. The Irvine Lease provides that commencing on the 34th month of the Term,
(a) the amount of the letter of credit that Oncocyte is required to maintain shall be reduced on a monthly basis, in equal installments,
to amortize the required amount to zero at the end of the Term, and (b) Oncocyte has the right to cancel the letter of credit at
any time if it meets certain market capitalization and balance sheets thresholds; provided, in each case, that Oncocyte is not in then
default under the Irvine Lease beyond any applicable notice and cure period and the lessor has not determined that an event exists that
would lead to an event of default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">To
obtain the letter of credit, Oncocyte has provided the issuing bank with a restricted cash deposit that the bank will hold to cover its
obligation to pay any draws on the letter of credit by the lessor. The restricted cash may not be used for any other purpose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
August 27, 2021, Oncocyte entered into a lease agreement to add an additional suite to its Nashville office space, containing approximately
<span id="xdx_90A_eus-gaap--AreaOfLand_iI_usqft_c20210827__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zeqqu9W28Cc" title="Area of Land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2021-08-27_custom_LeaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">1,928</ix:nonFraction></span> square feet of rentable space located at 2 International Plaza, Suite 103, Nashville TN. The term of the lease commences on October
1, 2021 and extends through April 9, 2024 and will serve as additional office space for Insight&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Irvine Lease is an operating lease under ASC 842 included in the tables below. The tables below provide the amounts recorded in connection
with the application of ASC 842 as of, and during, the six months ended June 30, 2023, for Oncocyte&#8217;s operating and financing leases
(see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On December 31, 2019, in connection with Oncocyte&#8217;s purchase <span style="background-color: white">of&#160;<span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20191231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zbOoKPL2yEgh" title="Outstanding equity"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2019-12-31_custom_DevelopmentAgreementMember_custom_OncocyteCorpMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%
of the outstanding equity of Razor,</span> Oncocyte entered into a Laboratory Services Agreement with Razor and Encore Clinical, Inc.
(&#8220;Encore&#8221;), a former stockholder of Razor (the &#8220;Laboratory Agreement&#8221;). Under
the Laboratory Agreement (which expired on September 29, 2021), Oncocyte assumed all of Razor&#8217;s Laboratory
Agreement payment obligations. Although Oncocyte is not a party to any lease agreement with Razor or Encore, under the terms of the Laboratory
Agreement, Oncocyte received the landlord&#8217;s consent for the use of the laboratory at Razor&#8217;s Brisbane, California location
(the &#8220;Brisbane Facility&#8221;) under the terms of a sublease to which Encore is the sublessee. The sublease expired on March 31,
2023 (the &#8220;Brisbane Lease&#8221;). The laboratory fee payments to Encore include both laboratory services and the use of the Brisbane
Facility. Under the provisions of the Laboratory Agreement, if Oncocyte terminates the Laboratory Agreement prior to the expiration of
the Brisbane Lease, Oncocyte shall assume the costs related to the subletting or early termination of the Brisbane Lease. The Laboratory
Agreement terminated on March 31, 2023. Oncocyte determined that the Laboratory Agreement contains an embedded operating lease for the
Brisbane Facility and Oncocyte allocated the aggregate payments to this lease component for purposes of calculating the net present value
of the right-of-use asset and liability as of the inception of the Laboratory Agreement in accordance with ASC 842, as shown in the table
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Financing
lease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023, Oncocyte has one financing lease remaining through December 2023 for certain laboratory equipment with aggregate remaining
payments of $<span id="xdx_900_ecustom--PaymentObligationAmount_iI_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zHOBNw9OAqJc" title="Payment obligation amount."><ix:nonFraction name="OCX:PaymentObligationAmount" contextRef="AsOf2023-06-30_custom_LaboratoryEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,000</ix:nonFraction></span> shown in the table below. Oncocyte&#8217;s lease obligations are collateralized by the equipment financed under the
lease schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Operating
and Financing leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="OCX:ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock_zoU8xW86RGY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents supplemental cash flow information related to operating and financing leases for the six months ended June 30,
2023 and 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_zyuipxi6fFNe" style="display: none">Schedule
of Supplemental Cash Flow Information Related to Operating and Financing Lease</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20230630_zrziQ1NGvGJ7" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20220630_z7DsbwjOiTcd" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left">Cash paid for amounts included in the measurement of financing lease liabilities:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zk6EhQKz8Lp1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; color: Black; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">538</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">564</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zNUwHdSkQLlg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Operating cash flows from financing leases</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_zp4CfHoNVK93" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Financing cash flows from financing leases</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></p></td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zZQtCPQOCSYd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="OCX:ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock"><p id="xdx_894_ecustom--ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock_zRGLBGVydjE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents supplemental balance sheets information related to operating and financing leases as of June 30, 2023 and June
30, 2022 (in thousands, except lease term and discount rate):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span id="xdx_8BD_zPcrYALQFgAk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Schedule
of Supplemental Balance Sheet Information Related to Operating and Financing Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zC8bf6TbF4Uk" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zw782dUt37jf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left">Operating lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zdS95JagOMV5" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; color: Black; text-align: left; padding-bottom: 1.5pt">Right-of-use assets, net</td><td style="width: 2%; color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,855</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,343</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zWsyf8iLJFS7" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Right-of-use lease liabilities, current</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">677</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">728</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zOPDzbD2GxH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Right-of-use lease liabilities, noncurrent</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,398</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,075</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_z73ADENYoPJ2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Total operating lease liabilities</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,075</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,803</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold; text-align: left">Financing lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Machinery and equipment</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">536</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">537</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iNI_pn3n3_di_zNTJmeu4eYrf" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">391</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseRightOfUseAsset_iTI_pn3n3_zE52rflxHsU5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Machinery and equipment, net</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">146</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_zvxSbovxTIBc" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Current liabilities</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_zj1n66HYwRh8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Noncurrent liabilities</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1751">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_zkWZXDTZAsK3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Total financing lease liabilities</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">170</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold">Weighted average remaining lease term</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Operating lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zgYHD3sS8Vi7" title="Weighted average remaining lease term, Operating lease"><ix:nonNumeric contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.1</ix:nonNumeric></span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zZ2Y4YZTjPs1" title="Weighted average remaining lease term, Operating lease"><ix:nonNumeric contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.9</ix:nonNumeric> </span>years</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Financing lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_z2Dj1XQz6bNi" title="Weighted average remaining lease term, Financing lease"><ix:nonNumeric contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">0.5</ix:nonNumeric></span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zAoDhPfBHfBd" title="Weighted average remaining lease term, Financing lease"><ix:nonNumeric contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">1.5</ix:nonNumeric></span> years</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Weighted average discount rate</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_z8p3245Ffea1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Operating lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.28</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.20</ix:nonFraction></td><td style="color: Black; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_z7JXatNuyIo2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Financing lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.55</ix:nonFraction></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.55</ix:nonFraction></td><td style="color: Black; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zDIFOGO3x0pj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="OCX:ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock_zB3YPOSoONha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Future
minimum lease commitments are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zguNJzI8MRc2" style="display: none">Schedule of Future Minimum Lease Commitments for Operating and Financing Leases</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 75%; margin-left: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Operating</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Financing</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Leases</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Leases</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold">Year Ending December 31,</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; color: Black; text-align: left">2023</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zriheRiF3Ar7" title="2023" style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">510</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zk4J6fj1OAoe" title="2023" style="width: 14%; color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62</ix:nonFraction></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">2024</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zLm8IT4JXrZ7" title="2024" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">903</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zl6gGSFeX7Ff" title="2024" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1779">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">2025</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zZH0wxnUymN3" title="2025" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">869</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zjb7BBgNdOG5" title="2025" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1783">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">2026</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zT3Liqw1f3Gl" title="2026" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">899</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zgaX8I51rNqg" title="2025" style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1787">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">2027</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zjYefaNdgpl7" title="2027" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">695</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pdn3_c20230630_zy7DLtobbh96" title="2026" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1791">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Total minimum lease payments</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zk776WVUaCAd" title="Total minimum lease payments" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,876</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zXrlp9B8YUU5" title="Total minimum lease payments" style="color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62</ix:nonFraction></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Less amounts representing interest</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20230630_z4N4SumEecal" title="Less amounts representing interest" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">801</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20230630_zqvhCVW531H3" title="Less amounts representing interest" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Present value of net minimum lease payments</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_985_ecustom--PresentValueOfNetMinimumLeasePayments_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zJHJcUKQCTb" title="Present value of net minimum lease payments" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="OCX:PresentValueOfNetMinimumLeasePayments" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,075</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_c20230630_z4EJo3AOkYn2" title="Present value of net minimum lease payments" style="border-bottom: Black 2.5pt double; color: Black; text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zKjMvDu5xRzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Litigation
&#8211; General</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
may be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business
transactions, employee-related matters, and other matters. When Oncocyte is aware of a claim or potential claim, it assesses the likelihood
of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, Oncocyte will
record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, Oncocyte discloses
the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Tax
Filings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments
of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes Oncocyte
has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could
be significantly different than the amounts recorded in the unaudited condensed consolidated interim financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Employment
Contracts</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
has entered into employment and severance benefit contracts with certain executive officers. Under the provisions of the contracts, Oncocyte
may be required to incur severance obligations for matters relating to changes in control, as defined, and certain terminations of executives.
As of June 30, 2023, Oncocyte accrued approximately $<span id="xdx_90E_eus-gaap--SeveranceCosts1_pn5n6_c20230101__20230630__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zgDoVsDPXsuh" title="Severance costs"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2023-01-012023-06-30_custom_ExecutiveOfficersMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million in severance obligations for certain executive officers, in accordance
with the severance benefit provisions of their respective employment and severance benefit agreements, primarily related to Oncocyte&#8217;s
acquisition of Chronix in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
the normal course of business, Oncocyte may provide indemnification of varying scope under Oncocyte&#8217;s agreements with other
companies or consultants, typically Oncocyte&#8217;s clinical research organizations, investigators, clinical sites, suppliers and
others. Pursuant to these agreements, Oncocyte will generally agree to indemnify, hold harmless, and reimburse the indemnified
parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection
with the use or testing of Oncocyte&#8217;s diagnostic tests. Indemnification provisions could also cover third party infringement
claims with respect to patent rights, copyrights, or other intellectual property pertaining to Oncocyte&#8217;s diagnostic tests.
Oncocyte&#8217;s office and laboratory facility leases also will generally contain indemnification obligations, including
obligations for indemnification of the lessor for environmental law matters and injuries to persons or property of others, arising
from Oncocyte&#8217;s use or occupancy of the leased property. The term of these indemnification agreements will generally continue
in effect after the termination or expiration of the particular research, development, services, lease, or license agreement to
which they relate. The Razor Stock Purchase Agreement also contains provisions under which Oncocyte has agreed to indemnify Razor
and Encore from losses and expenses resulting from breaches or inaccuracy of Oncocyte&#8217;s representations and warranties and
breaches or nonfulfillment of Oncocyte&#8217;s covenants, agreements, and obligations under the Razor Stock Purchase Agreement.
Oncocyte periodically enters into underwriting and securities sales agreements with broker-dealers in connection with the offer and
sale of Oncocyte securities. The terms of those underwriting and securities sales agreements include indemnification provisions
pursuant to which Oncocyte agrees to indemnify the broker-dealers from certain liabilities, including liabilities arising under the
Securities Act, in connection with the offer and sale of Oncocyte securities. The potential future payments Oncocyte could be
required to make under these indemnification agreements will generally not be subject to any specified maximum amounts.
Historically, Oncocyte has not been subject to any claims or demands for indemnification. Oncocyte also maintains various liability
insurance policies that limit Oncocyte&#8217;s financial exposure. As a result, Oncocyte management believes that the fair value of
these indemnification agreements is minimal. Accordingly, Oncocyte has not recorded any liabilities for these agreements as of June
30, 2023 and December 31, 2022.</span></p>
<!-- Field: Split-Segment; Name: 002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="OCX:WorkforceReductionTextBlock"><p id="xdx_805_ecustom--WorkforceReductionTextBlock_z0ZbrsvAieTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>11.
<span id="xdx_826_zJtUJox1dgxl">Workforce Reduction</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
August 2022, the Company initiated a workforce reduction plan to strategically realign its operations and implement cost reduction programs
to prioritize near term revenue generators and to manage and preserve cash. In connection with the reduction, the Company eliminated
14 positions, implemented tighter expense controls, and ceased non-core activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Further,
on December 16, 2022, Oncocyte initiated an additional reduction in work force involving over 40% of its full-time employees. The transition
began on December 16, 2022 and was completed in February 2023. As of December 31, 2022, the Company incurred an aggregate of $<span id="xdx_90D_eus-gaap--SeveranceCosts1_pn5n6_c20220101__20221231_zxqyAalFq5L6" title="Employee severance"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span> million
related to employee severance and benefits costs in connection with its reductions in force during fiscal year 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 12, 2023, Oncocyte announced a reduction in force involving approximately 20% of its workforce (the &#8220;April 2023 Reduction&#8221;),
which management believes will extend Oncocyte&#8217;s cash runway into 2024. In connection with the April 2023 Reduction, we incurred
approximately $<span id="xdx_90A_eus-gaap--SeveranceCosts1_pn5n6_c20230401__20230630_z2zdQJ5iBoj" title="Employee severance"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million related to employee severance and benefits costs during the second quarter of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zHEsm1tJBM8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>12.
<span id="xdx_820_zZjc3SqBJq3c">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Financing
Transactions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 13, 2022, Oncocyte entered into the Securities Purchase Agreement with the Investors, including Broadwood<span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and John Peter Gutfreund, a former director of Oncocyte, for
the Series A Preferred Stock Offering. Each of Broadwood and Mr. Gutfreund has a direct material interest in the Series A Preferred Stock
Offering and agreed to purchase <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp2d_c20220412__20220412__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zlqiyxSHG4Ve" title="Offering shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-122022-04-12_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_BroadwoodCapitalLPMember" format="ixt:numdotdecimal" decimals="2" unitRef="Shares">5,882.35</ix:nonFraction></span> and <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp2d_c20220413__20220413__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zALKRSt9jAKb" title="Offering shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-132022-04-13_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_BroadwoodCapitalLPMember" format="ixt:numdotdecimal" decimals="2" unitRef="Shares">1,176.48</ix:nonFraction></span> shares, respectively, in the Series A Preferred Stock Offering and on the same terms
as other investors. Additionally, Halle Capital Management, L.P. received $<span id="xdx_900_eus-gaap--LegalFees_c20220413__20220413__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zbLpeAvh8qQd" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-04-132022-04-13_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_BroadwoodCapitalLPMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></span> from the Company as reimbursement for its legal fees
and expenses. Mr. Gutfreund is the Managing Partner of Halle Capital Management, L.P. See Note 15 for additional information about the
Series A Preferred Stock Offering.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, on April 13, 2022, Oncocyte
entered into the Underwriting Agreement with the Underwriters for the Underwritten Offering. Pursuant to the Underwritten Offering, Broadwood
acquired from us (i) <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zOEM9YizVJd6" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_BroadwoodCapitalLPMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">261,032</ix:nonFraction></span> shares of common stock, and (ii) <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zC9ghIA6VO2e" title="Warrant to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_BroadwoodCapitalLPMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,187</ix:nonFraction></span> April 2022 Warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember__srt--RangeAxis__srt--MaximumMember_zgqrkiRphIb4" title="Warrant to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_PuraVidaInvestmentsLLCMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,093</ix:nonFraction></span> shares of common
stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zjWykj2AlOvd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_BroadwoodCapitalLPMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.60</ix:nonFraction></span> per share. However, the total number of shares of common stock that Broadwood purchased in the Underwritten
Offering was <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zHA37fRuHzQj" title="Warrant to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_BroadwoodCapitalLPMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,187</ix:nonFraction></span>, of which <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zYXTQjNAtji4" title="Warrant to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_UnderwritersMember_custom_BroadwoodCapitalLPMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,154</ix:nonFraction></span> existing shares were acquired by the underwriters in the open market and re-sold to Broadwood.
Pura Vida acquired from us (i) <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember_zx8ZVGI7wsMi" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_PuraVidaInvestmentsLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">249,204</ix:nonFraction></span> shares of common stock, and (ii) <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember_zoEaPeiKT1z9" title="Warrant to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_PuraVidaInvestmentsLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">286,585</ix:nonFraction></span> April 2022 Warrants to purchase up to <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember__srt--RangeAxis__srt--MaximumMember_z5Nc6XXf05Ya" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_custom_BroadwoodCapitalLPMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">143,292</ix:nonFraction></span> shares
of common stock. However, the total number of shares of common stock that Pura Vida purchased in the Underwritten Offering was <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember_zNHEvch00Twa" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_PuraVidaInvestmentsLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">286,585</ix:nonFraction></span>,
of which <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z9H4CxzjYARe" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_custom_PuraVidaInvestmentsLLCMember_custom_UnderwritersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,380</ix:nonFraction></span> existing shares were acquired by the underwriters in the open market and re-sold to Pura Vida. Halle Special Situations
Fund LLC purchased from us (i) <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember_z3D1sO3EcSw" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_HalleSpecialSituationsFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">309,976</ix:nonFraction></span> shares of common stock, and (ii) <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember_z588Go5psBv3" title="Warrant to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">356,472</ix:nonFraction></span> 2022 Warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember__srt--RangeAxis__srt--MaximumMember_zP95YY1jNjOb" title="Warrant to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">178,236</ix:nonFraction></span> shares of
common stock. Mr. Gutfreund is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of Halle
Special Situations Fund LLC. However, the total number of shares of common stock that Halle Special Situations Fund LLC purchased in the
Underwritten was <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember_zEGKj0A7JJT7" title="Warrant to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">356,472</ix:nonFraction></span>, of which <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zOcZ21AOdKS8" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember_custom_UnderwritersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,496</ix:nonFraction></span> existing shares were acquired by the underwriters in the open market and re-sold to Halle
Special Situations Fund LLC. See Note 15 for additional information about the Underwritten Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 3, 2023, Oncocyte entered
into a securities purchase agreement (the &#8220;2023 Securities Purchase Agreement&#8221;) with certain investors, including Broadwood,
Pura Vida and entities affiliated with AWM, and certain individuals, including our Chairman Andrew Arno and former director John Peter
Gutfreund (and certain of their affiliated parties), which provides for the sale and issuance by the Company of an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zMsTlEQa9qA3" title="Offering shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,274,709</ix:nonFraction></span>
shares of common stock at an offering price of: <span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zix9qv3MCfH2" title="Related party transaction, description"><ix:nonNumeric contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember" name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction">(i) $6.03 to investors who are not considered to be &#8220;insiders&#8221; of the Company
pursuant to Nasdaq Listing Rules (&#8220;Insiders&#8221;), which amount reflects the average closing price of the Common Stock on Nasdaq
during the five trading day period immediately prior to pricing, and (ii) $7.08 to Insiders, which amount reflects the final closing
price of the Common Stock on Nasdaq on the last trading day immediately prior to pricing (the &#8220;2023 Registered Direct Offering&#8221;)</ix:nonNumeric></span>.
Broadwood purchased <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember_z5XIG6KjyRhk" title="Offering shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_BroadwoodPartnersLPMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,341,381</ix:nonFraction></span> shares of common stock for $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember_zgi7nOooYcxl" title="Proceeds from issuance of stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_BroadwoodPartnersLPMember" format="ixt:numdotdecimal" decimals="2" unitRef="USD">8,093,361.84</ix:nonFraction></span>, Pura Vida purchased <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PuraVidaMember_zOWvY25l0Uf5" title="Offering shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_PuraVidaMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,150</ix:nonFraction></span> shares of common stock for $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PuraVidaMember_zyA3gb8xWtM9" title="Proceeds from issuance of stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_PuraVidaMember" format="ixt:numdotdecimal" decimals="2" unitRef="USD">200,013.84</ix:nonFraction></span>
and entities affiliated with AVM purchased <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--AVMMember_zVPxGawD1iRe" title="Offering shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_AVMMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">472,354</ix:nonFraction></span> shares of common stock for $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--AVMMember_zLrBrFqzNs9j" title="Proceeds from issuance of stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_AVMMember" format="ixt:numdotdecimal" decimals="2" unitRef="USD">2,849,999.92</ix:nonFraction></span>. Mr. Arno and his affiliated parties purchased
<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--ArnoMember_z1sFbNXKb87h" title="Offering shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_ArnoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,162</ix:nonFraction></span> shares of common stock for $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--ArnoMember_zrqVnimk2ZQe" title="Proceeds from issuance of stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_ArnoMember" format="ixt:numdotdecimal" decimals="2" unitRef="USD">150,000.51</ix:nonFraction></span>, and Mr. Gutfreund and his affiliated parties purchased <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--MrGutfreundMember_zweVaocFJeN3" title="Offering shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_MrGutfreundMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,250</ix:nonFraction></span> for $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--MrGutfreundMember_zShhhQIXlpCi" title="Proceeds from issuance of stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_MrGutfreundMember" format="ixt:numdotdecimal" decimals="2" unitRef="USD">604,252.00</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 5, 2023, Oncocyte redeemed
all of the <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pp5d_c20220405__20220405__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zffpYiREbyQ2" title="Stock issued during period, shares, conversion of units"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-04-052022-04-05_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="5" unitRef="Shares">588.23529</ix:nonFraction></span> shares of Series A Preferred Stock held by Mr. Gutfreund for $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pp2d_c20220405__20220405__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8r7Yh5acMoh" title="Stock issued during period, value conversion of units"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2022-04-052022-04-05_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="2" unitRef="USD">618,672.34</ix:nonFraction></span>. Mr. Gutfreund is no longer a related party
as of June 23, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Company Employee(s)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2023, the
Company employed the son of Andrew Arno, Chairman of the Board as its Senior Manager, Investor Relations, Corporate Planning &amp;
Development. As of June 30, 2023, the total compensation paid by the Company to Mr. Arno&#8217;s son since January 1, 2022 is
approximately $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20230630__us-gaap--RelatedPartyTransactionAxis__custom--ArnoMember_zUQI2BjgQCmf" title="Total compensation paid"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-06-30_custom_ArnoMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span>
million. Mr. Arno&#8217;s son is no longer an employee of the Company as of July 28, 2023.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_805_eus-gaap--LongTermDebtTextBlock_zdqR29ID3GN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>13.
<span id="xdx_828_zrMTYXD6zsN1">Loan Payable to Silicon Valley Bank</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Amended
Loan Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
October 17, 2019, Oncocyte entered into a First Amendment to Loan and Security Agreement (the &#8220;Amended Loan Agreement&#8221;) with
Silicon Valley Bank (&#8220;the Bank&#8221;) pursuant to which Oncocyte obtained a new $<span id="xdx_905_eus-gaap--LinesOfCreditCurrent_iI_pn6n6_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zkwh5lsbnqO6" title="Line of credit, current"><ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">3</ix:nonFraction></span> million secured credit facility (&#8220;Tranche
1&#8221;), a portion of which was used to repay the remaining balance of approximately $<span id="xdx_903_eus-gaap--RepaymentsOfLinesOfCredit_c20191016__20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zSbNPVsuVGk3" title="Repayments of lines of credit"><ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="From2019-10-162019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">400,000</ix:nonFraction></span> on outstanding loans from the Bank, plus
a final payment of $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zkkDswSjbCF" title="Debt instrument, final payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" contextRef="AsOf2019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,000</ix:nonFraction></span>, under the February 21, 2017 Loan Agreement. The credit line under the Amended Loan Agreement may be increased
by an additional $<span id="xdx_908_eus-gaap--LinesOfCreditCurrent_iI_pn6n6_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zXb5yFwe35" title="Line of credit, current"><ix:nonFraction name="us-gaap:LinesOfCreditCurrent" contextRef="AsOf2019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span> million (&#8220;Tranche 2&#8221;) if Oncocyte obtains at least $<span id="xdx_909_eus-gaap--AdditionalPaidInCapital_iI_pn6n6_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zuJoOEOQblx9" title="Additional paid in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million of additional equity capital, as was the
case with the original Loan Agreement, and a positive final coverage determination is received from CMS for DetermaRx at a specified
minimum price point per test (the &#8220;Tranche 2 Milestone&#8221;), and Oncocyte is not in default under the Amended Loan Agreement.
As of June 30, 2023, Oncocyte had satisfied the Tranche 2 Milestone and was eligible to borrow the $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_do_c20230630__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zMVCgLpOOy61" title="Line of credit facility, maximum borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2023-06-30_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></span> million Tranche 2 funds. However,
Oncocyte has not yet borrowed any funds under Tranche 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Payments
of interest only on the principal balance were due monthly from the draw date through March 31, 2020, followed by 24 monthly payments
of principal and interest, but the Bank has agreed to a deferral of principal payments, as discussed below. The outstanding principal
balance of the loan will bear interest at a stated floating annual interest equal to the greater of (a) the prime rate or (b) <span id="xdx_90C_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zzHOBuJr9S8b" title="Interest rate"><ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" contextRef="AsOf2019-10-17_custom_AmendedLoanAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% per
annum. During August 2022, period in which the loan was paid off, the published prime rate was <span id="xdx_90E_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230630_zzUrc3mk0Gj8" title="Interest rate"><ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.5</ix:nonFraction></span>% per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 2, 2020, as part of the Bank&#8217;s COVID-19 pandemic relief program, Oncocyte and the Bank entered into a Loan Deferral Agreement
(&#8220;Loan Deferral&#8221;) with respect to the Amended Loan Agreement. <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20200401__20200402__us-gaap--TypeOfArrangementAxis__custom--LoanDeferralAgreementMember_zazUK3crrSD4" title="Debt instrument maturity date description"><ix:nonNumeric contextRef="From2020-04-012020-04-02_custom_LoanDeferralAgreementMember" name="us-gaap:DebtInstrumentMaturityDateDescription">Under the Loan Deferral Agreement, the Bank agreed to (i) extend
the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal
payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May
1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided
at no additional fees to Oncocyte</ix:nonNumeric></span>. No other terms of the Amended Loan Agreement were changed or modified. The Loan Deferral was accounted
for as a modification of debt in accordance with ASC 470-50, <i>Debt &#8211; Modifications and Extinguishments</i>, thus there was no
gain or loss recognized on the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">At
maturity of the loan, Oncocyte agreed to pay the Bank an additional final payment fee of $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20191031__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zLE3svKM2k21" title="Debt instrument, final payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" contextRef="AsOf2019-10-31_custom_BankWarrantMember_custom_AmendedLoanAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>, which was recorded as a deferred financing
charge in October 2019 and is being amortized to interest expense over the term of the loan using the effective interest method. As of
June 30, 2023, there is no remaining unamortized deferred financing cost and the full principal balance of the loan in addition to the
final payment fee have been paid off.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Bank
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
2017, in connection with the Loan Agreement, Oncocyte issued common stock purchase warrants to the Bank (the &#8220;2017 Bank Warrants&#8221;)
entitling the Bank to purchase shares of Oncocyte common stock in tranches related to the loan tranches under the Loan Agreement. In
conjunction with the availability of the loan, the Bank was issued warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0BAs5j803Wf" title="Warrants to purchase, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2017-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">412</ix:nonFraction></span> shares of Oncocyte common stock at an exercise
price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z09BO9ImYD2j" title="Warrant exercise price, per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2017-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">97.00</ix:nonFraction></span> per share, through February 21, 2027. On March 23, 2017, the Bank was issued warrants to purchase an additional <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20170323__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zTAL024Hgzea" title="Warrants to purchase, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2017-03-23_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">366</ix:nonFraction></span> shares
at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20170323__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsWZL0Dh2Ci2" title="Warrant exercise price, per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2017-03-23_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">109.20</ix:nonFraction></span> per share, through March 23, 2027. The Bank may elect to exercise the 2017 Bank Warrants on a &#8220;cashless
exercise&#8221; basis and receive a number of shares determined by multiplying the number of shares for which the applicable tranche
is being exercised by (A) the excess of the fair market value of the common stock over the applicable exercise price, divided by (B)
the fair market value of the common stock. The fair market value of the common stock will be the last closing or sale price on a national
securities exchange, inter-dealer quotation system, or over-the-counter market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
October 17, 2019, in conjunction with Tranche 1 becoming available under the Amended Loan Agreement, Oncocyte issued a common stock purchase
warrant to the Bank (the &#8220;2019 Bank Warrant&#8221;) entitling the Bank to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zEFZgzEkwh0k" title="Warrants to purchase, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2019-10-17_custom_BankWarrantMember_custom_AmendedLoanAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,928</ix:nonFraction></span> shares of Oncocyte common stock at the
initial &#8220;Warrant Price&#8221; of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_z9pnCFgayZb9" title="Warrant exercise price, per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-10-17_custom_BankWarrantMember_custom_AmendedLoanAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">33.80</ix:nonFraction></span> per share through October 17, 2029. The number of shares of common stock issuable upon
the exercise of the 2019 Bank Warrant will increase on the date of each draw, if any, on Tranche 2. The number of additional shares of
common stock issuable upon the exercise of the 2019 Bank Warrant will be equal to <span id="xdx_906_ecustom--PercentageForWarrantExercisePricePerShare_pid_dp_uPure_c20191016__20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zSlgxVF4OsTh" title="Percentage for warrant exercise price per share"><ix:nonFraction name="OCX:PercentageForWarrantExercisePricePerShare" contextRef="From2019-10-162019-10-17_custom_BankWarrantMember_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.02</ix:nonFraction></span>% of Oncocyte&#8217;s fully diluted equity outstanding
for each $<span id="xdx_908_ecustom--DilutedEquityOutstanding_pn6n6_c20191016__20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zBM5N48O83U3" title="Diluted equity outstanding"><ix:nonFraction name="OCX:DilutedEquityOutstanding" contextRef="From2019-10-162019-10-17_custom_BankWarrantMember_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million draw under Tranche 2. The Warrant Price for Tranche 2 warrant shares will be determined upon each draw of Tranche
2 funds and will be closing price of Oncocyte common stock on the date immediately before
the applicable date on which Oncocyte borrows funds under Tranche 2. The Bank may elect to exercise the 2019 Bank Warrant on a &#8220;cashless
exercise&#8221; basis and receive a number of shares determined by multiplying the number of shares for which the 2019 Bank Warrant is
being exercised by (A) the excess of the fair market value of the common stock over the applicable Warrant Price, divided by (B) the
fair market value of the common stock. The fair market value of the common stock will be last closing or sale price on a national securities
exchange, interdealer quotation system, or over-the-counter market. As of June 30, 2023, Oncocyte has not borrowed any funds under Tranche
2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="OCX:CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock"><p id="xdx_80F_ecustom--CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock_zobTcfDT6Tqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>14.
<span id="xdx_828_zZwTbgUjSyeb">Co-Development Agreement with Life Technologies Corporation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
January 13, 2022, Oncocyte entered into a Collaboration Agreement (the &#8220;LTC Agreement&#8221;) with Life Technologies Corporation,
a Delaware corporation and subsidiary of Thermo Fisher Scientific (&#8220;LTC&#8221; and together with Oncocyte, the &#8220;Parties&#8221;
or individually, a &#8220;Party&#8221;), in order to partner in the development and collaborate in the commercialization of Thermo Fisher
Scientific&#8217;s existing Oncomine Comprehensive Assay Plus (&#8220;OCA Plus&#8221;) and Oncocyte&#8217;s DetermaIO assay for use with
LTC&#8217;s Ion Torrent<sup>TM</sup> Genexus<sup>TM</sup> Integrated Sequencer and LTC&#8217;s Ion Torrent<sup>TM</sup> Genexus<sup>TM
</sup>Purification System (&#8220;Genexus system&#8221;) in order to obtain <i>in vitro </i>diagnostic (&#8220;IVD&#8221;) regulatory
approval. On February 7, 2023, Oncocyte entered into a Termination Agreement (the &#8220;Termination Agreement&#8221;) with LTC, pursuant
to which the parties terminated the LTC Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023, Oncocyte was responsible for reimbursing LTC for $<span id="xdx_901_eus-gaap--DevelopmentCosts_c20230101__20230630__dei--LegalEntityAxis__custom--LifeTechnologiesCorporationMember_zfCvAuebcka4" title="Development costs"><ix:nonFraction name="us-gaap:DevelopmentCosts" contextRef="From2023-01-012023-06-30_custom_LifeTechnologiesCorporationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">749,000</ix:nonFraction></span> of certain development costs under the terms of the LTC Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b>&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="OCX:AprilTwentyTwentyTwoOfferingsTextBlock"><p id="xdx_809_ecustom--AprilTwentyTwentyTwoOfferingsTextBlock_z7bMY3Mjbwdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>15.
<span id="xdx_822_z1Lt1DpVWOP2">Equity Offerings</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Series
A Preferred Stock Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 13, 2022, Oncocyte entered into the Securities Purchase Agreement with Investors, including Broadwood, in a registered direct offering
of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHkNo2g6D8C8" title="Stock issued during period, shares, conversion of units"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,765</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">shares of our Series A Preferred
Stock, which shares of Series A Preferred Stock are convertible into a total of <span id="xdx_906_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKLvE8EwmGTd" title="Preferred stock, convertible, shares issuable"><ix:nonFraction name="us-gaap:PreferredStockConvertibleSharesIssuable" contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">384,477</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">shares of our common stock, at
a conversion price of $<span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMQHkgXeJKv9" title="Preferred stock, convertible, conversion price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.60</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.
The purchase price of each share of Series A Preferred Stock was $<span id="xdx_901_ecustom--PurchasePrice_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpePk84Xj6pg" title="Purchase price"><ix:nonFraction name="OCX:PurchasePrice" contextRef="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">850</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">,
which included an original issue discount to the stated value of $<span id="xdx_907_ecustom--StatedValue_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHCuAznQ42Mb" title="Stated value"><ix:nonFraction name="OCX:StatedValue" contextRef="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">per share. The rights, preferences
and privileges of the Series A Convertible Preferred Stock are set forth in the Company&#8217;s Certificate of Determination, which the
Company filed with the Secretary of State of the State of California. The Securities Purchase Agreement provides that the closing of
the Series A Preferred Stock Offering will occur, subject to the satisfaction of certain closing conditions, in two equal tranches of
$<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--AwardTypeAxis__custom--TwoEqualTranchesMember_zp2vVD2j2rV6" title="Proceeds from issuance of preferred stock and preference stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember_custom_TwoEqualTranchesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">each for aggregate gross proceeds
from both closings of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHmN7jFCvz52" title="Proceeds from issuance of preferred stock and preference stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.
The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220601__20220601__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z5u8wT87iHX7" title="Net proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-06-012022-06-01_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.9</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">million from the Series A Preferred
Stock issued from the first tranche. The second closing would occur, subject to the satisfaction of certain closing conditions (including
but not limited to a requirement that the Company has not received, in the 12 months preceding the second closing, a notice from Nasdaq
that the Company is not in compliance with the listing and maintenance and listing requirements of Nasdaq), on the earlier of (a) the
second trading day following the date that Oncocyte receives notice from an Investor to accelerate the second closing and (b) a date
selected by Oncocyte on or after October 8, 2022 and on or prior to March 8, 2023. On August 9, 2022, Oncocyte received a letter from
Nasdaq indicating that the Company no longer met the minimum bid price requirement of the Nasdaq continued
listing requirements. Accordingly</span>, the second closing did not occur and no additional proceeds were received under the Securities
Purchase Agreement. On August 8, 2023, the Company received a letter from Nasdaq indicating that the Company had regained compliance
with the minimum bid price requirement of the Nasdaq continued listing requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock is convertible into shares of common stock at any time at the holder&#8217;s option. The conversion price will
be subject to customary anti-dilution adjustments for matters such as stock splits, stock dividends and other distributions on common
stock, and recapitalizations. <span id="xdx_902_eus-gaap--ConversionOfStockDescription_c20220412__20220413_zpQT5S2YFPoj" title="Conversion of stock description"><ix:nonNumeric contextRef="From2022-04-122022-04-13" name="us-gaap:ConversionOfStockDescription">The holder will be prohibited from converting shares of Series A Preferred Stock into shares of common
stock if, as a result of such conversion, the holder, together with its affiliates, would own more than <span id="xdx_905_ecustom--PercentageOfIssuedAndOutstandingShares_pid_dp_uPure_c20220412__20220413_zdiZERYD99zc" title="Percentage of issued and outstanding shares"><ix:nonFraction name="OCX:PercentageOfIssuedAndOutstandingShares" contextRef="From2022-04-122022-04-13" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span>% of the shares of common
stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation
solely as to itself up to 19.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion,
provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance
of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the
holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)</ix:nonNumeric></span>. On July 15, 2022, the
Company received such shareholder approval to remove the beneficial ownership limitation with respect to the Series A Preferred Stock
held by Broadwood. Oncocyte may force the conversion of up to one-third of the shares of Series A Preferred Stock originally
issued, subject to customary equity conditions, <span id="xdx_904_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20220714__20220715__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zNNjsrs7T0Uf" title="Equity method investment description"><ix:nonNumeric contextRef="From2022-07-142022-07-15_us-gaap_SeriesAPreferredStockMember_custom_OncocyteCorpMember" name="us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities">if the daily volume weighted average price of our common stock for 20 out of 30 trading
days exceeds <span id="xdx_90C_ecustom--ConversionPricePercentage_dp_uPure_c20220714__20220715_zBcnfG6qw7q3"><ix:nonFraction name="OCX:ConversionPricePercentage" contextRef="From2022-07-142022-07-15" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">140</ix:nonFraction></span>% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000
shares of our common stock</ix:nonNumeric></span>. Oncocyte may only effect one forced conversion during any 30-trading day period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of the Company&#8217;s liquidation, dissolution, or winding up, holders of Series A Preferred Stock will receive a payment
equal to the stated value of the Series A Preferred Stock plus accrued but unpaid dividends and any other amounts that may have become
payable on the Series A Preferred Stock due to any failure or delay that may have occurred in issuing shares of common stock upon conversion
of a portion of the Series A Preferred Stock, before any distribution or payment to the holders of common stock or any of Oncocyte&#8217;s
other junior equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Series A Preferred Stock generally has no voting rights, except as required by law and except that the consent of holders of a majority
of the outstanding Series A Preferred Stock will be required to amend any provision of our certificate of incorporation that would have
a materially adverse effect on the rights of the holders of the Series A Preferred Stock. Additionally, as long as any shares of Series
A Preferred Stock remain outstanding, unless the holders of at least <span id="xdx_908_ecustom--PreferredStockRemainsOutstandingPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWtuwefAG66c" title="Preferred stock outstanding percentage"><ix:nonFraction name="OCX:PreferredStockRemainsOutstandingPercentage" contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">51</ix:nonFraction></span>% of the then outstanding shares of Series A Preferred Stock shall
have otherwise given prior written consent, the Company, on a consolidated basis with its subsidiaries, is not permitted to (1) have
less than $<span id="xdx_90F_eus-gaap--Cash_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrGbCIpHHeG9" title="Cash in hand"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">8</ix:nonFraction></span> million of unrestricted, unencumbered cash on hand (&#8220;Cash Minimum Requirement&#8221;); (2) other than certain permitted
indebtedness, incur indebtedness to the extent that our aggregate indebtedness exceeds $<span id="xdx_901_ecustom--IndebtednessExpenses_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXrh9NtXVYUl" title="Indebtedness expenses"><ix:nonFraction name="OCX:IndebtednessExpenses" contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">15</ix:nonFraction></span> million; (3) enter into any agreement (including
any indenture, credit agreement or other debt instrument) that by its terms prohibits, prevents, or otherwise limits our ability to pay
dividends on, or redeem, the Series A Preferred Stock in accordance with the terms of the Certificate of Determination; or (4) authorize
or issue any class or series of preferred stock or other capital stock of the Company that ranks senior or pari passu with the Series
A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Series A Preferred Stock will be entitled to receive cumulative dividends at a rate per share (as a percentage of stated value) of
6% per annum, payable quarterly in cash or, at our option, by accreting such dividends to the stated value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is required to redeem, for cash, the shares of Series A Preferred Stock on the earlier to occur of (1) April 8, 2024, (2) the
commencement of certain a voluntary or involuntary bankruptcy, receivership, or similar proceedings against us or our assets, (3) a Change
of Control Transaction (as defined herein) and (4) at the election and upon notice of 51% in interest of the holders, if the Company
fails to meet the Cash Minimum Requirement. A &#8220;Change of Control Transaction&#8221; means the occurrence of any of (a) an acquisition
by an individual or legal entity or &#8220;group&#8221; (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective
control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess of <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zt3FhiR5dqwf" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember_custom_OncocyteCorpMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
of the voting securities of the Company (other than by means of conversion of Series A Preferred Stock), (b) the Company merges into
or consolidates with any other person, or any person merges into or consolidates with the Company and, after giving effect to such transaction,
the stockholders of the Company immediately prior to such transaction own less than <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SecurityMember_zc8URNam80lb" title="Ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember_custom_SecurityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the aggregate voting power of the Company
or the successor entity of such transaction, or (c) the Company sells or transfers all or substantially all of its assets to another
person. Additionally, the Company has the right to redeem the Series A Preferred Stock for cash upon 30 days prior notice to the holders;
provided if the Company undertakes a capital raise in connection with such redemption, the Investors will have the right to participate
in such financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance and sale of the Series A Preferred Stock was completed pursuant to the Company&#8217;s effective shelf registration statement
on Form S-3 (Registration No. 333-256650), filed with the SEC on May 28, 2021 and declared effective by
the SEC on June 8, 2021, and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the registered direct offering in April 2023, the Company used approximately $<span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zuPcvV2JzAvj" title="Net proceeds to immediately redeem"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million of the net proceeds to immediately
redeem an aggregate of <span id="xdx_901_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjccM0IMidKg" title="Number of stock redeem"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,064</ix:nonFraction></span> shares of its Series A Preferred Stock and may thereafter elect to redeem additional shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock dividend for all issued and outstanding shares is set at <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBVX0IP0j7I5" title="Preferred stock, dividend rate, percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2023-01-012023-06-30_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% per annum per share. As of June 30, 2023, the Company
elected to accrete dividends of $<span id="xdx_905_eus-gaap--DividendsPreferredStock_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2vPxXQiYTYg" title="Dividends, preferred stock"><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2023-01-012023-06-30_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">321,000</ix:nonFraction></span>, net of the April 2023 redemption, with respect to shares of Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, Oncocyte had <span id="xdx_908_eus-gaap--TemporaryEquitySharesIssued_iI_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zancJFOFUNh2" title="Number of shares issued"><span id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKtCuCVF48kj" title="Number of shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2023-06-30_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,818</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding. The future right or obligation associated with the Series A Preferred
Stock to be issued in the second closing was written off since the second closing was not received as of June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Underwritten
Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 13, 2022, Oncocyte entered into the Underwriting Agreement with the Underwriters, pursuant to which the Company agreed to issue
and sell to the Underwriters an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_z5cvbXFKqjM5" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-122022-04-13_us-gaap_OverAllotmentOptionMember_custom_AprilTwoThousandTwentyTwoWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,313,320</ix:nonFraction></span> shares of common stock and <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_zJ2JaG4Z3Fcc" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-13_us-gaap_IPOMember_custom_AprilTwoThousandTwentyTwoWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,313,320</ix:nonFraction></span> April 2022 Warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlzplsDO1AX" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-13_us-gaap_IPOMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">656,660</ix:nonFraction></span>
shares of common stock. Each share of common stock and the accompanying April 2022 Warrant was sold at a combined offering price of $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_zArsGT6Feauj" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-04-13_us-gaap_IPOMember_custom_AprilTwoThousandTwentyTwoWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">26.65</ix:nonFraction></span>,
representing an offering price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBKsZLYRlKXf" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-04-13_us-gaap_IPOMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">26.45</ix:nonFraction></span> per share of common stock and $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuauwKKWFnae" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-13_us-gaap_IPOMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.20</ix:nonFraction></span> per accompanying April 2022 Warrant, before underwriting
discounts and commissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Underwriting Agreement, the Company also granted to the Underwriters an over-allotment option, exercisable in whole
or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase up to an additional <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_zVBDxM5BxTpf" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-122022-04-13_custom_UnderwritingAgreementMember_custom_AprilTwoThousandTwentyTwoWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">196,998</ix:nonFraction></span> shares
of common stock and <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsU71sbHzO2h" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-13_custom_UnderwritingAgreementMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">196,998</ix:nonFraction></span> April 2022 Warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbGV7DgeWKlj" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-13_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">98,499</ix:nonFraction></span> shares of common stock to cover over-allotments, if any. The over-allotment
option may be exercised separately for shares of common stock at a price to the underwriters of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_z0A5bI6Lc27h" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-04-13_custom_UnderwritingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.85</ix:nonFraction></span> per share, and April 2022 Warrants
at a price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220413__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaUkRKySMzTb" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-04-13_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.20</ix:nonFraction></span> per April 2022 Warrant. On April 14, 2022, the Underwriters exercised their option to purchase the <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zqZ8aHbKM2T7" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-122022-04-13_custom_UnderwritingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">196,998</ix:nonFraction></span> April
2022 Warrants pursuant to the over-allotment option but did not exercise their option to purchase the additional <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zNPFOf32TESf" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-122022-04-13_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">196,998</ix:nonFraction></span> shares of common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received net proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220418__20220419__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z8RSGCj7oAMd" title="Proceeds from issuance initial public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-04-182022-04-19_us-gaap_OverAllotmentOptionMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">32.8</ix:nonFraction></span> million from the Underwritten Offering, which includes the April 2022 Warrants sold
upon the exercise of the Underwriters&#8217; overallotment option. The Underwritten Offering closed on April 19, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwritten Offering was made pursuant to the Company&#8217;s effective &#8220;shelf&#8221; registration statement on Form S-3 (Registration
No. 333-256650) filed with the SEC Commission on May 28, 2021 and declared effective by the SEC on June 8, 2021,
and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Registered
Direct Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 3, 2023, Oncocyte entered into an agreement with certain members of the Company&#8217;s board of directors, and several institutional
and accredited investors, including Broadwood, the Company&#8217;s largest shareholder, and certain members of the Company&#8217;s board
of directors (and certain of their affiliated parties), relating to their purchase of an aggregate of up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--RangeAxis__srt--MaximumMember_zPrVMZICxex3" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,278,121</ix:nonFraction></span> shares of its common
stock at an offering price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--BoardMembersMember_z6ErrnuHCXza" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-04-03_custom_RegisteredDirectOfferingMember_custom_BoardMembersMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.08</ix:nonFraction></span> per share to board members and $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--OtherInvestorsMember_zaI3G4Mx9rE2" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-04-03_custom_RegisteredDirectOfferingMember_custom_OtherInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.03</ix:nonFraction></span> per share to the other investors participating in the offering.
The offering was intended to be priced at-the-market for purposes of complying with applicable Nasdaq Listing Rules. The aggregate gross
proceeds from the offering were approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember_zTATHj93Nwf7" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">13.9</ix:nonFraction></span> million. The Company used approximately $<span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9lzrGVuCRZe" title="Net proceeds to immediately redeem"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million of the net proceeds to immediately
redeem an aggregate of <span id="xdx_901_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBG8ioUQcEXf" title="Number of stock redeem"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,064</ix:nonFraction></span> shares of its Series A Preferred Stock and may thereafter elect to redeem additional shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"><p id="xdx_800_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zmtyUnKr1rF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
<span id="xdx_828_zjDs3QD2cCw4">Assets Held for Sale and Discontinued Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Razor
Disposal </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2022, the Company entered into the Razor Stock Purchase Agreement with Dragon and Razor. Pursuant to the Razor Stock Purchase
Agreement, Oncocyte agreed to sell, and Dragon agreed to purchase, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221214__20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DragonMember_zhnzNri45yRb" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-12-142022-12-15_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_DragonMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,188,181</ix:nonFraction></span> shares of common stock of Razor, which constitutes approximately
<span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_z6WarqAjJeZd" title="Equity method investment ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-12-15_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember_custom_DragonMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>% of the issued and outstanding equity interests of Razor on a fully-diluted basis. On February 16, 2023, Oncocyte completed the Razor
Sale Transaction. In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx.
While <span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_dp_c20230216__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_zmqFraAOBuE5" title="Cash received on stock transaction">no</span> monetary consideration was received for the sale of <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_zh4YBVstOJJ6" title="Equity method investment ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_custom_RazorMember_us-gaap_CommonStockMember_custom_DragonMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>% of the equity interests of Razor, the transaction allows the Company
to eliminate all development and commercialization costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to
own <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230216__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zZnX60kItHAi" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-162023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,366,364</ix:nonFraction></span> shares of common stock of Razor, which constitutes approximately <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zlp8TfKYFJv4" title="Equity method investment ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></span>% of the issued and outstanding equity interests of
Razor on a fully-diluted basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the transfer of <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_zPTA9Kgah2kh" title="Equity method investment ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_custom_RazorMember_us-gaap_CommonStockMember_custom_DragonMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>% of the equity interests of Razor, the Razor Stock Purchase Agreement provided that Dragon would purchase
furniture, fixtures, and equipment from the Company for a cash consideration of $<span id="xdx_90A_eus-gaap--BusinessCombinationConsiderationTransferred1_c20230216__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--BusinessAcquisitionAxis__custom--RazorMember_zKYXIdHUoHrb" title="Consideration transferred"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2023-02-162023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember26469671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,660</ix:nonFraction></span>. Upon the Razor Closing, the Company deconsolidated
the assets and liabilities of Razor as control of Razor has transferred to Dragon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded the final adjustment related to the disposal, including final working capital adjustments, and recognized a loss of
$<span id="xdx_90A_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_iN_pn5n6_di_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zHN3nfvUWC82" title="Loss on disposal"><ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="From2023-01-012023-03-31_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">1.3</ix:nonFraction></span> million during the first quarter of 2023. Including the impairment losses we recognized as of December 31, 2022 related to this
transaction, we recorded an overall loss of $<span id="xdx_902_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_iN_pn5n6_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zosQd1370lpe" title="Loss on disposal"><ix:nonFraction name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="From2022-01-012022-12-31_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">27.2</ix:nonFraction></span> million. The operating results for Razor have been recorded in discontinued operations
of the accompanying unaudited condensed consolidated statements of operations for all periods presented, and we have reclassified their
assets and liabilities as held for sale for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Laboratory
equipment sold and held for sale</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2023, the Company entered into an agreement to sell laboratory equipment for $<span id="xdx_908_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_pn5n6_c20230131__20230131__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_z18Xsr3O9IRb" title="Proceeds from sale of equipment"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-01-312023-01-31_custom_LaboratoryEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million. As of June 30, 2023, the Company
classified the equipment not yet sold as held for sale in current assets in the unaudited condensed consolidated balance sheet, as all
the criteria of ASC subtopic 360-10, Property, Plant, and Equipment (&#8220;ASC 360-10&#8221;) have been met and the transaction was
qualified as assets held for sale. The balance included in current assets held for sale related to this transaction was $<span id="xdx_906_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroupCurrent_iI_pn5n6_c20230630__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_zcw9dyVgiJhf" title="Assets held for sale"><ix:nonFraction name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" contextRef="AsOf2023-06-30_custom_LaboratoryEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company entered into an agreement to auction equipment for $<span id="xdx_909_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_pn5n6_c20230301__20230331__us-gaap--TypeOfArrangementAxis__custom--AuctionEquipmentAgreementMember_zw0lFlDJCEYl" title="Proceeds from sale of equipment"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-03-012023-03-31_custom_AuctionEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million net proceeds. The auction was finalized on March
21, 2023, and the Company recorded a loss of $<span id="xdx_90C_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pn5n6_c20230301__20230331__us-gaap--TypeOfArrangementAxis__custom--AuctionEquipmentAgreementMember_z5flXigqZRc3" title="Loss on disposal and held-for-sale assets"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-03-012023-03-31_custom_AuctionEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million which is included in the loss on disposal and held-for-sale assets, on the
unaudited condensed consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 31, 2023, the Company entered into an agreement to sell laboratory equipment for $<span id="xdx_90C_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_pn5n6_c20230331__20230331__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_zcV0ZQdbK0ad" title="Proceeds from sale of equipment"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-03-312023-03-31_custom_LaboratoryEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million. As a result, the Company classified
the equipment as held for sale as current assets, in the unaudited condensed consolidated balance sheet, as all the criteria of ASC subtopic
360-10, Property, Plant, and Equipment (&#8220;ASC 360-10&#8221;) have been met and the transaction was qualified as assets held for
sale. This equipment was written down to its fair value, less cost to sell, to $<span id="xdx_90E_eus-gaap--DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_pn5n6_c20230331__20230331__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_zqPlOSOvvYOe" title="Proceeds from sale of equipment"><ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" contextRef="From2023-03-312023-03-31_custom_LaboratoryEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million in the unaudited condensed consolidated balance
sheet. As a result of the expected sale, the Company recorded an impairment loss and loss on disposal of $<span id="xdx_909_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn5n6_c20230331__20230331__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_zV3plvjPvVcg" title="Impairment loss"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2023-03-312023-03-31_custom_LaboratoryEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million on held-for-sale
assets, in the unaudited condensed consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classified its results of operations as discontinued operations for all periods presented in the accompanying unaudited condensed
consolidated statements of operations. We have retrospectively adjusted the amounts reported for the period ended June 30, 2022, in the
following table to give effect to such reporting of discontinued operations. For the period ended June 30, 2023, discontinued operations
reflect operating results of Razor up to the closing of the sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s unaudited condensed consolidated balance sheets and consolidated statements of operations report discontinued operations
separate from continuing operations. Our unaudited condensed consolidated statements of comprehensive loss, statements of shareholders&#8217;
equity and statements of cash flows combined continuing and discontinued operations. A summary of financial information related to the
Company&#8217;s discontinued operations is as follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zGdZMxHT2XY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the results of the discontinued operation of Razor (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zxGaizYTg6zc">Schedule
of Discontinued Operations</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230401__20230630_z0gyMZVfHy8h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220401__20220630_zdqYEtBar4F8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20230630_zuBpcQRtcPfg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220630_zYCwMq5QzTl3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_maILFDOz7EG_zskB8uCAfHda" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-align: left; padding-left: 0pt">Net revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2050">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,830</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">421</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,874</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_pn3n3_msILFDOz7EG_zXMm03wbM6zg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2055">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,175</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">507</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,999</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_pn3n3_msILFDOz7EG_zoOVqv17lnm4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2060">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">702</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,251</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_pn3n3_msILFDOz7EG_ztcBHCsHHzIf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2065">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">498</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,366</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_pn3n3_msILFDOz7EG_zK53DyhlaqE2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2070">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">329</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax_pn3n3_msILFDOz7EG_zSQ2ie5pvEHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Loss from impairment of held for sale assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2075">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2076">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,311</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2078">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pn3n3_maNILziQi_mtILFDOz7EG_z5leA6WS1ql3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Net loss from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2080">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,936</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,926</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,814</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AE_zmJnvLI4Imul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2023-01-012023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember" escape="true" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hus-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zOQtzHOB0hf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the carrying amounts of the held for sale related assets and liabilities as of June 30, 2023 and carrying
amounts of the held for sale related assets and liabilities of discontinued operations as of December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z5eSjrfdTnxh" style="display: none">Schedule
of Assets and Liabilities of Disposal Group Held for Sale</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230630__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zOzjMJC91CUk" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zDPDc331bJjh" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zo0L4cJtyTE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_iB_zLWgqZ0u2nTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_z4rcUtCfq877" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2093">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,510</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_znknJj3nFopb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2096">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">346</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_iI_z03BhLjQQiia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Machinery and equipment, net, and construction in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2099">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">211</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_iI_zJJS9apEFwda" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2102">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,920</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_iI_ztiYQ2fmOHCe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Impairment of held for sale assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2105">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales" contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">25,866</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--Assets_iTI_zjuNc9dwbuNg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2108">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,121</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zxlqfIG4mWg7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_zBjMqrQ9nRXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">492</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_iI_pn3n3_zpnkOBYVPVti" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2117">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationAccruedCompensation" contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">248</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_iI_zdWefBMn5567" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2120">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OCX:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,265</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_iI_zibFh2pWp4lf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,005</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Liabilities_iTI_zIjraUnT43Od" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,005</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes cash used related to Razor as of and for the six months ended June 30, 2023 and 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230630_zPeD0kFUQLb4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20220630_zFYgXi0vnvqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInDiscontinuedOperationsAbstract_iB_zQ4AOA5Y2PY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_i01_zbwC2PUjf0r1" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Net cash used in operating activities</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="From2023-01-01to2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,357</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,549</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zIpX1ulQNjo2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_i01_zfXsAZWSjqc4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2138">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="From2022-01-012022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">96</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zIiql2e3Nr1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-06-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_z3jEItIc8Rw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_82F_zBr8zJmCDqQa">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2023, the Company implemented a <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20230723__20230724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlXf9FZENefa" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-07-232023-07-24_us-gaap_SubsequentEventMember" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-20 reverse stock split</ix:nonNumeric></span> of the outstanding shares of its common stock. The par value per
share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split.
All common stock share and per-share amounts for all periods presented in these condensed financial statements have been adjusted to
reflect the reverse stock split. The number of authorized shares of common stock remains at <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20230724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlNOOzxLrOdg" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-07-24_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="Shares">230</ix:nonFraction></span> million shares.</span></p>

</ix:nonNumeric><p id="xdx_81C_zXuSVfBPIERh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="rs_001"></span>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
matters addressed in this Item 2 that are not historical information constitute &#8220;forward-looking statements&#8221; within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, including statements
about any of the following: any projections
of earnings, revenue, cash, effective tax rate, use of net operating losses, or any other financial items; the plans, strategies and
objectives of management for future operations or prospects for achieving such plans, and any statements of assumptions underlying any
of the foregoing. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements.
Without limiting the foregoing, the words &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221;
&#8220;seeks,&#8221; &#8220;estimates,&#8221; and similar expressions are intended to identify forward-looking statements. While Oncocyte
may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the Oncocyte
estimates change and readers should not rely on those forward-looking statements as representing Oncocyte views as of any date subsequent
to the date of the filing of this Report. Although we believe that the expectations reflected in these forward-looking statements
are reasonable, such statements are inherently subject to risks and Oncocyte can give no assurances that its expectations will prove
to be correct. Actual results could differ materially from those described in this report because of numerous factors, many of which
are beyond the control of Oncocyte. A number of important factors could cause the results of the company to differ materially from those
indicated by such forward-looking statements, including those detailed under the heading &#8220;Risk Factors&#8221; in our Form 10-K
for the year ended December 31, 2022, and our other reports filed with the SEC from time to time.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion should be read in conjunction with Oncocyte&#8217;s unaudited condensed consolidated interim financial statements
and the related notes provided under &#8220;Item 1- Financial Statements&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
a special meeting of our shareholders, held on July 24, 2023, our shareholders approved a proposal granting the Company&#8217;s board
of directors the authority to exercise its discretion to amend the Articles of Incorporation of the Company, as currently in effect,
to effect a reverse stock split of the outstanding shares of the Company&#8217;s common stock at any time within one year after the date
such shareholder approval was obtained at the special meeting and at any of certain specified reverse split ratios that were approved
by the shareholders of the Company in connection therewith. On July 24, 2023, our board of directors approved the reverse stock split
at a ratio of 1-for-20, and on that date, we filed a Certificate of Amendment of Articles of Incorporation with the Secretary State of
the State of California to effect the reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise noted, all share and per share amounts set forth in this Report have been adjusted to reflect the impact of the reverse
stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations discusses and analyzes data in our unaudited
condensed consolidated interim financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles.
Preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets,
liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Management bases its estimates on historical
experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Senior
management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors.
Actual conditions may differ from our assumptions and actual results may differ from our estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
accounting policy is deemed critical if it requires an accounting estimate to be made based on assumptions about matters that are highly
uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate are
reasonably likely to occur, that could materially impact the financial statements. Management believes that there have been no significant
changes during the six months ended June 30, 2023 to the matters that we disclosed as our critical accounting policies and estimates
in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for
the year ended December 31, 2022, except as disclosed in Note 2 to our unaudited condensed consolidated interim financial statements
included elsewhere in this Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a summary of our critical accounting policies and estimates, refer to Management&#8217;s Discussion and Analysis section of our Annual
Report on Form 10-K for the year ended December 31, 2022, which we filed with the SEC. There have been no material changes to our critical accounting policies and estimates during the six months ended June
30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Summary for the Three and Six Months ended June 30, 2023 and 2022 (amounts in thousands, except percentage changes)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
    Months Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Six
    Months Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: italic bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></p>
                                                                                                                                       <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change</span></p></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: italic bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
    Change</span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: italic bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change</span></p></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: italic bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
    Change</span></td><td style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">463</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">237</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">226</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">760</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">617</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">143</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of revenues and amortization of acquired intangibles</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">191</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">206</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-7</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">478</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">339</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,435</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,444</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,562</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,451</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
    and marketing expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">805</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">127</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">678</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">534</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">393</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,107</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">282</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,531</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,445</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,914</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-35</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,943</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,092</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,149</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-37</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of contingent consideration</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,795</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,359</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,154</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-128</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16,512</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,015</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,497</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
    loss from intangible assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>n/a</i></span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,950</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,950</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    on disposal and held for sale assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>n/a</i></span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,283</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,283</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,294</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,626</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,668</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">410</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,444</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,643</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,150</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-47</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total other
    income (expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(39</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">262</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(301</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right">-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(134</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">204</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-152</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    before income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,333</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,364</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,969</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">511</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,374</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,777</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,403</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-50</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from continuing operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,333</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,364</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,969</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">511</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,374</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,777</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,403</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-50</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from discontinued operations</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,936</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,936</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-100</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,926</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,814</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,888</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-79</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,333</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,300</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,300</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,591</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,291</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-71</span></td><td style="font: italic 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Results
of Operations &#8211; Three Months Ended June 30, 2023 Compared with the Three Months Ended June 30, 2022</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from continuing operations increased by $0.3 million to $0.5 million for the three months ended June 30, 2023, as compared to $0.2 million
in the comparable prior year quarter, due to increased revenues in pharma services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
before income taxes was $8.3 million for the three months ended June 30, 2023, and $1.4 million for the three months ended June 30, 2022.
Net change before income taxes was comprised primarily of the changes in operating expenses and other income and expenses from continuing
operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharma
                                            Services revenue increased by $0.2 million due to an increased number of contracts performed
                                            during the period.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of revenue and amortization of acquired intangibles remained at $0.2
million, primarily related to labor and allocated overhead associated with performing our Pharma Services, as well as noncash amortization
of acquired intangible assets such as our customer relationship intangible assets acquired as part of the Insight merger.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses remained at $2.4 million, as the Company
continues development of DetermaIO, VitaGraft (formerly TheraSure Transplant Monitor), and DetermaCNI (formerly TheraSure - CNI Monitor).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales and marketing expenses increased by $0.7 million to $0.8 million
primarily attributable to continued ramp in sales and marketing activities related to the transplant business, as well as support the
commercialization efforts within oncology.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses decreased by $1.9 million to $3.6 million,
primarily due to decreased consulting, and personnel expenses.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of contingent considerations decreased by $8.2 million,
from a gain of $6.4 million to a loss of $1.8 million, due to changes in discount rates and revised estimates on the timing of possible
future payouts. Change driven in part by the Chronix Amendment which amended the earnout considerations eliminated the Chronix Milestone
Payments, 15% Royalty Payments and Sale Payment obligations (see Note 3).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            income decreased by $0.3 million, from a gain of $0.3 million to a loss of $39,000, primarily
                                            due to unrealized gain and loss on marketable equity securities.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Results
of Operations &#8211; Six Months Ended June 30, 2023 Compared with the Six Months Ended June 30, 2022</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from continuing operations increased by $0.2 million to $0.8 million for the six months ended June 30, 2023, as compared to $0.6
million in the comparable prior year quarter, due to increased revenues in pharma services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
before income taxes was $2.4 million for the six months ended June 30, 2023, and $4.8 million for the six months ended June 30, 2022.
Net change before income taxes was comprised primarily of the changes in operating expenses and other income and expenses from continuing
operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharma
                                            Services revenue increased by $0.1 million due to an increased number of contracts performed
                                            during the period.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
                                            of revenue and amortization of acquired intangibles increased $0.1 million to $0.5 million
                                            primarily due to increased labor and allocated overhead associated with performing our Pharma
                                            Services, as well as noncash amortization of acquired intangible assets such as our customer
                                            relationship intangible assets acquired as part of the Insight merger.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
                                            and development expenses increased by $0.1 million to $4.6 million, primarily due to continued
                                            development of DetermaIO, VitaGraft (formerly TheraSure Transplant Monitor), and DetermaCNI
                                            (formerly TheraSure - CNI Monitor).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
                                            and marketing expenses increased by $1.1 million to $1.5 million primarily attributable to
                                            continued ramp in sales and marketing activities related to the transplant business, as well
                                            as support the commercialization efforts within oncology.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
                                            and administrative expenses decreased by $4.1 million to $7.0 million, primarily due to decreased
                                            consulting, and personnel expenses.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of contingent considerations increased by $5.5 million,
from a gain of $11.0 million to a gain of $16.5 million, due to changes in discount rates and revised estimates on the timing of possible
future payouts. Change driven in part by the Chronix Amendment which amended the earnout considerations eliminated the Chronix Milestone
Payments, 15% Royalty Payments and Sale Payment obligations (see Note 3).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.25in; padding-left: 0pt">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
                                            income was $0.1 million for the six months ended June 30, 2023 compared to an expense of
                                            $0.1 million for the six months ended June 30, 2022, primarily due to unrealized gain
                                            and loss on marketable equity securities.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues
(amounts in thousands, except percentage changes)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the classification of the Company&#8217;s Razor&#8217;s operations to discontinued operations, all revenue derived from DetermaRx
has been classified as discontinued operations. The remaining revenue for the periods presented below are derived from Pharma Services
generated primarily by our wholly owned subsidiary, Insight.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows our revenues for the six months ended June 30, 2023 and 2022 (in thousands, except percentage change values).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">$ Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">$ Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-left: 0pt">Revenues from continuing operations</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">463</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">237</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 5%; font-style: italic; text-align: right">226</td><td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 5%; font-style: italic; text-align: right">95</td><td style="width: 1%; font-style: italic; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">760</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">617</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 5%; font-style: italic; text-align: right">143</td><td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 5%; font-style: italic; text-align: right">23</td><td style="width: 1%; font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Revenues from discontinuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,830</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">(1,830</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">)</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">-100</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">421</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,874</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">(2,453</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">)</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">-85</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">463</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,067</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,604</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">-78</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,181</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,491</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">(2,310</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">)</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">-66</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharma
Services are generally performed on a time and materials basis. Upon our completion of the service to the customer in accordance with
the contract, we have the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognize
the Pharma Services revenue at that time, on an accrual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharma
Services revenues are generated under discrete agreements for particular customer projects that generally expire with the completion
or termination of the customer&#8217;s project. Accordingly, different customers may account for greater or lesser portions of Pharma
Services during different accounting periods, and Pharma Services revenues may exhibit a larger variance from accounting period to accounting
period than other revenues such as DetermaRx testing revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost
of revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenues generally consists of cost of materials; direct labor including payroll, payroll taxes, bonus, benefit and stock-based compensation;
equipment and infrastructure expenses; clinical sample costs associated with performing Pharma Services; and amortization of acquired
intangible assets. Infrastructure expenses include depreciation of laboratory equipment; allocated rent costs; and leasehold improvements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenues for Pharma Services varies depending on the nature, timing, and scope of customer projects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and development expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the main drivers of the change in research and development expenses for the periods presented, is as follows <i>(amounts in
thousands, except percentage changes):</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">$ Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">$ Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-left: 0pt">Personnel-related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">1,004</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">904</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">$</td><td style="width: 5%; font-style: italic; text-align: right">100</td><td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 5%; font-style: italic; text-align: right">11</td><td style="width: 1%; font-style: italic; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">1,927</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">1,719</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">$</td><td style="width: 5%; font-style: italic; text-align: right">208</td><td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 5%; font-style: italic; text-align: right">12</td><td style="width: 1%; font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">352</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">271</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">335</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">715</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">147</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">568</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">386</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">201</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">108</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">54</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">251</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">66</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Laboratory supplies and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">362</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">(29</td><td style="font-style: italic; text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-8</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">575</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">715</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">(140</td><td style="font-style: italic; text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-20</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Facilities and insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">64</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">58</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">97</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">45</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Professional fees, legal, and outside services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">693</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">(628</td><td style="font-style: italic; text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-91</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">967</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">(799</td><td style="font-style: italic; text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-83</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Severance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">159</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">100</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">159</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">100</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">(65</td><td style="font-style: italic; text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-69</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">(84</td><td style="font-style: italic; text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-67</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Clinical trials</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">10</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">100</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">182</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">(149</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">)</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">-82</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,435</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,444</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">(9</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">)</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">0</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,562</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,451</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">111</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">2</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">% of Net Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,031</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-505</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">721</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-121</td><td style="text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur a significant amount of research and development expenses during the foreseeable future. As of June 30, 2023
we will continue development of DetermaIO and VitaGraft. Our future research and development efforts and expenses will also depend on
the amount of capital that we are able to raise to finance those activities and whether we acquire rights to any new diagnostic tests.
A portion of our costs for leasing and operating our CLIA laboratories in California and Tennessee, and in Germany with Chronix, will
also be included in research and development expenses to the extent allocated to the development of our diagnostic tests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We may commence clinical trials of DetermaIO if we develop that diagnostic test to the point where we determine that its use as a clinical diagnostic
appears to be feasible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
and marketing expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the main drivers of the change in sales and marketing expenses for the periods presented, is as follows <i>(amounts in thousands,
except percentage changes):</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">$ Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">$ Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-left: 0pt">Personnel-related expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">579</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">49</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 5%; font-style: italic; text-align: right">1082</td><td style="width: 1%; font-style: italic; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">1,008</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">188</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">820</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 5%; font-style: italic; text-align: right">436</td><td style="width: 1%; font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">100</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">139</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">379</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Facilities and insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">2067</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">107</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">1189</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Professional fees, legal, and outside services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55</td><td style="text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-75</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48</td><td style="text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-30</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Marketing &amp; Advertising</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">100</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">100</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">1800</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">786</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">805</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">127</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">678</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">534</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">393</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">1,107</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">282</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">% of Net Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">120</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur sales and marketing expenses during the foreseeable future as we complete product development and begin commercialization
efforts for DetermaIO as a clinical test. Sales and marketing expenses will also increase if we successfully develop and begin commercializing
DetermaCNI, and VitaGraft, or if we acquire and commercialize other diagnostic tests. Our commercialization efforts and expenses will
also depend on the amount of capital that we are able to raise to finance commercialization of our tests. Our future expenditures on
sales and marketing will also depend on the amount of revenue that those efforts are likely to generate. Because physicians are more
likely to prescribe a test for their patients if the cost is covered by Medicare or health insurance, demand for our diagnostic and other
tests and our expenditures on sales and marketing are likely to increase if our diagnostic or other tests qualify for reimbursement by
Medicare or private health insurance companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and administrative expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the main drivers of the change in general and administrative expenses for the periods presented, is as follows <i>(amounts
in thousands, except percentage changes):</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">$ Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">$ Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; padding-left: 0pt">Personnel-related expenses and board fees</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">899</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">2,220</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">$</td><td style="width: 5%; font-style: italic; text-align: right">(1,321</td><td style="width: 1%; font-style: italic; text-align: left">)</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 5%; font-style: italic; text-align: right">-60</td><td style="width: 1%; font-style: italic; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">2,090</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">4,557</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">$</td><td style="width: 5%; font-style: italic; text-align: right">(2,467</td><td style="width: 1%; font-style: italic; text-align: left">)</td><td style="width: 2%; font-style: italic">&#160;</td>
    <td style="width: 1%; font-style: italic; text-align: left">&#160;</td><td style="width: 5%; font-style: italic; text-align: right">-54</td><td style="width: 1%; font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Professional fees, legal, and outside services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">929</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">971</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">(42</td><td style="font-style: italic; text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-4</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,946</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,241</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">(295</td><td style="font-style: italic; text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-13</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Facilities and insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">(95</td><td style="font-style: italic; text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-15</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,339</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">(120</td><td style="font-style: italic; text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-9</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">460</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,283</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">(823</td><td style="font-style: italic; text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-64</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">867</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,463</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">(1,596</td><td style="font-style: italic; text-align: left">)</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">-65</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Severance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">481</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">357</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">288</td><td style="font-style: italic; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">481</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">357</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">288</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">216</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">206</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">10</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">5</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">340</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">368</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">(28</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">)</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">-8</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,531</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,445</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">(1,914</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">)</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">-35</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,943</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,092</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">(4,149</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">)</td><td style="font-style: italic; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-style: italic; text-align: right">-37</td><td style="padding-bottom: 2.5pt; font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">% of Net Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">763</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,297</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-1,535</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">914</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,798</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-884</td><td style="text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change
in fair value of contingent consideration</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay contingent consideration if various payment milestones are triggered under the merger agreements through which we acquired Insight
and Chronix. See Note 3 to our unaudited condensed consolidated interim financial statements included in this Report. Changes in the
fair value of the contingent consideration will be based on our reassessment of the key assumptions underlying the determination of this
liability as changes in circumstances and conditions occur from the Insight and Chronix acquisition dates to the reporting period being
presented, with the subsequent change in fair value recorded as part of our consolidated loss from operations for that period. For the
six months ended June 30, 2023, we recorded a gain of approximately $16.5 million related to the decrease in the fair value of contingent
consideration primarily attributable to change in discount rates and a revised estimate of the timing of the possible future payouts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
income and expenses, net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income and expenses, net, is primarily comprised of interest income and interest expenses, net, and unrealized gains and losses on Lineage
and AgeX marketable equity securities we hold. Interest income is earned from money market funds we hold for capital preservation. In
the prior year, interest expense was incurred under our loan payable to the Silicon Valley Bank, and under financing lease obligations.
Interest expense, net, reflects the interest expense incurred on our loans and financing obligations in excess of interest income earned
from money market accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
taxes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
did not record any provision or benefit for income taxes for the six months ended June 30, 2023 and June 30, 2022, as Oncocyte had a
full valuation allowance for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. We
established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from our net
operating loss carry-forwards and other deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
formation, we have financed our operations primarily through the sale of our common stock, preferred stock and warrants. We have incurred
operating losses and negative cash flows since inception and had an accumulated deficit of $266.0 million at June 30, 2023. We expect
to continue to incur operating losses and negative cash flows for the near future. Our expectation to generate operating losses and negative operating cash
flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability
to continue as a going concern for a period of one year after the date that the financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
June 30, 2023, we had $17.4 million of cash and cash equivalents, and held shares of Lineage and AgeX common stock as marketable equity
securities valued at $0.5 million. In 2022, we raised approximately $30,000 in net cash proceeds through sales of shares of our common
stock through the ATM Offering. On June 1, 2022, Oncocyte received net proceeds of approximately $4.9 million from the Series A Preferred
Stock issued from the first tranche of the Series A Preferred Stock Offering. On April 19, 2022, Oncocyte received net proceeds of approximately
$32.8 million from the Underwritten Offering of 1,313,320 shares of common stock and 1,313,320 shares of April 2022 Warrants to purchase
up to 656,660 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 3, 2023, the Company entered into an agreement with certain members of the Company&#8217;s board of directors, and several institutional
and accredited investors, including Broadwood Capital, L.P., the Company&#8217;s largest shareholder, relating to their purchase of an
aggregate of up to 2,278,121 shares of its common stock at an offering price of $7.08 per share to board members and $6.03 per
share to the other investors participating in the offering. The offering was intended to be priced &#8216;at-the market&#8217; for purposes
of complying with applicable Nasdaq Listing Rules. The aggregate gross proceeds from the offering were approximately $13.9 million before
deducting offering expenses payable by the Company. The Company used approximately $1.1 million of the net proceeds to immediately redeem
an aggregate of 1,064 shares of its Series A Convertible Preferred Stock and may thereafter elect to redeem additional shares. See Notes
1 and 15 for additional information about the Company&#8217;s equity offerings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"></p>


<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our operating expenses will remain flat as we continue to manage our available cash. Although we intend to market our diagnostic
tests in the United States through our own sales force, we are also beginning to make marketing arrangements with distributors in other
countries. We may also explore a range of other commercialization options in order to enter overseas markets and to reduce our capital
needs and expenditures, and the risks associated the timelines and uncertainty for attaining the Medicare reimbursement approvals that
will be essential for the successful commercialization of additional cancer diagnostic tests. Those alternative arrangements could include
marketing arrangements with other diagnostic companies through which we might receive a licensing fee and royalty on sales, or through
which we might form a joint venture to market one or more tests and share in net revenues, in the United States or abroad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to sales and marketing expenses, we will incur expenses from leasing and improving our new office and laboratory facilities
in Nashville, Tennessee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to meet significant cash payment or stock obligations to former Insight and Chronix shareholders in connection with our acquisition
of those companies, as disclosed in Note 3 to the unaudited condensed consolidated interim financial statements included elsewhere in
this Report. To meet the future cash payment obligations, we may have to utilize cash on hand that would otherwise be available to us
for other business and operational purposes, which could cause us to delay or reduce activities in the development and commercialization
of our cancer tests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to continue to raise additional capital to finance our operations, including the development and commercialization of our diagnostic
tests, and making payments that may become due under our obligations to former Chronix shareholders and former Insight shareholders,
until such time as we are able to generate sufficient revenues to cover our operating expenses. Delays in the development of DetermaIO,
or obtaining reimbursement coverage from Medicare for that diagnostic test and for the other diagnostic tests that we may develop or
acquire, could prevent us from raising sufficient additional capital to finance the completion of development and commercial launch of
those tests. Investors may be reluctant to provide us with capital until our tests are approved for reimbursement by Medicare or reimbursement
by private healthcare insurers or healthcare providers, or until we begin generating significant amounts of revenue from performing those
tests. The unavailability or inadequacy of financing or revenues to meet future capital needs could force us to modify, curtail, delay,
or suspend some or all aspects of our planned operations. Sales of additional equity securities could result in the dilution of the interests
of our shareholders. We cannot assure that adequate financing will be available on favorable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
used in operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, our total research and development expenses from continuing operations were $4.6 million, our sales
and marketing expenses were $1.5 million, and our general and administrative expenses were $7.0 million. We also incurred $0.5 million
in cost of revenues, including $44,000 amortization of intangible expenses, in the first six months of 2023. Net loss for the six months
ended June 30, 2023 amounted to $5.3 million and net cash used in operating activities amounted to $16.5 million. Our cash used in operating
activities during the six months ended June 30, 2023 does not include the following noncash items: $1.7 million in stock-based compensation;
$16.5 million in gain from change in fair value of contingent consideration; $5.0 million loss from intangible asset impairment; $0.1
million loss of discontinued operations; $1.3 million loss on disposal and held for sale assets; $0.9 million in depreciation and amortization
expenses; and $98,000 in unrealized gain on marketable equity securities. Changes in operating assets and liabilities were approximately
$3.6 million as an additional use of cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash used in investing activities </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the six months ended June
30, 2022, net cash provided by investing activities was $0.1 million, attributable to proceeds from sale of equipment.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
provided by financing activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, net cash provided by financing activities was $12.2 million, attributable to the $13.4 million of
net cash proceeds from the sale of shares of common stock, offset by redemption of Series A Preferred Stock of $1.1 million and repayments
of financing lease obligations of $0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023 and December 31, 2022, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of SEC Regulation
S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="rs_002"></span>Item
3. Quantitative and Qualitative Disclosures about Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="rs_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Evaluation
of Disclosure Controls and Procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is management&#8217;s responsibility to establish and maintain adequate internal control over all financial reporting pursuant to Rule
13a-15 under the Securities Exchange Act of 1934 (&#8220;Exchange Act&#8221;). Our management, including our principal executive officer
and principal financial officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of the end
of the period covered by this report. Following this review and evaluation, the principal executive officer and principal financial officer
determined that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports
that we file or submit under the Exchange Act (i) is recorded, processed, summarized, and reported within the time periods specified
in SEC rules and forms, and (ii) is accumulated and communicated to management, including our principal executive officer, and principal
financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Previously
Identified Material Weaknesses in Internal Control over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the audit as of and for the year ended December 31, 2022, we previously identified material weaknesses in our internal
control over financial reporting. The material weaknesses were related to design and maintain effective controls to address the initial
application of complex accounting standards and accounting treatment of non-routine, unusual or complex events and transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
response to the material weaknesses, management completed the following remediation actions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have designed and implemented controls to address the identification, accounting for, and review of non-routine, unusual or complex
    and initial applications of complex accounting standards, including the continued engagement of external consultants to provide support
    and to assist us in our evaluation of such transactions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management assessed the effectiveness of our internal control over financial reporting as of June 30,2023, based on criteria established
in the 2013 Internal Control - Integrated Framework issued by COSO. Based on this assessment, management believes that, as of that date,
our internal control over financial reporting was effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
in Internal Controls</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in">The material weaknesses identified above were identified in the prior period
and are considered remediated as the applicable controls have operated for a sufficient period of time and management has concluded, through
testing, that these controls surrounding non-routine, unusual or complex and initial applications of complex accounting standards are
operating effectively. Therefore,<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> there
were no changes in our internal control over financial reporting that occurred during the period covered by this Report that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="rs_004"></span>PART
II - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="rs_005"></span>Item
1. Legal Proceedings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be involved in routine litigation incidental to the conduct of our business. We are not presently involved in any
material litigation or proceedings, and to our knowledge no such litigation or proceedings are contemplated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="rs_006"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business, financial condition, results of operations and future growth prospects are subject to various risks, including those described
in Item 1A &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 12,
2023, which we encourage you to review. Other than as noted below, there have been no material changes
from the risk factors disclosed in our most recent Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
recently implemented reverse stock split may decrease the liquidity of our common stock and result in higher transaction costs.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
liquidity of our common stock may be negatively impacted by our implementation of a 1-for-20 reverse stock split on July 24, 2023, given
the significantly reduced number of shares that are now issued and outstanding after the reverse stock split, and because our stock price
did not increase commensurate with the ratio of the reverse stock split. In addition, as a result of our reverse stock split, we now
have a greater number of shareholders who own &#8220;odd lots&#8221; of fewer than 100 shares of our common stock. Brokerage commission
and other costs of transactions for the sale of odd lots are generally higher than the costs of transactions of more than 100 shares
of common stock. Accordingly, a reverse stock split may not achieve the desired results of increasing marketability and liquidity of
our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
effective increase in the authorized number of shares of our common stock as a result of our reverse stock split could have anti-takeover
implications and result in further dilution to our existing shareholders.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the recent implementation of the reverse stock split, we maintained the total number of authorized shares of our common
stock. The combination of a reverse stock split of our issued and outstanding shares, and maintaining the number of our authorized shares,
has significantly increased our authorized shares relative to our issued and outstanding shares. This effective increase in the number
of authorized shares will allow us to sell additional shares of our common stock (or securities convertible or exchangeable for our common
stock), which would result in further dilution of our current shareholders. In addition, the effective increase in the number of authorized
shares could, under certain circumstances, have anti-takeover implications. For example, the additional shares of common stock that have
become available for issuance could be used by us to oppose a hostile takeover attempt or to delay or prevent changes in control or our
management. Although our reverse stock split was prompted by business and financial considerations and not by the threat of any hostile
takeover attempt, shareholders should be aware that our reverse stock split could facilitate future efforts by us to deter or prevent
changes in control, including transactions in which our shareholders might otherwise receive a premium for their shares over then-current
market prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>There is substantial doubt about our ability to
continue as a going concern and management&#8217;s plans to alleviate this condition may be unsuccessful. We will need to raise additional
funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us
to delay, limit or terminate our operations. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our expectation to generate operating
losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial
doubt regarding our ability to continue as a going concern for a period of one year after the date that the financial statements are issued.
See Part I, Item 2 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations-Liquidity and Capital
Resources&#8221; of this Report for a discussion of our cash position. Accordingly, we intend to complete additional equity financings
and reduce spending in the remainder of fiscal 2023 and in 2024. However, due to several factors, including those outside management&#8217;s
control, there can be no assurance that we will be able to complete additional equity financings. If we are unable to complete additional
financings, management&#8217;s plans include further reducing or delaying operating expenses. We have concluded the likelihood that our
plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible,
is less than probable. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for
a period of at least twelve months from the date of issuance of these unaudited condensed consolidated interim financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our fundraising efforts to raise
additional funding may divert our management from their day-to-day activities, which may adversely affect our ability to conduct operations.
In addition, we cannot guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover,
the terms of any financing may adversely affect the holdings or the rights of our shareholders and the issuance of additional securities,
whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional
equity or convertible securities would dilute all of our shareholders. The incurrence of indebtedness would result in increased fixed
payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional
debt, limitations on our ability to acquire assets and other operating restrictions that could adversely impact our ability to conduct
our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage
than otherwise would be desirable, which may result in terms unfavorable to us, any of which may have a material adverse effect on our
business, operating results and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In addition to general economic
and capital market trends and conditions, Oncocyte&#8217;s ability to raise sufficient additional capital to finance its operations from
time to time will depend on a number of factors specific to Oncocyte&#8217;s operations such as operating revenues and expenses, progress
in development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future laboratory tests that Oncocyte
may develop or acquire.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to obtain funding on a timely basis, or if revenues from
collaboration arrangements or financing sources are less than we have projected, we may be required to further revise our business plan
and strategy, which may result in us significantly curtailing, delaying or discontinuing portions or all of our operations, or may result
in our being unable to expand our operations or otherwise capitalize on our business opportunities. As a result, our business, financial
condition and results of operations could be materially affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="rs_007"></span>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="rs_008"></span>Item
3. Default Upon Senior Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="rs_009"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="rs_010"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="rs_011"></span>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; width: 0.75in; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Numbers</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; width: 0.1in; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0pt; vertical-align: top; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1642380/000149315223025396/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment of Articles of Incorporation of Oncocyte Corporation, as filed with the Secretary of State of the State of California on July 24, 2023</a></span></p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0pt; vertical-align: top; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0pt; vertical-align: top; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1642380/000149315223011292/ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated April 3, 2023, by and among Oncocyte Corporation and each purchaser identified on the signatures pages thereto (Incorporated by reference to Oncocyte Corporation&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2023)</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0pt; vertical-align: top; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1642380/000149315223024074/formdef14a.htm" style="-sec-extract: exhibit">Amendment to 2018 Equity Incentive Plan (Incorporated by reference to Oncocyte Corporation&#8217;s Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on July 10, 2023)</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0pt; vertical-align: top; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1642380/000149315223020623/ex10-1.htm" style="-sec-extract: exhibit">Amended and Restated Employment Agreement, dated June 6, 2023, by and between Oncocyte Corporation and Joshua Riggs (Incorporated by reference to Oncocyte Corporation&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2023)</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0pt; vertical-align: top; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1642380/000149315223024532/ex10-1.htm" style="-sec-extract: exhibit">Amendment to Amended and Restated Employment Agreement, dated July 13, 2023, by and between Oncocyte Corporation and Joshua Riggs (Incorporated by reference to Oncocyte Corporation&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 14, 2023)</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification
    of Joshua Riggs, President and Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification
    of Anish John, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certifications
    of Joshua Riggs, President and Chief Financial Officer, and Anish John, Chief Financial Officer, pursuant to U.S.C. Section 1350,
    as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interactive
    Data Files</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
    the Inline XBRL document)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: top; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; vertical-align: bottom; text-align: justify; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
This certification is not deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under
the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the registrant specifically incorporates
it by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="rs_012"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 50%; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 50%; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ONCOCYTE CORPORATION</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 10, 2023</span></td>
    <td style="border-bottom: black 1.5pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joshua Riggs</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Riggs</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 10, 2023</span></td>
    <td style="border-bottom: black 1.5pt solid; padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    James Liu</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Liu</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controller
    and Principal Accounting Officer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Joshua Riggs, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed
    this quarterly report on Form 10-Q of Oncocyte Corporation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my
    knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
    the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my
    knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
    other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
    Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
    and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this periodic report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
    external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report
    any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
    fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
    over financial reporting; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
    other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent
    functions):</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies
    and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
    affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not
    material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
    financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
August 10, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: black 1.5pt solid; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Joshua Riggs</I></FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Riggs</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
James Liu, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed
    this quarterly report on Form 10-Q of Oncocyte Corporation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my
    knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
    the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my
    knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
    other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
    Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
    and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure
    controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
    information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
    particularly during the period in which this periodic report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
    external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report
    any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
    fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
    over financial reporting; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s
    other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent
    functions):</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies
    and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
    affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not
    material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
    financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
August 10, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: black 1.5pt solid; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Liu</I></FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Liu</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controller
    and Principal Accounting Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></P></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Quarterly Report on Form 10-Q of Oncocyte Corporation (the &ldquo;Company&rdquo;) for the quarter ended June 30,
2023, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), we, Joshua Riggs, President
and Chief Executive Officer, and James Liu, Controller and Principal Accounting Officer of the Company, certify pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies
    with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained
    in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
August 10, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: black 1.5pt solid; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Joshua Riggs</I></FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Riggs</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James Liu</I></FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Liu</FONT></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controller
    and Principal Accounting Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></P></TD>
    <TD STYLE="padding-right: 0pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ocx-20230630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWayH2bP9z5Z8SekhvWBzbVl6DykrN0CriyxEaBMmYbgI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:OCX="http://oncocyte.com/20230630" elementFormDefault="qualified" targetNamespace="http://oncocyte.com/20230630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://oncocyte.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
          <link:definition>00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/StatementsOfShareholdersEquity" id="StatementsOfShareholdersEquity">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" id="OrganizationDescriptionOfBusinessAndLiquidity">
          <link:definition>00000008 - Disclosure - Organization, Description of the Business and Liquidity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
          <link:definition>00000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/BusinessCombinations" id="BusinessCombinations">
          <link:definition>00000010 - Disclosure - Business Combinations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/IntangibleAssetsNet" id="IntangibleAssetsNet">
          <link:definition>00000011 - Disclosure - Intangible Assets, net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ShareholdersEquity" id="ShareholdersEquity">
          <link:definition>00000012 - Disclosure - Shareholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>00000013 - Disclosure - Stock-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk" id="DisaggregationOfRevenuesAndConcentrationRisk">
          <link:definition>00000014 - Disclosure - Disaggregation of Revenues and Concentration Risk</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000015 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" id="Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress">
          <link:definition>00000016 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000017 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/WorkforceReduction" id="WorkforceReduction">
          <link:definition>00000018 - Disclosure - Workforce Reduction</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000019 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" id="LoanPayableToSiliconValleyBank">
          <link:definition>00000020 - Disclosure - Loan Payable to Silicon Valley Bank</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation" id="Co-developmentAgreementWithLifeTechnologiesCorporation">
          <link:definition>00000021 - Disclosure - Co-Development Agreement with Life Technologies Corporation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/EquityOfferings" id="EquityOfferings">
          <link:definition>00000022 - Disclosure - Equity Offerings</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperations" id="AssetsHeldForSaleAndDiscontinuedOperations">
          <link:definition>00000023 - Disclosure - Assets Held for Sale and Discontinued Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000024 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000025 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/BusinessCombinationsTables" id="BusinessCombinationsTables">
          <link:definition>00000027 - Disclosure - Business Combinations (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/IntangibleAssetsNetTables" id="IntangibleAssetsNetTables">
          <link:definition>00000028 - Disclosure - Intangible Assets, net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>00000029 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables" id="DisaggregationOfRevenuesAndConcentrationRiskTables">
          <link:definition>00000030 - Disclosure - Disaggregation of Revenues and Concentration Risk (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" id="Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables">
          <link:definition>00000031 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>00000032 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables" id="AssetsHeldForSaleAndDiscontinuedOperationsTables">
          <link:definition>00000033 - Disclosure - Assets Held for Sale and Discontinued Operations (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" id="OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative">
          <link:definition>00000034 - Disclosure - Organization, Description of the Business and Liquidity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" id="ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails">
          <link:definition>00000035 - Disclosure - Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" id="ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
          <link:definition>00000036 - Disclosure - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" id="ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails">
          <link:definition>00000037 - Disclosure - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" id="ScheduleOfFairValueOfContingentConsiderationLiabilityDetails">
          <link:definition>00000039 - Disclosure - Schedule of Fair Value of Contingent Consideration Liability (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" id="ScheduleOfContingentConsiderationMeasuredAtFairValueDetails">
          <link:definition>00000040 - Disclosure - Schedule of Contingent Consideration, Measured at Fair Value (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" id="BusinessCombinationsDetailsNarrative">
          <link:definition>00000041 - Disclosure - Business Combinations (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" id="ScheduleOfGoodwillAndIntangibleAssetsDetails">
          <link:definition>00000042 - Disclosure - Schedule of Goodwill and Intangible Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" id="ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails">
          <link:definition>00000043 - Disclosure - Schedule of Intangible Assets Future Amortization Expense (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" id="IntangibleAssetsNetDetailsNarrative">
          <link:definition>00000044 - Disclosure - Intangible Assets, net (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" id="ShareholdersEquityDetailsNarrative">
          <link:definition>00000045 - Disclosure - Shareholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" id="ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails">
          <link:definition>00000046 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" id="SummaryOfStockOptionActivityDetails">
          <link:definition>00000047 - Disclosure - Summary of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" id="SummaryOfStock-basedCompensationExpenseDetails">
          <link:definition>00000048 - Disclosure - Summary of Stock-based Compensation Expense (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>00000049 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" id="ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails">
          <link:definition>00000050 - Disclosure - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails" id="ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails">
          <link:definition>00000051 - Disclosure - Schedule of Consolidated Revenues Attributable to Products or Services (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" id="ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails">
          <link:definition>00000052 - Disclosure - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" id="ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails">
          <link:definition>00000053 - Disclosure - Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" id="Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative">
          <link:definition>00000054 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" id="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails">
          <link:definition>00000055 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" id="ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails">
          <link:definition>00000056 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" id="ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails">
          <link:definition>00000057 - Disclosure - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000058 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/WorkforceReductionDetailsNarrative" id="WorkforceReductionDetailsNarrative">
          <link:definition>00000059 - Disclosure - Workforce Reduction (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000060 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" id="LoanPayableToSiliconValleyBankDetailsNarrative">
          <link:definition>00000061 - Disclosure - Loan Payable to Silicon Valley Bank (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative" id="Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative">
          <link:definition>00000062 - Disclosure - Co-Development Agreement with Life Technologies Corporation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/EquityOfferingsDetailsNarrative" id="EquityOfferingsDetailsNarrative">
          <link:definition>00000063 - Disclosure - Equity Offerings (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" id="ScheduleOfDiscontinuedOperationsDetails">
          <link:definition>00000064 - Disclosure - Schedule of Discontinued Operations (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails" id="ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails">
          <link:definition>00000065 - Disclosure - Schedule of Assets and Liabilities of Disposal Group Held for Sale (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative" id="AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative">
          <link:definition>00000066 - Disclosure - Assets Held for Sale and Discontinued Operations (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://oncocyte.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000067 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ocx-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ocx-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ocx-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ocx-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="OCX_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RazorGenomicsIncMember" name="RazorGenomicsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RazorStockPurchaseAgreementMember" name="RazorStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DragonScientificLLCMember" name="DragonScientificLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RazorMember" name="RazorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DragonMember" name="DragonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_AtTheMarketSalesAgreementMember" name="AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_BTIGLLCMember" name="BTIGLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_UnderwritingAgreementMember" name="UnderwritingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_UnderwriterMember" name="UnderwriterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_BoardMembersMember" name="BoardMembersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_OtherInvestorsMember" name="OtherInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_MarketableEquitySecuritiesMember" name="MarketableEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ContingentConsiderationLiabilitiesMember" name="ContingentConsiderationLiabilitiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_VariousAgreementsMember" name="VariousAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember" name="MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PharmaServicesMember" name="PharmaServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_LineageAndAgeXMember" name="LineageAndAgeXMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_InsightMergerMember" name="InsightMergerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ChronixMergerMember" name="ChronixMergerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_MilestoneOneMember" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_MilestoneTwoMember" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_MilestoneThreeMember" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RoyaltyOneMember" name="RoyaltyOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RoyaltyTwoMember" name="RoyaltyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_OncocyteCorpMember" name="OncocyteCorpMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DevelopmentAgreementMember" name="DevelopmentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_SublicenseAgreementMember" name="SublicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_MergerAgreementMember" name="MergerAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ChronixBiomedicalIncMember" name="ChronixBiomedicalIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ChronixEquityMember" name="ChronixEquityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ChronixMilestoneMember" name="ChronixMilestoneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ChronixMember" name="ChronixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DetermaIOMember" name="DetermaIOMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DetermaCNIAndVitaGraftMember" name="DetermaCNIAndVitaGraftMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_InvestorsMember" name="InvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_InterestMember" name="InterestMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_SecurityMember" name="SecurityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_TwoThousandTenStockOptionPlanMember" name="TwoThousandTenStockOptionPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_MonteCarloValuationTechniqueMember" name="MonteCarloValuationTechniqueMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PerformanceBasedOptionsMember" name="PerformanceBasedOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ExecutiveOfficersAndEmployeesMember" name="ExecutiveOfficersAndEmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_MarketBasedAwardsMember" name="MarketBasedAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_VitaGraftMember" name="VitaGraftMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DetermalOMember" name="DetermalOMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DetermaCNIMember" name="DetermaCNIMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_TwoThousandEighteenIncentivePlanMember" name="TwoThousandEighteenIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_TwoThousandTenPlanActivityMember" name="TwoThousandTenPlanActivityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_TwoThousandEighteenPalnActivityMember" name="TwoThousandEighteenPalnActivityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_CostOfRevenuesMember" name="CostOfRevenuesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DiscontinuedOperationsMember" name="DiscontinuedOperationsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PharmaServicesCompanyAMember" name="PharmaServicesCompanyAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PharmaServicesCompanyBMember" name="PharmaServicesCompanyBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DiscontinuedOperationsDetermaRxMember" name="DiscontinuedOperationsDetermaRxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DetermaRxMember" name="DetermaRxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_OutsideUnitedStatesPharmaServicesMember" name="OutsideUnitedStatesPharmaServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DiscontinuedOperationsOutsideUnitedStatesLicensingMember" name="DiscontinuedOperationsOutsideUnitedStatesLicensingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_OfficeLeaseAgreementMember" name="OfficeLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_MonthlyRentMember" name="MonthlyRentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_FirstTenCalendarMember" name="FirstTenCalendarMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_LandlordMember" name="LandlordMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_LeaseAgreementMember" name="LeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ExecutiveOfficersMember" name="ExecutiveOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_OperatingAndFinancingLeasesMember" name="OperatingAndFinancingLeasesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_BroadwoodCapitalLPMember" name="BroadwoodCapitalLPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_UnderwrittenOfferingMember" name="UnderwrittenOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PuraVidaInvestmentsLLCMember" name="PuraVidaInvestmentsLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_UnderwritersMember" name="UnderwritersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_HalleSpecialSituationsFundLLCMember" name="HalleSpecialSituationsFundLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_BroadwoodPartnersLPMember" name="BroadwoodPartnersLPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PuraVidaMember" name="PuraVidaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_AVMMember" name="AVMMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ArnoMember" name="ArnoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_MrGutfreundMember" name="MrGutfreundMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_AmendedLoanAgreementMember" name="AmendedLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_LoanDeferralAgreementMember" name="LoanDeferralAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_BankWarrantMember" name="BankWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_LifeTechnologiesCorporationMember" name="LifeTechnologiesCorporationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_TwoEqualTranchesMember" name="TwoEqualTranchesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_AprilTwoThousandTwentyTwoWarrantsMember" name="AprilTwoThousandTwentyTwoWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_LaboratoryEquipmentAgreementMember" name="LaboratoryEquipmentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_AuctionEquipmentAgreementMember" name="AuctionEquipmentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_MachineryAndEquipmentNetAndConstructionInProgress" name="MachineryAndEquipmentNetAndConstructionInProgress" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_AccruedSeveranceFromAcquisitionCurrent" name="AccruedSeveranceFromAcquisitionCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent" name="RightOfUseAndFinancingLeaseLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent" name="RightOfUseAndFinancingLeaseLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_TemporaryEquityNoParValue" name="TemporaryEquityNoParValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles" name="CostOfRevenuesAmortizationOfAcquiredIntangibles" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" name="DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards" name="StockIssuedDuringPeriodValueVestingOfBonusAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" name="DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" name="StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" name="ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" name="AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" name="FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" name="ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PaymentForFinancingCostsForAtthemarketSales" name="PaymentForFinancingCostsForAtthemarketSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RepaymentOfFinancingLeaseObligations" name="RepaymentOfFinancingLeaseObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability" name="ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DisclosureWorkforceReductionAbstract" name="DisclosureWorkforceReductionAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_WorkforceReductionTextBlock" name="WorkforceReductionTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract" name="DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock" name="CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DisclosureEquityOfferingsAbstract" name="DisclosureEquityOfferingsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_AprilTwentyTwentyTwoOfferingsTextBlock" name="AprilTwentyTwentyTwoOfferingsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock" name="BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_SalesAndMarketingExpensesPolicyTextBlock" name="SalesAndMarketingExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_AccountingForSharesOfCommonStockPolicyTextBlock" name="AccountingForSharesOfCommonStockPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock" name="ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock" name="ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock" name="ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock" name="ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock" name="ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DividendOnPreferredStock" name="DividendOnPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DeemedDividendOnPreferredStock" name="DeemedDividendOnPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_CommonStockSharesHeldAsAvailableForSaleSecurities" name="CommonStockSharesHeldAsAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ContingentConsiderationLiabilityContractualValue" name="ContingentConsiderationLiabilityContractualValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_FairValueOfContingentConsideration" name="FairValueOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ClinicalTrialExpenseReserveAmount" name="ClinicalTrialExpenseReserveAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_EarnoutPercentageOnCollectionsForSales" name="EarnoutPercentageOnCollectionsForSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_EarnoutPercentageOnCollectionsForSaleOrLicense" name="EarnoutPercentageOnCollectionsForSaleOrLicense" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_EarnoutPercentageOnCollectionsForSale" name="EarnoutPercentageOnCollectionsForSale" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RoyaltyPaymentsPercentage" name="RoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ConversionPricePercentage" name="ConversionPricePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PreferredStockRemainsOutstandingPercentage" name="PreferredStockRemainsOutstandingPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_IndebtednessExpenses" name="IndebtednessExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DividendsRatePerPercentage" name="DividendsRatePerPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited" name="StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations" name="RightofuseAssetsMachineryAndEquipmentContinuingOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations" name="RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_RightofuseAssetsMachineryAndEquipmentNet" name="RightofuseAssetsMachineryAndEquipmentNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PresentValueOfNetMinimumLeasePayments" name="PresentValueOfNetMinimumLeasePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_CapitalLeaseAgreementImputedAnnualInterestRate" name="CapitalLeaseAgreementImputedAnnualInterestRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_ObligatedToPayExpensesAndTaxesPercentage" name="ObligatedToPayExpensesAndTaxesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment" name="PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PaymentObligationAmount" name="PaymentObligationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PercentageForWarrantExercisePricePerShare" name="PercentageForWarrantExercisePricePerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DilutedEquityOutstanding" name="DilutedEquityOutstanding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PurchasePrice" name="PurchasePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_StatedValue" name="StatedValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_PercentageOfIssuedAndOutstandingShares" name="PercentageOfIssuedAndOutstandingShares" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" name="DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" name="DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales" name="DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation" name="DisposalGroupIncludingDiscontinuedOperationAccruedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" name="DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OCX_NetLossAttributableToCommonStockholdersBasicAndDiluted" name="NetLossAttributableToCommonStockholdersBasicAndDiluted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ocx-20230630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://oncocyte.com/role/Cover" xlink:href="ocx-20230630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BalanceSheets" xlink:href="ocx-20230630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BalanceSheetsParenthetical" xlink:href="ocx-20230630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfOperations" xlink:href="ocx-20230630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfComprehensiveLoss" xlink:href="ocx-20230630.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfShareholdersEquity" xlink:href="ocx-20230630.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfCashFlows" xlink:href="ocx-20230630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:href="ocx-20230630.xsd#OrganizationDescriptionOfBusinessAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="ocx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BusinessCombinations" xlink:href="ocx-20230630.xsd#BusinessCombinations" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/IntangibleAssetsNet" xlink:href="ocx-20230630.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquity" xlink:href="ocx-20230630.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Stock-basedCompensation" xlink:href="ocx-20230630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk" xlink:href="ocx-20230630.xsd#DisaggregationOfRevenuesAndConcentrationRisk" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxes" xlink:href="ocx-20230630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" xlink:href="ocx-20230630.xsd#Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingencies" xlink:href="ocx-20230630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/WorkforceReduction" xlink:href="ocx-20230630.xsd#WorkforceReduction" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/RelatedPartyTransactions" xlink:href="ocx-20230630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" xlink:href="ocx-20230630.xsd#LoanPayableToSiliconValleyBank" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation" xlink:href="ocx-20230630.xsd#Co-developmentAgreementWithLifeTechnologiesCorporation" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/EquityOfferings" xlink:href="ocx-20230630.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperations" xlink:href="ocx-20230630.xsd#AssetsHeldForSaleAndDiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/SubsequentEvents" xlink:href="ocx-20230630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ocx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ocx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BusinessCombinationsTables" xlink:href="ocx-20230630.xsd#BusinessCombinationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/IntangibleAssetsNetTables" xlink:href="ocx-20230630.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Stock-basedCompensationTables" xlink:href="ocx-20230630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables" xlink:href="ocx-20230630.xsd#DisaggregationOfRevenuesAndConcentrationRiskTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" xlink:href="ocx-20230630.xsd#Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesTables" xlink:href="ocx-20230630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables" xlink:href="ocx-20230630.xsd#AssetsHeldForSaleAndDiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:href="ocx-20230630.xsd#OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" xlink:href="ocx-20230630.xsd#ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="ocx-20230630.xsd#ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" xlink:href="ocx-20230630.xsd#ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ocx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" xlink:href="ocx-20230630.xsd#ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" xlink:href="ocx-20230630.xsd#ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" xlink:href="ocx-20230630.xsd#BusinessCombinationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:href="ocx-20230630.xsd#ScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" xlink:href="ocx-20230630.xsd#ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="ocx-20230630.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" xlink:href="ocx-20230630.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" xlink:href="ocx-20230630.xsd#ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" xlink:href="ocx-20230630.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" xlink:href="ocx-20230630.xsd#SummaryOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="ocx-20230630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" xlink:href="ocx-20230630.xsd#ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails" xlink:href="ocx-20230630.xsd#ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" xlink:href="ocx-20230630.xsd#ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" xlink:href="ocx-20230630.xsd#ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" xlink:href="ocx-20230630.xsd#Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" xlink:href="ocx-20230630.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:href="ocx-20230630.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" xlink:href="ocx-20230630.xsd#ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ocx-20230630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/WorkforceReductionDetailsNarrative" xlink:href="ocx-20230630.xsd#WorkforceReductionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ocx-20230630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" xlink:href="ocx-20230630.xsd#LoanPayableToSiliconValleyBankDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative" xlink:href="ocx-20230630.xsd#Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/EquityOfferingsDetailsNarrative" xlink:href="ocx-20230630.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" xlink:href="ocx-20230630.xsd#ScheduleOfDiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails" xlink:href="ocx-20230630.xsd#ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative" xlink:href="ocx-20230630.xsd#AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/SubsequentEventsDetailsNarrative" xlink:href="ocx-20230630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapEquitySecuritiesFvNi" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_us-gaapAssetsHeldForSaleNotPartOfDisposalGroupCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MachineryAndEquipmentNetAndConstructionInProgress" xlink:label="loc_OCXMachineryAndEquipmentNetAndConstructionInProgress" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_OCXMachineryAndEquipmentNetAndConstructionInProgress" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AccruedSeveranceFromAcquisitionCurrent" xlink:label="loc_OCXAccruedSeveranceFromAcquisitionCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_OCXAccruedSeveranceFromAcquisitionCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent" xlink:label="loc_OCXRightOfUseAndFinancingLeaseLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_OCXRightOfUseAndFinancingLeaseLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent" xlink:label="loc_OCXRightOfUseAndFinancingLeaseLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_OCXRightOfUseAndFinancingLeaseLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" weight="1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles" xlink:label="loc_OCXCostOfRevenuesAmortizationOfAcquiredIntangibles" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_OCXCostOfRevenuesAmortizationOfAcquiredIntangibles" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" xlink:label="loc_OCXDividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_OCXDividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" xlink:label="loc_OCXChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OCXChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaapDisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" xlink:label="loc_OCXAccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OCXAccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaapIncreaseDecreaseInAssetsHeldForSale" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAssetsHeldForSale" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfMachineryAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfMachineryAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" xlink:label="loc_OCXFinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_OCXFinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" xlink:label="loc_OCXProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_OCXProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PaymentForFinancingCostsForAtthemarketSales" xlink:label="loc_OCXPaymentForFinancingCostsForAtthemarketSales" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_OCXPaymentForFinancingCostsForAtthemarketSales" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RepaymentOfFinancingLeaseObligations" xlink:label="loc_OCXRepaymentOfFinancingLeaseObligations" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_OCXRepaymentOfFinancingLeaseObligations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:title="00000008 - Disclosure - Organization, Description of the Business and Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BusinessCombinations" xlink:title="00000010 - Disclosure - Business Combinations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IntangibleAssetsNet" xlink:title="00000011 - Disclosure - Intangible Assets, net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - Shareholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Stock-basedCompensation" xlink:title="00000013 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk" xlink:title="00000014 - Disclosure - Disaggregation of Revenues and Concentration Risk" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" xlink:title="00000016 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/WorkforceReduction" xlink:title="00000018 - Disclosure - Workforce Reduction" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/RelatedPartyTransactions" xlink:title="00000019 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" xlink:title="00000020 - Disclosure - Loan Payable to Silicon Valley Bank" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation" xlink:title="00000021 - Disclosure - Co-Development Agreement with Life Technologies Corporation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/EquityOfferings" xlink:title="00000022 - Disclosure - Equity Offerings" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperations" xlink:title="00000023 - Disclosure - Assets Held for Sale and Discontinued Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000025 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BusinessCombinationsTables" xlink:title="00000027 - Disclosure - Business Combinations (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IntangibleAssetsNetTables" xlink:title="00000028 - Disclosure - Intangible Assets, net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Stock-basedCompensationTables" xlink:title="00000029 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables" xlink:title="00000030 - Disclosure - Disaggregation of Revenues and Concentration Risk (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" xlink:title="00000031 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesTables" xlink:title="00000032 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables" xlink:title="00000033 - Disclosure - Assets Held for Sale and Discontinued Operations (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:title="00000034 - Disclosure - Organization, Description of the Business and Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" xlink:title="00000035 - Disclosure - Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="00000036 - Disclosure - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" xlink:title="00000037 - Disclosure - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" xlink:title="00000039 - Disclosure - Schedule of Fair Value of Contingent Consideration Liability (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" xlink:title="00000040 - Disclosure - Schedule of Contingent Consideration, Measured at Fair Value (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" xlink:title="00000041 - Disclosure - Business Combinations (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:title="00000042 - Disclosure - Schedule of Goodwill and Intangible Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" xlink:title="00000043 - Disclosure - Schedule of Intangible Assets Future Amortization Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000044 - Disclosure - Intangible Assets, net (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - Shareholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" xlink:title="00000046 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" xlink:title="00000047 - Disclosure - Summary of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" xlink:title="00000048 - Disclosure - Summary of Stock-based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000049 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" xlink:title="00000050 - Disclosure - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails" xlink:title="00000051 - Disclosure - Schedule of Consolidated Revenues Attributable to Products or Services (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" xlink:title="00000052 - Disclosure - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" xlink:title="00000053 - Disclosure - Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" xlink:title="00000054 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" xlink:title="00000055 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:title="00000056 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" xlink:title="00000057 - Disclosure - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000058 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/WorkforceReductionDetailsNarrative" xlink:title="00000059 - Disclosure - Workforce Reduction (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000060 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" xlink:title="00000061 - Disclosure - Loan Payable to Silicon Valley Bank (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative" xlink:title="00000062 - Disclosure - Co-Development Agreement with Life Technologies Corporation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000063 - Disclosure - Equity Offerings (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" xlink:title="00000064 - Disclosure - Schedule of Discontinued Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:label="loc_OCXDisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_OCXDisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" xlink:label="loc_OCXDisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_OCXDisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" xlink:label="loc_us-gaapIncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaapIncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails" xlink:title="00000065 - Disclosure - Schedule of Assets and Liabilities of Disposal Group Held for Sale (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative" xlink:title="00000066 - Disclosure - Assets Held for Sale and Discontinued Operations (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000067 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ocx-20230630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://oncocyte.com/role/Cover" xlink:href="ocx-20230630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BalanceSheets" xlink:href="ocx-20230630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BalanceSheetsParenthetical" xlink:href="ocx-20230630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfOperations" xlink:href="ocx-20230630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfComprehensiveLoss" xlink:href="ocx-20230630.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfShareholdersEquity" xlink:href="ocx-20230630.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfCashFlows" xlink:href="ocx-20230630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:href="ocx-20230630.xsd#OrganizationDescriptionOfBusinessAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="ocx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BusinessCombinations" xlink:href="ocx-20230630.xsd#BusinessCombinations" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/IntangibleAssetsNet" xlink:href="ocx-20230630.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquity" xlink:href="ocx-20230630.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Stock-basedCompensation" xlink:href="ocx-20230630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk" xlink:href="ocx-20230630.xsd#DisaggregationOfRevenuesAndConcentrationRisk" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxes" xlink:href="ocx-20230630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" xlink:href="ocx-20230630.xsd#Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingencies" xlink:href="ocx-20230630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/WorkforceReduction" xlink:href="ocx-20230630.xsd#WorkforceReduction" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/RelatedPartyTransactions" xlink:href="ocx-20230630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" xlink:href="ocx-20230630.xsd#LoanPayableToSiliconValleyBank" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation" xlink:href="ocx-20230630.xsd#Co-developmentAgreementWithLifeTechnologiesCorporation" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/EquityOfferings" xlink:href="ocx-20230630.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperations" xlink:href="ocx-20230630.xsd#AssetsHeldForSaleAndDiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/SubsequentEvents" xlink:href="ocx-20230630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ocx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ocx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BusinessCombinationsTables" xlink:href="ocx-20230630.xsd#BusinessCombinationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/IntangibleAssetsNetTables" xlink:href="ocx-20230630.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Stock-basedCompensationTables" xlink:href="ocx-20230630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables" xlink:href="ocx-20230630.xsd#DisaggregationOfRevenuesAndConcentrationRiskTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" xlink:href="ocx-20230630.xsd#Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesTables" xlink:href="ocx-20230630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables" xlink:href="ocx-20230630.xsd#AssetsHeldForSaleAndDiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:href="ocx-20230630.xsd#OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" xlink:href="ocx-20230630.xsd#ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="ocx-20230630.xsd#ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" xlink:href="ocx-20230630.xsd#ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ocx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" xlink:href="ocx-20230630.xsd#ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" xlink:href="ocx-20230630.xsd#ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" xlink:href="ocx-20230630.xsd#BusinessCombinationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:href="ocx-20230630.xsd#ScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" xlink:href="ocx-20230630.xsd#ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="ocx-20230630.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" xlink:href="ocx-20230630.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" xlink:href="ocx-20230630.xsd#ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" xlink:href="ocx-20230630.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" xlink:href="ocx-20230630.xsd#SummaryOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="ocx-20230630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" xlink:href="ocx-20230630.xsd#ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails" xlink:href="ocx-20230630.xsd#ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" xlink:href="ocx-20230630.xsd#ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" xlink:href="ocx-20230630.xsd#ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" xlink:href="ocx-20230630.xsd#Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" xlink:href="ocx-20230630.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:href="ocx-20230630.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" xlink:href="ocx-20230630.xsd#ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ocx-20230630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/WorkforceReductionDetailsNarrative" xlink:href="ocx-20230630.xsd#WorkforceReductionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ocx-20230630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" xlink:href="ocx-20230630.xsd#LoanPayableToSiliconValleyBankDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative" xlink:href="ocx-20230630.xsd#Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/EquityOfferingsDetailsNarrative" xlink:href="ocx-20230630.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" xlink:href="ocx-20230630.xsd#ScheduleOfDiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails" xlink:href="ocx-20230630.xsd#ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative" xlink:href="ocx-20230630.xsd#AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/SubsequentEventsDetailsNarrative" xlink:href="ocx-20230630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_OCXSeriesARedeemableConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_OCXSeriesARedeemableConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TemporaryEquityNoParValue" xlink:label="loc_OCXTemporaryEquityNoParValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXTemporaryEquityNoParValue_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaapTemporaryEquityLiquidationPreference_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityLiquidationPreference_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaapPreferredStockNoParValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockNoParValue_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockNoParValue_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_OCXSeriesARedeemableConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_OCXSeriesARedeemableConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards" xlink:label="loc_OCXStockIssuedDuringPeriodValueVestingOfBonusAwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodValueVestingOfBonusAwards_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" xlink:label="loc_OCXDeemedDividendOnSeriesRedeemableConvertiblePreferredStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXDeemedDividendOnSeriesRedeemableConvertiblePreferredStock_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" xlink:label="loc_OCXStockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_60" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:title="00000008 - Disclosure - Organization, Description of the Business and Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BusinessCombinations" xlink:title="00000010 - Disclosure - Business Combinations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IntangibleAssetsNet" xlink:title="00000011 - Disclosure - Intangible Assets, net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - Shareholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Stock-basedCompensation" xlink:title="00000013 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk" xlink:title="00000014 - Disclosure - Disaggregation of Revenues and Concentration Risk" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" xlink:title="00000016 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/WorkforceReduction" xlink:title="00000018 - Disclosure - Workforce Reduction" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/RelatedPartyTransactions" xlink:title="00000019 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" xlink:title="00000020 - Disclosure - Loan Payable to Silicon Valley Bank" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation" xlink:title="00000021 - Disclosure - Co-Development Agreement with Life Technologies Corporation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/EquityOfferings" xlink:title="00000022 - Disclosure - Equity Offerings" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperations" xlink:title="00000023 - Disclosure - Assets Held for Sale and Discontinued Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000025 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BusinessCombinationsTables" xlink:title="00000027 - Disclosure - Business Combinations (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_InsightMergerMember" xlink:label="loc_OCXInsightMergerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXInsightMergerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixMergerMember" xlink:label="loc_OCXChronixMergerMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXChronixMergerMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock" xlink:label="loc_OCXScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IntangibleAssetsNetTables" xlink:title="00000028 - Disclosure - Intangible Assets, net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Stock-basedCompensationTables" xlink:title="00000029 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandTenPlanActivityMember" xlink:label="loc_OCXTwoThousandTenPlanActivityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXTwoThousandTenPlanActivityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables" xlink:title="00000030 - Disclosure - Disaggregation of Revenues and Concentration Risk (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" xlink:title="00000031 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesTables" xlink:title="00000032 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables" xlink:title="00000033 - Disclosure - Assets Held for Sale and Discontinued Operations (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaapDisposalGroupClassificationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapDisposalGroupClassificationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaapDiscontinuedOperationsHeldforsaleMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisposalGroupClassificationDomain" xlink:to="loc_us-gaapDiscontinuedOperationsHeldforsaleMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:title="00000034 - Disclosure - Organization, Description of the Business and Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorGenomicsIncMember" xlink:label="loc_OCXRazorGenomicsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXRazorGenomicsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DragonScientificLLCMember" xlink:label="loc_OCXDragonScientificLLCMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXDragonScientificLLCMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorMember" xlink:label="loc_OCXRazorMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXRazorMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorStockPurchaseAgreementMember" xlink:label="loc_OCXRazorStockPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXRazorStockPurchaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AtTheMarketSalesAgreementMember" xlink:label="loc_OCXAtTheMarketSalesAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXAtTheMarketSalesAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecuritiesPurchaseAgreementMember" xlink:label="loc_OCXSecuritiesPurchaseAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXSecuritiesPurchaseAgreementMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwritingAgreementMember" xlink:label="loc_OCXUnderwritingAgreementMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXUnderwritingAgreementMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RegisteredDirectOfferingMember" xlink:label="loc_OCXRegisteredDirectOfferingMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXRegisteredDirectOfferingMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DragonMember" xlink:label="loc_OCXDragonMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXDragonMember_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwriterMember" xlink:label="loc_OCXUnderwriterMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXUnderwriterMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BoardMembersMember" xlink:label="loc_OCXBoardMembersMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXBoardMembersMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OtherInvestorsMember" xlink:label="loc_OCXOtherInvestorsMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXOtherInvestorsMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BTIGLLCMember" xlink:label="loc_OCXBTIGLLCMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXBTIGLLCMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_OCXSeriesARedeemableConvertiblePreferredStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_OCXSeriesARedeemableConvertiblePreferredStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_190" xlink:type="arc" order="194" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_210" xlink:type="arc" order="213" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_280" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_280" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_280" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_280" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_280" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_280" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNi_280" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_280" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_280" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_280" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_280" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_280" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_280" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_280" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_280" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_280" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_280" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_280" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" xlink:title="00000035 - Disclosure - Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MarketableEquitySecuritiesMember" xlink:label="loc_OCXMarketableEquitySecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXMarketableEquitySecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ContingentConsiderationLiabilitiesMember" xlink:label="loc_OCXContingentConsiderationLiabilitiesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXContingentConsiderationLiabilitiesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_250" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="00000036 - Disclosure - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" xlink:title="00000037 - Disclosure - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_OCXSeriesARedeemableConvertiblePreferredStockMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_OCXSeriesARedeemableConvertiblePreferredStockMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossIncludingPortionAttributableToNoncontrollingInterest_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapIncomeLossIncludingPortionAttributableToNoncontrollingInterest_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DividendOnPreferredStock" xlink:label="loc_OCXDividendOnPreferredStock_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_OCXDividendOnPreferredStock_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_us-gaapRedeemablePreferredStockDividends_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapRedeemablePreferredStockDividends_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DeemedDividendOnPreferredStock" xlink:label="loc_OCXDeemedDividendOnPreferredStock_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_OCXDeemedDividendOnPreferredStock_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_210" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_VariousAgreementsMember" xlink:label="loc_OCXVariousAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXVariousAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember" xlink:label="loc_OCXMedicareforDetermaRxandMedicareAdvantageforDetermaRxMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXMedicareforDetermaRxandMedicareAdvantageforDetermaRxMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PharmaServicesMember" xlink:label="loc_OCXPharmaServicesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXPharmaServicesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LineageAndAgeXMember" xlink:label="loc_OCXLineageAndAgeXMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_OCXLineageAndAgeXMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaapIncreaseDecreaseInAssetsHeldForSale_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInAssetsHeldForSale_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryWriteDown_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableSale" xlink:label="loc_us-gaapAccountsReceivableSale_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAccountsReceivableSale_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:label="loc_OCXCommonStockSharesHeldAsAvailableForSaleSecurities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_OCXCommonStockSharesHeldAsAvailableForSaleSecurities_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNi_100" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" xlink:title="00000039 - Disclosure - Schedule of Fair Value of Contingent Consideration Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MilestoneOneMember" xlink:label="loc_OCXMilestoneOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXMilestoneOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MilestoneTwoMember" xlink:label="loc_OCXMilestoneTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXMilestoneTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MilestoneThreeMember" xlink:label="loc_OCXMilestoneThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXMilestoneThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RoyaltyOneMember" xlink:label="loc_OCXRoyaltyOneMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXRoyaltyOneMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RoyaltyTwoMember" xlink:label="loc_OCXRoyaltyTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXRoyaltyTwoMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ContingentConsiderationLiabilityContractualValue" xlink:label="loc_OCXContingentConsiderationLiabilityContractualValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXContingentConsiderationLiabilityContractualValue_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" xlink:title="00000040 - Disclosure - Schedule of Contingent Consideration, Measured at Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_InsightMergerMember" xlink:label="loc_OCXInsightMergerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXInsightMergerMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixMergerMember" xlink:label="loc_OCXChronixMergerMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXChronixMergerMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" xlink:label="loc_OCXBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_130" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" xlink:title="00000041 - Disclosure - Business Combinations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorGenomicsIncMember" xlink:label="loc_OCXRazorGenomicsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXRazorGenomicsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixBiomedicalIncMember" xlink:label="loc_OCXChronixBiomedicalIncMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXChronixBiomedicalIncMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixEquityMember" xlink:label="loc_OCXChronixEquityMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXChronixEquityMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixMilestoneMember" xlink:label="loc_OCXChronixMilestoneMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXChronixMilestoneMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixMember" xlink:label="loc_OCXChronixMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXChronixMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OncocyteCorpMember" xlink:label="loc_OCXOncocyteCorpMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXOncocyteCorpMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DevelopmentAgreementMember" xlink:label="loc_OCXDevelopmentAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXDevelopmentAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SublicenseAgreementMember" xlink:label="loc_OCXSublicenseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXSublicenseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MergerAgreementMember" xlink:label="loc_OCXMergerAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXMergerAgreementMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixBiomedicalIncMember" xlink:label="loc_OCXChronixBiomedicalIncMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXChronixBiomedicalIncMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_FairValueOfContingentConsideration" xlink:label="loc_OCXFairValueOfContingentConsideration_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXFairValueOfContingentConsideration_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ClinicalTrialExpenseReserveAmount" xlink:label="loc_OCXClinicalTrialExpenseReserveAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXClinicalTrialExpenseReserveAmount_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_EarnoutPercentageOnCollectionsForSales" xlink:label="loc_OCXEarnoutPercentageOnCollectionsForSales_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXEarnoutPercentageOnCollectionsForSales_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_EarnoutPercentageOnCollectionsForSaleOrLicense" xlink:label="loc_OCXEarnoutPercentageOnCollectionsForSaleOrLicense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXEarnoutPercentageOnCollectionsForSaleOrLicense_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_EarnoutPercentageOnCollectionsForSale" xlink:label="loc_OCXEarnoutPercentageOnCollectionsForSale_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXEarnoutPercentageOnCollectionsForSale_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RoyaltyPaymentsPercentage" xlink:label="loc_OCXRoyaltyPaymentsPercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXRoyaltyPaymentsPercentage_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapDeferredTaxLiabilities_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapGoodwill_110" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:title="00000042 - Disclosure - Schedule of Goodwill and Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaIOMember" xlink:label="loc_OCXDetermaIOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXDetermaIOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaCNIAndVitaGraftMember" xlink:label="loc_OCXDetermaCNIAndVitaGraftMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXDetermaCNIAndVitaGraftMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="loc_us-gaapIndefinitelivedIntangibleAssetsAcquired_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefinitelivedIntangibleAssetsAcquired_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetResidualValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetResidualValue_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_90" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" xlink:title="00000043 - Disclosure - Schedule of Intangible Assets Future Amortization Expense (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000044 - Disclosure - Intangible Assets, net (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - Shareholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_OCXSeriesARedeemableConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_OCXSeriesARedeemableConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecuritiesPurchaseAgreementMember" xlink:label="loc_OCXSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RegisteredDirectOfferingMember" xlink:label="loc_OCXRegisteredDirectOfferingMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXRegisteredDirectOfferingMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_InvestorsMember" xlink:label="loc_OCXInvestorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXInvestorsMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OncocyteCorpMember" xlink:label="loc_OCXOncocyteCorpMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXOncocyteCorpMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_InterestMember" xlink:label="loc_OCXInterestMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXInterestMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecurityMember" xlink:label="loc_OCXSecurityMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXSecurityMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaapConversionOfStockDescription_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockDescription_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="loc_us-gaapEquityMethodInvestmentDescriptionOfPrincipalActivities_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentDescriptionOfPrincipalActivities_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ConversionPricePercentage" xlink:label="loc_OCXConversionPricePercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_OCXConversionPricePercentage_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PreferredStockRemainsOutstandingPercentage" xlink:label="loc_OCXPreferredStockRemainsOutstandingPercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_OCXPreferredStockRemainsOutstandingPercentage_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCash_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_IndebtednessExpenses" xlink:label="loc_OCXIndebtednessExpenses_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_OCXIndebtednessExpenses_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DividendsRatePerPercentage" xlink:label="loc_OCXDividendsRatePerPercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_OCXDividendsRatePerPercentage_200" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_200" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_200" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_200" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_200" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_200" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_200" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaapPreferredStockNoParValue_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockNoParValue_200" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_200" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_200" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_200" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" xlink:title="00000046 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MarketBasedAwardsMember" xlink:label="loc_OCXMarketBasedAwardsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_OCXMarketBasedAwardsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" xlink:title="00000047 - Disclosure - Summary of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandTenPlanActivityMember" xlink:label="loc_OCXTwoThousandTenPlanActivityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXTwoThousandTenPlanActivityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandEighteenPalnActivityMember" xlink:label="loc_OCXTwoThousandEighteenPalnActivityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXTwoThousandEighteenPalnActivityMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" xlink:label="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited" xlink:label="loc_OCXStockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares" xlink:label="loc_OCXSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares" xlink:label="loc_OCXSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_70" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="36" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" xlink:title="00000048 - Disclosure - Summary of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CostOfRevenuesMember" xlink:label="loc_OCXCostOfRevenuesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_OCXCostOfRevenuesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaapSellingAndMarketingExpenseMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingAndMarketingExpenseMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsMember" xlink:label="loc_OCXDiscontinuedOperationsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_OCXDiscontinuedOperationsMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_250" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000049 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandTenStockOptionPlanMember" xlink:label="loc_OCXTwoThousandTenStockOptionPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXTwoThousandTenStockOptionPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PerformanceBasedOptionsMember" xlink:label="loc_OCXPerformanceBasedOptionsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXPerformanceBasedOptionsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandEighteenIncentivePlanMember" xlink:label="loc_OCXTwoThousandEighteenIncentivePlanMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXTwoThousandEighteenIncentivePlanMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MonteCarloValuationTechniqueMember" xlink:label="loc_OCXMonteCarloValuationTechniqueMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXMonteCarloValuationTechniqueMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MarketBasedAwardsMember" xlink:label="loc_OCXMarketBasedAwardsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_OCXMarketBasedAwardsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ExecutiveOfficersAndEmployeesMember" xlink:label="loc_OCXExecutiveOfficersAndEmployeesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXExecutiveOfficersAndEmployeesMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_VitaGraftMember" xlink:label="loc_OCXVitaGraftMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXVitaGraftMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermalOMember" xlink:label="loc_OCXDetermalOMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXDetermalOMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaCNIMember" xlink:label="loc_OCXDetermaCNIMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXDetermaCNIMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:label="loc_us-gaapIncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_170" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" xlink:title="00000050 - Disclosure - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PharmaServicesCompanyAMember" xlink:label="loc_OCXPharmaServicesCompanyAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXPharmaServicesCompanyAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PharmaServicesCompanyBMember" xlink:label="loc_OCXPharmaServicesCompanyBMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXPharmaServicesCompanyBMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsDetermaRxMember" xlink:label="loc_OCXDiscontinuedOperationsDetermaRxMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXDiscontinuedOperationsDetermaRxMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails" xlink:title="00000051 - Disclosure - Schedule of Consolidated Revenues Attributable to Products or Services (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PharmaServicesMember" xlink:label="loc_OCXPharmaServicesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXPharmaServicesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaRxMember" xlink:label="loc_OCXDetermaRxMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXDetermaRxMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsMember" xlink:label="loc_OCXDiscontinuedOperationsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXDiscontinuedOperationsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" xlink:title="00000052 - Disclosure - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OutsideUnitedStatesPharmaServicesMember" xlink:label="loc_OCXOutsideUnitedStatesPharmaServicesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_OCXOutsideUnitedStatesPharmaServicesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaRxMember" xlink:label="loc_OCXDetermaRxMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_OCXDetermaRxMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsOutsideUnitedStatesLicensingMember" xlink:label="loc_OCXDiscontinuedOperationsOutsideUnitedStatesLicensingMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_OCXDiscontinuedOperationsOutsideUnitedStatesLicensingMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsDetermaRxMember" xlink:label="loc_OCXDiscontinuedOperationsDetermaRxMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_OCXDiscontinuedOperationsDetermaRxMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_250" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" xlink:title="00000053 - Disclosure - Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" xlink:title="00000054 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" xlink:title="00000055 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:title="00000056 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OperatingAndFinancingLeasesMember" xlink:label="loc_OCXOperatingAndFinancingLeasesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_OCXOperatingAndFinancingLeasesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAccumulatedAmortization_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAccumulatedAmortization_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseLiability_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_30" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" xlink:title="00000057 - Disclosure - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000058 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OfficeLeaseAgreementMember" xlink:label="loc_OCXOfficeLeaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXOfficeLeaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LeaseAgreementMember" xlink:label="loc_OCXLeaseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXLeaseAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DevelopmentAgreementMember" xlink:label="loc_OCXDevelopmentAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXDevelopmentAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MonthlyRentMember" xlink:label="loc_OCXMonthlyRentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_OCXMonthlyRentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_FirstTenCalendarMember" xlink:label="loc_OCXFirstTenCalendarMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_OCXFirstTenCalendarMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LandlordMember" xlink:label="loc_OCXLandlordMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXLandlordMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ExecutiveOfficersMember" xlink:label="loc_OCXExecutiveOfficersMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXExecutiveOfficersMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OncocyteCorpMember" xlink:label="loc_OCXOncocyteCorpMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXOncocyteCorpMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LaboratoryEquipmentMember" xlink:label="loc_OCXLaboratoryEquipmentMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_OCXLaboratoryEquipmentMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CapitalLeaseAgreementImputedAnnualInterestRate" xlink:label="loc_OCXCapitalLeaseAgreementImputedAnnualInterestRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXCapitalLeaseAgreementImputedAnnualInterestRate_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ObligatedToPayExpensesAndTaxesPercentage" xlink:label="loc_OCXObligatedToPayExpensesAndTaxesPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXObligatedToPayExpensesAndTaxesPercentage_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="loc_us-gaapPaymentsForProceedsFromTenantAllowance_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForProceedsFromTenantAllowance_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment" xlink:label="loc_OCXPercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXPercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecurityDeposit_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLinesOfCreditCurrent_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PaymentObligationAmount" xlink:label="loc_OCXPaymentObligationAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXPaymentObligationAmount_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSeveranceCosts1_100" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/WorkforceReductionDetailsNarrative" xlink:title="00000059 - Disclosure - Workforce Reduction (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000060 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecuritiesPurchaseAgreementMember" xlink:label="loc_OCXSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BroadwoodCapitalLPMember" xlink:label="loc_OCXBroadwoodCapitalLPMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXBroadwoodCapitalLPMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PuraVidaInvestmentsLLCMember" xlink:label="loc_OCXPuraVidaInvestmentsLLCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXPuraVidaInvestmentsLLCMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_HalleSpecialSituationsFundLLCMember" xlink:label="loc_OCXHalleSpecialSituationsFundLLCMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXHalleSpecialSituationsFundLLCMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BroadwoodPartnersLPMember" xlink:label="loc_OCXBroadwoodPartnersLPMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXBroadwoodPartnersLPMember_150" xlink:type="arc" order="153" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PuraVidaMember" xlink:label="loc_OCXPuraVidaMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXPuraVidaMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AVMMember" xlink:label="loc_OCXAVMMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXAVMMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwrittenOfferingMember" xlink:label="loc_OCXUnderwrittenOfferingMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_OCXUnderwrittenOfferingMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwritersMember" xlink:label="loc_OCXUnderwritersMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXUnderwritersMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ArnoMember" xlink:label="loc_OCXArnoMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_OCXArnoMember_180" xlink:type="arc" order="183" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MrGutfreundMember" xlink:label="loc_OCXMrGutfreundMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_OCXMrGutfreundMember_190" xlink:type="arc" order="193" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees_230" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_230" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_230" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_230" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction_230" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_230" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_230" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_230" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_230" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" xlink:title="00000061 - Disclosure - Loan Payable to Silicon Valley Bank (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AmendedLoanAgreementMember" xlink:label="loc_OCXAmendedLoanAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXAmendedLoanAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LoanDeferralAgreementMember" xlink:label="loc_OCXLoanDeferralAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXLoanDeferralAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BankWarrantMember" xlink:label="loc_OCXBankWarrantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_OCXBankWarrantMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLinesOfCreditCurrent_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateAtPeriodEnd_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateAtPeriodEnd_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PercentageForWarrantExercisePricePerShare" xlink:label="loc_OCXPercentageForWarrantExercisePricePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_OCXPercentageForWarrantExercisePricePerShare_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DilutedEquityOutstanding" xlink:label="loc_OCXDilutedEquityOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_OCXDilutedEquityOutstanding_130" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative" xlink:title="00000062 - Disclosure - Co-Development Agreement with Life Technologies Corporation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LifeTechnologiesCorporationMember" xlink:label="loc_OCXLifeTechnologiesCorporationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXLifeTechnologiesCorporationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopmentCosts" xlink:label="loc_us-gaapDevelopmentCosts_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDevelopmentCosts_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000063 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoEqualTranchesMember" xlink:label="loc_OCXTwoEqualTranchesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_OCXTwoEqualTranchesMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecuritiesPurchaseAgreementMember" xlink:label="loc_OCXSecuritiesPurchaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXSecuritiesPurchaseAgreementMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RegisteredDirectOfferingMember" xlink:label="loc_OCXRegisteredDirectOfferingMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXRegisteredDirectOfferingMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwritingAgreementMember" xlink:label="loc_OCXUnderwritingAgreementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXUnderwritingAgreementMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OncocyteCorpMember" xlink:label="loc_OCXOncocyteCorpMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXOncocyteCorpMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecurityMember" xlink:label="loc_OCXSecurityMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXSecurityMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AprilTwoThousandTwentyTwoWarrantsMember" xlink:label="loc_OCXAprilTwoThousandTwentyTwoWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_OCXAprilTwoThousandTwentyTwoWarrantsMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BoardMembersMember" xlink:label="loc_OCXBoardMembersMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXBoardMembersMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OtherInvestorsMember" xlink:label="loc_OCXOtherInvestorsMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXOtherInvestorsMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_290" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaapPreferredStockConvertibleSharesIssuable_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleSharesIssuable_290" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_290" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PurchasePrice" xlink:label="loc_OCXPurchasePrice_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXPurchasePrice_290" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_StatedValue" xlink:label="loc_OCXStatedValue_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStatedValue_290" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_290" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_290" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaapConversionOfStockDescription_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockDescription_290" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PercentageOfIssuedAndOutstandingShares" xlink:label="loc_OCXPercentageOfIssuedAndOutstandingShares_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXPercentageOfIssuedAndOutstandingShares_290" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="loc_us-gaapEquityMethodInvestmentDescriptionOfPrincipalActivities_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentDescriptionOfPrincipalActivities_290" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ConversionPricePercentage" xlink:label="loc_OCXConversionPricePercentage_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXConversionPricePercentage_290" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PreferredStockRemainsOutstandingPercentage" xlink:label="loc_OCXPreferredStockRemainsOutstandingPercentage_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXPreferredStockRemainsOutstandingPercentage_290" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_290" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_IndebtednessExpenses" xlink:label="loc_OCXIndebtednessExpenses_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXIndebtednessExpenses_290" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_290" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_290" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_290" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_290" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_290" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_290" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_290" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_290" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_290" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_290" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_290" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_290" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_290" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" xlink:title="00000064 - Disclosure - Schedule of Discontinued Operations (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails" xlink:title="00000065 - Disclosure - Schedule of Assets and Liabilities of Disposal Group Held for Sale (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaapDisposalGroupClassificationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapDisposalGroupClassificationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaapDiscontinuedOperationsHeldforsaleMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisposalGroupClassificationDomain" xlink:to="loc_us-gaapDiscontinuedOperationsHeldforsaleMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapAssetsAbstract_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" xlink:label="loc_OCXDisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_OCXDisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales" xlink:label="loc_OCXDisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_OCXDisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapAssets_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation" xlink:label="loc_OCXDisposalGroupIncludingDiscontinuedOperationAccruedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_OCXDisposalGroupIncludingDiscontinuedOperationAccruedCompensation_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" xlink:label="loc_OCXDisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_OCXDisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapLiabilities_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperationsAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperationsAbstract_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperationsAbstract_50" xlink:to="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_50" xlink:to="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_50" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative" xlink:title="00000066 - Disclosure - Assets Held for Sale and Discontinued Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorStockPurchaseAgreementMember" xlink:label="loc_OCXRazorStockPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXRazorStockPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LaboratoryEquipmentAgreementMember" xlink:label="loc_OCXLaboratoryEquipmentAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXLaboratoryEquipmentAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AuctionEquipmentAgreementMember" xlink:label="loc_OCXAuctionEquipmentAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXAuctionEquipmentAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DragonMember" xlink:label="loc_OCXDragonMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXDragonMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorMember" xlink:label="loc_OCXRazorMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXRazorMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorMember" xlink:label="loc_OCXRazorMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXRazorMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_us-gaapAssetsHeldForSaleNotPartOfDisposalGroupCurrent_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsHeldForSaleNotPartOfDisposalGroupCurrent_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaapDisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf_140" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000067 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MachineryAndEquipmentNetAndConstructionInProgress" xlink:label="loc_OCXMachineryAndEquipmentNetAndConstructionInProgress" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_OCXMachineryAndEquipmentNetAndConstructionInProgress" xlink:type="arc" order="1000" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ocx-20230630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="OCX_SeriesARedeemableConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="OCX_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_SeriesARedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorGenomicsIncMember" xlink:label="OCX_RazorGenomicsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RazorGenomicsIncMember" xlink:to="OCX_RazorGenomicsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RazorGenomicsIncMember_lbl" xml:lang="en-US">Razor Genomics, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorStockPurchaseAgreementMember" xlink:label="OCX_RazorStockPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RazorStockPurchaseAgreementMember" xlink:to="OCX_RazorStockPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RazorStockPurchaseAgreementMember_lbl" xml:lang="en-US">Razor Stock Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DragonScientificLLCMember" xlink:label="OCX_DragonScientificLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DragonScientificLLCMember" xlink:to="OCX_DragonScientificLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DragonScientificLLCMember_lbl" xml:lang="en-US">Dragon Scientific LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorMember" xlink:label="OCX_RazorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RazorMember" xlink:to="OCX_RazorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RazorMember_lbl" xml:lang="en-US">Razor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DragonMember" xlink:label="OCX_DragonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DragonMember" xlink:to="OCX_DragonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DragonMember_lbl" xml:lang="en-US">Dragon [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AtTheMarketSalesAgreementMember" xlink:label="OCX_AtTheMarketSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AtTheMarketSalesAgreementMember" xlink:to="OCX_AtTheMarketSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_AtTheMarketSalesAgreementMember_lbl" xml:lang="en-US">At The Market Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BTIGLLCMember" xlink:label="OCX_BTIGLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BTIGLLCMember" xlink:to="OCX_BTIGLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_BTIGLLCMember_lbl" xml:lang="en-US">BTIG, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecuritiesPurchaseAgreementMember" xlink:label="OCX_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SecuritiesPurchaseAgreementMember" xlink:to="OCX_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwritingAgreementMember" xlink:label="OCX_UnderwritingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_UnderwritingAgreementMember" xlink:to="OCX_UnderwritingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_UnderwritingAgreementMember_lbl" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwriterMember" xlink:label="OCX_UnderwriterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_UnderwriterMember" xlink:to="OCX_UnderwriterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_UnderwriterMember_lbl" xml:lang="en-US">Underwriter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RegisteredDirectOfferingMember" xlink:label="OCX_RegisteredDirectOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RegisteredDirectOfferingMember" xlink:to="OCX_RegisteredDirectOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RegisteredDirectOfferingMember_lbl" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BoardMembersMember" xlink:label="OCX_BoardMembersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BoardMembersMember" xlink:to="OCX_BoardMembersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_BoardMembersMember_lbl" xml:lang="en-US">Board Members [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OtherInvestorsMember" xlink:label="OCX_OtherInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_OtherInvestorsMember" xlink:to="OCX_OtherInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_OtherInvestorsMember_lbl" xml:lang="en-US">Other Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MarketableEquitySecuritiesMember" xlink:label="OCX_MarketableEquitySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MarketableEquitySecuritiesMember" xlink:to="OCX_MarketableEquitySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_MarketableEquitySecuritiesMember_lbl" xml:lang="en-US">Marketable Equity Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ContingentConsiderationLiabilitiesMember" xlink:label="OCX_ContingentConsiderationLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ContingentConsiderationLiabilitiesMember" xlink:to="OCX_ContingentConsiderationLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ContingentConsiderationLiabilitiesMember_lbl" xml:lang="en-US">Contingent Consideration Liabilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_VariousAgreementsMember" xlink:label="OCX_VariousAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_VariousAgreementsMember" xlink:to="OCX_VariousAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_VariousAgreementsMember_lbl" xml:lang="en-US">Various Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember" xlink:label="OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember" xlink:to="OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember_lbl" xml:lang="en-US">Medicare for DetermaRx and Medicare Advantage for DetermaRx [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PharmaServicesMember" xlink:label="OCX_PharmaServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PharmaServicesMember" xlink:to="OCX_PharmaServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PharmaServicesMember_lbl" xml:lang="en-US">Pharma Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LineageAndAgeXMember" xlink:label="OCX_LineageAndAgeXMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LineageAndAgeXMember" xlink:to="OCX_LineageAndAgeXMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_LineageAndAgeXMember_lbl" xml:lang="en-US">Lineage and AgeX [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_InsightMergerMember" xlink:label="OCX_InsightMergerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_InsightMergerMember" xlink:to="OCX_InsightMergerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_InsightMergerMember_lbl" xml:lang="en-US">Insight Merger [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixMergerMember" xlink:label="OCX_ChronixMergerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ChronixMergerMember" xlink:to="OCX_ChronixMergerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ChronixMergerMember_lbl" xml:lang="en-US">Chronix Merger [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MilestoneOneMember" xlink:label="OCX_MilestoneOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MilestoneOneMember" xlink:to="OCX_MilestoneOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_MilestoneOneMember_lbl" xml:lang="en-US">Milestone 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MilestoneTwoMember" xlink:label="OCX_MilestoneTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MilestoneTwoMember" xlink:to="OCX_MilestoneTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_MilestoneTwoMember_lbl" xml:lang="en-US">Milestone 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MilestoneThreeMember" xlink:label="OCX_MilestoneThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MilestoneThreeMember" xlink:to="OCX_MilestoneThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_MilestoneThreeMember_lbl" xml:lang="en-US">Milestone 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RoyaltyOneMember" xlink:label="OCX_RoyaltyOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RoyaltyOneMember" xlink:to="OCX_RoyaltyOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RoyaltyOneMember_lbl" xml:lang="en-US">Royalty 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RoyaltyTwoMember" xlink:label="OCX_RoyaltyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RoyaltyTwoMember" xlink:to="OCX_RoyaltyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RoyaltyTwoMember_lbl" xml:lang="en-US">Royalty 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OncocyteCorpMember" xlink:label="OCX_OncocyteCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_OncocyteCorpMember" xlink:to="OCX_OncocyteCorpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_OncocyteCorpMember_lbl" xml:lang="en-US">Oncocyte Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DevelopmentAgreementMember" xlink:label="OCX_DevelopmentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DevelopmentAgreementMember" xlink:to="OCX_DevelopmentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DevelopmentAgreementMember_lbl" xml:lang="en-US">Development Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SublicenseAgreementMember" xlink:label="OCX_SublicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SublicenseAgreementMember" xlink:to="OCX_SublicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_SublicenseAgreementMember_lbl" xml:lang="en-US">Sublicense Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MergerAgreementMember" xlink:label="OCX_MergerAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MergerAgreementMember" xlink:to="OCX_MergerAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixBiomedicalIncMember" xlink:label="OCX_ChronixBiomedicalIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ChronixBiomedicalIncMember" xlink:to="OCX_ChronixBiomedicalIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ChronixBiomedicalIncMember_lbl" xml:lang="en-US">Chronix Biomedical Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixEquityMember" xlink:label="OCX_ChronixEquityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ChronixEquityMember" xlink:to="OCX_ChronixEquityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ChronixEquityMember_lbl" xml:lang="en-US">Chronix Equity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixMilestoneMember" xlink:label="OCX_ChronixMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ChronixMilestoneMember" xlink:to="OCX_ChronixMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ChronixMilestoneMember_lbl" xml:lang="en-US">Chronix Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixMember" xlink:label="OCX_ChronixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ChronixMember" xlink:to="OCX_ChronixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ChronixMember_lbl" xml:lang="en-US">Chronix [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaIOMember" xlink:label="OCX_DetermaIOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DetermaIOMember" xlink:to="OCX_DetermaIOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DetermaIOMember_lbl" xml:lang="en-US">DetermaIO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaCNIAndVitaGraftMember" xlink:label="OCX_DetermaCNIAndVitaGraftMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DetermaCNIAndVitaGraftMember" xlink:to="OCX_DetermaCNIAndVitaGraftMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DetermaCNIAndVitaGraftMember_lbl" xml:lang="en-US">DetermaCNI and VitaGraft [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer Relationships [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_InvestorsMember" xlink:label="OCX_InvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_InvestorsMember" xlink:to="OCX_InvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_InvestorsMember_lbl" xml:lang="en-US">Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_InterestMember" xlink:label="OCX_InterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_InterestMember" xlink:to="OCX_InterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_InterestMember_lbl" xml:lang="en-US">Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecurityMember" xlink:label="OCX_SecurityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SecurityMember" xlink:to="OCX_SecurityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_SecurityMember_lbl" xml:lang="en-US">Security [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandTenStockOptionPlanMember" xlink:label="OCX_TwoThousandTenStockOptionPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_TwoThousandTenStockOptionPlanMember" xlink:to="OCX_TwoThousandTenStockOptionPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_TwoThousandTenStockOptionPlanMember_lbl" xml:lang="en-US">2010 Stock Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MonteCarloValuationTechniqueMember" xlink:label="OCX_MonteCarloValuationTechniqueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MonteCarloValuationTechniqueMember" xlink:to="OCX_MonteCarloValuationTechniqueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_MonteCarloValuationTechniqueMember_lbl" xml:lang="en-US">Monte Carlo Valuation Technique [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PerformanceBasedOptionsMember" xlink:label="OCX_PerformanceBasedOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PerformanceBasedOptionsMember" xlink:to="OCX_PerformanceBasedOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PerformanceBasedOptionsMember_lbl" xml:lang="en-US">Performance-Based Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ExecutiveOfficersAndEmployeesMember" xlink:label="OCX_ExecutiveOfficersAndEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ExecutiveOfficersAndEmployeesMember" xlink:to="OCX_ExecutiveOfficersAndEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ExecutiveOfficersAndEmployeesMember_lbl" xml:lang="en-US">Executive Officers and Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MarketBasedAwardsMember" xlink:label="OCX_MarketBasedAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MarketBasedAwardsMember" xlink:to="OCX_MarketBasedAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_MarketBasedAwardsMember_lbl" xml:lang="en-US">Market Based Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_VitaGraftMember" xlink:label="OCX_VitaGraftMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_VitaGraftMember" xlink:to="OCX_VitaGraftMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_VitaGraftMember_lbl" xml:lang="en-US">Vita Graft [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermalOMember" xlink:label="OCX_DetermalOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DetermalOMember" xlink:to="OCX_DetermalOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DetermalOMember_lbl" xml:lang="en-US">Determal O [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaCNIMember" xlink:label="OCX_DetermaCNIMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DetermaCNIMember" xlink:to="OCX_DetermaCNIMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DetermaCNIMember_lbl" xml:lang="en-US">Determa CNI [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandEighteenIncentivePlanMember" xlink:label="OCX_TwoThousandEighteenIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_TwoThousandEighteenIncentivePlanMember" xlink:to="OCX_TwoThousandEighteenIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_TwoThousandEighteenIncentivePlanMember_lbl" xml:lang="en-US">2018 Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandTenPlanActivityMember" xlink:label="OCX_TwoThousandTenPlanActivityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_TwoThousandTenPlanActivityMember" xlink:to="OCX_TwoThousandTenPlanActivityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_TwoThousandTenPlanActivityMember_lbl" xml:lang="en-US">2010 Plan Activity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandEighteenPalnActivityMember" xlink:label="OCX_TwoThousandEighteenPalnActivityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_TwoThousandEighteenPalnActivityMember" xlink:to="OCX_TwoThousandEighteenPalnActivityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_TwoThousandEighteenPalnActivityMember_lbl" xml:lang="en-US">2018 Paln Activity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CostOfRevenuesMember" xlink:label="OCX_CostOfRevenuesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_CostOfRevenuesMember" xlink:to="OCX_CostOfRevenuesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_CostOfRevenuesMember_lbl" xml:lang="en-US">Cost Of Revenues [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsMember" xlink:label="OCX_DiscontinuedOperationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DiscontinuedOperationsMember" xlink:to="OCX_DiscontinuedOperationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DiscontinuedOperationsMember_lbl" xml:lang="en-US">Discontinued Operations [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PharmaServicesCompanyAMember" xlink:label="OCX_PharmaServicesCompanyAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PharmaServicesCompanyAMember" xlink:to="OCX_PharmaServicesCompanyAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PharmaServicesCompanyAMember_lbl" xml:lang="en-US">Pharma Services Company A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="us-gaap_ProductConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductConcentrationRiskMember" xlink:to="us-gaap_ProductConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductConcentrationRiskMember_lbl" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PharmaServicesCompanyBMember" xlink:label="OCX_PharmaServicesCompanyBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PharmaServicesCompanyBMember" xlink:to="OCX_PharmaServicesCompanyBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PharmaServicesCompanyBMember_lbl" xml:lang="en-US">Pharma Services Company B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsDetermaRxMember" xlink:label="OCX_DiscontinuedOperationsDetermaRxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DiscontinuedOperationsDetermaRxMember" xlink:to="OCX_DiscontinuedOperationsDetermaRxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DiscontinuedOperationsDetermaRxMember_lbl" xml:lang="en-US">Discontinued Operations Determa Rx [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaRxMember" xlink:label="OCX_DetermaRxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DetermaRxMember" xlink:to="OCX_DetermaRxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DetermaRxMember_lbl" xml:lang="en-US">DetermaRx [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OutsideUnitedStatesPharmaServicesMember" xlink:label="OCX_OutsideUnitedStatesPharmaServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_OutsideUnitedStatesPharmaServicesMember" xlink:to="OCX_OutsideUnitedStatesPharmaServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_OutsideUnitedStatesPharmaServicesMember_lbl" xml:lang="en-US">Outside United States Pharma Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsOutsideUnitedStatesLicensingMember" xlink:label="OCX_DiscontinuedOperationsOutsideUnitedStatesLicensingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DiscontinuedOperationsOutsideUnitedStatesLicensingMember" xlink:to="OCX_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_lbl" xml:lang="en-US">Discontinued Operations Outside United States Licensing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OfficeLeaseAgreementMember" xlink:label="OCX_OfficeLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_OfficeLeaseAgreementMember" xlink:to="OCX_OfficeLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_OfficeLeaseAgreementMember_lbl" xml:lang="en-US">Office Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MonthlyRentMember" xlink:label="OCX_MonthlyRentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MonthlyRentMember" xlink:to="OCX_MonthlyRentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_MonthlyRentMember_lbl" xml:lang="en-US">Monthly Rent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_FirstTenCalendarMember" xlink:label="OCX_FirstTenCalendarMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_FirstTenCalendarMember" xlink:to="OCX_FirstTenCalendarMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_FirstTenCalendarMember_lbl" xml:lang="en-US">First Ten Calendar [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LandlordMember" xlink:label="OCX_LandlordMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LandlordMember" xlink:to="OCX_LandlordMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_LandlordMember_lbl" xml:lang="en-US">Landlord [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LeaseAgreementMember" xlink:label="OCX_LeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LeaseAgreementMember" xlink:to="OCX_LeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_LeaseAgreementMember_lbl" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LaboratoryEquipmentMember" xlink:label="OCX_LaboratoryEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LaboratoryEquipmentMember" xlink:to="OCX_LaboratoryEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ExecutiveOfficersMember" xlink:label="OCX_ExecutiveOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ExecutiveOfficersMember" xlink:to="OCX_ExecutiveOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ExecutiveOfficersMember_lbl" xml:lang="en-US">Executive Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OperatingAndFinancingLeasesMember" xlink:label="OCX_OperatingAndFinancingLeasesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_OperatingAndFinancingLeasesMember" xlink:to="OCX_OperatingAndFinancingLeasesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_OperatingAndFinancingLeasesMember_lbl" xml:lang="en-US">Operating and Financing Leases [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BroadwoodCapitalLPMember" xlink:label="OCX_BroadwoodCapitalLPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BroadwoodCapitalLPMember" xlink:to="OCX_BroadwoodCapitalLPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_BroadwoodCapitalLPMember_lbl" xml:lang="en-US">Broadwood Capital LP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwrittenOfferingMember" xlink:label="OCX_UnderwrittenOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_UnderwrittenOfferingMember" xlink:to="OCX_UnderwrittenOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_UnderwrittenOfferingMember_lbl" xml:lang="en-US">Underwritten Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PuraVidaInvestmentsLLCMember" xlink:label="OCX_PuraVidaInvestmentsLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PuraVidaInvestmentsLLCMember" xlink:to="OCX_PuraVidaInvestmentsLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PuraVidaInvestmentsLLCMember_lbl" xml:lang="en-US">Pura Vida Investments LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwritersMember" xlink:label="OCX_UnderwritersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_UnderwritersMember" xlink:to="OCX_UnderwritersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_UnderwritersMember_lbl" xml:lang="en-US">Underwriters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_HalleSpecialSituationsFundLLCMember" xlink:label="OCX_HalleSpecialSituationsFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_HalleSpecialSituationsFundLLCMember" xlink:to="OCX_HalleSpecialSituationsFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_HalleSpecialSituationsFundLLCMember_lbl" xml:lang="en-US">Halle Special Situations Fund L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BroadwoodPartnersLPMember" xlink:label="OCX_BroadwoodPartnersLPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BroadwoodPartnersLPMember" xlink:to="OCX_BroadwoodPartnersLPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_BroadwoodPartnersLPMember_lbl" xml:lang="en-US">Broadwood Partners LP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PuraVidaMember" xlink:label="OCX_PuraVidaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PuraVidaMember" xlink:to="OCX_PuraVidaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PuraVidaMember_lbl" xml:lang="en-US">Pura Vida [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AVMMember" xlink:label="OCX_AVMMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AVMMember" xlink:to="OCX_AVMMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_AVMMember_lbl" xml:lang="en-US">AVM [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ArnoMember" xlink:label="OCX_ArnoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ArnoMember" xlink:to="OCX_ArnoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ArnoMember_lbl" xml:lang="en-US">Arno [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MrGutfreundMember" xlink:label="OCX_MrGutfreundMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MrGutfreundMember" xlink:to="OCX_MrGutfreundMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_MrGutfreundMember_lbl" xml:lang="en-US">Mr Gutfreund [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AmendedLoanAgreementMember" xlink:label="OCX_AmendedLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AmendedLoanAgreementMember" xlink:to="OCX_AmendedLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_AmendedLoanAgreementMember_lbl" xml:lang="en-US">Amended Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LoanDeferralAgreementMember" xlink:label="OCX_LoanDeferralAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LoanDeferralAgreementMember" xlink:to="OCX_LoanDeferralAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_LoanDeferralAgreementMember_lbl" xml:lang="en-US">Loan Deferral Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BankWarrantMember" xlink:label="OCX_BankWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BankWarrantMember" xlink:to="OCX_BankWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_BankWarrantMember_lbl" xml:lang="en-US">Bank Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LifeTechnologiesCorporationMember" xlink:label="OCX_LifeTechnologiesCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LifeTechnologiesCorporationMember" xlink:to="OCX_LifeTechnologiesCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_LifeTechnologiesCorporationMember_lbl" xml:lang="en-US">Life Technologies Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoEqualTranchesMember" xlink:label="OCX_TwoEqualTranchesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_TwoEqualTranchesMember" xlink:to="OCX_TwoEqualTranchesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_TwoEqualTranchesMember_lbl" xml:lang="en-US">Two Equal Tranches [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AprilTwoThousandTwentyTwoWarrantsMember" xlink:label="OCX_AprilTwoThousandTwentyTwoWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AprilTwoThousandTwentyTwoWarrantsMember" xlink:to="OCX_AprilTwoThousandTwentyTwoWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_AprilTwoThousandTwentyTwoWarrantsMember_lbl" xml:lang="en-US">April 2022 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LaboratoryEquipmentAgreementMember" xlink:label="OCX_LaboratoryEquipmentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LaboratoryEquipmentAgreementMember" xlink:to="OCX_LaboratoryEquipmentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_LaboratoryEquipmentAgreementMember_lbl" xml:lang="en-US">Laboratory Equipment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AuctionEquipmentAgreementMember" xlink:label="OCX_AuctionEquipmentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AuctionEquipmentAgreementMember" xlink:to="OCX_AuctionEquipmentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_AuctionEquipmentAgreementMember_lbl" xml:lang="en-US">Auction Equipment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="us-gaap_DiscontinuedOperationsHeldforsaleMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:to="us-gaap_DiscontinuedOperationsHeldforsaleMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsHeldforsaleMember_lbl" xml:lang="en-US">Discontinued Operations, Held-for-Sale [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance of $178 and $154, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US">Marketable equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xml:lang="en-US">Assets held for sale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Current assets of discontinuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NONCURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use and financing lease assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MachineryAndEquipmentNetAndConstructionInProgress" xlink:label="OCX_MachineryAndEquipmentNetAndConstructionInProgress" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MachineryAndEquipmentNetAndConstructionInProgress" xlink:to="OCX_MachineryAndEquipmentNetAndConstructionInProgress_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_MachineryAndEquipmentNetAndConstructionInProgress_lbl" xml:lang="en-US">Machinery and equipment, net, and construction in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other noncurrent assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AccruedSeveranceFromAcquisitionCurrent" xlink:label="OCX_AccruedSeveranceFromAcquisitionCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AccruedSeveranceFromAcquisitionCurrent" xlink:to="OCX_AccruedSeveranceFromAcquisitionCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_AccruedSeveranceFromAcquisitionCurrent_lbl" xml:lang="en-US">Accrued severance from acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Accrued liabilities from acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent" xlink:label="OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent" xlink:to="OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent_lbl" xml:lang="en-US">Right-of-use and financing lease liabilities, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Current liabilities of discontinuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NONCURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent" xlink:label="OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent" xlink:to="OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent_lbl" xml:lang="en-US">Right-of-use and financing lease liabilities, noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US">Contingent consideration liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 and 6 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $5,140 and $6,091 as of June 30, 2023 and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, no par value, 230,000 shares authorized; 8,241 and 5,932 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable, allowance for credit loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TemporaryEquityNoParValue" xlink:label="OCX_TemporaryEquityNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_TemporaryEquityNoParValue" xlink:to="OCX_TemporaryEquityNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_TemporaryEquityNoParValue_lbl" xml:lang="en-US">Temporary equity, no par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Temporary equity, stated par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Temporary equity, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Temporary equity, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US">Temporary equity, liquidation preference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US">Preferred stock, no par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US">Common stock, no par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles" xlink:label="OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles" xlink:to="OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles_lbl" xml:lang="en-US">Cost of revenues &#8211; amortization of acquired intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment loss from intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xml:lang="en-US">Loss on disposal and held for sale assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSES), NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income (expenses), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain (loss) on marketable equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expenses), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expenses), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Loss from continuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Loss from discontinuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" xlink:label="OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" xlink:to="OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">LESS: DIVIDENDS AND ACCRETION OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS: BASIC</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Net loss from continuing operations per share: basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Net loss from continuing operations per share: diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Net loss from discontinuing operations per share: basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Net loss from discontinuing operations per share: diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share: basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share: diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding: basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares outstanding: diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">COMPREHENSIVE LOSS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards" xlink:label="OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards" xlink:to="OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards_lbl" xml:lang="en-US">Vesting of bonus awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Sale of common shares, net of financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Sale of common shares, net of financing costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" xlink:label="OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" xlink:to="OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Deemed dividend on Series A redeemable convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xml:lang="en-US">Redemption of Series A redeemable convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xml:lang="en-US">Redemption of SeriesA redeemable convertible preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Shares issued upon vesting of RSU, net of shares retired to pay employees&#8217; taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Shares issued upon vesting of RSU, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" xlink:label="OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" xlink:to="OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue_lbl" xml:lang="en-US">Accretion of Series A convertible preferred stock to redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Issuance of Series A redeemable convertible preferred stock, net of financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Unrealized (gain) loss on marketable equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" xlink:label="OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" xlink:to="OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation_lbl" xml:lang="en-US">Change in fair value of Series A redeemable convertible preferred stock second tranche obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" xml:lang="en-US">Loss on disposal of discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Loss on disposal and held for sale assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" xlink:label="OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" xlink:to="OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition_lbl" xml:lang="en-US">Accrued severance and liabilities from Chronix Biomedical acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="us-gaap_IncreaseDecreaseInAssetsHeldForSale" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:to="us-gaap_IncreaseDecreaseInAssetsHeldForSale_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAssetsHeldForSale_lbl" xml:lang="en-US">Assets held for sale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Construction in progress and purchases of furniture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Financing costs to issue common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from sale of redeemable convertible Series A preferred shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Redemption of redeemable convertible Series A preferred shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" xlink:label="OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" xlink:to="OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares_lbl" xml:lang="en-US">Financing costs to issue redeemable convertible Series A preferred shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" xlink:label="OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" xlink:to="OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions_lbl" xml:lang="en-US">Proceeds from sale of common shares under at-the-market transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PaymentForFinancingCostsForAtthemarketSales" xlink:label="OCX_PaymentForFinancingCostsForAtthemarketSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PaymentForFinancingCostsForAtthemarketSales" xlink:to="OCX_PaymentForFinancingCostsForAtthemarketSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OCX_PaymentForFinancingCostsForAtthemarketSales_lbl" xml:lang="en-US">Financing costs for at-the-market sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayment of loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RepaymentOfFinancingLeaseObligations" xlink:label="OCX_RepaymentOfFinancingLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RepaymentOfFinancingLeaseObligations" xlink:to="OCX_RepaymentOfFinancingLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OCX_RepaymentOfFinancingLeaseObligations_lbl" xml:lang="en-US">Repayment of financing lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability" xlink:label="OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability" xlink:to="OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability_lbl" xml:lang="en-US">Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Description of the Business and Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Business Combinations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenues and Concentration Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Right-of-use assets, machinery and equipment, net, and construction in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisclosureWorkforceReductionAbstract" xlink:label="OCX_DisclosureWorkforceReductionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisclosureWorkforceReductionAbstract" xlink:to="OCX_DisclosureWorkforceReductionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DisclosureWorkforceReductionAbstract_lbl" xml:lang="en-US">Workforce Reduction</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_WorkforceReductionTextBlock" xlink:label="OCX_WorkforceReductionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_WorkforceReductionTextBlock" xlink:to="OCX_WorkforceReductionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OCX_WorkforceReductionTextBlock_lbl" xml:lang="en-US">Workforce Reduction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Loan Payable to Silicon Valley Bank</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract" xlink:label="OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract" xlink:to="OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract_lbl" xml:lang="en-US">Co-development Agreement With Life Technologies Corporation</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock" xlink:label="OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock" xlink:to="OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock_lbl" xml:lang="en-US">Co-Development Agreement with Life Technologies Corporation</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisclosureEquityOfferingsAbstract" xlink:label="OCX_DisclosureEquityOfferingsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisclosureEquityOfferingsAbstract" xlink:to="OCX_DisclosureEquityOfferingsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DisclosureEquityOfferingsAbstract_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AprilTwentyTwentyTwoOfferingsTextBlock" xlink:label="OCX_AprilTwentyTwentyTwoOfferingsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AprilTwentyTwentyTwoOfferingsTextBlock" xlink:to="OCX_AprilTwentyTwentyTwoOfferingsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OCX_AprilTwentyTwentyTwoOfferingsTextBlock_lbl" xml:lang="en-US">Equity Offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Assets Held for Sale and Discontinued Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock" xlink:label="OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock" xlink:to="OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock_lbl" xml:lang="en-US">Business combinations and fair value measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xml:lang="en-US">Assets Held for Sale and Discontinued Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill and intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Long-lived intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy_lbl" xml:lang="en-US">Contingent consideration liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US">Investments in capital stock of privately held companies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SalesAndMarketingExpensesPolicyTextBlock" xlink:label="OCX_SalesAndMarketingExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SalesAndMarketingExpensesPolicyTextBlock" xlink:to="OCX_SalesAndMarketingExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_SalesAndMarketingExpensesPolicyTextBlock_lbl" xml:lang="en-US">Sales and marketing expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AccountingForSharesOfCommonStockPolicyTextBlock" xlink:label="OCX_AccountingForSharesOfCommonStockPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AccountingForSharesOfCommonStockPolicyTextBlock" xlink:to="OCX_AccountingForSharesOfCommonStockPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_AccountingForSharesOfCommonStockPolicyTextBlock_lbl" xml:lang="en-US">Accounting for Lineage and AgeX shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Measurement of Financial Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Contingent Consideration Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock" xlink:label="OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock" xlink:to="OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Contingent Consideration, Measured at Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of Goodwill and Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets Future Amortization Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions Used to Calculate Fair Value of Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Summary of Stock-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions Used to Calculate Fair Value of Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Consolidated Revenues Generated by Unaffiliated Customers</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock" xlink:label="OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock" xlink:to="OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock_lbl" xml:lang="en-US">Schedule of Consolidated Revenues Attributable to Products or Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock" xlink:label="OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock" xlink:to="OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock" xlink:label="OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock" xlink:to="OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock" xlink:label="OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock" xlink:to="OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Lease Commitments for Operating and Financing Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of Assets and Liabilities of Disposal Group Held for Sale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Purchase of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquitySecuritiesFvNi_2_lbl" xml:lang="en-US">Marketable equity securities fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Gross proceeds from offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Fair value of common stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2_lbl" xml:lang="en-US">Convertible preferred shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock stated value per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Purchase of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_2_lbl" xml:lang="en-US">Net proceeds to immediately redeem</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_2_lbl" xml:lang="en-US">Number of stock redeem</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_lbl" xml:lang="en-US">Cash from discontinuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash shown in the statements of cash flows</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss attributable to Oncocyte Corporation</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DividendOnPreferredStock" xlink:label="OCX_DividendOnPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DividendOnPreferredStock" xlink:to="OCX_DividendOnPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DividendOnPreferredStock_lbl" xml:lang="en-US">Dividend on Series A redeemable convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="us-gaap_RedeemablePreferredStockDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemablePreferredStockDividends" xlink:to="us-gaap_RedeemablePreferredStockDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RedeemablePreferredStockDividends_lbl" xml:lang="en-US">Accretion of Series A redeemable convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DeemedDividendOnPreferredStock" xlink:label="OCX_DeemedDividendOnPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DeemedDividendOnPreferredStock" xlink:to="OCX_DeemedDividendOnPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OCX_DeemedDividendOnPreferredStock_lbl" xml:lang="en-US">Deemed dividend on Series A redeemable convertible preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net loss attributable to common stockholders - Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2_lbl" xml:lang="en-US">Net income (loss) attributable to common stockholders - diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average number of shares outstanding, basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average number of shares outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic net loss per common share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Earnings Per Share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:to="us-gaap_IncreaseDecreaseInAssetsHeldForSale_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAssetsHeldForSale_2_lbl" xml:lang="en-US">Increase (decrease) in asset, held-for-sale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory write down</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset impairment charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Long-lived intangible assets, useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableSale" xlink:label="us-gaap_AccountsReceivableSale" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableSale" xlink:to="us-gaap_AccountsReceivableSale_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableSale_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:label="OCX_CommonStockSharesHeldAsAvailableForSaleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:to="OCX_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_CommonStockSharesHeldAsAvailableForSaleSecurities_lbl" xml:lang="en-US">Common stock, shares held as available for sale securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNi_3_lbl" xml:lang="en-US">Fair value of equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ContingentConsiderationLiabilityContractualValue" xlink:label="OCX_ContingentConsiderationLiabilityContractualValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ContingentConsiderationLiabilityContractualValue" xlink:to="OCX_ContingentConsiderationLiabilityContractualValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ContingentConsiderationLiabilityContractualValue_lbl" xml:lang="en-US">Contractual Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Fair Value on the Merger Date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" xlink:label="OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" xlink:to="OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_lbl" xml:lang="en-US">Change in estimated fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_FairValueOfContingentConsideration" xlink:label="OCX_FairValueOfContingentConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_FairValueOfContingentConsideration" xlink:to="OCX_FairValueOfContingentConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_FairValueOfContingentConsideration_lbl" xml:lang="en-US">Fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_2_lbl" xml:lang="en-US">Outstanding equity</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ClinicalTrialExpenseReserveAmount" xlink:label="OCX_ClinicalTrialExpenseReserveAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ClinicalTrialExpenseReserveAmount" xlink:to="OCX_ClinicalTrialExpenseReserveAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ClinicalTrialExpenseReserveAmount_lbl" xml:lang="en-US">Clinical trial expense reserve amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Business combination consideration transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_EarnoutPercentageOnCollectionsForSales" xlink:label="OCX_EarnoutPercentageOnCollectionsForSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_EarnoutPercentageOnCollectionsForSales" xlink:to="OCX_EarnoutPercentageOnCollectionsForSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_EarnoutPercentageOnCollectionsForSales_lbl" xml:lang="en-US">Earnout percentage on collections for sales</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_EarnoutPercentageOnCollectionsForSaleOrLicense" xlink:label="OCX_EarnoutPercentageOnCollectionsForSaleOrLicense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_EarnoutPercentageOnCollectionsForSaleOrLicense" xlink:to="OCX_EarnoutPercentageOnCollectionsForSaleOrLicense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_EarnoutPercentageOnCollectionsForSaleOrLicense_lbl" xml:lang="en-US">Earnout percentage on collections for sale or license</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_EarnoutPercentageOnCollectionsForSale" xlink:label="OCX_EarnoutPercentageOnCollectionsForSale" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_EarnoutPercentageOnCollectionsForSale" xlink:to="OCX_EarnoutPercentageOnCollectionsForSale_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_EarnoutPercentageOnCollectionsForSale_lbl" xml:lang="en-US">Gross proceeds percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RoyaltyPaymentsPercentage" xlink:label="OCX_RoyaltyPaymentsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RoyaltyPaymentsPercentage" xlink:to="OCX_RoyaltyPaymentsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RoyaltyPaymentsPercentage_lbl" xml:lang="en-US">Royalty payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Net deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" xml:lang="en-US">Intangible assets acquired IPR&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_lbl" xml:lang="en-US">Acquired intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Total intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_2_lbl" xml:lang="en-US">Impairment of intangible</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Offering shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_3_lbl" xml:lang="en-US">Preferred stock offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Stated value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Gross proceeds, closing</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Net proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockDescription" xlink:label="us-gaap_ConversionOfStockDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockDescription_lbl" xml:lang="en-US">Conversion of stock, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl" xml:lang="en-US">Equity method investment, description of principal activities</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ConversionPricePercentage" xlink:label="OCX_ConversionPricePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ConversionPricePercentage" xlink:to="OCX_ConversionPricePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ConversionPricePercentage_lbl" xml:lang="en-US">Conversion price percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PreferredStockRemainsOutstandingPercentage" xlink:label="OCX_PreferredStockRemainsOutstandingPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PreferredStockRemainsOutstandingPercentage" xlink:to="OCX_PreferredStockRemainsOutstandingPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PreferredStockRemainsOutstandingPercentage_lbl" xml:lang="en-US">Preferred stock outstanding percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash in hand</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_IndebtednessExpenses" xlink:label="OCX_IndebtednessExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_IndebtednessExpenses" xlink:to="OCX_IndebtednessExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_IndebtednessExpenses_lbl" xml:lang="en-US">Indebtedness expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DividendsRatePerPercentage" xlink:label="OCX_DividendsRatePerPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DividendsRatePerPercentage" xlink:to="OCX_DividendsRatePerPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DividendsRatePerPercentage_lbl" xml:lang="en-US">Dividends rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_3_lbl" xml:lang="en-US">Ownership percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_3_lbl" xml:lang="en-US">Number of stock redeem value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockNoParValue_2_lbl" xml:lang="en-US">Preferred stock no par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Number of common stock purchase warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value of awards granted during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Shares available for grant options, beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options outstanding, beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options outstanding, beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Shares available for grant options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of options outstanding, option exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Shares available for grant options forfeited, cancelled and expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options outstanding, options forfeited, cancelled and expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options forfeited, cancelled and expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Shares available for grant outstanding, end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options outstanding, end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, outstanding end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number of options outstanding, exercisable, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted average exercise price, exercisable, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of RSUs Outstanding, beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_lbl" xml:lang="en-US">Shares available for grant options RSUs vested</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of options outstanding, option RSUs vested</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_lbl" xml:lang="en-US">Number of RSUs Outstanding, option RSUs vested</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" xlink:to="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_lbl" xml:lang="en-US">Weighted average exercise price, options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares available for grant options RSUs granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options outstanding, option RSUs granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_lbl" xml:lang="en-US">Number of RSUs Outstanding, option RSUs granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice" xlink:to="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, option RSUs granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_lbl" xml:lang="en-US">Shares available for grant options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options outstanding, option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of RSUs Outstanding, option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited" xlink:label="OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited" xlink:to="OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_lbl" xml:lang="en-US">Shares available for grant options forfeited, cancelled and expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of RSUs Outstanding, options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares" xlink:label="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares" xlink:to="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Shares available for grant RSUs, cancelled and expired</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options outstanding, options forfeited, RSUs cancelled and expired</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_lbl" xml:lang="en-US">Number of RSUs Outstanding, options forfeited, canceled and expired</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options forfeited, RSUs cancelled and expired</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares" xlink:label="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares" xlink:to="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Shares available for grant performance RSUs, cancelled and expired</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options outstanding, options forfeited, performance RSUs cancelled and expired</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_lbl" xml:lang="en-US">Number of Performance RSUs Outstanding, options forfeited, canceled and expired</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options forfeited, performance RSUs cancelled and expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of RSUs Outstanding, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Expected Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vested percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Share based payment award description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:label="us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:to="us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_lbl" xml:lang="en-US">Increase in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xml:lang="en-US">Share based payment award vesting rights description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Machinery and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Right-of-use assets, machinery and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xml:lang="en-US">Construction in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations" xlink:label="OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations" xlink:to="OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations_lbl" xml:lang="en-US">Right-of-use assets, machinery and equipment, net, and construction in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations" xlink:label="OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations" xlink:to="OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations_lbl" xml:lang="en-US">Right-of-use assets, machinery and equipment, net, and construction in progress from discontinuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RightofuseAssetsMachineryAndEquipmentNet" xlink:label="OCX_RightofuseAssetsMachineryAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RightofuseAssetsMachineryAndEquipmentNet" xlink:to="OCX_RightofuseAssetsMachineryAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OCX_RightofuseAssetsMachineryAndEquipmentNet_lbl" xml:lang="en-US">Right-of-use assets, machinery and equipment, net, and construction in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl" xml:lang="en-US">Operating cash flows from financing leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Financing cash flows from financing leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right-of-use assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Right-of-use lease liabilities, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Right-of-use lease liabilities, noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_lbl" xml:lang="en-US">Machinery and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Machinery and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Noncurrent liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Total financing lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term, Operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term, Financing lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Financing lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less amounts representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PresentValueOfNetMinimumLeasePayments" xlink:label="OCX_PresentValueOfNetMinimumLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PresentValueOfNetMinimumLeasePayments" xlink:to="OCX_PresentValueOfNetMinimumLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="OCX_PresentValueOfNetMinimumLeasePayments_lbl" xml:lang="en-US">Present value of net minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less amounts representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of Land</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payments for rent</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CapitalLeaseAgreementImputedAnnualInterestRate" xlink:label="OCX_CapitalLeaseAgreementImputedAnnualInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_CapitalLeaseAgreementImputedAnnualInterestRate" xlink:to="OCX_CapitalLeaseAgreementImputedAnnualInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_CapitalLeaseAgreementImputedAnnualInterestRate_lbl" xml:lang="en-US">Interest rate on lease agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ObligatedToPayExpensesAndTaxesPercentage" xlink:label="OCX_ObligatedToPayExpensesAndTaxesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ObligatedToPayExpensesAndTaxesPercentage" xlink:to="OCX_ObligatedToPayExpensesAndTaxesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ObligatedToPayExpensesAndTaxesPercentage_lbl" xml:lang="en-US">Obligated to pay expenses and taxes percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xml:lang="en-US">Total tenant improvement allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment" xlink:label="OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment" xlink:to="OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment_lbl" xml:lang="en-US">Percentage of administrative fee paid on original cost of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LinesOfCreditCurrent_lbl" xml:lang="en-US">Line of Credit, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PaymentObligationAmount" xlink:label="OCX_PaymentObligationAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PaymentObligationAmount" xlink:to="OCX_PaymentObligationAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PaymentObligationAmount_lbl" xml:lang="en-US">Payment obligation amount.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeveranceCosts1_2_lbl" xml:lang="en-US">Employee severance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Sale of stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrant to purchase common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">Related party transaction, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_3_lbl" xml:lang="en-US">Stock issued during period, shares, conversion of units</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_2_lbl" xml:lang="en-US">Stock issued during period, value conversion of units</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Total compensation paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LinesOfCreditCurrent_2_lbl" xml:lang="en-US">Line of credit, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Repayments of lines of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US">Debt instrument, final payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Debt instrument maturity date description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrant exercise price, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PercentageForWarrantExercisePricePerShare" xlink:label="OCX_PercentageForWarrantExercisePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PercentageForWarrantExercisePricePerShare" xlink:to="OCX_PercentageForWarrantExercisePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PercentageForWarrantExercisePricePerShare_lbl" xml:lang="en-US">Percentage for warrant exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DilutedEquityOutstanding" xlink:label="OCX_DilutedEquityOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DilutedEquityOutstanding" xlink:to="OCX_DilutedEquityOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DilutedEquityOutstanding_lbl" xml:lang="en-US">Diluted equity outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopmentCosts" xlink:label="us-gaap_DevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentCosts" xlink:to="us-gaap_DevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentCosts_lbl" xml:lang="en-US">Development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Preferred stock, convertible, shares issuable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_2_lbl" xml:lang="en-US">Preferred stock, convertible, conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PurchasePrice" xlink:label="OCX_PurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PurchasePrice" xlink:to="OCX_PurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PurchasePrice_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_StatedValue" xlink:label="OCX_StatedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_StatedValue" xlink:to="OCX_StatedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_StatedValue_lbl" xml:lang="en-US">Stated value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_lbl" xml:lang="en-US">Proceeds from issuance of preferred stock and preference stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockDescription_2_lbl" xml:lang="en-US">Conversion of stock description</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PercentageOfIssuedAndOutstandingShares" xlink:label="OCX_PercentageOfIssuedAndOutstandingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PercentageOfIssuedAndOutstandingShares" xlink:to="OCX_PercentageOfIssuedAndOutstandingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PercentageOfIssuedAndOutstandingShares_lbl" xml:lang="en-US">Percentage of issued and outstanding shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_2_lbl" xml:lang="en-US">Equity method investment description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred stock, dividend rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividends, preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_2_lbl" xml:lang="en-US">Number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from issuance initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Net revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_lbl" xml:lang="en-US">Sales and marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" xlink:label="us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" xlink:to="us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax_lbl" xml:lang="en-US">Loss from impairment of held for sale assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2_lbl" xml:lang="en-US">Net loss from discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_lbl" xml:lang="en-US">Machinery and equipment, net, and construction in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_lbl" xml:lang="en-US">Impairment of held for sale assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_2_lbl" xml:lang="en-US">LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Cash received on stock transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_2_lbl" xml:lang="en-US">Consideration transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl" xml:lang="en-US">Loss on disposal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal and held-for-sale assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_lbl" xml:lang="en-US">Proceeds from sale of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US">Impairment loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MachineryAndEquipmentNetAndConstructionInProgress" xlink:to="OCX_MachineryAndEquipmentNetAndConstructionInProgress_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_MachineryAndEquipmentNetAndConstructionInProgress_doc" xml:lang="en-US">Machinery and equipment net and construction in progress.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AccruedSeveranceFromAcquisitionCurrent" xlink:to="OCX_AccruedSeveranceFromAcquisitionCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_AccruedSeveranceFromAcquisitionCurrent_doc" xml:lang="en-US">Accrued severance from acquisition current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ContingentConsiderationLiabilityContractualValue" xlink:to="OCX_ContingentConsiderationLiabilityContractualValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ContingentConsiderationLiabilityContractualValue_doc" xml:lang="en-US">Business Combination, Contingent Consideration, Liability Contractual value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MilestoneOneMember" xlink:to="OCX_MilestoneOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_MilestoneOneMember_doc" xml:lang="en-US">Milestone 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MilestoneTwoMember" xlink:to="OCX_MilestoneTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_MilestoneTwoMember_doc" xml:lang="en-US">Milestone 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MilestoneThreeMember" xlink:to="OCX_MilestoneThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_MilestoneThreeMember_doc" xml:lang="en-US">Milestone 3 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="OCX_SeriesARedeemableConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_SeriesARedeemableConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RoyaltyOneMember" xlink:to="OCX_RoyaltyOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RoyaltyOneMember_doc" xml:lang="en-US">Royalty 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RoyaltyTwoMember" xlink:to="OCX_RoyaltyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RoyaltyTwoMember_doc" xml:lang="en-US">Royalty 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_FairValueOfContingentConsideration" xlink:to="OCX_FairValueOfContingentConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_FairValueOfContingentConsideration_doc" xml:lang="en-US">Fair value of contingent consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock" xlink:to="OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_doc" xml:lang="en-US">Schedule of contingent consideration measured at fair value [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_InsightMergerMember" xlink:to="OCX_InsightMergerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_InsightMergerMember_doc" xml:lang="en-US">Insight Merger [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" xlink:to="OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_doc" xml:lang="en-US">Change in estimated fair value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RazorGenomicsIncMember" xlink:to="OCX_RazorGenomicsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RazorGenomicsIncMember_doc" xml:lang="en-US">Razor Genomics, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_OncocyteCorpMember" xlink:to="OCX_OncocyteCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_OncocyteCorpMember_doc" xml:lang="en-US">Oncocyte Corp [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ClinicalTrialExpenseReserveAmount" xlink:to="OCX_ClinicalTrialExpenseReserveAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ClinicalTrialExpenseReserveAmount_doc" xml:lang="en-US">Clinical trial expense reserve amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DevelopmentAgreementMember" xlink:to="OCX_DevelopmentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DevelopmentAgreementMember_doc" xml:lang="en-US">Development Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MergerAgreementMember" xlink:to="OCX_MergerAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_MergerAgreementMember_doc" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ChronixBiomedicalIncMember" xlink:to="OCX_ChronixBiomedicalIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ChronixBiomedicalIncMember_doc" xml:lang="en-US">Chronix Biomedical Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_EarnoutPercentageOnCollectionsForSales" xlink:to="OCX_EarnoutPercentageOnCollectionsForSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_EarnoutPercentageOnCollectionsForSales_doc" xml:lang="en-US">Earnout percentage on collections for sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_EarnoutPercentageOnCollectionsForSaleOrLicense" xlink:to="OCX_EarnoutPercentageOnCollectionsForSaleOrLicense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_EarnoutPercentageOnCollectionsForSaleOrLicense_doc" xml:lang="en-US">Earnout percentage on collections for sale or license.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ChronixEquityMember" xlink:to="OCX_ChronixEquityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ChronixEquityMember_doc" xml:lang="en-US">Chronix Equity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_EarnoutPercentageOnCollectionsForSale" xlink:to="OCX_EarnoutPercentageOnCollectionsForSale_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_EarnoutPercentageOnCollectionsForSale_doc" xml:lang="en-US">Earnout percentage on collections for sale.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RoyaltyPaymentsPercentage" xlink:to="OCX_RoyaltyPaymentsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RoyaltyPaymentsPercentage_doc" xml:lang="en-US">Royalty payments percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ChronixMilestoneMember" xlink:to="OCX_ChronixMilestoneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ChronixMilestoneMember_doc" xml:lang="en-US">Chronix Milestone [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ChronixMember" xlink:to="OCX_ChronixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ChronixMember_doc" xml:lang="en-US">Chronix [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles" xlink:to="OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles_doc" xml:lang="en-US">Cost of revenues &amp;#8211; amortization of acquired intangibles.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ChronixMergerMember" xlink:to="OCX_ChronixMergerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ChronixMergerMember_doc" xml:lang="en-US">Chronix Merger [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_WorkforceReductionTextBlock" xlink:to="OCX_WorkforceReductionTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_WorkforceReductionTextBlock_doc" xml:lang="en-US">Workforce reduction [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DetermaIOMember" xlink:to="OCX_DetermaIOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DetermaIOMember_doc" xml:lang="en-US">DetermaI O [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DetermaCNIAndVitaGraftMember" xlink:to="OCX_DetermaCNIAndVitaGraftMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DetermaCNIAndVitaGraftMember_doc" xml:lang="en-US">DetermaCNI and VitaGraft [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SecuritiesPurchaseAgreementMember" xlink:to="OCX_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ConversionPricePercentage" xlink:to="OCX_ConversionPricePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ConversionPricePercentage_doc" xml:lang="en-US">Conversion price percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PreferredStockRemainsOutstandingPercentage" xlink:to="OCX_PreferredStockRemainsOutstandingPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PreferredStockRemainsOutstandingPercentage_doc" xml:lang="en-US">Preferred stock remains outstanding percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_IndebtednessExpenses" xlink:to="OCX_IndebtednessExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_IndebtednessExpenses_doc" xml:lang="en-US">Indebtedness expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DividendsRatePerPercentage" xlink:to="OCX_DividendsRatePerPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DividendsRatePerPercentage_doc" xml:lang="en-US">Dividends rate per percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_InterestMember" xlink:to="OCX_InterestMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_InterestMember_doc" xml:lang="en-US">Interest [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SecurityMember" xlink:to="OCX_SecurityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_SecurityMember_doc" xml:lang="en-US">Security [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RegisteredDirectOfferingMember" xlink:to="OCX_RegisteredDirectOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RegisteredDirectOfferingMember_doc" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_TwoThousandTenStockOptionPlanMember" xlink:to="OCX_TwoThousandTenStockOptionPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_TwoThousandTenStockOptionPlanMember_doc" xml:lang="en-US">2010 Stock Option Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MonteCarloValuationTechniqueMember" xlink:to="OCX_MonteCarloValuationTechniqueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_MonteCarloValuationTechniqueMember_doc" xml:lang="en-US">Monte Carlo Valuation Technique [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PerformanceBasedOptionsMember" xlink:to="OCX_PerformanceBasedOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PerformanceBasedOptionsMember_doc" xml:lang="en-US">Performance-Based Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ExecutiveOfficersAndEmployeesMember" xlink:to="OCX_ExecutiveOfficersAndEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ExecutiveOfficersAndEmployeesMember_doc" xml:lang="en-US">Executive Officers and Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MarketBasedAwardsMember" xlink:to="OCX_MarketBasedAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_MarketBasedAwardsMember_doc" xml:lang="en-US">Market Based Awards [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_VitaGraftMember" xlink:to="OCX_VitaGraftMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_VitaGraftMember_doc" xml:lang="en-US">Vita Graft [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DetermalOMember" xlink:to="OCX_DetermalOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DetermalOMember_doc" xml:lang="en-US">Determal O [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DetermaCNIMember" xlink:to="OCX_DetermaCNIMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DetermaCNIMember_doc" xml:lang="en-US">Determa CNI [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AmendedLoanAgreementMember" xlink:to="OCX_AmendedLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_AmendedLoanAgreementMember_doc" xml:lang="en-US">Amended Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_TwoThousandTenPlanActivityMember" xlink:to="OCX_TwoThousandTenPlanActivityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_TwoThousandTenPlanActivityMember_doc" xml:lang="en-US">2010 Plan Activity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" xlink:to="OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock_doc" xml:lang="en-US">Deemed dividend on Series A redeemable convertible preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LoanDeferralAgreementMember" xlink:to="OCX_LoanDeferralAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_LoanDeferralAgreementMember_doc" xml:lang="en-US">Loan Deferral Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BankWarrantMember" xlink:to="OCX_BankWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_BankWarrantMember_doc" xml:lang="en-US">Bank Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_TwoThousandEighteenIncentivePlanMember" xlink:to="OCX_TwoThousandEighteenIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_TwoThousandEighteenIncentivePlanMember_doc" xml:lang="en-US">2018 Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PercentageForWarrantExercisePricePerShare" xlink:to="OCX_PercentageForWarrantExercisePricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PercentageForWarrantExercisePricePerShare_doc" xml:lang="en-US">Percentage for warrant exercise price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DilutedEquityOutstanding" xlink:to="OCX_DilutedEquityOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DilutedEquityOutstanding_doc" xml:lang="en-US">Diluted equity outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" xlink:to="OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue_doc" xml:lang="en-US">Accretion of Series A convertible preferred stock to redemption value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_TwoThousandEighteenPalnActivityMember" xlink:to="OCX_TwoThousandEighteenPalnActivityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_TwoThousandEighteenPalnActivityMember_doc" xml:lang="en-US">2018 Paln Activity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options available restricted stock options vested in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options available restricted stock options grants in period gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share based Payment Award Options Available Grants In Period Gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock" xlink:to="OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock_doc" xml:lang="en-US">Co development agreementwith life technologies corporation [TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AprilTwentyTwentyTwoOfferingsTextBlock" xlink:to="OCX_AprilTwentyTwentyTwoOfferingsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_AprilTwentyTwentyTwoOfferingsTextBlock_doc" xml:lang="en-US">April twenty twenty two offerings[TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited" xlink:to="OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_doc" xml:lang="en-US">Stock issued during period shares stock options nonvested options forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares" xlink:to="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award options nonvested restricted stock options forfeited number of shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PurchasePrice" xlink:to="OCX_PurchasePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PurchasePrice_doc" xml:lang="en-US">Purchase Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_doc" xml:lang="en-US">Share Based CompensationArrangement By Share Based Payment Award Restricted Stock Options Vested In Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_doc" xml:lang="en-US">Number of Options Outstanding, Option RSUs Granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_StatedValue" xlink:to="OCX_StatedValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_StatedValue_doc" xml:lang="en-US">Stated Value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_TwoEqualTranchesMember" xlink:to="OCX_TwoEqualTranchesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_TwoEqualTranchesMember_doc" xml:lang="en-US">Two Equal Tranches [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award restricted stock units options forfeitures in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_doc" xml:lang="en-US">Number of RSUs Outstanding, option RSUs vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_doc" xml:lang="en-US">Number of RSUs Outstanding, option RSUs granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options restricted stock options forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" xlink:to="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Vesting Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice" xlink:to="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award restricted stock grants in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Sharebased compensation arrangements by sharebased payment award restricted stock units options forfeitures in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PercentageOfIssuedAndOutstandingShares" xlink:to="OCX_PercentageOfIssuedAndOutstandingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PercentageOfIssuedAndOutstandingShares_doc" xml:lang="en-US">Percentage of Issued and Outstanding Shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AprilTwoThousandTwentyTwoWarrantsMember" xlink:to="OCX_AprilTwoThousandTwentyTwoWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_AprilTwoThousandTwentyTwoWarrantsMember_doc" xml:lang="en-US">April 2022 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_UnderwritingAgreementMember" xlink:to="OCX_UnderwritingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_UnderwritingAgreementMember_doc" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" xlink:to="OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation_doc" xml:lang="en-US">Change in fair value of Series A redeemable convertible preferred stock second tranche obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PharmaServicesCompanyAMember" xlink:to="OCX_PharmaServicesCompanyAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PharmaServicesCompanyAMember_doc" xml:lang="en-US">Pharma Services Company A [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" xlink:to="OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition_doc" xml:lang="en-US">Accrued Severance And Liabilities From Chronix Biomedical Acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BoardMembersMember" xlink:to="OCX_BoardMembersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_BoardMembersMember_doc" xml:lang="en-US">Board Members [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_OtherInvestorsMember" xlink:to="OCX_OtherInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_OtherInvestorsMember_doc" xml:lang="en-US">Other Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PaymentForFinancingCostsForAtthemarketSales" xlink:to="OCX_PaymentForFinancingCostsForAtthemarketSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PaymentForFinancingCostsForAtthemarketSales_doc" xml:lang="en-US">Payment For Financing Costs For Atthemarket Sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RepaymentOfFinancingLeaseObligations" xlink:to="OCX_RepaymentOfFinancingLeaseObligations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RepaymentOfFinancingLeaseObligations_doc" xml:lang="en-US">Repayment Of Financing Lease Obligations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" xlink:to="OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions_doc" xml:lang="en-US">Proceeds from sale of common shares under At the market transactions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RazorStockPurchaseAgreementMember" xlink:to="OCX_RazorStockPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RazorStockPurchaseAgreementMember_doc" xml:lang="en-US">Razor Stock Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RazorMember" xlink:to="OCX_RazorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RazorMember_doc" xml:lang="en-US">Razor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DragonMember" xlink:to="OCX_DragonMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DragonMember_doc" xml:lang="en-US">Dragon [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" xlink:to="OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares_doc" xml:lang="en-US">Change in fair value of Series A redeemable convertible preferred stock second tranche obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability" xlink:to="OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability_doc" xml:lang="en-US">Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DragonScientificLLCMember" xlink:to="OCX_DragonScientificLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DragonScientificLLCMember_doc" xml:lang="en-US">Dragon Scientific LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LaboratoryEquipmentAgreementMember" xlink:to="OCX_LaboratoryEquipmentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_LaboratoryEquipmentAgreementMember_doc" xml:lang="en-US">Laboratory Equipment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AuctionEquipmentAgreementMember" xlink:to="OCX_AuctionEquipmentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_AuctionEquipmentAgreementMember_doc" xml:lang="en-US">Auction Equipment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AtTheMarketSalesAgreementMember" xlink:to="OCX_AtTheMarketSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_AtTheMarketSalesAgreementMember_doc" xml:lang="en-US">At The Market Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BTIGLLCMember" xlink:to="OCX_BTIGLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_BTIGLLCMember_doc" xml:lang="en-US">BTIG, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PharmaServicesCompanyBMember" xlink:to="OCX_PharmaServicesCompanyBMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PharmaServicesCompanyBMember_doc" xml:lang="en-US">Pharma Services Company B [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DiscontinuedOperationsDetermaRxMember" xlink:to="OCX_DiscontinuedOperationsDetermaRxMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DiscontinuedOperationsDetermaRxMember_doc" xml:lang="en-US">Discontinued Operations Determa Rx [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_doc" xml:lang="en-US">Disposal group including discontinued operation research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_doc" xml:lang="en-US">Disposal group including discontinued operation sales and marketing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock" xlink:to="OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock_doc" xml:lang="en-US">Schedule of consolidated revenues attributable to products or services [TableTextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PharmaServicesMember" xlink:to="OCX_PharmaServicesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PharmaServicesMember_doc" xml:lang="en-US">Pharma Services [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DiscontinuedOperationsMember" xlink:to="OCX_DiscontinuedOperationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DiscontinuedOperationsMember_doc" xml:lang="en-US">Discontinued Operations [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DetermaRxMember" xlink:to="OCX_DetermaRxMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DetermaRxMember_doc" xml:lang="en-US">Determa Rx [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock" xlink:to="OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock_doc" xml:lang="en-US">Business Combinations and Fair Value Measurements [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MarketableEquitySecuritiesMember" xlink:to="OCX_MarketableEquitySecuritiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_MarketableEquitySecuritiesMember_doc" xml:lang="en-US">Marketable Equity Securities [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ContingentConsiderationLiabilitiesMember" xlink:to="OCX_ContingentConsiderationLiabilitiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ContingentConsiderationLiabilitiesMember_doc" xml:lang="en-US">Contingent Consideration Liabilities [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_VariousAgreementsMember" xlink:to="OCX_VariousAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_VariousAgreementsMember_doc" xml:lang="en-US">Various Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations" xlink:to="OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations_doc" xml:lang="en-US">Right of use assets machinery and equipment continuing operations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations" xlink:to="OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations_doc" xml:lang="en-US">Right of use Assets Machinery And Equipment Discontinuing Operations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RightofuseAssetsMachineryAndEquipmentNet" xlink:to="OCX_RightofuseAssetsMachineryAndEquipmentNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RightofuseAssetsMachineryAndEquipmentNet_doc" xml:lang="en-US">Right-of-use assets, machinery and equipment, net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_doc" xml:lang="en-US">Disposal group including discontinued operation machinery and equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_doc" xml:lang="en-US">Disposal group including discontinued operation impairment of held for sale assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_doc" xml:lang="en-US">Disposal group including discontinued operation accrued compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_doc" xml:lang="en-US">Disposal group including discontinued operation accrued expenses other current liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_OfficeLeaseAgreementMember" xlink:to="OCX_OfficeLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_OfficeLeaseAgreementMember_doc" xml:lang="en-US">Office Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_CapitalLeaseAgreementImputedAnnualInterestRate" xlink:to="OCX_CapitalLeaseAgreementImputedAnnualInterestRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_CapitalLeaseAgreementImputedAnnualInterestRate_doc" xml:lang="en-US">Refers to annual interest rate on capital lease agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MonthlyRentMember" xlink:to="OCX_MonthlyRentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_MonthlyRentMember_doc" xml:lang="en-US">Monthly Rent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_FirstTenCalendarMember" xlink:to="OCX_FirstTenCalendarMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_FirstTenCalendarMember_doc" xml:lang="en-US">First Ten Calendar [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ObligatedToPayExpensesAndTaxesPercentage" xlink:to="OCX_ObligatedToPayExpensesAndTaxesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ObligatedToPayExpensesAndTaxesPercentage_doc" xml:lang="en-US">Obligated to pay expenses and taxes percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment" xlink:to="OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment_doc" xml:lang="en-US">Percentage of administrative fee paid on original cost of equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LandlordMember" xlink:to="OCX_LandlordMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_LandlordMember_doc" xml:lang="en-US">Landlord [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LeaseAgreementMember" xlink:to="OCX_LeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_LeaseAgreementMember_doc" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PaymentObligationAmount" xlink:to="OCX_PaymentObligationAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PaymentObligationAmount_doc" xml:lang="en-US">Payment obligation amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LaboratoryEquipmentMember" xlink:to="OCX_LaboratoryEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_LaboratoryEquipmentMember_doc" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock" xlink:to="OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock_doc" xml:lang="en-US">Schedule of operating and finance lease cash flow [TableTextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SalesAndMarketingExpensesPolicyTextBlock" xlink:to="OCX_SalesAndMarketingExpensesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_SalesAndMarketingExpensesPolicyTextBlock_doc" xml:lang="en-US">Sales and Marketing Expenses [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock" xlink:to="OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock_doc" xml:lang="en-US">Schedule of operating and finance lease balance sheet [TableTextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_OperatingAndFinancingLeasesMember" xlink:to="OCX_OperatingAndFinancingLeasesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_OperatingAndFinancingLeasesMember_doc" xml:lang="en-US">Operating and Financing Leases [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock" xlink:to="OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock_doc" xml:lang="en-US">Schedule of future minimum lease commitments for operating and financing leases [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PresentValueOfNetMinimumLeasePayments" xlink:to="OCX_PresentValueOfNetMinimumLeasePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PresentValueOfNetMinimumLeasePayments_doc" xml:lang="en-US">Present value of net minimum lease payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ExecutiveOfficersMember" xlink:to="OCX_ExecutiveOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ExecutiveOfficersMember_doc" xml:lang="en-US">Executive Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AccountingForSharesOfCommonStockPolicyTextBlock" xlink:to="OCX_AccountingForSharesOfCommonStockPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_AccountingForSharesOfCommonStockPolicyTextBlock_doc" xml:lang="en-US">Accounting For Shares OfCommon Stock [PolicyTextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:to="OCX_CommonStockSharesHeldAsAvailableForSaleSecurities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_CommonStockSharesHeldAsAvailableForSaleSecurities_doc" xml:lang="en-US">Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury) held by the entity as available for sale securities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LineageAndAgeXMember" xlink:to="OCX_LineageAndAgeXMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_LineageAndAgeXMember_doc" xml:lang="en-US">Lineage and AgeX [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DividendOnPreferredStock" xlink:to="OCX_DividendOnPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DividendOnPreferredStock_doc" xml:lang="en-US">Dividend on Series A redeemable convertible preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares" xlink:to="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options nonvested performance restricted stock options forfeited number of shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award performance restricted stock units options forfeitures in period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options performance restricted stock options forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award performance restricted stock units options forfeitures in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DeemedDividendOnPreferredStock" xlink:to="OCX_DeemedDividendOnPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DeemedDividendOnPreferredStock_doc" xml:lang="en-US">Deemed dividend on preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_LifeTechnologiesCorporationMember" xlink:to="OCX_LifeTechnologiesCorporationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_LifeTechnologiesCorporationMember_doc" xml:lang="en-US">Life Technologies Corporation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent" xlink:to="OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent_doc" xml:lang="en-US">Right-of-use and financing lease liabilities, current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent" xlink:to="OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent_doc" xml:lang="en-US">Right-of-use and financing lease liabilities, noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_TemporaryEquityNoParValue" xlink:to="OCX_TemporaryEquityNoParValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_TemporaryEquityNoParValue_doc" xml:lang="en-US">Temporary equity no par value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards" xlink:to="OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards_doc" xml:lang="en-US">Stock issued during period value vesting of bonus awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_UnderwriterMember" xlink:to="OCX_UnderwriterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_UnderwriterMember_doc" xml:lang="en-US">Underwriter [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember" xlink:to="OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember_doc" xml:lang="en-US">Medicare for DetermaRx and Medicare Advantage for DetermaRx [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_SublicenseAgreementMember" xlink:to="OCX_SublicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_SublicenseAgreementMember_doc" xml:lang="en-US">Sublicense Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ArnoMember" xlink:to="OCX_ArnoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_ArnoMember_doc" xml:lang="en-US">Arno [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_InvestorsMember" xlink:to="OCX_InvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_InvestorsMember_doc" xml:lang="en-US">Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" xlink:to="OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock_doc" xml:lang="en-US">Dividends and Accretion of Series A Redeemable Convertible Preferred Stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_NetLossAttributableToCommonStockholdersBasicAndDiluted" xlink:label="OCX_NetLossAttributableToCommonStockholdersBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_NetLossAttributableToCommonStockholdersBasicAndDiluted" xlink:to="OCX_NetLossAttributableToCommonStockholdersBasicAndDiluted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_NetLossAttributableToCommonStockholdersBasicAndDiluted_doc" xml:lang="en-US">Net loss attributable to common stockholders basic and diluted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BroadwoodCapitalLPMember" xlink:to="OCX_BroadwoodCapitalLPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_BroadwoodCapitalLPMember_doc" xml:lang="en-US">Broadwood Capital LP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_UnderwrittenOfferingMember" xlink:to="OCX_UnderwrittenOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_UnderwrittenOfferingMember_doc" xml:lang="en-US">Underwritten Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PuraVidaInvestmentsLLCMember" xlink:to="OCX_PuraVidaInvestmentsLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PuraVidaInvestmentsLLCMember_doc" xml:lang="en-US">Pura Vida Investments LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_UnderwritersMember" xlink:to="OCX_UnderwritersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_UnderwritersMember_doc" xml:lang="en-US">Underwriters [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_BroadwoodPartnersLPMember" xlink:to="OCX_BroadwoodPartnersLPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_BroadwoodPartnersLPMember_doc" xml:lang="en-US">Broadwood Partners LP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PuraVidaMember" xlink:to="OCX_PuraVidaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_PuraVidaMember_doc" xml:lang="en-US">Pura Vida [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AVMMember" xlink:to="OCX_AVMMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OCX_AVMMember_doc" xml:lang="en-US">AVM [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_2_lbl" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_2_lbl" xml:lang="en-US">Payments for Repurchase of Redeemable Convertible Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" xlink:to="OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares_3_lbl" xml:lang="en-US">FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PaymentForFinancingCostsForAtthemarketSales" xlink:to="OCX_PaymentForFinancingCostsForAtthemarketSales_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PaymentForFinancingCostsForAtthemarketSales_3_lbl" xml:lang="en-US">PaymentForFinancingCostsForAtthemarketSales</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_2_lbl" xml:lang="en-US">Repayments of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RepaymentOfFinancingLeaseObligations" xlink:to="OCX_RepaymentOfFinancingLeaseObligations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RepaymentOfFinancingLeaseObligations_3_lbl" xml:lang="en-US">RepaymentOfFinancingLeaseObligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_WorkforceReductionTextBlock" xlink:to="OCX_WorkforceReductionTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_WorkforceReductionTextBlock_3_lbl" xml:lang="en-US">WorkforceReductionTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_AprilTwentyTwentyTwoOfferingsTextBlock" xlink:to="OCX_AprilTwentyTwentyTwoOfferingsTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_AprilTwentyTwentyTwoOfferingsTextBlock_3_lbl" xml:lang="en-US">AprilTwentyTwentyTwoOfferingsTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_2_lbl" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="us-gaap_ContingentLiabilityReserveEstimatePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentLiabilityReserveEstimatePolicy_2_lbl" xml:lang="en-US">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_2_lbl" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2_lbl" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemablePreferredStockDividends" xlink:to="us-gaap_RedeemablePreferredStockDividends_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemablePreferredStockDividends_2_lbl" xml:lang="en-US">Redeemable Preferred Stock Dividends</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DeemedDividendOnPreferredStock" xlink:to="OCX_DeemedDividendOnPreferredStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DeemedDividendOnPreferredStock_3_lbl" xml:lang="en-US">DeemedDividendOnPreferredStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" xlink:to="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited" xlink:to="OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" xlink:to="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations" xlink:to="OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations_3_lbl" xml:lang="en-US">RightofuseAssetsMachineryAndEquipmentContinuingOperations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_RightofuseAssetsMachineryAndEquipmentNet" xlink:to="OCX_RightofuseAssetsMachineryAndEquipmentNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_RightofuseAssetsMachineryAndEquipmentNet_3_lbl" xml:lang="en-US">Right-of-use assets, machinery and equipment, net, and construction in progress [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_2_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_2_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_2_lbl" xml:lang="en-US">Finance Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_PresentValueOfNetMinimumLeasePayments" xlink:to="OCX_PresentValueOfNetMinimumLeasePayments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_PresentValueOfNetMinimumLeasePayments_3_lbl" xml:lang="en-US">Present value of net minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationAccruedCompensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" xlink:to="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_3_lbl" xml:lang="en-US">DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2_lbl" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_2_lbl" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ocx-20230630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://oncocyte.com/role/Cover" xlink:href="ocx-20230630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BalanceSheets" xlink:href="ocx-20230630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BalanceSheetsParenthetical" xlink:href="ocx-20230630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfOperations" xlink:href="ocx-20230630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfComprehensiveLoss" xlink:href="ocx-20230630.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfShareholdersEquity" xlink:href="ocx-20230630.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/StatementsOfCashFlows" xlink:href="ocx-20230630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:href="ocx-20230630.xsd#OrganizationDescriptionOfBusinessAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="ocx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BusinessCombinations" xlink:href="ocx-20230630.xsd#BusinessCombinations" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/IntangibleAssetsNet" xlink:href="ocx-20230630.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquity" xlink:href="ocx-20230630.xsd#ShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Stock-basedCompensation" xlink:href="ocx-20230630.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk" xlink:href="ocx-20230630.xsd#DisaggregationOfRevenuesAndConcentrationRisk" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/IncomeTaxes" xlink:href="ocx-20230630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" xlink:href="ocx-20230630.xsd#Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingencies" xlink:href="ocx-20230630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/WorkforceReduction" xlink:href="ocx-20230630.xsd#WorkforceReduction" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/RelatedPartyTransactions" xlink:href="ocx-20230630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" xlink:href="ocx-20230630.xsd#LoanPayableToSiliconValleyBank" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation" xlink:href="ocx-20230630.xsd#Co-developmentAgreementWithLifeTechnologiesCorporation" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/EquityOfferings" xlink:href="ocx-20230630.xsd#EquityOfferings" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperations" xlink:href="ocx-20230630.xsd#AssetsHeldForSaleAndDiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/SubsequentEvents" xlink:href="ocx-20230630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ocx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ocx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BusinessCombinationsTables" xlink:href="ocx-20230630.xsd#BusinessCombinationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/IntangibleAssetsNetTables" xlink:href="ocx-20230630.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Stock-basedCompensationTables" xlink:href="ocx-20230630.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables" xlink:href="ocx-20230630.xsd#DisaggregationOfRevenuesAndConcentrationRiskTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" xlink:href="ocx-20230630.xsd#Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesTables" xlink:href="ocx-20230630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables" xlink:href="ocx-20230630.xsd#AssetsHeldForSaleAndDiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:href="ocx-20230630.xsd#OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" xlink:href="ocx-20230630.xsd#ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="ocx-20230630.xsd#ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" xlink:href="ocx-20230630.xsd#ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ocx-20230630.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" xlink:href="ocx-20230630.xsd#ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" xlink:href="ocx-20230630.xsd#ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" xlink:href="ocx-20230630.xsd#BusinessCombinationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:href="ocx-20230630.xsd#ScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" xlink:href="ocx-20230630.xsd#ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="ocx-20230630.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" xlink:href="ocx-20230630.xsd#ShareholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" xlink:href="ocx-20230630.xsd#ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" xlink:href="ocx-20230630.xsd#SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" xlink:href="ocx-20230630.xsd#SummaryOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="ocx-20230630.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" xlink:href="ocx-20230630.xsd#ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails" xlink:href="ocx-20230630.xsd#ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" xlink:href="ocx-20230630.xsd#ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" xlink:href="ocx-20230630.xsd#ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" xlink:href="ocx-20230630.xsd#Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" xlink:href="ocx-20230630.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:href="ocx-20230630.xsd#ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" xlink:href="ocx-20230630.xsd#ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ocx-20230630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/WorkforceReductionDetailsNarrative" xlink:href="ocx-20230630.xsd#WorkforceReductionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ocx-20230630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" xlink:href="ocx-20230630.xsd#LoanPayableToSiliconValleyBankDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative" xlink:href="ocx-20230630.xsd#Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/EquityOfferingsDetailsNarrative" xlink:href="ocx-20230630.xsd#EquityOfferingsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" xlink:href="ocx-20230630.xsd#ScheduleOfDiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails" xlink:href="ocx-20230630.xsd#ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative" xlink:href="ocx-20230630.xsd#AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://oncocyte.com/role/SubsequentEventsDetailsNarrative" xlink:href="ocx-20230630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapEquitySecuritiesFvNi" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_us-gaapAssetsHeldForSaleNotPartOfDisposalGroupCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MachineryAndEquipmentNetAndConstructionInProgress" xlink:label="loc_OCXMachineryAndEquipmentNetAndConstructionInProgress" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_OCXMachineryAndEquipmentNetAndConstructionInProgress" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AccruedSeveranceFromAcquisitionCurrent" xlink:label="loc_OCXAccruedSeveranceFromAcquisitionCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_OCXAccruedSeveranceFromAcquisitionCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent" xlink:label="loc_OCXRightOfUseAndFinancingLeaseLiabilitiesCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_OCXRightOfUseAndFinancingLeaseLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent" xlink:label="loc_OCXRightOfUseAndFinancingLeaseLiabilitiesNoncurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_OCXRightOfUseAndFinancingLeaseLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_OCXSeriesARedeemableConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_OCXSeriesARedeemableConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TemporaryEquityNoParValue" xlink:label="loc_OCXTemporaryEquityNoParValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXTemporaryEquityNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaapTemporaryEquityLiquidationPreference" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaapPreferredStockNoParValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaapCommonStockNoParValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockNoParValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles" xlink:label="loc_OCXCostOfRevenuesAmortizationOfAcquiredIntangibles" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_OCXCostOfRevenuesAmortizationOfAcquiredIntangibles" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" xlink:label="loc_OCXDividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_OCXDividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerDilutedShare" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfShareholdersEquity" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Shareholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_OCXSeriesARedeemableConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_OCXSeriesARedeemableConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards" xlink:label="loc_OCXStockIssuedDuringPeriodValueVestingOfBonusAwards" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodValueVestingOfBonusAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock" xlink:label="loc_OCXDeemedDividendOnSeriesRedeemableConvertiblePreferredStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXDeemedDividendOnSeriesRedeemableConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" xlink:label="loc_OCXStockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" xlink:label="loc_OCXChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_OCXChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaapDisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" xlink:label="loc_OCXAccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_OCXAccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaapIncreaseDecreaseInAssetsHeldForSale" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAssetsHeldForSale" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfMachineryAndEquipment" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfMachineryAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" xlink:label="loc_OCXFinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_OCXFinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" xlink:label="loc_OCXProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_OCXProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PaymentForFinancingCostsForAtthemarketSales" xlink:label="loc_OCXPaymentForFinancingCostsForAtthemarketSales" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_OCXPaymentForFinancingCostsForAtthemarketSales" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RepaymentOfFinancingLeaseObligations" xlink:label="loc_OCXRepaymentOfFinancingLeaseObligations" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_OCXRepaymentOfFinancingLeaseObligations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability" xlink:label="loc_OCXConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_OCXConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity" xlink:title="00000008 - Disclosure - Organization, Description of the Business and Liquidity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BusinessCombinations" xlink:title="00000010 - Disclosure - Business Combinations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IntangibleAssetsNet" xlink:title="00000011 - Disclosure - Intangible Assets, net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquity" xlink:title="00000012 - Disclosure - Shareholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Stock-basedCompensation" xlink:title="00000013 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk" xlink:title="00000014 - Disclosure - Disaggregation of Revenues and Concentration Risk">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IncomeTaxes" xlink:title="00000015 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress" xlink:title="00000016 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingencies" xlink:title="00000017 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/WorkforceReduction" xlink:title="00000018 - Disclosure - Workforce Reduction">
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisclosureWorkforceReductionAbstract" xlink:label="loc_OCXDisclosureWorkforceReductionAbstract" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_WorkforceReductionTextBlock" xlink:label="loc_OCXWorkforceReductionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OCXDisclosureWorkforceReductionAbstract" xlink:to="loc_OCXWorkforceReductionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/RelatedPartyTransactions" xlink:title="00000019 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBank" xlink:title="00000020 - Disclosure - Loan Payable to Silicon Valley Bank">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation" xlink:title="00000021 - Disclosure - Co-Development Agreement with Life Technologies Corporation">
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract" xlink:label="loc_OCXDisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock" xlink:label="loc_OCXCoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OCXDisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract" xlink:to="loc_OCXCoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/EquityOfferings" xlink:title="00000022 - Disclosure - Equity Offerings">
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisclosureEquityOfferingsAbstract" xlink:label="loc_OCXDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AprilTwentyTwentyTwoOfferingsTextBlock" xlink:label="loc_OCXAprilTwentyTwentyTwoOfferingsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OCXDisclosureEquityOfferingsAbstract" xlink:to="loc_OCXAprilTwentyTwentyTwoOfferingsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperations" xlink:title="00000023 - Disclosure - Assets Held for Sale and Discontinued Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000025 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock" xlink:label="loc_OCXBusinessCombinationsAndFairValueMeasurementsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_OCXBusinessCombinationsAndFairValueMeasurementsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaapDiscontinuedOperationsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDiscontinuedOperationsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:label="loc_us-gaapContingentLiabilityReserveEstimatePolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContingentLiabilityReserveEstimatePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaapEquityMethodInvestmentsPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SalesAndMarketingExpensesPolicyTextBlock" xlink:label="loc_OCXSalesAndMarketingExpensesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_OCXSalesAndMarketingExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AccountingForSharesOfCommonStockPolicyTextBlock" xlink:label="loc_OCXAccountingForSharesOfCommonStockPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_OCXAccountingForSharesOfCommonStockPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BusinessCombinationsTables" xlink:title="00000027 - Disclosure - Business Combinations (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_InsightMergerMember" xlink:label="loc_OCXInsightMergerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXInsightMergerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixMergerMember" xlink:label="loc_OCXChronixMergerMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXChronixMergerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock" xlink:label="loc_OCXScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IntangibleAssetsNetTables" xlink:title="00000028 - Disclosure - Intangible Assets, net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Stock-basedCompensationTables" xlink:title="00000029 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandTenPlanActivityMember" xlink:label="loc_OCXTwoThousandTenPlanActivityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXTwoThousandTenPlanActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables" xlink:title="00000030 - Disclosure - Disaggregation of Revenues and Concentration Risk (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock" xlink:label="loc_OCXScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_OCXScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables" xlink:title="00000031 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesTables" xlink:title="00000032 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock" xlink:label="loc_OCXScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_OCXScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock" xlink:label="loc_OCXScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_OCXScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock" xlink:label="loc_OCXScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_OCXScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables" xlink:title="00000033 - Disclosure - Assets Held for Sale and Discontinued Operations (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaapDisposalGroupClassificationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapDisposalGroupClassificationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaapDiscontinuedOperationsHeldforsaleMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupClassificationDomain" xlink:to="loc_us-gaapDiscontinuedOperationsHeldforsaleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative" xlink:title="00000034 - Disclosure - Organization, Description of the Business and Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorGenomicsIncMember" xlink:label="loc_OCXRazorGenomicsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXRazorGenomicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DragonScientificLLCMember" xlink:label="loc_OCXDragonScientificLLCMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXDragonScientificLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorMember" xlink:label="loc_OCXRazorMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXRazorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorStockPurchaseAgreementMember" xlink:label="loc_OCXRazorStockPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXRazorStockPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AtTheMarketSalesAgreementMember" xlink:label="loc_OCXAtTheMarketSalesAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXAtTheMarketSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecuritiesPurchaseAgreementMember" xlink:label="loc_OCXSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwritingAgreementMember" xlink:label="loc_OCXUnderwritingAgreementMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXUnderwritingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RegisteredDirectOfferingMember" xlink:label="loc_OCXRegisteredDirectOfferingMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXRegisteredDirectOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DragonMember" xlink:label="loc_OCXDragonMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXDragonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwriterMember" xlink:label="loc_OCXUnderwriterMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXUnderwriterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BoardMembersMember" xlink:label="loc_OCXBoardMembersMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXBoardMembersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OtherInvestorsMember" xlink:label="loc_OCXOtherInvestorsMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXOtherInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BTIGLLCMember" xlink:label="loc_OCXBTIGLLCMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXBTIGLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_OCXSeriesARedeemableConvertiblePreferredStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_OCXSeriesARedeemableConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNi" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails" xlink:title="00000035 - Disclosure - Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MarketableEquitySecuritiesMember" xlink:label="loc_OCXMarketableEquitySecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXMarketableEquitySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ContingentConsiderationLiabilitiesMember" xlink:label="loc_OCXContingentConsiderationLiabilitiesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXContingentConsiderationLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="00000036 - Disclosure - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails" xlink:title="00000037 - Disclosure - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_OCXSeriesARedeemableConvertiblePreferredStockMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_OCXSeriesARedeemableConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapIncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DividendOnPreferredStock" xlink:label="loc_OCXDividendOnPreferredStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_OCXDividendOnPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemablePreferredStockDividends" xlink:label="loc_us-gaapRedeemablePreferredStockDividends" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapRedeemablePreferredStockDividends" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DeemedDividendOnPreferredStock" xlink:label="loc_OCXDeemedDividendOnPreferredStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_OCXDeemedDividendOnPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_VariousAgreementsMember" xlink:label="loc_OCXVariousAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXVariousAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember" xlink:label="loc_OCXMedicareforDetermaRxandMedicareAdvantageforDetermaRxMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXMedicareforDetermaRxandMedicareAdvantageforDetermaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PharmaServicesMember" xlink:label="loc_OCXPharmaServicesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXPharmaServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LineageAndAgeXMember" xlink:label="loc_OCXLineageAndAgeXMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_OCXLineageAndAgeXMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAssetsHeldForSale" xlink:label="loc_us-gaapIncreaseDecreaseInAssetsHeldForSale" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInAssetsHeldForSale" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableSale" xlink:label="loc_us-gaapAccountsReceivableSale" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAccountsReceivableSale" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CommonStockSharesHeldAsAvailableForSaleSecurities" xlink:label="loc_OCXCommonStockSharesHeldAsAvailableForSaleSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_OCXCommonStockSharesHeldAsAvailableForSaleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNi" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails" xlink:title="00000039 - Disclosure - Schedule of Fair Value of Contingent Consideration Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MilestoneOneMember" xlink:label="loc_OCXMilestoneOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXMilestoneOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MilestoneTwoMember" xlink:label="loc_OCXMilestoneTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXMilestoneTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MilestoneThreeMember" xlink:label="loc_OCXMilestoneThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXMilestoneThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RoyaltyOneMember" xlink:label="loc_OCXRoyaltyOneMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXRoyaltyOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RoyaltyTwoMember" xlink:label="loc_OCXRoyaltyTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXRoyaltyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ContingentConsiderationLiabilityContractualValue" xlink:label="loc_OCXContingentConsiderationLiabilityContractualValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXContingentConsiderationLiabilityContractualValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails" xlink:title="00000040 - Disclosure - Schedule of Contingent Consideration, Measured at Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_InsightMergerMember" xlink:label="loc_OCXInsightMergerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXInsightMergerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixMergerMember" xlink:label="loc_OCXChronixMergerMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXChronixMergerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" xlink:label="loc_OCXBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/BusinessCombinationsDetailsNarrative" xlink:title="00000041 - Disclosure - Business Combinations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorGenomicsIncMember" xlink:label="loc_OCXRazorGenomicsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXRazorGenomicsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixBiomedicalIncMember" xlink:label="loc_OCXChronixBiomedicalIncMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXChronixBiomedicalIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixEquityMember" xlink:label="loc_OCXChronixEquityMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXChronixEquityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixMilestoneMember" xlink:label="loc_OCXChronixMilestoneMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXChronixMilestoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixMember" xlink:label="loc_OCXChronixMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXChronixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OncocyteCorpMember" xlink:label="loc_OCXOncocyteCorpMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXOncocyteCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DevelopmentAgreementMember" xlink:label="loc_OCXDevelopmentAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXDevelopmentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SublicenseAgreementMember" xlink:label="loc_OCXSublicenseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXSublicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MergerAgreementMember" xlink:label="loc_OCXMergerAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXMergerAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ChronixBiomedicalIncMember" xlink:label="loc_OCXChronixBiomedicalIncMember_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXChronixBiomedicalIncMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_FairValueOfContingentConsideration" xlink:label="loc_OCXFairValueOfContingentConsideration" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXFairValueOfContingentConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ClinicalTrialExpenseReserveAmount" xlink:label="loc_OCXClinicalTrialExpenseReserveAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXClinicalTrialExpenseReserveAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_EarnoutPercentageOnCollectionsForSales" xlink:label="loc_OCXEarnoutPercentageOnCollectionsForSales" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXEarnoutPercentageOnCollectionsForSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_EarnoutPercentageOnCollectionsForSaleOrLicense" xlink:label="loc_OCXEarnoutPercentageOnCollectionsForSaleOrLicense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXEarnoutPercentageOnCollectionsForSaleOrLicense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_EarnoutPercentageOnCollectionsForSale" xlink:label="loc_OCXEarnoutPercentageOnCollectionsForSale" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXEarnoutPercentageOnCollectionsForSale" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RoyaltyPaymentsPercentage" xlink:label="loc_OCXRoyaltyPaymentsPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_OCXRoyaltyPaymentsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:title="00000042 - Disclosure - Schedule of Goodwill and Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaIOMember" xlink:label="loc_OCXDetermaIOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXDetermaIOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaCNIAndVitaGraftMember" xlink:label="loc_OCXDetermaCNIAndVitaGraftMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXDetermaCNIAndVitaGraftMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="loc_us-gaapIndefinitelivedIntangibleAssetsAcquired" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefinitelivedIntangibleAssetsAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetResidualValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetResidualValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails" xlink:title="00000043 - Disclosure - Schedule of Intangible Assets Future Amortization Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000044 - Disclosure - Intangible Assets, net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ShareholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - Shareholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_OCXSeriesARedeemableConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_OCXSeriesARedeemableConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecuritiesPurchaseAgreementMember" xlink:label="loc_OCXSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RegisteredDirectOfferingMember" xlink:label="loc_OCXRegisteredDirectOfferingMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXRegisteredDirectOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_InvestorsMember" xlink:label="loc_OCXInvestorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapVestingAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OncocyteCorpMember" xlink:label="loc_OCXOncocyteCorpMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXOncocyteCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_InterestMember" xlink:label="loc_OCXInterestMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecurityMember" xlink:label="loc_OCXSecurityMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXSecurityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaapConversionOfStockDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="loc_us-gaapEquityMethodInvestmentDescriptionOfPrincipalActivities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ConversionPricePercentage" xlink:label="loc_OCXConversionPricePercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_OCXConversionPricePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PreferredStockRemainsOutstandingPercentage" xlink:label="loc_OCXPreferredStockRemainsOutstandingPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_OCXPreferredStockRemainsOutstandingPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_IndebtednessExpenses" xlink:label="loc_OCXIndebtednessExpenses" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_OCXIndebtednessExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DividendsRatePerPercentage" xlink:label="loc_OCXDividendsRatePerPercentage" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_OCXDividendsRatePerPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaapPreferredStockNoParValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockNoParValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails" xlink:title="00000046 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MarketBasedAwardsMember" xlink:label="loc_OCXMarketBasedAwardsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_OCXMarketBasedAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfStockOptionActivityDetails" xlink:title="00000047 - Disclosure - Summary of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandTenPlanActivityMember" xlink:label="loc_OCXTwoThousandTenPlanActivityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXTwoThousandTenPlanActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandEighteenPalnActivityMember" xlink:label="loc_OCXTwoThousandEighteenPalnActivityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXTwoThousandEighteenPalnActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" xlink:label="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited" xlink:label="loc_OCXStockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXStockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares" xlink:label="loc_OCXSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares" xlink:label="loc_OCXSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails" xlink:title="00000048 - Disclosure - Summary of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CostOfRevenuesMember" xlink:label="loc_OCXCostOfRevenuesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_OCXCostOfRevenuesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaapSellingAndMarketingExpenseMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingAndMarketingExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsMember" xlink:label="loc_OCXDiscontinuedOperationsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_OCXDiscontinuedOperationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000049 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandTenStockOptionPlanMember" xlink:label="loc_OCXTwoThousandTenStockOptionPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXTwoThousandTenStockOptionPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PerformanceBasedOptionsMember" xlink:label="loc_OCXPerformanceBasedOptionsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXPerformanceBasedOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoThousandEighteenIncentivePlanMember" xlink:label="loc_OCXTwoThousandEighteenIncentivePlanMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_OCXTwoThousandEighteenIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MonteCarloValuationTechniqueMember" xlink:label="loc_OCXMonteCarloValuationTechniqueMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXMonteCarloValuationTechniqueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaapPerformanceSharesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapPerformanceSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MarketBasedAwardsMember" xlink:label="loc_OCXMarketBasedAwardsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_OCXMarketBasedAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ExecutiveOfficersAndEmployeesMember" xlink:label="loc_OCXExecutiveOfficersAndEmployeesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXExecutiveOfficersAndEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_VitaGraftMember" xlink:label="loc_OCXVitaGraftMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXVitaGraftMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermalOMember" xlink:label="loc_OCXDetermalOMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXDetermalOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaCNIMember" xlink:label="loc_OCXDetermaCNIMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXDetermaCNIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_OCXShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:label="loc_us-gaapIncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails" xlink:title="00000050 - Disclosure - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PharmaServicesCompanyAMember" xlink:label="loc_OCXPharmaServicesCompanyAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXPharmaServicesCompanyAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PharmaServicesCompanyBMember" xlink:label="loc_OCXPharmaServicesCompanyBMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXPharmaServicesCompanyBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsDetermaRxMember" xlink:label="loc_OCXDiscontinuedOperationsDetermaRxMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXDiscontinuedOperationsDetermaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails" xlink:title="00000051 - Disclosure - Schedule of Consolidated Revenues Attributable to Products or Services (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PharmaServicesMember" xlink:label="loc_OCXPharmaServicesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXPharmaServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaRxMember" xlink:label="loc_OCXDetermaRxMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXDetermaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsMember" xlink:label="loc_OCXDiscontinuedOperationsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_OCXDiscontinuedOperationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails" xlink:title="00000052 - Disclosure - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OutsideUnitedStatesPharmaServicesMember" xlink:label="loc_OCXOutsideUnitedStatesPharmaServicesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_OCXOutsideUnitedStatesPharmaServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DetermaRxMember" xlink:label="loc_OCXDetermaRxMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_OCXDetermaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsOutsideUnitedStatesLicensingMember" xlink:label="loc_OCXDiscontinuedOperationsOutsideUnitedStatesLicensingMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_OCXDiscontinuedOperationsOutsideUnitedStatesLicensingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DiscontinuedOperationsDetermaRxMember" xlink:label="loc_OCXDiscontinuedOperationsDetermaRxMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_OCXDiscontinuedOperationsDetermaRxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaapProductConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapProductConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails" xlink:title="00000053 - Disclosure - Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaapConstructionInProgressGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapConstructionInProgressGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations" xlink:label="loc_OCXRightofuseAssetsMachineryAndEquipmentContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_OCXRightofuseAssetsMachineryAndEquipmentContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations" xlink:label="loc_OCXRightofuseAssetsMachineryAndEquipmentDiscontinuingOperations" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_OCXRightofuseAssetsMachineryAndEquipmentDiscontinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RightofuseAssetsMachineryAndEquipmentNet" xlink:label="loc_OCXRightofuseAssetsMachineryAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_OCXRightofuseAssetsMachineryAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative" xlink:title="00000054 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails" xlink:title="00000055 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails" xlink:title="00000056 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLesseeLeaseDescriptionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OperatingAndFinancingLeasesMember" xlink:label="loc_OCXOperatingAndFinancingLeasesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_OCXOperatingAndFinancingLeasesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAccumulatedAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails" xlink:title="00000057 - Disclosure - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PresentValueOfNetMinimumLeasePayments" xlink:label="loc_OCXPresentValueOfNetMinimumLeasePayments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_OCXPresentValueOfNetMinimumLeasePayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000058 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OfficeLeaseAgreementMember" xlink:label="loc_OCXOfficeLeaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXOfficeLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LeaseAgreementMember" xlink:label="loc_OCXLeaseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DevelopmentAgreementMember" xlink:label="loc_OCXDevelopmentAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXDevelopmentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MonthlyRentMember" xlink:label="loc_OCXMonthlyRentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_OCXMonthlyRentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_FirstTenCalendarMember" xlink:label="loc_OCXFirstTenCalendarMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_OCXFirstTenCalendarMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LandlordMember" xlink:label="loc_OCXLandlordMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXLandlordMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ExecutiveOfficersMember" xlink:label="loc_OCXExecutiveOfficersMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXExecutiveOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OncocyteCorpMember" xlink:label="loc_OCXOncocyteCorpMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXOncocyteCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LaboratoryEquipmentMember" xlink:label="loc_OCXLaboratoryEquipmentMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_OCXLaboratoryEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_CapitalLeaseAgreementImputedAnnualInterestRate" xlink:label="loc_OCXCapitalLeaseAgreementImputedAnnualInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXCapitalLeaseAgreementImputedAnnualInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ObligatedToPayExpensesAndTaxesPercentage" xlink:label="loc_OCXObligatedToPayExpensesAndTaxesPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXObligatedToPayExpensesAndTaxesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="loc_us-gaapPaymentsForProceedsFromTenantAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForProceedsFromTenantAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment" xlink:label="loc_OCXPercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXPercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PaymentObligationAmount" xlink:label="loc_OCXPaymentObligationAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXPaymentObligationAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/WorkforceReductionDetailsNarrative" xlink:title="00000059 - Disclosure - Workforce Reduction (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisclosureWorkforceReductionAbstract" xlink:label="loc_OCXDisclosureWorkforceReductionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OCXDisclosureWorkforceReductionAbstract" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000060 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecuritiesPurchaseAgreementMember" xlink:label="loc_OCXSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BroadwoodCapitalLPMember" xlink:label="loc_OCXBroadwoodCapitalLPMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXBroadwoodCapitalLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PuraVidaInvestmentsLLCMember" xlink:label="loc_OCXPuraVidaInvestmentsLLCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXPuraVidaInvestmentsLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_HalleSpecialSituationsFundLLCMember" xlink:label="loc_OCXHalleSpecialSituationsFundLLCMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXHalleSpecialSituationsFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BroadwoodPartnersLPMember" xlink:label="loc_OCXBroadwoodPartnersLPMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXBroadwoodPartnersLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PuraVidaMember" xlink:label="loc_OCXPuraVidaMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXPuraVidaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AVMMember" xlink:label="loc_OCXAVMMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXAVMMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwrittenOfferingMember" xlink:label="loc_OCXUnderwrittenOfferingMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_OCXUnderwrittenOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwritersMember" xlink:label="loc_OCXUnderwritersMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXUnderwritersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ArnoMember" xlink:label="loc_OCXArnoMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_OCXArnoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_MrGutfreundMember" xlink:label="loc_OCXMrGutfreundMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_OCXMrGutfreundMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDescriptionOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative" xlink:title="00000061 - Disclosure - Loan Payable to Silicon Valley Bank (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AmendedLoanAgreementMember" xlink:label="loc_OCXAmendedLoanAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXAmendedLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LoanDeferralAgreementMember" xlink:label="loc_OCXLoanDeferralAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXLoanDeferralAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapVestingAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BankWarrantMember" xlink:label="loc_OCXBankWarrantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_OCXBankWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="loc_us-gaapLinesOfCreditCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLinesOfCreditCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateAtPeriodEnd" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PercentageForWarrantExercisePricePerShare" xlink:label="loc_OCXPercentageForWarrantExercisePricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_OCXPercentageForWarrantExercisePricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DilutedEquityOutstanding" xlink:label="loc_OCXDilutedEquityOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_OCXDilutedEquityOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative" xlink:title="00000062 - Disclosure - Co-Development Agreement with Life Technologies Corporation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract" xlink:label="loc_OCXDisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OCXDisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LifeTechnologiesCorporationMember" xlink:label="loc_OCXLifeTechnologiesCorporationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_OCXLifeTechnologiesCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopmentCosts" xlink:label="loc_us-gaapDevelopmentCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDevelopmentCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/EquityOfferingsDetailsNarrative" xlink:title="00000063 - Disclosure - Equity Offerings (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisclosureEquityOfferingsAbstract" xlink:label="loc_OCXDisclosureEquityOfferingsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OCXDisclosureEquityOfferingsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_TwoEqualTranchesMember" xlink:label="loc_OCXTwoEqualTranchesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_OCXTwoEqualTranchesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecuritiesPurchaseAgreementMember" xlink:label="loc_OCXSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RegisteredDirectOfferingMember" xlink:label="loc_OCXRegisteredDirectOfferingMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXRegisteredDirectOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_UnderwritingAgreementMember" xlink:label="loc_OCXUnderwritingAgreementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXUnderwritingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapVestingAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OncocyteCorpMember" xlink:label="loc_OCXOncocyteCorpMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXOncocyteCorpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_SecurityMember" xlink:label="loc_OCXSecurityMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXSecurityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AprilTwoThousandTwentyTwoWarrantsMember" xlink:label="loc_OCXAprilTwoThousandTwentyTwoWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_OCXAprilTwoThousandTwentyTwoWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_BoardMembersMember" xlink:label="loc_OCXBoardMembersMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXBoardMembersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_OtherInvestorsMember" xlink:label="loc_OCXOtherInvestorsMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXOtherInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaapPreferredStockConvertibleSharesIssuable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleSharesIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PurchasePrice" xlink:label="loc_OCXPurchasePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_StatedValue" xlink:label="loc_OCXStatedValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXStatedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockDescription" xlink:label="loc_us-gaapConversionOfStockDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PercentageOfIssuedAndOutstandingShares" xlink:label="loc_OCXPercentageOfIssuedAndOutstandingShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXPercentageOfIssuedAndOutstandingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:label="loc_us-gaapEquityMethodInvestmentDescriptionOfPrincipalActivities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_ConversionPricePercentage" xlink:label="loc_OCXConversionPricePercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXConversionPricePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_PreferredStockRemainsOutstandingPercentage" xlink:label="loc_OCXPreferredStockRemainsOutstandingPercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXPreferredStockRemainsOutstandingPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_IndebtednessExpenses" xlink:label="loc_OCXIndebtednessExpenses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_OCXIndebtednessExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails" xlink:title="00000064 - Disclosure - Schedule of Discontinued Operations (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:label="loc_OCXDisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_OCXDisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" xlink:label="loc_OCXDisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_OCXDisposalGroupIncludingDiscontinuedOperationSalesAndMarketing" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" xlink:label="loc_us-gaapIncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapIncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails" xlink:title="00000065 - Disclosure - Schedule of Assets and Liabilities of Disposal Group Held for Sale (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaapDisposalGroupClassificationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="loc_us-gaapDisposalGroupClassificationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaapDisposalGroupClassificationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupClassificationAxis" xlink:to="loc_us-gaapDisposalGroupClassificationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaapDiscontinuedOperationsHeldforsaleMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisposalGroupClassificationDomain" xlink:to="loc_us-gaapDiscontinuedOperationsHeldforsaleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" xlink:label="loc_OCXDisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_OCXDisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales" xlink:label="loc_OCXDisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_OCXDisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation" xlink:label="loc_OCXDisposalGroupIncludingDiscontinuedOperationAccruedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_OCXDisposalGroupIncludingDiscontinuedOperationAccruedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" xlink:label="loc_OCXDisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_OCXDisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperationsAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative" xlink:title="00000066 - Disclosure - Assets Held for Sale and Discontinued Operations (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorStockPurchaseAgreementMember" xlink:label="loc_OCXRazorStockPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXRazorStockPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_LaboratoryEquipmentAgreementMember" xlink:label="loc_OCXLaboratoryEquipmentAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXLaboratoryEquipmentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_AuctionEquipmentAgreementMember" xlink:label="loc_OCXAuctionEquipmentAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_OCXAuctionEquipmentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_DragonMember" xlink:label="loc_OCXDragonMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OCXDragonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorMember" xlink:label="loc_OCXRazorMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_OCXRazorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ocx-20230630.xsd#OCX_RazorMember" xlink:label="loc_OCXRazorMember_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_OCXRazorMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="loc_us-gaapAssetsHeldForSaleNotPartOfDisposalGroupCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:label="loc_us-gaapDisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://oncocyte.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000067 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871823719424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-37648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Oncocyte
Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001642380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-1041563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15
Cushing<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">409-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OCX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,240,928<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871820963968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,368<span></span>
</td>
<td class="nump">$ 19,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance of $178 and $154, respectively</a></td>
<td class="nump">1,716<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">191<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinuing operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,121<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">20,984<span></span>
</td>
<td class="nump">25,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NONCURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use and financing lease assets, net</a></td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">2,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_MachineryAndEquipmentNetAndConstructionInProgress', window );">Machinery and equipment, net, and construction in progress</a></td>
<td class="nump">5,997<span></span>
</td>
<td class="nump">8,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">56,639<span></span>
</td>
<td class="nump">61,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">87,540<span></span>
</td>
<td class="nump">100,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">875<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">1,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,196<span></span>
</td>
<td class="nump">3,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_AccruedSeveranceFromAcquisitionCurrent', window );">Accrued severance from acquisition</a></td>
<td class="nump">2,314<span></span>
</td>
<td class="nump">2,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Accrued liabilities from acquisition</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent', window );">Right-of-use and financing lease liabilities, current</a></td>
<td class="nump">737<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinuing operations</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,667<span></span>
</td>
<td class="nump">12,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NONCURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent', window );">Right-of-use and financing lease liabilities, noncurrent</a></td>
<td class="nump">2,398<span></span>
</td>
<td class="nump">2,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liabilities</a></td>
<td class="nump">29,150<span></span>
</td>
<td class="nump">45,662<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">39,215<span></span>
</td>
<td class="nump">60,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 and 6 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $5,140 and $6,091 as of June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">4,725<span></span>
</td>
<td class="nump">5,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, no par value, 230,000 shares authorized; 8,241 and 5,932 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">309,535<span></span>
</td>
<td class="nump">294,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(265,976)<span></span>
</td>
<td class="num">(260,676)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">43,600<span></span>
</td>
<td class="nump">34,292<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 87,540<span></span>
</td>
<td class="nump">$ 100,091<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_AccruedSeveranceFromAcquisitionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued severance from acquisition current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_AccruedSeveranceFromAcquisitionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_MachineryAndEquipmentNetAndConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Machinery and equipment net and construction in progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_MachineryAndEquipmentNetAndConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use and financing lease liabilities, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use and financing lease liabilities, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482309/360-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821204560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ / shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts receivable, allowance for credit loss</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">230,000,000<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">8,241,000<span></span>
</td>
<td class="nump">5,932,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">8,240,928<span></span>
</td>
<td class="nump">5,932,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_TemporaryEquityNoParValue', window );">Temporary equity, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, stated par value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">4,818<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">4,818<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Temporary equity, liquidation preference</a></td>
<td class="nump">$ 5,140<span></span>
</td>
<td class="nump">$ 6,091<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_TemporaryEquityNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity no par value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_TemporaryEquityNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871822679712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 463<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles', window );">Cost of revenues &#8211; amortization of acquired intangibles</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,435<span></span>
</td>
<td class="nump">2,444<span></span>
</td>
<td class="nump">4,562<span></span>
</td>
<td class="nump">4,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,531<span></span>
</td>
<td class="nump">5,445<span></span>
</td>
<td class="nump">6,943<span></span>
</td>
<td class="nump">11,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="num">(6,359)<span></span>
</td>
<td class="num">(16,512)<span></span>
</td>
<td class="num">(11,015)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss from intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,950<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Loss on disposal and held for sale assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,283<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,566<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
<td class="nump">2,726<span></span>
</td>
<td class="nump">4,921<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,294)<span></span>
</td>
<td class="num">(1,626)<span></span>
</td>
<td class="num">(2,444)<span></span>
</td>
<td class="num">(4,643)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSES), NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expenses), net</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable equity securities</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="num">(325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expenses), net</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expenses), net</a></td>
<td class="num">(39)<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(8,333)<span></span>
</td>
<td class="num">(1,364)<span></span>
</td>
<td class="num">(2,374)<span></span>
</td>
<td class="num">(4,777)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="num">(8,333)<span></span>
</td>
<td class="num">(1,364)<span></span>
</td>
<td class="num">(2,374)<span></span>
</td>
<td class="num">(4,777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinuing operations</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(6,936)<span></span>
</td>
<td class="num">(2,926)<span></span>
</td>
<td class="num">(13,814)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(8,333)<span></span>
</td>
<td class="num">(8,300)<span></span>
</td>
<td class="num">(5,300)<span></span>
</td>
<td class="num">(18,591)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock', window );">LESS: DIVIDENDS AND ACCRETION OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK</a></td>
<td class="num">(311)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(541)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS: BASIC</a></td>
<td class="num">(8,644)<span></span>
</td>
<td class="num">(8,372)<span></span>
</td>
<td class="num">(5,841)<span></span>
</td>
<td class="num">(18,663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS DILUTED</a></td>
<td class="num">$ (8,644)<span></span>
</td>
<td class="num">$ (8,372)<span></span>
</td>
<td class="num">$ (5,841)<span></span>
</td>
<td class="num">$ (18,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss from continuing operations per share: basic</a></td>
<td class="num">$ (1.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss from continuing operations per share: diluted</a></td>
<td class="num">(1.03)<span></span>
</td>
<td class="num">(0.24)<span></span>
</td>
<td class="num">(0.34)<span></span>
</td>
<td class="num">(0.93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Net loss from discontinuing operations per share: basic</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1.23)<span></span>
</td>
<td class="num">(0.42)<span></span>
</td>
<td class="num">(2.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Net loss from discontinuing operations per share: diluted</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1.23)<span></span>
</td>
<td class="num">(0.42)<span></span>
</td>
<td class="num">(2.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share: basic</a></td>
<td class="num">(1.07)<span></span>
</td>
<td class="num">(1.48)<span></span>
</td>
<td class="num">(0.83)<span></span>
</td>
<td class="num">(3.63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share: diluted</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (3.63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding: basic</a></td>
<td class="nump">8,090<span></span>
</td>
<td class="nump">5,652<span></span>
</td>
<td class="nump">7,030<span></span>
</td>
<td class="nump">5,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding: diluted</a></td>
<td class="nump">8,090<span></span>
</td>
<td class="nump">5,652<span></span>
</td>
<td class="nump">7,030<span></span>
</td>
<td class="nump">5,135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of revenues &amp;#8211; amortization of acquired intangibles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends and Accretion of Series A Redeemable Convertible Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821853280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (8,333)<span></span>
</td>
<td class="num">$ (8,300)<span></span>
</td>
<td class="num">$ (5,300)<span></span>
</td>
<td class="num">$ (18,591)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE LOSS</a></td>
<td class="num">$ (8,335)<span></span>
</td>
<td class="num">$ (8,307)<span></span>
</td>
<td class="num">$ (5,298)<span></span>
</td>
<td class="num">$ (18,597)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871818180160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Redeemable Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 252,954<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="num">$ (187,774)<span></span>
</td>
<td class="nump">$ 65,217<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,591)<span></span>
</td>
<td class="num">(18,591)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,242<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Shares issued upon vesting of RSU, net of shares retired to pay employees&#8217; taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Shares issued upon vesting of RSU, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue', window );">Accretion of Series A convertible preferred stock to redemption value</a></td>
<td class="nump">72<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 32,453<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of Series A redeemable convertible preferred stock, net of financing costs</a></td>
<td class="nump">$ 4,782<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares</a></td>
<td class="nump">11,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 4,854<span></span>
</td>
<td class="nump">$ 289,649<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(206,437)<span></span>
</td>
<td class="nump">83,243<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2022</a></td>
<td class="nump">11,765<span></span>
</td>
<td class="nump">5,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 254,994<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="num">(198,065)<span></span>
</td>
<td class="nump">56,967<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,300)<span></span>
</td>
<td class="num">(8,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,232<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Shares issued upon vesting of RSU, net of shares retired to pay employees&#8217; taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Shares issued upon vesting of RSU, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue', window );">Accretion of Series A convertible preferred stock to redemption value</a></td>
<td class="nump">72<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 32,423<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of Series A redeemable convertible preferred stock, net of financing costs</a></td>
<td class="nump">$ 4,782<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares</a></td>
<td class="nump">11,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 4,854<span></span>
</td>
<td class="nump">$ 289,649<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(206,437)<span></span>
</td>
<td class="nump">83,243<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2022</a></td>
<td class="nump">11,765<span></span>
</td>
<td class="nump">5,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 5,302<span></span>
</td>
<td class="nump">$ 294,929<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="num">(260,676)<span></span>
</td>
<td class="nump">34,292<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">5,882<span></span>
</td>
<td class="nump">5,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,300)<span></span>
</td>
<td class="num">(5,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,668<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards', window );">Vesting of bonus awards</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common shares, net of financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 13,421<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common shares, net of financing costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock', window );">Deemed dividend on Series A redeemable convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (118)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Redemption of Series A redeemable convertible preferred stock</a></td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Redemption of SeriesA redeemable convertible preferred stock, shares</a></td>
<td class="num">(1,064)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Shares issued upon vesting of RSU, net of shares retired to pay employees&#8217; taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Shares issued upon vesting of RSU, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue', window );">Accretion of Series A convertible preferred stock to redemption value</a></td>
<td class="nump">423<span></span>
</td>
<td class="num">$ (423)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(423)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 4,725<span></span>
</td>
<td class="nump">$ 309,535<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">(265,976)<span></span>
</td>
<td class="nump">43,600<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">4,818<span></span>
</td>
<td class="nump">8,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 5,532<span></span>
</td>
<td class="nump">$ 295,533<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="num">(257,643)<span></span>
</td>
<td class="nump">37,933<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">5,882<span></span>
</td>
<td class="nump">5,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,333)<span></span>
</td>
<td class="num">(8,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">834<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards', window );">Vesting of bonus awards</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common shares, net of financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 13,421<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common shares, net of financing costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock', window );">Deemed dividend on Series A redeemable convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (118)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Redemption of Series A redeemable convertible preferred stock</a></td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Redemption of SeriesA redeemable convertible preferred stock, shares</a></td>
<td class="num">(1,064)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Shares issued upon vesting of RSU, net of shares retired to pay employees&#8217; taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Shares issued upon vesting of RSU, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue', window );">Accretion of Series A convertible preferred stock to redemption value</a></td>
<td class="nump">193<span></span>
</td>
<td class="num">$ (193)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 4,725<span></span>
</td>
<td class="nump">$ 309,535<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="num">$ (265,976)<span></span>
</td>
<td class="nump">$ 43,600<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">4,818<span></span>
</td>
<td class="nump">8,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on Series A redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of Series A convertible preferred stock to redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value vesting of bonus awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821056384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,300)<span></span>
</td>
<td class="num">$ (18,591)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">885<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="nump">4,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized (gain) loss on marketable equity securities</a></td>
<td class="num">(97)<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(16,512)<span></span>
</td>
<td class="num">(11,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation', window );">Change in fair value of Series A redeemable convertible preferred stock second tranche obligation</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss from intangible assets</a></td>
<td class="nump">4,950<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Loss on disposal of discontinued operations</a></td>
<td class="nump">149<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal and held for sale assets</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">296<span></span>
</td>
<td class="num">(365)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">376<span></span>
</td>
<td class="num">(773)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(4,319)<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition', window );">Accrued severance and liabilities from Chronix Biomedical acquisition</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(118)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAssetsHeldForSale', window );">Assets held for sale</a></td>
<td class="nump">191<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(16,504)<span></span>
</td>
<td class="num">(24,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">123<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Construction in progress and purchases of furniture and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,679)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">123<span></span>
</td>
<td class="num">(2,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common shares</a></td>
<td class="nump">13,848<span></span>
</td>
<td class="nump">32,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Financing costs to issue common shares</a></td>
<td class="num">(427)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from sale of redeemable convertible Series A preferred shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock', window );">Redemption of redeemable convertible Series A preferred shares</a></td>
<td class="num">(1,118)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares', window );">Financing costs to issue redeemable convertible Series A preferred shares</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions', window );">Proceeds from sale of common shares under at-the-market transactions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_PaymentForFinancingCostsForAtthemarketSales', window );">Financing costs for at-the-market sales</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_RepaymentOfFinancingLeaseObligations', window );">Repayment of financing lease obligations</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,246<span></span>
</td>
<td class="nump">36,434<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="num">(4,135)<span></span>
</td>
<td class="nump">9,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING</a></td>
<td class="nump">23,203<span></span>
</td>
<td class="nump">37,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING</a></td>
<td class="nump">19,068<span></span>
</td>
<td class="nump">46,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability', window );">Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 1,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Severance And Liabilities From Chronix Biomedical Acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of Series A redeemable convertible preferred stock second tranche obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of Series A redeemable convertible preferred stock second tranche obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_PaymentForFinancingCostsForAtthemarketSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Financing Costs For Atthemarket Sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_PaymentForFinancingCostsForAtthemarketSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of common shares under At the market transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_RepaymentOfFinancingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Financing Lease Obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_RepaymentOfFinancingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in book value of long-lived assets that the reporting entity plans to sell within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871826885184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Description of the Business and Liquidity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Description of the Business and Liquidity</a></td>
<td class="text"><p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zmQ7sEi77j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.
<span id="xdx_82F_zrJiSVKexLfd">Organization, Description of the Business and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
Corporation (&#8220;Oncocyte,&#8221; the &#8220;Company,&#8221; &#8220;we&#8221; or &#8220;us&#8221;), incorporated in 2009 in the state of California, is a precision diagnostics
company focused on developing and commercializing proprietary tests in three areas: DetermaIO is a gene expression test that assesses
the tumor microenvironment to predict response to immunotherapies, VitaGraft is a blood-based solid organ transplantation monitoring
test, and DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte&#8217;s
first product for commercial release was a proprietary treatment stratification test called DetermaRx that identifies which patients
with early-stage non-small cell lung cancer may benefit from chemotherapy, resulting in a significantly higher, five-year survival rate.
Beginning in September 2019 through February 23, 2021, Oncocyte held a <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210223__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorGenomicsIncMember_ztWDR584VUid" title="Equity ownership percentage">25</span>% equity interest in Razor Genomics, Inc. (&#8220;Razor&#8221;),
a privately held company, that has developed and licensed to Oncocyte the lung cancer treatment stratification laboratory test that Oncocyte
is commercializing as DetermaRx. On February 24, 2021, Oncocyte completed the purchase of all the remaining issued and outstanding shares
of common stock of Razor. As a result of the purchase of the Razor common stock, Oncocyte became the sole shareholder of Razor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
December 15, 2022, the Company, entered into a Stock Purchase Agreement (the &#8220;Razor Stock Purchase Agreement&#8221;) with Dragon
Scientific, LLC, a Delaware limited liability company (&#8220;Dragon&#8221;) and Razor. Pursuant to the Razor Stock Purchase Agreement,
Oncocyte agreed to sell to Dragon, <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221215__20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DragonScientificLLCMember_zGR6pcci908j" title="Number of common stock issued">3,188,181</span> shares of common stock of Razor, which constitutes approximately <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DragonScientificLLCMember_zCIY2Et1gq3f" title="Equity ownership percentage">70</span>% of the issued and outstanding
equity interests of Razor on a fully-diluted basis, and transfer to Razor all of the assets and liabilities related to DetermaRx (the
&#8220;Razor Sale Transaction&#8221;). </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Certain
amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of Razor in order to conform
to the current period presentation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
a result of the divestiture of Razor, the Company has retrospectively revised the condensed consolidated statements of operations for
the periods ended June 30, 2022, to reflect the operations and cash flows of Razor as discontinued operations and the related assets
and liabilities disposed. See Note 16 for additional information about assets held for sale and discontinued operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2023, Oncocyte completed the Razor Sale Transaction (the &#8220;Razor Closing&#8221;). In connection with the Razor Closing,
Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. While no monetary consideration was received for
the sale of <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DragonMember_z8kqT2L6gt5c" title="Equity ownership percentage">70</span>% of the equity interests of Razor, the transaction allowed the Company to eliminate all development and commercialization
costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to own <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230215__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8ByWFZO8lCk" title="Stock issued during period, shares, new issues">1,366,364</span> shares of common stock of Razor, which
constitutes approximately <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zUCufJrESbp2" title="Equity interest">30</span>% of the issued and outstanding equity interests of Razor on a fully-diluted basis. <span style="background-color: white">See
Note 16 for a full discussion of the Razor Sale Transaction.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2023, the Company implemented a <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20230723__20230724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6McoWJBE5Qk" title="Reverse stock split">1-for-20 reverse stock split</span> of the outstanding shares of its common stock. The par value per
share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split.
All common stock share and per-share amounts for all periods presented in these condensed financial statements have been adjusted to
reflect the reverse stock split. The number of authorized shares of common stock remains at <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20230724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqma1QdPTce" title="Common stock, shares authorized">230</span> million shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $<span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230630_zRCntyEOk3uk" title="Accumulated deficit">266.0</span> million as of June 30,
2023. Oncocyte expects to continue to incur operating losses and negative cash flows for the foreseeable future. Since its formation,
Oncocyte has financed its operations primarily through the sale of shares of its common stock, convertible preferred stock and warrants
to acquire common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, Oncocyte had $<span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20230630_zlK5HQqKluE8" title="Cash and cash equivalents">17.4</span> million of cash and cash equivalents and held shares of Lineage Cell Therapeutics, Inc. (&#8220;Lineage&#8221;)
and AgeX Therapeutics, Inc. (&#8220;AgeX&#8221;) common stock as marketable equity securities with a combined fair market value of $<span id="xdx_907_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20230630_zTuLBRCkxT4c" title="Marketable equity securities fair value">0.5</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 11, 2021, Oncocyte entered into an at-the-market sales agreement with BTIG, LLC as sales agent and/or principal (the &#8220;Agent&#8221;
or &#8220;BTIG&#8221;) pursuant to which Oncocyte may sell up to an aggregate of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20210610__20210611__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--BTIGLLCMember_zjadrUkvWD6k" title="Fair value of common stock sold">50,000,000</span> of shares of Oncocyte common stock from
time to time through the Agent (the &#8220;ATM Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
July 1, 2021 and June 30, 2023, Oncocyte sold <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210701__20230630__dei--LegalEntityAxis__custom--BTIGLLCMember_zZnINzCZmY95" title="Fair value of common stock sold">56,167 </span>shares
of common stock at an average offering price of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230630__dei--LegalEntityAxis__custom--BTIGLLCMember_ziMRQ2HM90I6" title="Sale of stock, price per share">111.60</span>
per share, for gross proceeds of approximately $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn4n6_c20210701__20230630__dei--LegalEntityAxis__custom--BTIGLLCMember_zBMWnzPVy9Ja" title="Gross proceeds from offering">6.27</span>
million through the ATM Offering. The most recent sale of common stock through the ATM Offering took place in January 2022. Oncocyte
will need to raise additional capital to finance its operations, including the development and commercialization of its cancer
diagnostic and other tests, until such time as it is able to generate sufficient revenues from the commercialization of one or more
of its laboratory tests and other tests, and performing Pharma Services to cover its operating expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 13, 2022, Oncocyte entered into a securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;) with
institutional accredited investors (the &#8220;Investors&#8221;), including Broadwood Partners, L.P. (&#8220;Broadwood&#8221;),
Oncocyte&#8217;s largest shareholder, in a registered direct offering of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znckcjBsFEUc">11,765 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Series A Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;), which are convertible into a total of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zROBhDIdg7Rk" title="Convertible preferred shares">384,477 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of common stock, at a conversion price of $<span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYlfgKahIF2c" title="Conversion price">30.60 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(the
&#8220;Series A Preferred Stock Offering&#8221;). The purchase price of each share of Series A Preferred Stock was $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zVA3C6kJwBBi" title="Net proceeds">850</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which included an original issue discount to the stated value of $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zS4ZRvMHMi4e" title="Preferred stock stated value per share">1,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. The Securities Purchase Agreement provides that the closing of the Series A Preferred Stock Offering will occur, subject to
the satisfaction of certain closing conditions, in two equal tranches of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zo5NZcmzcnNh" title="Net proceeds">5,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
for aggregate gross proceeds from both closings of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220601__20220601__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zvNv0qK2Tmo7" title="Net proceeds">10,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220601__20220601__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zvp1lPe40oHk" title="Net proceeds">4.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
from the Series A Preferred Stock issued from the first tranche. The second closing would occur, subject to the satisfaction of
certain closing conditions (including but not limited to a requirement that the Company has not received, in the 12 months preceding
the second closing, a notice from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that the Company is not in compliance with the
listing and maintenance and listing requirements of Nasdaq), on the earlier of (a) the second trading day following the date that
Oncocyte receives notice from an Investor to accelerate the second closing and (b) a date selected by Oncocyte on or after October
8, 2022 and on or prior to March 8, 2023. On August 9, 2022, Oncocyte received a letter from Nasdaq indicating that the Company no
longer met the minimum bid price requirement of the Nasdaq continued listing requirements. Accordingly as of June 30, 2023, no
additional proceeds are expected from the second closing of the Securities Purchase Agreement. On August 8, 2023, the Company
received a letter from Nasdaq indicating that the Company had regained compliance with the minimum bid price requirement of the Nasdaq continued listing requirements. See Note 15 for additional information about the Series A Preferred Stock Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, on April 13, 2022, Oncocyte
entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with BTIG, LLC, as representative of the underwriters
named therein (the &#8220;Underwriters&#8221;), pursuant to which Oncocyte issued and sold to the Underwriters an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220412__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_znOvFlImpvwl" title="Number of common stock issued">1,313,320</span>
shares of common stock, and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220412__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zC1OHcE1BEBb" title="Purchase of warrant">1,313,320</span> warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220412__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__srt--RangeAxis__srt--MinimumMember_zyAPMpdP2pdb" title="Purchase of warrant">656,660</span> shares of common stock (&#8220;April 2022 Warrants&#8221;) (the
&#8220;Underwritten Offering,&#8221; and collectively with the Series A Preferred Stock Offering, the &#8220;April 2022 Offerings&#8221;).
The Underwritten Offering closed on April 19, 2022, and Oncocyte received net proceeds of approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220418__20220419__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdHdcmedVVrg" title="Net proceeds">32.8</span> million from the Underwritten
Offering. See Note 15 for additional information about the Underwritten Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 3, 2023, Oncocyte entered into an agreement with certain members of the Company&#8217;s board of directors,
and several institutional and accredited investors, including Broadwood, the Company&#8217;s largest shareholder, relating to their purchase
of an aggregate of up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--BoardMembersMember__srt--RangeAxis__srt--MaximumMember_z595chI480fb" title="Purchase of warrant">2,278,121</span> shares of its common stock at an offering price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--BoardMembersMember_zXgMKP3e90xb" title="Shares issued price per share">7.08</span> per share to board members and $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--OtherInvestorsMember_zlOFqicx7tSl" title="Shares issued price per share">6.03</span> per share
to the other investors participating in the offering. The offering was intended to be priced at-the-market for purposes of complying with
applicable Nasdaq Listing Rules. The aggregate gross proceeds from the offering were approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember_z4ThkXHnQ9z9" title="Proceeds from issuance of common stock">13.9</span> million. The Company used approximately
$<span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwE95qVzgSE4" title="Net proceeds to immediately redeem">1.1</span> million of the net proceeds to immediately redeem an aggregate of <span id="xdx_902_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaTI3UioATvh" title="Number of stock redeem">1,064</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its Series A Preferred Stock and may thereafter elect
to redeem additional shares.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, Oncocyte is completing clinical development and planning commercialization of DetermaIO, although DetermaIO is currently
available for biopharma diagnostic development and research use only as a companion test in immunotherapy drug development to select
patients for clinical trials; and the clinical launch of VitaGraft. While Oncocyte plans to primarily market its laboratory tests in
the United States through its own sales force, it is also beginning to make marketing arrangements with distributors in other countries.
In order to reduce capital needs and to expedite the commercialization of any new laboratory tests that may become available for clinical
use, Oncocyte may also pursue marketing arrangements with other diagnostic companies through which Oncocyte might receive licensing fees
and royalty on sales, or through which it might form a joint venture to market its tests and share in net revenues, in the United States
or abroad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, Going Concern, we evaluated whether there are
conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern
within one year after the date that the unaudited condensed consolidated interim financial statements included in this Report are
issued. This evaluation initially does not take into consideration the potential mitigating effect of our plans that have not been
fully implemented as of the date the unaudited condensed consolidated interim financial statements included in this Report are
issued. When substantial doubt exists under this methodology, we evaluate whether the mitigating effect of its plans sufficiently
alleviates substantial doubt about our ability to continue as a going concern. The mitigating effect of our plans, however, is only
considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that such
financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or
events that raise substantial doubt about our ability to continue as a going concern within one year after the date that such
financial statements are issued. In performing this analysis, we excluded certain elements of our operating plan that cannot be
considered probable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to
support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year
after the date that the financial statements are issued. Management intends to complete additional equity financings and reduce
spending in the remainder of fiscal 2023 and in 2024. However, due to several factors, including those outside management&#8217;s
control, there can be no assurance that we will be able to complete additional equity financings. If we are unable to complete
additional financings, management&#8217;s plans include further reducing or delaying operating expenses. We have concluded the
likelihood that our plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce
expenditures, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about
our ability to continue as a going concern for a period of at least twelve months from the date of issuance of these unaudited
condensed consolidated interim financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction
of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability
and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the
uncertainties described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to general economic and capital market trends and conditions, Oncocyte&#8217;s ability to raise sufficient additional capital
to finance its operations from time to time will depend on a number of factors specific to Oncocyte&#8217;s operations such as operating
revenues and expenses, progress in development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future
laboratory tests that Oncocyte may develop or acquire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unavailability or inadequacy of financing or revenues to meet future capital needs could force Oncocyte to modify, curtail, delay, or
suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests
of its shareholders. Oncocyte cannot assure that adequate financing will be available on favorable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871823722656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_zHZOs2dGQqB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_824_znUtGPNE8S4i">Basis of Presentation and Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNUiTmKaFlFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zkS5tceeAXY1">Basis
of presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance
with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with the instructions to
Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures
normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance
sheets as of December 31, 2022 was derived from the audited consolidated financial statements at that date. These unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included
in Oncocyte&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated interim financial
statements presented herein as of June 30, 2023 is not representative of the full fiscal year or any future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zBEPow0Ifnt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zrKXO5Nmd15e">Principles
of consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 31, 2020, with the
acquisition of Insight Genetics, Inc. (&#8220;Insight&#8221;) through a merger with a newly incorporated wholly owned subsidiary of Oncocyte
(the &#8220;Insight Merger&#8221;) under the terms of an Agreement and Plan of Merger (the &#8220;Insight Merger Agreement&#8221;), Insight
became a wholly owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight&#8217;s operations and results with
Oncocyte&#8217;s operations and results (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 24, 2021, with the
acquisition of the remaining equity interests in Razor, Razor became a wholly owned subsidiary of Oncocyte, and on that date Oncocyte
began consolidating Razor&#8217;s results with Oncocyte&#8217;s operations and results (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (&#8220;Chronix&#8221;) pursuant to an Agreement
and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated,
the &#8220;Chronix Merger Agreement&#8221;), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary
of Oncocyte (&#8220;Merger Sub&#8221;), Chronix became a wholly owned subsidiary of Oncocyte (the &#8220;Chronix Merger&#8221;), and on
that date Oncocyte began consolidating Chronix&#8217;s operations and results with Oncocyte&#8217;s operations and results (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have reflected the operations of Razor as discontinued operations for all periods presented. See Note 16 for further information. Unless
otherwise noted, amounts and disclosures throughout these Notes to unaudited condensed consolidated interim financial statements relate
solely to continuing operations and exclude all discontinued operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting
only of normal recurring adjustments, necessary for a fair presentation of Oncocyte&#8217;s financial condition and results of operations.
The unaudited condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other
interim period or for the entire year. All material intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--UseOfEstimates_z9HUDZz4sJRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zwTeAy75rgGb">Use
of estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and contingent assets and liabilities, at the date of the unaudited condensed consolidated financial
statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates
estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the
use of judgment to prepare financial projections, timing of potential commercialization of acquired in-process intangible assets, applicable
discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable
companies or transactions, determination of fair value of the assets acquired and liabilities assumed including those relating to contingent
consideration, assumptions related to going concern assessments, allocation of direct and indirect expenses, useful lives associated
with long-lived intangible assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies,
valuation allowances related to deferred income taxes, and assumptions used to value debt and stock-based awards and other equity instruments.
Actual results may differ materially from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
Oncocyte assessed certain accounting matters that generally require consideration of forecasted financial information. The accounting
matters assessed included, but were not limited to, Oncocyte&#8217;s equity investments, the carrying value of goodwill, going concern
assessment, acquired in-process intangible assets and other long-lived assets. Those assessments as well as other estimates referenced
above were made in the context of information reasonably available to Oncocyte.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock_zm0JZ0NZggYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zVjdQpE4iuY4">Business
combinations and fair value measurements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at
fair value on the acquisition date in accordance with ASC 820, <i>Fair Value Measurement</i>. ASC 820 establishes a single authoritative
definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement.
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered
observable and the last unobservable, that may be used to measure fair value, which are the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<i>Level 1 </i>&#8211; Quoted prices in active markets for identical assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<i>Level 2 </i>&#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for
similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated
by observable market data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<i>Level 3 </i>&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable
to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted
on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets
and identifiable intangible assets acquired, including in-process research and development, and liabilities assumed, including any contingent
consideration, as of the acquisition date. Goodwill is recognized as any amount of the fair value of the tangible and identifiable intangible
assets acquired and liabilities assumed in excess of the consideration transferred. ASC 805 precludes the recognition of an assembled
workforce as an asset, effectively subsuming any assembled workforce value into goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented,
Oncocyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for money market funds and marketable
equity securities of Lineage and AgeX common stock held by Oncocyte described below. These assets are measured at fair value using the
period-end quoted market prices as a Level 1 input. Oncocyte also has certain contingent consideration liabilities which are carried
at fair value based on Level 3 inputs (see Note 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3RKpaWznMh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of June 30, 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zmTaNgYcWYHf" style="display: none">Schedule of Fair
Value Measurement of Financial Assets and Liabilities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total carrying and estimated fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left; padding-bottom: 1.5pt">Marketable equity securities</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zrte2Oe4Xsje" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">530</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zmlsnasuFB8l" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">530</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zLhWjk5r3sIa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zJWYuvYPxmpa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zn3zRaxWFSh9" style="border-bottom: Black 2.5pt double; text-align: right">530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJ3K5CDPnLqg" style="border-bottom: Black 2.5pt double; text-align: right">530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zqMfCKTnq4B7" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV4fpBbD8sD8" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent consideration liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zhUYvCFL4uY8" style="border-bottom: Black 1.5pt solid; text-align: right">29,150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zFvKQVbzLoxe" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zDj19v3hYJN1" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zjKMlaBqLsR3" style="border-bottom: Black 1.5pt solid; text-align: right">29,150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630_ztZ3r8fTeEY8" style="border-bottom: Black 2.5pt double; text-align: right">29,150</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuX5gETrWj07" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRbVr03xVsNj" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh2pOmfCD0gh" style="border-bottom: Black 2.5pt double; text-align: right">29,150</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total carrying and estimated fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left; padding-bottom: 1.5pt">Marketable equity securities</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_z4Tev33z1EWi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">433</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zdTflE7GPOx2" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">433</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zzdrgphbJ4M3" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zeuvjS5nU5Gi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zBQNHaivDNA1" style="border-bottom: Black 2.5pt double; text-align: right">433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zezVqYduTUk5" style="border-bottom: Black 2.5pt double; text-align: right">433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMgrynHvJ4Be" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYOxUVrvdDij" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent consideration liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zzdaxrShvpDh" style="border-bottom: Black 1.5pt solid; text-align: right">45,662</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zIc6J1GvURw2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zfUTVBs0Ucrc" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zVAT8i4bZSM8" style="border-bottom: Black 1.5pt solid; text-align: right">45,662</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231_zyECdBhHNRMf" style="border-bottom: Black 2.5pt double; text-align: right">45,662</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGDRKTs94eGk" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDefP5WOZrh9" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0985">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zigpHVQl2mfd" style="border-bottom: Black 2.5pt double; text-align: right">45,662</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zKaCNtGVNq65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate
fair values because of the short-term nature of these items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zlIkj3sDupkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zGQbyBZFOfBi">Cash,
cash equivalents, and restricted cash</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s reconciliation of cash and cash equivalents, and restricted cash reported within the unaudited condensed consolidated
balance sheets that sum to the total of the same amounts shown in the unaudited condensed consolidated statements of cash flows were
as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zdytl4la5juf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B2_zJpqATCenCh1">Schedule
of Cash and Cash Equivalents and Restricted Cash</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20230630_zJ6xNQ6lEwZd" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zbOy4sanmZce" style="text-align: center; font-weight: bold">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_maCCERCzBSt_zf6VijB9xmCh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,368</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,993</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RestrictedCash_iI_maCCERCzBSt_zgED1GuzIi3k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,700</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_iI_maCCERCzBSt_zl8as0JpcIH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash from discontinuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0998">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,510</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_mtCCERCzBSt_zusozGCYoAfl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash shown in the statements of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,068</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,203</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_8AF_z1Pt03fS2p2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_841_eus-gaap--DiscontinuedOperationsPolicyTextBlock_z6jQVYPfHbq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zX7Hlyt3Qfbj">Assets
Held for Sale and Discontinued Operations</span></i></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, the Company classified laboratory equipment previously presented in machinery and equipment as held for sale in current
assets, in the unaudited condensed consolidated balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment
(&#8220;ASC 360-10&#8221;) have been met and the transaction was qualified as assets held for sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, the Company entered into various agreements to sell laboratory equipment for an aggregate amount of
$<span id="xdx_905_eus-gaap--IncreaseDecreaseInAssetsHeldForSale_pn5n6_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--VariousAgreementsMember_zba3kXUdbysg" title="Increase (decrease) in asset, held-for-sale">0.6</span> million. As a result, the Company classified the equipment as held for sale as current assets, in the unaudited condensed consolidated
balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment (&#8220;ASC 360-10&#8221;) have been met and
the transaction was qualified as assets held for sale. The equipment was written down to its fair value, less cost to sell, to $<span id="xdx_90C_eus-gaap--InventoryWriteDown_pn5n6_c20230101__20230630_zm94u4G9nNs8" title="Inventory write down">0.2</span> million
in the unaudited condensed consolidated balance sheet. As a result of the sale, the Company recorded an impairment loss of $<span id="xdx_90B_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20230630_zpYCbYN0Vjz7" title="Asset impairment charges">1.3</span> million
on held-for-sale assets, in the unaudited condensed consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management,
having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in
their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate
a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable
and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation
to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the
plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified
as held for sale in the unaudited condensed consolidated balance sheet. Assets classified as held for sale are reported at the lower
of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for
sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discontinued
operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business
that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a
major effect on the Company&#8217;s operations and financial results according to Accounting Standard Codification (&#8220;ASC&#8221;)
Topic 205, <i>Presentation of Financial Statements</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
details surrounding the Company&#8217;s assets and liabilities held for sale and discontinued operations are included in Note 16.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zdALh9iWRtf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_z9k4q47cS8wj">Goodwill
and intangible assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 350, <i>Intangibles &#8211; Goodwill and Other</i>, in-process research and development (&#8220;IPR&amp;D&#8221;)
projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived
intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the
project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts
are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&amp;D assets, including the
current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability
to obtain local determination coverage (&#8220;LCD&#8221;) from the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) for
Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement
of competitors&#8217; diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the
eventual realized value of the IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges
may occur in future periods. During the period between completion or abandonment, the IPR&amp;D assets will not be amortized but will
be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in
circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts (see
Notes 3 and 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&amp;D,
is not amortized but is tested for impairment at least annually, or if circumstances indicate its value may no longer be recoverable.
Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant
events and factors affecting Oncocyte&#8217;s business. Based on the qualitative assessment, if it is determined that the fair value
of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared
with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte
continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at
the enterprise level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D discussed in Notes 3 and
4. As of June 30, 2023, goodwill has been fully impaired and acquired IPR&amp;D has been partially impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z43I1D7VHtqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zpKA0ODzalm9">Long-lived
intangible assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
intangible assets, consisting primarily of acquired customer relationships, are stated at acquired cost, less accumulated amortization.
Amortization expense is computed using the straight-line method over the estimated useful life of <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230630_zgG4WqZN1Jhc" title="Long-lived intangible assets, useful life">5</span> years (see Notes 3 and 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ContingentLiabilityReserveEstimatePolicy_zrQpGIlIQKhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zYjoCbRT84U6">Contingent
consideration liabilities</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of Oncocyte&#8217;s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former
selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones,
from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable
agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and
timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows (see Notes 3 and 4). These obligations
are referred to as contingent consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration
transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling
shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones.
Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings,
such as &#8220;earn-out&#8221; provisions or percentage of future revenues, including royalties paid to the selling shareholders based
on a percentage of certain revenues generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions
occur, with the subsequent change in fair value recorded in the condensed consolidated statements of operations. Changes in key assumptions
can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that
Oncocyte records in its unaudited condensed consolidated interim financial statements. See Notes 3 and 4 for a full discussion of these
liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_84C_eus-gaap--EquityMethodInvestmentsPolicy_zZ7s92dN3mxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zB5wx3auyJye">Investments
in capital stock of privately held companies</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable
interest entity (&#8220;VIE&#8221;) model, and then under the voting interest model in accordance with accounting guidance for consolidations
under Accounting Standards Codification (&#8220;ASC&#8221;) 810-10. If consolidation of the entity is not required under either the VIE
model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with
ASC 323, <i>Investments &#8211; Equity Method and Joint Ventures</i>. The equity method applies to investments in common stock or in-substance
common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically
represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment
balance based on Oncocyte&#8217;s pro rata share of earnings or losses from the investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
February 24, 2021, the date of Oncocyte&#8217;s acquisition of the remaining interests in Razor, through February 16, 2023 the date of
its disposition, Razor entity&#8217;s financial statements have been consolidated with Oncocyte. See Notes 3, 4, and 16 for additional
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zoQTYhsYePXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_z5dg3AsKZ7gi">Impairment
of long-lived assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired
and the carrying value may not be recoverable. Oncocyte&#8217;s long-lived assets consist primarily of intangible assets, right-of-use
assets for operating leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are
less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair
value, is recorded. See Notes 3, 4, and 16 for additional information with respect to impairments of long-lived assets. See Note 16 for
disclosure of machinery and equipment impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zsk7ub5YDnIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zYx3gprohqnj">Revenue
recognition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to ASC 606, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration
Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
identifying the contract with a customer,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
identifying the performance obligations in the contract,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
determining the transaction price,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
allocating the transaction price to the performance obligations, and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
recognizing revenue when, or as, an entity satisfies a performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services
in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable
consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal
in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently
resolved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">DetermaRx
testing revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received
from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria (i) through (v)
above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered
complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no
shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered
and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx.
Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the
transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires
significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving
payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual
reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient
history to reliably estimate payment patterns or has had contractual reimbursement arrangements, or both, in place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, Oncocyte had accounts receivable of $<span id="xdx_904_eus-gaap--AccountsReceivableSale_pn5n6_c20230101__20230630__srt--ProductOrServiceAxis__custom--MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember_zbTDkx4S4eEk" title="Accounts receivable">1.6</span> million from Medicare and Medicare Advantage covered DetermaRx tests (see
Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain an allowance for expected credit losses at an amount we estimate to be sufficient to provide adequate protection against losses
resulting from extending credit to our customers. We base this allowance, in the aggregate, on historical collection experience, age
of receivables and general economic conditions. Our bad debts have not been material and have been within management expectations. During
the first quarter of 2023, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, <i>Financial Instruments-Credit
Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> and subsequent amendments to the initial guidance under
ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial
assets, including trade and other receivables. Adoption of this standard did not have a material impact on the Company&#8217;s consolidated
financial statements and related disclosures. As of June 30, 2023 and December 31, 2022, we had a credit loss reserve of $<span id="xdx_90F_eus-gaap--ProvisionForDoubtfulAccounts_pn5n6_c20230101__20230630_zK53gXfBx3ri" title="Provision for doubtful accounts"><span id="xdx_904_eus-gaap--ProvisionForDoubtfulAccounts_pn5n6_c20220101__20221231_zYX0GVuuq9Bf" title="Provision for doubtful accounts">0.2</span></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Pharma
services revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
recognized include Pharma Services performed by Oncocyte&#8217;s Insight and Chronix subsidiaries for its pharmaceutical customers, including
testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These
Pharma Services are generally performed under individual scope of work (&#8220;SOW&#8221;) arrangements or license agreements (together
with SOW the &#8220;Pharma Services Agreements&#8221;) with specific deliverables defined by the customer. Pharma Services are performed
on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with
a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable
basis) and recognizes Pharma Service revenue at that time. Insight identifies each sale of its Pharma Service offering as a single performance
obligation. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license
agreements with customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
of the service and satisfaction of the performance obligation is typically evidenced by access to the report or test made available to
the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs
under which work is performed pursuant to the customer&#8217;s highly customized specifications, Oncocyte has the enforceable right to
bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period
during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage
of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements,
any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed
to the customer as of the date of Oncocyte&#8217;s condensed consolidated financial statements are recorded as contract assets and are
included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified
to accounts receivable in Oncocyte&#8217;s condensed consolidated financial statements when the customer is invoiced according to the
billing schedule in the contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
establishes credit loss reserve accounts based on the evaluation of the collectability of its Pharma Services accounts receivables after
considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer&#8217;s
ability to pay, such as a bankruptcy filing or deterioration in the customer&#8217;s operating results or financial position, reasonable
and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to
customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections
and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its
historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are
written off against the credit loss reserve accounts. As of June 30, 2023, Oncocyte has not recorded any losses or credit loss reserve
accounts on its account receivables from Pharma Services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, Oncocyte had accounts receivable from Pharma Services customers of $<span id="xdx_901_eus-gaap--AccountsReceivableSale_pn5n6_c20230101__20230630__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_zjG4mfP83gx6" title="Accounts receivable">0.3</span> million, as compared to $<span id="xdx_90A_eus-gaap--AccountsReceivableSale_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_z02GYWvfQmt2" title="Accounts receivable">0.3</span> million as of
December 31, 2022 (see Note 7). As of June 30, 2023 and December 31, 2022, we have not reserved a credit loss reserve for Pharma Services
accounts receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Licensing
revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte&#8217;s proprietary
testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose
of marketing Oncocyte&#8217;s tests within a defined geographic territory. A license agreement may specify milestone deliverables or
performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte&#8217;s performance
obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing
fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and
ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--CostOfSalesPolicyTextBlock_zxfsZ5sugvq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zgAik2cMrqKd">Cost
of revenues</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and
infrastructure expenses, clinical sample related costs associated with performing DetermaRx tests and Pharma Services, providing deliverables
according to our licensing agreements, license fees due to third parties, and amortization of acquired intangible assets such as the
Razor asset and customer relationship intangible assets. Infrastructure expenses include depreciation of laboratory equipment, allocated
rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte&#8217;s CLIA laboratories in
California and Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless
of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues
generated using the associated technology are recorded as expenses at the time the related revenues are recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_z9VYzThSZKkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zmAQLAXY8zZk">Research
and development expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based
compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure
expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development
expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications,
property taxes, and insurance. Research and development costs are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--SalesAndMarketingExpensesPolicyTextBlock_zSZzKJiXdkvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zhPOYeNSdVCh">Sales
and marketing expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses,
branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead
allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property
taxes, and insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z9lDskHkVHDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z3870c4zEFu7">General
and administrative expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive
and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property
taxes, and insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zmvDJyck8SM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z6KeBeISQsx6">Net
loss per common share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and
accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. Diluted loss
per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion
of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that
would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted
method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the
computation if their effect is antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zpRphtLnuNF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents
the calculation of basic and diluted loss per share of common stock (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zQpZ5bBe8SVf">Schedule
of Common Stock Computation of Diluted Net Loss Per Share of Common Stock</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230401__20230630_zi6VhUSRhcLf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220401__20220630_z250A9VByK31" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20230630_zZLffxMsbPOe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20220630_zGHbu2Vm7Qw6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossIncludingPortionAttributableToNoncontrollingInterest_zjjvwqg2rtfd" style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Net loss attributable to Oncocyte Corporation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(8,333</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(8,300</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(5,300</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(18,591</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--DividendOnPreferredStock_zyO5mNeeH4A2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend on Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(166</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--RedeemablePreferredStockDividends_iN_pn3n3_di_zI6LFGQVusXe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(117</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(257</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--DeemedDividendOnPreferredStock_iN_pn3n3_di_zB0jDxh8Nn73" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deemed dividend on Series A redeemable convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_z9ehePWv2Rxk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230401__20230630_zYnUNlYpzbi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted">(8,644</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220401__20220630_z4N0PXtRYJFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted">(8,372</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230630_zllfG01ZWKT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted">(5,841</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220630_zC6uczPfyZx6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted">(18,663</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zR1QiUYWycd4" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders - Basic </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,644</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,372</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,841</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,663</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average shares used in computing net loss per share attributable to common stockholders - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230401__20230630_zRFBQSfPOkbi" title="Weighted average number of shares outstanding, basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230401__20230630_zsUr2lKy1a2k" title="Weighted average number of shares outstanding, diluted">8,090</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220401__20220630_zLJZeVYaGELj" title="Weighted average number of shares outstanding, basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220401__20220630_zSirTTGqB954" title="Weighted average number of shares outstanding, diluted">5,652</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230630_zrwt9ABffUmi" title="Weighted average number of shares outstanding, basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230630_zQW8KDSFUm3" title="Weighted average number of shares outstanding, diluted">7,030</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220630_z7b2pwLFNBO9" title="Weighted average number of shares outstanding, basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220630_z4eHT6aWOVzk" title="Weighted average number of shares outstanding, diluted">5,135</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EarningsPerShareBasic_pid_z2zA7tJPerI4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98F_eus-gaap--EarningsPerShareDiluted_pid_c20230401__20230630_zjxqFaYQCnb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted">(1.07</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220401__20220630_z3A48JpK1jNi" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted">(1.48</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230630_zsjAZl3ZjXgf" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted">(0.83</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220630_z8t0RQsbemKa" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted">(3.63</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pid_zlGdnrGr1wy3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic  net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.07</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.48</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.83</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.63</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgjK9PEZ67Uf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">483</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">731</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">657</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zaYmmxPLXS79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfRcuUjnwSP3" style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">845</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zmgQqoSMUupa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Series A redeemable convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zjFch4FZu3ad" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,582</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,384</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,508</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zd9x3szxLcDa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,582</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,384</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,508</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/></span></p>

<p id="xdx_8A5_z7z5mTtaPrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zAR2qsO6DnPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_867_z57se08r5Vei">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
accounts for leases in accordance with ASC 842, <i>Leases</i>. Oncocyte determines if an arrangement is a lease at inception. Leases
are classified as either financing or operating, with classification affecting the pattern of expense recognition in the condensed consolidated
statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease
components as a single lease component. Oncocyte recognizes right-of-use (&#8220;ROU&#8221;) assets and lease liabilities for leases
with terms greater than twelve months in the condensed consolidated balance sheet. ROU assets represent the right to use an underlying
asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease
ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most
leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate
the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a
straight-line basis over the lease term. Operating leases are included as right-of-use assets in machinery and equipment, and ROU lease
liabilities, current and long-term, in the condensed consolidated balance sheets. Financing leases are included in machinery and equipment,
and in financing lease liabilities, current and long-term, in the condensed consolidated balance sheets. Oncocyte discloses the amortization
of our ROU assets and operating lease payments as a net amount, &#8220;Amortization of right-of-use assets and liabilities&#8221;, on
the condensed consolidated statements of cash flows. Based on the available practical expedients under the standard, Oncocyte elected
not to capitalize leases that have terms of twelve months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
prior years, Oncocyte entered into various operating leases and an embedded operating lease in accordance with ASC 842 discussed in Note
10. Oncocyte&#8217;s accounting for financing leases remained substantially unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_84E_ecustom--AccountingForSharesOfCommonStockPolicyTextBlock_zpQoUHH9QS8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_863_zGtUX57eq779">Accounting
for Lineage and AgeX shares of common stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
accounts for the shares of Lineage and AgeX common stock it holds as marketable equity securities in accordance with ASC 320-10-25, <i>Investments
&#8211; Debt and Equity Securities</i>, as amended by Accounting Standards Update (&#8220;ASU&#8221;) 2016-01, <i>Financial Instruments&#8211;Overall:
Recognition and Measurement of Financial Assets and Financial Liabilities</i>, as the shares have a readily determinable fair value quoted
on the NYSE American and are held principally to meet future working capital purposes, as necessary. The securities are measured at fair
value, with related gains and losses in the value of such securities recorded in the condensed consolidated statements of operations
in other income (expense), and are reported as current assets on the condensed consolidated balance sheets based on the closing trading
price of the security as of the date being presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023 and December 31, 2022, Oncocyte held <span id="xdx_903_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20230630__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zEZd0tzlxVGj" title="Common stock, shares held as available for sale securities">353,264</span> and <span id="xdx_90E_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zImG2PjERDme" title="Common stock, shares held as available for sale securities">35,326</span> shares of common stock of Lineage and AgeX, respectively, as
marketable equity securities had a combined fair market value of $<span id="xdx_904_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20230630__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zLN7EUyPGDPl" title="Fair value of equity securities">0.5</span> million and $<span id="xdx_901_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zztEm86lPzuh" title="Fair value of equity securities">0.4</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zj4d3sWVNN3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_867_zX90kLV5ULI3">Recent
accounting pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13,
<i>Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> and subsequent amendments
to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit
losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a
valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets,
which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent
changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Previously, U.S. GAAP
required entities to write down credit losses only when losses are probable and loss reversals are not permitted. The Company adopted
this ASU in the first quarter of 2023. Adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial
statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): <i>Accounting for Contract Assets and Contract Liabilities
from Contracts with Customers,</i> to provide specific guidance to eliminate diversity in practice on how to recognize and measure acquired
contract assets and contract liabilities from revenue contracts from customers in a business combination consistent with revenue contracts
with customers not acquired in an acquisition. The amendments in this update provide that the acquirer should consider the terms of the
acquired contracts, such as timing of payment, identify each performance obligation in the contracts, and allocate the total transaction
price to each identified performance obligation on a relative standalone selling price basis as of contract inception (that is, the date
the acquiree entered into the contracts) or contract modification to determine what should be recorded at the acquisition date. These
amendments are effective for the Company beginning with fiscal year 2023. The impact of the adoption of the amendments in this update
will depend on the magnitude of any customer contracts assumed in a business combination in 2023 and beyond.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871822485520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text"><p id="xdx_804_eus-gaap--BusinessCombinationDisclosureTextBlock_zT8FqY89fnt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>3.
<span id="xdx_82A_z2eG6KiFBee2">Business Combinations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Acquisition
of Insight Genetics, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
January 31, 2020 (the &#8220;Insight Merger Date&#8221;), Oncocyte completed its acquisition of Insight pursuant to the Insight Merger
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Contingent
consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future
if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration
also includes additional future payments to selling shareholders based on achievement of components of earnings, such as &#8220;earn-out&#8221;
provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of revenues generated
from DetermaIO and Insight Pharma Services over their respective useful life. Accordingly, Oncocyte determined there are two types
of contingent consideration in connection with the Insight Merger, the Milestone Contingent Consideration and the Royalty Contingent
Consideration discussed below, which are collectively referred to as the &#8220;Contingent Consideration&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">There
are three milestones comprising the Milestone Contingent Consideration, collectively referred to as the Milestones, in connection with
the Insight Merger which Oncocyte valued and recorded as part of Contingent Consideration as of the Insight Merger Date (see table below),
which consist of (i) a payment for clinical trial completion and related data publication (&#8220;Milestone 1&#8221;), (ii) a payment
for an affirmative final local coverage determination from CMS for a specified lung cancer test (&#8220;Milestone 2&#8221;), and (iii)
a payment for achieving specified CMS reimbursement milestones (&#8220;Milestone 3&#8221;). If achieved, any respective Milestone will
be paid at the contractual value shown below, with the payment made either in cash or in shares of Oncocyte common stock as determined
by Oncocyte. There can be no assurance that any of the Milestones will be achieved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zr62CmVli4Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective
Contingent Consideration liability (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zXLzQ9fEPZy1" style="display: none">Schedule
of Fair Value of Contingent Consideration Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Fair</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Contractual</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Value on the</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Merger Date</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black">Milestone 1</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_988_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_zW5aIZGI60W8" style="width: 14%; color: Black; text-align: right" title="Contractual Value">1,500</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_z6iz8Hc5EKF7" style="width: 14%; color: Black; text-align: right" title="Fair Value on the Merger Date">1,340</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Milestone 2</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_z8AAqFL8bsy" style="color: Black; text-align: right" title="Contractual Value">3,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_zGhydEVa15pg" style="color: Black; text-align: right" title="Fair Value on the Merger Date">1,830</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Milestone 3 <sup id="xdx_F45_zVGjZGh31Un2">(a)</sup></span></td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_zpWwOxo6gMld" style="color: Black; text-align: right" title="Contractual Value">1,500</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_z2cZ4qX0fw0e" style="color: Black; text-align: right" title="Fair Value on the Merger Date">770</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Royalty 1 <sup id="xdx_F44_zb4wasIRrhe5">(b)</sup></span></td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See(b) </span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyOneMember_fKGIp_zVn3EkJpMAO8" style="color: Black; text-align: right" title="Fair Value on the Merger Date">5,980</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Royalty 2 <sup id="xdx_F4D_zwRw9dSDKHw7">(b)</sup></span></td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See(b) </span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyTwoMember_fKGIp_zhj5TRoXpMWk" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Fair Value on the Merger Date">1,210</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630_zDaGfAJD9Rda" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Contractual Value">6,000</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630_zwyBT5L1AwFi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Fair Value on the Merger Date">11,130</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><sup id="xdx_F01_zb2eceMRkTc3">(a)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_znT1wWChX9nd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Indicates
    the maximum payable if the Milestone is achieved.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><sup id="xdx_F04_zTzRw6bHRPqj">(b)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zcX7SCTMlHB4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
    defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful
    life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.</span></td></tr>
  </table>
<p id="xdx_8A6_z3k9HRBwMhfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of the Contingent Consideration after the Insight Merger Date is reassessed by Oncocyte as changes in circumstances and conditions
occur, with the subsequent change in fair value recorded in Oncocyte&#8217;s condensed consolidated statements of operations. As of June
30, 2023, based on Oncocyte&#8217;s reassessment of the significant assumptions noted above, there was a decrease of approximately $<span id="xdx_905_ecustom--FairValueOfContingentConsideration_pn5n6_c20230101__20230630_zhtxecgaS3I1" title="Fair value of contingent consideration">2.5</span>
million to the fair value of the Contingent Consideration primarily attributable to revised estimates of the timing of the possible future
payouts and, accordingly, this decrease was recorded as change in fair value of contingent consideration in the unaudited condensed consolidated
statements of operations for the six months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zNbFLAlRDEJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following tables reflect the activity for Oncocyte&#8217;s Contingent Consideration for the six months ended June 30, 2023 and 2022,
measured at fair value using Level 3 inputs (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_zWcmSODB5ZF3" style="display: none">Schedule
of Contingent Consideration, Measured at Fair Value</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; color: Black">Balance at December 31, 2021</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zHLOuhwRwX1l" style="width: 16%; color: Black; text-align: right" title="Beginning balance">7,060</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zkpPhq7UfiGc" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Change in estimated fair value">1,400</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 2.5pt">Balance at June 30, 2022</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zR1ZhP0Pwvu6" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Beginning balance">8,460</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; color: Black">Balance at December 31, 2022</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_z7klqkL6XAlf" style="width: 16%; color: Black; text-align: right" title="Beginning balance">5,370</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zhgZfEG7nRY6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Change in estimated fair value">(2,500</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 2.5pt">Balance at June 30, 2023</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zhyHgOLlU4r9" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Beginning balance">2,870</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zqVr8LkLaasi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Contingent
consideration is not deductible for tax purposes, even if paid; therefore, no deferred tax assets related to the Contingent Consideration
were recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Asset
acquisition of Razor Genomics, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
February 24, 2021, Oncocyte completed the purchase of all the issued and outstanding shares of common stock of Razor. As a result of
Oncocyte is the sole shareholder of Razor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
December 15, 2022, the Company entered into a Stock Purchase Agreement in which the Company agreed to sell approximately <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221215__dei--LegalEntityAxis__custom--RazorGenomicsIncMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zsP8901u4iSa" title="Outstanding equity">70</span>% of the issued
and outstanding equity interest of Razor on a fully-diluted basis. On February 16, 2023, the sale of Razor was completed. <span style="background-color: white">See
Note 16 for additional information.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span style="text-decoration: underline">Development
Agreement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On December 31, 2019, in connection with Oncocyte&#8217;s purchase <span style="background-color: white">of&#160;<span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20191231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_z7YXMzqjlYsl" title="Outstanding equity">25</span>%
of the outstanding equity of Razor,</span> Oncocyte entered into a Development Agreement with Razor and Encore Clinical, Inc. (&#8220;Encore&#8221;),
a former stockholder of Razor (the &#8220;Development Agreement&#8221;). Under
the Development Agreement, Razor reserved as a &#8220;Clinical Trial Expense Reserve&#8221; $<span id="xdx_908_ecustom--ClinicalTrialExpenseReserveAmount_iI_pn5n6_c20230630__us-gaap--TypeOfArrangementAxis__custom--DevelopmentAgreementMember__dei--LegalEntityAxis__custom--RazorGenomicsIncMember_z46ZfEP6wgPf" title="Clinical trial expense reserve amount">4.0</span> million of the proceeds it received
at the Initial Closing from the sale of the Razor Preferred Stock to Oncocyte, to fund Razor&#8217;s share of costs incurred in connection
with a clinical trial of DetermaRx for purposes of promoting commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The
Development Agreement was terminated on February 16, 2023 in connection with the Razor Stock Purchase Agreement. See Note 16 for more
details regarding the Razor Stock Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span style="text-decoration: underline">Sublicense
Agreement</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On December 31, 2019, in connection with Oncocyte&#8217;s purchase <span style="background-color: white">of&#160;<span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20191231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zW1qK9xIv1H1" title="Outstanding equity">25</span>%
of the outstanding equity of Razor,</span> Oncocyte entered into a Sublicense and Distribution Agreement with Razor and Encore Clinical,
Inc. (&#8220;Encore&#8221;), a former stockholder of Razor (the &#8220;Sublicense Agreement&#8221;). Under
the Sublicense Agreement, Razor granted to Oncocyte an exclusive worldwide sublicense under certain patent rights applicable to DetermaRx
in the field of use covered by the applicable license held by Razor for purposes of commercialization and development of DetermaRx.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Sublicense Agreement was terminated on February 16, 2023 in connection with the Razor Stock Purchase Agreement. See Notes 16 for more
details regarding the Razor Stock Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Acquisition
of Chronix Biomedical, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 15, 2021 (the &#8220;Chronix Merger Date&#8221;), Oncocyte completed its acquisition of Chronix pursuant the Chronix Merger Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span style="text-decoration: underline">Contingent
Consideration</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
additional consideration for holders of certain classes and series of Chronix capital stock, the Chronix Merger Agreement originally
required Oncocyte to pay &#8220;Chronix Contingent Consideration&#8221; consisting of (i) &#8220;Chronix Milestone Payments&#8221; of
up to $<span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferred1_pn6n6_c20210414__20210415__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixBiomedicalIncMember_zO1hMYSvrZ25" title="Business combination consideration transferred">14</span> million in any combination of cash or Oncocyte common stock if certain milestones specified in the Chronix Merger Agreement
are achieved, (ii) &#8220;Royalty Payments&#8221; of up to <span id="xdx_906_ecustom--EarnoutPercentageOnCollectionsForSales_pid_dp_uPure_c20210414__20210415__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixBiomedicalIncMember_zOT7846rt91k" title="Earnout percentage on collections for sales">15</span>% of net collections for sales of specified tests and products during the
five-to-ten year earnout periods, and (iii) &#8220;Transplant Sale Payments&#8221; of up to <span id="xdx_905_ecustom--EarnoutPercentageOnCollectionsForSaleOrLicense_pid_dp_uPure_c20210414__20210415__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixBiomedicalIncMember_z5bWiy7suAq1" title="Earnout percentage on collections for sale or license">75</span>% of net collections from the sale or license
to a third party of Chronix&#8217;s patents for use in transplantation medicine during a seven-year earnout period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
February 8, 2023, the Company and equity holder representative entered into Amendment No. 1 to the Merger Agreement (the
&#8220;Chronix Amendment&#8221;), pursuant to which the parties agreed that (i) Chronix&#8217;s equity holders will be paid earnout
consideration of <span id="xdx_90D_ecustom--EarnoutPercentageOnCollectionsForSales_pid_dp_uPure_c20230207__20230208__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixEquityMember_zA8dt6e3Sn08" title="Earnout percentage on collections for sales">10</span>%
of net collections for sales of specified tests and products, until the expiration of intellectual property related to such tests
and products, (ii) Chronix&#8217;s equity holders will be paid <span id="xdx_90C_ecustom--EarnoutPercentageOnCollectionsForSale_pid_dp_uPure_c20230207__20230208__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixEquityMember_z4BAgvEqkP82" title="Gross proceeds percentage">5</span>%
of the gross proceeds received from any sale of all or substantially all of the rights, titles, and interests in and to
Chronix&#8217;s patents for use in transplantation medicine to such third party, and (iii) the Chronix Milestone Payments, <span id="xdx_901_ecustom--RoyaltyPaymentsPercentage_pid_dp_uPure_c20230207__20230208__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixMilestoneMember_zAkyMSYsWqmj" title="Royalty payments">15</span>%
Royalty Payments and Transplant Sale Payment obligations were eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of the Chronix Contingent Consideration after the Chronix Merger Date is reassessed by Oncocyte as changes in circumstances
and conditions occur, with the subsequent change in fair value recorded in Oncocyte&#8217;s condensed consolidated statements of operations.
As of June 30, 2023, based on Oncocyte&#8217;s reassessment of the significant assumptions noted above, there was a decrease of approximately
$<span id="xdx_908_ecustom--FairValueOfContingentConsideration_pn5n6_c20230101__20230630__dei--LegalEntityAxis__custom--ChronixMember_z85PzHMf9Se6" title="Fair value">14.0</span> million to the fair value of the Contingent Consideration primarily attributable to revised estimates of the timing of the possible
future payouts and, accordingly, this decrease was recorded as a change in fair value of contingent consideration in the unaudited condensed
consolidated statements of operations for the six months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_892_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zVFsHijgf9R1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following tables reflect the activity for Oncocyte&#8217;s Contingent Consideration for the six months ended June 30, 2023 and June 30,
2022, measured at fair value using Level 3 inputs (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zryJ7Rbu1YH5" style="display: none">Schedule
of Contingent Consideration, Measured at Fair Value</span><span style="color: Black">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; color: Black">Balance at December 31, 2021</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_z5g0QnsIAr39" style="width: 16%; color: Black; text-align: right" title="Beginning balance">69,621</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_989_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_znlqDc29oDY2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Change in estimated fair value">(12,415</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 2.5pt">Balance at June 30, 2022</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zePuBAVIo0X9" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Ending balance">57,206</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Fair
    Value</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Balance
    at December 31, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</span></td>
    <td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zq0O6vjV7D09" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">40,292</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Change
    in estimated fair value</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td id="xdx_988_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_z7lb0Qit2Vxh" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in estimated fair value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(14,012</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Balance
    at June 30, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</span></td>
    <td id="xdx_983_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zAxmVVnZ6Z6a" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">26,280</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  </table>
<p id="xdx_8A3_zvgtJJ4Jw9Hb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Goodwill
</i>- Goodwill is calculated as the difference between the acquisition date fair value of the Aggregate Chronix Merger Consideration
transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill also includes the $<span id="xdx_90B_eus-gaap--DeferredTaxLiabilities_iI_pn5n6_c20230630__us-gaap--BusinessAcquisitionAxis__custom--ChronixBiomedicalIncMember_zVzw2sOKdUF9" title="Net deferred tax liabilities">2.2</span> million of net deferred
tax liabilities recorded principally related to the VitaGraft discussed above. Oncocyte recognized approximately $<span id="xdx_902_eus-gaap--Goodwill_iI_pn5n6_c20230630__us-gaap--BusinessAcquisitionAxis__custom--ChronixBiomedicalIncMember_zPFqHQEpzNo5" title="Goodwill">9.5</span> million of goodwill
related to the Chronix acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">None
of the goodwill recognized is expected to be deductible for income tax purposes. Goodwill is not amortized but is tested for impairment
at least annually, or more frequently if circumstances indicate potential impairment. During 2022, the Company identified circumstances
that could indicate a potential impairment and after a valuation of the Company&#8217;s assets and liabilities was performed, management
concluded that goodwill was impaired as of December 31, 2022. (see Notes 2 and 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871822485520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, net</a></td>
<td class="text"><p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_zggyCJUTfJp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>4.
<span id="xdx_825_zq1y9iRbkQpd">Intangible Assets, net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
part of the Insight and Chronix acquisitions, which were accounted for as business combinations under ASC 805, completed
on January 31, 2020, and April 15, 2021, respectively, the Company has acquired in process research and development (&#8220;IPR&amp;D&#8221;)
and customer relationships.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the first quarter of 2023, due to changes in management and the economic condition of the Company, management shifted the Company&#8217;s
business strategy to direct efforts on fewer studies and to transition from test that are laboratory developed tests (&#8220;LDT&#8221;)
to research use only (&#8220;RUO&#8221;) sales. Due to the change in strategy, the Company&#8217;s long range plan forecasts were updated
and anticipated future benefits derived from the Company&#8217;s assets. The change in strategy represent a significant indicator for
change in value of the Company&#8217;s long lived assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
original IPR&amp;D balance was reassessed based on the updated long range plan (&#8220;LRP&#8221;), using the multiple period excess
earnings method (&#8220;MPEEM&#8221;) approach, the results of the valuation noted that the carrying value of the DetermaIO related IPR&amp;D
intangible assets was greater than the fair market value, whereas the CNI and VitaGraft related IPR&amp;D intangible assets carrying
value was lower than the fair market value. Accordingly, the Company recorded an impairment of approximately $<span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn5n6_c20230101__20230630_zY7zfMhJclk5" title="Impairment of intangible">5.0</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zkuWtg5fnVwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">At
June 30, 2023 and December 31, 2022, intangible assets, net, consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BF_z1ntElUJtXUf" style="display: none">Schedule
of Goodwill and Intangible Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Intangible assets:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Acquired IPR&amp;D - DetermaIO <sup id="xdx_F45_z50d1JgML9p8">(1)</sup></span></td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230630__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zd0UJXxJJbn6" style="width: 16%; color: Black; text-align: right" title="Intangible assets acquired IPR&amp;D">9,700</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zX4pGhgdrW7e" style="width: 16%; color: Black; text-align: right" title="Intangible assets acquired IPR&amp;D">14,650</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Acquired IPR&amp;D - DetermaCNI and VitaGraft <sup id="xdx_F4B_zbFL00dbpQ5">(2)</sup></span></td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230630__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zCGNkZococe" style="color: Black; text-align: right" title="Intangible assets acquired IPR&amp;D">46,800</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zOz5SV12oK97" style="color: Black; text-align: right" title="Intangible assets acquired IPR&amp;D">46,800</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Intangible assets subject to amortization:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Acquired intangible assets - customer relationship</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpvNVGqMyt49" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Acquired intangible assets">440</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z00ckkSXCPCf" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Acquired intangible assets">440</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Total intangible assets</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20230630_zJ75ddvYgyFg" style="color: Black; text-align: right" title="Total intangible assets">56,940</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20221231_z8PLkXFu9Whe" style="color: Black; text-align: right" title="Total intangible assets">61,890</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accumulated amortization - customer relationship<sup id="xdx_F41_zz21ALezTe4j">(3)</sup></span></td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zwOyH1flKbod" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Finite-lived intangible assets, accumulated amortization">(301</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zBfDr8zMLMJe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Finite-lived intangible assets, accumulated amortization">(257</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20230630_zXvCCFA7Cwjb" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Intangible assets, net">56,639</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20221231_zAFMNxxZ9SLk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Intangible assets, net">61,633</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zb3i25T8jMbd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zM4dTMPHLKd2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
    Note 3 for information on the Insight Merger.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0A_zf1xpeCdv4Nh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_z4MzpgPX1bUl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
    Note 3 for information on the Chronix Merger.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0E_z4YcBThmyYY4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zrznRYC4dSy1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Amortization
    of intangible assets is included in &#8220;Cost of revenues &#8211; amortization of acquired intangibles&#8221; on the condensed
    consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired
    intangibles.</span></td></tr>
  </table>
<p id="xdx_8A7_zYTeDvFxU5vj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zlmAtQRW29pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Future
amortization expense of intangible assets subject to amortization is expected to be the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zNjId23XsWCd" style="display: none">Schedule
of Intangible Assets Future Amortization Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230630_zy6ik692tCF7" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Amortization</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Year ending December 31,</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzyWn_z0zj0iJZHfg7" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; color: Black; text-align: left">2023</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 16%; color: Black; text-align: right">44</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzyWn_zc1zdTU4h8Q6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">2024</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">88</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzyWn_zoSArfeed3Wk" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">2025</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">7</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzyWn_z2O6eEIFz0Hc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">139</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zx5jEpHcdZF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871914353216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwdQQ4cBeOQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>5.
<span id="xdx_824_zvW4mSQ9OOqb">Shareholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Series
A Redeemable Convertible Preferred Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 13, 2022, the Company entered into the Securities Purchase Agreement with the Investors in a registered direct offering of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_z2KvzPhwOX69" title="Offering shares">11,765
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">shares of the Company&#8217;s Series
A Preferred Stock, which shares of Series A Preferred Stock are convertible into a total of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znxyqV2Hvvf5" title="Convertible preferred shares">384,477
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">shares of common stock, at a conversion
price of $<span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTzhSUeLZoW8" title="Conversion price">30.60</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.
The purchase price of each share of Series A Preferred Stock was $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zn4bkusr0hO" title="Preferred stock offering">850</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">,
which included an original issue discount to the stated value of $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDOVOEDpAFr6" title="Stated value per share">1,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">per share. The rights, preferences
and privileges of the Series A Preferred Stock are set forth in the Company&#8217;s Certificate of Determination, which the Company filed
with the Secretary of State of the State of California. The Securities Purchase Agreement provides that the closing of the Series A Preferred
Stock Offering will occur, subject to the satisfaction of certain closing conditions, in two equal tranches of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zaTYO1W8Drqb" title="Preferred stock offering">5,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">each for aggregate gross proceeds
from both closings of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zozNK6Oxl05j" title="Gross proceeds, closing">10,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.
The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zj8MiLmaxZ9h" title="Net proceeds">4.9
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">million from the Series A Preferred
Stock issued from the first tranche. The second closing would occur, subject to the satisfaction of certain closing conditions (including
but not limited to a requirement that the Company has not received, in the 12 months preceding the second closing, a notice from Nasdaq
that the Company is not in compliance with the listing and maintenance and listing requirements of Nasdaq), on the earlier of (a) the
second trading day following the date that Oncocyte receives notice from an Investor to accelerate the second closing and (b) a date
selected by Oncocyte on or after October 8, 2022 and on or prior to March 8, 2023. On August 9, 2022, Oncocyte received a letter from
Nasdaq indicating that the Company no longer met the minimum bid price requirement of the Nasdaq continued
listing requirements. Accordingly, the second closing did not occur and no additional proceed</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s
were received under the Securities Purchase Agreement. On August 8, 2023, the Company received a letter from Nasdaq indicating that
the Company had regained compliance with the minimum bid price requirement of the Nasdaq continued listing requirements. See Note 15 for additional
information about the Series A Preferred Stock Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Series A Preferred Stock is convertible into shares of the Company&#8217;s common stock at any time at the holder&#8217;s option. The
conversion price will be subject to customary anti-dilution adjustments for matters such as stock splits, stock dividends and other distributions
on our common stock, and recapitalizations. <span id="xdx_90C_eus-gaap--ConversionOfStockDescription_c20230101__20230630_zRjjaUnk7bPi" title="Conversion of stock, description">A holder is prohibited from converting shares of Series A Preferred Stock into shares of
common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of
our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership
limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to
the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect
to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer
apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)</span>. On July
15, 2022, the Company received such shareholder approval to remove the beneficial ownership limitation with respect to the Series A Preferred
Stock held by Broadwood. The Company may force the conversion of up to one-third of the shares of Series A Preferred Stock
originally issued, subject to customary equity conditions, <span id="xdx_905_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_z9KKBKFKc825" title="Equity method investment, description of principal activities">if the daily volume weighted average price of our common stock for 20 out
of 30 trading days exceeds <span id="xdx_90E_ecustom--ConversionPricePercentage_dp_uPure_c20220714__20220715_zxCCzDgJI6El">140</span>% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or
exceeds 20,000 shares of our common stock</span>. The Company may only effect one forced conversion during any 30-trading day period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
the event of the Company&#8217;s liquidation, dissolution, or winding up, holders of Series A Preferred Stock will receive a payment
equal to the stated value of the Series A Preferred Stock plus accrued but unpaid dividends and any other amounts that may have become
payable on the Series A Preferred Stock due to any failure or delay that may have occurred in issuing shares of common stock upon conversion
of a portion of the Series A Preferred Stock, before any distribution or payment to the holders of common stock or any of our other junior
equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
of Series A Preferred Stock generally have no voting rights, except as required by law and except that the consent of holders of
a majority of the outstanding Series A Preferred Stock will be required to amend any provision of our certificate of incorporation that
would have a materially adverse effect on the rights of the holders of the Series A Preferred Stock. Additionally, as long as any shares
of Series A Preferred Stock remain outstanding, unless the holders of at least <span id="xdx_90D_ecustom--PreferredStockRemainsOutstandingPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_za9Qp0Q7e1k9" title="Preferred stock outstanding percentage">51</span>% of the then outstanding shares of Series A Preferred
Stock shall have otherwise given prior written consent, we, on a consolidated basis with our subsidiaries, are not permitted to (1) have
less than $<span id="xdx_900_eus-gaap--Cash_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z6Hicb4W9sEe" title="Cash in hand">8</span> million of unrestricted, unencumbered cash on hand (&#8220;Cash Minimum Requirement&#8221;); (2) other than certain permitted
indebtedness, incur indebtedness to the extent that our aggregate indebtedness exceeds $<span id="xdx_90B_ecustom--IndebtednessExpenses_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zcU48xM07Lgf" title="Indebtedness expenses">15</span> million; (3) enter into any agreement (including
any indenture, credit agreement or other debt instrument) that by its terms prohibits, prevents, or otherwise limits our ability to pay
dividends on, or redeem, the Series A Preferred Stock in accordance with the terms of the Certificate of Determination; or (4) authorize
or issue any class or series of preferred stock or other capital stock of the Company that ranks senior or pari passu with the Series
A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Shares
of Series A Preferred Stock are entitled to receive cumulative dividends at a rate per share (as a percentage of stated value) of
<span id="xdx_907_ecustom--DividendsRatePerPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zixFccYnMMWg" title="Dividends rate">6</span>% per annum, payable quarterly in cash or, at our option, by accreting such dividends to the stated value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company is required to redeem, for cash, the shares of Series A Preferred Stock on the earlier to occur of (1) April 8, 2024, (2) the
commencement of certain a voluntary or involuntary bankruptcy, receivership, or similar proceedings against the Company or its assets,
(3) a Change of Control Transaction (as defined herein) and (4) at the election and upon notice of <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InterestMember_zPuZLzD3uCua" title="Ownership percentage">51</span>% in interest of the holders, if
the Company fails to meet the Cash Minimum Requirement. A &#8220;Change of Control Transaction&#8221; means the occurrence of any of
(a) an acquisition by an individual or legal entity or &#8220;group&#8221; (as described in Rule 13d-5(b)(1) promulgated under the Exchange
Act) of effective control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of
in excess of <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_z8VqlYAtzo6l" title="Ownership percentage">50</span>% of the voting securities of the Company (other than by means of conversion of Series A Preferred Stock), (b) the Company
merges into or consolidates with any other person, or any person merges into or consolidates with the Company and, after giving effect
to such transaction, the stockholders of the Company immediately prior to such transaction own less than <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SecurityMember_zhOynCNCprej" title="Ownership percentage">50</span>% of the aggregate voting
power of the Company or the successor entity of such transaction, or (c) the Company sells or transfers all or substantially all of its
assets to another person. Additionally, the Company has the right to redeem the Series A Preferred Stock for cash upon 30 days prior
notice to the holders; provided if the Company undertakes a capital raise in connection with such redemption, the Investors will have
the right to participate in such financing. On April 5, 2023, the Company redeemed <span id="xdx_901_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230404__20230405__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7yo2bp0iT44" title="Number of stock redeem">1,064</span> shares of the Series A Preferred Stock for approximately
$<span id="xdx_908_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230404__20230405__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkkVV88XsEX1" title="Number of stock redeem value">1.1</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023, Oncocyte had <span id="xdx_901_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z4mv9Ns6Z9Di" title="Temporary equity, shares issued"><span id="xdx_90D_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zujHw6qI6Ae3" title="Temporary equity, shares outstanding">4,818</span></span> shares issued and outstanding. The future right or obligation associated with the Series A Preferred
Stock to be issued in the second closing was written off in the prior year since the second closing was not completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Common
Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023 and December 31, 2022, Oncocyte has <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3pP1GE86ex9" title="Common stock, shares authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zple5sn9d7X" title="Common stock, shares authorized">230,000,000</span></span> shares of common stock, <span id="xdx_908_eus-gaap--PreferredStockNoParValue_iI_pid_do_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPVLfI1kcjD4" title="Preferred stock no par value"><span id="xdx_90D_eus-gaap--PreferredStockNoParValue_iI_pid_do_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQB8MzRWlm77" title="Preferred stock no par value">no</span></span>-par value, authorized. As of June 30, 2023
and December 31, 2022, Oncocyte had <span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230630_zB17FF9GO6rd" title="Common stock, shares outstanding">8,240,928</span> and <span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zogPhqe0kEjb" title="Common stock, shares outstanding">5,932,191</span> shares of common stock issued and outstanding, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Common
Stock Purchase Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023, Oncocyte had an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630_zswm8m17NPy7" title="Number of common stock purchase warrants">819,767</span> common stock purchase warrants issued and outstanding with exercise prices ranging
from $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__srt--RangeAxis__srt--MinimumMember_zJkBB6TPrWg9" title="Warrant exercise price per share">30.60</span> to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__srt--RangeAxis__srt--MaximumMember_zEGob5kqrAzd" title="Warrant exercise price per share">109.20</span> per warrant. The warrants will expire on various dates ranging from February 2024 to October 2029. Certain warrants
have &#8220;cashless exercise&#8221; provisions meaning that the value of a portion of warrant shares may be used to pay the exercise
price rather than payment in cash, which may be exercised under any circumstances in the case of the 2017 Bank Warrants and 2019 Bank
Warrants or, in the case of certain other warrants, only if a registration statement for the warrants and underlying shares of common
stock is not effective under the Securities Act or a prospectus in the registration statement is not available for the issuance of shares
upon the exercise of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
has considered the guidance in ASC 815-40, <i>Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in,
a Company&#8217;s Own Stock, </i>which states that contracts that require or may require the issuer to settle the contract for cash are
liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement
feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement
for transactions outside of the company&#8217;s control and, in which the form of consideration to the warrant holder may not be the
same as to all other shareholders in connection with the transaction. However, if a transaction is not within the company&#8217;s control
but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders
in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification
criteria are met. Based on the above guidance and, among other factors, the fact that the warrants cannot be cash settled under any circumstance
but require share settlement, all of the outstanding warrants meet the equity classification criteria and have been classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871826713280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zJsOujnmJlCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>6.
<span id="xdx_82B_ztPRACyljOu8">Stock-Based Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
had a 2010 Stock Option Plan (the &#8220;2010 Plan&#8221;) under which <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenStockOptionPlanMember_zRifiA3HRJE8" title="Common stock, shares authorized">260,000</span> shares of common stock were authorized for the grant of
stock options or the sale of restricted stock. On August 27, 2018, Oncocyte shareholders approved a new Equity Incentive Plan (the &#8220;2018
Incentive Plan&#8221;) to replace the 2010 Plan. In adopting the 2018 Incentive Plan, Oncocyte terminated the 2010 Plan and will not
grant any additional stock options or sell any stock under restricted stock purchase agreements under the 2010 Plan; however, stock options
issued under the 2010 Plan will continue in effect in accordance with their terms and the terms of the 2010 Plan until the exercise or
expiration of the individual options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2022, the Company awarded executive share-based payment awards under the 2018 Plan to certain executive officers
and employees with time-based, market-based and performance-based vesting conditions (&#8220;2022 equity awards&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of the 2022 equity awards with performance-based vesting condition was estimated using the Black-Scholes option-pricing model
assuming that performance goals will be achieved. If such performance conditions are not met, no compensation cost is recognized and
any recognized compensation cost is reversed. The probability of 2022 equity awards performance-based vesting conditions will be evaluated
each reporting period and the Company will true-up the amount of cumulative cost recognized for the 2022 performance-based awards at
each reporting period based on the most up-to-date probability estimates. The Company will recognize the compensation expense for 2022
performance-based awards expected to vest on a straight-line basis over the respective service period for each separately vesting tranche.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
fair value of the 2022 equity awards with market-based vesting condition was estimated using the Monte Carlo simulation model. Assumptions
and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated
period to achievement of the performance and market conditions, which are subject to the achievement of the market-based goals established
by the Company and the continued employment of the participant. These awards vest only to the extent that the market-based conditions
are satisfied as specified in the vesting conditions. Unlike the performance-based awards, the grant date fair value and associated compensation
cost of the market-based awards reflect the probability of the market condition being achieved, and the Company will recognize this compensation
cost regardless of the actual achievement of the market condition. Assumptions utilized in connection with the Monte Carlo valuation
technique included: estimated risk-free interest rate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zPyhBbWkC0E1" title="Risk-free interest rates">2.0</span> percent; term of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zV8FMPrYlugj" title="Expected life (in years)">2.8</span> years; expected volatility of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zLCKwsPZeEv6" title="Expected Volatility">100</span> percent; and expected
dividend yield of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_z1ALEfkqpaB4" title="Dividend yield">0</span> percent. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues.
The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations
regarding dividend payments. The total grant date fair value of the market-based awards was $<span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_c20230101__20230630__us-gaap--PlanNameAxis__custom--PerformanceBasedOptionsMember_zr7yY7AG4PM7" title="Grant date fair value">117,625</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
May 2022, the Company approved amendments to vesting conditions of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220501__20220531__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndEmployeesMember_zeZmunvDFnRf" title="Share based awards vesting">61,875</span> performance-based and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220501__20220531__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndEmployeesMember_zfLSqOEYlmQi" title="Share based awards vesting">12,500</span> market-based awards of certain
executive officers and employees. The performance-based awards were modified such that the stock awards will be eligible to vest as follows:
(i) <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220501__20220531__dei--LegalEntityAxis__custom--VitaGraftMember_zZTF9LXezoq9">50</span>% will vest on December 31, 2023 if the Company achieves LCD reimbursement for VitaGraft (formerly TheraSure<sup> </sup>Transplant
Monitor) for one organ no later than December 31, 2022 and (ii) <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220501__20220531__dei--LegalEntityAxis__custom--DetermalOMember_zPUwwusTQ5Ij">50</span>% will vest on December 31, 2023 if DetermaIO or DetermaCNI (formerly
TheraSure - CNI Monitor) submission for LCD is completed no later than December 31, 2022. Additional performance-based restricted stock
unit (&#8220;RSU&#8221;) awards were modified to be eligible to vest upon the achievement by <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220501__20220531_z7iY7vXqNkTe" title="Share based payment award description">the Company of average market capitalization
minimum, target, and maximum goals of (i) $300 million; (ii) $400 million; and (iii) $500 million, respectively, during the period beginning
on January 1, 2022 and ending on December 31, 2024</span>. The market-based RSU awards were modified such that the awards will be eligible to
vest upon the achievement of product commercial launch minimum, target, and maximum goals as follows: (i) one laboratory test product in
the US; (ii) two laboratory test products in US, and (iii) three laboratory test products in the US, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
accordance with ASC 718, the Company calculated the fair value of the market-based awards on the date of modification, noting an increase
in the fair value of approximately $<span id="xdx_90B_eus-gaap--IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_c20230101__20230630_zJLiRFx1D9f5" title="Increase in fair value">58,500</span> on the date of modification, with the incremental increase in fair value representing additional
unrecognized stock-based compensation expense. The following assumptions were used in calculating the fair value of the market-based
options on the date of modification:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_znVbihcDDGN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_zbFjVRKNuywk" style="display: none">Schedule
of Assumptions Used to Calculate Fair Value of Stock Options</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; color: Black; text-align: left">Risk-free interest rates</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zS6GXqshyhFl" style="width: 16%; color: Black; text-align: right" title="Risk-free interest rates">2.72</td><td style="width: 1%; color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Expected term (in years)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zScan6519KL9" title="Expected term (in years)">2.6</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Volatility</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zfqfI8JqNsMc" style="color: Black; text-align: right" title="Volatility">95.0</td><td style="color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Grant date fair value of awards granted during the period</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zqwwvt1LEdea" style="color: Black; text-align: right" title="Grant date fair value of awards granted during the period">22.60</td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_z1uHSVncfNq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
July 2022, the Company approved amendments to vesting conditions of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220701__20220731__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndEmployeesMember_zlX8RTBUmRle" title="Share based awards vesting">23,750</span> performance-based awards of certain executive officers and
employees. Certain performance-based awards were modified such that the stock awards will be eligible to vest as follows: (i) fifty percent
(<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20220701__20220731__dei--LegalEntityAxis__custom--VitaGraftMember_zayDBC727wxk" title="Vested percentage">50</span>%) of the options will vest on December 31, 2023 (the &#8220;Vesting Date&#8221;), subject to Continuous Service through the Vesting
Date, if local coverage determination is issued and priced for VitaGraft (Transplant) with respect to one organ no later than December
31, 2022; and (ii) fifty percent (<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220701__20220731__dei--LegalEntityAxis__custom--DetermalOMember_zNaIcQEEHDp8" title="Vested percentage">50</span>%) of the options will vest on the Vesting Date, subject to Continuous Service through the Vesting
Date, if the Company submits a local coverage determination request for DetermaIO or DetermaCNI no later than December 31, 2022. Additional
performance-based stock awards were modified to be eligible to vest upon <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220701__20220731_zTHL6RUiECM1" title="Share based payment award description">the achievement of performance minimum, target, and maximum
goals of (i) 90% of revenue goal; (ii) 100% of revenue goal; and (iii) exceed revenue goal by up to 150%, respectively, during fiscal
year 2022</span>. These same awards contained budget performance goals which were modified to be eligible to vest upon the achievement of performance
minimum, target, and maximum goals of (i) complete fiscal year 2022 with sufficient cash to continue operations for 12 months; (ii) complete
fiscal year 2022 with sufficient cash to continue operations for 15 months; and (iii) complete fiscal year 2022 with sufficient cash
to continue operations for 16 months, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of December 31, 2022, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zC92BXiduMbk" title="Share based payment award description">50</span>% of the performance-based were forfeited since the Company did not achieve LCD reimbursement for VitaGraft.
<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221214__20221216__dei--LegalEntityAxis__custom--DetermaCNIMember_zADgkkHvn5P3" title="Share based payment award vesting rights description">The remaining 50% is eligible to vest on December 31, 2023, since the Company completed the LCD submission for DetermaCNI on December
16, 2022</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2022, the Company accelerated the vesting of certain equity awards in accordance with the 2018 Incentive
Plan after the departure of officers of the Company and the adoption of the workforce reduction plan. Due to the acceleration of such
awards all associated unrecognized compensation was accelerated and recognized in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zUo4G291Qxh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A
summary of Oncocyte&#8217;s 2010 Plan activity and related information follows (in thousands except weighted average exercise price):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B3_zUVPAoU1vP1i" style="display: none">Summary
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 75%; margin-left: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Shares</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Number</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Weighted</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Available</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">of Options</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Average</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold">Options</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">for Grant</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; color: Black">Balance at December 31, 2022</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_z3bPk7Z2hlC3" style="width: 14%; color: Black; text-align: right" title="Shares available for grant options, beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zFOGPbH0leT7" style="width: 12%; color: Black; text-align: right" title="Number of options outstanding, beginning of period">30</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zADSJFwO0K48" style="width: 16%; color: Black; text-align: right" title="Weighted average exercise price, options outstanding, beginning of period">80.78</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Options exercised</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zqOvjuGnwdt6" style="color: Black; text-align: right" title="Shares available for grant options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1406">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zjUVWaMiQIF5" style="color: Black; text-align: right" title="Number of options outstanding, option exercised"><span style="-sec-ix-hidden: xdx2ixbrl1408">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zhTpksbXooPj" style="color: Black; text-align: right" title="Weighted average exercise price, options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1410">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Options forfeited, cancelled and expired</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zM59qaMLhB44" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Shares available for grant options forfeited, cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1412">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zv8eGHd0dz36" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, options forfeited, cancelled and expired">(1</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zJLp9a92ow0b" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, options forfeited, cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1416">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; padding-bottom: 2.5pt">Balance at June 30, 2023</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zeAulXHuE4Wk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Shares available for grant outstanding, end of period"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zdkmWa1lVQB7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, end of period">29</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zoLDCyCZx97e" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price, outstanding end of period">80.58</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 1.5pt">Exercisable at June 30, 2023</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_z9qBjbwvr848" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, exercisable, end of period">29</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zy6hs1gHwlV8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercisable, end of period">80.58</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z67g7wUSLcXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenIncentivePlanMember_zIDoKr6cCvIl" title="Common stock, shares authorized">1,050,000</span> shares of common stock were reserved under the 2018 Incentive Plan for the grant of stock options or the
sale of restricted stock or for the settlement of RSUs. Oncocyte may also grant stock appreciation rights under the 2018 Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z5LNGTnwPm19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A
summary of Oncocyte&#8217;s 2018 Incentive Plan activity and related information follows (in thousands except weighted average exercise
price):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B8_z1p5ZtaNnrsl" style="display: none">Summary
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Shares</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Number</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Number</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Weighted</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Available</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">of Options</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">of RSUs</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Average</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">for Grant</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Outstanding</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Outstanding</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Exercise Price</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black">Balance at December 31, 2022</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zWpYo9KcyF76" style="width: 11%; color: Black; text-align: right" title="Shares available for grant options, beginning of period">442</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zZpp1RzLqs2f" style="width: 11%; color: Black; text-align: right" title="Number of options outstanding, beginning of period">428</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z3AMQbzxUvv7" style="width: 8%; color: Black; text-align: right" title="Number of RSUs Outstanding, beginning of period">22</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zXNv18lN5Ei6" style="width: 14%; color: Black; text-align: right" title="Weighted average exercise price, options outstanding, beginning of period">59.23</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">RSUs vested</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zYb3QJGBQePf" style="color: Black; text-align: right" title="Shares available for grant options RSUs vested"><span style="-sec-ix-hidden: xdx2ixbrl1440">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zbAJWodSEFh8" style="color: Black; text-align: right" title="Number of options outstanding, option RSUs vested"><span style="-sec-ix-hidden: xdx2ixbrl1442">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zkdiDQKHUL8k" style="color: Black; text-align: right" title="Number of RSUs Outstanding, option RSUs vested">(11</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zJ6XNesZvlwd" style="color: Black; text-align: right" title="Weighted average exercise price, options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1446">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">RSUs granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zbYCBYIRLTL8" style="color: Black; text-align: right" title="Shares available for grant options RSUs granted">(10</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zuWhw0y11dIa" style="color: Black; text-align: right" title="Number of options outstanding, option RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1450">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zLrAvC8ibjQ7" style="color: Black; text-align: right" title="Number of RSUs Outstanding, option RSUs granted">5</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zM3rSyS54Dbh" style="color: Black; text-align: right" title="Weighted average exercise price, option RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1454">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Options granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z2ZDnY6hiFm7" style="color: Black; text-align: right" title="Shares available for grant options granted">(178</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z8lyqrBOxt6c" style="color: Black; text-align: right" title="Number of options outstanding, option granted">178</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zSWQasQEY5H9" style="color: Black; text-align: right" title="Number of RSUs Outstanding, option granted"><span style="-sec-ix-hidden: xdx2ixbrl1460">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zc2i2Yt6Wre8" style="color: Black; text-align: right" title="Weighted average exercise price, option granted">7.72</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Options forfeited/cancelled</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z88uUJWhN4Ze" style="color: Black; text-align: right" title="Shares available for grant options forfeited, cancelled and expired">150</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zxTQetor3MVa" style="color: Black; text-align: right" title="Number of options outstanding, options forfeited, cancelled and expired">(150</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z6iEOpEvAp2h" style="color: Black; text-align: right" title="Number of RSUs Outstanding, options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1468">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zjfFUTP8YKsj" style="color: Black; text-align: right" title="Weighted average exercise price, options forfeited, cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1470">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">RSUs forfeited/cancelled</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zSFd1P701Tf3" style="color: Black; text-align: right" title="Shares available for grant RSUs, cancelled and expired">2</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zOIAXOfygFyh" style="color: Black; text-align: right" title="Number of options outstanding, options forfeited, RSUs cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1474">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zynL5Qcb5eJ5" style="color: Black; text-align: right" title="Number of RSUs Outstanding, options forfeited, canceled and expired">(1</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zry2kFdeHEq7" style="color: Black; text-align: right" title="Weighted average exercise price, options forfeited, RSUs cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1478">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Performance RSUs forfeited/cancelled</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zq93vvRHWQr2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Shares available for grant performance RSUs, cancelled and expired">15</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zb3PM74cW644" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, options forfeited, performance RSUs cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1482">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zcD410D3Owf5" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Performance RSUs Outstanding, options forfeited, canceled and expired">(8</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zXdTYCrQ4ho3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, options forfeited, performance RSUs cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1486">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Balance at June 30, 2023</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zBE452ssKTMk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Shares available for grant outstanding, end of period">421</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zb1bjooPGIp6" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, end of period">456</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zOqu6EdR1Py3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of RSUs Outstanding, end of period">7</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z58qbI1LVeLj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price, outstanding end of period">38.33</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Options exercisable at June 30, 2023</td><td style="color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zQPjFDJSbtw5" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, exercisable, end of period">199</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zIOpWwt77GY4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercisable, end of period">89.54</td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zXqrjqkuAcmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zumb57BYa663" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations
for the three and six months ended June 30, 2023 and 2022 (unaudited and in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B8_zjSkLQRZWvOg" style="display: none">Summary
of Stock-based Compensation Expense</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230401__20230630_z4wQRtx3Fgn1" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220401__20220630_zumjx50dv8Ik" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230630_zpEcUDfgDAqf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20220630_z10e4bZGfdug" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Three Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfRevenuesMember_zCkPYa49noYi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black">Cost of revenues</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 11%; color: Black; text-align: right">2</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 11%; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 11%; color: Black; text-align: right">12</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 11%; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1505">-</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpey2jkfKDj8" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Research and development</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">309</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">201</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">632</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">381</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zoISYlpmpp86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Sales and marketing</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">62</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1513">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">139</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">29</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zBWFQgwYRVy6" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">General and administrative</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">461</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">1,283</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">867</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">2,463</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--DiscontinuedOperationsMember_zT9Otyru4NB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Discontinuing operations</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1522">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">748</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">18</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">1,369</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zEDH6FLrnMz6" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">834</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">2,232</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">1,668</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">4,242</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zLds1KQEk77a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zQGSpIbAmENg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
assumptions that were used to calculate the grant date fair value of Oncocyte&#8217;s employee and non-employee stock option grants for
the six months ended June 30, 2023 and 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z4UZFSnKmyK7" style="display: none">Schedule
of Assumptions Used to Calculate Fair Value of Stock Options</span><span style="color: Black">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 60%; margin-left: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; color: Black; text-align: left">Expected life (in years)</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630_zeUtM678C3X5" title="Expected life (in years)">6.25</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630_zFHUw2fgj3Zf" title="Expected life (in years)">6.01</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Risk-free interest rates</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630_zm4Uj6iHd28e" style="color: Black; text-align: right" title="Risk-free interest rates">3.76</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630_zVCdVzMVxWr7" style="color: Black; text-align: right" title="Risk-free interest rates">2.24</td><td style="color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Volatility</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630_z80XuOQGEzJ4" style="color: Black; text-align: right" title="Volatility">105.99</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630_zZREqp28xlml" style="color: Black; text-align: right" title="Volatility">106.98</td><td style="color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Dividend yield</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230101__20230630_z0ANCgUDMkf7" title="Dividend yield">0</span></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d0_c20220101__20220630_zQb5GWKZB7Uk" title="Dividend yield">0</span></td><td style="color: Black; text-align: left">%</td></tr>
  </table>


<p id="xdx_8A5_zlmvJy65BHZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and
assumptions requiring the use of judgment. If Oncocyte had made different assumptions, its stock-based compensation expense and net loss
for the three and six months ended June 30, 2023, and 2022 may have been significantly different.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified
disposition has occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871826910304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregation of Revenues and Concentration Risk<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Disaggregation of Revenues and Concentration Risk</a></td>
<td class="text"><p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_z6chgspCk2Pb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>7.
<span id="xdx_82D_zTvKItJCUZbj">Disaggregation of Revenues and Concentration Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zqy0QgGJbp92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents the percentage of consolidated revenues generated by unaffiliated customers that individually represent greater
than ten percent of consolidated revenues:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z3jVQvNEEGnl" style="display: none">Schedule
of Consolidated Revenues Generated by Unaffiliated Customers</span><span style="color: Black">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Three Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black; text-align: left">Pharma services - Company A</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zxfp3alJLkY2" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage">68</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zJCpZ7jkoO6h" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span id="xdx_F2F_z7vMN5d4eRS3" style="color: Black">*</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zlLKyU3olChk" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage">27</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zdjux8jRKO21" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">-</span><span id="xdx_F20_zGRwEbtdpCja">*</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Pharma services - Company B</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zElYATED5ts8" style="color: Black; text-align: right" title="Concentration risk, percentage"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span id="xdx_F25_zyjuziASFAL3" style="color: Black">*</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____z79HgCpzdRdj" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1564">-</span></span></span><span id="xdx_F2F_zu6qsSTvG9V7" style="color: Black">*</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z8V8EfpYmt53" style="color: Black; text-align: right" title="Concentration risk, percentage">14</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zuO8xPUMUUCh" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1568">-</span></span></span><span id="xdx_F2A_zTHi7s59lrpk">*</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Discontinuing operations</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____z9kJz2RKVz3h" style="color: Black; text-align: right" title="Concentration risk, percentage"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span id="xdx_F2C_zqqmO4eaVu6a" style="color: Black">*</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zzpR3hpLL0fd" style="color: Black; text-align: right" title="Concentration risk, percentage">89</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_ztNbN4TIqCR6" style="color: Black; text-align: right" title="Concentration risk, percentage">38</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z1s74MtfTMa7" style="color: Black; text-align: right" title="Concentration risk, percentage">82</td><td style="color: Black; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F02_zNlR4QJccOi" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i id="xdx_F14_z8ncoxfAiM4c">Less
    than 10%</i></span></td></tr>
  </table>
<p id="xdx_8AF_zEayKbcQkpRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_89B_ecustom--ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock_z2uDC0RRZNUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents the percentage of consolidated revenues by products or services classes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_z2Hu4PVXQd88" style="display: none">Schedule
of Consolidated Revenues Attributable to Products or Services</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; color: Black">&#160;</td><td style="text-align: center; color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Three Months Ended</td><td style="text-align: center; color: Black; font-weight: bold">&#160;</td><td style="text-align: center; color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="text-align: center; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; color: Black">&#160;</td><td style="text-align: center; color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="text-align: center; color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black; text-align: left">Pharma Services</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9Xjrdg7WES3" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage">94</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zvZ9H0lKKCqe" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage">11</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmc4BTMqLoLd" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage">62</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zzN1D0DgLeBa" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage">18</td><td style="width: 1%; color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">DetermaRx&#8482;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zTYfckakGv1e" style="color: Black; text-align: right" title="Concentration risk, percentage">6</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zEqjMu4engE6" style="color: Black; text-align: right" title="Concentration risk, percentage">0</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zJh79XNBWHk8" style="color: Black; text-align: right" title="Concentration risk, percentage">3</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zZ6NDbOs1tHa" style="color: Black; text-align: right" title="Concentration risk, percentage">0</td><td style="color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Discontinuing operations</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zrPabShcwCIl" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage">0</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zThxy0Kpeh4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage">89</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHggRznVbJZ1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage">35</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmfTXAdFMYzg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage">82</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zan6Cbz7T2pc" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zExgskS5WBt4" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHHBSHiQqXQ3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHsgQISwGKG2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AE_z0kS2WzHsYj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zfyWsQxLnOp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents the percentage of consolidated revenues attributable to geographical locations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B4_z0uLsoGhqduh" style="display: none">Schedule
of Percentage of Consolidated Revenues Attributable to Geographical Locations</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20230630_zdDOIsZiUdE8" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220401__20220630_zdI6I9JfrP6h" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230630_z6XgtebHtHSc" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20220630_zh59t8KWLAvf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Three Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zip8EzMyc6vj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black; text-align: left">United States &#8211; Pharma Services</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 11%; color: Black; text-align: right">74</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 11%; color: Black; text-align: right">50</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 11%; color: Black; text-align: right">39</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 11%; color: Black; text-align: right">65</td><td style="width: 1%; color: Black; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--OutsideUnitedStatesPharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zBgnqatcKvq1" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Outside of the United States &#8211; Pharma Services</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">20</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">2</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">23</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">5</td><td style="color: Black; text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zbOL5HCtHxZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">DetermaRx&#8482;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">6</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">0</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">3</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">0</td><td style="color: Black; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DiscontinuedOperationsOutsideUnitedStatesLicensingMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zW4KqOI5Va0b" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Discontinuing operations &#8211; Outside of the United States &#8211; Licensing</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">0</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">48</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">0</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">30</td><td style="color: Black; text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zS9pnQ5RHtt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Discontinuing operations &#8211; United States &#8211; DetermaRx&#8482;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">0</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">0</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">35</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">0</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zyh8OVaiiftb" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AC_zRFBErKJTnfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871914430160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_z7AEZ80Y4uBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>8.
<span id="xdx_82C_zPrpK9h5Mrwa">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270,
<i>Income Taxes, Interim Reporting</i>. The effective tax rate may be subject to fluctuations during the year as new information is obtained,
which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against
deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or
the interpretation of tax laws in jurisdictions where Oncocyte conducts business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
did not record any provision or benefit for income taxes for the six months ended June 30, 2023 and 2022, as Oncocyte had a full valuation
allowance for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A
valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Oncocyte
established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net
operating loss carry-forwards and other deferred tax assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871824192960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets, machinery and equipment, net, and construction in progress<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Right-of-use assets, machinery and equipment, net, and construction in progress</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zlI40JiDP3m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>9.
<span id="xdx_82F_z0gDgBo9MBVb">Right-of-use assets, machinery and equipment, net, and construction in progress</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zvPDTIkyIMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023 and December 31, 2022, right-of-use assets, machinery and equipment, net, and construction in progress were as follows
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_z0BVyoOH8m5b" style="display: none">Schedule
of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230630_zUpRJVoNE2Lg" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30, 2023<br/> (unaudited)</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zuM7ETkm63H3" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_z5jNeFxA5Ht5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20230630_zIG0BrdyttC9" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230630%23MachineryAndEquipmentNetAndConstructionInProgress"><span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20221231_z6b6xO9VJ40a" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230630%23MachineryAndEquipmentNetAndConstructionInProgress"><span style="-sec-ix-hidden: xdx2ixbrl1653"><span style="-sec-ix-hidden: xdx2ixbrl1654">Right-of-use assets</span></span></span></span> <sup id="xdx_F40_zN6xqg4WcXQc">(1)</sup></span></td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right">4,036</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right">3,499</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_zQRBYqk1aqEl" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Machinery and equipment</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">8,644</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">9,408</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_zwtKrC6CA9ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(5,310</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(4,196</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_z0d4N7kgAzAd" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Right-of-use assets, machinery and equipment, net</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">7,370</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">8,711</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ConstructionInProgressGross_iI_pn3n3_zMVwAzmE96Bf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">518</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">2,140</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RightofuseAssetsMachineryAndEquipmentContinuingOperations_iI_pn3n3_ztd6090Il5Mk" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Right-of-use assets, machinery and equipment, net, and construction in progress</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">7,888</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">10,851</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations_iI_pn3n3_zuglr7g44059" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Right-of-use assets, machinery and equipment, net, and construction in progress from discontinuing operations</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1671">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">211</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RightofuseAssetsMachineryAndEquipmentNet_iI_pn3n3_zGONvbakKhIe" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Right-of-use assets, machinery and equipment, net, and construction in progress</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">7,888</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">11,062</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F05_z31mCAvn6Jb4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zmttJPpFz7y8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
    recorded certain right-of-use assets and liabilities for operating leases in accordance with ASC 842 (see Note 10).</span></td></tr>
  </table>
<p id="xdx_8A0_zbULD6GkgIkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Depreciation
expense amounted to $<span id="xdx_90E_eus-gaap--DepreciationAndAmortization_c20230401__20230630_zinxV2FPFZVd" title="Depreciation expense">435,000</span> and $<span id="xdx_907_eus-gaap--DepreciationAndAmortization_c20220401__20220630_zFRCuEwx0HL3" title="Depreciation expense">384,000</span> for the three months ended June 30, 2023 and 2022, respectively, and $<span id="xdx_904_eus-gaap--DepreciationAndAmortization_c20230101__20230630_zUnvH1sL4YDd" title="Depreciation expense">885,000</span> and $<span id="xdx_905_eus-gaap--DepreciationAndAmortization_c20220101__20220630_zq7x7D4Uga01" title="Depreciation expense">671,000</span>
for the six months ended June 30, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871828375648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zNVv5lHb1z2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>10.
<span id="xdx_82D_zZqPae8kp7b8">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
has certain commitments other than discussed in Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Office
Lease Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
December 23, 2019, Oncocyte entered into an Office Lease Agreement (the &#8220;Irvine Lease&#8221;) of a building containing approximately
<span id="xdx_90B_eus-gaap--AreaOfLand_iI_usqft_c20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_ziN80D2S9sK8" title="Area of Land">26,800</span> square feet of rentable space located at 15 Cushing in Irvine, California (the &#8220;Premises&#8221;) that will serve as Oncocyte&#8217;s
new principal executive and administrative offices and laboratory facility. Oncocyte completed the relocation of its offices to the Premises
in January 2020 and subsequently constructed a laboratory at the Irvine facility to perform cancer diagnostic tests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Irvine Lease has an initial term of 89 calendar months (the &#8220;Term&#8221;), which commenced on June 1, 2020 (the &#8220;Commencement
Date&#8221;). Oncocyte has an option to extend the Term for a period of five years (the &#8220;Extended Term&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
agreed to pay base monthly rent in the amount of $<span id="xdx_904_eus-gaap--PaymentsForRent_c20191222__20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zYJA6vXGAFEe" title="Payments for rent">61,640</span> during the first 12 months of the Term. Base monthly rent increases annually,
over the base monthly rent then in effect, by <span id="xdx_90E_ecustom--CapitalLeaseAgreementImputedAnnualInterestRate_pid_dp_uPure_c20191222__20191223__srt--StatementScenarioAxis__custom--MonthlyRentMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zyODDrbEVAub" title="Interest rate on lease agreement">3.5</span>%. Oncocyte was entitled to an abatement of <span id="xdx_905_ecustom--CapitalLeaseAgreementImputedAnnualInterestRate_pid_dp_uPure_c20191222__20191223__srt--StatementScenarioAxis__custom--FirstTenCalendarMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_z5kdl1ffgeic" title="Interest rate on lease agreement">50</span>% of the base monthly rent during the
first ten calendar months of the Term. If the Irvine Lease is terminated based on the occurrence of an &#8220;event of default,&#8221;
Oncocyte will be obligated to pay the abated rent to the lessor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
Oncocyte exercises its option to extend the Term, the initial base monthly rent during the Extended Term will be the greater of the base
monthly rent in effect during the last year of the Term or the prevailing market rate. The prevailing market rate will be determined
based on annual rental rates per square foot for comparable space in the area where the Premises are located. If Oncocyte does not agree
with the prevailing market rate proposed by the lessor, the rate may be determined through an appraisal process. The base monthly rent
during the Extended Term shall be subject to the same annual rent adjustment as applicable for base monthly rent during the Term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
addition to base monthly rent, Oncocyte agreed to pay in monthly installments (a) all costs and expenses, other than certain excluded expenses,
incurred by the lessor in each calendar year in connection with operating, maintaining, repairing (including replacements if repairs
are not feasible or would not be effective) and managing the Premises and the building in which the Premises are located (&#8220;Expenses&#8221;),
and (b) all real estate taxes and assessments on the Premises and the building in which the Premises are located, all personal property
taxes for property that is owned by lessor and used in connection with the operation, maintenance and repair of the Premises, and costs
and fees incurred in connection with seeking reductions in such tax liabilities (&#8220;Taxes&#8221;). Subject to certain exceptions,
Expenses shall not be increased by more than 4% annually on a cumulative, compounded basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
was entitled to an abatement of its obligations to pay Expenses and Taxes while constructing improvements to the Premises constituting
&#8220;Tenant&#8217;s Work&#8221; under the Irvine Lease prior to the Commencement Date, except that Oncocyte was obligated to pay <span id="xdx_905_ecustom--ObligatedToPayExpensesAndTaxesPercentage_pid_dp_uPure_c20191222__20191223__srt--StatementScenarioAxis__custom--MonthlyRentMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_z4B2cdxoccS8" title="Obligated to pay expenses and taxes percentage">43.7</span>%
of Expenses and Taxes during the period prior to the Commencement Date for its use of the second floor of the Premises, which was already
built out as office space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
lessor provided Oncocyte with a &#8220;Tenant Improvement Allowance&#8221; in the amount of $<span id="xdx_905_eus-gaap--PaymentsForProceedsFromTenantAllowance_pn5n6_c20191222__20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zo841TY6aBSe" title="Payments for (Proceeds from) Tenant Allowance">1.3</span> million to pay for the plan, design,
permitting, and construction of the improvements constituting Tenant&#8217;s Work. The lessor retained <span id="xdx_908_ecustom--PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment_pid_dp_uPure_c20191222__20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zKZSftwiIE15" title="Percentage of administrative fee paid on original cost of equipment">1.5</span>% of the Tenant Improvement
Allowance as an administrative fee as provided in the Irvine Lease. As of June 30, 2023, the lessor had provided $<span id="xdx_903_eus-gaap--PaymentsForProceedsFromTenantAllowance_pn5n6_c20230101__20230630__srt--TitleOfIndividualAxis__custom--LandlordMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_z6ZKTr3IFFd3" title="Total tenant improvement allowance">1.3</span> million of the
total Tenant Improvement Allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
has provided the lessor with a security deposit in the amount of $<span id="xdx_905_eus-gaap--SecurityDeposit_iI_c20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zM9p05LQ7st8" title="Security Deposit">150,000</span> and a letter of credit in the amount of $<span id="xdx_90D_eus-gaap--LinesOfCreditCurrent_iI_pn5n6_c20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zMUZco8xWw55" title="Line of Credit, Current">1.7</span> million. The lessor
may apply the security deposit, in whole or in part, for the payment of rent and any other amount that Oncocyte is or becomes obligated
to pay under the Irvine Lease but fails to pay when due and beyond any cure period. The lessor may draw on the letter of credit from
time to time to pay any amount that is unpaid and due, or if the original issuing bank notifies the lessor that the letter of credit
will not be renewed or extended for the period required under the Irvine Lease and Oncocyte fails to timely provide a replacement letter
of credit, or an event of default under the Irvine Lease occurs and continues beyond the applicable cure period, or if certain insolvency
or bankruptcy or insolvency with respect to Oncocyte occur. Oncocyte is required to restore any portion of the security deposit that
is applied by the lessor to payments due under the Irvine Lease, and Oncocyte is required to restore the amount available under the letter
of credit to the required amount if any portion of the letter of credit is drawn by the lessor. The Irvine Lease provides that commencing on the 34th month of the Term,
(a) the amount of the letter of credit that Oncocyte is required to maintain shall be reduced on a monthly basis, in equal installments,
to amortize the required amount to zero at the end of the Term, and (b) Oncocyte has the right to cancel the letter of credit at
any time if it meets certain market capitalization and balance sheets thresholds; provided, in each case, that Oncocyte is not in then
default under the Irvine Lease beyond any applicable notice and cure period and the lessor has not determined that an event exists that
would lead to an event of default.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">To
obtain the letter of credit, Oncocyte has provided the issuing bank with a restricted cash deposit that the bank will hold to cover its
obligation to pay any draws on the letter of credit by the lessor. The restricted cash may not be used for any other purpose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
August 27, 2021, Oncocyte entered into a lease agreement to add an additional suite to its Nashville office space, containing approximately
<span id="xdx_90A_eus-gaap--AreaOfLand_iI_usqft_c20210827__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zeqqu9W28Cc" title="Area of Land">1,928</span> square feet of rentable space located at 2 International Plaza, Suite 103, Nashville TN. The term of the lease commences on October
1, 2021 and extends through April 9, 2024 and will serve as additional office space for Insight&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Irvine Lease is an operating lease under ASC 842 included in the tables below. The tables below provide the amounts recorded in connection
with the application of ASC 842 as of, and during, the six months ended June 30, 2023, for Oncocyte&#8217;s operating and financing leases
(see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On December 31, 2019, in connection with Oncocyte&#8217;s purchase <span style="background-color: white">of&#160;<span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20191231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zbOoKPL2yEgh" title="Outstanding equity">25</span>%
of the outstanding equity of Razor,</span> Oncocyte entered into a Laboratory Services Agreement with Razor and Encore Clinical, Inc.
(&#8220;Encore&#8221;), a former stockholder of Razor (the &#8220;Laboratory Agreement&#8221;). Under
the Laboratory Agreement (which expired on September 29, 2021), Oncocyte assumed all of Razor&#8217;s Laboratory
Agreement payment obligations. Although Oncocyte is not a party to any lease agreement with Razor or Encore, under the terms of the Laboratory
Agreement, Oncocyte received the landlord&#8217;s consent for the use of the laboratory at Razor&#8217;s Brisbane, California location
(the &#8220;Brisbane Facility&#8221;) under the terms of a sublease to which Encore is the sublessee. The sublease expired on March 31,
2023 (the &#8220;Brisbane Lease&#8221;). The laboratory fee payments to Encore include both laboratory services and the use of the Brisbane
Facility. Under the provisions of the Laboratory Agreement, if Oncocyte terminates the Laboratory Agreement prior to the expiration of
the Brisbane Lease, Oncocyte shall assume the costs related to the subletting or early termination of the Brisbane Lease. The Laboratory
Agreement terminated on March 31, 2023. Oncocyte determined that the Laboratory Agreement contains an embedded operating lease for the
Brisbane Facility and Oncocyte allocated the aggregate payments to this lease component for purposes of calculating the net present value
of the right-of-use asset and liability as of the inception of the Laboratory Agreement in accordance with ASC 842, as shown in the table
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Financing
lease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023, Oncocyte has one financing lease remaining through December 2023 for certain laboratory equipment with aggregate remaining
payments of $<span id="xdx_900_ecustom--PaymentObligationAmount_iI_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zHOBNw9OAqJc" title="Payment obligation amount.">62,000</span> shown in the table below. Oncocyte&#8217;s lease obligations are collateralized by the equipment financed under the
lease schedule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Operating
and Financing leases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_890_ecustom--ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock_zoU8xW86RGY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents supplemental cash flow information related to operating and financing leases for the six months ended June 30,
2023 and 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_zyuipxi6fFNe" style="display: none">Schedule
of Supplemental Cash Flow Information Related to Operating and Financing Lease</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20230630_zrziQ1NGvGJ7" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20220630_z7DsbwjOiTcd" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left">Cash paid for amounts included in the measurement of financing lease liabilities:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zk6EhQKz8Lp1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; color: Black; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">538</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">564</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zNUwHdSkQLlg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Operating cash flows from financing leases</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">5</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">12</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_zp4CfHoNVK93" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Financing cash flows from financing leases</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">57</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">51</p></td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zZQtCPQOCSYd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_894_ecustom--ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock_zRGLBGVydjE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents supplemental balance sheets information related to operating and financing leases as of June 30, 2023 and June
30, 2022 (in thousands, except lease term and discount rate):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span id="xdx_8BD_zPcrYALQFgAk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Schedule
of Supplemental Balance Sheet Information Related to Operating and Financing Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zC8bf6TbF4Uk" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zw782dUt37jf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left">Operating lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zdS95JagOMV5" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; color: Black; text-align: left; padding-bottom: 1.5pt">Right-of-use assets, net</td><td style="width: 2%; color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right">1,855</td><td style="width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right">2,343</td><td style="width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zWsyf8iLJFS7" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Right-of-use lease liabilities, current</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">677</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">728</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zOPDzbD2GxH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Right-of-use lease liabilities, noncurrent</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">2,398</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">3,075</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_z73ADENYoPJ2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Total operating lease liabilities</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">3,075</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">3,803</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold; text-align: left">Financing lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Machinery and equipment</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">536</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">537</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iNI_pn3n3_di_zNTJmeu4eYrf" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(500</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(391</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseRightOfUseAsset_iTI_pn3n3_zE52rflxHsU5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Machinery and equipment, net</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">36</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">146</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_zvxSbovxTIBc" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Current liabilities</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">60</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">110</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_zj1n66HYwRh8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Noncurrent liabilities</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1751">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">60</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_zkWZXDTZAsK3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Total financing lease liabilities</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">60</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">170</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold">Weighted average remaining lease term</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Operating lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zgYHD3sS8Vi7" title="Weighted average remaining lease term, Operating lease">4.1</span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zZ2Y4YZTjPs1" title="Weighted average remaining lease term, Operating lease">4.9 </span>years</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Financing lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_z2Dj1XQz6bNi" title="Weighted average remaining lease term, Financing lease">0.5</span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zAoDhPfBHfBd" title="Weighted average remaining lease term, Financing lease">1.5</span> years</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Weighted average discount rate</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_z8p3245Ffea1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Operating lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">11.28</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">11.20</td><td style="color: Black; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_z7JXatNuyIo2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Financing lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">11.55</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">11.55</td><td style="color: Black; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A9_zDIFOGO3x0pj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p id="xdx_891_ecustom--ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock_zB3YPOSoONha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Future
minimum lease commitments are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zguNJzI8MRc2" style="display: none">Schedule of Future Minimum Lease Commitments for Operating and Financing Leases</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 75%; margin-left: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Operating</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Financing</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Leases</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Leases</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold">Year Ending December 31,</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; color: Black; text-align: left">2023</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zriheRiF3Ar7" style="width: 14%; color: Black; text-align: right" title="2023">510</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zk4J6fj1OAoe" style="width: 14%; color: Black; text-align: right" title="2023">62</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">2024</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zLm8IT4JXrZ7" style="color: Black; text-align: right" title="2024">903</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zl6gGSFeX7Ff" style="color: Black; text-align: right" title="2024"><span style="-sec-ix-hidden: xdx2ixbrl1779">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">2025</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zZH0wxnUymN3" style="color: Black; text-align: right" title="2025">869</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zjb7BBgNdOG5" style="color: Black; text-align: right" title="2025"><span style="-sec-ix-hidden: xdx2ixbrl1783">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">2026</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zT3Liqw1f3Gl" style="color: Black; text-align: right" title="2026">899</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zgaX8I51rNqg" style="color: Black; text-align: right" title="2025"><span style="-sec-ix-hidden: xdx2ixbrl1787">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">2027</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zjYefaNdgpl7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="2027">695</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pdn3_c20230630_zy7DLtobbh96" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="2026"><span style="-sec-ix-hidden: xdx2ixbrl1791">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Total minimum lease payments</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zk776WVUaCAd" style="color: Black; text-align: right" title="Total minimum lease payments">3,876</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zXrlp9B8YUU5" style="color: Black; text-align: right" title="Total minimum lease payments">62</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Less amounts representing interest</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20230630_z4N4SumEecal" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Less amounts representing interest">(801</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20230630_zqvhCVW531H3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Less amounts representing interest">(2</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Present value of net minimum lease payments</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_985_ecustom--PresentValueOfNetMinimumLeasePayments_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zJHJcUKQCTb" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Present value of net minimum lease payments">3,075</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_c20230630_z4EJo3AOkYn2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Present value of net minimum lease payments">60</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zKjMvDu5xRzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Litigation
&#8211; General</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
may be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business
transactions, employee-related matters, and other matters. When Oncocyte is aware of a claim or potential claim, it assesses the likelihood
of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, Oncocyte will
record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, Oncocyte discloses
the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Tax
Filings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments
of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes Oncocyte
has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could
be significantly different than the amounts recorded in the unaudited condensed consolidated interim financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Employment
Contracts</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
has entered into employment and severance benefit contracts with certain executive officers. Under the provisions of the contracts, Oncocyte
may be required to incur severance obligations for matters relating to changes in control, as defined, and certain terminations of executives.
As of June 30, 2023, Oncocyte accrued approximately $<span id="xdx_90E_eus-gaap--SeveranceCosts1_pn5n6_c20230101__20230630__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zgDoVsDPXsuh" title="Severance costs">3.1</span> million in severance obligations for certain executive officers, in accordance
with the severance benefit provisions of their respective employment and severance benefit agreements, primarily related to Oncocyte&#8217;s
acquisition of Chronix in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
the normal course of business, Oncocyte may provide indemnification of varying scope under Oncocyte&#8217;s agreements with other
companies or consultants, typically Oncocyte&#8217;s clinical research organizations, investigators, clinical sites, suppliers and
others. Pursuant to these agreements, Oncocyte will generally agree to indemnify, hold harmless, and reimburse the indemnified
parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection
with the use or testing of Oncocyte&#8217;s diagnostic tests. Indemnification provisions could also cover third party infringement
claims with respect to patent rights, copyrights, or other intellectual property pertaining to Oncocyte&#8217;s diagnostic tests.
Oncocyte&#8217;s office and laboratory facility leases also will generally contain indemnification obligations, including
obligations for indemnification of the lessor for environmental law matters and injuries to persons or property of others, arising
from Oncocyte&#8217;s use or occupancy of the leased property. The term of these indemnification agreements will generally continue
in effect after the termination or expiration of the particular research, development, services, lease, or license agreement to
which they relate. The Razor Stock Purchase Agreement also contains provisions under which Oncocyte has agreed to indemnify Razor
and Encore from losses and expenses resulting from breaches or inaccuracy of Oncocyte&#8217;s representations and warranties and
breaches or nonfulfillment of Oncocyte&#8217;s covenants, agreements, and obligations under the Razor Stock Purchase Agreement.
Oncocyte periodically enters into underwriting and securities sales agreements with broker-dealers in connection with the offer and
sale of Oncocyte securities. The terms of those underwriting and securities sales agreements include indemnification provisions
pursuant to which Oncocyte agrees to indemnify the broker-dealers from certain liabilities, including liabilities arising under the
Securities Act, in connection with the offer and sale of Oncocyte securities. The potential future payments Oncocyte could be
required to make under these indemnification agreements will generally not be subject to any specified maximum amounts.
Historically, Oncocyte has not been subject to any claims or demands for indemnification. Oncocyte also maintains various liability
insurance policies that limit Oncocyte&#8217;s financial exposure. As a result, Oncocyte management believes that the fair value of
these indemnification agreements is minimal. Accordingly, Oncocyte has not recorded any liabilities for these agreements as of June
30, 2023 and December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871824192960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Workforce Reduction<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DisclosureWorkforceReductionAbstract', window );"><strong>Workforce Reduction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_WorkforceReductionTextBlock', window );">Workforce Reduction</a></td>
<td class="text"><p id="xdx_805_ecustom--WorkforceReductionTextBlock_z0ZbrsvAieTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>11.
<span id="xdx_826_zJtUJox1dgxl">Workforce Reduction</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
August 2022, the Company initiated a workforce reduction plan to strategically realign its operations and implement cost reduction programs
to prioritize near term revenue generators and to manage and preserve cash. In connection with the reduction, the Company eliminated
14 positions, implemented tighter expense controls, and ceased non-core activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Further,
on December 16, 2022, Oncocyte initiated an additional reduction in work force involving over 40% of its full-time employees. The transition
began on December 16, 2022 and was completed in February 2023. As of December 31, 2022, the Company incurred an aggregate of $<span id="xdx_90D_eus-gaap--SeveranceCosts1_pn5n6_c20220101__20221231_zxqyAalFq5L6" title="Employee severance">1.9</span> million
related to employee severance and benefits costs in connection with its reductions in force during fiscal year 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 12, 2023, Oncocyte announced a reduction in force involving approximately 20% of its workforce (the &#8220;April 2023 Reduction&#8221;),
which management believes will extend Oncocyte&#8217;s cash runway into 2024. In connection with the April 2023 Reduction, we incurred
approximately $<span id="xdx_90A_eus-gaap--SeveranceCosts1_pn5n6_c20230401__20230630_z2zdQJ5iBoj" title="Employee severance">0.3</span> million related to employee severance and benefits costs during the second quarter of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DisclosureWorkforceReductionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DisclosureWorkforceReductionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_WorkforceReductionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Workforce reduction [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_WorkforceReductionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871826906784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zHEsm1tJBM8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>12.
<span id="xdx_820_zZjc3SqBJq3c">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Financing
Transactions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 13, 2022, Oncocyte entered into the Securities Purchase Agreement with the Investors, including Broadwood<span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and John Peter Gutfreund, a former director of Oncocyte, for
the Series A Preferred Stock Offering. Each of Broadwood and Mr. Gutfreund has a direct material interest in the Series A Preferred Stock
Offering and agreed to purchase <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp2d_c20220412__20220412__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zlqiyxSHG4Ve" title="Offering shares">5,882.35</span> and <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp2d_c20220413__20220413__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zALKRSt9jAKb" title="Offering shares">1,176.48</span> shares, respectively, in the Series A Preferred Stock Offering and on the same terms
as other investors. Additionally, Halle Capital Management, L.P. received $<span id="xdx_900_eus-gaap--LegalFees_c20220413__20220413__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zbLpeAvh8qQd" title="Legal fees">85,000</span> from the Company as reimbursement for its legal fees
and expenses. Mr. Gutfreund is the Managing Partner of Halle Capital Management, L.P. See Note 15 for additional information about the
Series A Preferred Stock Offering.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, on April 13, 2022, Oncocyte
entered into the Underwriting Agreement with the Underwriters for the Underwritten Offering. Pursuant to the Underwritten Offering, Broadwood
acquired from us (i) <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zOEM9YizVJd6" title="Sale of stock, shares">261,032</span> shares of common stock, and (ii) <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zC9ghIA6VO2e" title="Warrant to purchase common stock">300,187</span> April 2022 Warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember__srt--RangeAxis__srt--MaximumMember_zgqrkiRphIb4" title="Warrant to purchase common stock">150,093</span> shares of common
stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zjWykj2AlOvd" title="Warrant exercise price">30.60</span> per share. However, the total number of shares of common stock that Broadwood purchased in the Underwritten
Offering was <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zHA37fRuHzQj" title="Warrant to purchase common stock">300,187</span>, of which <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zYXTQjNAtji4" title="Warrant to purchase common stock">39,154</span> existing shares were acquired by the underwriters in the open market and re-sold to Broadwood.
Pura Vida acquired from us (i) <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember_zx8ZVGI7wsMi" title="Sale of stock, shares">249,204</span> shares of common stock, and (ii) <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember_zoEaPeiKT1z9" title="Warrant to purchase common stock">286,585</span> April 2022 Warrants to purchase up to <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember__srt--RangeAxis__srt--MaximumMember_z5Nc6XXf05Ya" title="Sale of stock, shares">143,292</span> shares
of common stock. However, the total number of shares of common stock that Pura Vida purchased in the Underwritten Offering was <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember_zNHEvch00Twa" title="Issuance of shares">286,585</span>,
of which <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z9H4CxzjYARe" title="Issuance of shares">37,380</span> existing shares were acquired by the underwriters in the open market and re-sold to Pura Vida. Halle Special Situations
Fund LLC purchased from us (i) <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember_z3D1sO3EcSw" title="Sale of stock, shares">309,976</span> shares of common stock, and (ii) <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember_z588Go5psBv3" title="Warrant to purchase common stock">356,472</span> 2022 Warrants to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember__srt--RangeAxis__srt--MaximumMember_zP95YY1jNjOb" title="Warrant to purchase common stock">178,236</span> shares of
common stock. Mr. Gutfreund is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of Halle
Special Situations Fund LLC. However, the total number of shares of common stock that Halle Special Situations Fund LLC purchased in the
Underwritten was <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember_zEGKj0A7JJT7" title="Warrant to purchase common stock">356,472</span>, of which <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zOcZ21AOdKS8" title="Issuance of shares">46,496</span> existing shares were acquired by the underwriters in the open market and re-sold to Halle
Special Situations Fund LLC. See Note 15 for additional information about the Underwritten Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 3, 2023, Oncocyte entered
into a securities purchase agreement (the &#8220;2023 Securities Purchase Agreement&#8221;) with certain investors, including Broadwood,
Pura Vida and entities affiliated with AWM, and certain individuals, including our Chairman Andrew Arno and former director John Peter
Gutfreund (and certain of their affiliated parties), which provides for the sale and issuance by the Company of an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zMsTlEQa9qA3" title="Offering shares">2,274,709</span>
shares of common stock at an offering price of: <span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zix9qv3MCfH2" title="Related party transaction, description">(i) $6.03 to investors who are not considered to be &#8220;insiders&#8221; of the Company
pursuant to Nasdaq Listing Rules (&#8220;Insiders&#8221;), which amount reflects the average closing price of the Common Stock on Nasdaq
during the five trading day period immediately prior to pricing, and (ii) $7.08 to Insiders, which amount reflects the final closing
price of the Common Stock on Nasdaq on the last trading day immediately prior to pricing (the &#8220;2023 Registered Direct Offering&#8221;)</span>.
Broadwood purchased <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember_z5XIG6KjyRhk" title="Offering shares">1,341,381</span> shares of common stock for $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember_zgi7nOooYcxl" title="Proceeds from issuance of stock">8,093,361.84</span>, Pura Vida purchased <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PuraVidaMember_zOWvY25l0Uf5" title="Offering shares">33,150</span> shares of common stock for $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PuraVidaMember_zyA3gb8xWtM9" title="Proceeds from issuance of stock">200,013.84</span>
and entities affiliated with AVM purchased <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--AVMMember_zVPxGawD1iRe" title="Offering shares">472,354</span> shares of common stock for $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--AVMMember_zLrBrFqzNs9j" title="Proceeds from issuance of stock">2,849,999.92</span>. Mr. Arno and his affiliated parties purchased
<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--ArnoMember_z1sFbNXKb87h" title="Offering shares">21,162</span> shares of common stock for $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--ArnoMember_zrqVnimk2ZQe" title="Proceeds from issuance of stock">150,000.51</span>, and Mr. Gutfreund and his affiliated parties purchased <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--MrGutfreundMember_zweVaocFJeN3" title="Offering shares">85,250</span> for $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--MrGutfreundMember_zShhhQIXlpCi" title="Proceeds from issuance of stock">604,252.00</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 5, 2023, Oncocyte redeemed
all of the <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pp5d_c20220405__20220405__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zffpYiREbyQ2" title="Stock issued during period, shares, conversion of units">588.23529</span> shares of Series A Preferred Stock held by Mr. Gutfreund for $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pp2d_c20220405__20220405__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8r7Yh5acMoh" title="Stock issued during period, value conversion of units">618,672.34</span>. Mr. Gutfreund is no longer a related party
as of June 23, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Company Employee(s)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2023, the
Company employed the son of Andrew Arno, Chairman of the Board as its Senior Manager, Investor Relations, Corporate Planning &amp;
Development. As of June 30, 2023, the total compensation paid by the Company to Mr. Arno&#8217;s son since January 1, 2022 is
approximately $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20230630__us-gaap--RelatedPartyTransactionAxis__custom--ArnoMember_zUQI2BjgQCmf" title="Total compensation paid">0.2</span>
million. Mr. Arno&#8217;s son is no longer an employee of the Company as of July 28, 2023.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871914356736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Payable to Silicon Valley Bank<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Loan Payable to Silicon Valley Bank</a></td>
<td class="text"><p id="xdx_805_eus-gaap--LongTermDebtTextBlock_zdqR29ID3GN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>13.
<span id="xdx_828_zrMTYXD6zsN1">Loan Payable to Silicon Valley Bank</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Amended
Loan Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
October 17, 2019, Oncocyte entered into a First Amendment to Loan and Security Agreement (the &#8220;Amended Loan Agreement&#8221;) with
Silicon Valley Bank (&#8220;the Bank&#8221;) pursuant to which Oncocyte obtained a new $<span id="xdx_905_eus-gaap--LinesOfCreditCurrent_iI_pn6n6_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zkwh5lsbnqO6" title="Line of credit, current">3</span> million secured credit facility (&#8220;Tranche
1&#8221;), a portion of which was used to repay the remaining balance of approximately $<span id="xdx_903_eus-gaap--RepaymentsOfLinesOfCredit_c20191016__20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zSbNPVsuVGk3" title="Repayments of lines of credit">400,000</span> on outstanding loans from the Bank, plus
a final payment of $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zkkDswSjbCF" title="Debt instrument, final payment">116,000</span>, under the February 21, 2017 Loan Agreement. The credit line under the Amended Loan Agreement may be increased
by an additional $<span id="xdx_908_eus-gaap--LinesOfCreditCurrent_iI_pn6n6_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zXb5yFwe35" title="Line of credit, current">2</span> million (&#8220;Tranche 2&#8221;) if Oncocyte obtains at least $<span id="xdx_909_eus-gaap--AdditionalPaidInCapital_iI_pn6n6_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zuJoOEOQblx9" title="Additional paid in capital">20</span> million of additional equity capital, as was the
case with the original Loan Agreement, and a positive final coverage determination is received from CMS for DetermaRx at a specified
minimum price point per test (the &#8220;Tranche 2 Milestone&#8221;), and Oncocyte is not in default under the Amended Loan Agreement.
As of June 30, 2023, Oncocyte had satisfied the Tranche 2 Milestone and was eligible to borrow the $<span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_do_c20230630__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zMVCgLpOOy61" title="Line of credit facility, maximum borrowing capacity">2</span> million Tranche 2 funds. However,
Oncocyte has not yet borrowed any funds under Tranche 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Payments
of interest only on the principal balance were due monthly from the draw date through March 31, 2020, followed by 24 monthly payments
of principal and interest, but the Bank has agreed to a deferral of principal payments, as discussed below. The outstanding principal
balance of the loan will bear interest at a stated floating annual interest equal to the greater of (a) the prime rate or (b) <span id="xdx_90C_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zzHOBuJr9S8b" title="Interest rate">5</span>% per
annum. During August 2022, period in which the loan was paid off, the published prime rate was <span id="xdx_90E_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230630_zzUrc3mk0Gj8" title="Interest rate">5.5</span>% per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 2, 2020, as part of the Bank&#8217;s COVID-19 pandemic relief program, Oncocyte and the Bank entered into a Loan Deferral Agreement
(&#8220;Loan Deferral&#8221;) with respect to the Amended Loan Agreement. <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20200401__20200402__us-gaap--TypeOfArrangementAxis__custom--LoanDeferralAgreementMember_zazUK3crrSD4" title="Debt instrument maturity date description">Under the Loan Deferral Agreement, the Bank agreed to (i) extend
the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal
payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May
1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided
at no additional fees to Oncocyte</span>. No other terms of the Amended Loan Agreement were changed or modified. The Loan Deferral was accounted
for as a modification of debt in accordance with ASC 470-50, <i>Debt &#8211; Modifications and Extinguishments</i>, thus there was no
gain or loss recognized on the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">At
maturity of the loan, Oncocyte agreed to pay the Bank an additional final payment fee of $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20191031__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zLE3svKM2k21" title="Debt instrument, final payment">200,000</span>, which was recorded as a deferred financing
charge in October 2019 and is being amortized to interest expense over the term of the loan using the effective interest method. As of
June 30, 2023, there is no remaining unamortized deferred financing cost and the full principal balance of the loan in addition to the
final payment fee have been paid off.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Bank
Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
2017, in connection with the Loan Agreement, Oncocyte issued common stock purchase warrants to the Bank (the &#8220;2017 Bank Warrants&#8221;)
entitling the Bank to purchase shares of Oncocyte common stock in tranches related to the loan tranches under the Loan Agreement. In
conjunction with the availability of the loan, the Bank was issued warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0BAs5j803Wf" title="Warrants to purchase, shares">412</span> shares of Oncocyte common stock at an exercise
price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z09BO9ImYD2j" title="Warrant exercise price, per share">97.00</span> per share, through February 21, 2027. On March 23, 2017, the Bank was issued warrants to purchase an additional <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20170323__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zTAL024Hgzea" title="Warrants to purchase, shares">366</span> shares
at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20170323__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsWZL0Dh2Ci2" title="Warrant exercise price, per share">109.20</span> per share, through March 23, 2027. The Bank may elect to exercise the 2017 Bank Warrants on a &#8220;cashless
exercise&#8221; basis and receive a number of shares determined by multiplying the number of shares for which the applicable tranche
is being exercised by (A) the excess of the fair market value of the common stock over the applicable exercise price, divided by (B)
the fair market value of the common stock. The fair market value of the common stock will be the last closing or sale price on a national
securities exchange, inter-dealer quotation system, or over-the-counter market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
October 17, 2019, in conjunction with Tranche 1 becoming available under the Amended Loan Agreement, Oncocyte issued a common stock purchase
warrant to the Bank (the &#8220;2019 Bank Warrant&#8221;) entitling the Bank to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zEFZgzEkwh0k" title="Warrants to purchase, shares">4,928</span> shares of Oncocyte common stock at the
initial &#8220;Warrant Price&#8221; of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_z9pnCFgayZb9" title="Warrant exercise price, per share">33.80</span> per share through October 17, 2029. The number of shares of common stock issuable upon
the exercise of the 2019 Bank Warrant will increase on the date of each draw, if any, on Tranche 2. The number of additional shares of
common stock issuable upon the exercise of the 2019 Bank Warrant will be equal to <span id="xdx_906_ecustom--PercentageForWarrantExercisePricePerShare_pid_dp_uPure_c20191016__20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zSlgxVF4OsTh" title="Percentage for warrant exercise price per share">0.02</span>% of Oncocyte&#8217;s fully diluted equity outstanding
for each $<span id="xdx_908_ecustom--DilutedEquityOutstanding_pn6n6_c20191016__20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zBM5N48O83U3" title="Diluted equity outstanding">1</span> million draw under Tranche 2. The Warrant Price for Tranche 2 warrant shares will be determined upon each draw of Tranche
2 funds and will be closing price of Oncocyte common stock on the date immediately before
the applicable date on which Oncocyte borrows funds under Tranche 2. The Bank may elect to exercise the 2019 Bank Warrant on a &#8220;cashless
exercise&#8221; basis and receive a number of shares determined by multiplying the number of shares for which the 2019 Bank Warrant is
being exercised by (A) the excess of the fair market value of the common stock over the applicable Warrant Price, divided by (B) the
fair market value of the common stock. The fair market value of the common stock will be last closing or sale price on a national securities
exchange, interdealer quotation system, or over-the-counter market. As of June 30, 2023, Oncocyte has not borrowed any funds under Tranche
2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871826736400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with Life Technologies Corporation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract', window );"><strong>Co-development Agreement With Life Technologies Corporation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock', window );">Co-Development Agreement with Life Technologies Corporation</a></td>
<td class="text"><p id="xdx_80F_ecustom--CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock_zobTcfDT6Tqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>14.
<span id="xdx_828_zZwTbgUjSyeb">Co-Development Agreement with Life Technologies Corporation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
January 13, 2022, Oncocyte entered into a Collaboration Agreement (the &#8220;LTC Agreement&#8221;) with Life Technologies Corporation,
a Delaware corporation and subsidiary of Thermo Fisher Scientific (&#8220;LTC&#8221; and together with Oncocyte, the &#8220;Parties&#8221;
or individually, a &#8220;Party&#8221;), in order to partner in the development and collaborate in the commercialization of Thermo Fisher
Scientific&#8217;s existing Oncomine Comprehensive Assay Plus (&#8220;OCA Plus&#8221;) and Oncocyte&#8217;s DetermaIO assay for use with
LTC&#8217;s Ion Torrent<sup>TM</sup> Genexus<sup>TM</sup> Integrated Sequencer and LTC&#8217;s Ion Torrent<sup>TM</sup> Genexus<sup>TM
</sup>Purification System (&#8220;Genexus system&#8221;) in order to obtain <i>in vitro </i>diagnostic (&#8220;IVD&#8221;) regulatory
approval. On February 7, 2023, Oncocyte entered into a Termination Agreement (the &#8220;Termination Agreement&#8221;) with LTC, pursuant
to which the parties terminated the LTC Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023, Oncocyte was responsible for reimbursing LTC for $<span id="xdx_901_eus-gaap--DevelopmentCosts_c20230101__20230630__dei--LegalEntityAxis__custom--LifeTechnologiesCorporationMember_zfCvAuebcka4" title="Development costs">749,000</span> of certain development costs under the terms of the LTC Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b>&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Co development agreementwith life technologies corporation [TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871823956176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DisclosureEquityOfferingsAbstract', window );"><strong>Equity Offerings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_AprilTwentyTwentyTwoOfferingsTextBlock', window );">Equity Offerings</a></td>
<td class="text"><p id="xdx_809_ecustom--AprilTwentyTwentyTwoOfferingsTextBlock_z7bMY3Mjbwdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>15.
<span id="xdx_822_z1Lt1DpVWOP2">Equity Offerings</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Series
A Preferred Stock Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 13, 2022, Oncocyte entered into the Securities Purchase Agreement with Investors, including Broadwood, in a registered direct offering
of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHkNo2g6D8C8" title="Stock issued during period, shares, conversion of units">11,765
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">shares of our Series A Preferred
Stock, which shares of Series A Preferred Stock are convertible into a total of <span id="xdx_906_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKLvE8EwmGTd" title="Preferred stock, convertible, shares issuable">384,477
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">shares of our common stock, at
a conversion price of $<span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMQHkgXeJKv9" title="Preferred stock, convertible, conversion price">30.60</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.
The purchase price of each share of Series A Preferred Stock was $<span id="xdx_901_ecustom--PurchasePrice_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpePk84Xj6pg" title="Purchase price">850</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">,
which included an original issue discount to the stated value of $<span id="xdx_907_ecustom--StatedValue_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHCuAznQ42Mb" title="Stated value">1,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">per share. The rights, preferences
and privileges of the Series A Convertible Preferred Stock are set forth in the Company&#8217;s Certificate of Determination, which the
Company filed with the Secretary of State of the State of California. The Securities Purchase Agreement provides that the closing of
the Series A Preferred Stock Offering will occur, subject to the satisfaction of certain closing conditions, in two equal tranches of
$<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--AwardTypeAxis__custom--TwoEqualTranchesMember_zp2vVD2j2rV6" title="Proceeds from issuance of preferred stock and preference stock">5,000,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">each for aggregate gross proceeds
from both closings of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHmN7jFCvz52" title="Proceeds from issuance of preferred stock and preference stock">10,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">.
The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220601__20220601__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z5u8wT87iHX7" title="Net proceeds">4.9
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">million from the Series A Preferred
Stock issued from the first tranche. The second closing would occur, subject to the satisfaction of certain closing conditions (including
but not limited to a requirement that the Company has not received, in the 12 months preceding the second closing, a notice from Nasdaq
that the Company is not in compliance with the listing and maintenance and listing requirements of Nasdaq), on the earlier of (a) the
second trading day following the date that Oncocyte receives notice from an Investor to accelerate the second closing and (b) a date
selected by Oncocyte on or after October 8, 2022 and on or prior to March 8, 2023. On August 9, 2022, Oncocyte received a letter from
Nasdaq indicating that the Company no longer met the minimum bid price requirement of the Nasdaq continued
listing requirements. Accordingly</span>, the second closing did not occur and no additional proceeds were received under the Securities
Purchase Agreement. On August 8, 2023, the Company received a letter from Nasdaq indicating that the Company had regained compliance
with the minimum bid price requirement of the Nasdaq continued listing requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock is convertible into shares of common stock at any time at the holder&#8217;s option. The conversion price will
be subject to customary anti-dilution adjustments for matters such as stock splits, stock dividends and other distributions on common
stock, and recapitalizations. <span id="xdx_902_eus-gaap--ConversionOfStockDescription_c20220412__20220413_zpQT5S2YFPoj" title="Conversion of stock description">The holder will be prohibited from converting shares of Series A Preferred Stock into shares of common
stock if, as a result of such conversion, the holder, together with its affiliates, would own more than <span id="xdx_905_ecustom--PercentageOfIssuedAndOutstandingShares_pid_dp_uPure_c20220412__20220413_zdiZERYD99zc" title="Percentage of issued and outstanding shares">4.99</span>% of the shares of common
stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation
solely as to itself up to 19.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion,
provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance
of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the
holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)</span>. On July 15, 2022, the
Company received such shareholder approval to remove the beneficial ownership limitation with respect to the Series A Preferred Stock
held by Broadwood. Oncocyte may force the conversion of up to one-third of the shares of Series A Preferred Stock originally
issued, subject to customary equity conditions, <span id="xdx_904_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20220714__20220715__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zNNjsrs7T0Uf" title="Equity method investment description">if the daily volume weighted average price of our common stock for 20 out of 30 trading
days exceeds <span id="xdx_90C_ecustom--ConversionPricePercentage_dp_uPure_c20220714__20220715_zBcnfG6qw7q3">140</span>% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000
shares of our common stock</span>. Oncocyte may only effect one forced conversion during any 30-trading day period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of the Company&#8217;s liquidation, dissolution, or winding up, holders of Series A Preferred Stock will receive a payment
equal to the stated value of the Series A Preferred Stock plus accrued but unpaid dividends and any other amounts that may have become
payable on the Series A Preferred Stock due to any failure or delay that may have occurred in issuing shares of common stock upon conversion
of a portion of the Series A Preferred Stock, before any distribution or payment to the holders of common stock or any of Oncocyte&#8217;s
other junior equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Series A Preferred Stock generally has no voting rights, except as required by law and except that the consent of holders of a majority
of the outstanding Series A Preferred Stock will be required to amend any provision of our certificate of incorporation that would have
a materially adverse effect on the rights of the holders of the Series A Preferred Stock. Additionally, as long as any shares of Series
A Preferred Stock remain outstanding, unless the holders of at least <span id="xdx_908_ecustom--PreferredStockRemainsOutstandingPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWtuwefAG66c" title="Preferred stock outstanding percentage">51</span>% of the then outstanding shares of Series A Preferred Stock shall
have otherwise given prior written consent, the Company, on a consolidated basis with its subsidiaries, is not permitted to (1) have
less than $<span id="xdx_90F_eus-gaap--Cash_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrGbCIpHHeG9" title="Cash in hand">8</span> million of unrestricted, unencumbered cash on hand (&#8220;Cash Minimum Requirement&#8221;); (2) other than certain permitted
indebtedness, incur indebtedness to the extent that our aggregate indebtedness exceeds $<span id="xdx_901_ecustom--IndebtednessExpenses_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXrh9NtXVYUl" title="Indebtedness expenses">15</span> million; (3) enter into any agreement (including
any indenture, credit agreement or other debt instrument) that by its terms prohibits, prevents, or otherwise limits our ability to pay
dividends on, or redeem, the Series A Preferred Stock in accordance with the terms of the Certificate of Determination; or (4) authorize
or issue any class or series of preferred stock or other capital stock of the Company that ranks senior or pari passu with the Series
A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Series A Preferred Stock will be entitled to receive cumulative dividends at a rate per share (as a percentage of stated value) of
6% per annum, payable quarterly in cash or, at our option, by accreting such dividends to the stated value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is required to redeem, for cash, the shares of Series A Preferred Stock on the earlier to occur of (1) April 8, 2024, (2) the
commencement of certain a voluntary or involuntary bankruptcy, receivership, or similar proceedings against us or our assets, (3) a Change
of Control Transaction (as defined herein) and (4) at the election and upon notice of 51% in interest of the holders, if the Company
fails to meet the Cash Minimum Requirement. A &#8220;Change of Control Transaction&#8221; means the occurrence of any of (a) an acquisition
by an individual or legal entity or &#8220;group&#8221; (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective
control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess of <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zt3FhiR5dqwf" title="Ownership percentage">50</span>%
of the voting securities of the Company (other than by means of conversion of Series A Preferred Stock), (b) the Company merges into
or consolidates with any other person, or any person merges into or consolidates with the Company and, after giving effect to such transaction,
the stockholders of the Company immediately prior to such transaction own less than <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SecurityMember_zc8URNam80lb" title="Ownership percentage">50</span>% of the aggregate voting power of the Company
or the successor entity of such transaction, or (c) the Company sells or transfers all or substantially all of its assets to another
person. Additionally, the Company has the right to redeem the Series A Preferred Stock for cash upon 30 days prior notice to the holders;
provided if the Company undertakes a capital raise in connection with such redemption, the Investors will have the right to participate
in such financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance and sale of the Series A Preferred Stock was completed pursuant to the Company&#8217;s effective shelf registration statement
on Form S-3 (Registration No. 333-256650), filed with the SEC on May 28, 2021 and declared effective by
the SEC on June 8, 2021, and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the registered direct offering in April 2023, the Company used approximately $<span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zuPcvV2JzAvj" title="Net proceeds to immediately redeem">1.1</span> million of the net proceeds to immediately
redeem an aggregate of <span id="xdx_901_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjccM0IMidKg" title="Number of stock redeem">1,064</span> shares of its Series A Preferred Stock and may thereafter elect to redeem additional shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Preferred Stock dividend for all issued and outstanding shares is set at <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBVX0IP0j7I5" title="Preferred stock, dividend rate, percentage">6</span>% per annum per share. As of June 30, 2023, the Company
elected to accrete dividends of $<span id="xdx_905_eus-gaap--DividendsPreferredStock_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2vPxXQiYTYg" title="Dividends, preferred stock">321,000</span>, net of the April 2023 redemption, with respect to shares of Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, Oncocyte had <span id="xdx_908_eus-gaap--TemporaryEquitySharesIssued_iI_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zancJFOFUNh2" title="Number of shares issued"><span id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKtCuCVF48kj" title="Number of shares outstanding">4,818</span></span> shares issued and outstanding. The future right or obligation associated with the Series A Preferred
Stock to be issued in the second closing was written off since the second closing was not received as of June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Underwritten
Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 13, 2022, Oncocyte entered into the Underwriting Agreement with the Underwriters, pursuant to which the Company agreed to issue
and sell to the Underwriters an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_z5cvbXFKqjM5" title="Stock issued during period, shares, new issues">1,313,320</span> shares of common stock and <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_zJ2JaG4Z3Fcc" title="Number of warrants">1,313,320</span> April 2022 Warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlzplsDO1AX" title="Number of warrants">656,660</span>
shares of common stock. Each share of common stock and the accompanying April 2022 Warrant was sold at a combined offering price of $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_zArsGT6Feauj" title="Sale of stock, price per share">26.65</span>,
representing an offering price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBKsZLYRlKXf" title="Sale of stock, price per share">26.45</span> per share of common stock and $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuauwKKWFnae" title="Exercise price">0.20</span> per accompanying April 2022 Warrant, before underwriting
discounts and commissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Underwriting Agreement, the Company also granted to the Underwriters an over-allotment option, exercisable in whole
or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase up to an additional <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_zVBDxM5BxTpf" title="Stock issued during period, shares, new issues">196,998</span> shares
of common stock and <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsU71sbHzO2h" title="Number of warrants">196,998</span> April 2022 Warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbGV7DgeWKlj" title="Number of warrants">98,499</span> shares of common stock to cover over-allotments, if any. The over-allotment
option may be exercised separately for shares of common stock at a price to the underwriters of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_z0A5bI6Lc27h" title="Shares issued, price per share">24.85</span> per share, and April 2022 Warrants
at a price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220413__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaUkRKySMzTb" title="Shares issued, price per share">0.20</span> per April 2022 Warrant. On April 14, 2022, the Underwriters exercised their option to purchase the <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zqZ8aHbKM2T7" title="Stock issued during period, shares, new issues">196,998</span> April
2022 Warrants pursuant to the over-allotment option but did not exercise their option to purchase the additional <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zNPFOf32TESf" title="Stock issued during period, shares, new issues">196,998</span> shares of common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received net proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220418__20220419__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z8RSGCj7oAMd" title="Proceeds from issuance initial public offering">32.8</span> million from the Underwritten Offering, which includes the April 2022 Warrants sold
upon the exercise of the Underwriters&#8217; overallotment option. The Underwritten Offering closed on April 19, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwritten Offering was made pursuant to the Company&#8217;s effective &#8220;shelf&#8221; registration statement on Form S-3 (Registration
No. 333-256650) filed with the SEC Commission on May 28, 2021 and declared effective by the SEC on June 8, 2021,
and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Registered
Direct Offering</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 3, 2023, Oncocyte entered into an agreement with certain members of the Company&#8217;s board of directors, and several institutional
and accredited investors, including Broadwood, the Company&#8217;s largest shareholder, and certain members of the Company&#8217;s board
of directors (and certain of their affiliated parties), relating to their purchase of an aggregate of up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--RangeAxis__srt--MaximumMember_zPrVMZICxex3" title="Number of shares issued">2,278,121</span> shares of its common
stock at an offering price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--BoardMembersMember_z6ErrnuHCXza" title="Shares issued price per share">7.08</span> per share to board members and $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--OtherInvestorsMember_zaI3G4Mx9rE2" title="Shares issued price per share">6.03</span> per share to the other investors participating in the offering.
The offering was intended to be priced at-the-market for purposes of complying with applicable Nasdaq Listing Rules. The aggregate gross
proceeds from the offering were approximately $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember_zTATHj93Nwf7" title="Proceeds from issuance of common stock">13.9</span> million. The Company used approximately $<span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9lzrGVuCRZe" title="Net proceeds to immediately redeem">1.1</span> million of the net proceeds to immediately
redeem an aggregate of <span id="xdx_901_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBG8ioUQcEXf" title="Number of stock redeem">1,064</span> shares of its Series A Preferred Stock and may thereafter elect to redeem additional shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_AprilTwentyTwentyTwoOfferingsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>April twenty twenty two offerings[TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_AprilTwentyTwentyTwoOfferingsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DisclosureEquityOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DisclosureEquityOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871826799312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets Held for Sale and Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Assets Held for Sale and Discontinued Operations</a></td>
<td class="text"><p id="xdx_800_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zmtyUnKr1rF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
<span id="xdx_828_zjDs3QD2cCw4">Assets Held for Sale and Discontinued Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Razor
Disposal </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2022, the Company entered into the Razor Stock Purchase Agreement with Dragon and Razor. Pursuant to the Razor Stock Purchase
Agreement, Oncocyte agreed to sell, and Dragon agreed to purchase, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221214__20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DragonMember_zhnzNri45yRb" title="Number of shares issued">3,188,181</span> shares of common stock of Razor, which constitutes approximately
<span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_z6WarqAjJeZd" title="Equity method investment ownership percentage">70</span>% of the issued and outstanding equity interests of Razor on a fully-diluted basis. On February 16, 2023, Oncocyte completed the Razor
Sale Transaction. In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx.
While <span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_dp_c20230216__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_zmqFraAOBuE5" title="Cash received on stock transaction">no</span> monetary consideration was received for the sale of <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_zh4YBVstOJJ6" title="Equity method investment ownership percentage">70</span>% of the equity interests of Razor, the transaction allows the Company
to eliminate all development and commercialization costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to
own <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230216__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zZnX60kItHAi" title="Number of shares issued">1,366,364</span> shares of common stock of Razor, which constitutes approximately <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zlp8TfKYFJv4" title="Equity method investment ownership percentage">30</span>% of the issued and outstanding equity interests of
Razor on a fully-diluted basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the transfer of <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_zPTA9Kgah2kh" title="Equity method investment ownership percentage">70</span>% of the equity interests of Razor, the Razor Stock Purchase Agreement provided that Dragon would purchase
furniture, fixtures, and equipment from the Company for a cash consideration of $<span id="xdx_90A_eus-gaap--BusinessCombinationConsiderationTransferred1_c20230216__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--BusinessAcquisitionAxis__custom--RazorMember_zKYXIdHUoHrb" title="Consideration transferred">115,660</span>. Upon the Razor Closing, the Company deconsolidated
the assets and liabilities of Razor as control of Razor has transferred to Dragon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded the final adjustment related to the disposal, including final working capital adjustments, and recognized a loss of
$<span id="xdx_90A_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_iN_pn5n6_di_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zHN3nfvUWC82" title="Loss on disposal">1.3</span> million during the first quarter of 2023. Including the impairment losses we recognized as of December 31, 2022 related to this
transaction, we recorded an overall loss of $<span id="xdx_902_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_iN_pn5n6_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zosQd1370lpe" title="Loss on disposal">27.2</span> million. The operating results for Razor have been recorded in discontinued operations
of the accompanying unaudited condensed consolidated statements of operations for all periods presented, and we have reclassified their
assets and liabilities as held for sale for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Laboratory
equipment sold and held for sale</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 31, 2023, the Company entered into an agreement to sell laboratory equipment for $<span id="xdx_908_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_pn5n6_c20230131__20230131__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_z18Xsr3O9IRb" title="Proceeds from sale of equipment">0.2</span> million. As of June 30, 2023, the Company
classified the equipment not yet sold as held for sale in current assets in the unaudited condensed consolidated balance sheet, as all
the criteria of ASC subtopic 360-10, Property, Plant, and Equipment (&#8220;ASC 360-10&#8221;) have been met and the transaction was
qualified as assets held for sale. The balance included in current assets held for sale related to this transaction was $<span id="xdx_906_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroupCurrent_iI_pn5n6_c20230630__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_zcw9dyVgiJhf" title="Assets held for sale">0.2</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company entered into an agreement to auction equipment for $<span id="xdx_909_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_pn5n6_c20230301__20230331__us-gaap--TypeOfArrangementAxis__custom--AuctionEquipmentAgreementMember_zw0lFlDJCEYl" title="Proceeds from sale of equipment">0.1</span> million net proceeds. The auction was finalized on March
21, 2023, and the Company recorded a loss of $<span id="xdx_90C_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pn5n6_c20230301__20230331__us-gaap--TypeOfArrangementAxis__custom--AuctionEquipmentAgreementMember_z5flXigqZRc3" title="Loss on disposal and held-for-sale assets">0.3</span> million which is included in the loss on disposal and held-for-sale assets, on the
unaudited condensed consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 31, 2023, the Company entered into an agreement to sell laboratory equipment for $<span id="xdx_90C_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_pn5n6_c20230331__20230331__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_zcV0ZQdbK0ad" title="Proceeds from sale of equipment">0.2</span> million. As a result, the Company classified
the equipment as held for sale as current assets, in the unaudited condensed consolidated balance sheet, as all the criteria of ASC subtopic
360-10, Property, Plant, and Equipment (&#8220;ASC 360-10&#8221;) have been met and the transaction was qualified as assets held for
sale. This equipment was written down to its fair value, less cost to sell, to $<span id="xdx_90E_eus-gaap--DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_pn5n6_c20230331__20230331__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_zqPlOSOvvYOe" title="Proceeds from sale of equipment">0.2</span> million in the unaudited condensed consolidated balance
sheet. As a result of the expected sale, the Company recorded an impairment loss and loss on disposal of $<span id="xdx_909_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn5n6_c20230331__20230331__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_zV3plvjPvVcg" title="Impairment loss">1.0</span> million on held-for-sale
assets, in the unaudited condensed consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company classified its results of operations as discontinued operations for all periods presented in the accompanying unaudited condensed
consolidated statements of operations. We have retrospectively adjusted the amounts reported for the period ended June 30, 2022, in the
following table to give effect to such reporting of discontinued operations. For the period ended June 30, 2023, discontinued operations
reflect operating results of Razor up to the closing of the sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s unaudited condensed consolidated balance sheets and consolidated statements of operations report discontinued operations
separate from continuing operations. Our unaudited condensed consolidated statements of comprehensive loss, statements of shareholders&#8217;
equity and statements of cash flows combined continuing and discontinued operations. A summary of financial information related to the
Company&#8217;s discontinued operations is as follows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ONCOCYTE
CORPORATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zGdZMxHT2XY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the results of the discontinued operation of Razor (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zxGaizYTg6zc">Schedule
of Discontinued Operations</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230401__20230630_z0gyMZVfHy8h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220401__20220630_zdqYEtBar4F8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20230630_zuBpcQRtcPfg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220630_zYCwMq5QzTl3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_maILFDOz7EG_zskB8uCAfHda" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-align: left; padding-left: 0pt">Net revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2050">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,830</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">421</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,874</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_pn3n3_msILFDOz7EG_zXMm03wbM6zg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2055">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,999</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_pn3n3_msILFDOz7EG_zoOVqv17lnm4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2060">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,251</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_pn3n3_msILFDOz7EG_ztcBHCsHHzIf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2065">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,366</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_pn3n3_msILFDOz7EG_zK53DyhlaqE2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2070">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax_pn3n3_msILFDOz7EG_zSQ2ie5pvEHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Loss from impairment of held for sale assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2075">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2076">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,311</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2078">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pn3n3_maNILziQi_mtILFDOz7EG_z5leA6WS1ql3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Net loss from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2080">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,936</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,926</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,814</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p id="xdx_8AE_zmJnvLI4Imul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_899_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hus-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zOQtzHOB0hf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the carrying amounts of the held for sale related assets and liabilities as of June 30, 2023 and carrying
amounts of the held for sale related assets and liabilities of discontinued operations as of December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z5eSjrfdTnxh" style="display: none">Schedule
of Assets and Liabilities of Disposal Group Held for Sale</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230630__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zOzjMJC91CUk" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zDPDc331bJjh" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zo0L4cJtyTE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_iB_zLWgqZ0u2nTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_z4rcUtCfq877" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2093">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,510</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_znknJj3nFopb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2096">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_iI_z03BhLjQQiia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Machinery and equipment, net, and construction in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2099">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_iI_zJJS9apEFwda" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2102">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,920</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_iI_ztiYQ2fmOHCe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Impairment of held for sale assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2105">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,866</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--Assets_iTI_zjuNc9dwbuNg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2108">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,121</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zxlqfIG4mWg7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_zBjMqrQ9nRXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">492</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_iI_pn3n3_zpnkOBYVPVti" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2117">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_iI_zdWefBMn5567" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2120">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,265</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_iI_zibFh2pWp4lf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,005</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Liabilities_iTI_zIjraUnT43Od" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">135</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,005</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes cash used related to Razor as of and for the six months ended June 30, 2023 and 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230630_zPeD0kFUQLb4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20220630_zFYgXi0vnvqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInDiscontinuedOperationsAbstract_iB_zQ4AOA5Y2PY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_i01_zbwC2PUjf0r1" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Net cash used in operating activities</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(4,357</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(10,549</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zIpX1ulQNjo2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_i01_zfXsAZWSjqc4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2138">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(96</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A7_zIiql2e3Nr1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871826753808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_z3jEItIc8Rw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_82F_zBr8zJmCDqQa">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 24, 2023, the Company implemented a <span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20230723__20230724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlXf9FZENefa" title="Reverse stock split">1-for-20 reverse stock split</span> of the outstanding shares of its common stock. The par value per
share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split.
All common stock share and per-share amounts for all periods presented in these condensed financial statements have been adjusted to
reflect the reverse stock split. The number of authorized shares of common stock remains at <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20230724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlNOOzxLrOdg" title="Common stock, shares authorized">230</span> million shares.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821748752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNUiTmKaFlFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zkS5tceeAXY1">Basis
of presentation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance
with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and with the instructions to
Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures
normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance
sheets as of December 31, 2022 was derived from the audited consolidated financial statements at that date. These unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included
in Oncocyte&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated interim financial
statements presented herein as of June 30, 2023 is not representative of the full fiscal year or any future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zBEPow0Ifnt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zrKXO5Nmd15e">Principles
of consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 31, 2020, with the
acquisition of Insight Genetics, Inc. (&#8220;Insight&#8221;) through a merger with a newly incorporated wholly owned subsidiary of Oncocyte
(the &#8220;Insight Merger&#8221;) under the terms of an Agreement and Plan of Merger (the &#8220;Insight Merger Agreement&#8221;), Insight
became a wholly owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight&#8217;s operations and results with
Oncocyte&#8217;s operations and results (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 24, 2021, with the
acquisition of the remaining equity interests in Razor, Razor became a wholly owned subsidiary of Oncocyte, and on that date Oncocyte
began consolidating Razor&#8217;s results with Oncocyte&#8217;s operations and results (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (&#8220;Chronix&#8221;) pursuant to an Agreement
and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated,
the &#8220;Chronix Merger Agreement&#8221;), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary
of Oncocyte (&#8220;Merger Sub&#8221;), Chronix became a wholly owned subsidiary of Oncocyte (the &#8220;Chronix Merger&#8221;), and on
that date Oncocyte began consolidating Chronix&#8217;s operations and results with Oncocyte&#8217;s operations and results (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have reflected the operations of Razor as discontinued operations for all periods presented. See Note 16 for further information. Unless
otherwise noted, amounts and disclosures throughout these Notes to unaudited condensed consolidated interim financial statements relate
solely to continuing operations and exclude all discontinued operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting
only of normal recurring adjustments, necessary for a fair presentation of Oncocyte&#8217;s financial condition and results of operations.
The unaudited condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other
interim period or for the entire year. All material intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p id="xdx_842_eus-gaap--UseOfEstimates_z9HUDZz4sJRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zwTeAy75rgGb">Use
of estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and contingent assets and liabilities, at the date of the unaudited condensed consolidated financial
statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates
estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the
use of judgment to prepare financial projections, timing of potential commercialization of acquired in-process intangible assets, applicable
discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable
companies or transactions, determination of fair value of the assets acquired and liabilities assumed including those relating to contingent
consideration, assumptions related to going concern assessments, allocation of direct and indirect expenses, useful lives associated
with long-lived intangible assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies,
valuation allowances related to deferred income taxes, and assumptions used to value debt and stock-based awards and other equity instruments.
Actual results may differ materially from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly,
Oncocyte assessed certain accounting matters that generally require consideration of forecasted financial information. The accounting
matters assessed included, but were not limited to, Oncocyte&#8217;s equity investments, the carrying value of goodwill, going concern
assessment, acquired in-process intangible assets and other long-lived assets. Those assessments as well as other estimates referenced
above were made in the context of information reasonably available to Oncocyte.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock', window );">Business combinations and fair value measurements</a></td>
<td class="text"><p id="xdx_84B_ecustom--BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock_zm0JZ0NZggYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zVjdQpE4iuY4">Business
combinations and fair value measurements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at
fair value on the acquisition date in accordance with ASC 820, <i>Fair Value Measurement</i>. ASC 820 establishes a single authoritative
definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement.
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered
observable and the last unobservable, that may be used to measure fair value, which are the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<i>Level 1 </i>&#8211; Quoted prices in active markets for identical assets and liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<i>Level 2 </i>&#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for
similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated
by observable market data for substantially the full term of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
<i>Level 3 </i>&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable
to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted
on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets
and identifiable intangible assets acquired, including in-process research and development, and liabilities assumed, including any contingent
consideration, as of the acquisition date. Goodwill is recognized as any amount of the fair value of the tangible and identifiable intangible
assets acquired and liabilities assumed in excess of the consideration transferred. ASC 805 precludes the recognition of an assembled
workforce as an asset, effectively subsuming any assembled workforce value into goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented,
Oncocyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for money market funds and marketable
equity securities of Lineage and AgeX common stock held by Oncocyte described below. These assets are measured at fair value using the
period-end quoted market prices as a Level 1 input. Oncocyte also has certain contingent consideration liabilities which are carried
at fair value based on Level 3 inputs (see Note 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3RKpaWznMh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of June 30, 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zmTaNgYcWYHf" style="display: none">Schedule of Fair
Value Measurement of Financial Assets and Liabilities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total carrying and estimated fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left; padding-bottom: 1.5pt">Marketable equity securities</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zrte2Oe4Xsje" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">530</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zmlsnasuFB8l" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">530</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zLhWjk5r3sIa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zJWYuvYPxmpa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zn3zRaxWFSh9" style="border-bottom: Black 2.5pt double; text-align: right">530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJ3K5CDPnLqg" style="border-bottom: Black 2.5pt double; text-align: right">530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zqMfCKTnq4B7" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV4fpBbD8sD8" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent consideration liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zhUYvCFL4uY8" style="border-bottom: Black 1.5pt solid; text-align: right">29,150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zFvKQVbzLoxe" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zDj19v3hYJN1" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zjKMlaBqLsR3" style="border-bottom: Black 1.5pt solid; text-align: right">29,150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630_ztZ3r8fTeEY8" style="border-bottom: Black 2.5pt double; text-align: right">29,150</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuX5gETrWj07" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRbVr03xVsNj" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh2pOmfCD0gh" style="border-bottom: Black 2.5pt double; text-align: right">29,150</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total carrying and estimated fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left; padding-bottom: 1.5pt">Marketable equity securities</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_z4Tev33z1EWi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">433</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zdTflE7GPOx2" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">433</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zzdrgphbJ4M3" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zeuvjS5nU5Gi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zBQNHaivDNA1" style="border-bottom: Black 2.5pt double; text-align: right">433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zezVqYduTUk5" style="border-bottom: Black 2.5pt double; text-align: right">433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMgrynHvJ4Be" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYOxUVrvdDij" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent consideration liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zzdaxrShvpDh" style="border-bottom: Black 1.5pt solid; text-align: right">45,662</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zIc6J1GvURw2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zfUTVBs0Ucrc" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zVAT8i4bZSM8" style="border-bottom: Black 1.5pt solid; text-align: right">45,662</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231_zyECdBhHNRMf" style="border-bottom: Black 2.5pt double; text-align: right">45,662</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGDRKTs94eGk" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDefP5WOZrh9" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0985">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zigpHVQl2mfd" style="border-bottom: Black 2.5pt double; text-align: right">45,662</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zKaCNtGVNq65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate
fair values because of the short-term nature of these items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="text"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zlIkj3sDupkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zGQbyBZFOfBi">Cash,
cash equivalents, and restricted cash</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s reconciliation of cash and cash equivalents, and restricted cash reported within the unaudited condensed consolidated
balance sheets that sum to the total of the same amounts shown in the unaudited condensed consolidated statements of cash flows were
as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zdytl4la5juf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B2_zJpqATCenCh1">Schedule
of Cash and Cash Equivalents and Restricted Cash</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20230630_zJ6xNQ6lEwZd" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zbOy4sanmZce" style="text-align: center; font-weight: bold">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_maCCERCzBSt_zf6VijB9xmCh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,368</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,993</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RestrictedCash_iI_maCCERCzBSt_zgED1GuzIi3k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,700</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_iI_maCCERCzBSt_zl8as0JpcIH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash from discontinuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0998">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,510</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_mtCCERCzBSt_zusozGCYoAfl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash shown in the statements of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,068</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,203</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_8AF_z1Pt03fS2p2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Assets Held for Sale and Discontinued Operations</a></td>
<td class="text"><p id="xdx_841_eus-gaap--DiscontinuedOperationsPolicyTextBlock_z6jQVYPfHbq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zX7Hlyt3Qfbj">Assets
Held for Sale and Discontinued Operations</span></i></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, the Company classified laboratory equipment previously presented in machinery and equipment as held for sale in current
assets, in the unaudited condensed consolidated balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment
(&#8220;ASC 360-10&#8221;) have been met and the transaction was qualified as assets held for sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, the Company entered into various agreements to sell laboratory equipment for an aggregate amount of
$<span id="xdx_905_eus-gaap--IncreaseDecreaseInAssetsHeldForSale_pn5n6_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--VariousAgreementsMember_zba3kXUdbysg" title="Increase (decrease) in asset, held-for-sale">0.6</span> million. As a result, the Company classified the equipment as held for sale as current assets, in the unaudited condensed consolidated
balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment (&#8220;ASC 360-10&#8221;) have been met and
the transaction was qualified as assets held for sale. The equipment was written down to its fair value, less cost to sell, to $<span id="xdx_90C_eus-gaap--InventoryWriteDown_pn5n6_c20230101__20230630_zm94u4G9nNs8" title="Inventory write down">0.2</span> million
in the unaudited condensed consolidated balance sheet. As a result of the sale, the Company recorded an impairment loss of $<span id="xdx_90B_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20230630_zpYCbYN0Vjz7" title="Asset impairment charges">1.3</span> million
on held-for-sale assets, in the unaudited condensed consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management,
having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in
their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate
a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable
and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation
to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the
plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified
as held for sale in the unaudited condensed consolidated balance sheet. Assets classified as held for sale are reported at the lower
of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for
sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discontinued
operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business
that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a
major effect on the Company&#8217;s operations and financial results according to Accounting Standard Codification (&#8220;ASC&#8221;)
Topic 205, <i>Presentation of Financial Statements</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
details surrounding the Company&#8217;s assets and liabilities held for sale and discontinued operations are included in Note 16.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and intangible assets</a></td>
<td class="text"><p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zdALh9iWRtf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_z9k4q47cS8wj">Goodwill
and intangible assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 350, <i>Intangibles &#8211; Goodwill and Other</i>, in-process research and development (&#8220;IPR&amp;D&#8221;)
projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived
intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the
project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts
are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&amp;D assets, including the
current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability
to obtain local determination coverage (&#8220;LCD&#8221;) from the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) for
Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement
of competitors&#8217; diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the
eventual realized value of the IPR&amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;D impairment charges
may occur in future periods. During the period between completion or abandonment, the IPR&amp;D assets will not be amortized but will
be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in
circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts (see
Notes 3 and 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&amp;D,
is not amortized but is tested for impairment at least annually, or if circumstances indicate its value may no longer be recoverable.
Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant
events and factors affecting Oncocyte&#8217;s business. Based on the qualitative assessment, if it is determined that the fair value
of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared
with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte
continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at
the enterprise level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;D discussed in Notes 3 and
4. As of June 30, 2023, goodwill has been fully impaired and acquired IPR&amp;D has been partially impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Long-lived intangible assets</a></td>
<td class="text"><p id="xdx_847_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z43I1D7VHtqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zpKA0ODzalm9">Long-lived
intangible assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
intangible assets, consisting primarily of acquired customer relationships, are stated at acquired cost, less accumulated amortization.
Amortization expense is computed using the straight-line method over the estimated useful life of <span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230630_zgG4WqZN1Jhc" title="Long-lived intangible assets, useful life">5</span> years (see Notes 3 and 4).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent consideration liabilities</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ContingentLiabilityReserveEstimatePolicy_zrQpGIlIQKhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zYjoCbRT84U6">Contingent
consideration liabilities</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of Oncocyte&#8217;s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former
selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones,
from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable
agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and
timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows (see Notes 3 and 4). These obligations
are referred to as contingent consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration
transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling
shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones.
Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings,
such as &#8220;earn-out&#8221; provisions or percentage of future revenues, including royalties paid to the selling shareholders based
on a percentage of certain revenues generated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions
occur, with the subsequent change in fair value recorded in the condensed consolidated statements of operations. Changes in key assumptions
can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that
Oncocyte records in its unaudited condensed consolidated interim financial statements. See Notes 3 and 4 for a full discussion of these
liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investments in capital stock of privately held companies</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--EquityMethodInvestmentsPolicy_zZ7s92dN3mxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zB5wx3auyJye">Investments
in capital stock of privately held companies</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable
interest entity (&#8220;VIE&#8221;) model, and then under the voting interest model in accordance with accounting guidance for consolidations
under Accounting Standards Codification (&#8220;ASC&#8221;) 810-10. If consolidation of the entity is not required under either the VIE
model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with
ASC 323, <i>Investments &#8211; Equity Method and Joint Ventures</i>. The equity method applies to investments in common stock or in-substance
common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically
represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment
balance based on Oncocyte&#8217;s pro rata share of earnings or losses from the investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
February 24, 2021, the date of Oncocyte&#8217;s acquisition of the remaining interests in Razor, through February 16, 2023 the date of
its disposition, Razor entity&#8217;s financial statements have been consolidated with Oncocyte. See Notes 3, 4, and 16 for additional
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zoQTYhsYePXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_z5dg3AsKZ7gi">Impairment
of long-lived assets</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired
and the carrying value may not be recoverable. Oncocyte&#8217;s long-lived assets consist primarily of intangible assets, right-of-use
assets for operating leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are
less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair
value, is recorded. See Notes 3, 4, and 16 for additional information with respect to impairments of long-lived assets. See Note 16 for
disclosure of machinery and equipment impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zsk7ub5YDnIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zYx3gprohqnj">Revenue
recognition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to ASC 606, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration
Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
identifying the contract with a customer,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
identifying the performance obligations in the contract,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
determining the transaction price,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
allocating the transaction price to the performance obligations, and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
recognizing revenue when, or as, an entity satisfies a performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services
in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable
consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal
in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently
resolved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">DetermaRx
testing revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received
from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria (i) through (v)
above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered
complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no
shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered
and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx.
Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the
transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires
significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving
payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual
reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient
history to reliably estimate payment patterns or has had contractual reimbursement arrangements, or both, in place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, Oncocyte had accounts receivable of $<span id="xdx_904_eus-gaap--AccountsReceivableSale_pn5n6_c20230101__20230630__srt--ProductOrServiceAxis__custom--MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember_zbTDkx4S4eEk" title="Accounts receivable">1.6</span> million from Medicare and Medicare Advantage covered DetermaRx tests (see
Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain an allowance for expected credit losses at an amount we estimate to be sufficient to provide adequate protection against losses
resulting from extending credit to our customers. We base this allowance, in the aggregate, on historical collection experience, age
of receivables and general economic conditions. Our bad debts have not been material and have been within management expectations. During
the first quarter of 2023, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, <i>Financial Instruments-Credit
Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> and subsequent amendments to the initial guidance under
ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial
assets, including trade and other receivables. Adoption of this standard did not have a material impact on the Company&#8217;s consolidated
financial statements and related disclosures. As of June 30, 2023 and December 31, 2022, we had a credit loss reserve of $<span id="xdx_90F_eus-gaap--ProvisionForDoubtfulAccounts_pn5n6_c20230101__20230630_zK53gXfBx3ri" title="Provision for doubtful accounts"><span id="xdx_904_eus-gaap--ProvisionForDoubtfulAccounts_pn5n6_c20220101__20221231_zYX0GVuuq9Bf" title="Provision for doubtful accounts">0.2</span></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Pharma
services revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
recognized include Pharma Services performed by Oncocyte&#8217;s Insight and Chronix subsidiaries for its pharmaceutical customers, including
testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These
Pharma Services are generally performed under individual scope of work (&#8220;SOW&#8221;) arrangements or license agreements (together
with SOW the &#8220;Pharma Services Agreements&#8221;) with specific deliverables defined by the customer. Pharma Services are performed
on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with
a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable
basis) and recognizes Pharma Service revenue at that time. Insight identifies each sale of its Pharma Service offering as a single performance
obligation. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license
agreements with customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
of the service and satisfaction of the performance obligation is typically evidenced by access to the report or test made available to
the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs
under which work is performed pursuant to the customer&#8217;s highly customized specifications, Oncocyte has the enforceable right to
bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period
during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage
of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements,
any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed
to the customer as of the date of Oncocyte&#8217;s condensed consolidated financial statements are recorded as contract assets and are
included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified
to accounts receivable in Oncocyte&#8217;s condensed consolidated financial statements when the customer is invoiced according to the
billing schedule in the contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oncocyte
establishes credit loss reserve accounts based on the evaluation of the collectability of its Pharma Services accounts receivables after
considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer&#8217;s
ability to pay, such as a bankruptcy filing or deterioration in the customer&#8217;s operating results or financial position, reasonable
and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to
customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections
and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its
historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are
written off against the credit loss reserve accounts. As of June 30, 2023, Oncocyte has not recorded any losses or credit loss reserve
accounts on its account receivables from Pharma Services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, Oncocyte had accounts receivable from Pharma Services customers of $<span id="xdx_901_eus-gaap--AccountsReceivableSale_pn5n6_c20230101__20230630__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_zjG4mfP83gx6" title="Accounts receivable">0.3</span> million, as compared to $<span id="xdx_90A_eus-gaap--AccountsReceivableSale_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_z02GYWvfQmt2" title="Accounts receivable">0.3</span> million as of
December 31, 2022 (see Note 7). As of June 30, 2023 and December 31, 2022, we have not reserved a credit loss reserve for Pharma Services
accounts receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Licensing
revenue</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte&#8217;s proprietary
testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose
of marketing Oncocyte&#8217;s tests within a defined geographic territory. A license agreement may specify milestone deliverables or
performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte&#8217;s performance
obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing
fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and
ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of revenues</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CostOfSalesPolicyTextBlock_zxfsZ5sugvq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zgAik2cMrqKd">Cost
of revenues</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and
infrastructure expenses, clinical sample related costs associated with performing DetermaRx tests and Pharma Services, providing deliverables
according to our licensing agreements, license fees due to third parties, and amortization of acquired intangible assets such as the
Razor asset and customer relationship intangible assets. Infrastructure expenses include depreciation of laboratory equipment, allocated
rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte&#8217;s CLIA laboratories in
California and Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless
of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues
generated using the associated technology are recorded as expenses at the time the related revenues are recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_z9VYzThSZKkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zmAQLAXY8zZk">Research
and development expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based
compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure
expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development
expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications,
property taxes, and insurance. Research and development costs are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_SalesAndMarketingExpensesPolicyTextBlock', window );">Sales and marketing expenses</a></td>
<td class="text"><p id="xdx_84C_ecustom--SalesAndMarketingExpensesPolicyTextBlock_zSZzKJiXdkvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zhPOYeNSdVCh">Sales
and marketing expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses,
branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead
allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property
taxes, and insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and administrative expenses</a></td>
<td class="text"><p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z9lDskHkVHDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_z3870c4zEFu7">General
and administrative expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive
and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property
taxes, and insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per common share</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zmvDJyck8SM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z6KeBeISQsx6">Net
loss per common share</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and
accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. Diluted loss
per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion
of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that
would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted
method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the
computation if their effect is antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zpRphtLnuNF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents
the calculation of basic and diluted loss per share of common stock (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zQpZ5bBe8SVf">Schedule
of Common Stock Computation of Diluted Net Loss Per Share of Common Stock</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230401__20230630_zi6VhUSRhcLf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220401__20220630_z250A9VByK31" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20230630_zZLffxMsbPOe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20220630_zGHbu2Vm7Qw6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossIncludingPortionAttributableToNoncontrollingInterest_zjjvwqg2rtfd" style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Net loss attributable to Oncocyte Corporation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(8,333</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(8,300</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(5,300</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(18,591</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--DividendOnPreferredStock_zyO5mNeeH4A2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend on Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(166</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--RedeemablePreferredStockDividends_iN_pn3n3_di_zI6LFGQVusXe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(117</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(257</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--DeemedDividendOnPreferredStock_iN_pn3n3_di_zB0jDxh8Nn73" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deemed dividend on Series A redeemable convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_z9ehePWv2Rxk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230401__20230630_zYnUNlYpzbi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted">(8,644</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220401__20220630_z4N0PXtRYJFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted">(8,372</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230630_zllfG01ZWKT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted">(5,841</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220630_zC6uczPfyZx6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted">(18,663</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zR1QiUYWycd4" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders - Basic </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,644</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,372</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,841</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,663</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average shares used in computing net loss per share attributable to common stockholders - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230401__20230630_zRFBQSfPOkbi" title="Weighted average number of shares outstanding, basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230401__20230630_zsUr2lKy1a2k" title="Weighted average number of shares outstanding, diluted">8,090</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220401__20220630_zLJZeVYaGELj" title="Weighted average number of shares outstanding, basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220401__20220630_zSirTTGqB954" title="Weighted average number of shares outstanding, diluted">5,652</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230630_zrwt9ABffUmi" title="Weighted average number of shares outstanding, basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230630_zQW8KDSFUm3" title="Weighted average number of shares outstanding, diluted">7,030</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220630_z7b2pwLFNBO9" title="Weighted average number of shares outstanding, basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220630_z4eHT6aWOVzk" title="Weighted average number of shares outstanding, diluted">5,135</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EarningsPerShareBasic_pid_z2zA7tJPerI4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98F_eus-gaap--EarningsPerShareDiluted_pid_c20230401__20230630_zjxqFaYQCnb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted">(1.07</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220401__20220630_z3A48JpK1jNi" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted">(1.48</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230630_zsjAZl3ZjXgf" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted">(0.83</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220630_z8t0RQsbemKa" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted">(3.63</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pid_zlGdnrGr1wy3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic  net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.07</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.48</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.83</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.63</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgjK9PEZ67Uf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">483</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">731</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">657</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zaYmmxPLXS79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfRcuUjnwSP3" style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">845</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zmgQqoSMUupa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Series A redeemable convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zjFch4FZu3ad" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,582</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,384</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,508</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zd9x3szxLcDa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,582</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,384</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,508</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/></span></p>

<p id="xdx_8A5_z7z5mTtaPrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zAR2qsO6DnPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_867_z57se08r5Vei">Leases</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
accounts for leases in accordance with ASC 842, <i>Leases</i>. Oncocyte determines if an arrangement is a lease at inception. Leases
are classified as either financing or operating, with classification affecting the pattern of expense recognition in the condensed consolidated
statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease
components as a single lease component. Oncocyte recognizes right-of-use (&#8220;ROU&#8221;) assets and lease liabilities for leases
with terms greater than twelve months in the condensed consolidated balance sheet. ROU assets represent the right to use an underlying
asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease
ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most
leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate
the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a
straight-line basis over the lease term. Operating leases are included as right-of-use assets in machinery and equipment, and ROU lease
liabilities, current and long-term, in the condensed consolidated balance sheets. Financing leases are included in machinery and equipment,
and in financing lease liabilities, current and long-term, in the condensed consolidated balance sheets. Oncocyte discloses the amortization
of our ROU assets and operating lease payments as a net amount, &#8220;Amortization of right-of-use assets and liabilities&#8221;, on
the condensed consolidated statements of cash flows. Based on the available practical expedients under the standard, Oncocyte elected
not to capitalize leases that have terms of twelve months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
prior years, Oncocyte entered into various operating leases and an embedded operating lease in accordance with ASC 842 discussed in Note
10. Oncocyte&#8217;s accounting for financing leases remained substantially unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_AccountingForSharesOfCommonStockPolicyTextBlock', window );">Accounting for Lineage and AgeX shares of common stock</a></td>
<td class="text"><p id="xdx_84E_ecustom--AccountingForSharesOfCommonStockPolicyTextBlock_zpQoUHH9QS8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_863_zGtUX57eq779">Accounting
for Lineage and AgeX shares of common stock</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
accounts for the shares of Lineage and AgeX common stock it holds as marketable equity securities in accordance with ASC 320-10-25, <i>Investments
&#8211; Debt and Equity Securities</i>, as amended by Accounting Standards Update (&#8220;ASU&#8221;) 2016-01, <i>Financial Instruments&#8211;Overall:
Recognition and Measurement of Financial Assets and Financial Liabilities</i>, as the shares have a readily determinable fair value quoted
on the NYSE American and are held principally to meet future working capital purposes, as necessary. The securities are measured at fair
value, with related gains and losses in the value of such securities recorded in the condensed consolidated statements of operations
in other income (expense), and are reported as current assets on the condensed consolidated balance sheets based on the closing trading
price of the security as of the date being presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023 and December 31, 2022, Oncocyte held <span id="xdx_903_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20230630__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zEZd0tzlxVGj" title="Common stock, shares held as available for sale securities">353,264</span> and <span id="xdx_90E_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zImG2PjERDme" title="Common stock, shares held as available for sale securities">35,326</span> shares of common stock of Lineage and AgeX, respectively, as
marketable equity securities had a combined fair market value of $<span id="xdx_904_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20230630__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zLN7EUyPGDPl" title="Fair value of equity securities">0.5</span> million and $<span id="xdx_901_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zztEm86lPzuh" title="Fair value of equity securities">0.4</span> million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zj4d3sWVNN3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_867_zX90kLV5ULI3">Recent
accounting pronouncements</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13,
<i>Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> and subsequent amendments
to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit
losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a
valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets,
which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent
changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Previously, U.S. GAAP
required entities to write down credit losses only when losses are probable and loss reversals are not permitted. The Company adopted
this ASU in the first quarter of 2023. Adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial
statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): <i>Accounting for Contract Assets and Contract Liabilities
from Contracts with Customers,</i> to provide specific guidance to eliminate diversity in practice on how to recognize and measure acquired
contract assets and contract liabilities from revenue contracts from customers in a business combination consistent with revenue contracts
with customers not acquired in an acquisition. The amendments in this update provide that the acquirer should consider the terms of the
acquired contracts, such as timing of payment, identify each performance obligation in the contracts, and allocate the total transaction
price to each identified performance obligation on a relative standalone selling price basis as of contract inception (that is, the date
the acquiree entered into the contracts) or contract modification to determine what should be recorded at the acquisition date. These
amendments are effective for the Company beginning with fiscal year 2023. The impact of the adoption of the amendments in this update
will depend on the magnitude of any customer contracts assumed in a business combination in 2023 and beyond.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_AccountingForSharesOfCommonStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting For Shares OfCommon Stock [PolicyTextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_AccountingForSharesOfCommonStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combinations and Fair Value Measurements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_SalesAndMarketingExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales and Marketing Expenses [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_SalesAndMarketingExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821727184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Measurement of Financial Assets and Liabilities</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3RKpaWznMh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of June 30, 2023 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zmTaNgYcWYHf" style="display: none">Schedule of Fair
Value Measurement of Financial Assets and Liabilities</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total carrying and estimated fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left; padding-bottom: 1.5pt">Marketable equity securities</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zrte2Oe4Xsje" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">530</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zmlsnasuFB8l" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">530</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zLhWjk5r3sIa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zJWYuvYPxmpa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zn3zRaxWFSh9" style="border-bottom: Black 2.5pt double; text-align: right">530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJ3K5CDPnLqg" style="border-bottom: Black 2.5pt double; text-align: right">530</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zqMfCKTnq4B7" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV4fpBbD8sD8" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent consideration liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zhUYvCFL4uY8" style="border-bottom: Black 1.5pt solid; text-align: right">29,150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zFvKQVbzLoxe" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zDj19v3hYJN1" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zjKMlaBqLsR3" style="border-bottom: Black 1.5pt solid; text-align: right">29,150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630_ztZ3r8fTeEY8" style="border-bottom: Black 2.5pt double; text-align: right">29,150</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuX5gETrWj07" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRbVr03xVsNj" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh2pOmfCD0gh" style="border-bottom: Black 2.5pt double; text-align: right">29,150</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total carrying and estimated fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left; padding-bottom: 1.5pt">Marketable equity securities</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_z4Tev33z1EWi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">433</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zdTflE7GPOx2" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">433</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zzdrgphbJ4M3" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zeuvjS5nU5Gi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zBQNHaivDNA1" style="border-bottom: Black 2.5pt double; text-align: right">433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zezVqYduTUk5" style="border-bottom: Black 2.5pt double; text-align: right">433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMgrynHvJ4Be" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYOxUVrvdDij" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent consideration liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zzdaxrShvpDh" style="border-bottom: Black 1.5pt solid; text-align: right">45,662</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zIc6J1GvURw2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zfUTVBs0Ucrc" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zVAT8i4bZSM8" style="border-bottom: Black 1.5pt solid; text-align: right">45,662</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231_zyECdBhHNRMf" style="border-bottom: Black 2.5pt double; text-align: right">45,662</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGDRKTs94eGk" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDefP5WOZrh9" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0985">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zigpHVQl2mfd" style="border-bottom: Black 2.5pt double; text-align: right">45,662</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zdytl4la5juf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"><span id="xdx_8B2_zJpqATCenCh1">Schedule
of Cash and Cash Equivalents and Restricted Cash</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20230630_zJ6xNQ6lEwZd" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zbOy4sanmZce" style="text-align: center; font-weight: bold">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_maCCERCzBSt_zf6VijB9xmCh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17,368</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,993</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RestrictedCash_iI_maCCERCzBSt_zgED1GuzIi3k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,700</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_iI_maCCERCzBSt_zl8as0JpcIH2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash from discontinuing operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0998">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,510</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_mtCCERCzBSt_zusozGCYoAfl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash shown in the statements of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,068</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,203</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zpRphtLnuNF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents
the calculation of basic and diluted loss per share of common stock (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zQpZ5bBe8SVf">Schedule
of Common Stock Computation of Diluted Net Loss Per Share of Common Stock</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230401__20230630_zi6VhUSRhcLf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220401__20220630_z250A9VByK31" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20230630_zZLffxMsbPOe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20220630_zGHbu2Vm7Qw6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Numerator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossIncludingPortionAttributableToNoncontrollingInterest_zjjvwqg2rtfd" style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left">Net loss attributable to Oncocyte Corporation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(8,333</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(8,300</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(5,300</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(18,591</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_ecustom--DividendOnPreferredStock_zyO5mNeeH4A2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend on Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(166</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(29</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--RedeemablePreferredStockDividends_iN_pn3n3_di_zI6LFGQVusXe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of Series A redeemable convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(117</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(257</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_ecustom--DeemedDividendOnPreferredStock_iN_pn3n3_di_zB0jDxh8Nn73" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deemed dividend on Series A redeemable convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_z9ehePWv2Rxk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230401__20230630_zYnUNlYpzbi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted">(8,644</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220401__20220630_z4N0PXtRYJFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted">(8,372</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230630_zllfG01ZWKT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted">(5,841</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220630_zC6uczPfyZx6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted">(18,663</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zR1QiUYWycd4" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders - Basic </td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,644</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,372</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,841</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,663</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average shares used in computing net loss per share attributable to common stockholders - Basic and Diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230401__20230630_zRFBQSfPOkbi" title="Weighted average number of shares outstanding, basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230401__20230630_zsUr2lKy1a2k" title="Weighted average number of shares outstanding, diluted">8,090</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220401__20220630_zLJZeVYaGELj" title="Weighted average number of shares outstanding, basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220401__20220630_zSirTTGqB954" title="Weighted average number of shares outstanding, diluted">5,652</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230630_zrwt9ABffUmi" title="Weighted average number of shares outstanding, basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230630_zQW8KDSFUm3" title="Weighted average number of shares outstanding, diluted">7,030</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220630_z7b2pwLFNBO9" title="Weighted average number of shares outstanding, basic"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220630_z4eHT6aWOVzk" title="Weighted average number of shares outstanding, diluted">5,135</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EarningsPerShareBasic_pid_z2zA7tJPerI4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98F_eus-gaap--EarningsPerShareDiluted_pid_c20230401__20230630_zjxqFaYQCnb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted">(1.07</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220401__20220630_z3A48JpK1jNi" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted">(1.48</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230630_zsjAZl3ZjXgf" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted">(0.83</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220630_z8t0RQsbemKa" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted">(3.63</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pid_zlGdnrGr1wy3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic  net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.07</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.48</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.83</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.63</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgjK9PEZ67Uf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">483</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">731</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">657</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zaYmmxPLXS79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfRcuUjnwSP3" style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">845</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">820</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">845</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zmgQqoSMUupa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Series A redeemable convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zjFch4FZu3ad" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,582</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,384</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,508</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zd9x3szxLcDa" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,582</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,384</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,508</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871822249248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Fair Value of Contingent Consideration Liability</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zr62CmVli4Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective
Contingent Consideration liability (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BE_zXLzQ9fEPZy1" style="display: none">Schedule
of Fair Value of Contingent Consideration Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Fair</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Contractual</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Value on the</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Merger Date</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; color: Black">Milestone 1</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_988_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_zW5aIZGI60W8" style="width: 14%; color: Black; text-align: right" title="Contractual Value">1,500</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_z6iz8Hc5EKF7" style="width: 14%; color: Black; text-align: right" title="Fair Value on the Merger Date">1,340</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Milestone 2</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_z8AAqFL8bsy" style="color: Black; text-align: right" title="Contractual Value">3,000</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_zGhydEVa15pg" style="color: Black; text-align: right" title="Fair Value on the Merger Date">1,830</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Milestone 3 <sup id="xdx_F45_zVGjZGh31Un2">(a)</sup></span></td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_zpWwOxo6gMld" style="color: Black; text-align: right" title="Contractual Value">1,500</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_z2cZ4qX0fw0e" style="color: Black; text-align: right" title="Fair Value on the Merger Date">770</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Royalty 1 <sup id="xdx_F44_zb4wasIRrhe5">(b)</sup></span></td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See(b) </span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyOneMember_fKGIp_zVn3EkJpMAO8" style="color: Black; text-align: right" title="Fair Value on the Merger Date">5,980</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Royalty 2 <sup id="xdx_F4D_zwRw9dSDKHw7">(b)</sup></span></td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See(b) </span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyTwoMember_fKGIp_zhj5TRoXpMWk" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Fair Value on the Merger Date">1,210</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630_zDaGfAJD9Rda" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Contractual Value">6,000</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630_zwyBT5L1AwFi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Fair Value on the Merger Date">11,130</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><sup id="xdx_F01_zb2eceMRkTc3">(a)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_znT1wWChX9nd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Indicates
    the maximum payable if the Milestone is achieved.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><sup id="xdx_F04_zTzRw6bHRPqj">(b)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zcX7SCTMlHB4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
    defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful
    life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=OCX_InsightMergerMember', window );">Insight Merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock', window );">Schedule of Contingent Consideration, Measured at Fair Value</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zNbFLAlRDEJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following tables reflect the activity for Oncocyte&#8217;s Contingent Consideration for the six months ended June 30, 2023 and 2022,
measured at fair value using Level 3 inputs (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_zWcmSODB5ZF3" style="display: none">Schedule
of Contingent Consideration, Measured at Fair Value</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; color: Black">Balance at December 31, 2021</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zHLOuhwRwX1l" style="width: 16%; color: Black; text-align: right" title="Beginning balance">7,060</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98B_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zkpPhq7UfiGc" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Change in estimated fair value">1,400</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 2.5pt">Balance at June 30, 2022</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zR1ZhP0Pwvu6" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Beginning balance">8,460</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; color: Black">Balance at December 31, 2022</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_z7klqkL6XAlf" style="width: 16%; color: Black; text-align: right" title="Beginning balance">5,370</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98E_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zhgZfEG7nRY6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Change in estimated fair value">(2,500</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 2.5pt">Balance at June 30, 2023</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zhyHgOLlU4r9" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Beginning balance">2,870</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=OCX_ChronixMergerMember', window );">Chronix Merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock', window );">Schedule of Contingent Consideration, Measured at Fair Value</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zVFsHijgf9R1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following tables reflect the activity for Oncocyte&#8217;s Contingent Consideration for the six months ended June 30, 2023 and June 30,
2022, measured at fair value using Level 3 inputs (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zryJ7Rbu1YH5" style="display: none">Schedule
of Contingent Consideration, Measured at Fair Value</span><span style="color: Black">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; color: Black">Balance at December 31, 2021</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_z5g0QnsIAr39" style="width: 16%; color: Black; text-align: right" title="Beginning balance">69,621</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Change in estimated fair value</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_989_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_znlqDc29oDY2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Change in estimated fair value">(12,415</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 2.5pt">Balance at June 30, 2022</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zePuBAVIo0X9" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Ending balance">57,206</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Fair
    Value</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Balance
    at December 31, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</span></td>
    <td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zq0O6vjV7D09" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">40,292</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Change
    in estimated fair value</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td id="xdx_988_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_z7lb0Qit2Vxh" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in estimated fair value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(14,012</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Balance
    at June 30, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">$</span></td>
    <td id="xdx_983_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zAxmVVnZ6Z6a" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">26,280</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of contingent consideration measured at fair value [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=OCX_InsightMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=OCX_InsightMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=OCX_ChronixMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=OCX_ChronixMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871824587168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Goodwill and Intangible Assets</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zkuWtg5fnVwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">At
June 30, 2023 and December 31, 2022, intangible assets, net, consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BF_z1ntElUJtXUf" style="display: none">Schedule
of Goodwill and Intangible Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Intangible assets:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Acquired IPR&amp;D - DetermaIO <sup id="xdx_F45_z50d1JgML9p8">(1)</sup></span></td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230630__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zd0UJXxJJbn6" style="width: 16%; color: Black; text-align: right" title="Intangible assets acquired IPR&amp;D">9,700</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zX4pGhgdrW7e" style="width: 16%; color: Black; text-align: right" title="Intangible assets acquired IPR&amp;D">14,650</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Acquired IPR&amp;D - DetermaCNI and VitaGraft <sup id="xdx_F4B_zbFL00dbpQ5">(2)</sup></span></td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230630__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zCGNkZococe" style="color: Black; text-align: right" title="Intangible assets acquired IPR&amp;D">46,800</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zOz5SV12oK97" style="color: Black; text-align: right" title="Intangible assets acquired IPR&amp;D">46,800</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Intangible assets subject to amortization:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt">Acquired intangible assets - customer relationship</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpvNVGqMyt49" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Acquired intangible assets">440</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z00ckkSXCPCf" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Acquired intangible assets">440</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Total intangible assets</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20230630_zJ75ddvYgyFg" style="color: Black; text-align: right" title="Total intangible assets">56,940</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20221231_z8PLkXFu9Whe" style="color: Black; text-align: right" title="Total intangible assets">61,890</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accumulated amortization - customer relationship<sup id="xdx_F41_zz21ALezTe4j">(3)</sup></span></td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zwOyH1flKbod" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Finite-lived intangible assets, accumulated amortization">(301</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zBfDr8zMLMJe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Finite-lived intangible assets, accumulated amortization">(257</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20230630_zXvCCFA7Cwjb" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Intangible assets, net">56,639</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20221231_zAFMNxxZ9SLk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Intangible assets, net">61,633</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zb3i25T8jMbd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_zM4dTMPHLKd2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
    Note 3 for information on the Insight Merger.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0A_zf1xpeCdv4Nh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_z4MzpgPX1bUl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
    Note 3 for information on the Chronix Merger.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0E_z4YcBThmyYY4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zrznRYC4dSy1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Amortization
    of intangible assets is included in &#8220;Cost of revenues &#8211; amortization of acquired intangibles&#8221; on the condensed
    consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired
    intangibles.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Intangible Assets Future Amortization Expense</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zlmAtQRW29pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Future
amortization expense of intangible assets subject to amortization is expected to be the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B1_zNjId23XsWCd" style="display: none">Schedule
of Intangible Assets Future Amortization Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230630_zy6ik692tCF7" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Amortization</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Year ending December 31,</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzyWn_z0zj0iJZHfg7" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; color: Black; text-align: left">2023</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 16%; color: Black; text-align: right">44</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzyWn_zc1zdTU4h8Q6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">2024</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">88</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzyWn_zoSArfeed3Wk" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">2025</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">7</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzyWn_z2O6eEIFz0Hc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">139</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821454720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Calculate Fair Value of Stock Options</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_znVbihcDDGN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_zbFjVRKNuywk" style="display: none">Schedule
of Assumptions Used to Calculate Fair Value of Stock Options</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; color: Black; text-align: left">Risk-free interest rates</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zS6GXqshyhFl" style="width: 16%; color: Black; text-align: right" title="Risk-free interest rates">2.72</td><td style="width: 1%; color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Expected term (in years)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zScan6519KL9" title="Expected term (in years)">2.6</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Volatility</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zfqfI8JqNsMc" style="color: Black; text-align: right" title="Volatility">95.0</td><td style="color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Grant date fair value of awards granted during the period</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zqwwvt1LEdea" style="color: Black; text-align: right" title="Grant date fair value of awards granted during the period">22.60</td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z5LNGTnwPm19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A
summary of Oncocyte&#8217;s 2018 Incentive Plan activity and related information follows (in thousands except weighted average exercise
price):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B8_z1p5ZtaNnrsl" style="display: none">Summary
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Shares</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Number</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Number</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Weighted</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Available</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">of Options</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">of RSUs</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Average</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">for Grant</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Outstanding</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Outstanding</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Exercise Price</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black">Balance at December 31, 2022</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zWpYo9KcyF76" style="width: 11%; color: Black; text-align: right" title="Shares available for grant options, beginning of period">442</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zZpp1RzLqs2f" style="width: 11%; color: Black; text-align: right" title="Number of options outstanding, beginning of period">428</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z3AMQbzxUvv7" style="width: 8%; color: Black; text-align: right" title="Number of RSUs Outstanding, beginning of period">22</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zXNv18lN5Ei6" style="width: 14%; color: Black; text-align: right" title="Weighted average exercise price, options outstanding, beginning of period">59.23</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">RSUs vested</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zYb3QJGBQePf" style="color: Black; text-align: right" title="Shares available for grant options RSUs vested"><span style="-sec-ix-hidden: xdx2ixbrl1440">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zbAJWodSEFh8" style="color: Black; text-align: right" title="Number of options outstanding, option RSUs vested"><span style="-sec-ix-hidden: xdx2ixbrl1442">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zkdiDQKHUL8k" style="color: Black; text-align: right" title="Number of RSUs Outstanding, option RSUs vested">(11</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zJ6XNesZvlwd" style="color: Black; text-align: right" title="Weighted average exercise price, options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1446">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">RSUs granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zbYCBYIRLTL8" style="color: Black; text-align: right" title="Shares available for grant options RSUs granted">(10</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zuWhw0y11dIa" style="color: Black; text-align: right" title="Number of options outstanding, option RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1450">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zLrAvC8ibjQ7" style="color: Black; text-align: right" title="Number of RSUs Outstanding, option RSUs granted">5</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zM3rSyS54Dbh" style="color: Black; text-align: right" title="Weighted average exercise price, option RSUs granted"><span style="-sec-ix-hidden: xdx2ixbrl1454">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Options granted</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z2ZDnY6hiFm7" style="color: Black; text-align: right" title="Shares available for grant options granted">(178</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z8lyqrBOxt6c" style="color: Black; text-align: right" title="Number of options outstanding, option granted">178</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zSWQasQEY5H9" style="color: Black; text-align: right" title="Number of RSUs Outstanding, option granted"><span style="-sec-ix-hidden: xdx2ixbrl1460">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zc2i2Yt6Wre8" style="color: Black; text-align: right" title="Weighted average exercise price, option granted">7.72</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Options forfeited/cancelled</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z88uUJWhN4Ze" style="color: Black; text-align: right" title="Shares available for grant options forfeited, cancelled and expired">150</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zxTQetor3MVa" style="color: Black; text-align: right" title="Number of options outstanding, options forfeited, cancelled and expired">(150</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z6iEOpEvAp2h" style="color: Black; text-align: right" title="Number of RSUs Outstanding, options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1468">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zjfFUTP8YKsj" style="color: Black; text-align: right" title="Weighted average exercise price, options forfeited, cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1470">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">RSUs forfeited/cancelled</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zSFd1P701Tf3" style="color: Black; text-align: right" title="Shares available for grant RSUs, cancelled and expired">2</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zOIAXOfygFyh" style="color: Black; text-align: right" title="Number of options outstanding, options forfeited, RSUs cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1474">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zynL5Qcb5eJ5" style="color: Black; text-align: right" title="Number of RSUs Outstanding, options forfeited, canceled and expired">(1</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zry2kFdeHEq7" style="color: Black; text-align: right" title="Weighted average exercise price, options forfeited, RSUs cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1478">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Performance RSUs forfeited/cancelled</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zq93vvRHWQr2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Shares available for grant performance RSUs, cancelled and expired">15</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zb3PM74cW644" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, options forfeited, performance RSUs cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1482">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zcD410D3Owf5" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Performance RSUs Outstanding, options forfeited, canceled and expired">(8</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zXdTYCrQ4ho3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, options forfeited, performance RSUs cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1486">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Balance at June 30, 2023</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zBE452ssKTMk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Shares available for grant outstanding, end of period">421</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zb1bjooPGIp6" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, end of period">456</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zOqu6EdR1Py3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of RSUs Outstanding, end of period">7</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z58qbI1LVeLj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price, outstanding end of period">38.33</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Options exercisable at June 30, 2023</td><td style="color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zQPjFDJSbtw5" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, exercisable, end of period">199</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zIOpWwt77GY4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercisable, end of period">89.54</td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zumb57BYa663" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations
for the three and six months ended June 30, 2023 and 2022 (unaudited and in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B8_zjSkLQRZWvOg" style="display: none">Summary
of Stock-based Compensation Expense</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230401__20230630_z4wQRtx3Fgn1" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220401__20220630_zumjx50dv8Ik" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230630_zpEcUDfgDAqf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20220630_z10e4bZGfdug" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Three Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfRevenuesMember_zCkPYa49noYi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black">Cost of revenues</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 11%; color: Black; text-align: right">2</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 11%; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1503">-</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 11%; color: Black; text-align: right">12</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 11%; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1505">-</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpey2jkfKDj8" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Research and development</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">309</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">201</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">632</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">381</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zoISYlpmpp86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Sales and marketing</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">62</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1513">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">139</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">29</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zBWFQgwYRVy6" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">General and administrative</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">461</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">1,283</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">867</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">2,463</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--DiscontinuedOperationsMember_zT9Otyru4NB8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Discontinuing operations</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1522">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">748</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">18</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">1,369</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zEDH6FLrnMz6" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">834</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">2,232</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">1,668</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">4,242</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Calculate Fair Value of Stock Options</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zQGSpIbAmENg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
assumptions that were used to calculate the grant date fair value of Oncocyte&#8217;s employee and non-employee stock option grants for
the six months ended June 30, 2023 and 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z4UZFSnKmyK7" style="display: none">Schedule
of Assumptions Used to Calculate Fair Value of Stock Options</span><span style="color: Black">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 60%; margin-left: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; color: Black; text-align: left">Expected life (in years)</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630_zeUtM678C3X5" title="Expected life (in years)">6.25</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630_zFHUw2fgj3Zf" title="Expected life (in years)">6.01</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Risk-free interest rates</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630_zm4Uj6iHd28e" style="color: Black; text-align: right" title="Risk-free interest rates">3.76</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630_zVCdVzMVxWr7" style="color: Black; text-align: right" title="Risk-free interest rates">2.24</td><td style="color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">Volatility</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630_z80XuOQGEzJ4" style="color: Black; text-align: right" title="Volatility">105.99</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630_zZREqp28xlml" style="color: Black; text-align: right" title="Volatility">106.98</td><td style="color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Dividend yield</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230101__20230630_z0ANCgUDMkf7" title="Dividend yield">0</span></td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d0_c20220101__20220630_zQb5GWKZB7Uk" title="Dividend yield">0</span></td><td style="color: Black; text-align: left">%</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=OCX_TwoThousandTenPlanActivityMember', window );">2010 Plan Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zUo4G291Qxh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">A
summary of Oncocyte&#8217;s 2010 Plan activity and related information follows (in thousands except weighted average exercise price):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B3_zUVPAoU1vP1i" style="display: none">Summary
of Stock Option Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 75%; margin-left: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Shares</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Number</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Weighted</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Available</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">of Options</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Average</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold">Options</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">for Grant</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; color: Black">Balance at December 31, 2022</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_z3bPk7Z2hlC3" style="width: 14%; color: Black; text-align: right" title="Shares available for grant options, beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zFOGPbH0leT7" style="width: 12%; color: Black; text-align: right" title="Number of options outstanding, beginning of period">30</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zADSJFwO0K48" style="width: 16%; color: Black; text-align: right" title="Weighted average exercise price, options outstanding, beginning of period">80.78</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Options exercised</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zqOvjuGnwdt6" style="color: Black; text-align: right" title="Shares available for grant options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1406">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zjUVWaMiQIF5" style="color: Black; text-align: right" title="Number of options outstanding, option exercised"><span style="-sec-ix-hidden: xdx2ixbrl1408">-</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zhTpksbXooPj" style="color: Black; text-align: right" title="Weighted average exercise price, options exercised"><span style="-sec-ix-hidden: xdx2ixbrl1410">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Options forfeited, cancelled and expired</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zM59qaMLhB44" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Shares available for grant options forfeited, cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1412">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zv8eGHd0dz36" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, options forfeited, cancelled and expired">(1</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zJLp9a92ow0b" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, options forfeited, cancelled and expired"><span style="-sec-ix-hidden: xdx2ixbrl1416">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; padding-bottom: 2.5pt">Balance at June 30, 2023</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zeAulXHuE4Wk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Shares available for grant outstanding, end of period"><span style="-sec-ix-hidden: xdx2ixbrl1418">-</span></td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zdkmWa1lVQB7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, end of period">29</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zoLDCyCZx97e" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price, outstanding end of period">80.58</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; padding-bottom: 1.5pt">Exercisable at June 30, 2023</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_z9qBjbwvr848" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, exercisable, end of period">29</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zy6hs1gHwlV8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercisable, end of period">80.58</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=OCX_TwoThousandTenPlanActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=OCX_TwoThousandTenPlanActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821465920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disaggregation of Revenues and Concentration Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Consolidated Revenues Generated by Unaffiliated Customers</a></td>
<td class="text"><p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zqy0QgGJbp92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents the percentage of consolidated revenues generated by unaffiliated customers that individually represent greater
than ten percent of consolidated revenues:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z3jVQvNEEGnl" style="display: none">Schedule
of Consolidated Revenues Generated by Unaffiliated Customers</span><span style="color: Black">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Three Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black; text-align: left">Pharma services - Company A</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zxfp3alJLkY2" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage">68</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zJCpZ7jkoO6h" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span id="xdx_F2F_z7vMN5d4eRS3" style="color: Black">*</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zlLKyU3olChk" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage">27</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zdjux8jRKO21" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">-</span><span id="xdx_F20_zGRwEbtdpCja">*</span></td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Pharma services - Company B</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zElYATED5ts8" style="color: Black; text-align: right" title="Concentration risk, percentage"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span id="xdx_F25_zyjuziASFAL3" style="color: Black">*</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____z79HgCpzdRdj" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1564">-</span></span></span><span id="xdx_F2F_zu6qsSTvG9V7" style="color: Black">*</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z8V8EfpYmt53" style="color: Black; text-align: right" title="Concentration risk, percentage">14</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zuO8xPUMUUCh" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1568">-</span></span></span><span id="xdx_F2A_zTHi7s59lrpk">*</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Discontinuing operations</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____z9kJz2RKVz3h" style="color: Black; text-align: right" title="Concentration risk, percentage"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span><span id="xdx_F2C_zqqmO4eaVu6a" style="color: Black">*</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zzpR3hpLL0fd" style="color: Black; text-align: right" title="Concentration risk, percentage">89</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_ztNbN4TIqCR6" style="color: Black; text-align: right" title="Concentration risk, percentage">38</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z1s74MtfTMa7" style="color: Black; text-align: right" title="Concentration risk, percentage">82</td><td style="color: Black; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td id="xdx_F02_zNlR4QJccOi" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i id="xdx_F14_z8ncoxfAiM4c">Less
    than 10%</i></span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock', window );">Schedule of Consolidated Revenues Attributable to Products or Services</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock_z2uDC0RRZNUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents the percentage of consolidated revenues by products or services classes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_z2Hu4PVXQd88" style="display: none">Schedule
of Consolidated Revenues Attributable to Products or Services</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; color: Black">&#160;</td><td style="text-align: center; color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Three Months Ended</td><td style="text-align: center; color: Black; font-weight: bold">&#160;</td><td style="text-align: center; color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="text-align: center; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; color: Black">&#160;</td><td style="text-align: center; color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="text-align: center; color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="text-align: center; padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black; text-align: left">Pharma Services</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9Xjrdg7WES3" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage">94</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zvZ9H0lKKCqe" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage">11</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmc4BTMqLoLd" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage">62</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 1%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zzN1D0DgLeBa" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage">18</td><td style="width: 1%; color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">DetermaRx&#8482;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zTYfckakGv1e" style="color: Black; text-align: right" title="Concentration risk, percentage">6</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zEqjMu4engE6" style="color: Black; text-align: right" title="Concentration risk, percentage">0</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zJh79XNBWHk8" style="color: Black; text-align: right" title="Concentration risk, percentage">3</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zZ6NDbOs1tHa" style="color: Black; text-align: right" title="Concentration risk, percentage">0</td><td style="color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Discontinuing operations</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zrPabShcwCIl" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage">0</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zThxy0Kpeh4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage">89</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHggRznVbJZ1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage">35</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmfTXAdFMYzg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage">82</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zan6Cbz7T2pc" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zExgskS5WBt4" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHHBSHiQqXQ3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHsgQISwGKG2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zfyWsQxLnOp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents the percentage of consolidated revenues attributable to geographical locations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B4_z0uLsoGhqduh" style="display: none">Schedule
of Percentage of Consolidated Revenues Attributable to Geographical Locations</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20230630_zdDOIsZiUdE8" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220401__20220630_zdI6I9JfrP6h" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20230630_z6XgtebHtHSc" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20220630_zh59t8KWLAvf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Three Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zip8EzMyc6vj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; color: Black; text-align: left">United States &#8211; Pharma Services</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 11%; color: Black; text-align: right">74</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 11%; color: Black; text-align: right">50</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 11%; color: Black; text-align: right">39</td><td style="width: 1%; color: Black; text-align: left">%</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 11%; color: Black; text-align: right">65</td><td style="width: 1%; color: Black; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--OutsideUnitedStatesPharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zBgnqatcKvq1" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Outside of the United States &#8211; Pharma Services</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">20</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">2</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">23</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">5</td><td style="color: Black; text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zbOL5HCtHxZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">DetermaRx&#8482;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">6</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">0</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">3</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">0</td><td style="color: Black; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DiscontinuedOperationsOutsideUnitedStatesLicensingMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zW4KqOI5Va0b" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Discontinuing operations &#8211; Outside of the United States &#8211; Licensing</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">0</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">48</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">0</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">30</td><td style="color: Black; text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zS9pnQ5RHtt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Discontinuing operations &#8211; United States &#8211; DetermaRx&#8482;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">0</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">0</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">35</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">0</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zyh8OVaiiftb" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; padding-bottom: 2.5pt">Total</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">100</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of consolidated revenues attributable to products or services [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821053360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets, machinery and equipment, net, and construction in progress (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress</a></td>
<td class="text"><p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zvPDTIkyIMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023 and December 31, 2022, right-of-use assets, machinery and equipment, net, and construction in progress were as follows
(in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8B0_z0BVyoOH8m5b" style="display: none">Schedule
of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230630_zUpRJVoNE2Lg" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30, 2023<br/> (unaudited)</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_zuM7ETkm63H3" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td colspan="2" style="color: Black">&#160;</td><td style="color: Black">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_z5jNeFxA5Ht5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20230630_zIG0BrdyttC9" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230630%23MachineryAndEquipmentNetAndConstructionInProgress"><span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20221231_z6b6xO9VJ40a" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230630%23MachineryAndEquipmentNetAndConstructionInProgress"><span style="-sec-ix-hidden: xdx2ixbrl1653"><span style="-sec-ix-hidden: xdx2ixbrl1654">Right-of-use assets</span></span></span></span> <sup id="xdx_F40_zN6xqg4WcXQc">(1)</sup></span></td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right">4,036</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right">3,499</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_zQRBYqk1aqEl" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Machinery and equipment</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">8,644</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">9,408</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_zwtKrC6CA9ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(5,310</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(4,196</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_z0d4N7kgAzAd" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Right-of-use assets, machinery and equipment, net</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">7,370</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">8,711</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ConstructionInProgressGross_iI_pn3n3_zMVwAzmE96Bf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">518</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">2,140</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RightofuseAssetsMachineryAndEquipmentContinuingOperations_iI_pn3n3_ztd6090Il5Mk" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Right-of-use assets, machinery and equipment, net, and construction in progress</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">7,888</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">10,851</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations_iI_pn3n3_zuglr7g44059" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Right-of-use assets, machinery and equipment, net, and construction in progress from discontinuing operations</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1671">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">211</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RightofuseAssetsMachineryAndEquipmentNet_iI_pn3n3_zGONvbakKhIe" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Right-of-use assets, machinery and equipment, net, and construction in progress</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">7,888</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">11,062</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F05_z31mCAvn6Jb4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zmttJPpFz7y8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Oncocyte
    recorded certain right-of-use assets and liabilities for operating leases in accordance with ASC 842 (see Note 10).</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821168992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease</a></td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock_zoU8xW86RGY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents supplemental cash flow information related to operating and financing leases for the six months ended June 30,
2023 and 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_8BA_zyuipxi6fFNe" style="display: none">Schedule
of Supplemental Cash Flow Information Related to Operating and Financing Lease</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20230630_zrziQ1NGvGJ7" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20220630_z7DsbwjOiTcd" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="6" style="color: Black; font-weight: bold; text-align: center">Six Months Ended</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left">Cash paid for amounts included in the measurement of financing lease liabilities:</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zk6EhQKz8Lp1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; color: Black; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">538</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 14%; color: Black; text-align: right">564</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zNUwHdSkQLlg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Operating cash flows from financing leases</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">5</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">12</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_zp4CfHoNVK93" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Financing cash flows from financing leases</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">57</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">51</p></td><td style="color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases</a></td>
<td class="text"><p id="xdx_894_ecustom--ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock_zRGLBGVydjE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
following table presents supplemental balance sheets information related to operating and financing leases as of June 30, 2023 and June
30, 2022 (in thousands, except lease term and discount rate):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><span id="xdx_8BD_zPcrYALQFgAk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Schedule
of Supplemental Balance Sheet Information Related to Operating and Financing Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zC8bf6TbF4Uk" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zw782dUt37jf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left">Operating lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zdS95JagOMV5" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; color: Black; text-align: left; padding-bottom: 1.5pt">Right-of-use assets, net</td><td style="width: 2%; color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right">1,855</td><td style="width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right">2,343</td><td style="width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zWsyf8iLJFS7" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Right-of-use lease liabilities, current</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">677</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">728</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zOPDzbD2GxH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Right-of-use lease liabilities, noncurrent</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">2,398</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">3,075</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_z73ADENYoPJ2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Total operating lease liabilities</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">3,075</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">3,803</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold; text-align: left">Financing lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Machinery and equipment</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">536</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">537</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iNI_pn3n3_di_zNTJmeu4eYrf" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(500</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(391</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--FinanceLeaseRightOfUseAsset_iTI_pn3n3_zE52rflxHsU5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Machinery and equipment, net</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">36</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">146</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_zvxSbovxTIBc" style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">Current liabilities</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">60</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">110</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_zj1n66HYwRh8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Noncurrent liabilities</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1751">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">60</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_zkWZXDTZAsK3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Total financing lease liabilities</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">60</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">170</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold">Weighted average remaining lease term</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Operating lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zgYHD3sS8Vi7" title="Weighted average remaining lease term, Operating lease">4.1</span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zZ2Y4YZTjPs1" title="Weighted average remaining lease term, Operating lease">4.9 </span>years</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Financing lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_z2Dj1XQz6bNi" title="Weighted average remaining lease term, Financing lease">0.5</span> years</span></td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zAoDhPfBHfBd" title="Weighted average remaining lease term, Financing lease">1.5</span> years</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">Weighted average discount rate</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_z8p3245Ffea1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; color: Black; text-align: left">Operating lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">11.28</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">11.20</td><td style="color: Black; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_z7JXatNuyIo2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; color: Black; text-align: left">Financing lease</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">11.55</td><td style="color: Black; text-align: left">%</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">11.55</td><td style="color: Black; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Commitments for Operating and Financing Leases</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock_zB3YPOSoONha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Future
minimum lease commitments are as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zguNJzI8MRc2" style="display: none">Schedule of Future Minimum Lease Commitments for Operating and Financing Leases</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 75%; margin-left: auto">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Operating</td><td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold">&#160;</td>
    <td colspan="2" style="color: Black; font-weight: bold; text-align: center">Financing</td><td style="color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Leases</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">Leases</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold">Year Ending December 31,</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; color: Black; text-align: left">2023</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zriheRiF3Ar7" style="width: 14%; color: Black; text-align: right" title="2023">510</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zk4J6fj1OAoe" style="width: 14%; color: Black; text-align: right" title="2023">62</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">2024</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zLm8IT4JXrZ7" style="color: Black; text-align: right" title="2024">903</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zl6gGSFeX7Ff" style="color: Black; text-align: right" title="2024"><span style="-sec-ix-hidden: xdx2ixbrl1779">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left">2025</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zZH0wxnUymN3" style="color: Black; text-align: right" title="2025">869</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zjb7BBgNdOG5" style="color: Black; text-align: right" title="2025"><span style="-sec-ix-hidden: xdx2ixbrl1783">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">2026</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zT3Liqw1f3Gl" style="color: Black; text-align: right" title="2026">899</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zgaX8I51rNqg" style="color: Black; text-align: right" title="2025"><span style="-sec-ix-hidden: xdx2ixbrl1787">-</span></td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">2027</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zjYefaNdgpl7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="2027">695</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pdn3_c20230630_zy7DLtobbh96" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="2026"><span style="-sec-ix-hidden: xdx2ixbrl1791">-</span></td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Total minimum lease payments</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zk776WVUaCAd" style="color: Black; text-align: right" title="Total minimum lease payments">3,876</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zXrlp9B8YUU5" style="color: Black; text-align: right" title="Total minimum lease payments">62</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Less amounts representing interest</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20230630_z4N4SumEecal" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Less amounts representing interest">(801</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">$</td><td id="xdx_985_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20230630_zqvhCVW531H3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Less amounts representing interest">(2</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Present value of net minimum lease payments</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_985_ecustom--PresentValueOfNetMinimumLeasePayments_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zJHJcUKQCTb" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Present value of net minimum lease payments">3,075</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td id="xdx_98A_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_c20230630_z4EJo3AOkYn2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Present value of net minimum lease payments">60</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of future minimum lease commitments for operating and financing leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating and finance lease balance sheet [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating and finance lease cash flow [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871823710112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets Held for Sale and Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Assets and Liabilities of Disposal Group Held for Sale</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zGdZMxHT2XY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the results of the discontinued operation of Razor (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zxGaizYTg6zc">Schedule
of Discontinued Operations</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230401__20230630_z0gyMZVfHy8h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220401__20220630_zdqYEtBar4F8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20230630_zuBpcQRtcPfg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220630_zYCwMq5QzTl3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_maILFDOz7EG_zskB8uCAfHda" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-align: left; padding-left: 0pt">Net revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2050">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,830</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">421</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,874</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_pn3n3_msILFDOz7EG_zXMm03wbM6zg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2055">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,999</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_pn3n3_msILFDOz7EG_zoOVqv17lnm4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2060">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,251</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_pn3n3_msILFDOz7EG_ztcBHCsHHzIf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2065">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,366</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_pn3n3_msILFDOz7EG_zK53DyhlaqE2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2070">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax_pn3n3_msILFDOz7EG_zSQ2ie5pvEHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Loss from impairment of held for sale assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2075">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2076">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,311</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2078">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pn3n3_maNILziQi_mtILFDOz7EG_z5leA6WS1ql3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Net loss from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2080">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,936</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,926</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,814</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-Sale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Assets and Liabilities of Disposal Group Held for Sale</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hus-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zOQtzHOB0hf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents the carrying amounts of the held for sale related assets and liabilities as of June 30, 2023 and carrying
amounts of the held for sale related assets and liabilities of discontinued operations as of December 31, 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z5eSjrfdTnxh" style="display: none">Schedule
of Assets and Liabilities of Disposal Group Held for Sale</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20230630__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zOzjMJC91CUk" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zDPDc331bJjh" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zo0L4cJtyTE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_iB_zLWgqZ0u2nTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_z4rcUtCfq877" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2093">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,510</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_znknJj3nFopb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2096">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_iI_z03BhLjQQiia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Machinery and equipment, net, and construction in progress</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2099">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">211</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_iI_zJJS9apEFwda" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2102">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,920</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_iI_ztiYQ2fmOHCe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Impairment of held for sale assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2105">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,866</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--Assets_iTI_zjuNc9dwbuNg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2108">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,121</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zxlqfIG4mWg7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_zBjMqrQ9nRXg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">492</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_iI_pn3n3_zpnkOBYVPVti" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2117">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_iI_zdWefBMn5567" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2120">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,265</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_iI_zibFh2pWp4lf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,005</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Liabilities_iTI_zIjraUnT43Od" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0">135</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,005</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes cash used related to Razor as of and for the six months ended June 30, 2023 and 2022 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230630_zPeD0kFUQLb4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20220630_zFYgXi0vnvqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInDiscontinuedOperationsAbstract_iB_zQ4AOA5Y2PY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_i01_zbwC2PUjf0r1" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Net cash used in operating activities</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(4,357</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">(10,549</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zIpX1ulQNjo2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_i01_zfXsAZWSjqc4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2138">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(96</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871810891248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Description of the Business and Liquidity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 24, 2023</div></th>
<th class="th"><div>Apr. 05, 2023</div></th>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Dec. 15, 2022</div></th>
<th class="th"><div>Dec. 15, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Apr. 13, 2022</div></th>
<th class="th"><div>Apr. 12, 2022</div></th>
<th class="th"><div>Apr. 05, 2022</div></th>
<th class="th"><div>Jun. 11, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,976,000<span></span>
</td>
<td class="nump">$ 260,676,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,368,000<span></span>
</td>
<td class="nump">19,993,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,000<span></span>
</td>
<td class="nump">$ 433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,848,000<span></span>
</td>
<td class="nump">$ 32,812,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Net proceeds to immediately redeem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Convertible preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588.23529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_BTIGLLCMember', window );">BTIG, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Fair value of common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-20 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,314,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Net proceeds to immediately redeem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RazorStockPurchaseAgreementMember', window );">Razor Stock Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,366,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RazorStockPurchaseAgreementMember', window );">Razor Stock Purchase Agreement [Member] | Common Stock [Member] | Dragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,188,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_AtTheMarketSalesAgreementMember', window );">At The Market Sales Agreement [Member] | BTIG, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Convertible preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Series A Preferred Stock [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember', window );">Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Underwriter [Member] | Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Underwriter [Member] | Series A Redeemable Convertible Preferred Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Common Stock [Member] | Underwriter [Member] | Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,278,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Net proceeds to immediately redeem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Number of stock redeem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Net proceeds to immediately redeem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Number of stock redeem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Board Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Board Members [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,278,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Other Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_RazorGenomicsIncMember', window );">Razor Genomics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_DragonScientificLLCMember', window );">Dragon Scientific LLC [Member] | Razor Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,188,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_RazorMember', window );">Razor [Member] | Razor Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_RazorMember', window );">Razor [Member] | Razor Stock Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,366,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_RazorMember', window );">Razor [Member] | Razor Stock Purchase Agreement [Member] | Common Stock [Member] | Dragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_BTIGLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_BTIGLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_RazorStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_RazorStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_DragonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_DragonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_BoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_BoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_OtherInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_OtherInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_RazorGenomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_RazorGenomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_DragonScientificLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_DragonScientificLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_RazorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_RazorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871816130416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">$ 530<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
<td class="nump">29,150<span></span>
</td>
<td class="nump">45,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
<td class="nump">29,150<span></span>
</td>
<td class="nump">45,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_MarketableEquitySecuritiesMember', window );">Marketable Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_MarketableEquitySecuritiesMember', window );">Marketable Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_MarketableEquitySecuritiesMember', window );">Marketable Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_MarketableEquitySecuritiesMember', window );">Marketable Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_ContingentConsiderationLiabilitiesMember', window );">Contingent Consideration Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
<td class="nump">29,150<span></span>
</td>
<td class="nump">45,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_ContingentConsiderationLiabilitiesMember', window );">Contingent Consideration Liabilities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_ContingentConsiderationLiabilitiesMember', window );">Contingent Consideration Liabilities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_ContingentConsiderationLiabilitiesMember', window );">Contingent Consideration Liabilities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, Fair Value Disclosure</a></td>
<td class="nump">$ 29,150<span></span>
</td>
<td class="nump">$ 45,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_MarketableEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_MarketableEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_ContingentConsiderationLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_ContingentConsiderationLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871823824496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,368<span></span>
</td>
<td class="nump">$ 19,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Cash from discontinuing operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,510<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash shown in the statements of cash flows</a></td>
<td class="nump">$ 19,068<span></span>
</td>
<td class="nump">$ 23,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871810792992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss attributable to Oncocyte Corporation</a></td>
<td class="num">$ (8,333)<span></span>
</td>
<td class="num">$ (8,300)<span></span>
</td>
<td class="num">$ (5,300)<span></span>
</td>
<td class="num">$ (18,591)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DividendOnPreferredStock', window );">Dividend on Series A redeemable convertible preferred stock</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemablePreferredStockDividends', window );">Accretion of Series A redeemable convertible preferred stock</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="num">(257)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DeemedDividendOnPreferredStock', window );">Deemed dividend on Series A redeemable convertible preferred stock</a></td>
<td class="num">(118)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders - Basic</a></td>
<td class="num">(8,644)<span></span>
</td>
<td class="num">(8,372)<span></span>
</td>
<td class="num">(5,841)<span></span>
</td>
<td class="num">(18,663)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) attributable to common stockholders - diluted</a></td>
<td class="num">$ (8,644)<span></span>
</td>
<td class="num">$ (8,372)<span></span>
</td>
<td class="num">$ (5,841)<span></span>
</td>
<td class="num">$ (18,663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, basic</a></td>
<td class="nump">8,090<span></span>
</td>
<td class="nump">5,652<span></span>
</td>
<td class="nump">7,030<span></span>
</td>
<td class="nump">5,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, diluted</a></td>
<td class="nump">8,090<span></span>
</td>
<td class="nump">5,652<span></span>
</td>
<td class="nump">7,030<span></span>
</td>
<td class="nump">5,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (3.63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, diluted</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (3.63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</a></td>
<td class="nump">1,315,000<span></span>
</td>
<td class="nump">1,582,000<span></span>
</td>
<td class="nump">1,384,000<span></span>
</td>
<td class="nump">1,508,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</a></td>
<td class="nump">483,000<span></span>
</td>
<td class="nump">731,000<span></span>
</td>
<td class="nump">549,000<span></span>
</td>
<td class="nump">657,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</a></td>
<td class="nump">820,000<span></span>
</td>
<td class="nump">845,000<span></span>
</td>
<td class="nump">820,000<span></span>
</td>
<td class="nump">845,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DeemedDividendOnPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DeemedDividendOnPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DividendOnPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend on Series A redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DividendOnPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemablePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemablePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871815755584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAssetsHeldForSale', window );">Increase (decrease) in asset, held-for-sale</a></td>
<td class="num">$ (191)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write down</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Long-lived intangible assets, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair value of equity securities</a></td>
<td class="nump">$ 530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=OCX_LineageAndAgeXMember', window );">Lineage and AgeX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_CommonStockSharesHeldAsAvailableForSaleSecurities', window );">Common stock, shares held as available for sale securities</a></td>
<td class="nump">353,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair value of equity securities</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=OCX_PharmaServicesMember', window );">Pharma Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableSale', window );">Accounts receivable</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember', window );">Medicare for DetermaRx and Medicare Advantage for DetermaRx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableSale', window );">Accounts receivable</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_VariousAgreementsMember', window );">Various Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAssetsHeldForSale', window );">Increase (decrease) in asset, held-for-sale</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_CommonStockSharesHeldAsAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury) held by the entity as available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_CommonStockSharesHeldAsAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease from sale of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in book value of long-lived assets that the reporting entity plans to sell within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=OCX_LineageAndAgeXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=OCX_LineageAndAgeXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_VariousAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_VariousAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871822538768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value of Contingent Consideration Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ContingentConsiderationLiabilityContractualValue', window );">Contractual Value</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value on the Merger Date</a></td>
<td class="nump">11,130<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=OCX_MilestoneOneMember', window );">Milestone 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ContingentConsiderationLiabilityContractualValue', window );">Contractual Value</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value on the Merger Date</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=OCX_MilestoneTwoMember', window );">Milestone 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ContingentConsiderationLiabilityContractualValue', window );">Contractual Value</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value on the Merger Date</a></td>
<td class="nump">1,830<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=OCX_MilestoneThreeMember', window );">Milestone 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ContingentConsiderationLiabilityContractualValue', window );">Contractual Value</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value on the Merger Date</a></td>
<td class="nump">770<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=OCX_RoyaltyOneMember', window );">Royalty 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value on the Merger Date</a></td>
<td class="nump">5,980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=OCX_RoyaltyTwoMember', window );">Royalty 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value on the Merger Date</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Indicates
    the maximum payable if the Milestone is achieved.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">As
    defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful
    life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ContingentConsiderationLiabilityContractualValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability Contractual value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ContingentConsiderationLiabilityContractualValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=OCX_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=OCX_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=OCX_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=OCX_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=OCX_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=OCX_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=OCX_RoyaltyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=OCX_RoyaltyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=OCX_RoyaltyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=OCX_RoyaltyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871822116016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Contingent Consideration, Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 11,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Insight Merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">5,370<span></span>
</td>
<td class="nump">$ 7,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset', window );">Change in estimated fair value</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">2,870<span></span>
</td>
<td class="nump">8,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Chronix Merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">40,292<span></span>
</td>
<td class="nump">69,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset', window );">Change in estimated fair value</a></td>
<td class="num">(14,012)<span></span>
</td>
<td class="num">(12,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 26,280<span></span>
</td>
<td class="nump">$ 57,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in estimated fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=OCX_InsightMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=OCX_InsightMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=OCX_ChronixMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=OCX_ChronixMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871818150896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 08, 2023</div></th>
<th class="th"><div>Apr. 15, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 15, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_FairValueOfContingentConsideration', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=OCX_ChronixBiomedicalIncMember', window );">Chronix Biomedical Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_OncocyteCorpMember', window );">Oncocyte Corp [Member] | Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Outstanding equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_OncocyteCorpMember', window );">Oncocyte Corp [Member] | Sublicense Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Outstanding equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_RazorGenomicsIncMember', window );">Razor Genomics, Inc. [Member] | Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ClinicalTrialExpenseReserveAmount', window );">Clinical trial expense reserve amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_RazorGenomicsIncMember', window );">Razor Genomics, Inc. [Member] | Oncocyte Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Outstanding equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_ChronixBiomedicalIncMember', window );">Chronix Biomedical Inc [Member] | Merger Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_EarnoutPercentageOnCollectionsForSales', window );">Earnout percentage on collections for sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_EarnoutPercentageOnCollectionsForSaleOrLicense', window );">Earnout percentage on collections for sale or license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_ChronixEquityMember', window );">Chronix Equity [Member] | Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_EarnoutPercentageOnCollectionsForSales', window );">Earnout percentage on collections for sales</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_EarnoutPercentageOnCollectionsForSale', window );">Gross proceeds percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_ChronixMilestoneMember', window );">Chronix Milestone [Member] | Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_RoyaltyPaymentsPercentage', window );">Royalty payments</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_ChronixMember', window );">Chronix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_FairValueOfContingentConsideration', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ClinicalTrialExpenseReserveAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical trial expense reserve amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ClinicalTrialExpenseReserveAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_EarnoutPercentageOnCollectionsForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout percentage on collections for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_EarnoutPercentageOnCollectionsForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_EarnoutPercentageOnCollectionsForSaleOrLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout percentage on collections for sale or license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_EarnoutPercentageOnCollectionsForSaleOrLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_EarnoutPercentageOnCollectionsForSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout percentage on collections for sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_EarnoutPercentageOnCollectionsForSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_FairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_FairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_RoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payments percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_RoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=OCX_ChronixBiomedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=OCX_ChronixBiomedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_OncocyteCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_OncocyteCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_DevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_DevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_SublicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_SublicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_RazorGenomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_RazorGenomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_ChronixBiomedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_ChronixBiomedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_ChronixEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_ChronixEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_ChronixMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_ChronixMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_ChronixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_ChronixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871816134464">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Goodwill and Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 56,940<span></span>
</td>
<td class="nump">$ 61,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56,639<span></span>
</td>
<td class="nump">61,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue', window );">Acquired intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">440<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(301)<span></span>
</td>
<td class="num">(257)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_DetermaIOMember', window );">DetermaIO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Intangible assets acquired IPR&amp;D</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">9,700<span></span>
</td>
<td class="nump">14,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_DetermaCNIAndVitaGraftMember', window );">DetermaCNI and VitaGraft [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Intangible assets acquired IPR&amp;D</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 46,800<span></span>
</td>
<td class="nump">$ 46,800<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Amortization
    of intangible assets is included in &#8220;Cost of revenues &#8211; amortization of acquired intangibles&#8221; on the condensed
    consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired
    intangibles.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">See
    Note 3 for information on the Insight Merger.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">See
    Note 3 for information on the Chronix Merger.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expected value at the end of their useful life of a major finite-lived intangible asset class acquired during the period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_DetermaIOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_DetermaIOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_DetermaCNIAndVitaGraftMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_DetermaCNIAndVitaGraftMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821452928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Intangible Assets Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871827695472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, net (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,950<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871809186464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2023</div></th>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Jul. 15, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Apr. 13, 2022</div></th>
<th class="th"><div>Apr. 05, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Preferred stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,848,000<span></span>
</td>
<td class="nump">$ 32,812,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversion of stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holder will be prohibited from converting shares of Series A Preferred Stock into shares of common
stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of common
stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation
solely as to itself up to 19.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion,
provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance
of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the
holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A holder is prohibited from converting shares of Series A Preferred Stock into shares of
common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of
our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership
limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to
the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect
to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer
apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ConversionPricePercentage', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Number of stock redeem value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock no par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,240,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,240,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,932,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,314,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Preferred stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Number of stock redeem value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock no par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,278,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_PreferredStockRemainsOutstandingPercentage', window );">Preferred stock outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash in hand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_IndebtednessExpenses', window );">Indebtedness expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DividendsRatePerPercentage', window );">Dividends rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Convertible preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Preferred stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Number of stock redeem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,064,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,064,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Number of stock redeem value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member] | Oncocyte Corp [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member] | Interest [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member] | Security [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Convertible preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Preferred stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds, closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Preferred stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member] | Securities Purchase Agreement [Member] | Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Convertible preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,765<span></span>
</td>
<td class="nump">588.23529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds, closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_PreferredStockRemainsOutstandingPercentage', window );">Preferred stock outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash in hand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_IndebtednessExpenses', window );">Indebtedness expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Oncocyte Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Equity method investment, description of principal activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">if the daily volume weighted average price of our common stock for 20 out of 30 trading
days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000
shares of our common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">if the daily volume weighted average price of our common stock for 20 out
of 30 trading days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or
exceeds 20,000 shares of our common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Oncocyte Corp [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Security [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Number of stock redeem</a></td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Number of stock redeem value</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DividendsRatePerPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends rate per percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DividendsRatePerPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_IndebtednessExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indebtedness expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_IndebtednessExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_PreferredStockRemainsOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock remains outstanding percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_PreferredStockRemainsOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the principal activities of an investee accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=OCX_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_OncocyteCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_OncocyteCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_SecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_SecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821603840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">2.24%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">105.99%<span></span>
</td>
<td class="nump">106.98%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=OCX_MarketBasedAwardsMember', window );">Market Based Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">2.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value of awards granted during the period</a></td>
<td class="nump">$ 22.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=OCX_MarketBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=OCX_MarketBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871809094352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock Option Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=OCX_TwoThousandTenPlanActivityMember', window );">2010 Plan Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares available for grant options, beginning of period</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning of period</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, options outstanding, beginning of period | $ / shares</a></td>
<td class="nump">$ 80.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Shares available for grant options exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options outstanding, option exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Shares available for grant options forfeited, cancelled and expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options outstanding, options forfeited, cancelled and expired</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options forfeited, cancelled and expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares available for grant outstanding, end of period</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, end of period</a></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding end of period | $ / shares</a></td>
<td class="nump">$ 80.58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options outstanding, exercisable, end of period</a></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, exercisable, end of period | $ / shares</a></td>
<td class="nump">$ 80.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=OCX_TwoThousandEighteenPalnActivityMember', window );">2018 Paln Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares available for grant options, beginning of period</a></td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning of period</a></td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, options outstanding, beginning of period | $ / shares</a></td>
<td class="nump">$ 59.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options outstanding, options forfeited, cancelled and expired</a></td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options forfeited, cancelled and expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares available for grant outstanding, end of period</a></td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, end of period</a></td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding end of period | $ / shares</a></td>
<td class="nump">$ 38.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options outstanding, exercisable, end of period</a></td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price, exercisable, end of period | $ / shares</a></td>
<td class="nump">$ 89.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs Outstanding, beginning of period</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod', window );">Shares available for grant options RSUs vested</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod', window );">Number of options outstanding, option RSUs vested</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs', window );">Number of RSUs Outstanding, option RSUs vested</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice', window );">Weighted average exercise price, options exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross', window );">Shares available for grant options RSUs granted</a></td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross', window );">Number of options outstanding, option RSUs granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs', window );">Number of RSUs Outstanding, option RSUs granted</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, option RSUs granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross', window );">Shares available for grant options granted</a></td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options outstanding, option granted</a></td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs Outstanding, option granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, option granted | $ / shares</a></td>
<td class="nump">$ 7.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited', window );">Shares available for grant options forfeited, cancelled and expired</a></td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs Outstanding, options exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares', window );">Shares available for grant RSUs, cancelled and expired</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod', window );">Number of options outstanding, options forfeited, RSUs cancelled and expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited', window );">Number of RSUs Outstanding, options forfeited, canceled and expired</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options forfeited, RSUs cancelled and expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares', window );">Shares available for grant performance RSUs, cancelled and expired</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod', window );">Number of options outstanding, options forfeited, performance RSUs cancelled and expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited', window );">Number of Performance RSUs Outstanding, options forfeited, canceled and expired</a></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options forfeited, performance RSUs cancelled and expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs Outstanding, end of period</a></td>
<td class="nump">7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of RSUs Outstanding, option RSUs granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options performance restricted stock options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options restricted stock options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of RSUs Outstanding, option RSUs vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share based Payment Award Options Available Grants In Period Gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options available restricted stock options grants in period gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options available restricted stock options vested in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award performance restricted stock units options forfeitures in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Options Outstanding, Option RSUs Granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based CompensationArrangement By Share Based Payment Award Restricted Stock Options Vested In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award restricted stock units options forfeitures in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Vesting Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award performance restricted stock units options forfeitures in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award restricted stock grants in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangements by sharebased payment award restricted stock units options forfeitures in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options nonvested performance restricted stock options forfeited number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award options nonvested restricted stock options forfeited number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options nonvested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=OCX_TwoThousandTenPlanActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=OCX_TwoThousandTenPlanActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=OCX_TwoThousandEighteenPalnActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=OCX_TwoThousandEighteenPalnActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821107040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 834<span></span>
</td>
<td class="nump">$ 2,232<span></span>
</td>
<td class="nump">$ 1,668<span></span>
</td>
<td class="nump">$ 4,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Cost Of Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Selling and Marketing Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">62<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">867<span></span>
</td>
<td class="nump">2,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 1,369<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=OCX_CostOfRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=OCX_CostOfRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=OCX_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=OCX_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871822111168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 16, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">2.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.99%<span></span>
</td>
<td class="nump">106.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share based payment award description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the achievement of performance minimum, target, and maximum
goals of (i) 90% of revenue goal; (ii) 100% of revenue goal; and (iii) exceed revenue goal by up to 150%, respectively, during fiscal
year 2022<span></span>
</td>
<td class="text">the Company of average market capitalization
minimum, target, and maximum goals of (i) $300 million; (ii) $400 million; and (iii) $500 million, respectively, during the period beginning
on January 1, 2022 and ending on December 31, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption', window );">Increase in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_VitaGraftMember', window );">Vita Graft [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vested percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_DetermalOMember', window );">Determal O [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vested percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_DetermaCNIMember', window );">Determa CNI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based payment award vesting rights description</a></td>
<td class="text">The remaining 50% is eligible to vest on December 31, 2023, since the Company completed the LCD submission for DetermaCNI on December
16, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share based payment award description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member] | Executive Officers and Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,750<span></span>
</td>
<td class="nump">61,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=OCX_MarketBasedAwardsMember', window );">Market Based Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=OCX_MarketBasedAwardsMember', window );">Market Based Awards [Member] | Executive Officers and Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_MonteCarloValuationTechniqueMember', window );">Monte Carlo Valuation Technique [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=OCX_TwoThousandTenStockOptionPlanMember', window );">2010 Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=OCX_PerformanceBasedOptionsMember', window );">Performance-Based Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=OCX_TwoThousandEighteenIncentivePlanMember', window );">2018 Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_VitaGraftMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_VitaGraftMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_DetermalOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_DetermalOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_DetermaCNIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_DetermaCNIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_ExecutiveOfficersAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_ExecutiveOfficersAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=OCX_MarketBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=OCX_MarketBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_MonteCarloValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_MonteCarloValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=OCX_TwoThousandTenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=OCX_TwoThousandTenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=OCX_PerformanceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=OCX_PerformanceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=OCX_TwoThousandEighteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=OCX_TwoThousandEighteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871822535904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details) - Revenue Benchmark [Member] - Product Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Jun. 30, 2023</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=OCX_PharmaServicesCompanyAMember', window );">Pharma Services Company A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=OCX_PharmaServicesCompanyBMember', window );">Pharma Services Company B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=OCX_DiscontinuedOperationsDetermaRxMember', window );">Discontinued Operations Determa Rx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">89.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less
    than 10%</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=OCX_PharmaServicesCompanyAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=OCX_PharmaServicesCompanyAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=OCX_PharmaServicesCompanyBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=OCX_PharmaServicesCompanyBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=OCX_DiscontinuedOperationsDetermaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=OCX_DiscontinuedOperationsDetermaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871822235632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Consolidated Revenues Attributable to Products or Services (Details) - Revenue Benchmark [Member] - Product Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=OCX_PharmaServicesMember', window );">Pharma Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=OCX_DetermaRxMember', window );">DetermaRx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=OCX_DiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=OCX_PharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=OCX_PharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=OCX_DetermaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=OCX_DetermaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=OCX_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=OCX_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871823634176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details) - Revenue Benchmark [Member] - Product Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=OCX_OutsideUnitedStatesPharmaServicesMember', window );">Outside United States Pharma Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=OCX_DetermaRxMember', window );">DetermaRx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=OCX_DiscontinuedOperationsOutsideUnitedStatesLicensingMember', window );">Discontinued Operations Outside United States Licensing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=OCX_DiscontinuedOperationsDetermaRxMember', window );">Discontinued Operations Determa Rx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=OCX_OutsideUnitedStatesPharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=OCX_OutsideUnitedStatesPharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=OCX_DetermaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=OCX_DetermaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=OCX_DiscontinuedOperationsOutsideUnitedStatesLicensingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=OCX_DiscontinuedOperationsOutsideUnitedStatesLicensingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=OCX_DiscontinuedOperationsDetermaRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=OCX_DiscontinuedOperationsDetermaRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871823799376">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 4,036<span></span>
</td>
<td class="nump">$ 3,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Machinery and equipment, net, and construction in progress<span></span>
</td>
<td class="text">Machinery and equipment, net, and construction in progress<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,644<span></span>
</td>
<td class="nump">$ 9,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,310)<span></span>
</td>
<td class="num">(4,196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Right-of-use assets, machinery and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,370<span></span>
</td>
<td class="nump">8,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">518<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations', window );">Right-of-use assets, machinery and equipment, net, and construction in progress</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,888<span></span>
</td>
<td class="nump">10,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations', window );">Right-of-use assets, machinery and equipment, net, and construction in progress from discontinuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_RightofuseAssetsMachineryAndEquipmentNet', window );">Right-of-use assets, machinery and equipment, net, and construction in progress</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,888<span></span>
</td>
<td class="nump">$ 11,062<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Oncocyte
    recorded certain right-of-use assets and liabilities for operating leases in accordance with ASC 842 (see Note 10).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use assets machinery and equipment continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of use Assets Machinery And Equipment Discontinuing Operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_RightofuseAssetsMachineryAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets, machinery and equipment, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_RightofuseAssetsMachineryAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871823978432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets, machinery and equipment, net, and construction in progress (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 435,000<span></span>
</td>
<td class="nump">$ 384,000<span></span>
</td>
<td class="nump">$ 885,000<span></span>
</td>
<td class="nump">$ 671,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871821836048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 538<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from financing leases</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from financing leases</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871818155504">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 4,036<span></span>
</td>
<td class="nump">$ 3,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Machinery and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">$ 2,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total financing lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=OCX_OperatingAndFinancingLeasesMember', window );">Operating and Financing Leases [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Right-of-use lease liabilities, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use lease liabilities, noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,075<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Machinery and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Machinery and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total financing lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, Operating lease</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, Financing lease</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Financing lease</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.55%<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Oncocyte
    recorded certain right-of-use assets and liabilities for operating leases in accordance with ASC 842 (see Note 10).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=OCX_OperatingAndFinancingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=OCX_OperatingAndFinancingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871809087616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">3,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest</a></td>
<td class="num">(801)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_PresentValueOfNetMinimumLeasePayments', window );">Present value of net minimum lease payments</a></td>
<td class="nump">3,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total financing lease liabilities</a></td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_PresentValueOfNetMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of net minimum lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_PresentValueOfNetMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871809169632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 23, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 27, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=OCX_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_PaymentObligationAmount', window );">Payment obligation amount.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=OCX_ExecutiveOfficersMember', window );">Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_OfficeLeaseAgreementMember', window );">Office Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land | ft&#178;</a></td>
<td class="nump">26,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="nump">$ 61,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Total tenant improvement allowance</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment', window );">Percentage of administrative fee paid on original cost of equipment</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line of Credit, Current</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_OfficeLeaseAgreementMember', window );">Office Lease Agreement [Member] | Landlord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Total tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_OfficeLeaseAgreementMember', window );">Office Lease Agreement [Member] | Monthly Rent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_CapitalLeaseAgreementImputedAnnualInterestRate', window );">Interest rate on lease agreement</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ObligatedToPayExpensesAndTaxesPercentage', window );">Obligated to pay expenses and taxes percentage</a></td>
<td class="nump">43.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_OfficeLeaseAgreementMember', window );">Office Lease Agreement [Member] | First Ten Calendar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_CapitalLeaseAgreementImputedAnnualInterestRate', window );">Interest rate on lease agreement</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_LeaseAgreementMember', window );">Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_DevelopmentAgreementMember', window );">Development Agreement [Member] | Oncocyte Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Outstanding equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_CapitalLeaseAgreementImputedAnnualInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to annual interest rate on capital lease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_CapitalLeaseAgreementImputedAnnualInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ObligatedToPayExpensesAndTaxesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligated to pay expenses and taxes percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ObligatedToPayExpensesAndTaxesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_PaymentObligationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment obligation amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_PaymentObligationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of administrative fee paid on original cost of equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=OCX_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=OCX_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_ExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_ExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_OfficeLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_OfficeLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_LandlordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_LandlordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=OCX_MonthlyRentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=OCX_MonthlyRentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=OCX_FirstTenCalendarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=OCX_FirstTenCalendarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_LeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_LeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_DevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_DevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_OncocyteCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_OncocyteCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871827815152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Workforce Reduction (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DisclosureWorkforceReductionAbstract', window );"><strong>Workforce Reduction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee severance</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DisclosureWorkforceReductionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DisclosureWorkforceReductionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871812743888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Apr. 13, 2022</div></th>
<th class="th"><div>Apr. 13, 2022</div></th>
<th class="th"><div>Apr. 12, 2022</div></th>
<th class="th"><div>Apr. 05, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,453,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Stock issued during period, value conversion of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 834,000<span></span>
</td>
<td class="nump">$ 2,232,000<span></span>
</td>
<td class="nump">$ 1,668,000<span></span>
</td>
<td class="nump">$ 4,242,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=OCX_ArnoMember', window );">Arno [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,314,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,266,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,266,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,453,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Stock issued during period, value conversion of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_BroadwoodCapitalLPMember', window );">Broadwood Capital LP [Member] | Underwritten Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,187<span></span>
</td>
<td class="nump">300,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_BroadwoodCapitalLPMember', window );">Broadwood Capital LP [Member] | Underwritten Offering [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,154<span></span>
</td>
<td class="nump">39,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_BroadwoodCapitalLPMember', window );">Broadwood Capital LP [Member] | Underwritten Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_BroadwoodCapitalLPMember', window );">Broadwood Capital LP [Member] | Underwritten Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_PuraVidaInvestmentsLLCMember', window );">Pura Vida Investments LLC [Member] | Underwritten Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,585<span></span>
</td>
<td class="nump">286,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_PuraVidaInvestmentsLLCMember', window );">Pura Vida Investments LLC [Member] | Underwritten Offering [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_PuraVidaInvestmentsLLCMember', window );">Pura Vida Investments LLC [Member] | Underwritten Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,093<span></span>
</td>
<td class="nump">150,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_PuraVidaInvestmentsLLCMember', window );">Pura Vida Investments LLC [Member] | Underwritten Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_HalleSpecialSituationsFundLLCMember', window );">Halle Special Situations Fund L L C [Member] | Underwritten Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,472<span></span>
</td>
<td class="nump">356,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_HalleSpecialSituationsFundLLCMember', window );">Halle Special Situations Fund L L C [Member] | Underwritten Offering [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_HalleSpecialSituationsFundLLCMember', window );">Halle Special Situations Fund L L C [Member] | Underwritten Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,236<span></span>
</td>
<td class="nump">178,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_HalleSpecialSituationsFundLLCMember', window );">Halle Special Situations Fund L L C [Member] | Underwritten Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Stock issued during period, shares, conversion of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588.23529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Stock issued during period, value conversion of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 618,672.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Series A Preferred Stock [Member] | Broadwood Capital LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176.48<span></span>
</td>
<td class="nump">5,882.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares</a></td>
<td class="nump">2,274,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction, description</a></td>
<td class="text">(i) $6.03 to investors who are not considered to be &#8220;insiders&#8221; of the Company
pursuant to Nasdaq Listing Rules (&#8220;Insiders&#8221;), which amount reflects the average closing price of the Common Stock on Nasdaq
during the five trading day period immediately prior to pricing, and (ii) $7.08 to Insiders, which amount reflects the final closing
price of the Common Stock on Nasdaq on the last trading day immediately prior to pricing (the &#8220;2023 Registered Direct Offering&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Stock [Member] | Arno [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares</a></td>
<td class="nump">21,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts</a></td>
<td class="nump">$ 150,000.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Stock [Member] | Mr Gutfreund [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares</a></td>
<td class="nump">85,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts</a></td>
<td class="nump">$ 604,252.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Stock [Member] | Broadwood Partners LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares</a></td>
<td class="nump">1,341,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts</a></td>
<td class="nump">$ 8,093,361.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Stock [Member] | Pura Vida [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares</a></td>
<td class="nump">33,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts</a></td>
<td class="nump">$ 200,013.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Stock [Member] | AVM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering shares</a></td>
<td class="nump">472,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts</a></td>
<td class="nump">$ 2,849,999.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481440/840-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-7<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479741/842-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=OCX_ArnoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=OCX_ArnoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_BroadwoodCapitalLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_BroadwoodCapitalLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=OCX_UnderwrittenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=OCX_UnderwrittenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_PuraVidaInvestmentsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_PuraVidaInvestmentsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_HalleSpecialSituationsFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_HalleSpecialSituationsFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=OCX_MrGutfreundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=OCX_MrGutfreundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_BroadwoodPartnersLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_BroadwoodPartnersLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_PuraVidaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_PuraVidaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_AVMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_AVMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871822197248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loan Payable to Silicon Valley Bank (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 02, 2020</div></th>
<th class="th"><div>Oct. 17, 2019</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 23, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.00<span></span>
</td>
<td class="nump">$ 109.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_AmendedLoanAgreementMember', window );">Amended Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_AmendedLoanAgreementMember', window );">Amended Loan Agreement [Member] | Bank Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt instrument, final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_AmendedLoanAgreementMember', window );">Amended Loan Agreement [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line of credit, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt instrument, final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_AmendedLoanAgreementMember', window );">Amended Loan Agreement [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line of credit, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_AmendedLoanAgreementMember', window );">Amended Loan Agreement [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Bank Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_PercentageForWarrantExercisePricePerShare', window );">Percentage for warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DilutedEquityOutstanding', window );">Diluted equity outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_LoanDeferralAgreementMember', window );">Loan Deferral Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument maturity date description</a></td>
<td class="text">Under the Loan Deferral Agreement, the Bank agreed to (i) extend
the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal
payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May
1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided
at no additional fees to Oncocyte<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DilutedEquityOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Diluted equity outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DilutedEquityOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_PercentageForWarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage for warrant exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_PercentageForWarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=OCX_BankWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=OCX_BankWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_LoanDeferralAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_LoanDeferralAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871824175072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Co-Development Agreement with Life Technologies Corporation (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=OCX_LifeTechnologiesCorporationMember', window );">Life Technologies Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development costs</a></td>
<td class="nump">$ 749,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=OCX_LifeTechnologiesCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=OCX_LifeTechnologiesCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871814324304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offerings (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2023</div></th>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Jul. 15, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Apr. 13, 2022</div></th>
<th class="th"><div>Apr. 05, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,848,000<span></span>
</td>
<td class="nump">$ 32,812,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversion of stock description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holder will be prohibited from converting shares of Series A Preferred Stock into shares of common
stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of common
stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation
solely as to itself up to 19.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion,
provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance
of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the
holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A holder is prohibited from converting shares of Series A Preferred Stock into shares of
common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of
our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership
limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to
the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect
to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer
apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_PercentageOfIssuedAndOutstandingShares', window );">Percentage of issued and outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_ConversionPricePercentage', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Net proceeds to immediately redeem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=OCX_AprilTwoThousandTwentyTwoWarrantsMember', window );">April 2022 Warrants [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=OCX_AprilTwoThousandTwentyTwoWarrantsMember', window );">April 2022 Warrants [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Net proceeds to immediately redeem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,314,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Board Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Other Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,278,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Maximum [Member] | Board Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,278,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember', window );">Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | April 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember', window );">Underwriting Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Stock issued during period, shares, conversion of units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,765<span></span>
</td>
<td class="nump">588.23529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred stock, convertible, shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible, conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_PurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_StatedValue', window );">Stated value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock and preference stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_PreferredStockRemainsOutstandingPercentage', window );">Preferred stock outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash in hand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_IndebtednessExpenses', window );">Indebtedness expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends, preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Oncocyte Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Equity method investment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">if the daily volume weighted average price of our common stock for 20 out of 30 trading
days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000
shares of our common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">if the daily volume weighted average price of our common stock for 20 out
of 30 trading days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or
exceeds 20,000 shares of our common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Oncocyte Corp [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Security [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Net proceeds to immediately redeem</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Number of stock redeem</a></td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Two Equal Tranches [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock and preference stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Net proceeds to immediately redeem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Number of stock redeem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_ConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_ConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_IndebtednessExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indebtedness expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_IndebtednessExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_PercentageOfIssuedAndOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Issued and Outstanding Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_PercentageOfIssuedAndOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_PreferredStockRemainsOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock remains outstanding percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_PreferredStockRemainsOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_StatedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_StatedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the principal activities of an investee accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=OCX_AprilTwoThousandTwentyTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=OCX_AprilTwoThousandTwentyTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_BoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_BoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_OtherInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_OtherInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_OncocyteCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_OncocyteCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_SecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_SecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=OCX_TwoEqualTranchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=OCX_TwoEqualTranchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871915137024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Discontinued Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Net revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,830<span></span>
</td>
<td class="nump">$ 421<span></span>
</td>
<td class="nump">$ 2,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,175<span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment', window );">Research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,130<span></span>
</td>
<td class="nump">702<span></span>
</td>
<td class="nump">6,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing', window );">Sales and marketing</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,395<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="nump">6,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax', window );">Loss from impairment of held for sale assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,311<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss from discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (6,936)<span></span>
</td>
<td class="num">$ (2,926)<span></span>
</td>
<td class="num">$ (13,814)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation sales and marketing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to noncontrolling interest. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871822269136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Assets and Liabilities of Disposal Group Held for Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">$ 87,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">39,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(4,357)<span></span>
</td>
<td class="num">$ (10,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-Sale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment', window );">Machinery and equipment, net, and construction in progress</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent', window );">Intangible assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales', window );">Impairment of held for sale assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,866)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation', window );">Accrued compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation accrued expenses other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation impairment of held for sale assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OCX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871814146640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets Held for Sale and Discontinued Operations (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 15, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 191,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313,000<span></span>
</td>
<td class="nump">1,314,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RazorStockPurchaseAgreementMember', window );">Razor Stock Purchase Agreement [Member] | Razor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RazorStockPurchaseAgreementMember', window );">Razor Stock Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,366,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RazorStockPurchaseAgreementMember', window );">Razor Stock Purchase Agreement [Member] | Common Stock [Member] | Razor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RazorStockPurchaseAgreementMember', window );">Razor Stock Purchase Agreement [Member] | Common Stock [Member] | Razor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,366,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss on disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RazorStockPurchaseAgreementMember', window );">Razor Stock Purchase Agreement [Member] | Common Stock [Member] | Dragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,188,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_RazorStockPurchaseAgreementMember', window );">Razor Stock Purchase Agreement [Member] | Common Stock [Member] | Dragon [Member] | Razor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_LaboratoryEquipmentAgreementMember', window );">Laboratory Equipment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Proceeds from sale of equipment</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment loss</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=OCX_AuctionEquipmentAgreementMember', window );">Auction Equipment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal and held-for-sale assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482309/360-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_RazorStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_RazorStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_RazorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_RazorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=OCX_RazorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=OCX_RazorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OCX_DragonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OCX_DragonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_LaboratoryEquipmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_LaboratoryEquipmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=OCX_AuctionEquipmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=OCX_AuctionEquipmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139871822249056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jul. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-20 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:OCX="http://oncocyte.com/20230630"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ocx-20230630.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <instant>2023-08-03</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-02-23_custom_RazorGenomicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorGenomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-23</instant>
        </period>
    </context>
    <context id="From2022-12-152022-12-15_custom_RazorStockPurchaseAgreementMember_custom_DragonScientificLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:DragonScientificLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-15</startDate>
            <endDate>2022-12-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-15_custom_RazorStockPurchaseAgreementMember_custom_DragonScientificLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:DragonScientificLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-15</instant>
        </period>
    </context>
    <context id="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_custom_RazorMember_us-gaap_CommonStockMember_custom_DragonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:DragonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-16</instant>
        </period>
    </context>
    <context id="From2023-02-152023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_custom_RazorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-16</instant>
        </period>
    </context>
    <context id="From2023-07-232023-07-24_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-23</startDate>
            <endDate>2023-07-24</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-24_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-24</instant>
        </period>
    </context>
    <context id="From2021-06-102021-06-11_custom_AtTheMarketSalesAgreementMember_custom_BTIGLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BTIGLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-10</startDate>
            <endDate>2021-06-11</endDate>
        </period>
    </context>
    <context id="From2021-07-012023-06-30_custom_BTIGLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BTIGLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_BTIGLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BTIGLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="From2022-06-012022-06-01_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="From2022-06-012022-06-01_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="From2022-04-122022-04-12_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-12</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-12_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-12</instant>
        </period>
    </context>
    <context id="AsOf2022-04-12_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-12</instant>
        </period>
    </context>
    <context id="From2022-04-182022-04-19_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-18</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_custom_BoardMembersMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:BoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-03_custom_RegisteredDirectOfferingMember_custom_BoardMembersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:BoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-03</instant>
        </period>
    </context>
    <context id="AsOf2023-04-03_custom_RegisteredDirectOfferingMember_custom_OtherInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:OtherInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-03</instant>
        </period>
    </context>
    <context id="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_MarketableEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member_custom_MarketableEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member_custom_MarketableEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_MarketableEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_ContingentConsiderationLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member_custom_ContingentConsiderationLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member_custom_ContingentConsiderationLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_ContingentConsiderationLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MarketableEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_custom_MarketableEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_custom_MarketableEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MarketableEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ContingentConsiderationLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_custom_ContingentConsiderationLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_custom_ContingentConsiderationLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_ContingentConsiderationLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:ContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_VariousAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:VariousAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_PharmaServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PharmaServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:PharmaServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_LineageAndAgeXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">OCX:LineageAndAgeXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LineageAndAgeXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">OCX:LineageAndAgeXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_InsightMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_ChronixMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_MilestoneOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_MilestoneTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_MilestoneThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_RoyaltyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:RoyaltyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_RoyaltyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:RoyaltyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-15_custom_RazorGenomicsIncMember_custom_OncocyteCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:RazorGenomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-15</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_DevelopmentAgreementMember_custom_OncocyteCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_DevelopmentAgreementMember_custom_RazorGenomicsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:DevelopmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:RazorGenomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_SublicenseAgreementMember_custom_OncocyteCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2021-04-142021-04-15_srt_MaximumMember_custom_MergerAgreementMember_custom_ChronixBiomedicalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:ChronixBiomedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-14</startDate>
            <endDate>2021-04-15</endDate>
        </period>
    </context>
    <context id="From2023-02-072023-02-08_custom_MergerAgreementMember_custom_ChronixEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:ChronixEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-08</endDate>
        </period>
    </context>
    <context id="From2023-02-072023-02-08_custom_MergerAgreementMember_custom_ChronixMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:ChronixMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-07</startDate>
            <endDate>2023-02-08</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_ChronixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:ChronixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_ChronixBiomedicalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixBiomedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:InsightMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:ChronixMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_DetermaIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermaIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DetermaIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermaIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_DetermaCNIAndVitaGraftMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermaCNIAndVitaGraftMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_DetermaCNIAndVitaGraftMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermaCNIAndVitaGraftMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_SeriesAPreferredStockMember_custom_OncocyteCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-142022-07-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <startDate>2022-07-14</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_PreferredStockMember_custom_InterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:InterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_PreferredStockMember_custom_OncocyteCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_PreferredStockMember_custom_SecurityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:SecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OCX:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="From2023-04-042023-04-05_custom_RegisteredDirectOfferingMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-04</startDate>
            <endDate>2023-04-05</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_TwoThousandTenStockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandTenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_MonteCarloValuationTechniqueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:MonteCarloValuationTechniqueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_PerformanceBasedOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:PerformanceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-05-31_us-gaap_PerformanceSharesMember_custom_ExecutiveOfficersAndEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-05-31_custom_MarketBasedAwardsMember_custom_ExecutiveOfficersAndEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">OCX:MarketBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-05-31_custom_VitaGraftMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:VitaGraftMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-05-31_custom_DetermalOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermalOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-05-012022-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-07-31_us-gaap_PerformanceSharesMember_custom_ExecutiveOfficersAndEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:ExecutiveOfficersAndEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-07-31_custom_VitaGraftMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:VitaGraftMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-07-31_custom_DetermalOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermalOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-12-142022-12-16_custom_DetermaCNIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:DetermaCNIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_TwoThousandEighteenIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandEighteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandTenPlanActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_MarketBasedAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">OCX:MarketBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandTenPlanActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandTenPlanActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_TwoThousandTenPlanActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandTenPlanActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandEighteenPalnActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandEighteenPalnActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandEighteenPalnActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">OCX:TwoThousandEighteenPalnActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:CostOfRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:CostOfRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:CostOfRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:CostOfRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesCompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:PharmaServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">OCX:DiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:OutsideUnitedStatesPharmaServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:OutsideUnitedStatesPharmaServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:OutsideUnitedStatesPharmaServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:OutsideUnitedStatesPharmaServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsOutsideUnitedStatesLicensingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsOutsideUnitedStatesLicensingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsOutsideUnitedStatesLicensingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsOutsideUnitedStatesLicensingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">OCX:DiscontinuedOperationsDetermaRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-23_custom_OfficeLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:OfficeLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-23</instant>
        </period>
    </context>
    <context id="From2019-12-222019-12-23_custom_OfficeLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:OfficeLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-22</startDate>
            <endDate>2019-12-23</endDate>
        </period>
    </context>
    <context id="From2019-12-222019-12-23_custom_MonthlyRentMember_custom_OfficeLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">OCX:MonthlyRentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:OfficeLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-22</startDate>
            <endDate>2019-12-23</endDate>
        </period>
    </context>
    <context id="From2019-12-222019-12-23_custom_FirstTenCalendarMember_custom_OfficeLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">OCX:FirstTenCalendarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:OfficeLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-22</startDate>
            <endDate>2019-12-23</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_LandlordMember_custom_OfficeLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:LandlordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:OfficeLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-27_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-27</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">OCX:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_ExecutiveOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:ExecutiveOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">OCX:OperatingAndFinancingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">OCX:OperatingAndFinancingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-04-122022-04-12_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_BroadwoodCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-12</endDate>
        </period>
    </context>
    <context id="From2022-04-132022-04-13_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_BroadwoodCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-13</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_BroadwoodCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_BroadwoodCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_PuraVidaInvestmentsLLCMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:PuraVidaInvestmentsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_UnderwritersMember_custom_BroadwoodCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_PuraVidaInvestmentsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:PuraVidaInvestmentsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_PuraVidaInvestmentsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:PuraVidaInvestmentsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_custom_BroadwoodCapitalLPMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_custom_PuraVidaInvestmentsLLCMember_custom_UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:PuraVidaInvestmentsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_HalleSpecialSituationsFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:HalleSpecialSituationsFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:HalleSpecialSituationsFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:HalleSpecialSituationsFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember_custom_UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:UnderwritersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">OCX:UnderwrittenOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:HalleSpecialSituationsFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_BroadwoodPartnersLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:BroadwoodPartnersLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_PuraVidaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:PuraVidaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_AVMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:AVMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_ArnoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">OCX:ArnoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_MrGutfreundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">OCX:MrGutfreundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="From2022-04-052022-04-05_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_ArnoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">OCX:ArnoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-17</instant>
        </period>
    </context>
    <context id="From2019-10-162019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-16</startDate>
            <endDate>2019-10-17</endDate>
        </period>
    </context>
    <context id="AsOf2019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-17</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-10-17_custom_AmendedLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-17</instant>
        </period>
    </context>
    <context id="From2020-04-012020-04-02_custom_LoanDeferralAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:LoanDeferralAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-02</endDate>
        </period>
    </context>
    <context id="AsOf2019-10-31_custom_BankWarrantMember_custom_AmendedLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">OCX:BankWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-03-23_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-23</instant>
        </period>
    </context>
    <context id="AsOf2019-10-17_custom_BankWarrantMember_custom_AmendedLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">OCX:BankWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-17</instant>
        </period>
    </context>
    <context id="From2019-10-162019-10-17_custom_BankWarrantMember_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">OCX:BankWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-16</startDate>
            <endDate>2019-10-17</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_LifeTechnologiesCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">OCX:LifeTechnologiesCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember_custom_TwoEqualTranchesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">OCX:TwoEqualTranchesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="From2022-06-012022-06-01_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="From2022-04-122022-04-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="From2022-07-142022-07-15_us-gaap_SeriesAPreferredStockMember_custom_OncocyteCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-14</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember_custom_OncocyteCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:OncocyteCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember_custom_SecurityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:SecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_us-gaap_OverAllotmentOptionMember_custom_AprilTwoThousandTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">OCX:AprilTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-13_us-gaap_IPOMember_custom_AprilTwoThousandTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">OCX:AprilTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="AsOf2022-04-13_us-gaap_IPOMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="AsOf2022-04-13_us-gaap_IPOMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_custom_UnderwritingAgreementMember_custom_AprilTwoThousandTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">OCX:AprilTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_UnderwritingAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="AsOf2022-04-13_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_custom_UnderwritingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="From2022-04-122022-04-13_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-12</startDate>
            <endDate>2022-04-13</endDate>
        </period>
    </context>
    <context id="From2022-04-182022-04-19_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-18</startDate>
            <endDate>2022-04-19</endDate>
        </period>
    </context>
    <context id="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-04-03</endDate>
        </period>
    </context>
    <context id="From2022-12-142022-12-15_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_DragonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:DragonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-15_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember_custom_DragonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OCX:DragonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-15</instant>
        </period>
    </context>
    <context id="From2023-02-162023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-16</startDate>
            <endDate>2023-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-16</instant>
        </period>
    </context>
    <context id="From2023-02-162023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember26469671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">OCX:RazorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-16</startDate>
            <endDate>2023-02-16</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">OCX:RazorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:RazorStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-312023-01-31_custom_LaboratoryEquipmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:LaboratoryEquipmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_LaboratoryEquipmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:LaboratoryEquipmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-03-012023-03-31_custom_AuctionEquipmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:AuctionEquipmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-03-312023-03-31_custom_LaboratoryEquipmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">OCX:LaboratoryEquipmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001642380</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Number">
        <measure>OCX:Number</measure>
    </unit>
    <unit id="euro">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-06-30">0001642380</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-06-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0064"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl0066"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl0135"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl0164"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0165"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0373"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0378"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0386"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0526"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0542"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0548"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0600"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0605"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0607"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0613"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards
      contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0616"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards
      contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0618"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards
      contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0619"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0624"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0625"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock
      contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock
      contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock
      contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0633"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0636"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0637"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0638"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0639"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0645"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0648"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0655"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0668"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0674"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0678"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0684"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0685"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0691"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0693"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0696"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0699"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0702"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0704"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0705"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      id="xdx2ixbrl0710"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0711"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0712"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0713"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0714"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0719"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0720"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0721"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0722"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0727"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0728"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0769"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0775"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0779"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0782"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0785"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0799"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAssetsHeldForSale
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0806"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0815"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0817"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0832"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl0836"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0838"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0841"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:PaymentForFinancingCostsForAtthemarketSales
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0844"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0847"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl0868"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member_custom_MarketableEquitySecuritiesMember"
      id="xdx2ixbrl0957"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_MarketableEquitySecuritiesMember"
      id="xdx2ixbrl0958"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0961"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0962"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member_custom_ContingentConsiderationLiabilitiesMember"
      id="xdx2ixbrl0964"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member_custom_ContingentConsiderationLiabilitiesMember"
      id="xdx2ixbrl0965"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0968"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0969"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_custom_MarketableEquitySecuritiesMember"
      id="xdx2ixbrl0973"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_MarketableEquitySecuritiesMember"
      id="xdx2ixbrl0974"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0977"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0978"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_custom_ContingentConsiderationLiabilitiesMember"
      id="xdx2ixbrl0980"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_custom_ContingentConsiderationLiabilitiesMember"
      id="xdx2ixbrl0981"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0985"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl0998"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DeemedDividendOnPreferredStock
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl1064"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DeemedDividendOnPreferredStock
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl1066"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1126"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1128"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2022-12-31_custom_TwoThousandTenPlanActivityMember"
      id="xdx2ixbrl1400"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember"
      id="xdx2ixbrl1406"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember"
      id="xdx2ixbrl1408"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember"
      id="xdx2ixbrl1410"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember"
      id="xdx2ixbrl1412"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember"
      id="xdx2ixbrl1416"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-06-30_custom_TwoThousandTenPlanActivityMember"
      id="xdx2ixbrl1418"
      unitRef="Shares"
      xsi:nil="true"/>
    <OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      id="xdx2ixbrl1440"
      unitRef="Shares"
      xsi:nil="true"/>
    <OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      id="xdx2ixbrl1442"
      unitRef="Shares"
      xsi:nil="true"/>
    <OCX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      id="xdx2ixbrl1446"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      id="xdx2ixbrl1450"
      unitRef="Shares"
      xsi:nil="true"/>
    <OCX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      id="xdx2ixbrl1454"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      id="xdx2ixbrl1460"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      id="xdx2ixbrl1468"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      id="xdx2ixbrl1470"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      id="xdx2ixbrl1474"
      unitRef="Shares"
      xsi:nil="true"/>
    <OCX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      id="xdx2ixbrl1478"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      id="xdx2ixbrl1482"
      unitRef="Shares"
      xsi:nil="true"/>
    <OCX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      id="xdx2ixbrl1486"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember"
      id="xdx2ixbrl1503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember"
      id="xdx2ixbrl1505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember"
      id="xdx2ixbrl1513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember"
      id="xdx2ixbrl1522"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      id="xdx2ixbrl1564"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      id="xdx2ixbrl1568"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="AsOf2023-06-30" id="xdx2ixbrl1653">http://oncocyte.com/20230630#MachineryAndEquipmentNetAndConstructionInProgress</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="AsOf2022-12-31" id="xdx2ixbrl1654">http://oncocyte.com/20230630#MachineryAndEquipmentNetAndConstructionInProgress</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <OCX:RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl1671"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember"
      id="xdx2ixbrl1751"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl1779"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl1783"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl1787"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl1791"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl2050"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl2055"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl2060"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl2065"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl2070"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl2075"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax
      contextRef="From2022-04-012022-06-30"
      id="xdx2ixbrl2076"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax
      contextRef="From2022-01-012022-06-30"
      id="xdx2ixbrl2078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl2080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      id="xdx2ixbrl2093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      id="xdx2ixbrl2096"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment
      contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      id="xdx2ixbrl2099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent
      contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      id="xdx2ixbrl2102"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales
      contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      id="xdx2ixbrl2105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Assets
      contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      id="xdx2ixbrl2108"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DisposalGroupIncludingDiscontinuedOperationAccruedCompensation
      contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      id="xdx2ixbrl2117"
      unitRef="USD"
      xsi:nil="true"/>
    <OCX:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities
      contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      id="xdx2ixbrl2120"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="From2023-01-01to2023-06-30"
      id="xdx2ixbrl2138"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-01-01to2023-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-06-30">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-06-30">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-06-30">1-37648</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-06-30">Oncocyte Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-06-30">CA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-06-30">27-1041563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-06-30">15 Cushing</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-06-30">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-06-30">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-06-30">92618</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-06-30">(949)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-06-30">409-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-06-30">Common     Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-06-30">OCX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-08-03" decimals="INF" unitRef="Shares">8240928</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">17368000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">19993000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">178000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">154000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">1716000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2012000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:EquitySecuritiesFvNi contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">530000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">433000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">1179000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">977000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">191000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2121000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">20984000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">25536000</us-gaap:AssetsCurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">1891000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2088000</us-gaap:FinanceLeaseRightOfUseAsset>
    <OCX:MachineryAndEquipmentNetAndConstructionInProgress contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">5997000</OCX:MachineryAndEquipmentNetAndConstructionInProgress>
    <OCX:MachineryAndEquipmentNetAndConstructionInProgress contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">8763000</OCX:MachineryAndEquipmentNetAndConstructionInProgress>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">56639000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">61633000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:RestrictedCashNoncurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">1700000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1700000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">329000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">371000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">87540000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">100091000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">875000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1253000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">1301000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1771000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">2196000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3839000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <OCX:AccruedSeveranceFromAcquisitionCurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">2314000</OCX:AccruedSeveranceFromAcquisitionCurrent>
    <OCX:AccruedSeveranceFromAcquisitionCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2314000</OCX:AccruedSeveranceFromAcquisitionCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">109000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">109000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <OCX:RightOfUseAndFinancingLeaseLiabilitiesCurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">737000</OCX:RightOfUseAndFinancingLeaseLiabilitiesCurrent>
    <OCX:RightOfUseAndFinancingLeaseLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">815000</OCX:RightOfUseAndFinancingLeaseLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">135000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2005000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">7667000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">12106000</us-gaap:LiabilitiesCurrent>
    <OCX:RightOfUseAndFinancingLeaseLiabilitiesNoncurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">2398000</OCX:RightOfUseAndFinancingLeaseLiabilitiesNoncurrent>
    <OCX:RightOfUseAndFinancingLeaseLiabilitiesNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2729000</OCX:RightOfUseAndFinancingLeaseLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">29150000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">45662000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">39215000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">60497000</us-gaap:Liabilities>
    <OCX:TemporaryEquityNoParValue
      contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USDPShares">0</OCX:TemporaryEquityNoParValue>
    <OCX:TemporaryEquityNoParValue
      contextRef="AsOf2022-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USDPShares">0</OCX:TemporaryEquityNoParValue>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USDPShares">1000000</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USDPShares">1000000</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">5000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">5000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">6000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">6000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">5140000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="AsOf2022-12-31_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">6091000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">4725000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">5302000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2023-06-30"
      decimals="-3"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2022-12-31"
      decimals="-3"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-06-30" decimals="-3" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2023-06-30" decimals="-3" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-06-30" decimals="-3" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2023-06-30"
      decimals="-3"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="AsOf2022-12-31"
      decimals="-3"
      unitRef="USDPShares">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-06-30" decimals="-3" unitRef="Shares">230000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">230000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-06-30" decimals="-3" unitRef="Shares">8241000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-06-30" decimals="-3" unitRef="Shares">8241000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">5932000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="-3" unitRef="Shares">5932000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">309535000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">294929000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">39000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">-265976000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-260676000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">43600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">34292000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">87540000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">100091000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">760000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">169000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">183000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">434000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">288000</us-gaap:CostOfRevenue>
    <OCX:CostOfRevenuesAmortizationOfAcquiredIntangibles
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">22000</OCX:CostOfRevenuesAmortizationOfAcquiredIntangibles>
    <OCX:CostOfRevenuesAmortizationOfAcquiredIntangibles
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">23000</OCX:CostOfRevenuesAmortizationOfAcquiredIntangibles>
    <OCX:CostOfRevenuesAmortizationOfAcquiredIntangibles
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">44000</OCX:CostOfRevenuesAmortizationOfAcquiredIntangibles>
    <OCX:CostOfRevenuesAmortizationOfAcquiredIntangibles
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">51000</OCX:CostOfRevenuesAmortizationOfAcquiredIntangibles>
    <us-gaap:GrossProfit
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">272000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">31000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">282000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">278000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">2435000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">2444000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">4562000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">4451000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">805000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">127000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">1500000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">393000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">3531000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">5445000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">6943000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">11092000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">1795000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-6359000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-16512000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-11015000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">4950000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-1283000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:OperatingExpenses
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">8566000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">1657000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">2726000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">4921000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8294000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-1626000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-2444000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-4643000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">1000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-21000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-9000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-51000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-24000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">5000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">97000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-325000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-16000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">278000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-18000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">242000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-39000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">262000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">70000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-134000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8333000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-1364000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-2374000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-4777000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8333000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-1364000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-2374000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-4777000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-6936000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-2926000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-13814000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-8300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18591000</us-gaap:NetIncomeLoss>
    <OCX:DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-311000</OCX:DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock>
    <OCX:DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-72000</OCX:DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock>
    <OCX:DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-541000</OCX:DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock>
    <OCX:DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-72000</OCX:DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8644000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8644000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8644000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-8372000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-8372000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-8372000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5841000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5841000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5841000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18663000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18663000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18663000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8644000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-8372000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5841000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18663000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.24</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.24</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.34</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.34</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.93</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.93</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.24</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.34</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.93</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.23</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.23</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.42</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.42</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-2.69</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-2.69</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.23</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.42</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-2.69</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-3.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-3.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-3.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="Shares">8090</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="Shares">8090</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">5652</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">5652</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">7030</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">7030</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="Shares">5135</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="Shares">5135</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-8300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18591000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-7000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8335000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-8307000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5298000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18597000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">5882000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">5532000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">5964000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">295533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">43000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-257643000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="-3" unitRef="USD">37933000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-8333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8333000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">834000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">834000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">58000</OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards>
    <OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">58000</OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">2266000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">13421000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">13421000</us-gaap:StockIssuedDuringPeriodValueOther>
    <OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">-118000</OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock>
    <OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-118000</OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">-1064000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">-1000000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">11000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">193000</OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">-193000</OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-193000</OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">4818000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">4725000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">8241000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">309535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-265976000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">43600000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">4612000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">254994000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">38000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-198065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">56967000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-8300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-8300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-04-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-7000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-7000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2232000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">2232000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">1313000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">32423000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">32423000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">11765000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">4782000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">72000</OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-72000</OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-72000</OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">11765000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">4854000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">5930000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">289649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-206437000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="-3" unitRef="USD">83243000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">5882000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">5302000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">5932000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">294929000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">39000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-260676000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">34292000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-5300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1668000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">1668000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">58000</OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards>
    <OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">58000</OCX:StockIssuedDuringPeriodValueVestingOfBonusAwards>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">2266000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">13421000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">13421000</us-gaap:StockIssuedDuringPeriodValueOther>
    <OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">-118000</OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock>
    <OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-118000</OCX:DeemedDividendOnSeriesRedeemableConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">43000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">-1064000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">-1000000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2023-01-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">423000</OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2023-01-012023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">-423000</OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-423000</OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">4818000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">4725000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">8241000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">309535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-265976000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">43600000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">4612000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">252954000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-187774000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">65217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">252954000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">37000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-187774000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">65217000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-18591000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18591000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">4242000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">4242000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">1314000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">32453000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">32453000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-01-012022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">4000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">11765000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">4782000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2022-01-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">72000</OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2022-01-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-72000</OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue>
    <OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-72000</OCX:StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">11765000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">4854000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="Shares">5930000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">289649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-206437000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="-3" unitRef="USD">83243000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="USD">4854000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">289649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-206437000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="-3" unitRef="USD">83243000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18591000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">885000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">671000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">44000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">1904000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">1668000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">4242000</us-gaap:ShareBasedCompensation>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">97000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-325000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">11000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-16512000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-11015000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <OCX:ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-305000</OCX:ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">4950000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-149000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-1283000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-296000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">365000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-376000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">773000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-4319000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">239000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <OCX:AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-817000</OCX:AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-118000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-50000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAssetsHeldForSale
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-191000</us-gaap:IncreaseDecreaseInAssetsHeldForSale>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-16504000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-24524000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">123000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">2679000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">123000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-2679000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">13848000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">32812000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">427000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">389000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">4875000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">1118000</us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock>
    <OCX:FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">93000</OCX:FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares>
    <OCX:ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">31000</OCX:ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions>
    <OCX:PaymentForFinancingCostsForAtthemarketSales
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">1000</OCX:PaymentForFinancingCostsForAtthemarketSales>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">750000</us-gaap:RepaymentsOfDebt>
    <OCX:RepaymentOfFinancingLeaseObligations
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">57000</OCX:RepaymentOfFinancingLeaseObligations>
    <OCX:RepaymentOfFinancingLeaseObligations
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">51000</OCX:RepaymentOfFinancingLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">12246000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">36434000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-4135000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">9231000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">23203000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">37305000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">19068000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-06-30" decimals="-3" unitRef="USD">46536000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">21000</us-gaap:InterestPaidNet>
    <OCX:ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">16000</OCX:ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability>
    <OCX:ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">1331000</OCX:ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zmQ7sEi77j9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.
&lt;span id="xdx_82F_zrJiSVKexLfd"&gt;Organization, Description of the Business and Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
Corporation (&#x201c;Oncocyte,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we&#x201d; or &#x201c;us&#x201d;), incorporated in 2009 in the state of California, is a precision diagnostics
company focused on developing and commercializing proprietary tests in three areas: DetermaIO is a gene expression test that assesses
the tumor microenvironment to predict response to immunotherapies, VitaGraft is a blood-based solid organ transplantation monitoring
test, and DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte&#x2019;s
first product for commercial release was a proprietary treatment stratification test called DetermaRx that identifies which patients
with early-stage non-small cell lung cancer may benefit from chemotherapy, resulting in a significantly higher, five-year survival rate.
Beginning in September 2019 through February 23, 2021, Oncocyte held a &lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20210223__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorGenomicsIncMember_ztWDR584VUid" title="Equity ownership percentage"&gt;25&lt;/span&gt;% equity interest in Razor Genomics, Inc. (&#x201c;Razor&#x201d;),
a privately held company, that has developed and licensed to Oncocyte the lung cancer treatment stratification laboratory test that Oncocyte
is commercializing as DetermaRx. On February 24, 2021, Oncocyte completed the purchase of all the remaining issued and outstanding shares
of common stock of Razor. As a result of the purchase of the Razor common stock, Oncocyte became the sole shareholder of Razor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
December 15, 2022, the Company, entered into a Stock Purchase Agreement (the &#x201c;Razor Stock Purchase Agreement&#x201d;) with Dragon
Scientific, LLC, a Delaware limited liability company (&#x201c;Dragon&#x201d;) and Razor. Pursuant to the Razor Stock Purchase Agreement,
Oncocyte agreed to sell to Dragon, &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221215__20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DragonScientificLLCMember_zGR6pcci908j" title="Number of common stock issued"&gt;3,188,181&lt;/span&gt; shares of common stock of Razor, which constitutes approximately &lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DragonScientificLLCMember_zCIY2Et1gq3f" title="Equity ownership percentage"&gt;70&lt;/span&gt;% of the issued and outstanding
equity interests of Razor on a fully-diluted basis, and transfer to Razor all of the assets and liabilities related to DetermaRx (the
&#x201c;Razor Sale Transaction&#x201d;). &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Certain
amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of Razor in order to conform
to the current period presentation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;As
a result of the divestiture of Razor, the Company has retrospectively revised the condensed consolidated statements of operations for
the periods ended June 30, 2022, to reflect the operations and cash flows of Razor as discontinued operations and the related assets
and liabilities disposed. See Note 16 for additional information about assets held for sale and discontinued operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2023, Oncocyte completed the Razor Sale Transaction (the &#x201c;Razor Closing&#x201d;). In connection with the Razor Closing,
Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx. While no monetary consideration was received for
the sale of &lt;span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DragonMember_z8kqT2L6gt5c" title="Equity ownership percentage"&gt;70&lt;/span&gt;% of the equity interests of Razor, the transaction allowed the Company to eliminate all development and commercialization
costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to own &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230215__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8ByWFZO8lCk" title="Stock issued during period, shares, new issues"&gt;1,366,364&lt;/span&gt; shares of common stock of Razor, which
constitutes approximately &lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zUCufJrESbp2" title="Equity interest"&gt;30&lt;/span&gt;% of the issued and outstanding equity interests of Razor on a fully-diluted basis. &lt;span style="background-color: white"&gt;See
Note 16 for a full discussion of the Razor Sale Transaction.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 24, 2023, the Company implemented a &lt;span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20230723__20230724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6McoWJBE5Qk" title="Reverse stock split"&gt;1-for-20 reverse stock split&lt;/span&gt; of the outstanding shares of its common stock. The par value per
share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split.
All common stock share and per-share amounts for all periods presented in these condensed financial statements have been adjusted to
reflect the reverse stock split. The number of authorized shares of common stock remains at &lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20230724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zqma1QdPTce" title="Common stock, shares authorized"&gt;230&lt;/span&gt; million shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $&lt;span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230630_zRCntyEOk3uk" title="Accumulated deficit"&gt;266.0&lt;/span&gt; million as of June 30,
2023. Oncocyte expects to continue to incur operating losses and negative cash flows for the foreseeable future. Since its formation,
Oncocyte has financed its operations primarily through the sale of shares of its common stock, convertible preferred stock and warrants
to acquire common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, Oncocyte had $&lt;span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20230630_zlK5HQqKluE8" title="Cash and cash equivalents"&gt;17.4&lt;/span&gt; million of cash and cash equivalents and held shares of Lineage Cell Therapeutics, Inc. (&#x201c;Lineage&#x201d;)
and AgeX Therapeutics, Inc. (&#x201c;AgeX&#x201d;) common stock as marketable equity securities with a combined fair market value of $&lt;span id="xdx_907_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20230630_zTuLBRCkxT4c" title="Marketable equity securities fair value"&gt;0.5&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 11, 2021, Oncocyte entered into an at-the-market sales agreement with BTIG, LLC as sales agent and/or principal (the &#x201c;Agent&#x201d;
or &#x201c;BTIG&#x201d;) pursuant to which Oncocyte may sell up to an aggregate of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20210610__20210611__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketSalesAgreementMember__dei--LegalEntityAxis__custom--BTIGLLCMember_zjadrUkvWD6k" title="Fair value of common stock sold"&gt;50,000,000&lt;/span&gt; of shares of Oncocyte common stock from
time to time through the Agent (the &#x201c;ATM Offering&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Between
July 1, 2021 and June 30, 2023, Oncocyte sold &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210701__20230630__dei--LegalEntityAxis__custom--BTIGLLCMember_zZnINzCZmY95" title="Fair value of common stock sold"&gt;56,167 &lt;/span&gt;shares
of common stock at an average offering price of $&lt;span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230630__dei--LegalEntityAxis__custom--BTIGLLCMember_ziMRQ2HM90I6" title="Sale of stock, price per share"&gt;111.60&lt;/span&gt;
per share, for gross proceeds of approximately $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn4n6_c20210701__20230630__dei--LegalEntityAxis__custom--BTIGLLCMember_zBMWnzPVy9Ja" title="Gross proceeds from offering"&gt;6.27&lt;/span&gt;
million through the ATM Offering. The most recent sale of common stock through the ATM Offering took place in January 2022. Oncocyte
will need to raise additional capital to finance its operations, including the development and commercialization of its cancer
diagnostic and other tests, until such time as it is able to generate sufficient revenues from the commercialization of one or more
of its laboratory tests and other tests, and performing Pharma Services to cover its operating expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 13, 2022, Oncocyte entered into a securities purchase agreement (the &#x201c;Securities Purchase Agreement&#x201d;) with
institutional accredited investors (the &#x201c;Investors&#x201d;), including Broadwood Partners, L.P. (&#x201c;Broadwood&#x201d;),
Oncocyte&#x2019;s largest shareholder, in a registered direct offering of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znckcjBsFEUc"&gt;11,765 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of Series A Convertible Preferred Stock (the &#x201c;Series A Preferred Stock&#x201d;), which are convertible into a total of &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zROBhDIdg7Rk" title="Convertible preferred shares"&gt;384,477 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of common stock, at a conversion price of $&lt;span id="xdx_905_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYlfgKahIF2c" title="Conversion price"&gt;30.60 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(the
&#x201c;Series A Preferred Stock Offering&#x201d;). The purchase price of each share of Series A Preferred Stock was $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zVA3C6kJwBBi" title="Net proceeds"&gt;850&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
which included an original issue discount to the stated value of $&lt;span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zS4ZRvMHMi4e" title="Preferred stock stated value per share"&gt;1,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share. The Securities Purchase Agreement provides that the closing of the Series A Preferred Stock Offering will occur, subject to
the satisfaction of certain closing conditions, in two equal tranches of $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zo5NZcmzcnNh" title="Net proceeds"&gt;5,000,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;each
for aggregate gross proceeds from both closings of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220601__20220601__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zvNv0qK2Tmo7" title="Net proceeds"&gt;10,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220601__20220601__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zvp1lPe40oHk" title="Net proceeds"&gt;4.9 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
from the Series A Preferred Stock issued from the first tranche. The second closing would occur, subject to the satisfaction of
certain closing conditions (including but not limited to a requirement that the Company has not received, in the 12 months preceding
the second closing, a notice from The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) that the Company is not in compliance with the
listing and maintenance and listing requirements of Nasdaq), on the earlier of (a) the second trading day following the date that
Oncocyte receives notice from an Investor to accelerate the second closing and (b) a date selected by Oncocyte on or after October
8, 2022 and on or prior to March 8, 2023. On August 9, 2022, Oncocyte received a letter from Nasdaq indicating that the Company no
longer met the minimum bid price requirement of the Nasdaq continued listing requirements. Accordingly as of June 30, 2023, no
additional proceeds are expected from the second closing of the Securities Purchase Agreement. On August 8, 2023, the Company
received a letter from Nasdaq indicating that the Company had regained compliance with the minimum bid price requirement of the Nasdaq continued listing requirements. See Note 15 for additional information about the Series A Preferred Stock Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Further, on April 13, 2022, Oncocyte
entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with BTIG, LLC, as representative of the underwriters
named therein (the &#x201c;Underwriters&#x201d;), pursuant to which Oncocyte issued and sold to the Underwriters an aggregate of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220412__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_znOvFlImpvwl" title="Number of common stock issued"&gt;1,313,320&lt;/span&gt;
shares of common stock, and &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220412__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zC1OHcE1BEBb" title="Purchase of warrant"&gt;1,313,320&lt;/span&gt; warrants to purchase up to &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220412__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__srt--RangeAxis__srt--MinimumMember_zyAPMpdP2pdb" title="Purchase of warrant"&gt;656,660&lt;/span&gt; shares of common stock (&#x201c;April 2022 Warrants&#x201d;) (the
&#x201c;Underwritten Offering,&#x201d; and collectively with the Series A Preferred Stock Offering, the &#x201c;April 2022 Offerings&#x201d;).
The Underwritten Offering closed on April 19, 2022, and Oncocyte received net proceeds of approximately $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20220418__20220419__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdHdcmedVVrg" title="Net proceeds"&gt;32.8&lt;/span&gt; million from the Underwritten
Offering. See Note 15 for additional information about the Underwritten Offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On April 3, 2023, Oncocyte entered into an agreement with certain members of the Company&#x2019;s board of directors,
and several institutional and accredited investors, including Broadwood, the Company&#x2019;s largest shareholder, relating to their purchase
of an aggregate of up to &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--BoardMembersMember__srt--RangeAxis__srt--MaximumMember_z595chI480fb" title="Purchase of warrant"&gt;2,278,121&lt;/span&gt; shares of its common stock at an offering price of $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--BoardMembersMember_zXgMKP3e90xb" title="Shares issued price per share"&gt;7.08&lt;/span&gt; per share to board members and $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--OtherInvestorsMember_zlOFqicx7tSl" title="Shares issued price per share"&gt;6.03&lt;/span&gt; per share
to the other investors participating in the offering. The offering was intended to be priced at-the-market for purposes of complying with
applicable Nasdaq Listing Rules. The aggregate gross proceeds from the offering were approximately $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember_z4ThkXHnQ9z9" title="Proceeds from issuance of common stock"&gt;13.9&lt;/span&gt; million. The Company used approximately
$&lt;span id="xdx_909_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zwE95qVzgSE4" title="Net proceeds to immediately redeem"&gt;1.1&lt;/span&gt; million of the net proceeds to immediately redeem an aggregate of &lt;span id="xdx_902_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zaTI3UioATvh" title="Number of stock redeem"&gt;1,064&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of its Series A Preferred Stock and may thereafter elect
to redeem additional shares.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, Oncocyte is completing clinical development and planning commercialization of DetermaIO, although DetermaIO is currently
available for biopharma diagnostic development and research use only as a companion test in immunotherapy drug development to select
patients for clinical trials; and the clinical launch of VitaGraft. While Oncocyte plans to primarily market its laboratory tests in
the United States through its own sales force, it is also beginning to make marketing arrangements with distributors in other countries.
In order to reduce capital needs and to expedite the commercialization of any new laboratory tests that may become available for clinical
use, Oncocyte may also pursue marketing arrangements with other diagnostic companies through which Oncocyte might receive licensing fees
and royalty on sales, or through which it might form a joint venture to market its tests and share in net revenues, in the United States
or abroad.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 205-40, Going Concern, we evaluated whether there are
conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern
within one year after the date that the unaudited condensed consolidated interim financial statements included in this Report are
issued. This evaluation initially does not take into consideration the potential mitigating effect of our plans that have not been
fully implemented as of the date the unaudited condensed consolidated interim financial statements included in this Report are
issued. When substantial doubt exists under this methodology, we evaluate whether the mitigating effect of its plans sufficiently
alleviates substantial doubt about our ability to continue as a going concern. The mitigating effect of our plans, however, is only
considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that such
financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or
events that raise substantial doubt about our ability to continue as a going concern within one year after the date that such
financial statements are issued. In performing this analysis, we excluded certain elements of our operating plan that cannot be
considered probable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to
support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year
after the date that the financial statements are issued. Management intends to complete additional equity financings and reduce
spending in the remainder of fiscal 2023 and in 2024. However, due to several factors, including those outside management&#x2019;s
control, there can be no assurance that we will be able to complete additional equity financings. If we are unable to complete
additional financings, management&#x2019;s plans include further reducing or delaying operating expenses. We have concluded the
likelihood that our plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce
expenditures, while reasonably possible, is less than probable. Accordingly, we have concluded that substantial doubt exists about
our ability to continue as a going concern for a period of at least twelve months from the date of issuance of these unaudited
condensed consolidated interim financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction
of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability
and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the
uncertainties described above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to general economic and capital market trends and conditions, Oncocyte&#x2019;s ability to raise sufficient additional capital
to finance its operations from time to time will depend on a number of factors specific to Oncocyte&#x2019;s operations such as operating
revenues and expenses, progress in development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future
laboratory tests that Oncocyte may develop or acquire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unavailability or inadequacy of financing or revenues to meet future capital needs could force Oncocyte to modify, curtail, delay, or
suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests
of its shareholders. Oncocyte cannot assure that adequate financing will be available on favorable terms, if at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2021-02-23_custom_RazorGenomicsIncMember"
      decimals="INF"
      unitRef="Pure">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-12-152022-12-15_custom_RazorStockPurchaseAgreementMember_custom_DragonScientificLLCMember"
      decimals="INF"
      unitRef="Shares">3188181</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-15_custom_RazorStockPurchaseAgreementMember_custom_DragonScientificLLCMember"
      decimals="INF"
      unitRef="Pure">0.70</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_custom_RazorMember_us-gaap_CommonStockMember_custom_DragonMember"
      decimals="INF"
      unitRef="Pure">0.70</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-152023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1366364</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_custom_RazorMember"
      decimals="INF"
      unitRef="Pure">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-07-232023-07-24_us-gaap_SubsequentEventMember">1-for-20 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-07-24_us-gaap_SubsequentEventMember"
      decimals="-6"
      unitRef="Shares">230000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-06-30" decimals="-5" unitRef="USD">-266000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-06-30" decimals="-5" unitRef="USD">17400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:EquitySecuritiesFvNi contextRef="AsOf2023-06-30" decimals="-5" unitRef="USD">500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2021-06-102021-06-11_custom_AtTheMarketSalesAgreementMember_custom_BTIGLLCMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-07-012023-06-30_custom_BTIGLLCMember"
      decimals="INF"
      unitRef="Shares">56167</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-06-30_custom_BTIGLLCMember"
      decimals="INF"
      unitRef="USDPShares">111.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2021-07-012023-06-30_custom_BTIGLLCMember"
      decimals="-4"
      unitRef="USD">6270000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">11765</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">384477</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">30.60</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">850</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="0"
      unitRef="USD">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-06-012022-06-01_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-06-012022-06-01_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="-5"
      unitRef="USD">4900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-122022-04-12_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember"
      decimals="INF"
      unitRef="Shares">1313320</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-12_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember"
      decimals="INF"
      unitRef="Shares">1313320</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-12_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Shares">656660</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-182022-04-19_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_UnderwritingAgreementMember_custom_UnderwriterMember_us-gaap_CommonStockMember"
      decimals="-5"
      unitRef="USD">32800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_custom_BoardMembersMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">2278121</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-04-03_custom_RegisteredDirectOfferingMember_custom_BoardMembersMember"
      decimals="INF"
      unitRef="USDPShares">7.08</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-04-03_custom_RegisteredDirectOfferingMember_custom_OtherInvestorsMember"
      decimals="INF"
      unitRef="USDPShares">6.03</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember"
      decimals="-5"
      unitRef="USD">13900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesAPreferredStockMember"
      decimals="-5"
      unitRef="USD">1100000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1064</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_zHZOs2dGQqB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_824_znUtGPNE8S4i"&gt;Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNUiTmKaFlFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zkS5tceeAXY1"&gt;Basis
of presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance
with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to
Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures
normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance
sheets as of December 31, 2022 was derived from the audited consolidated financial statements at that date. These unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included
in Oncocyte&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated interim financial
statements presented herein as of June 30, 2023 is not representative of the full fiscal year or any future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zBEPow0Ifnt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zrKXO5Nmd15e"&gt;Principles
of consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January 31, 2020, with the
acquisition of Insight Genetics, Inc. (&#x201c;Insight&#x201d;) through a merger with a newly incorporated wholly owned subsidiary of Oncocyte
(the &#x201c;Insight Merger&#x201d;) under the terms of an Agreement and Plan of Merger (the &#x201c;Insight Merger Agreement&#x201d;), Insight
became a wholly owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight&#x2019;s operations and results with
Oncocyte&#x2019;s operations and results (see Note 3).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On February 24, 2021, with the
acquisition of the remaining equity interests in Razor, Razor became a wholly owned subsidiary of Oncocyte, and on that date Oncocyte
began consolidating Razor&#x2019;s results with Oncocyte&#x2019;s operations and results (see Note 3).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (&#x201c;Chronix&#x201d;) pursuant to an Agreement
and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated,
the &#x201c;Chronix Merger Agreement&#x201d;), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary
of Oncocyte (&#x201c;Merger Sub&#x201d;), Chronix became a wholly owned subsidiary of Oncocyte (the &#x201c;Chronix Merger&#x201d;), and on
that date Oncocyte began consolidating Chronix&#x2019;s operations and results with Oncocyte&#x2019;s operations and results (see Note 3).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have reflected the operations of Razor as discontinued operations for all periods presented. See Note 16 for further information. Unless
otherwise noted, amounts and disclosures throughout these Notes to unaudited condensed consolidated interim financial statements relate
solely to continuing operations and exclude all discontinued operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting
only of normal recurring adjustments, necessary for a fair presentation of Oncocyte&#x2019;s financial condition and results of operations.
The unaudited condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other
interim period or for the entire year. All material intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--UseOfEstimates_z9HUDZz4sJRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zwTeAy75rgGb"&gt;Use
of estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and contingent assets and liabilities, at the date of the unaudited condensed consolidated financial
statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates
estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the
use of judgment to prepare financial projections, timing of potential commercialization of acquired in-process intangible assets, applicable
discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable
companies or transactions, determination of fair value of the assets acquired and liabilities assumed including those relating to contingent
consideration, assumptions related to going concern assessments, allocation of direct and indirect expenses, useful lives associated
with long-lived intangible assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies,
valuation allowances related to deferred income taxes, and assumptions used to value debt and stock-based awards and other equity instruments.
Actual results may differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Similarly,
Oncocyte assessed certain accounting matters that generally require consideration of forecasted financial information. The accounting
matters assessed included, but were not limited to, Oncocyte&#x2019;s equity investments, the carrying value of goodwill, going concern
assessment, acquired in-process intangible assets and other long-lived assets. Those assessments as well as other estimates referenced
above were made in the context of information reasonably available to Oncocyte.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock_zm0JZ0NZggYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zVjdQpE4iuY4"&gt;Business
combinations and fair value measurements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at
fair value on the acquisition date in accordance with ASC 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;. ASC 820 establishes a single authoritative
definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement.
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered
observable and the last unobservable, that may be used to measure fair value, which are the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
&lt;i&gt;Level 1 &lt;/i&gt;&#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
&lt;i&gt;Level 2 &lt;/i&gt;&#x2013; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for
similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated
by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
&lt;i&gt;Level 3 &lt;/i&gt;&#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable
to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted
on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets
and identifiable intangible assets acquired, including in-process research and development, and liabilities assumed, including any contingent
consideration, as of the acquisition date. Goodwill is recognized as any amount of the fair value of the tangible and identifiable intangible
assets acquired and liabilities assumed in excess of the consideration transferred. ASC 805 precludes the recognition of an assembled
workforce as an asset, effectively subsuming any assembled workforce value into goodwill.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented,
Oncocyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for money market funds and marketable
equity securities of Lineage and AgeX common stock held by Oncocyte described below. These assets are measured at fair value using the
period-end quoted market prices as a Level 1 input. Oncocyte also has certain contingent consideration liabilities which are carried
at fair value based on Level 3 inputs (see Note 3).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3RKpaWznMh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of June 30, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zmTaNgYcWYHf" style="display: none"&gt;Schedule of Fair
Value Measurement of Financial Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total carrying and estimated fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left; padding-bottom: 1.5pt"&gt;Marketable equity securities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zrte2Oe4Xsje" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;530&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zmlsnasuFB8l" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;530&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zLhWjk5r3sIa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0957"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zJWYuvYPxmpa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0958"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zn3zRaxWFSh9" style="border-bottom: Black 2.5pt double; text-align: right"&gt;530&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJ3K5CDPnLqg" style="border-bottom: Black 2.5pt double; text-align: right"&gt;530&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zqMfCKTnq4B7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV4fpBbD8sD8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent consideration liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zhUYvCFL4uY8" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29,150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zFvKQVbzLoxe" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zDj19v3hYJN1" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zjKMlaBqLsR3" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29,150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630_ztZ3r8fTeEY8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,150&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuX5gETrWj07" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0968"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRbVr03xVsNj" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0969"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh2pOmfCD0gh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,150&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total carrying and estimated fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left; padding-bottom: 1.5pt"&gt;Marketable equity securities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_z4Tev33z1EWi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;433&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zdTflE7GPOx2" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;433&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zzdrgphbJ4M3" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zeuvjS5nU5Gi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0974"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zBQNHaivDNA1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zezVqYduTUk5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMgrynHvJ4Be" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYOxUVrvdDij" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent consideration liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zzdaxrShvpDh" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,662&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zIc6J1GvURw2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zfUTVBs0Ucrc" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zVAT8i4bZSM8" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,662&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231_zyECdBhHNRMf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;45,662&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGDRKTs94eGk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDefP5WOZrh9" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0985"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zigpHVQl2mfd" style="border-bottom: Black 2.5pt double; text-align: right"&gt;45,662&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zKaCNtGVNq65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate
fair values because of the short-term nature of these items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zlIkj3sDupkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zGQbyBZFOfBi"&gt;Cash,
cash equivalents, and restricted cash&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s reconciliation of cash and cash equivalents, and restricted cash reported within the unaudited condensed consolidated
balance sheets that sum to the total of the same amounts shown in the unaudited condensed consolidated statements of cash flows were
as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zdytl4la5juf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B2_zJpqATCenCh1"&gt;Schedule
of Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230630_zJ6xNQ6lEwZd" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zbOy4sanmZce" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_maCCERCzBSt_zf6VijB9xmCh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;19,993&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RestrictedCash_iI_maCCERCzBSt_zgED1GuzIi3k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_iI_maCCERCzBSt_zl8as0JpcIH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash from discontinuing operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0998"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,510&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_mtCCERCzBSt_zusozGCYoAfl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Cash, cash equivalents and restricted cash shown in the statements of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;19,068&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8AF_z1Pt03fS2p2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--DiscontinuedOperationsPolicyTextBlock_z6jQVYPfHbq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zX7Hlyt3Qfbj"&gt;Assets
Held for Sale and Discontinued Operations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, the Company classified laboratory equipment previously presented in machinery and equipment as held for sale in current
assets, in the unaudited condensed consolidated balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment
(&#x201c;ASC 360-10&#x201d;) have been met and the transaction was qualified as assets held for sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2023, the Company entered into various agreements to sell laboratory equipment for an aggregate amount of
$&lt;span id="xdx_905_eus-gaap--IncreaseDecreaseInAssetsHeldForSale_pn5n6_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--VariousAgreementsMember_zba3kXUdbysg" title="Increase (decrease) in asset, held-for-sale"&gt;0.6&lt;/span&gt; million. As a result, the Company classified the equipment as held for sale as current assets, in the unaudited condensed consolidated
balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment (&#x201c;ASC 360-10&#x201d;) have been met and
the transaction was qualified as assets held for sale. The equipment was written down to its fair value, less cost to sell, to $&lt;span id="xdx_90C_eus-gaap--InventoryWriteDown_pn5n6_c20230101__20230630_zm94u4G9nNs8" title="Inventory write down"&gt;0.2&lt;/span&gt; million
in the unaudited condensed consolidated balance sheet. As a result of the sale, the Company recorded an impairment loss of $&lt;span id="xdx_90B_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20230630_zpYCbYN0Vjz7" title="Asset impairment charges"&gt;1.3&lt;/span&gt; million
on held-for-sale assets, in the unaudited condensed consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management,
having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in
their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate
a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable
and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation
to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the
plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified
as held for sale in the unaudited condensed consolidated balance sheet. Assets classified as held for sale are reported at the lower
of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for
sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discontinued
operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business
that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a
major effect on the Company&#x2019;s operations and financial results according to Accounting Standard Codification (&#x201c;ASC&#x201d;)
Topic 205, &lt;i&gt;Presentation of Financial Statements&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additional
details surrounding the Company&#x2019;s assets and liabilities held for sale and discontinued operations are included in Note 16.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zdALh9iWRtf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_z9k4q47cS8wj"&gt;Goodwill
and intangible assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 350, &lt;i&gt;Intangibles &#x2013; Goodwill and Other&lt;/i&gt;, in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;)
projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived
intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the
project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts
are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&amp;amp;D assets, including the
current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability
to obtain local determination coverage (&#x201c;LCD&#x201d;) from the Centers for Medicare and Medicaid Services (&#x201c;CMS&#x201d;) for
Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement
of competitors&#x2019; diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the
eventual realized value of the IPR&amp;amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;amp;D impairment charges
may occur in future periods. During the period between completion or abandonment, the IPR&amp;amp;D assets will not be amortized but will
be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in
circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D projects below their respective carrying amounts (see
Notes 3 and 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&amp;amp;D,
is not amortized but is tested for impairment at least annually, or if circumstances indicate its value may no longer be recoverable.
Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant
events and factors affecting Oncocyte&#x2019;s business. Based on the qualitative assessment, if it is determined that the fair value
of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared
with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte
continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at
the enterprise level.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;amp;D discussed in Notes 3 and
4. As of June 30, 2023, goodwill has been fully impaired and acquired IPR&amp;amp;D has been partially impaired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z43I1D7VHtqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_zpKA0ODzalm9"&gt;Long-lived
intangible assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
intangible assets, consisting primarily of acquired customer relationships, are stated at acquired cost, less accumulated amortization.
Amortization expense is computed using the straight-line method over the estimated useful life of &lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230630_zgG4WqZN1Jhc" title="Long-lived intangible assets, useful life"&gt;5&lt;/span&gt; years (see Notes 3 and 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ContingentLiabilityReserveEstimatePolicy_zrQpGIlIQKhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_864_zYjoCbRT84U6"&gt;Contingent
consideration liabilities&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
of Oncocyte&#x2019;s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former
selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones,
from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable
agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and
timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows (see Notes 3 and 4). These obligations
are referred to as contingent consideration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration
transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling
shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones.
Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings,
such as &#x201c;earn-out&#x201d; provisions or percentage of future revenues, including royalties paid to the selling shareholders based
on a percentage of certain revenues generated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions
occur, with the subsequent change in fair value recorded in the condensed consolidated statements of operations. Changes in key assumptions
can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that
Oncocyte records in its unaudited condensed consolidated interim financial statements. See Notes 3 and 4 for a full discussion of these
liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--EquityMethodInvestmentsPolicy_zZ7s92dN3mxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zB5wx3auyJye"&gt;Investments
in capital stock of privately held companies&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable
interest entity (&#x201c;VIE&#x201d;) model, and then under the voting interest model in accordance with accounting guidance for consolidations
under Accounting Standards Codification (&#x201c;ASC&#x201d;) 810-10. If consolidation of the entity is not required under either the VIE
model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with
ASC 323, &lt;i&gt;Investments &#x2013; Equity Method and Joint Ventures&lt;/i&gt;. The equity method applies to investments in common stock or in-substance
common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically
represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment
balance based on Oncocyte&#x2019;s pro rata share of earnings or losses from the investment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
February 24, 2021, the date of Oncocyte&#x2019;s acquisition of the remaining interests in Razor, through February 16, 2023 the date of
its disposition, Razor entity&#x2019;s financial statements have been consolidated with Oncocyte. See Notes 3, 4, and 16 for additional
information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zoQTYhsYePXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_z5dg3AsKZ7gi"&gt;Impairment
of long-lived assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired
and the carrying value may not be recoverable. Oncocyte&#x2019;s long-lived assets consist primarily of intangible assets, right-of-use
assets for operating leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are
less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair
value, is recorded. See Notes 3, 4, and 16 for additional information with respect to impairments of long-lived assets. See Note 16 for
disclosure of machinery and equipment impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zsk7ub5YDnIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zYx3gprohqnj"&gt;Revenue
recognition&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to ASC 606, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration
Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)
identifying the contract with a customer,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)
identifying the performance obligations in the contract,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)
determining the transaction price,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv)
allocating the transaction price to the performance obligations, and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(v)
recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services
in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable
consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal
in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently
resolved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;DetermaRx
testing revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received
from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria (i) through (v)
above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered
complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no
shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered
and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx.
Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the
transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires
significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving
payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual
reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient
history to reliably estimate payment patterns or has had contractual reimbursement arrangements, or both, in place.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, Oncocyte had accounts receivable of $&lt;span id="xdx_904_eus-gaap--AccountsReceivableSale_pn5n6_c20230101__20230630__srt--ProductOrServiceAxis__custom--MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember_zbTDkx4S4eEk" title="Accounts receivable"&gt;1.6&lt;/span&gt; million from Medicare and Medicare Advantage covered DetermaRx tests (see
Note 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
maintain an allowance for expected credit losses at an amount we estimate to be sufficient to provide adequate protection against losses
resulting from extending credit to our customers. We base this allowance, in the aggregate, on historical collection experience, age
of receivables and general economic conditions. Our bad debts have not been material and have been within management expectations. During
the first quarter of 2023, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;i&gt;Financial Instruments-Credit
Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; and subsequent amendments to the initial guidance under
ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial
assets, including trade and other receivables. Adoption of this standard did not have a material impact on the Company&#x2019;s consolidated
financial statements and related disclosures. As of June 30, 2023 and December 31, 2022, we had a credit loss reserve of $&lt;span id="xdx_90F_eus-gaap--ProvisionForDoubtfulAccounts_pn5n6_c20230101__20230630_zK53gXfBx3ri" title="Provision for doubtful accounts"&gt;&lt;span id="xdx_904_eus-gaap--ProvisionForDoubtfulAccounts_pn5n6_c20220101__20221231_zYX0GVuuq9Bf" title="Provision for doubtful accounts"&gt;0.2&lt;/span&gt;&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Pharma
services revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
recognized include Pharma Services performed by Oncocyte&#x2019;s Insight and Chronix subsidiaries for its pharmaceutical customers, including
testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These
Pharma Services are generally performed under individual scope of work (&#x201c;SOW&#x201d;) arrangements or license agreements (together
with SOW the &#x201c;Pharma Services Agreements&#x201d;) with specific deliverables defined by the customer. Pharma Services are performed
on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with
a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable
basis) and recognizes Pharma Service revenue at that time. Insight identifies each sale of its Pharma Service offering as a single performance
obligation. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license
agreements with customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Completion
of the service and satisfaction of the performance obligation is typically evidenced by access to the report or test made available to
the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs
under which work is performed pursuant to the customer&#x2019;s highly customized specifications, Oncocyte has the enforceable right to
bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period
during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage
of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements,
any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed
to the customer as of the date of Oncocyte&#x2019;s condensed consolidated financial statements are recorded as contract assets and are
included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified
to accounts receivable in Oncocyte&#x2019;s condensed consolidated financial statements when the customer is invoiced according to the
billing schedule in the contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
establishes credit loss reserve accounts based on the evaluation of the collectability of its Pharma Services accounts receivables after
considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer&#x2019;s
ability to pay, such as a bankruptcy filing or deterioration in the customer&#x2019;s operating results or financial position, reasonable
and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to
customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections
and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its
historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are
written off against the credit loss reserve accounts. As of June 30, 2023, Oncocyte has not recorded any losses or credit loss reserve
accounts on its account receivables from Pharma Services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, Oncocyte had accounts receivable from Pharma Services customers of $&lt;span id="xdx_901_eus-gaap--AccountsReceivableSale_pn5n6_c20230101__20230630__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_zjG4mfP83gx6" title="Accounts receivable"&gt;0.3&lt;/span&gt; million, as compared to $&lt;span id="xdx_90A_eus-gaap--AccountsReceivableSale_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_z02GYWvfQmt2" title="Accounts receivable"&gt;0.3&lt;/span&gt; million as of
December 31, 2022 (see Note 7). As of June 30, 2023 and December 31, 2022, we have not reserved a credit loss reserve for Pharma Services
accounts receivables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Licensing
revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte&#x2019;s proprietary
testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose
of marketing Oncocyte&#x2019;s tests within a defined geographic territory. A license agreement may specify milestone deliverables or
performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte&#x2019;s performance
obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing
fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and
ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CostOfSalesPolicyTextBlock_zxfsZ5sugvq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zgAik2cMrqKd"&gt;Cost
of revenues&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost
of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and
infrastructure expenses, clinical sample related costs associated with performing DetermaRx tests and Pharma Services, providing deliverables
according to our licensing agreements, license fees due to third parties, and amortization of acquired intangible assets such as the
Razor asset and customer relationship intangible assets. Infrastructure expenses include depreciation of laboratory equipment, allocated
rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte&#x2019;s CLIA laboratories in
California and Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless
of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues
generated using the associated technology are recorded as expenses at the time the related revenues are recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_z9VYzThSZKkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zmAQLAXY8zZk"&gt;Research
and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based
compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure
expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development
expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications,
property taxes, and insurance. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--SalesAndMarketingExpensesPolicyTextBlock_zSZzKJiXdkvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zhPOYeNSdVCh"&gt;Sales
and marketing expenses&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses,
branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead
allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property
taxes, and insurance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z9lDskHkVHDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_z3870c4zEFu7"&gt;General
and administrative expenses&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive
and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property
taxes, and insurance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zmvDJyck8SM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_z6KeBeISQsx6"&gt;Net
loss per common share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and
accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. Diluted loss
per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion
of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that
would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted
method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the
computation if their effect is antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zpRphtLnuNF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents
the calculation of basic and diluted loss per share of common stock (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zQpZ5bBe8SVf"&gt;Schedule
of Common Stock Computation of Diluted Net Loss Per Share of Common Stock&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230401__20230630_zi6VhUSRhcLf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220401__20220630_z250A9VByK31" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20230630_zZLffxMsbPOe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20220630_zGHbu2Vm7Qw6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeLossIncludingPortionAttributableToNoncontrollingInterest_zjjvwqg2rtfd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Net loss attributable to Oncocyte Corporation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(8,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(8,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(5,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(18,591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DividendOnPreferredStock_zyO5mNeeH4A2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend on Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(76&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(166&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RedeemablePreferredStockDividends_iN_pn3n3_di_zI6LFGQVusXe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accretion of Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(117&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(257&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeemedDividendOnPreferredStock_iN_pn3n3_di_zB0jDxh8Nn73" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deemed dividend on Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1064"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1066"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_z9ehePWv2Rxk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to common stockholders - Basic and Diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230401__20230630_zYnUNlYpzbi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted"&gt;(8,644&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220401__20220630_z4N0PXtRYJFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted"&gt;(8,372&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230630_zllfG01ZWKT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted"&gt;(5,841&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220630_zC6uczPfyZx6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted"&gt;(18,663&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zR1QiUYWycd4" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to common stockholders - Basic &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8,644&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8,372&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,841&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,663&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted average shares used in computing net loss per share attributable to common stockholders - Basic and Diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230401__20230630_zRFBQSfPOkbi" title="Weighted average number of shares outstanding, basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230401__20230630_zsUr2lKy1a2k" title="Weighted average number of shares outstanding, diluted"&gt;8,090&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220401__20220630_zLJZeVYaGELj" title="Weighted average number of shares outstanding, basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220401__20220630_zSirTTGqB954" title="Weighted average number of shares outstanding, diluted"&gt;5,652&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230630_zrwt9ABffUmi" title="Weighted average number of shares outstanding, basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230630_zQW8KDSFUm3" title="Weighted average number of shares outstanding, diluted"&gt;7,030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220630_z7b2pwLFNBO9" title="Weighted average number of shares outstanding, basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220630_z4eHT6aWOVzk" title="Weighted average number of shares outstanding, diluted"&gt;5,135&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EarningsPerShareBasic_pid_z2zA7tJPerI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98F_eus-gaap--EarningsPerShareDiluted_pid_c20230401__20230630_zjxqFaYQCnb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted"&gt;(1.07&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220401__20220630_z3A48JpK1jNi" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted"&gt;(1.48&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230630_zsjAZl3ZjXgf" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted"&gt;(0.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220630_z8t0RQsbemKa" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted"&gt;(3.63&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pid_zlGdnrGr1wy3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic  net loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.07&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.48&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3.63&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgjK9PEZ67Uf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zaYmmxPLXS79" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1128"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfRcuUjnwSP3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;845&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;845&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zmgQqoSMUupa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zjFch4FZu3ad" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,582&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,384&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,508&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zd9x3szxLcDa" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,582&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,384&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,508&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A5_z7z5mTtaPrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zAR2qsO6DnPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&lt;span id="xdx_867_z57se08r5Vei"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
accounts for leases in accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;. Oncocyte determines if an arrangement is a lease at inception. Leases
are classified as either financing or operating, with classification affecting the pattern of expense recognition in the condensed consolidated
statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease
components as a single lease component. Oncocyte recognizes right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities for leases
with terms greater than twelve months in the condensed consolidated balance sheet. ROU assets represent the right to use an underlying
asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease
ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most
leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate
the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a
straight-line basis over the lease term. Operating leases are included as right-of-use assets in machinery and equipment, and ROU lease
liabilities, current and long-term, in the condensed consolidated balance sheets. Financing leases are included in machinery and equipment,
and in financing lease liabilities, current and long-term, in the condensed consolidated balance sheets. Oncocyte discloses the amortization
of our ROU assets and operating lease payments as a net amount, &#x201c;Amortization of right-of-use assets and liabilities&#x201d;, on
the condensed consolidated statements of cash flows. Based on the available practical expedients under the standard, Oncocyte elected
not to capitalize leases that have terms of twelve months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
prior years, Oncocyte entered into various operating leases and an embedded operating lease in accordance with ASC 842 discussed in Note
10. Oncocyte&#x2019;s accounting for financing leases remained substantially unchanged.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--AccountingForSharesOfCommonStockPolicyTextBlock_zpQoUHH9QS8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&lt;span id="xdx_863_zGtUX57eq779"&gt;Accounting
for Lineage and AgeX shares of common stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
accounts for the shares of Lineage and AgeX common stock it holds as marketable equity securities in accordance with ASC 320-10-25, &lt;i&gt;Investments
&#x2013; Debt and Equity Securities&lt;/i&gt;, as amended by Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-01, &lt;i&gt;Financial Instruments&#x2013;Overall:
Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/i&gt;, as the shares have a readily determinable fair value quoted
on the NYSE American and are held principally to meet future working capital purposes, as necessary. The securities are measured at fair
value, with related gains and losses in the value of such securities recorded in the condensed consolidated statements of operations
in other income (expense), and are reported as current assets on the condensed consolidated balance sheets based on the closing trading
price of the security as of the date being presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of June 30, 2023 and December 31, 2022, Oncocyte held &lt;span id="xdx_903_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20230630__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zEZd0tzlxVGj" title="Common stock, shares held as available for sale securities"&gt;353,264&lt;/span&gt; and &lt;span id="xdx_90E_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zImG2PjERDme" title="Common stock, shares held as available for sale securities"&gt;35,326&lt;/span&gt; shares of common stock of Lineage and AgeX, respectively, as
marketable equity securities had a combined fair market value of $&lt;span id="xdx_904_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20230630__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zLN7EUyPGDPl" title="Fair value of equity securities"&gt;0.5&lt;/span&gt; million and $&lt;span id="xdx_901_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zztEm86lPzuh" title="Fair value of equity securities"&gt;0.4&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zj4d3sWVNN3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&lt;span id="xdx_867_zX90kLV5ULI3"&gt;Recent
accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13,
&lt;i&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; and subsequent amendments
to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit
losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a
valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets,
which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent
changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Previously, U.S. GAAP
required entities to write down credit losses only when losses are probable and loss reversals are not permitted. The Company adopted
this ASU in the first quarter of 2023. Adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial
statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): &lt;i&gt;Accounting for Contract Assets and Contract Liabilities
from Contracts with Customers,&lt;/i&gt; to provide specific guidance to eliminate diversity in practice on how to recognize and measure acquired
contract assets and contract liabilities from revenue contracts from customers in a business combination consistent with revenue contracts
with customers not acquired in an acquisition. The amendments in this update provide that the acquirer should consider the terms of the
acquired contracts, such as timing of payment, identify each performance obligation in the contracts, and allocate the total transaction
price to each identified performance obligation on a relative standalone selling price basis as of contract inception (that is, the date
the acquiree entered into the contracts) or contract modification to determine what should be recorded at the acquisition date. These
amendments are effective for the Company beginning with fiscal year 2023. The impact of the adoption of the amendments in this update
will depend on the magnitude of any customer contracts assumed in a business combination in 2023 and beyond.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNUiTmKaFlFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86A_zkS5tceeAXY1"&gt;Basis
of presentation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance
with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to
Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures
normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance
sheets as of December 31, 2022 was derived from the audited consolidated financial statements at that date. These unaudited condensed
consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included
in Oncocyte&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022. The unaudited condensed consolidated interim financial
statements presented herein as of June 30, 2023 is not representative of the full fiscal year or any future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zBEPow0Ifnt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zrKXO5Nmd15e"&gt;Principles
of consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January 31, 2020, with the
acquisition of Insight Genetics, Inc. (&#x201c;Insight&#x201d;) through a merger with a newly incorporated wholly owned subsidiary of Oncocyte
(the &#x201c;Insight Merger&#x201d;) under the terms of an Agreement and Plan of Merger (the &#x201c;Insight Merger Agreement&#x201d;), Insight
became a wholly owned subsidiary of Oncocyte, and on that date Oncocyte began consolidating Insight&#x2019;s operations and results with
Oncocyte&#x2019;s operations and results (see Note 3).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On February 24, 2021, with the
acquisition of the remaining equity interests in Razor, Razor became a wholly owned subsidiary of Oncocyte, and on that date Oncocyte
began consolidating Razor&#x2019;s results with Oncocyte&#x2019;s operations and results (see Note 3).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (&#x201c;Chronix&#x201d;) pursuant to an Agreement
and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated,
the &#x201c;Chronix Merger Agreement&#x201d;), by and among Oncocyte, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary
of Oncocyte (&#x201c;Merger Sub&#x201d;), Chronix became a wholly owned subsidiary of Oncocyte (the &#x201c;Chronix Merger&#x201d;), and on
that date Oncocyte began consolidating Chronix&#x2019;s operations and results with Oncocyte&#x2019;s operations and results (see Note 3).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have reflected the operations of Razor as discontinued operations for all periods presented. See Note 16 for further information. Unless
otherwise noted, amounts and disclosures throughout these Notes to unaudited condensed consolidated interim financial statements relate
solely to continuing operations and exclude all discontinued operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting
only of normal recurring adjustments, necessary for a fair presentation of Oncocyte&#x2019;s financial condition and results of operations.
The unaudited condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other
interim period or for the entire year. All material intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_842_eus-gaap--UseOfEstimates_z9HUDZz4sJRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zwTeAy75rgGb"&gt;Use
of estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and contingent assets and liabilities, at the date of the unaudited condensed consolidated financial
statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates
estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the
use of judgment to prepare financial projections, timing of potential commercialization of acquired in-process intangible assets, applicable
discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable
companies or transactions, determination of fair value of the assets acquired and liabilities assumed including those relating to contingent
consideration, assumptions related to going concern assessments, allocation of direct and indirect expenses, useful lives associated
with long-lived intangible assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies,
valuation allowances related to deferred income taxes, and assumptions used to value debt and stock-based awards and other equity instruments.
Actual results may differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Similarly,
Oncocyte assessed certain accounting matters that generally require consideration of forecasted financial information. The accounting
matters assessed included, but were not limited to, Oncocyte&#x2019;s equity investments, the carrying value of goodwill, going concern
assessment, acquired in-process intangible assets and other long-lived assets. Those assessments as well as other estimates referenced
above were made in the context of information reasonably available to Oncocyte.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <OCX:BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84B_ecustom--BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock_zm0JZ0NZggYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_zVjdQpE4iuY4"&gt;Business
combinations and fair value measurements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at
fair value on the acquisition date in accordance with ASC 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;. ASC 820 establishes a single authoritative
definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement.
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered
observable and the last unobservable, that may be used to measure fair value, which are the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
&lt;i&gt;Level 1 &lt;/i&gt;&#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
&lt;i&gt;Level 2 &lt;/i&gt;&#x2013; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for
similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated
by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
&lt;i&gt;Level 3 &lt;/i&gt;&#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value
of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
a part of the purchase consideration consists of shares of Oncocyte common stock, Oncocyte calculates the purchase price attributable
to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted
on the principal national securities exchange on which the shares traded. Oncocyte recognizes estimated fair values of the tangible assets
and identifiable intangible assets acquired, including in-process research and development, and liabilities assumed, including any contingent
consideration, as of the acquisition date. Goodwill is recognized as any amount of the fair value of the tangible and identifiable intangible
assets acquired and liabilities assumed in excess of the consideration transferred. ASC 805 precludes the recognition of an assembled
workforce as an asset, effectively subsuming any assembled workforce value into goodwill.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
determining fair value, Oncocyte utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented,
Oncocyte has no financial assets or liabilities recorded at fair value on a recurring basis, except for money market funds and marketable
equity securities of Lineage and AgeX common stock held by Oncocyte described below. These assets are measured at fair value using the
period-end quoted market prices as a Level 1 input. Oncocyte also has certain contingent consideration liabilities which are carried
at fair value based on Level 3 inputs (see Note 3).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3RKpaWznMh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of June 30, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zmTaNgYcWYHf" style="display: none"&gt;Schedule of Fair
Value Measurement of Financial Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total carrying and estimated fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left; padding-bottom: 1.5pt"&gt;Marketable equity securities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zrte2Oe4Xsje" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;530&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zmlsnasuFB8l" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;530&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zLhWjk5r3sIa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0957"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zJWYuvYPxmpa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0958"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zn3zRaxWFSh9" style="border-bottom: Black 2.5pt double; text-align: right"&gt;530&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJ3K5CDPnLqg" style="border-bottom: Black 2.5pt double; text-align: right"&gt;530&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zqMfCKTnq4B7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV4fpBbD8sD8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent consideration liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zhUYvCFL4uY8" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29,150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zFvKQVbzLoxe" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zDj19v3hYJN1" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zjKMlaBqLsR3" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29,150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630_ztZ3r8fTeEY8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,150&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuX5gETrWj07" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0968"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRbVr03xVsNj" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0969"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh2pOmfCD0gh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,150&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total carrying and estimated fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left; padding-bottom: 1.5pt"&gt;Marketable equity securities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_z4Tev33z1EWi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;433&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zdTflE7GPOx2" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;433&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zzdrgphbJ4M3" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zeuvjS5nU5Gi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0974"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zBQNHaivDNA1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zezVqYduTUk5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMgrynHvJ4Be" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYOxUVrvdDij" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent consideration liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zzdaxrShvpDh" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,662&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zIc6J1GvURw2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zfUTVBs0Ucrc" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zVAT8i4bZSM8" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,662&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231_zyECdBhHNRMf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;45,662&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGDRKTs94eGk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDefP5WOZrh9" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0985"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zigpHVQl2mfd" style="border-bottom: Black 2.5pt double; text-align: right"&gt;45,662&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zKaCNtGVNq65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate
fair values because of the short-term nature of these items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</OCX:BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3RKpaWznMh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of June 30, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zmTaNgYcWYHf" style="display: none"&gt;Schedule of Fair
Value Measurement of Financial Assets and Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total carrying and estimated fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left; padding-bottom: 1.5pt"&gt;Marketable equity securities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zrte2Oe4Xsje" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;530&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zmlsnasuFB8l" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;530&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zLhWjk5r3sIa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0957"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zJWYuvYPxmpa" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0958"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20230630_zn3zRaxWFSh9" style="border-bottom: Black 2.5pt double; text-align: right"&gt;530&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJ3K5CDPnLqg" style="border-bottom: Black 2.5pt double; text-align: right"&gt;530&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zqMfCKTnq4B7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV4fpBbD8sD8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent consideration liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zhUYvCFL4uY8" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29,150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zFvKQVbzLoxe" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zDj19v3hYJN1" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zjKMlaBqLsR3" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29,150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630_ztZ3r8fTeEY8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,150&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuX5gETrWj07" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0968"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRbVr03xVsNj" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0969"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh2pOmfCD0gh" style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,150&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s assets and liabilities, measured and recognized at fair value on a recurring basis, classified
under the appropriate level of the fair value hierarchy as of December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total carrying and estimated fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Quoted prices in active markets (Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Significant other observable inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left; padding-bottom: 1.5pt"&gt;Marketable equity securities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_z4Tev33z1EWi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;433&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zdTflE7GPOx2" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;433&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zzdrgphbJ4M3" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--MarketableEquitySecuritiesMember_zeuvjS5nU5Gi" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0974"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zBQNHaivDNA1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zezVqYduTUk5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zMgrynHvJ4Be" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYOxUVrvdDij" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent consideration liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zzdaxrShvpDh" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,662&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zIc6J1GvURw2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zfUTVBs0Ucrc" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0981"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--TypeOfArrangementAxis__custom--ContingentConsiderationLiabilitiesMember_zVAT8i4bZSM8" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,662&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231_zyECdBhHNRMf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;45,662&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGDRKTs94eGk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0984"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zDefP5WOZrh9" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0985"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zigpHVQl2mfd" style="border-bottom: Black 2.5pt double; text-align: right"&gt;45,662&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-06-30_custom_MarketableEquitySecuritiesMember"
      decimals="-3"
      unitRef="USD">530000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member_custom_MarketableEquitySecuritiesMember"
      decimals="-3"
      unitRef="USD">530000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">530000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      unitRef="USD">530000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-06-30_custom_ContingentConsiderationLiabilitiesMember"
      decimals="-3"
      unitRef="USD">29150000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_ContingentConsiderationLiabilitiesMember"
      decimals="-3"
      unitRef="USD">29150000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">29150000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      unitRef="USD">29150000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_custom_MarketableEquitySecuritiesMember"
      decimals="-3"
      unitRef="USD">433000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_custom_MarketableEquitySecuritiesMember"
      decimals="-3"
      unitRef="USD">433000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">433000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      unitRef="USD">433000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_custom_ContingentConsiderationLiabilitiesMember"
      decimals="-3"
      unitRef="USD">45662000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_ContingentConsiderationLiabilitiesMember"
      decimals="-3"
      unitRef="USD">45662000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">45662000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      unitRef="USD">45662000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zlIkj3sDupkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zGQbyBZFOfBi"&gt;Cash,
cash equivalents, and restricted cash&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s reconciliation of cash and cash equivalents, and restricted cash reported within the unaudited condensed consolidated
balance sheets that sum to the total of the same amounts shown in the unaudited condensed consolidated statements of cash flows were
as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zdytl4la5juf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B2_zJpqATCenCh1"&gt;Schedule
of Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230630_zJ6xNQ6lEwZd" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zbOy4sanmZce" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_maCCERCzBSt_zf6VijB9xmCh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;19,993&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RestrictedCash_iI_maCCERCzBSt_zgED1GuzIi3k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_iI_maCCERCzBSt_zl8as0JpcIH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash from discontinuing operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0998"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,510&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_mtCCERCzBSt_zusozGCYoAfl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Cash, cash equivalents and restricted cash shown in the statements of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;19,068&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_8AF_z1Pt03fS2p2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_890_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zdytl4la5juf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B2_zJpqATCenCh1"&gt;Schedule
of Cash and Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230630_zJ6xNQ6lEwZd" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zbOy4sanmZce" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_maCCERCzBSt_zf6VijB9xmCh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,368&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;19,993&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RestrictedCash_iI_maCCERCzBSt_zgED1GuzIi3k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_iI_maCCERCzBSt_zl8as0JpcIH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash from discontinuing operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0998"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,510&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iTI_mtCCERCzBSt_zusozGCYoAfl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Cash, cash equivalents and restricted cash shown in the statements of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;19,068&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">17368000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">19993000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">1700000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1700000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">1510000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">19068000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">23203000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_841_eus-gaap--DiscontinuedOperationsPolicyTextBlock_z6jQVYPfHbq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zX7Hlyt3Qfbj"&gt;Assets
Held for Sale and Discontinued Operations&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, the Company classified laboratory equipment previously presented in machinery and equipment as held for sale in current
assets, in the unaudited condensed consolidated balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment
(&#x201c;ASC 360-10&#x201d;) have been met and the transaction was qualified as assets held for sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2023, the Company entered into various agreements to sell laboratory equipment for an aggregate amount of
$&lt;span id="xdx_905_eus-gaap--IncreaseDecreaseInAssetsHeldForSale_pn5n6_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--VariousAgreementsMember_zba3kXUdbysg" title="Increase (decrease) in asset, held-for-sale"&gt;0.6&lt;/span&gt; million. As a result, the Company classified the equipment as held for sale as current assets, in the unaudited condensed consolidated
balance sheet, as all the criteria of ASC subtopic 360-10, Property, Plant, and Equipment (&#x201c;ASC 360-10&#x201d;) have been met and
the transaction was qualified as assets held for sale. The equipment was written down to its fair value, less cost to sell, to $&lt;span id="xdx_90C_eus-gaap--InventoryWriteDown_pn5n6_c20230101__20230630_zm94u4G9nNs8" title="Inventory write down"&gt;0.2&lt;/span&gt; million
in the unaudited condensed consolidated balance sheet. As a result of the sale, the Company recorded an impairment loss of $&lt;span id="xdx_90B_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20230630_zpYCbYN0Vjz7" title="Asset impairment charges"&gt;1.3&lt;/span&gt; million
on held-for-sale assets, in the unaudited condensed consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management,
having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in
their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate
a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable
and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation
to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the
plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified
as held for sale in the unaudited condensed consolidated balance sheet. Assets classified as held for sale are reported at the lower
of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for
sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Discontinued
operations comprise activities that were disposed of or discontinued at the end of the period, represent a separate major line of business
that can be clearly distinguished for operational and financial reporting purposes and represent a strategic business shift having a
major effect on the Company&#x2019;s operations and financial results according to Accounting Standard Codification (&#x201c;ASC&#x201d;)
Topic 205, &lt;i&gt;Presentation of Financial Statements&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additional
details surrounding the Company&#x2019;s assets and liabilities held for sale and discontinued operations are included in Note 16.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:IncreaseDecreaseInAssetsHeldForSale
      contextRef="From2023-01-012023-06-30_custom_VariousAgreementsMember"
      decimals="-5"
      unitRef="USD">600000</us-gaap:IncreaseDecreaseInAssetsHeldForSale>
    <us-gaap:InventoryWriteDown
      contextRef="From2023-01-01to2023-06-30"
      decimals="-5"
      unitRef="USD">200000</us-gaap:InventoryWriteDown>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2023-01-01to2023-06-30"
      decimals="-5"
      unitRef="USD">1300000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zdALh9iWRtf3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_862_z9k4q47cS8wj"&gt;Goodwill
and intangible assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 350, &lt;i&gt;Intangibles &#x2013; Goodwill and Other&lt;/i&gt;, in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;)
projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived
intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the
project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts
are written off immediately. Oncocyte considers various factors and risks for potential impairment of IPR&amp;amp;D assets, including the
current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability
to obtain local determination coverage (&#x201c;LCD&#x201d;) from the Centers for Medicare and Medicaid Services (&#x201c;CMS&#x201d;) for
Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement
of competitors&#x2019; diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the
eventual realized value of the IPR&amp;amp;D project may vary from its fair value at the date of acquisition, and IPR&amp;amp;D impairment charges
may occur in future periods. During the period between completion or abandonment, the IPR&amp;amp;D assets will not be amortized but will
be tested for impairment on an annual basis and between annual tests if Oncocyte becomes aware of any events occurring or changes in
circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D projects below their respective carrying amounts (see
Notes 3 and 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&amp;amp;D,
is not amortized but is tested for impairment at least annually, or if circumstances indicate its value may no longer be recoverable.
Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant
events and factors affecting Oncocyte&#x2019;s business. Based on the qualitative assessment, if it is determined that the fair value
of goodwill is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared
with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. Oncocyte
continues to operate in one segment and considered to be the sole reporting unit and, therefore, goodwill is tested for impairment at
the enterprise level.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&amp;amp;D discussed in Notes 3 and
4. As of June 30, 2023, goodwill has been fully impaired and acquired IPR&amp;amp;D has been partially impaired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_847_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z43I1D7VHtqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_861_zpKA0ODzalm9"&gt;Long-lived
intangible assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
intangible assets, consisting primarily of acquired customer relationships, are stated at acquired cost, less accumulated amortization.
Amortization expense is computed using the straight-line method over the estimated useful life of &lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230630_zgG4WqZN1Jhc" title="Long-lived intangible assets, useful life"&gt;5&lt;/span&gt; years (see Notes 3 and 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2023-06-30">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ContingentLiabilityReserveEstimatePolicy contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_841_eus-gaap--ContingentLiabilityReserveEstimatePolicy_zrQpGIlIQKhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_864_zYjoCbRT84U6"&gt;Contingent
consideration liabilities&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
of Oncocyte&#x2019;s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former
selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones,
from Pharma Services or laboratory tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable
agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and
timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows (see Notes 3 and 4). These obligations
are referred to as contingent consideration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration
transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling
shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones.
Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings,
such as &#x201c;earn-out&#x201d; provisions or percentage of future revenues, including royalties paid to the selling shareholders based
on a percentage of certain revenues generated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of contingent consideration after the acquisition date is reassessed by Oncocyte as changes in circumstances and conditions
occur, with the subsequent change in fair value recorded in the condensed consolidated statements of operations. Changes in key assumptions
can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that
Oncocyte records in its unaudited condensed consolidated interim financial statements. See Notes 3 and 4 for a full discussion of these
liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ContingentLiabilityReserveEstimatePolicy>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84C_eus-gaap--EquityMethodInvestmentsPolicy_zZ7s92dN3mxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_867_zB5wx3auyJye"&gt;Investments
in capital stock of privately held companies&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable
interest entity (&#x201c;VIE&#x201d;) model, and then under the voting interest model in accordance with accounting guidance for consolidations
under Accounting Standards Codification (&#x201c;ASC&#x201d;) 810-10. If consolidation of the entity is not required under either the VIE
model or the voting interest model, Oncocyte determines whether the equity method of accounting should be applied in accordance with
ASC 323, &lt;i&gt;Investments &#x2013; Equity Method and Joint Ventures&lt;/i&gt;. The equity method applies to investments in common stock or in-substance
common stock if Oncocyte exercises significant influence over, but does not control, the entity, where significant influence is typically
represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment
balance based on Oncocyte&#x2019;s pro rata share of earnings or losses from the investment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
February 24, 2021, the date of Oncocyte&#x2019;s acquisition of the remaining interests in Razor, through February 16, 2023 the date of
its disposition, Razor entity&#x2019;s financial statements have been consolidated with Oncocyte. See Notes 3, 4, and 16 for additional
information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84F_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zoQTYhsYePXj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_z5dg3AsKZ7gi"&gt;Impairment
of long-lived assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired
and the carrying value may not be recoverable. Oncocyte&#x2019;s long-lived assets consist primarily of intangible assets, right-of-use
assets for operating leases, customer relationships, and machinery and equipment. If events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are
less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair
value, is recorded. See Notes 3, 4, and 16 for additional information with respect to impairments of long-lived assets. See Note 16 for
disclosure of machinery and equipment impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zsk7ub5YDnIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86C_zYx3gprohqnj"&gt;Revenue
recognition&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to ASC 606, revenues are recognized when control of services performed is transferred to customers, in an amount that reflects the consideration
Oncocyte expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)
identifying the contract with a customer,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)
identifying the performance obligations in the contract,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)
determining the transaction price,&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv)
allocating the transaction price to the performance obligations, and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(v)
recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services
in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable
consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal
in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently
resolved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;DetermaRx
testing revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to the Razor Sale Transaction, Oncocyte generated revenue from performing DetermaRx tests on clinical samples through orders received
from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria (i) through (v)
above are met with respect to DetermaRx tests, each test result is considered a single performance obligation and is generally considered
complete when the test result is delivered or made available to the prescribing physician electronically, and, as such, there are no
shipping or handling fees incurred by Oncocyte or billed to customers. Although Oncocyte has billed a list price for all tests ordered
and completed for all payer types, Oncocyte considers constraints on the variable consideration when recognizing revenue for DetermaRx.
Because DetermaRx is a novel test and there are no current reimbursement arrangements with third-party payers other than Medicare, the
transaction price represents variable consideration. Application of the constraint for variable consideration is an area that requires
significant judgment. For all payers other than Medicare, Oncocyte must consider the novelty of the test, the uncertainty of receiving
payment, or being subject to claims for a refund, from payers with whom it does not have a sufficient payment collection history or contractual
reimbursement agreements. Accordingly, for those payers, Oncocyte has recognized revenue upon payment because it has had insufficient
history to reliably estimate payment patterns or has had contractual reimbursement arrangements, or both, in place.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, Oncocyte had accounts receivable of $&lt;span id="xdx_904_eus-gaap--AccountsReceivableSale_pn5n6_c20230101__20230630__srt--ProductOrServiceAxis__custom--MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember_zbTDkx4S4eEk" title="Accounts receivable"&gt;1.6&lt;/span&gt; million from Medicare and Medicare Advantage covered DetermaRx tests (see
Note 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
maintain an allowance for expected credit losses at an amount we estimate to be sufficient to provide adequate protection against losses
resulting from extending credit to our customers. We base this allowance, in the aggregate, on historical collection experience, age
of receivables and general economic conditions. Our bad debts have not been material and have been within management expectations. During
the first quarter of 2023, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;i&gt;Financial Instruments-Credit
Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; and subsequent amendments to the initial guidance under
ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial
assets, including trade and other receivables. Adoption of this standard did not have a material impact on the Company&#x2019;s consolidated
financial statements and related disclosures. As of June 30, 2023 and December 31, 2022, we had a credit loss reserve of $&lt;span id="xdx_90F_eus-gaap--ProvisionForDoubtfulAccounts_pn5n6_c20230101__20230630_zK53gXfBx3ri" title="Provision for doubtful accounts"&gt;&lt;span id="xdx_904_eus-gaap--ProvisionForDoubtfulAccounts_pn5n6_c20220101__20221231_zYX0GVuuq9Bf" title="Provision for doubtful accounts"&gt;0.2&lt;/span&gt;&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Pharma
services revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
recognized include Pharma Services performed by Oncocyte&#x2019;s Insight and Chronix subsidiaries for its pharmaceutical customers, including
testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These
Pharma Services are generally performed under individual scope of work (&#x201c;SOW&#x201d;) arrangements or license agreements (together
with SOW the &#x201c;Pharma Services Agreements&#x201d;) with specific deliverables defined by the customer. Pharma Services are performed
on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with
a Pharma Services Agreement, Oncocyte has the right to bill the customer for the agreed upon price (either on a per test or per deliverable
basis) and recognizes Pharma Service revenue at that time. Insight identifies each sale of its Pharma Service offering as a single performance
obligation. Chronix identifies the processing of test samples as a separate performance obligation (considered a series) within license
agreements with customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Completion
of the service and satisfaction of the performance obligation is typically evidenced by access to the report or test made available to
the customer or any other form or applicable manner of delivery defined in the Pharma Services Agreements. However, for certain SOWs
under which work is performed pursuant to the customer&#x2019;s highly customized specifications, Oncocyte has the enforceable right to
bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, Oncocyte recognizes revenue over a period
during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage
of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Pharma Services Agreements,
any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed
to the customer as of the date of Oncocyte&#x2019;s condensed consolidated financial statements are recorded as contract assets and are
included in prepaids and other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified
to accounts receivable in Oncocyte&#x2019;s condensed consolidated financial statements when the customer is invoiced according to the
billing schedule in the contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Oncocyte
establishes credit loss reserve accounts based on the evaluation of the collectability of its Pharma Services accounts receivables after
considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer&#x2019;s
ability to pay, such as a bankruptcy filing or deterioration in the customer&#x2019;s operating results or financial position, reasonable
and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to
customers change, estimates of the recoverability of receivables would be further adjusted. Oncocyte continuously monitors collections
and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its
historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are
written off against the credit loss reserve accounts. As of June 30, 2023, Oncocyte has not recorded any losses or credit loss reserve
accounts on its account receivables from Pharma Services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, Oncocyte had accounts receivable from Pharma Services customers of $&lt;span id="xdx_901_eus-gaap--AccountsReceivableSale_pn5n6_c20230101__20230630__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_zjG4mfP83gx6" title="Accounts receivable"&gt;0.3&lt;/span&gt; million, as compared to $&lt;span id="xdx_90A_eus-gaap--AccountsReceivableSale_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--PharmaServicesMember_z02GYWvfQmt2" title="Accounts receivable"&gt;0.3&lt;/span&gt; million as of
December 31, 2022 (see Note 7). As of June 30, 2023 and December 31, 2022, we have not reserved a credit loss reserve for Pharma Services
accounts receivables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Licensing
revenue&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
recognized include licensing revenue derived from agreements with customers for exclusive rights to market Oncocyte&#x2019;s proprietary
testing technology. Under the agreements, Oncocyte grants exclusive rights to certain trademarks and technology of Oncocyte for the purpose
of marketing Oncocyte&#x2019;s tests within a defined geographic territory. A license agreement may specify milestone deliverables or
performance obligations, for which Oncocyte recognizes revenue when its licensee confirms the completion of Oncocyte&#x2019;s performance
obligation. A licensing agreement may also include ongoing sales support from Oncocyte and typically includes non-refundable licensing
fees and per-test Pharma Services revenues discussed above, for which Oncocyte treats the licensing of the technology, trademarks, and
ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:AccountsReceivableSale
      contextRef="From2023-01-012023-06-30_custom_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember"
      decimals="-5"
      unitRef="USD">1600000</us-gaap:AccountsReceivableSale>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2023-01-01to2023-06-30"
      decimals="-5"
      unitRef="USD">200000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2022-01-012022-12-31"
      decimals="-5"
      unitRef="USD">200000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AccountsReceivableSale
      contextRef="From2023-01-012023-06-30_custom_PharmaServicesMember"
      decimals="-5"
      unitRef="USD">300000</us-gaap:AccountsReceivableSale>
    <us-gaap:AccountsReceivableSale
      contextRef="From2022-01-012022-12-31_custom_PharmaServicesMember"
      decimals="-5"
      unitRef="USD">300000</us-gaap:AccountsReceivableSale>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84E_eus-gaap--CostOfSalesPolicyTextBlock_zxfsZ5sugvq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zgAik2cMrqKd"&gt;Cost
of revenues&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost
of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and
infrastructure expenses, clinical sample related costs associated with performing DetermaRx tests and Pharma Services, providing deliverables
according to our licensing agreements, license fees due to third parties, and amortization of acquired intangible assets such as the
Razor asset and customer relationship intangible assets. Infrastructure expenses include depreciation of laboratory equipment, allocated
rent costs, leasehold improvements, and allocated information technology costs for operations at Oncocyte&#x2019;s CLIA laboratories in
California and Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless
of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues
generated using the associated technology are recorded as expenses at the time the related revenues are recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84A_eus-gaap--ResearchAndDevelopmentExpensePolicy_z9VYzThSZKkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_zmAQLAXY8zZk"&gt;Research
and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits (including stock-based
compensation), laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure
expenses (including allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development
expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications,
property taxes, and insurance. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <OCX:SalesAndMarketingExpensesPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84C_ecustom--SalesAndMarketingExpensesPolicyTextBlock_zSZzKJiXdkvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zhPOYeNSdVCh"&gt;Sales
and marketing expenses&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sales
and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses,
branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead
allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, telecommunications, property
taxes, and insurance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</OCX:SalesAndMarketingExpensesPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z9lDskHkVHDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86D_z3870c4zEFu7"&gt;General
and administrative expenses&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive
and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, telecommunications, property
taxes, and insurance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zmvDJyck8SM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_865_z6KeBeISQsx6"&gt;Net
loss per common share&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and
accretion of the preferred stock, by the weighted average number of shares of common stock outstanding during the year. Diluted loss
per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion
of the preferred stock, by the weighted average number of common shares outstanding plus the number of additional common shares that
would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted
method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the
computation if their effect is antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zpRphtLnuNF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents
the calculation of basic and diluted loss per share of common stock (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zQpZ5bBe8SVf"&gt;Schedule
of Common Stock Computation of Diluted Net Loss Per Share of Common Stock&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230401__20230630_zi6VhUSRhcLf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220401__20220630_z250A9VByK31" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20230630_zZLffxMsbPOe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20220630_zGHbu2Vm7Qw6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeLossIncludingPortionAttributableToNoncontrollingInterest_zjjvwqg2rtfd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Net loss attributable to Oncocyte Corporation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(8,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(8,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(5,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(18,591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DividendOnPreferredStock_zyO5mNeeH4A2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend on Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(76&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(166&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RedeemablePreferredStockDividends_iN_pn3n3_di_zI6LFGQVusXe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accretion of Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(117&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(257&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeemedDividendOnPreferredStock_iN_pn3n3_di_zB0jDxh8Nn73" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deemed dividend on Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1064"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1066"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_z9ehePWv2Rxk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to common stockholders - Basic and Diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230401__20230630_zYnUNlYpzbi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted"&gt;(8,644&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220401__20220630_z4N0PXtRYJFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted"&gt;(8,372&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230630_zllfG01ZWKT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted"&gt;(5,841&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220630_zC6uczPfyZx6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted"&gt;(18,663&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zR1QiUYWycd4" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to common stockholders - Basic &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8,644&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8,372&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,841&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,663&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted average shares used in computing net loss per share attributable to common stockholders - Basic and Diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230401__20230630_zRFBQSfPOkbi" title="Weighted average number of shares outstanding, basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230401__20230630_zsUr2lKy1a2k" title="Weighted average number of shares outstanding, diluted"&gt;8,090&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220401__20220630_zLJZeVYaGELj" title="Weighted average number of shares outstanding, basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220401__20220630_zSirTTGqB954" title="Weighted average number of shares outstanding, diluted"&gt;5,652&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230630_zrwt9ABffUmi" title="Weighted average number of shares outstanding, basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230630_zQW8KDSFUm3" title="Weighted average number of shares outstanding, diluted"&gt;7,030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220630_z7b2pwLFNBO9" title="Weighted average number of shares outstanding, basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220630_z4eHT6aWOVzk" title="Weighted average number of shares outstanding, diluted"&gt;5,135&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EarningsPerShareBasic_pid_z2zA7tJPerI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98F_eus-gaap--EarningsPerShareDiluted_pid_c20230401__20230630_zjxqFaYQCnb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted"&gt;(1.07&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220401__20220630_z3A48JpK1jNi" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted"&gt;(1.48&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230630_zsjAZl3ZjXgf" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted"&gt;(0.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220630_z8t0RQsbemKa" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted"&gt;(3.63&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pid_zlGdnrGr1wy3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic  net loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.07&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.48&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3.63&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgjK9PEZ67Uf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zaYmmxPLXS79" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1128"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfRcuUjnwSP3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;845&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;845&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zmgQqoSMUupa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zjFch4FZu3ad" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,582&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,384&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,508&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zd9x3szxLcDa" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,582&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,384&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,508&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A5_z7z5mTtaPrQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zpRphtLnuNF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
common stock equivalents are antidilutive because Oncocyte reported a net loss for all periods presented. The following table presents
the calculation of basic and diluted loss per share of common stock (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_zQpZ5bBe8SVf"&gt;Schedule
of Common Stock Computation of Diluted Net Loss Per Share of Common Stock&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230401__20230630_zi6VhUSRhcLf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220401__20220630_z250A9VByK31" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20230630_zZLffxMsbPOe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20220101__20220630_zGHbu2Vm7Qw6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeLossIncludingPortionAttributableToNoncontrollingInterest_zjjvwqg2rtfd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Net loss attributable to Oncocyte Corporation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(8,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(8,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(5,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(18,591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DividendOnPreferredStock_zyO5mNeeH4A2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend on Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(76&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(166&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(29&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--RedeemablePreferredStockDividends_iN_pn3n3_di_zI6LFGQVusXe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accretion of Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(117&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(257&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeemedDividendOnPreferredStock_iN_pn3n3_di_zB0jDxh8Nn73" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deemed dividend on Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1064"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1066"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_z9ehePWv2Rxk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to common stockholders - Basic and Diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230401__20230630_zYnUNlYpzbi3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted"&gt;(8,644&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220401__20220630_z4N0PXtRYJFf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted"&gt;(8,372&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230630_zllfG01ZWKT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted"&gt;(5,841&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98E_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220630_zC6uczPfyZx6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income (loss) attributable to common stockholders - diluted"&gt;(18,663&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_zR1QiUYWycd4" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to common stockholders - Basic &lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8,644&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8,372&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,841&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,663&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted average shares used in computing net loss per share attributable to common stockholders - Basic and Diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230401__20230630_zRFBQSfPOkbi" title="Weighted average number of shares outstanding, basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230401__20230630_zsUr2lKy1a2k" title="Weighted average number of shares outstanding, diluted"&gt;8,090&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220401__20220630_zLJZeVYaGELj" title="Weighted average number of shares outstanding, basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220401__20220630_zSirTTGqB954" title="Weighted average number of shares outstanding, diluted"&gt;5,652&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230630_zrwt9ABffUmi" title="Weighted average number of shares outstanding, basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230630_zQW8KDSFUm3" title="Weighted average number of shares outstanding, diluted"&gt;7,030&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220630_z7b2pwLFNBO9" title="Weighted average number of shares outstanding, basic"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220630_z4eHT6aWOVzk" title="Weighted average number of shares outstanding, diluted"&gt;5,135&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EarningsPerShareBasic_pid_z2zA7tJPerI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted net loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98F_eus-gaap--EarningsPerShareDiluted_pid_c20230401__20230630_zjxqFaYQCnb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted"&gt;(1.07&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220401__20220630_z3A48JpK1jNi" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted"&gt;(1.48&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_98A_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230630_zsjAZl3ZjXgf" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted"&gt;(0.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbW1vbiBTdG9jayBDb21wdXRhdGlvbiBvZiBEaWx1dGVkIE5ldCBMb3NzIFBlciBTaGFyZSBvZiBDb21tb24gU3RvY2sgKERldGFpbHMpAA__" id="xdx_985_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220630_z8t0RQsbemKa" style="border-bottom: Black 2.5pt double; text-align: right" title="Earnings Per Share, diluted"&gt;(3.63&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pid_zlGdnrGr1wy3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Basic  net loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.07&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1.48&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.83&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3.63&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zgjK9PEZ67Uf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;731&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;549&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zaYmmxPLXS79" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;RSUs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1128"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zfRcuUjnwSP3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;845&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;845&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zmgQqoSMUupa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Series A redeemable convertible preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zjFch4FZu3ad" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,582&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,384&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,508&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zd9x3szxLcDa" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,315&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,582&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,384&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,508&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8333000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-8300000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5300000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18591000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <OCX:DividendOnPreferredStock
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-76000</OCX:DividendOnPreferredStock>
    <OCX:DividendOnPreferredStock
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-29000</OCX:DividendOnPreferredStock>
    <OCX:DividendOnPreferredStock
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-166000</OCX:DividendOnPreferredStock>
    <OCX:DividendOnPreferredStock
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-29000</OCX:DividendOnPreferredStock>
    <us-gaap:RedeemablePreferredStockDividends
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">117000</us-gaap:RedeemablePreferredStockDividends>
    <us-gaap:RedeemablePreferredStockDividends
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">43000</us-gaap:RedeemablePreferredStockDividends>
    <us-gaap:RedeemablePreferredStockDividends
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">257000</us-gaap:RedeemablePreferredStockDividends>
    <us-gaap:RedeemablePreferredStockDividends
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">43000</us-gaap:RedeemablePreferredStockDividends>
    <OCX:DeemedDividendOnPreferredStock
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">118000</OCX:DeemedDividendOnPreferredStock>
    <OCX:DeemedDividendOnPreferredStock
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">118000</OCX:DeemedDividendOnPreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8644000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8644000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-8372000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-8372000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5841000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5841000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18663000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18663000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">-8644000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-8372000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-5841000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-18663000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="Shares">8090</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="Shares">8090</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">5652</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="Shares">5652</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">7030</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="Shares">7030</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="Shares">5135</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="Shares">5135</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-3.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-3.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012023-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-04-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="USDPShares">-3.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012023-06-30_us-gaap_StockOptionMember"
      decimals="-3"
      unitRef="Shares">483000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012022-06-30_us-gaap_StockOptionMember"
      decimals="-3"
      unitRef="Shares">731000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_us-gaap_StockOptionMember"
      decimals="-3"
      unitRef="Shares">549000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-06-30_us-gaap_StockOptionMember"
      decimals="-3"
      unitRef="Shares">657000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      unitRef="Shares">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      unitRef="Shares">10000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012023-06-30_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">820000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012022-06-30_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">845000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">820000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-06-30_us-gaap_WarrantMember"
      decimals="-3"
      unitRef="Shares">845000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">5000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012022-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">5000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-3"
      unitRef="Shares">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="Shares">1315000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="Shares">1582000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="Shares">1384000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="Shares">1508000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="Shares">1315000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="Shares">1582000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="Shares">1384000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="Shares">1508000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_847_eus-gaap--LesseeLeasesPolicyTextBlock_zAR2qsO6DnPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&lt;span id="xdx_867_z57se08r5Vei"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
accounts for leases in accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;. Oncocyte determines if an arrangement is a lease at inception. Leases
are classified as either financing or operating, with classification affecting the pattern of expense recognition in the condensed consolidated
statements of operations. Under the available practical expedients for the adoption of ASC 842, Oncocyte accounts for the lease and non-lease
components as a single lease component. Oncocyte recognizes right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities for leases
with terms greater than twelve months in the condensed consolidated balance sheet. ROU assets represent the right to use an underlying
asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease
ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most
leases do not provide an implicit rate, Oncocyte uses an incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments. Oncocyte uses the implicit rate when it is readily determinable. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate
the lease when it is reasonably certain that Oncocyte will exercise that option. Lease expense for lease payments is recognized on a
straight-line basis over the lease term. Operating leases are included as right-of-use assets in machinery and equipment, and ROU lease
liabilities, current and long-term, in the condensed consolidated balance sheets. Financing leases are included in machinery and equipment,
and in financing lease liabilities, current and long-term, in the condensed consolidated balance sheets. Oncocyte discloses the amortization
of our ROU assets and operating lease payments as a net amount, &#x201c;Amortization of right-of-use assets and liabilities&#x201d;, on
the condensed consolidated statements of cash flows. Based on the available practical expedients under the standard, Oncocyte elected
not to capitalize leases that have terms of twelve months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
prior years, Oncocyte entered into various operating leases and an embedded operating lease in accordance with ASC 842 discussed in Note
10. Oncocyte&#x2019;s accounting for financing leases remained substantially unchanged.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <OCX:AccountingForSharesOfCommonStockPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84E_ecustom--AccountingForSharesOfCommonStockPolicyTextBlock_zpQoUHH9QS8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&lt;span id="xdx_863_zGtUX57eq779"&gt;Accounting
for Lineage and AgeX shares of common stock&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
accounts for the shares of Lineage and AgeX common stock it holds as marketable equity securities in accordance with ASC 320-10-25, &lt;i&gt;Investments
&#x2013; Debt and Equity Securities&lt;/i&gt;, as amended by Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-01, &lt;i&gt;Financial Instruments&#x2013;Overall:
Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/i&gt;, as the shares have a readily determinable fair value quoted
on the NYSE American and are held principally to meet future working capital purposes, as necessary. The securities are measured at fair
value, with related gains and losses in the value of such securities recorded in the condensed consolidated statements of operations
in other income (expense), and are reported as current assets on the condensed consolidated balance sheets based on the closing trading
price of the security as of the date being presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of June 30, 2023 and December 31, 2022, Oncocyte held &lt;span id="xdx_903_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20230630__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zEZd0tzlxVGj" title="Common stock, shares held as available for sale securities"&gt;353,264&lt;/span&gt; and &lt;span id="xdx_90E_ecustom--CommonStockSharesHeldAsAvailableForSaleSecurities_iI_pid_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zImG2PjERDme" title="Common stock, shares held as available for sale securities"&gt;35,326&lt;/span&gt; shares of common stock of Lineage and AgeX, respectively, as
marketable equity securities had a combined fair market value of $&lt;span id="xdx_904_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20230630__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zLN7EUyPGDPl" title="Fair value of equity securities"&gt;0.5&lt;/span&gt; million and $&lt;span id="xdx_901_eus-gaap--EquitySecuritiesFvNi_iI_pn5n6_c20221231__srt--ConsolidatedEntitiesAxis__custom--LineageAndAgeXMember_zztEm86lPzuh" title="Fair value of equity securities"&gt;0.4&lt;/span&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</OCX:AccountingForSharesOfCommonStockPolicyTextBlock>
    <OCX:CommonStockSharesHeldAsAvailableForSaleSecurities
      contextRef="AsOf2023-06-30_custom_LineageAndAgeXMember"
      decimals="INF"
      unitRef="Shares">353264</OCX:CommonStockSharesHeldAsAvailableForSaleSecurities>
    <OCX:CommonStockSharesHeldAsAvailableForSaleSecurities
      contextRef="AsOf2022-12-31_custom_LineageAndAgeXMember"
      decimals="INF"
      unitRef="Shares">35326</OCX:CommonStockSharesHeldAsAvailableForSaleSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="AsOf2023-06-30_custom_LineageAndAgeXMember"
      decimals="-5"
      unitRef="USD">500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="AsOf2022-12-31_custom_LineageAndAgeXMember"
      decimals="-5"
      unitRef="USD">400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zj4d3sWVNN3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&lt;span id="xdx_867_zX90kLV5ULI3"&gt;Recent
accounting pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13,
&lt;i&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; and subsequent amendments
to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit
losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a
valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets,
which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent
changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Previously, U.S. GAAP
required entities to write down credit losses only when losses are probable and loss reversals are not permitted. The Company adopted
this ASU in the first quarter of 2023. Adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial
statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): &lt;i&gt;Accounting for Contract Assets and Contract Liabilities
from Contracts with Customers,&lt;/i&gt; to provide specific guidance to eliminate diversity in practice on how to recognize and measure acquired
contract assets and contract liabilities from revenue contracts from customers in a business combination consistent with revenue contracts
with customers not acquired in an acquisition. The amendments in this update provide that the acquirer should consider the terms of the
acquired contracts, such as timing of payment, identify each performance obligation in the contracts, and allocate the total transaction
price to each identified performance obligation on a relative standalone selling price basis as of contract inception (that is, the date
the acquiree entered into the contracts) or contract modification to determine what should be recorded at the acquisition date. These
amendments are effective for the Company beginning with fiscal year 2023. The impact of the adoption of the amendments in this update
will depend on the magnitude of any customer contracts assumed in a business combination in 2023 and beyond.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_804_eus-gaap--BusinessCombinationDisclosureTextBlock_zT8FqY89fnt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;3.
&lt;span id="xdx_82A_z2eG6KiFBee2"&gt;Business Combinations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;i&gt;Acquisition
of Insight Genetics, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
January 31, 2020 (the &#x201c;Insight Merger Date&#x201d;), Oncocyte completed its acquisition of Insight pursuant to the Insight Merger
Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Contingent
consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future
if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration
also includes additional future payments to selling shareholders based on achievement of components of earnings, such as &#x201c;earn-out&#x201d;
provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of revenues generated
from DetermaIO and Insight Pharma Services over their respective useful life. Accordingly, Oncocyte determined there are two types
of contingent consideration in connection with the Insight Merger, the Milestone Contingent Consideration and the Royalty Contingent
Consideration discussed below, which are collectively referred to as the &#x201c;Contingent Consideration&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;There
are three milestones comprising the Milestone Contingent Consideration, collectively referred to as the Milestones, in connection with
the Insight Merger which Oncocyte valued and recorded as part of Contingent Consideration as of the Insight Merger Date (see table below),
which consist of (i) a payment for clinical trial completion and related data publication (&#x201c;Milestone 1&#x201d;), (ii) a payment
for an affirmative final local coverage determination from CMS for a specified lung cancer test (&#x201c;Milestone 2&#x201d;), and (iii)
a payment for achieving specified CMS reimbursement milestones (&#x201c;Milestone 3&#x201d;). If achieved, any respective Milestone will
be paid at the contractual value shown below, with the payment made either in cash or in shares of Oncocyte common stock as determined
by Oncocyte. There can be no assurance that any of the Milestones will be achieved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zr62CmVli4Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective
Contingent Consideration liability (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BE_zXLzQ9fEPZy1" style="display: none"&gt;Schedule
of Fair Value of Contingent Consideration Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Value on the&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Merger Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; color: Black"&gt;Milestone 1&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_zW5aIZGI60W8" style="width: 14%; color: Black; text-align: right" title="Contractual Value"&gt;1,500&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_z6iz8Hc5EKF7" style="width: 14%; color: Black; text-align: right" title="Fair Value on the Merger Date"&gt;1,340&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Milestone 2&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_z8AAqFL8bsy" style="color: Black; text-align: right" title="Contractual Value"&gt;3,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_zGhydEVa15pg" style="color: Black; text-align: right" title="Fair Value on the Merger Date"&gt;1,830&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Milestone 3 &lt;sup id="xdx_F45_zVGjZGh31Un2"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_zpWwOxo6gMld" style="color: Black; text-align: right" title="Contractual Value"&gt;1,500&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_z2cZ4qX0fw0e" style="color: Black; text-align: right" title="Fair Value on the Merger Date"&gt;770&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Royalty 1 &lt;sup id="xdx_F44_zb4wasIRrhe5"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;See(b) &lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyOneMember_fKGIp_zVn3EkJpMAO8" style="color: Black; text-align: right" title="Fair Value on the Merger Date"&gt;5,980&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Royalty 2 &lt;sup id="xdx_F4D_zwRw9dSDKHw7"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;See(b) &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyTwoMember_fKGIp_zhj5TRoXpMWk" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Fair Value on the Merger Date"&gt;1,210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630_zDaGfAJD9Rda" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Contractual Value"&gt;6,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630_zwyBT5L1AwFi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Fair Value on the Merger Date"&gt;11,130&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;sup id="xdx_F01_zb2eceMRkTc3"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_znT1wWChX9nd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Indicates
    the maximum payable if the Milestone is achieved.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;sup id="xdx_F04_zTzRw6bHRPqj"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zcX7SCTMlHB4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
    defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful
    life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_z3k9HRBwMhfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
fair value of the Contingent Consideration after the Insight Merger Date is reassessed by Oncocyte as changes in circumstances and conditions
occur, with the subsequent change in fair value recorded in Oncocyte&#x2019;s condensed consolidated statements of operations. As of June
30, 2023, based on Oncocyte&#x2019;s reassessment of the significant assumptions noted above, there was a decrease of approximately $&lt;span id="xdx_905_ecustom--FairValueOfContingentConsideration_pn5n6_c20230101__20230630_zhtxecgaS3I1" title="Fair value of contingent consideration"&gt;2.5&lt;/span&gt;
million to the fair value of the Contingent Consideration primarily attributable to revised estimates of the timing of the possible future
payouts and, accordingly, this decrease was recorded as change in fair value of contingent consideration in the unaudited condensed consolidated
statements of operations for the six months ended June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zNbFLAlRDEJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following tables reflect the activity for Oncocyte&#x2019;s Contingent Consideration for the six months ended June 30, 2023 and 2022,
measured at fair value using Level 3 inputs (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B0_zWcmSODB5ZF3" style="display: none"&gt;Schedule
of Contingent Consideration, Measured at Fair Value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; color: Black"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zHLOuhwRwX1l" style="width: 16%; color: Black; text-align: right" title="Beginning balance"&gt;7,060&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Change in estimated fair value&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zkpPhq7UfiGc" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Change in estimated fair value"&gt;1,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;Balance at June 30, 2022&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zR1ZhP0Pwvu6" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Beginning balance"&gt;8,460&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; color: Black"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_z7klqkL6XAlf" style="width: 16%; color: Black; text-align: right" title="Beginning balance"&gt;5,370&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Change in estimated fair value&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zhgZfEG7nRY6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Change in estimated fair value"&gt;(2,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;Balance at June 30, 2023&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zhyHgOLlU4r9" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Beginning balance"&gt;2,870&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zqVr8LkLaasi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Contingent
consideration is not deductible for tax purposes, even if paid; therefore, no deferred tax assets related to the Contingent Consideration
were recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;i&gt;Asset
acquisition of Razor Genomics, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
February 24, 2021, Oncocyte completed the purchase of all the issued and outstanding shares of common stock of Razor. As a result of
Oncocyte is the sole shareholder of Razor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
December 15, 2022, the Company entered into a Stock Purchase Agreement in which the Company agreed to sell approximately &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221215__dei--LegalEntityAxis__custom--RazorGenomicsIncMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zsP8901u4iSa" title="Outstanding equity"&gt;70&lt;/span&gt;% of the issued
and outstanding equity interest of Razor on a fully-diluted basis. On February 16, 2023, the sale of Razor was completed. &lt;span style="background-color: white"&gt;See
Note 16 for additional information.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Development
Agreement&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On December 31, 2019, in connection with Oncocyte&#x2019;s purchase &lt;span style="background-color: white"&gt;of&#160;&lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20191231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_z7YXMzqjlYsl" title="Outstanding equity"&gt;25&lt;/span&gt;%
of the outstanding equity of Razor,&lt;/span&gt; Oncocyte entered into a Development Agreement with Razor and Encore Clinical, Inc. (&#x201c;Encore&#x201d;),
a former stockholder of Razor (the &#x201c;Development Agreement&#x201d;). Under
the Development Agreement, Razor reserved as a &#x201c;Clinical Trial Expense Reserve&#x201d; $&lt;span id="xdx_908_ecustom--ClinicalTrialExpenseReserveAmount_iI_pn5n6_c20230630__us-gaap--TypeOfArrangementAxis__custom--DevelopmentAgreementMember__dei--LegalEntityAxis__custom--RazorGenomicsIncMember_z46ZfEP6wgPf" title="Clinical trial expense reserve amount"&gt;4.0&lt;/span&gt; million of the proceeds it received
at the Initial Closing from the sale of the Razor Preferred Stock to Oncocyte, to fund Razor&#x2019;s share of costs incurred in connection
with a clinical trial of DetermaRx for purposes of promoting commercialization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"&gt;The
Development Agreement was terminated on February 16, 2023 in connection with the Razor Stock Purchase Agreement. See Note 16 for more
details regarding the Razor Stock Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Sublicense
Agreement&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On December 31, 2019, in connection with Oncocyte&#x2019;s purchase &lt;span style="background-color: white"&gt;of&#160;&lt;span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20191231__us-gaap--TypeOfArrangementAxis__custom--SublicenseAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zW1qK9xIv1H1" title="Outstanding equity"&gt;25&lt;/span&gt;%
of the outstanding equity of Razor,&lt;/span&gt; Oncocyte entered into a Sublicense and Distribution Agreement with Razor and Encore Clinical,
Inc. (&#x201c;Encore&#x201d;), a former stockholder of Razor (the &#x201c;Sublicense Agreement&#x201d;). Under
the Sublicense Agreement, Razor granted to Oncocyte an exclusive worldwide sublicense under certain patent rights applicable to DetermaRx
in the field of use covered by the applicable license held by Razor for purposes of commercialization and development of DetermaRx.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Sublicense Agreement was terminated on February 16, 2023 in connection with the Razor Stock Purchase Agreement. See Notes 16 for more
details regarding the Razor Stock Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;i&gt;Acquisition
of Chronix Biomedical, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
April 15, 2021 (the &#x201c;Chronix Merger Date&#x201d;), Oncocyte completed its acquisition of Chronix pursuant the Chronix Merger Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Contingent
Consideration&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
additional consideration for holders of certain classes and series of Chronix capital stock, the Chronix Merger Agreement originally
required Oncocyte to pay &#x201c;Chronix Contingent Consideration&#x201d; consisting of (i) &#x201c;Chronix Milestone Payments&#x201d; of
up to $&lt;span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferred1_pn6n6_c20210414__20210415__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixBiomedicalIncMember_zO1hMYSvrZ25" title="Business combination consideration transferred"&gt;14&lt;/span&gt; million in any combination of cash or Oncocyte common stock if certain milestones specified in the Chronix Merger Agreement
are achieved, (ii) &#x201c;Royalty Payments&#x201d; of up to &lt;span id="xdx_906_ecustom--EarnoutPercentageOnCollectionsForSales_pid_dp_uPure_c20210414__20210415__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixBiomedicalIncMember_zOT7846rt91k" title="Earnout percentage on collections for sales"&gt;15&lt;/span&gt;% of net collections for sales of specified tests and products during the
five-to-ten year earnout periods, and (iii) &#x201c;Transplant Sale Payments&#x201d; of up to &lt;span id="xdx_905_ecustom--EarnoutPercentageOnCollectionsForSaleOrLicense_pid_dp_uPure_c20210414__20210415__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixBiomedicalIncMember_z5bWiy7suAq1" title="Earnout percentage on collections for sale or license"&gt;75&lt;/span&gt;% of net collections from the sale or license
to a third party of Chronix&#x2019;s patents for use in transplantation medicine during a seven-year earnout period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
February 8, 2023, the Company and equity holder representative entered into Amendment No. 1 to the Merger Agreement (the
&#x201c;Chronix Amendment&#x201d;), pursuant to which the parties agreed that (i) Chronix&#x2019;s equity holders will be paid earnout
consideration of &lt;span id="xdx_90D_ecustom--EarnoutPercentageOnCollectionsForSales_pid_dp_uPure_c20230207__20230208__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixEquityMember_zA8dt6e3Sn08" title="Earnout percentage on collections for sales"&gt;10&lt;/span&gt;%
of net collections for sales of specified tests and products, until the expiration of intellectual property related to such tests
and products, (ii) Chronix&#x2019;s equity holders will be paid &lt;span id="xdx_90C_ecustom--EarnoutPercentageOnCollectionsForSale_pid_dp_uPure_c20230207__20230208__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixEquityMember_z4BAgvEqkP82" title="Gross proceeds percentage"&gt;5&lt;/span&gt;%
of the gross proceeds received from any sale of all or substantially all of the rights, titles, and interests in and to
Chronix&#x2019;s patents for use in transplantation medicine to such third party, and (iii) the Chronix Milestone Payments, &lt;span id="xdx_901_ecustom--RoyaltyPaymentsPercentage_pid_dp_uPure_c20230207__20230208__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ChronixMilestoneMember_zAkyMSYsWqmj" title="Royalty payments"&gt;15&lt;/span&gt;%
Royalty Payments and Transplant Sale Payment obligations were eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
fair value of the Chronix Contingent Consideration after the Chronix Merger Date is reassessed by Oncocyte as changes in circumstances
and conditions occur, with the subsequent change in fair value recorded in Oncocyte&#x2019;s condensed consolidated statements of operations.
As of June 30, 2023, based on Oncocyte&#x2019;s reassessment of the significant assumptions noted above, there was a decrease of approximately
$&lt;span id="xdx_908_ecustom--FairValueOfContingentConsideration_pn5n6_c20230101__20230630__dei--LegalEntityAxis__custom--ChronixMember_z85PzHMf9Se6" title="Fair value"&gt;14.0&lt;/span&gt; million to the fair value of the Contingent Consideration primarily attributable to revised estimates of the timing of the possible
future payouts and, accordingly, this decrease was recorded as a change in fair value of contingent consideration in the unaudited condensed
consolidated statements of operations for the six months ended June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zVFsHijgf9R1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following tables reflect the activity for Oncocyte&#x2019;s Contingent Consideration for the six months ended June 30, 2023 and June 30,
2022, measured at fair value using Level 3 inputs (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zryJ7Rbu1YH5" style="display: none"&gt;Schedule
of Contingent Consideration, Measured at Fair Value&lt;/span&gt;&lt;span style="color: Black"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; color: Black"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_z5g0QnsIAr39" style="width: 16%; color: Black; text-align: right" title="Beginning balance"&gt;69,621&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Change in estimated fair value&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_znlqDc29oDY2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Change in estimated fair value"&gt;(12,415&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;Balance at June 30, 2022&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zePuBAVIo0X9" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Ending balance"&gt;57,206&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Fair
    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 84%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Balance
    at December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zq0O6vjV7D09" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;40,292&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Change
    in estimated fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_z7lb0Qit2Vxh" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in estimated fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(14,012&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Balance
    at June 30, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zAxmVVnZ6Z6a" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;26,280&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_zvgtJJ4Jw9Hb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Goodwill
&lt;/i&gt;- Goodwill is calculated as the difference between the acquisition date fair value of the Aggregate Chronix Merger Consideration
transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill also includes the $&lt;span id="xdx_90B_eus-gaap--DeferredTaxLiabilities_iI_pn5n6_c20230630__us-gaap--BusinessAcquisitionAxis__custom--ChronixBiomedicalIncMember_zVzw2sOKdUF9" title="Net deferred tax liabilities"&gt;2.2&lt;/span&gt; million of net deferred
tax liabilities recorded principally related to the VitaGraft discussed above. Oncocyte recognized approximately $&lt;span id="xdx_902_eus-gaap--Goodwill_iI_pn5n6_c20230630__us-gaap--BusinessAcquisitionAxis__custom--ChronixBiomedicalIncMember_zPFqHQEpzNo5" title="Goodwill"&gt;9.5&lt;/span&gt; million of goodwill
related to the Chronix acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;None
of the goodwill recognized is expected to be deductible for income tax purposes. Goodwill is not amortized but is tested for impairment
at least annually, or more frequently if circumstances indicate potential impairment. During 2022, the Company identified circumstances
that could indicate a potential impairment and after a valuation of the Company&#x2019;s assets and liabilities was performed, management
concluded that goodwill was impaired as of December 31, 2022. (see Notes 2 and 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_89E_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_zr62CmVli4Hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table shows the Insight Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective
Contingent Consideration liability (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BE_zXLzQ9fEPZy1" style="display: none"&gt;Schedule
of Fair Value of Contingent Consideration Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Fair&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Value on the&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Merger Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; color: Black"&gt;Milestone 1&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_zW5aIZGI60W8" style="width: 14%; color: Black; text-align: right" title="Contractual Value"&gt;1,500&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneOneMember_z6iz8Hc5EKF7" style="width: 14%; color: Black; text-align: right" title="Fair Value on the Merger Date"&gt;1,340&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Milestone 2&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_z8AAqFL8bsy" style="color: Black; text-align: right" title="Contractual Value"&gt;3,000&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneTwoMember_zGhydEVa15pg" style="color: Black; text-align: right" title="Fair Value on the Merger Date"&gt;1,830&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Milestone 3 &lt;sup id="xdx_F45_zVGjZGh31Un2"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_zpWwOxo6gMld" style="color: Black; text-align: right" title="Contractual Value"&gt;1,500&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--MilestoneThreeMember_fKGEp_z2cZ4qX0fw0e" style="color: Black; text-align: right" title="Fair Value on the Merger Date"&gt;770&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Royalty 1 &lt;sup id="xdx_F44_zb4wasIRrhe5"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;See(b) &lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyOneMember_fKGIp_zVn3EkJpMAO8" style="color: Black; text-align: right" title="Fair Value on the Merger Date"&gt;5,980&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Royalty 2 &lt;sup id="xdx_F4D_zwRw9dSDKHw7"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;See(b) &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630__us-gaap--BusinessAcquisitionAxis__custom--RoyaltyTwoMember_fKGIp_zhj5TRoXpMWk" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Fair Value on the Merger Date"&gt;1,210&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ContingentConsiderationLiabilityContractualValue_iI_pn3n3_c20230630_zDaGfAJD9Rda" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Contractual Value"&gt;6,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20230630_zwyBT5L1AwFi" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Fair Value on the Merger Date"&gt;11,130&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;sup id="xdx_F01_zb2eceMRkTc3"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_znT1wWChX9nd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Indicates
    the maximum payable if the Milestone is achieved.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;sup id="xdx_F04_zTzRw6bHRPqj"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1F_zcX7SCTMlHB4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
    defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful
    life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <OCX:ContingentConsiderationLiabilityContractualValue
      contextRef="AsOf2023-06-30_custom_MilestoneOneMember"
      decimals="-3"
      unitRef="USD">1500000</OCX:ContingentConsiderationLiabilityContractualValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-06-30_custom_MilestoneOneMember"
      decimals="-3"
      unitRef="USD">1340000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <OCX:ContingentConsiderationLiabilityContractualValue
      contextRef="AsOf2023-06-30_custom_MilestoneTwoMember"
      decimals="-3"
      unitRef="USD">3000000</OCX:ContingentConsiderationLiabilityContractualValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-06-30_custom_MilestoneTwoMember"
      decimals="-3"
      unitRef="USD">1830000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <OCX:ContingentConsiderationLiabilityContractualValue
      contextRef="AsOf2023-06-30_custom_MilestoneThreeMember"
      decimals="-3"
      id="Fact001176"
      unitRef="USD">1500000</OCX:ContingentConsiderationLiabilityContractualValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-06-30_custom_MilestoneThreeMember"
      decimals="-3"
      id="Fact001178"
      unitRef="USD">770000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-06-30_custom_RoyaltyOneMember"
      decimals="-3"
      id="Fact001180"
      unitRef="USD">5980000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-06-30_custom_RoyaltyTwoMember"
      decimals="-3"
      id="Fact001182"
      unitRef="USD">1210000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <OCX:ContingentConsiderationLiabilityContractualValue contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">6000000</OCX:ContingentConsiderationLiabilityContractualValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">11130000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <OCX:FairValueOfContingentConsideration
      contextRef="From2023-01-01to2023-06-30"
      decimals="-5"
      unitRef="USD">2500000</OCX:FairValueOfContingentConsideration>
    <OCX:ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock contextRef="From2023-01-012023-06-30_custom_InsightMergerMember">&lt;p id="xdx_899_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zNbFLAlRDEJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following tables reflect the activity for Oncocyte&#x2019;s Contingent Consideration for the six months ended June 30, 2023 and 2022,
measured at fair value using Level 3 inputs (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B0_zWcmSODB5ZF3" style="display: none"&gt;Schedule
of Contingent Consideration, Measured at Fair Value&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; color: Black"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zHLOuhwRwX1l" style="width: 16%; color: Black; text-align: right" title="Beginning balance"&gt;7,060&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Change in estimated fair value&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zkpPhq7UfiGc" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Change in estimated fair value"&gt;1,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;Balance at June 30, 2022&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zR1ZhP0Pwvu6" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Beginning balance"&gt;8,460&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; color: Black"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_z7klqkL6XAlf" style="width: 16%; color: Black; text-align: right" title="Beginning balance"&gt;5,370&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Change in estimated fair value&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zhgZfEG7nRY6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Change in estimated fair value"&gt;(2,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;Balance at June 30, 2023&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--InsightMergerMember_zhyHgOLlU4r9" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Beginning balance"&gt;2,870&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OCX:ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember"
      decimals="-3"
      unitRef="USD">7060000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <OCX:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset
      contextRef="From2022-01-012022-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember"
      decimals="-3"
      unitRef="USD">1400000</OCX:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2022-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember"
      decimals="-3"
      unitRef="USD">8460000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember"
      decimals="-3"
      unitRef="USD">5370000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <OCX:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset
      contextRef="From2023-01-012023-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember"
      decimals="-3"
      unitRef="USD">-2500000</OCX:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember"
      decimals="-3"
      unitRef="USD">2870000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-15_custom_RazorGenomicsIncMember_custom_OncocyteCorpMember"
      decimals="INF"
      unitRef="Pure">0.70</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2019-12-31_custom_DevelopmentAgreementMember_custom_OncocyteCorpMember"
      decimals="INF"
      unitRef="Pure">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <OCX:ClinicalTrialExpenseReserveAmount
      contextRef="AsOf2023-06-30_custom_DevelopmentAgreementMember_custom_RazorGenomicsIncMember"
      decimals="-5"
      unitRef="USD">4000000.0</OCX:ClinicalTrialExpenseReserveAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2019-12-31_custom_SublicenseAgreementMember_custom_OncocyteCorpMember"
      decimals="INF"
      unitRef="Pure">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2021-04-142021-04-15_srt_MaximumMember_custom_MergerAgreementMember_custom_ChronixBiomedicalIncMember"
      decimals="-6"
      unitRef="USD">14000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <OCX:EarnoutPercentageOnCollectionsForSales
      contextRef="From2021-04-142021-04-15_srt_MaximumMember_custom_MergerAgreementMember_custom_ChronixBiomedicalIncMember"
      decimals="INF"
      unitRef="Pure">0.15</OCX:EarnoutPercentageOnCollectionsForSales>
    <OCX:EarnoutPercentageOnCollectionsForSaleOrLicense
      contextRef="From2021-04-142021-04-15_srt_MaximumMember_custom_MergerAgreementMember_custom_ChronixBiomedicalIncMember"
      decimals="INF"
      unitRef="Pure">0.75</OCX:EarnoutPercentageOnCollectionsForSaleOrLicense>
    <OCX:EarnoutPercentageOnCollectionsForSales
      contextRef="From2023-02-072023-02-08_custom_MergerAgreementMember_custom_ChronixEquityMember"
      decimals="INF"
      unitRef="Pure">0.10</OCX:EarnoutPercentageOnCollectionsForSales>
    <OCX:EarnoutPercentageOnCollectionsForSale
      contextRef="From2023-02-072023-02-08_custom_MergerAgreementMember_custom_ChronixEquityMember"
      decimals="INF"
      unitRef="Pure">0.05</OCX:EarnoutPercentageOnCollectionsForSale>
    <OCX:RoyaltyPaymentsPercentage
      contextRef="From2023-02-072023-02-08_custom_MergerAgreementMember_custom_ChronixMilestoneMember"
      decimals="INF"
      unitRef="Pure">0.15</OCX:RoyaltyPaymentsPercentage>
    <OCX:FairValueOfContingentConsideration
      contextRef="From2023-01-012023-06-30_custom_ChronixMember"
      decimals="-5"
      unitRef="USD">14000000.0</OCX:FairValueOfContingentConsideration>
    <OCX:ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock contextRef="From2023-01-012023-06-30_custom_ChronixMergerMember">&lt;p id="xdx_892_ecustom--ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock_hus-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zVFsHijgf9R1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following tables reflect the activity for Oncocyte&#x2019;s Contingent Consideration for the six months ended June 30, 2023 and June 30,
2022, measured at fair value using Level 3 inputs (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zryJ7Rbu1YH5" style="display: none"&gt;Schedule
of Contingent Consideration, Measured at Fair Value&lt;/span&gt;&lt;span style="color: Black"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; color: Black"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_z5g0QnsIAr39" style="width: 16%; color: Black; text-align: right" title="Beginning balance"&gt;69,621&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Change in estimated fair value&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_znlqDc29oDY2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Change in estimated fair value"&gt;(12,415&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;Balance at June 30, 2022&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20220101__20220630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zePuBAVIo0X9" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Ending balance"&gt;57,206&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;Fair
    Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 84%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Balance
    at December 31, 2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zq0O6vjV7D09" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;40,292&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Change
    in estimated fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_z7lb0Qit2Vxh" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in estimated fair value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(14,012&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Balance
    at June 30, 2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_pn3n3_c20230101__20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--BusinessAcquisitionAxis__custom--ChronixMergerMember_zAxmVVnZ6Z6a" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;26,280&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</OCX:ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember"
      decimals="-3"
      unitRef="USD">69621000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <OCX:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset
      contextRef="From2022-01-012022-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember"
      decimals="-3"
      unitRef="USD">-12415000</OCX:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2022-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember"
      decimals="-3"
      unitRef="USD">57206000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember"
      decimals="-3"
      unitRef="USD">40292000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <OCX:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset
      contextRef="From2023-01-012023-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember"
      decimals="-3"
      unitRef="USD">-14012000</OCX:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member_custom_ChronixMergerMember"
      decimals="-3"
      unitRef="USD">26280000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2023-06-30_custom_ChronixBiomedicalIncMember"
      decimals="-5"
      unitRef="USD">2200000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:Goodwill
      contextRef="AsOf2023-06-30_custom_ChronixBiomedicalIncMember"
      decimals="-5"
      unitRef="USD">9500000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_zggyCJUTfJp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;4.
&lt;span id="xdx_825_zq1y9iRbkQpd"&gt;Intangible Assets, net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
part of the Insight and Chronix acquisitions, which were accounted for as business combinations under ASC 805, completed
on January 31, 2020, and April 15, 2021, respectively, the Company has acquired in process research and development (&#x201c;IPR&amp;amp;D&#x201d;)
and customer relationships.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the first quarter of 2023, due to changes in management and the economic condition of the Company, management shifted the Company&#x2019;s
business strategy to direct efforts on fewer studies and to transition from test that are laboratory developed tests (&#x201c;LDT&#x201d;)
to research use only (&#x201c;RUO&#x201d;) sales. Due to the change in strategy, the Company&#x2019;s long range plan forecasts were updated
and anticipated future benefits derived from the Company&#x2019;s assets. The change in strategy represent a significant indicator for
change in value of the Company&#x2019;s long lived assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
original IPR&amp;amp;D balance was reassessed based on the updated long range plan (&#x201c;LRP&#x201d;), using the multiple period excess
earnings method (&#x201c;MPEEM&#x201d;) approach, the results of the valuation noted that the carrying value of the DetermaIO related IPR&amp;amp;D
intangible assets was greater than the fair market value, whereas the CNI and VitaGraft related IPR&amp;amp;D intangible assets carrying
value was lower than the fair market value. Accordingly, the Company recorded an impairment of approximately $&lt;span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pn5n6_c20230101__20230630_zY7zfMhJclk5" title="Impairment of intangible"&gt;5.0&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zkuWtg5fnVwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;At
June 30, 2023 and December 31, 2022, intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BF_z1ntElUJtXUf" style="display: none"&gt;Schedule
of Goodwill and Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Intangible assets:&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Acquired IPR&amp;amp;D - DetermaIO &lt;sup id="xdx_F45_z50d1JgML9p8"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230630__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zd0UJXxJJbn6" style="width: 16%; color: Black; text-align: right" title="Intangible assets acquired IPR&amp;amp;D"&gt;9,700&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zX4pGhgdrW7e" style="width: 16%; color: Black; text-align: right" title="Intangible assets acquired IPR&amp;amp;D"&gt;14,650&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Acquired IPR&amp;amp;D - DetermaCNI and VitaGraft &lt;sup id="xdx_F4B_zbFL00dbpQ5"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230630__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zCGNkZococe" style="color: Black; text-align: right" title="Intangible assets acquired IPR&amp;amp;D"&gt;46,800&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zOz5SV12oK97" style="color: Black; text-align: right" title="Intangible assets acquired IPR&amp;amp;D"&gt;46,800&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Intangible assets subject to amortization:&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Acquired intangible assets - customer relationship&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpvNVGqMyt49" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Acquired intangible assets"&gt;440&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z00ckkSXCPCf" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Acquired intangible assets"&gt;440&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Total intangible assets&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20230630_zJ75ddvYgyFg" style="color: Black; text-align: right" title="Total intangible assets"&gt;56,940&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20221231_z8PLkXFu9Whe" style="color: Black; text-align: right" title="Total intangible assets"&gt;61,890&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Accumulated amortization - customer relationship&lt;sup id="xdx_F41_zz21ALezTe4j"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zwOyH1flKbod" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Finite-lived intangible assets, accumulated amortization"&gt;(301&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zBfDr8zMLMJe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Finite-lived intangible assets, accumulated amortization"&gt;(257&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 2.5pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20230630_zXvCCFA7Cwjb" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Intangible assets, net"&gt;56,639&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20221231_zAFMNxxZ9SLk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Intangible assets, net"&gt;61,633&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F06_zb3i25T8jMbd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zM4dTMPHLKd2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;See
    Note 3 for information on the Insight Merger.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0A_zf1xpeCdv4Nh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_z4MzpgPX1bUl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;See
    Note 3 for information on the Chronix Merger.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0E_z4YcBThmyYY4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zrznRYC4dSy1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Amortization
    of intangible assets is included in &#x201c;Cost of revenues &#x2013; amortization of acquired intangibles&#x201d; on the condensed
    consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired
    intangibles.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A7_zYTeDvFxU5vj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zlmAtQRW29pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Future
amortization expense of intangible assets subject to amortization is expected to be the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B1_zNjId23XsWCd" style="display: none"&gt;Schedule
of Intangible Assets Future Amortization Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230630_zy6ik692tCF7" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzyWn_z0zj0iJZHfg7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; color: Black; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; color: Black; text-align: right"&gt;44&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzyWn_zc1zdTU4h8Q6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;88&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzyWn_zoSArfeed3Wk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzyWn_z2O6eEIFz0Hc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;139&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zx5jEpHcdZF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-01-01to2023-06-30"
      decimals="-5"
      unitRef="USD">5000000.0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_890_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zkuWtg5fnVwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;At
June 30, 2023 and December 31, 2022, intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BF_z1ntElUJtXUf" style="display: none"&gt;Schedule
of Goodwill and Intangible Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Intangible assets:&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Acquired IPR&amp;amp;D - DetermaIO &lt;sup id="xdx_F45_z50d1JgML9p8"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230630__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zd0UJXxJJbn6" style="width: 16%; color: Black; text-align: right" title="Intangible assets acquired IPR&amp;amp;D"&gt;9,700&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaIOMember_fKDEp_zX4pGhgdrW7e" style="width: 16%; color: Black; text-align: right" title="Intangible assets acquired IPR&amp;amp;D"&gt;14,650&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Acquired IPR&amp;amp;D - DetermaCNI and VitaGraft &lt;sup id="xdx_F4B_zbFL00dbpQ5"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20230101__20230630__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zCGNkZococe" style="color: Black; text-align: right" title="Intangible assets acquired IPR&amp;amp;D"&gt;46,800&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IndefinitelivedIntangibleAssetsAcquired_pn3n3_c20220101__20221231__dei--LegalEntityAxis__custom--DetermaCNIAndVitaGraftMember_fKDIp_zOz5SV12oK97" style="color: Black; text-align: right" title="Intangible assets acquired IPR&amp;amp;D"&gt;46,800&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Intangible assets subject to amortization:&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Acquired intangible assets - customer relationship&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpvNVGqMyt49" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Acquired intangible assets"&gt;440&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AcquiredFiniteLivedIntangibleAssetResidualValue_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z00ckkSXCPCf" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Acquired intangible assets"&gt;440&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Total intangible assets&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20230630_zJ75ddvYgyFg" style="color: Black; text-align: right" title="Total intangible assets"&gt;56,940&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_pn3n3_c20221231_z8PLkXFu9Whe" style="color: Black; text-align: right" title="Total intangible assets"&gt;61,890&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Accumulated amortization - customer relationship&lt;sup id="xdx_F41_zz21ALezTe4j"&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20230630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zwOyH1flKbod" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Finite-lived intangible assets, accumulated amortization"&gt;(301&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_fKDMp_zBfDr8zMLMJe" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Finite-lived intangible assets, accumulated amortization"&gt;(257&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 2.5pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20230630_zXvCCFA7Cwjb" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Intangible assets, net"&gt;56,639&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20221231_zAFMNxxZ9SLk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Intangible assets, net"&gt;61,633&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F06_zb3i25T8jMbd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_zM4dTMPHLKd2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;See
    Note 3 for information on the Insight Merger.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0A_zf1xpeCdv4Nh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_z4MzpgPX1bUl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;See
    Note 3 for information on the Chronix Merger.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0E_z4YcBThmyYY4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zrznRYC4dSy1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Amortization
    of intangible assets is included in &#x201c;Cost of revenues &#x2013; amortization of acquired intangibles&#x201d; on the condensed
    consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired
    intangibles.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="From2023-01-012023-06-30_custom_DetermaIOMember"
      decimals="-3"
      id="Fact001252"
      unitRef="USD">9700000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="From2022-01-012022-12-31_custom_DetermaIOMember"
      decimals="-3"
      id="Fact001254"
      unitRef="USD">14650000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="From2023-01-012023-06-30_custom_DetermaCNIAndVitaGraftMember"
      decimals="-3"
      id="Fact001256"
      unitRef="USD">46800000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="From2022-01-012022-12-31_custom_DetermaCNIAndVitaGraftMember"
      decimals="-3"
      id="Fact001258"
      unitRef="USD">46800000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue
      contextRef="AsOf2023-06-30_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">440000</us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue
      contextRef="AsOf2022-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">440000</us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">56940000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">61890000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-06-30_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001268"
      unitRef="USD">-301000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001270"
      unitRef="USD">-257000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">56639000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">61633000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zlmAtQRW29pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Future
amortization expense of intangible assets subject to amortization is expected to be the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B1_zNjId23XsWCd" style="display: none"&gt;Schedule
of Intangible Assets Future Amortization Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230630_zy6ik692tCF7" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzyWn_z0zj0iJZHfg7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; color: Black; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; color: Black; text-align: right"&gt;44&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzyWn_zc1zdTU4h8Q6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;88&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzyWn_zoSArfeed3Wk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzyWn_z2O6eEIFz0Hc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;139&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">44000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">88000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">7000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">139000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwdQQ4cBeOQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;5.
&lt;span id="xdx_824_zvW4mSQ9OOqb"&gt;Shareholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Series
A Redeemable Convertible Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
April 13, 2022, the Company entered into the Securities Purchase Agreement with the Investors in a registered direct offering of &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_z2KvzPhwOX69" title="Offering shares"&gt;11,765
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;shares of the Company&#x2019;s Series
A Preferred Stock, which shares of Series A Preferred Stock are convertible into a total of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znxyqV2Hvvf5" title="Convertible preferred shares"&gt;384,477
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;shares of common stock, at a conversion
price of $&lt;span id="xdx_904_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTzhSUeLZoW8" title="Conversion price"&gt;30.60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;.
The purchase price of each share of Series A Preferred Stock was $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zn4bkusr0hO" title="Preferred stock offering"&gt;850&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;,
which included an original issue discount to the stated value of $&lt;span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zDOVOEDpAFr6" title="Stated value per share"&gt;1,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;per share. The rights, preferences
and privileges of the Series A Preferred Stock are set forth in the Company&#x2019;s Certificate of Determination, which the Company filed
with the Secretary of State of the State of California. The Securities Purchase Agreement provides that the closing of the Series A Preferred
Stock Offering will occur, subject to the satisfaction of certain closing conditions, in two equal tranches of $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zaTYO1W8Drqb" title="Preferred stock offering"&gt;5,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;each for aggregate gross proceeds
from both closings of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zozNK6Oxl05j" title="Gross proceeds, closing"&gt;10,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;.
The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220412__20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zj8MiLmaxZ9h" title="Net proceeds"&gt;4.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;million from the Series A Preferred
Stock issued from the first tranche. The second closing would occur, subject to the satisfaction of certain closing conditions (including
but not limited to a requirement that the Company has not received, in the 12 months preceding the second closing, a notice from Nasdaq
that the Company is not in compliance with the listing and maintenance and listing requirements of Nasdaq), on the earlier of (a) the
second trading day following the date that Oncocyte receives notice from an Investor to accelerate the second closing and (b) a date
selected by Oncocyte on or after October 8, 2022 and on or prior to March 8, 2023. On August 9, 2022, Oncocyte received a letter from
Nasdaq indicating that the Company no longer met the minimum bid price requirement of the Nasdaq continued
listing requirements. Accordingly, the second closing did not occur and no additional proceed&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s
were received under the Securities Purchase Agreement. On August 8, 2023, the Company received a letter from Nasdaq indicating that
the Company had regained compliance with the minimum bid price requirement of the Nasdaq continued listing requirements. See Note 15 for additional
information about the Series A Preferred Stock Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Series A Preferred Stock is convertible into shares of the Company&#x2019;s common stock at any time at the holder&#x2019;s option. The
conversion price will be subject to customary anti-dilution adjustments for matters such as stock splits, stock dividends and other distributions
on our common stock, and recapitalizations. &lt;span id="xdx_90C_eus-gaap--ConversionOfStockDescription_c20230101__20230630_zRjjaUnk7bPi" title="Conversion of stock, description"&gt;A holder is prohibited from converting shares of Series A Preferred Stock into shares of
common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of
our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership
limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to
the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect
to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer
apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)&lt;/span&gt;. On July
15, 2022, the Company received such shareholder approval to remove the beneficial ownership limitation with respect to the Series A Preferred
Stock held by Broadwood. The Company may force the conversion of up to one-third of the shares of Series A Preferred Stock
originally issued, subject to customary equity conditions, &lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_z9KKBKFKc825" title="Equity method investment, description of principal activities"&gt;if the daily volume weighted average price of our common stock for 20 out
of 30 trading days exceeds &lt;span id="xdx_90E_ecustom--ConversionPricePercentage_dp_uPure_c20220714__20220715_zxCCzDgJI6El"&gt;140&lt;/span&gt;% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or
exceeds 20,000 shares of our common stock&lt;/span&gt;. The Company may only effect one forced conversion during any 30-trading day period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
the event of the Company&#x2019;s liquidation, dissolution, or winding up, holders of Series A Preferred Stock will receive a payment
equal to the stated value of the Series A Preferred Stock plus accrued but unpaid dividends and any other amounts that may have become
payable on the Series A Preferred Stock due to any failure or delay that may have occurred in issuing shares of common stock upon conversion
of a portion of the Series A Preferred Stock, before any distribution or payment to the holders of common stock or any of our other junior
equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;ONCOCYTE
CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Shares
of Series A Preferred Stock generally have no voting rights, except as required by law and except that the consent of holders of
a majority of the outstanding Series A Preferred Stock will be required to amend any provision of our certificate of incorporation that
would have a materially adverse effect on the rights of the holders of the Series A Preferred Stock. Additionally, as long as any shares
of Series A Preferred Stock remain outstanding, unless the holders of at least &lt;span id="xdx_90D_ecustom--PreferredStockRemainsOutstandingPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_za9Qp0Q7e1k9" title="Preferred stock outstanding percentage"&gt;51&lt;/span&gt;% of the then outstanding shares of Series A Preferred
Stock shall have otherwise given prior written consent, we, on a consolidated basis with our subsidiaries, are not permitted to (1) have
less than $&lt;span id="xdx_900_eus-gaap--Cash_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z6Hicb4W9sEe" title="Cash in hand"&gt;8&lt;/span&gt; million of unrestricted, unencumbered cash on hand (&#x201c;Cash Minimum Requirement&#x201d;); (2) other than certain permitted
indebtedness, incur indebtedness to the extent that our aggregate indebtedness exceeds $&lt;span id="xdx_90B_ecustom--IndebtednessExpenses_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zcU48xM07Lgf" title="Indebtedness expenses"&gt;15&lt;/span&gt; million; (3) enter into any agreement (including
any indenture, credit agreement or other debt instrument) that by its terms prohibits, prevents, or otherwise limits our ability to pay
dividends on, or redeem, the Series A Preferred Stock in accordance with the terms of the Certificate of Determination; or (4) authorize
or issue any class or series of preferred stock or other capital stock of the Company that ranks senior or pari passu with the Series
A Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Shares
of Series A Preferred Stock are entitled to receive cumulative dividends at a rate per share (as a percentage of stated value) of
&lt;span id="xdx_907_ecustom--DividendsRatePerPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zixFccYnMMWg" title="Dividends rate"&gt;6&lt;/span&gt;% per annum, payable quarterly in cash or, at our option, by accreting such dividends to the stated value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Company is required to redeem, for cash, the shares of Series A Preferred Stock on the earlier to occur of (1) April 8, 2024, (2) the
commencement of certain a voluntary or involuntary bankruptcy, receivership, or similar proceedings against the Company or its assets,
(3) a Change of Control Transaction (as defined herein) and (4) at the election and upon notice of &lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InterestMember_zPuZLzD3uCua" title="Ownership percentage"&gt;51&lt;/span&gt;% in interest of the holders, if
the Company fails to meet the Cash Minimum Requirement. A &#x201c;Change of Control Transaction&#x201d; means the occurrence of any of
(a) an acquisition by an individual or legal entity or &#x201c;group&#x201d; (as described in Rule 13d-5(b)(1) promulgated under the Exchange
Act) of effective control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of
in excess of &lt;span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_z8VqlYAtzo6l" title="Ownership percentage"&gt;50&lt;/span&gt;% of the voting securities of the Company (other than by means of conversion of Series A Preferred Stock), (b) the Company
merges into or consolidates with any other person, or any person merges into or consolidates with the Company and, after giving effect
to such transaction, the stockholders of the Company immediately prior to such transaction own less than &lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SecurityMember_zhOynCNCprej" title="Ownership percentage"&gt;50&lt;/span&gt;% of the aggregate voting
power of the Company or the successor entity of such transaction, or (c) the Company sells or transfers all or substantially all of its
assets to another person. Additionally, the Company has the right to redeem the Series A Preferred Stock for cash upon 30 days prior
notice to the holders; provided if the Company undertakes a capital raise in connection with such redemption, the Investors will have
the right to participate in such financing. On April 5, 2023, the Company redeemed &lt;span id="xdx_901_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230404__20230405__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7yo2bp0iT44" title="Number of stock redeem"&gt;1,064&lt;/span&gt; shares of the Series A Preferred Stock for approximately
$&lt;span id="xdx_908_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230404__20230405__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkkVV88XsEX1" title="Number of stock redeem value"&gt;1.1&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of June 30, 2023, Oncocyte had &lt;span id="xdx_901_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_z4mv9Ns6Z9Di" title="Temporary equity, shares issued"&gt;&lt;span id="xdx_90D_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesARedeemableConvertiblePreferredStockMember_zujHw6qI6Ae3" title="Temporary equity, shares outstanding"&gt;4,818&lt;/span&gt;&lt;/span&gt; shares issued and outstanding. The future right or obligation associated with the Series A Preferred
Stock to be issued in the second closing was written off in the prior year since the second closing was not completed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of June 30, 2023 and December 31, 2022, Oncocyte has &lt;span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3pP1GE86ex9" title="Common stock, shares authorized"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zple5sn9d7X" title="Common stock, shares authorized"&gt;230,000,000&lt;/span&gt;&lt;/span&gt; shares of common stock, &lt;span id="xdx_908_eus-gaap--PreferredStockNoParValue_iI_pid_do_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPVLfI1kcjD4" title="Preferred stock no par value"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockNoParValue_iI_pid_do_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQB8MzRWlm77" title="Preferred stock no par value"&gt;no&lt;/span&gt;&lt;/span&gt;-par value, authorized. As of June 30, 2023
and December 31, 2022, Oncocyte had &lt;span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230630_zB17FF9GO6rd" title="Common stock, shares outstanding"&gt;8,240,928&lt;/span&gt; and &lt;span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zogPhqe0kEjb" title="Common stock, shares outstanding"&gt;5,932,191&lt;/span&gt; shares of common stock issued and outstanding, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Common
Stock Purchase Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of June 30, 2023, Oncocyte had an aggregate of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630_zswm8m17NPy7" title="Number of common stock purchase warrants"&gt;819,767&lt;/span&gt; common stock purchase warrants issued and outstanding with exercise prices ranging
from $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__srt--RangeAxis__srt--MinimumMember_zJkBB6TPrWg9" title="Warrant exercise price per share"&gt;30.60&lt;/span&gt; to $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__srt--RangeAxis__srt--MaximumMember_zEGob5kqrAzd" title="Warrant exercise price per share"&gt;109.20&lt;/span&gt; per warrant. The warrants will expire on various dates ranging from February 2024 to October 2029. Certain warrants
have &#x201c;cashless exercise&#x201d; provisions meaning that the value of a portion of warrant shares may be used to pay the exercise
price rather than payment in cash, which may be exercised under any circumstances in the case of the 2017 Bank Warrants and 2019 Bank
Warrants or, in the case of certain other warrants, only if a registration statement for the warrants and underlying shares of common
stock is not effective under the Securities Act or a prospectus in the registration statement is not available for the issuance of shares
upon the exercise of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;ONCOCYTE
CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
has considered the guidance in ASC 815-40, &lt;i&gt;Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in,
a Company&#x2019;s Own Stock, &lt;/i&gt;which states that contracts that require or may require the issuer to settle the contract for cash are
liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement
feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement
for transactions outside of the company&#x2019;s control and, in which the form of consideration to the warrant holder may not be the
same as to all other shareholders in connection with the transaction. However, if a transaction is not within the company&#x2019;s control
but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders
in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification
criteria are met. Based on the above guidance and, among other factors, the fact that the warrants cannot be cash settled under any circumstance
but require share settlement, all of the outstanding warrants meet the equity classification criteria and have been classified as equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_custom_InvestorsMember"
      decimals="INF"
      unitRef="Shares">11765</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">384477</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">30.60</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">850</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="0"
      unitRef="USD">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-04-122022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      unitRef="USD">4900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ConversionOfStockDescription contextRef="From2023-01-01to2023-06-30">A holder is prohibited from converting shares of Series A Preferred Stock into shares of
common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of
our common stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership
limitation solely as to itself up to 19.99% of the number of shares of our common stock outstanding immediately after giving effect to
the conversion, provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect
to the issuance of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer
apply to the holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)</us-gaap:ConversionOfStockDescription>
    <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="From2023-01-012023-06-30_us-gaap_SeriesAPreferredStockMember_custom_OncocyteCorpMember">if the daily volume weighted average price of our common stock for 20 out
of 30 trading days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or
exceeds 20,000 shares of our common stock</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
    <OCX:ConversionPricePercentage
      contextRef="From2022-07-142022-07-15"
      decimals="INF"
      unitRef="Pure">1.40</OCX:ConversionPricePercentage>
    <OCX:PreferredStockRemainsOutstandingPercentage
      contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.51</OCX:PreferredStockRemainsOutstandingPercentage>
    <us-gaap:Cash
      contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-6"
      unitRef="USD">8000000</us-gaap:Cash>
    <OCX:IndebtednessExpenses
      contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="-6"
      unitRef="USD">15000000</OCX:IndebtednessExpenses>
    <OCX:DividendsRatePerPercentage
      contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.06</OCX:DividendsRatePerPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_PreferredStockMember_custom_InterestMember"
      decimals="INF"
      unitRef="Pure">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_PreferredStockMember_custom_OncocyteCorpMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-04-13_custom_SeriesARedeemableConvertiblePreferredStockMember_us-gaap_PreferredStockMember_custom_SecurityMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2023-04-042023-04-05_custom_RegisteredDirectOfferingMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1064</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-042023-04-05_custom_RegisteredDirectOfferingMember_us-gaap_SeriesAPreferredStockMember"
      decimals="-5"
      unitRef="USD">1100000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">4818</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-06-30_custom_SeriesARedeemableConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">4818</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">230000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">230000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockNoParValue
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">0</us-gaap:PreferredStockNoParValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">8240928</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">5932191</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2023-06-30" decimals="INF" unitRef="Shares">819767</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-30_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">30.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-30_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">109.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_808_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zJsOujnmJlCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;6.
&lt;span id="xdx_82B_ztPRACyljOu8"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
had a 2010 Stock Option Plan (the &#x201c;2010 Plan&#x201d;) under which &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenStockOptionPlanMember_zRifiA3HRJE8" title="Common stock, shares authorized"&gt;260,000&lt;/span&gt; shares of common stock were authorized for the grant of
stock options or the sale of restricted stock. On August 27, 2018, Oncocyte shareholders approved a new Equity Incentive Plan (the &#x201c;2018
Incentive Plan&#x201d;) to replace the 2010 Plan. In adopting the 2018 Incentive Plan, Oncocyte terminated the 2010 Plan and will not
grant any additional stock options or sell any stock under restricted stock purchase agreements under the 2010 Plan; however, stock options
issued under the 2010 Plan will continue in effect in accordance with their terms and the terms of the 2010 Plan until the exercise or
expiration of the individual options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2022, the Company awarded executive share-based payment awards under the 2018 Plan to certain executive officers
and employees with time-based, market-based and performance-based vesting conditions (&#x201c;2022 equity awards&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
fair value of the 2022 equity awards with performance-based vesting condition was estimated using the Black-Scholes option-pricing model
assuming that performance goals will be achieved. If such performance conditions are not met, no compensation cost is recognized and
any recognized compensation cost is reversed. The probability of 2022 equity awards performance-based vesting conditions will be evaluated
each reporting period and the Company will true-up the amount of cumulative cost recognized for the 2022 performance-based awards at
each reporting period based on the most up-to-date probability estimates. The Company will recognize the compensation expense for 2022
performance-based awards expected to vest on a straight-line basis over the respective service period for each separately vesting tranche.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
fair value of the 2022 equity awards with market-based vesting condition was estimated using the Monte Carlo simulation model. Assumptions
and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated
period to achievement of the performance and market conditions, which are subject to the achievement of the market-based goals established
by the Company and the continued employment of the participant. These awards vest only to the extent that the market-based conditions
are satisfied as specified in the vesting conditions. Unlike the performance-based awards, the grant date fair value and associated compensation
cost of the market-based awards reflect the probability of the market condition being achieved, and the Company will recognize this compensation
cost regardless of the actual achievement of the market condition. Assumptions utilized in connection with the Monte Carlo valuation
technique included: estimated risk-free interest rate of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zPyhBbWkC0E1" title="Risk-free interest rates"&gt;2.0&lt;/span&gt; percent; term of &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zV8FMPrYlugj" title="Expected life (in years)"&gt;2.8&lt;/span&gt; years; expected volatility of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_zLCKwsPZeEv6" title="Expected Volatility"&gt;100&lt;/span&gt; percent; and expected
dividend yield of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--MonteCarloValuationTechniqueMember_z1ALEfkqpaB4" title="Dividend yield"&gt;0&lt;/span&gt; percent. The risk-free interest rate was determined based on the yields available on U.S. Treasury zero-coupon issues.
The expected stock price volatility was determined using historical volatility. The expected dividend yield was based on expectations
regarding dividend payments. The total grant date fair value of the market-based awards was $&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_c20230101__20230630__us-gaap--PlanNameAxis__custom--PerformanceBasedOptionsMember_zr7yY7AG4PM7" title="Grant date fair value"&gt;117,625&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
May 2022, the Company approved amendments to vesting conditions of &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220501__20220531__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndEmployeesMember_zeZmunvDFnRf" title="Share based awards vesting"&gt;61,875&lt;/span&gt; performance-based and &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220501__20220531__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndEmployeesMember_zfLSqOEYlmQi" title="Share based awards vesting"&gt;12,500&lt;/span&gt; market-based awards of certain
executive officers and employees. The performance-based awards were modified such that the stock awards will be eligible to vest as follows:
(i) &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220501__20220531__dei--LegalEntityAxis__custom--VitaGraftMember_zZTF9LXezoq9"&gt;50&lt;/span&gt;% will vest on December 31, 2023 if the Company achieves LCD reimbursement for VitaGraft (formerly TheraSure&lt;sup&gt; &lt;/sup&gt;Transplant
Monitor) for one organ no later than December 31, 2022 and (ii) &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220501__20220531__dei--LegalEntityAxis__custom--DetermalOMember_zPUwwusTQ5Ij"&gt;50&lt;/span&gt;% will vest on December 31, 2023 if DetermaIO or DetermaCNI (formerly
TheraSure - CNI Monitor) submission for LCD is completed no later than December 31, 2022. Additional performance-based restricted stock
unit (&#x201c;RSU&#x201d;) awards were modified to be eligible to vest upon the achievement by &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220501__20220531_z7iY7vXqNkTe" title="Share based payment award description"&gt;the Company of average market capitalization
minimum, target, and maximum goals of (i) $300 million; (ii) $400 million; and (iii) $500 million, respectively, during the period beginning
on January 1, 2022 and ending on December 31, 2024&lt;/span&gt;. The market-based RSU awards were modified such that the awards will be eligible to
vest upon the achievement of product commercial launch minimum, target, and maximum goals as follows: (i) one laboratory test product in
the US; (ii) two laboratory test products in US, and (iii) three laboratory test products in the US, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
accordance with ASC 718, the Company calculated the fair value of the market-based awards on the date of modification, noting an increase
in the fair value of approximately $&lt;span id="xdx_90B_eus-gaap--IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_c20230101__20230630_zJLiRFx1D9f5" title="Increase in fair value"&gt;58,500&lt;/span&gt; on the date of modification, with the incremental increase in fair value representing additional
unrecognized stock-based compensation expense. The following assumptions were used in calculating the fair value of the market-based
options on the date of modification:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_znVbihcDDGN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BA_zbFjVRKNuywk" style="display: none"&gt;Schedule
of Assumptions Used to Calculate Fair Value of Stock Options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; color: Black; text-align: left"&gt;Risk-free interest rates&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zS6GXqshyhFl" style="width: 16%; color: Black; text-align: right" title="Risk-free interest rates"&gt;2.72&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zScan6519KL9" title="Expected term (in years)"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Volatility&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zfqfI8JqNsMc" style="color: Black; text-align: right" title="Volatility"&gt;95.0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Grant date fair value of awards granted during the period&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zqwwvt1LEdea" style="color: Black; text-align: right" title="Grant date fair value of awards granted during the period"&gt;22.60&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_z1uHSVncfNq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
July 2022, the Company approved amendments to vesting conditions of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220701__20220731__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersAndEmployeesMember_zlX8RTBUmRle" title="Share based awards vesting"&gt;23,750&lt;/span&gt; performance-based awards of certain executive officers and
employees. Certain performance-based awards were modified such that the stock awards will be eligible to vest as follows: (i) fifty percent
(&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20220701__20220731__dei--LegalEntityAxis__custom--VitaGraftMember_zayDBC727wxk" title="Vested percentage"&gt;50&lt;/span&gt;%) of the options will vest on December 31, 2023 (the &#x201c;Vesting Date&#x201d;), subject to Continuous Service through the Vesting
Date, if local coverage determination is issued and priced for VitaGraft (Transplant) with respect to one organ no later than December
31, 2022; and (ii) fifty percent (&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_c20220701__20220731__dei--LegalEntityAxis__custom--DetermalOMember_zNaIcQEEHDp8" title="Vested percentage"&gt;50&lt;/span&gt;%) of the options will vest on the Vesting Date, subject to Continuous Service through the Vesting
Date, if the Company submits a local coverage determination request for DetermaIO or DetermaCNI no later than December 31, 2022. Additional
performance-based stock awards were modified to be eligible to vest upon &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220701__20220731_zTHL6RUiECM1" title="Share based payment award description"&gt;the achievement of performance minimum, target, and maximum
goals of (i) 90% of revenue goal; (ii) 100% of revenue goal; and (iii) exceed revenue goal by up to 150%, respectively, during fiscal
year 2022&lt;/span&gt;. These same awards contained budget performance goals which were modified to be eligible to vest upon the achievement of performance
minimum, target, and maximum goals of (i) complete fiscal year 2022 with sufficient cash to continue operations for 12 months; (ii) complete
fiscal year 2022 with sufficient cash to continue operations for 15 months; and (iii) complete fiscal year 2022 with sufficient cash
to continue operations for 16 months, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of December 31, 2022, &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zC92BXiduMbk" title="Share based payment award description"&gt;50&lt;/span&gt;% of the performance-based were forfeited since the Company did not achieve LCD reimbursement for VitaGraft.
&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20221214__20221216__dei--LegalEntityAxis__custom--DetermaCNIMember_zADgkkHvn5P3" title="Share based payment award vesting rights description"&gt;The remaining 50% is eligible to vest on December 31, 2023, since the Company completed the LCD submission for DetermaCNI on December
16, 2022&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;During
the year ended December 31, 2022, the Company accelerated the vesting of certain equity awards in accordance with the 2018 Incentive
Plan after the departure of officers of the Company and the adoption of the workforce reduction plan. Due to the acceleration of such
awards all associated unrecognized compensation was accelerated and recognized in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zUo4G291Qxh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;A
summary of Oncocyte&#x2019;s 2010 Plan activity and related information follows (in thousands except weighted average exercise price):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B3_zUVPAoU1vP1i" style="display: none"&gt;Summary
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 75%; margin-left: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Available&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;of Options&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold"&gt;Options&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;for Grant&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; color: Black"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_z3bPk7Z2hlC3" style="width: 14%; color: Black; text-align: right" title="Shares available for grant options, beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1400"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zFOGPbH0leT7" style="width: 12%; color: Black; text-align: right" title="Number of options outstanding, beginning of period"&gt;30&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zADSJFwO0K48" style="width: 16%; color: Black; text-align: right" title="Weighted average exercise price, options outstanding, beginning of period"&gt;80.78&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zqOvjuGnwdt6" style="color: Black; text-align: right" title="Shares available for grant options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1406"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zjUVWaMiQIF5" style="color: Black; text-align: right" title="Number of options outstanding, option exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1408"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zhTpksbXooPj" style="color: Black; text-align: right" title="Weighted average exercise price, options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1410"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Options forfeited, cancelled and expired&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zM59qaMLhB44" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Shares available for grant options forfeited, cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1412"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zv8eGHd0dz36" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, options forfeited, cancelled and expired"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zJLp9a92ow0b" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, options forfeited, cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1416"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;Balance at June 30, 2023&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zeAulXHuE4Wk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Shares available for grant outstanding, end of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1418"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zdkmWa1lVQB7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, end of period"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zoLDCyCZx97e" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price, outstanding end of period"&gt;80.58&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; padding-bottom: 1.5pt"&gt;Exercisable at June 30, 2023&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_z9qBjbwvr848" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, exercisable, end of period"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zy6hs1gHwlV8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercisable, end of period"&gt;80.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z67g7wUSLcXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of June 30, 2023, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenIncentivePlanMember_zIDoKr6cCvIl" title="Common stock, shares authorized"&gt;1,050,000&lt;/span&gt; shares of common stock were reserved under the 2018 Incentive Plan for the grant of stock options or the
sale of restricted stock or for the settlement of RSUs. Oncocyte may also grant stock appreciation rights under the 2018 Incentive Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z5LNGTnwPm19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;A
summary of Oncocyte&#x2019;s 2018 Incentive Plan activity and related information follows (in thousands except weighted average exercise
price):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B8_z1p5ZtaNnrsl" style="display: none"&gt;Summary
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Available&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;of Options&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;of RSUs&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;for Grant&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; color: Black"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zWpYo9KcyF76" style="width: 11%; color: Black; text-align: right" title="Shares available for grant options, beginning of period"&gt;442&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zZpp1RzLqs2f" style="width: 11%; color: Black; text-align: right" title="Number of options outstanding, beginning of period"&gt;428&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z3AMQbzxUvv7" style="width: 8%; color: Black; text-align: right" title="Number of RSUs Outstanding, beginning of period"&gt;22&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zXNv18lN5Ei6" style="width: 14%; color: Black; text-align: right" title="Weighted average exercise price, options outstanding, beginning of period"&gt;59.23&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;RSUs vested&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zYb3QJGBQePf" style="color: Black; text-align: right" title="Shares available for grant options RSUs vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1440"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zbAJWodSEFh8" style="color: Black; text-align: right" title="Number of options outstanding, option RSUs vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1442"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zkdiDQKHUL8k" style="color: Black; text-align: right" title="Number of RSUs Outstanding, option RSUs vested"&gt;(11&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zJ6XNesZvlwd" style="color: Black; text-align: right" title="Weighted average exercise price, options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1446"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;RSUs granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zbYCBYIRLTL8" style="color: Black; text-align: right" title="Shares available for grant options RSUs granted"&gt;(10&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zuWhw0y11dIa" style="color: Black; text-align: right" title="Number of options outstanding, option RSUs granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1450"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zLrAvC8ibjQ7" style="color: Black; text-align: right" title="Number of RSUs Outstanding, option RSUs granted"&gt;5&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zM3rSyS54Dbh" style="color: Black; text-align: right" title="Weighted average exercise price, option RSUs granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1454"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Options granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z2ZDnY6hiFm7" style="color: Black; text-align: right" title="Shares available for grant options granted"&gt;(178&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z8lyqrBOxt6c" style="color: Black; text-align: right" title="Number of options outstanding, option granted"&gt;178&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zSWQasQEY5H9" style="color: Black; text-align: right" title="Number of RSUs Outstanding, option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1460"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zc2i2Yt6Wre8" style="color: Black; text-align: right" title="Weighted average exercise price, option granted"&gt;7.72&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Options forfeited/cancelled&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z88uUJWhN4Ze" style="color: Black; text-align: right" title="Shares available for grant options forfeited, cancelled and expired"&gt;150&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zxTQetor3MVa" style="color: Black; text-align: right" title="Number of options outstanding, options forfeited, cancelled and expired"&gt;(150&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z6iEOpEvAp2h" style="color: Black; text-align: right" title="Number of RSUs Outstanding, options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1468"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zjfFUTP8YKsj" style="color: Black; text-align: right" title="Weighted average exercise price, options forfeited, cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1470"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;RSUs forfeited/cancelled&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zSFd1P701Tf3" style="color: Black; text-align: right" title="Shares available for grant RSUs, cancelled and expired"&gt;2&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zOIAXOfygFyh" style="color: Black; text-align: right" title="Number of options outstanding, options forfeited, RSUs cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1474"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zynL5Qcb5eJ5" style="color: Black; text-align: right" title="Number of RSUs Outstanding, options forfeited, canceled and expired"&gt;(1&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zry2kFdeHEq7" style="color: Black; text-align: right" title="Weighted average exercise price, options forfeited, RSUs cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1478"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Performance RSUs forfeited/cancelled&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zq93vvRHWQr2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Shares available for grant performance RSUs, cancelled and expired"&gt;15&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zb3PM74cW644" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, options forfeited, performance RSUs cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1482"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zcD410D3Owf5" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Performance RSUs Outstanding, options forfeited, canceled and expired"&gt;(8&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zXdTYCrQ4ho3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, options forfeited, performance RSUs cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1486"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Balance at June 30, 2023&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zBE452ssKTMk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Shares available for grant outstanding, end of period"&gt;421&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zb1bjooPGIp6" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, end of period"&gt;456&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zOqu6EdR1Py3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of RSUs Outstanding, end of period"&gt;7&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z58qbI1LVeLj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price, outstanding end of period"&gt;38.33&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Options exercisable at June 30, 2023&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zQPjFDJSbtw5" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, exercisable, end of period"&gt;199&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zIOpWwt77GY4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercisable, end of period"&gt;89.54&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zXqrjqkuAcmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zumb57BYa663" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations
for the three and six months ended June 30, 2023 and 2022 (unaudited and in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B8_zjSkLQRZWvOg" style="display: none"&gt;Summary
of Stock-based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230401__20230630_z4wQRtx3Fgn1" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220401__20220630_zumjx50dv8Ik" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230630_zpEcUDfgDAqf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20220630_z10e4bZGfdug" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfRevenuesMember_zCkPYa49noYi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; color: Black"&gt;Cost of revenues&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1503"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1505"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpey2jkfKDj8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;309&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;201&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;632&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;381&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zoISYlpmpp86" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Sales and marketing&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;62&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1513"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;139&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;29&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zBWFQgwYRVy6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;461&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;1,283&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;867&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;2,463&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--DiscontinuedOperationsMember_zT9Otyru4NB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Discontinuing operations&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1522"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;748&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;1,369&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zEDH6FLrnMz6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;834&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;2,232&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;1,668&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;4,242&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zLds1KQEk77a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zQGSpIbAmENg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
assumptions that were used to calculate the grant date fair value of Oncocyte&#x2019;s employee and non-employee stock option grants for
the six months ended June 30, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z4UZFSnKmyK7" style="display: none"&gt;Schedule
of Assumptions Used to Calculate Fair Value of Stock Options&lt;/span&gt;&lt;span style="color: Black"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 60%; margin-left: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; color: Black; text-align: left"&gt;Expected life (in years)&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; color: Black; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630_zeUtM678C3X5" title="Expected life (in years)"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; color: Black; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630_zFHUw2fgj3Zf" title="Expected life (in years)"&gt;6.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Risk-free interest rates&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630_zm4Uj6iHd28e" style="color: Black; text-align: right" title="Risk-free interest rates"&gt;3.76&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630_zVCdVzMVxWr7" style="color: Black; text-align: right" title="Risk-free interest rates"&gt;2.24&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Volatility&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630_z80XuOQGEzJ4" style="color: Black; text-align: right" title="Volatility"&gt;105.99&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630_zZREqp28xlml" style="color: Black; text-align: right" title="Volatility"&gt;106.98&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230101__20230630_z0ANCgUDMkf7" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d0_c20220101__20220630_zQb5GWKZB7Uk" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A5_zlmvJy65BHZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and
assumptions requiring the use of judgment. If Oncocyte had made different assumptions, its stock-based compensation expense and net loss
for the three and six months ended June 30, 2023, and 2022 may have been significantly different.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified
disposition has occurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2023-06-30_custom_TwoThousandTenStockOptionPlanMember"
      decimals="INF"
      unitRef="Shares">260000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-06-30_custom_MonteCarloValuationTechniqueMember"
      decimals="INF"
      unitRef="Pure">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-06-30_custom_MonteCarloValuationTechniqueMember">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-06-30_custom_MonteCarloValuationTechniqueMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-06-30_custom_MonteCarloValuationTechniqueMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
      contextRef="From2023-01-012023-06-30_custom_PerformanceBasedOptionsMember"
      decimals="0"
      unitRef="USD">117625</OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-05-012022-05-31_us-gaap_PerformanceSharesMember_custom_ExecutiveOfficersAndEmployeesMember"
      decimals="INF"
      unitRef="Shares">61875</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-05-012022-05-31_custom_MarketBasedAwardsMember_custom_ExecutiveOfficersAndEmployeesMember"
      decimals="INF"
      unitRef="Shares">12500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2022-05-012022-05-31_custom_VitaGraftMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2022-05-012022-05-31_custom_DetermalOMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-05-012022-05-31">the Company of average market capitalization
minimum, target, and maximum goals of (i) $300 million; (ii) $400 million; and (iii) $500 million, respectively, during the period beginning
on January 1, 2022 and ending on December 31, 2024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">58500</us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_znVbihcDDGN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BA_zbFjVRKNuywk" style="display: none"&gt;Schedule
of Assumptions Used to Calculate Fair Value of Stock Options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; color: Black; text-align: left"&gt;Risk-free interest rates&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zS6GXqshyhFl" style="width: 16%; color: Black; text-align: right" title="Risk-free interest rates"&gt;2.72&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zScan6519KL9" title="Expected term (in years)"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Volatility&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zfqfI8JqNsMc" style="color: Black; text-align: right" title="Volatility"&gt;95.0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Grant date fair value of awards granted during the period&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230630__us-gaap--AwardTypeAxis__custom--MarketBasedAwardsMember_zqwwvt1LEdea" style="color: Black; text-align: right" title="Grant date fair value of awards granted during the period"&gt;22.60&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-06-30_custom_MarketBasedAwardsMember"
      decimals="INF"
      unitRef="Pure">0.0272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-06-30_custom_MarketBasedAwardsMember">P2Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-06-30_custom_MarketBasedAwardsMember"
      decimals="INF"
      unitRef="Pure">0.950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-06-30_custom_MarketBasedAwardsMember"
      decimals="INF"
      unitRef="USDPShares">22.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-012022-07-31_us-gaap_PerformanceSharesMember_custom_ExecutiveOfficersAndEmployeesMember"
      decimals="INF"
      unitRef="Shares">23750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2022-07-012022-07-31_custom_VitaGraftMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2022-07-012022-07-31_custom_DetermalOMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-07-012022-07-31">the achievement of performance minimum, target, and maximum
goals of (i) 90% of revenue goal; (ii) 100% of revenue goal; and (iii) exceed revenue goal by up to 150%, respectively, during fiscal
year 2022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-01-012022-12-31_us-gaap_PerformanceSharesMember">50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="From2022-12-142022-12-16_custom_DetermaCNIMember">The remaining 50% is eligible to vest on December 31, 2023, since the Company completed the LCD submission for DetermaCNI on December
16, 2022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember">&lt;p id="xdx_895_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zUo4G291Qxh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;A
summary of Oncocyte&#x2019;s 2010 Plan activity and related information follows (in thousands except weighted average exercise price):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B3_zUVPAoU1vP1i" style="display: none"&gt;Summary
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 75%; margin-left: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Available&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;of Options&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold"&gt;Options&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;for Grant&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; color: Black"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_z3bPk7Z2hlC3" style="width: 14%; color: Black; text-align: right" title="Shares available for grant options, beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1400"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zFOGPbH0leT7" style="width: 12%; color: Black; text-align: right" title="Number of options outstanding, beginning of period"&gt;30&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zADSJFwO0K48" style="width: 16%; color: Black; text-align: right" title="Weighted average exercise price, options outstanding, beginning of period"&gt;80.78&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zqOvjuGnwdt6" style="color: Black; text-align: right" title="Shares available for grant options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1406"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zjUVWaMiQIF5" style="color: Black; text-align: right" title="Number of options outstanding, option exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1408"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zhTpksbXooPj" style="color: Black; text-align: right" title="Weighted average exercise price, options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1410"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Options forfeited, cancelled and expired&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zM59qaMLhB44" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Shares available for grant options forfeited, cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1412"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zv8eGHd0dz36" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, options forfeited, cancelled and expired"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zJLp9a92ow0b" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, options forfeited, cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1416"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;Balance at June 30, 2023&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zeAulXHuE4Wk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Shares available for grant outstanding, end of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1418"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zdkmWa1lVQB7" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, end of period"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zoLDCyCZx97e" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price, outstanding end of period"&gt;80.58&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; padding-bottom: 1.5pt"&gt;Exercisable at June 30, 2023&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_z9qBjbwvr848" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, exercisable, end of period"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandTenPlanActivityMember_zy6hs1gHwlV8" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercisable, end of period"&gt;80.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_TwoThousandTenPlanActivityMember"
      decimals="-3"
      unitRef="Shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_TwoThousandTenPlanActivityMember"
      decimals="INF"
      unitRef="USDPShares">80.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-06-30_custom_TwoThousandTenPlanActivityMember"
      decimals="-3"
      unitRef="Shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_custom_TwoThousandTenPlanActivityMember"
      decimals="-3"
      unitRef="Shares">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_custom_TwoThousandTenPlanActivityMember"
      decimals="INF"
      unitRef="USDPShares">80.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-06-30_custom_TwoThousandTenPlanActivityMember"
      decimals="-3"
      unitRef="Shares">29000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2023-06-30_custom_TwoThousandTenPlanActivityMember"
      decimals="INF"
      unitRef="USDPShares">80.58</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2023-06-30_custom_TwoThousandEighteenIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">1050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z5LNGTnwPm19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;A
summary of Oncocyte&#x2019;s 2018 Incentive Plan activity and related information follows (in thousands except weighted average exercise
price):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B8_z1p5ZtaNnrsl" style="display: none"&gt;Summary
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Available&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;of Options&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;of RSUs&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;for Grant&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; color: Black"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zWpYo9KcyF76" style="width: 11%; color: Black; text-align: right" title="Shares available for grant options, beginning of period"&gt;442&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zZpp1RzLqs2f" style="width: 11%; color: Black; text-align: right" title="Number of options outstanding, beginning of period"&gt;428&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z3AMQbzxUvv7" style="width: 8%; color: Black; text-align: right" title="Number of RSUs Outstanding, beginning of period"&gt;22&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zXNv18lN5Ei6" style="width: 14%; color: Black; text-align: right" title="Weighted average exercise price, options outstanding, beginning of period"&gt;59.23&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;RSUs vested&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zYb3QJGBQePf" style="color: Black; text-align: right" title="Shares available for grant options RSUs vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1440"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zbAJWodSEFh8" style="color: Black; text-align: right" title="Number of options outstanding, option RSUs vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1442"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zkdiDQKHUL8k" style="color: Black; text-align: right" title="Number of RSUs Outstanding, option RSUs vested"&gt;(11&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zJ6XNesZvlwd" style="color: Black; text-align: right" title="Weighted average exercise price, options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1446"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;RSUs granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zbYCBYIRLTL8" style="color: Black; text-align: right" title="Shares available for grant options RSUs granted"&gt;(10&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zuWhw0y11dIa" style="color: Black; text-align: right" title="Number of options outstanding, option RSUs granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1450"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zLrAvC8ibjQ7" style="color: Black; text-align: right" title="Number of RSUs Outstanding, option RSUs granted"&gt;5&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zM3rSyS54Dbh" style="color: Black; text-align: right" title="Weighted average exercise price, option RSUs granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1454"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Options granted&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z2ZDnY6hiFm7" style="color: Black; text-align: right" title="Shares available for grant options granted"&gt;(178&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z8lyqrBOxt6c" style="color: Black; text-align: right" title="Number of options outstanding, option granted"&gt;178&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zSWQasQEY5H9" style="color: Black; text-align: right" title="Number of RSUs Outstanding, option granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1460"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zc2i2Yt6Wre8" style="color: Black; text-align: right" title="Weighted average exercise price, option granted"&gt;7.72&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Options forfeited/cancelled&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z88uUJWhN4Ze" style="color: Black; text-align: right" title="Shares available for grant options forfeited, cancelled and expired"&gt;150&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zxTQetor3MVa" style="color: Black; text-align: right" title="Number of options outstanding, options forfeited, cancelled and expired"&gt;(150&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z6iEOpEvAp2h" style="color: Black; text-align: right" title="Number of RSUs Outstanding, options exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1468"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zjfFUTP8YKsj" style="color: Black; text-align: right" title="Weighted average exercise price, options forfeited, cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1470"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;RSUs forfeited/cancelled&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zSFd1P701Tf3" style="color: Black; text-align: right" title="Shares available for grant RSUs, cancelled and expired"&gt;2&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zOIAXOfygFyh" style="color: Black; text-align: right" title="Number of options outstanding, options forfeited, RSUs cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1474"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zynL5Qcb5eJ5" style="color: Black; text-align: right" title="Number of RSUs Outstanding, options forfeited, canceled and expired"&gt;(1&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zry2kFdeHEq7" style="color: Black; text-align: right" title="Weighted average exercise price, options forfeited, RSUs cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1478"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Performance RSUs forfeited/cancelled&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zq93vvRHWQr2" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Shares available for grant performance RSUs, cancelled and expired"&gt;15&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zb3PM74cW644" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, options forfeited, performance RSUs cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1482"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited_iN_pn3n3_di_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zcD410D3Owf5" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of Performance RSUs Outstanding, options forfeited, canceled and expired"&gt;(8&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zXdTYCrQ4ho3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, options forfeited, performance RSUs cancelled and expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1486"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Balance at June 30, 2023&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zBE452ssKTMk" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Shares available for grant outstanding, end of period"&gt;421&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zb1bjooPGIp6" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of options outstanding, end of period"&gt;456&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zOqu6EdR1Py3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Number of RSUs Outstanding, end of period"&gt;7&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_z58qbI1LVeLj" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Weighted average exercise price, outstanding end of period"&gt;38.33&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Options exercisable at June 30, 2023&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pn3n3_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zQPjFDJSbtw5" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Number of options outstanding, exercisable, end of period"&gt;199&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iE_pid_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandEighteenPalnActivityMember_zIOpWwt77GY4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Weighted average exercise price, exercisable, end of period"&gt;89.54&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2022-12-31_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">442000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">428000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">22000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_TwoThousandEighteenPalnActivityMember"
      decimals="INF"
      unitRef="USDPShares">59.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">-11000</OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs>
    <OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">-10000</OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross>
    <OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">5000</OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs>
    <OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">-178000</OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">178000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="INF"
      unitRef="USDPShares">7.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <OCX:StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">150000</OCX:StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <OCX:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">2000</OCX:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares>
    <OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">1000</OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited>
    <OCX:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">15000</OCX:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares>
    <OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited
      contextRef="From2023-01-012023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">8000</OCX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">421000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">456000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="INF"
      unitRef="USDPShares">38.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="-3"
      unitRef="Shares">199000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2023-06-30_custom_TwoThousandEighteenPalnActivityMember"
      decimals="INF"
      unitRef="USDPShares">89.54</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zumb57BYa663" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations
for the three and six months ended June 30, 2023 and 2022 (unaudited and in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B8_zjSkLQRZWvOg" style="display: none"&gt;Summary
of Stock-based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230401__20230630_z4wQRtx3Fgn1" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220401__20220630_zumjx50dv8Ik" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230630_zpEcUDfgDAqf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20220630_z10e4bZGfdug" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--CostOfRevenuesMember_zCkPYa49noYi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; color: Black"&gt;Cost of revenues&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1503"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1505"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpey2jkfKDj8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;309&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;201&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;632&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;381&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zoISYlpmpp86" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Sales and marketing&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;62&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1513"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;139&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;29&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zBWFQgwYRVy6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;461&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;1,283&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;867&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;2,463&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--DiscontinuedOperationsMember_zT9Otyru4NB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Discontinuing operations&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1522"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;748&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;1,369&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zEDH6FLrnMz6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 2.5pt"&gt;Total stock-based compensation expense&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;834&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;2,232&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;1,668&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;4,242&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember"
      decimals="-3"
      unitRef="USD">12000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">309000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">201000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">632000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">381000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      unitRef="USD">62000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      unitRef="USD">139000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      unitRef="USD">29000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      unitRef="USD">461000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      unitRef="USD">1283000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      unitRef="USD">867000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      unitRef="USD">2463000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember"
      decimals="-3"
      unitRef="USD">748000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember"
      decimals="-3"
      unitRef="USD">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-06-30_us-gaap_EmployeeStockOptionMember_custom_DiscontinuedOperationsMember"
      decimals="-3"
      unitRef="USD">1369000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      unitRef="USD">834000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">2232000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">1668000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">4242000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zQGSpIbAmENg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
assumptions that were used to calculate the grant date fair value of Oncocyte&#x2019;s employee and non-employee stock option grants for
the six months ended June 30, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z4UZFSnKmyK7" style="display: none"&gt;Schedule
of Assumptions Used to Calculate Fair Value of Stock Options&lt;/span&gt;&lt;span style="color: Black"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 60%; margin-left: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; color: Black; text-align: left"&gt;Expected life (in years)&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; color: Black; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230630_zeUtM678C3X5" title="Expected life (in years)"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; color: Black; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220630_zFHUw2fgj3Zf" title="Expected life (in years)"&gt;6.01&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Risk-free interest rates&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230630_zm4Uj6iHd28e" style="color: Black; text-align: right" title="Risk-free interest rates"&gt;3.76&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220630_zVCdVzMVxWr7" style="color: Black; text-align: right" title="Risk-free interest rates"&gt;2.24&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;Volatility&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230630_z80XuOQGEzJ4" style="color: Black; text-align: right" title="Volatility"&gt;105.99&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220630_zZREqp28xlml" style="color: Black; text-align: right" title="Volatility"&gt;106.98&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230101__20230630_z0ANCgUDMkf7" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d0_c20220101__20220630_zQb5GWKZB7Uk" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-01to2023-06-30">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-06-30">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="Pure">0.0376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="Pure">0.0224</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-01to2023-06-30"
      decimals="INF"
      unitRef="Pure">1.0599</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-06-30"
      decimals="INF"
      unitRef="Pure">1.0698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_z6chgspCk2Pb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;7.
&lt;span id="xdx_82D_zTvKItJCUZbj"&gt;Disaggregation of Revenues and Concentration Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zqy0QgGJbp92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table presents the percentage of consolidated revenues generated by unaffiliated customers that individually represent greater
than ten percent of consolidated revenues:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_z3jVQvNEEGnl" style="display: none"&gt;Schedule
of Consolidated Revenues Generated by Unaffiliated Customers&lt;/span&gt;&lt;span style="color: Black"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; color: Black; text-align: left"&gt;Pharma services - Company A&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zxfp3alJLkY2" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;68&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zJCpZ7jkoO6h" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span id="xdx_F2F_z7vMN5d4eRS3" style="color: Black"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zlLKyU3olChk" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;27&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zdjux8jRKO21" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;-&lt;/span&gt;&lt;span id="xdx_F20_zGRwEbtdpCja"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Pharma services - Company B&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zElYATED5ts8" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span id="xdx_F25_zyjuziASFAL3" style="color: Black"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____z79HgCpzdRdj" title="Concentration risk, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1564"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_F2F_zu6qsSTvG9V7" style="color: Black"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z8V8EfpYmt53" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;14&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zuO8xPUMUUCh" title="Concentration risk, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1568"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_F2A_zTHi7s59lrpk"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Discontinuing operations&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____z9kJz2RKVz3h" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span id="xdx_F2C_zqqmO4eaVu6a" style="color: Black"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zzpR3hpLL0fd" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;89&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_ztNbN4TIqCR6" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;38&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z1s74MtfTMa7" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;82&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td id="xdx_F02_zNlR4QJccOi" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i id="xdx_F14_z8ncoxfAiM4c"&gt;Less
    than 10%&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zEayKbcQkpRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock_z2uDC0RRZNUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table presents the percentage of consolidated revenues by products or services classes:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B0_z2Hu4PVXQd88" style="display: none"&gt;Schedule
of Consolidated Revenues Attributable to Products or Services&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="text-align: center; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="text-align: center; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; color: Black; text-align: left"&gt;Pharma Services&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9Xjrdg7WES3" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;94&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zvZ9H0lKKCqe" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;11&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmc4BTMqLoLd" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;62&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zzN1D0DgLeBa" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;18&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;DetermaRx&#x2122;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zTYfckakGv1e" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;6&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zEqjMu4engE6" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zJh79XNBWHk8" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;3&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zZ6NDbOs1tHa" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Discontinuing operations&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zrPabShcwCIl" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zThxy0Kpeh4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage"&gt;89&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHggRznVbJZ1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage"&gt;35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmfTXAdFMYzg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage"&gt;82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zan6Cbz7T2pc" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zExgskS5WBt4" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHHBSHiQqXQ3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHsgQISwGKG2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z0kS2WzHsYj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zfyWsQxLnOp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table presents the percentage of consolidated revenues attributable to geographical locations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B4_z0uLsoGhqduh" style="display: none"&gt;Schedule
of Percentage of Consolidated Revenues Attributable to Geographical Locations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230401__20230630_zdDOIsZiUdE8" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220401__20220630_zdI6I9JfrP6h" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20230630_z6XgtebHtHSc" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20220630_zh59t8KWLAvf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zip8EzMyc6vj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; color: Black; text-align: left"&gt;United States &#x2013; Pharma Services&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;74&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;50&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;39&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;65&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--OutsideUnitedStatesPharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zBgnqatcKvq1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Outside of the United States &#x2013; Pharma Services&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;20&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;2&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;23&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;5&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zbOL5HCtHxZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;DetermaRx&#x2122;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;6&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;3&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DiscontinuedOperationsOutsideUnitedStatesLicensingMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zW4KqOI5Va0b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Discontinuing operations &#x2013; Outside of the United States &#x2013; Licensing&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;48&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;30&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zS9pnQ5RHtt" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Discontinuing operations &#x2013; United States &#x2013; DetermaRx&#x2122;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zyh8OVaiiftb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zRFBErKJTnfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zqy0QgGJbp92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table presents the percentage of consolidated revenues generated by unaffiliated customers that individually represent greater
than ten percent of consolidated revenues:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_z3jVQvNEEGnl" style="display: none"&gt;Schedule
of Consolidated Revenues Generated by Unaffiliated Customers&lt;/span&gt;&lt;span style="color: Black"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; color: Black; text-align: left"&gt;Pharma services - Company A&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zxfp3alJLkY2" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;68&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zJCpZ7jkoO6h" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span id="xdx_F2F_z7vMN5d4eRS3" style="color: Black"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zlLKyU3olChk" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;27&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zdjux8jRKO21" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;-&lt;/span&gt;&lt;span id="xdx_F20_zGRwEbtdpCja"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Pharma services - Company B&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zElYATED5ts8" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span id="xdx_F25_zyjuziASFAL3" style="color: Black"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____z79HgCpzdRdj" title="Concentration risk, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1564"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_F2F_zu6qsSTvG9V7" style="color: Black"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z8V8EfpYmt53" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;14&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesCompanyBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____zuO8xPUMUUCh" title="Concentration risk, percentage"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1568"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_F2A_zTHi7s59lrpk"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Discontinuing operations&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_fKg_____z9kJz2RKVz3h" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;span id="xdx_F2C_zqqmO4eaVu6a" style="color: Black"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zzpR3hpLL0fd" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;89&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_ztNbN4TIqCR6" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;38&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z1s74MtfTMa7" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;82&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td id="xdx_F02_zNlR4QJccOi" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i id="xdx_F14_z8ncoxfAiM4c"&gt;Less
    than 10%&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.68</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      id="Fact001556"
      unitRef="Pure">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      id="Fact001560"
      unitRef="Pure">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      id="Fact001562"
      unitRef="Pure">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_custom_PharmaServicesCompanyBMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      id="Fact001570"
      unitRef="Pure">-0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.89</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.82</us-gaap:ConcentrationRiskPercentage1>
    <OCX:ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_89B_ecustom--ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock_z2uDC0RRZNUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table presents the percentage of consolidated revenues by products or services classes:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B0_z2Hu4PVXQd88" style="display: none"&gt;Schedule
of Consolidated Revenues Attributable to Products or Services&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="text-align: center; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="text-align: center; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; color: Black; text-align: left"&gt;Pharma Services&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z9Xjrdg7WES3" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;94&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zvZ9H0lKKCqe" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;11&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmc4BTMqLoLd" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;62&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--PharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zzN1D0DgLeBa" style="width: 11%; color: Black; text-align: right" title="Concentration risk, percentage"&gt;18&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;DetermaRx&#x2122;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zTYfckakGv1e" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;6&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zEqjMu4engE6" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zJh79XNBWHk8" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;3&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zZ6NDbOs1tHa" style="color: Black; text-align: right" title="Concentration risk, percentage"&gt;0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Discontinuing operations&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zrPabShcwCIl" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zThxy0Kpeh4" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage"&gt;89&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHggRznVbJZ1" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage"&gt;35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__srt--ProductOrServiceAxis__custom--DiscontinuedOperationsMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zmfTXAdFMYzg" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Concentration risk, percentage"&gt;82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zan6Cbz7T2pc" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220401__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zExgskS5WBt4" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHHBSHiQqXQ3" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zHsgQISwGKG2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Concentration risk, percentage"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OCX:ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.94</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.62</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.03</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.89</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_custom_DiscontinuedOperationsMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.82</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_896_eus-gaap--ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_zfyWsQxLnOp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table presents the percentage of consolidated revenues attributable to geographical locations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B4_z0uLsoGhqduh" style="display: none"&gt;Schedule
of Percentage of Consolidated Revenues Attributable to Geographical Locations&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230401__20230630_zdDOIsZiUdE8" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220401__20220630_zdI6I9JfrP6h" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230101__20230630_z6XgtebHtHSc" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220101__20220630_zh59t8KWLAvf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__country--US__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zip8EzMyc6vj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; color: Black; text-align: left"&gt;United States &#x2013; Pharma Services&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;74&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;50&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;39&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; color: Black; text-align: right"&gt;65&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--OutsideUnitedStatesPharmaServicesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zBgnqatcKvq1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Outside of the United States &#x2013; Pharma Services&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;20&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;2&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;23&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;5&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zbOL5HCtHxZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;DetermaRx&#x2122;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;6&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;3&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DiscontinuedOperationsOutsideUnitedStatesLicensingMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zW4KqOI5Va0b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Discontinuing operations &#x2013; Outside of the United States &#x2013; Licensing&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;48&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;30&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hsrt--StatementGeographicalAxis__custom--DiscontinuedOperationsDetermaRxMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zS9pnQ5RHtt" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Discontinuing operations &#x2013; United States &#x2013; DetermaRx&#x2122;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_hus-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zyh8OVaiiftb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_custom_OutsideUnitedStatesPharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460937"
      decimals="INF"
      unitRef="Pure">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460953"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460953"
      decimals="INF"
      unitRef="Pure">0.03</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_custom_DetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26460968"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.48</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_custom_DiscontinuedOperationsOutsideUnitedStatesLicensingMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461015"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461031"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461031"
      decimals="INF"
      unitRef="Pure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_custom_DiscontinuedOperationsDetermaRxMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember26461046"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-04-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-04-012022-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_z7AEZ80Y4uBg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;8.
&lt;span id="xdx_82C_zPrpK9h5Mrwa"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270,
&lt;i&gt;Income Taxes, Interim Reporting&lt;/i&gt;. The effective tax rate may be subject to fluctuations during the year as new information is obtained,
which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against
deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or
the interpretation of tax laws in jurisdictions where Oncocyte conducts business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
did not record any provision or benefit for income taxes for the six months ended June 30, 2023 and 2022, as Oncocyte had a full valuation
allowance for the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;A
valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. Oncocyte
established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net
operating loss carry-forwards and other deferred tax assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zlI40JiDP3m8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;9.
&lt;span id="xdx_82F_z0gDgBo9MBVb"&gt;Right-of-use assets, machinery and equipment, net, and construction in progress&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zvPDTIkyIMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of June 30, 2023 and December 31, 2022, right-of-use assets, machinery and equipment, net, and construction in progress were as follows
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B0_z0BVyoOH8m5b" style="display: none"&gt;Schedule
of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230630_zUpRJVoNE2Lg" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;br/&gt; (unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zuM7ETkm63H3" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_z5jNeFxA5Ht5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20230630_zIG0BrdyttC9" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230630%23MachineryAndEquipmentNetAndConstructionInProgress"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20221231_z6b6xO9VJ40a" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230630%23MachineryAndEquipmentNetAndConstructionInProgress"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1653"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1654"&gt;Right-of-use assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;sup id="xdx_F40_zN6xqg4WcXQc"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; color: Black; text-align: right"&gt;4,036&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; color: Black; text-align: right"&gt;3,499&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_zQRBYqk1aqEl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;8,644&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;9,408&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_zwtKrC6CA9ak" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation and amortization&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(5,310&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(4,196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_z0d4N7kgAzAd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Right-of-use assets, machinery and equipment, net&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;7,370&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;8,711&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ConstructionInProgressGross_iI_pn3n3_zMVwAzmE96Bf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Construction in progress&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;518&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;2,140&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--RightofuseAssetsMachineryAndEquipmentContinuingOperations_iI_pn3n3_ztd6090Il5Mk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 2.5pt"&gt;Right-of-use assets, machinery and equipment, net, and construction in progress&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;7,888&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;10,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations_iI_pn3n3_zuglr7g44059" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Right-of-use assets, machinery and equipment, net, and construction in progress from discontinuing operations&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1671"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;211&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--RightofuseAssetsMachineryAndEquipmentNet_iI_pn3n3_zGONvbakKhIe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 2.5pt"&gt;Right-of-use assets, machinery and equipment, net, and construction in progress&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;7,888&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;11,062&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F05_z31mCAvn6Jb4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F17_zmttJPpFz7y8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
    recorded certain right-of-use assets and liabilities for operating leases in accordance with ASC 842 (see Note 10).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_zbULD6GkgIkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Depreciation
expense amounted to $&lt;span id="xdx_90E_eus-gaap--DepreciationAndAmortization_c20230401__20230630_zinxV2FPFZVd" title="Depreciation expense"&gt;435,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--DepreciationAndAmortization_c20220401__20220630_zFRCuEwx0HL3" title="Depreciation expense"&gt;384,000&lt;/span&gt; for the three months ended June 30, 2023 and 2022, respectively, and $&lt;span id="xdx_904_eus-gaap--DepreciationAndAmortization_c20230101__20230630_zUnvH1sL4YDd" title="Depreciation expense"&gt;885,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--DepreciationAndAmortization_c20220101__20220630_zq7x7D4Uga01" title="Depreciation expense"&gt;671,000&lt;/span&gt;
for the six months ended June 30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zvPDTIkyIMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of June 30, 2023 and December 31, 2022, right-of-use assets, machinery and equipment, net, and construction in progress were as follows
(in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8B0_z0BVyoOH8m5b" style="display: none"&gt;Schedule
of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230630_zUpRJVoNE2Lg" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;br/&gt; (unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_zuM7ETkm63H3" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_z5jNeFxA5Ht5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; color: Black; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20230630_zIG0BrdyttC9" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230630%23MachineryAndEquipmentNetAndConstructionInProgress"&gt;&lt;span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_iI_dxL_c20221231_z6b6xO9VJ40a" title="::XDX::http%3A%2F%2Foncocyte.com%2F20230630%23MachineryAndEquipmentNetAndConstructionInProgress"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1653"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1654"&gt;Right-of-use assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;sup id="xdx_F40_zN6xqg4WcXQc"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; color: Black; text-align: right"&gt;4,036&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; color: Black; text-align: right"&gt;3,499&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_zQRBYqk1aqEl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;8,644&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;9,408&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_zwtKrC6CA9ak" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation and amortization&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(5,310&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(4,196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iI_pn3n3_z0d4N7kgAzAd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Right-of-use assets, machinery and equipment, net&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;7,370&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;8,711&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ConstructionInProgressGross_iI_pn3n3_zMVwAzmE96Bf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Construction in progress&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;518&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;2,140&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--RightofuseAssetsMachineryAndEquipmentContinuingOperations_iI_pn3n3_ztd6090Il5Mk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 2.5pt"&gt;Right-of-use assets, machinery and equipment, net, and construction in progress&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;7,888&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;10,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations_iI_pn3n3_zuglr7g44059" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Right-of-use assets, machinery and equipment, net, and construction in progress from discontinuing operations&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1671"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;211&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--RightofuseAssetsMachineryAndEquipmentNet_iI_pn3n3_zGONvbakKhIe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 2.5pt"&gt;Right-of-use assets, machinery and equipment, net, and construction in progress&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;7,888&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: right"&gt;11,062&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F05_z31mCAvn6Jb4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F17_zmttJPpFz7y8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
    recorded certain right-of-use assets and liabilities for operating leases in accordance with ASC 842 (see Note 10).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="Fact001651"
      unitRef="USD">4036000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001652"
      unitRef="USD">3499000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">8644000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">9408000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">5310000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">4196000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">7370000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">8711000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ConstructionInProgressGross contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">518000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2140000</us-gaap:ConstructionInProgressGross>
    <OCX:RightofuseAssetsMachineryAndEquipmentContinuingOperations contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">7888000</OCX:RightofuseAssetsMachineryAndEquipmentContinuingOperations>
    <OCX:RightofuseAssetsMachineryAndEquipmentContinuingOperations contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">10851000</OCX:RightofuseAssetsMachineryAndEquipmentContinuingOperations>
    <OCX:RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">211000</OCX:RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations>
    <OCX:RightofuseAssetsMachineryAndEquipmentNet contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">7888000</OCX:RightofuseAssetsMachineryAndEquipmentNet>
    <OCX:RightofuseAssetsMachineryAndEquipmentNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">11062000</OCX:RightofuseAssetsMachineryAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">435000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">384000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-01to2023-06-30"
      decimals="0"
      unitRef="USD">885000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-012022-06-30"
      decimals="0"
      unitRef="USD">671000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zNVv5lHb1z2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;10.
&lt;span id="xdx_82D_zZqPae8kp7b8"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
has certain commitments other than discussed in Note 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Office
Lease Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
December 23, 2019, Oncocyte entered into an Office Lease Agreement (the &#x201c;Irvine Lease&#x201d;) of a building containing approximately
&lt;span id="xdx_90B_eus-gaap--AreaOfLand_iI_usqft_c20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_ziN80D2S9sK8" title="Area of Land"&gt;26,800&lt;/span&gt; square feet of rentable space located at 15 Cushing in Irvine, California (the &#x201c;Premises&#x201d;) that will serve as Oncocyte&#x2019;s
new principal executive and administrative offices and laboratory facility. Oncocyte completed the relocation of its offices to the Premises
in January 2020 and subsequently constructed a laboratory at the Irvine facility to perform cancer diagnostic tests.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Irvine Lease has an initial term of 89 calendar months (the &#x201c;Term&#x201d;), which commenced on June 1, 2020 (the &#x201c;Commencement
Date&#x201d;). Oncocyte has an option to extend the Term for a period of five years (the &#x201c;Extended Term&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
agreed to pay base monthly rent in the amount of $&lt;span id="xdx_904_eus-gaap--PaymentsForRent_c20191222__20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zYJA6vXGAFEe" title="Payments for rent"&gt;61,640&lt;/span&gt; during the first 12 months of the Term. Base monthly rent increases annually,
over the base monthly rent then in effect, by &lt;span id="xdx_90E_ecustom--CapitalLeaseAgreementImputedAnnualInterestRate_pid_dp_uPure_c20191222__20191223__srt--StatementScenarioAxis__custom--MonthlyRentMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zyODDrbEVAub" title="Interest rate on lease agreement"&gt;3.5&lt;/span&gt;%. Oncocyte was entitled to an abatement of &lt;span id="xdx_905_ecustom--CapitalLeaseAgreementImputedAnnualInterestRate_pid_dp_uPure_c20191222__20191223__srt--StatementScenarioAxis__custom--FirstTenCalendarMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_z5kdl1ffgeic" title="Interest rate on lease agreement"&gt;50&lt;/span&gt;% of the base monthly rent during the
first ten calendar months of the Term. If the Irvine Lease is terminated based on the occurrence of an &#x201c;event of default,&#x201d;
Oncocyte will be obligated to pay the abated rent to the lessor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;If
Oncocyte exercises its option to extend the Term, the initial base monthly rent during the Extended Term will be the greater of the base
monthly rent in effect during the last year of the Term or the prevailing market rate. The prevailing market rate will be determined
based on annual rental rates per square foot for comparable space in the area where the Premises are located. If Oncocyte does not agree
with the prevailing market rate proposed by the lessor, the rate may be determined through an appraisal process. The base monthly rent
during the Extended Term shall be subject to the same annual rent adjustment as applicable for base monthly rent during the Term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
addition to base monthly rent, Oncocyte agreed to pay in monthly installments (a) all costs and expenses, other than certain excluded expenses,
incurred by the lessor in each calendar year in connection with operating, maintaining, repairing (including replacements if repairs
are not feasible or would not be effective) and managing the Premises and the building in which the Premises are located (&#x201c;Expenses&#x201d;),
and (b) all real estate taxes and assessments on the Premises and the building in which the Premises are located, all personal property
taxes for property that is owned by lessor and used in connection with the operation, maintenance and repair of the Premises, and costs
and fees incurred in connection with seeking reductions in such tax liabilities (&#x201c;Taxes&#x201d;). Subject to certain exceptions,
Expenses shall not be increased by more than 4% annually on a cumulative, compounded basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
was entitled to an abatement of its obligations to pay Expenses and Taxes while constructing improvements to the Premises constituting
&#x201c;Tenant&#x2019;s Work&#x201d; under the Irvine Lease prior to the Commencement Date, except that Oncocyte was obligated to pay &lt;span id="xdx_905_ecustom--ObligatedToPayExpensesAndTaxesPercentage_pid_dp_uPure_c20191222__20191223__srt--StatementScenarioAxis__custom--MonthlyRentMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_z4B2cdxoccS8" title="Obligated to pay expenses and taxes percentage"&gt;43.7&lt;/span&gt;%
of Expenses and Taxes during the period prior to the Commencement Date for its use of the second floor of the Premises, which was already
built out as office space.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
lessor provided Oncocyte with a &#x201c;Tenant Improvement Allowance&#x201d; in the amount of $&lt;span id="xdx_905_eus-gaap--PaymentsForProceedsFromTenantAllowance_pn5n6_c20191222__20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zo841TY6aBSe" title="Payments for (Proceeds from) Tenant Allowance"&gt;1.3&lt;/span&gt; million to pay for the plan, design,
permitting, and construction of the improvements constituting Tenant&#x2019;s Work. The lessor retained &lt;span id="xdx_908_ecustom--PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment_pid_dp_uPure_c20191222__20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zKZSftwiIE15" title="Percentage of administrative fee paid on original cost of equipment"&gt;1.5&lt;/span&gt;% of the Tenant Improvement
Allowance as an administrative fee as provided in the Irvine Lease. As of June 30, 2023, the lessor had provided $&lt;span id="xdx_903_eus-gaap--PaymentsForProceedsFromTenantAllowance_pn5n6_c20230101__20230630__srt--TitleOfIndividualAxis__custom--LandlordMember__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_z6ZKTr3IFFd3" title="Total tenant improvement allowance"&gt;1.3&lt;/span&gt; million of the
total Tenant Improvement Allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
has provided the lessor with a security deposit in the amount of $&lt;span id="xdx_905_eus-gaap--SecurityDeposit_iI_c20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zM9p05LQ7st8" title="Security Deposit"&gt;150,000&lt;/span&gt; and a letter of credit in the amount of $&lt;span id="xdx_90D_eus-gaap--LinesOfCreditCurrent_iI_pn5n6_c20191223__us-gaap--TypeOfArrangementAxis__custom--OfficeLeaseAgreementMember_zMUZco8xWw55" title="Line of Credit, Current"&gt;1.7&lt;/span&gt; million. The lessor
may apply the security deposit, in whole or in part, for the payment of rent and any other amount that Oncocyte is or becomes obligated
to pay under the Irvine Lease but fails to pay when due and beyond any cure period. The lessor may draw on the letter of credit from
time to time to pay any amount that is unpaid and due, or if the original issuing bank notifies the lessor that the letter of credit
will not be renewed or extended for the period required under the Irvine Lease and Oncocyte fails to timely provide a replacement letter
of credit, or an event of default under the Irvine Lease occurs and continues beyond the applicable cure period, or if certain insolvency
or bankruptcy or insolvency with respect to Oncocyte occur. Oncocyte is required to restore any portion of the security deposit that
is applied by the lessor to payments due under the Irvine Lease, and Oncocyte is required to restore the amount available under the letter
of credit to the required amount if any portion of the letter of credit is drawn by the lessor. The Irvine Lease provides that commencing on the 34th month of the Term,
(a) the amount of the letter of credit that Oncocyte is required to maintain shall be reduced on a monthly basis, in equal installments,
to amortize the required amount to zero at the end of the Term, and (b) Oncocyte has the right to cancel the letter of credit at
any time if it meets certain market capitalization and balance sheets thresholds; provided, in each case, that Oncocyte is not in then
default under the Irvine Lease beyond any applicable notice and cure period and the lessor has not determined that an event exists that
would lead to an event of default.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;To
obtain the letter of credit, Oncocyte has provided the issuing bank with a restricted cash deposit that the bank will hold to cover its
obligation to pay any draws on the letter of credit by the lessor. The restricted cash may not be used for any other purpose.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
August 27, 2021, Oncocyte entered into a lease agreement to add an additional suite to its Nashville office space, containing approximately
&lt;span id="xdx_90A_eus-gaap--AreaOfLand_iI_usqft_c20210827__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zeqqu9W28Cc" title="Area of Land"&gt;1,928&lt;/span&gt; square feet of rentable space located at 2 International Plaza, Suite 103, Nashville TN. The term of the lease commences on October
1, 2021 and extends through April 9, 2024 and will serve as additional office space for Insight&#x2019;s operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
Irvine Lease is an operating lease under ASC 842 included in the tables below. The tables below provide the amounts recorded in connection
with the application of ASC 842 as of, and during, the six months ended June 30, 2023, for Oncocyte&#x2019;s operating and financing leases
(see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On December 31, 2019, in connection with Oncocyte&#x2019;s purchase &lt;span style="background-color: white"&gt;of&#160;&lt;span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20191231__us-gaap--TypeOfArrangementAxis__custom--DevelopmentAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zbOoKPL2yEgh" title="Outstanding equity"&gt;25&lt;/span&gt;%
of the outstanding equity of Razor,&lt;/span&gt; Oncocyte entered into a Laboratory Services Agreement with Razor and Encore Clinical, Inc.
(&#x201c;Encore&#x201d;), a former stockholder of Razor (the &#x201c;Laboratory Agreement&#x201d;). Under
the Laboratory Agreement (which expired on September 29, 2021), Oncocyte assumed all of Razor&#x2019;s Laboratory
Agreement payment obligations. Although Oncocyte is not a party to any lease agreement with Razor or Encore, under the terms of the Laboratory
Agreement, Oncocyte received the landlord&#x2019;s consent for the use of the laboratory at Razor&#x2019;s Brisbane, California location
(the &#x201c;Brisbane Facility&#x201d;) under the terms of a sublease to which Encore is the sublessee. The sublease expired on March 31,
2023 (the &#x201c;Brisbane Lease&#x201d;). The laboratory fee payments to Encore include both laboratory services and the use of the Brisbane
Facility. Under the provisions of the Laboratory Agreement, if Oncocyte terminates the Laboratory Agreement prior to the expiration of
the Brisbane Lease, Oncocyte shall assume the costs related to the subletting or early termination of the Brisbane Lease. The Laboratory
Agreement terminated on March 31, 2023. Oncocyte determined that the Laboratory Agreement contains an embedded operating lease for the
Brisbane Facility and Oncocyte allocated the aggregate payments to this lease component for purposes of calculating the net present value
of the right-of-use asset and liability as of the inception of the Laboratory Agreement in accordance with ASC 842, as shown in the table
below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Financing
lease&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of June 30, 2023, Oncocyte has one financing lease remaining through December 2023 for certain laboratory equipment with aggregate remaining
payments of $&lt;span id="xdx_900_ecustom--PaymentObligationAmount_iI_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zHOBNw9OAqJc" title="Payment obligation amount."&gt;62,000&lt;/span&gt; shown in the table below. Oncocyte&#x2019;s lease obligations are collateralized by the equipment financed under the
lease schedule.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Operating
and Financing leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock_zoU8xW86RGY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table presents supplemental cash flow information related to operating and financing leases for the six months ended June 30,
2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BA_zyuipxi6fFNe" style="display: none"&gt;Schedule
of Supplemental Cash Flow Information Related to Operating and Financing Lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20230630_zrziQ1NGvGJ7" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20220630_z7DsbwjOiTcd" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; font-weight: bold; text-align: left"&gt;Cash paid for amounts included in the measurement of financing lease liabilities:&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zk6EhQKz8Lp1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; color: Black; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;564&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zNUwHdSkQLlg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Operating cash flows from financing leases&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;5&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;12&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_zp4CfHoNVK93" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Financing cash flows from financing leases&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;57&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;51&lt;/p&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zZQtCPQOCSYd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock_zRGLBGVydjE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table presents supplemental balance sheets information related to operating and financing leases as of June 30, 2023 and June
30, 2022 (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span id="xdx_8BD_zPcrYALQFgAk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Schedule
of Supplemental Balance Sheet Information Related to Operating and Financing Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zC8bf6TbF4Uk" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zw782dUt37jf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; font-weight: bold; text-align: left"&gt;Operating lease&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zdS95JagOMV5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Right-of-use assets, net&lt;/td&gt;&lt;td style="width: 2%; color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right"&gt;1,855&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right"&gt;2,343&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zWsyf8iLJFS7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Right-of-use lease liabilities, current&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;677&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;728&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zOPDzbD2GxH1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Right-of-use lease liabilities, noncurrent&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;2,398&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;3,075&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_z73ADENYoPJ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;3,075&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;3,803&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; font-weight: bold; text-align: left"&gt;Financing lease&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;536&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;537&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iNI_pn3n3_di_zNTJmeu4eYrf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(391&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeaseRightOfUseAsset_iTI_pn3n3_zE52rflxHsU5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Machinery and equipment, net&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;36&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;146&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_zvxSbovxTIBc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Current liabilities&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;60&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;110&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_zj1n66HYwRh8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Noncurrent liabilities&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1751"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_zkWZXDTZAsK3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Total financing lease liabilities&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;60&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;170&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; font-weight: bold"&gt;Weighted average remaining lease term&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Operating lease&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zgYHD3sS8Vi7" title="Weighted average remaining lease term, Operating lease"&gt;4.1&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zZ2Y4YZTjPs1" title="Weighted average remaining lease term, Operating lease"&gt;4.9 &lt;/span&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Financing lease&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_z2Dj1XQz6bNi" title="Weighted average remaining lease term, Financing lease"&gt;0.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zAoDhPfBHfBd" title="Weighted average remaining lease term, Financing lease"&gt;1.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Weighted average discount rate&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_z8p3245Ffea1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Operating lease&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;11.28&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;11.20&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_z7JXatNuyIo2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Financing lease&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;11.55&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;11.55&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zDIFOGO3x0pj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock_zB3YPOSoONha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Future
minimum lease commitments are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zguNJzI8MRc2" style="display: none"&gt;Schedule of Future Minimum Lease Commitments for Operating and Financing Leases&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 75%; margin-left: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Operating&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Financing&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; font-weight: bold"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; color: Black; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zriheRiF3Ar7" style="width: 14%; color: Black; text-align: right" title="2023"&gt;510&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zk4J6fj1OAoe" style="width: 14%; color: Black; text-align: right" title="2023"&gt;62&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zLm8IT4JXrZ7" style="color: Black; text-align: right" title="2024"&gt;903&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zl6gGSFeX7Ff" style="color: Black; text-align: right" title="2024"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1779"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zZH0wxnUymN3" style="color: Black; text-align: right" title="2025"&gt;869&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zjb7BBgNdOG5" style="color: Black; text-align: right" title="2025"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1783"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zT3Liqw1f3Gl" style="color: Black; text-align: right" title="2026"&gt;899&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zgaX8I51rNqg" style="color: Black; text-align: right" title="2025"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1787"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zjYefaNdgpl7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="2027"&gt;695&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pdn3_c20230630_zy7DLtobbh96" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="2026"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1791"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Total minimum lease payments&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zk776WVUaCAd" style="color: Black; text-align: right" title="Total minimum lease payments"&gt;3,876&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zXrlp9B8YUU5" style="color: Black; text-align: right" title="Total minimum lease payments"&gt;62&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Less amounts representing interest&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20230630_z4N4SumEecal" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Less amounts representing interest"&gt;(801&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20230630_zqvhCVW531H3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Less amounts representing interest"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 2.5pt"&gt;Present value of net minimum lease payments&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--PresentValueOfNetMinimumLeasePayments_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zJHJcUKQCTb" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Present value of net minimum lease payments"&gt;3,075&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_c20230630_z4EJo3AOkYn2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Present value of net minimum lease payments"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zKjMvDu5xRzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Litigation
&#x2013; General&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
may be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business
transactions, employee-related matters, and other matters. When Oncocyte is aware of a claim or potential claim, it assesses the likelihood
of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, Oncocyte will
record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, Oncocyte discloses
the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Tax
Filings&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments
of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes Oncocyte
has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could
be significantly different than the amounts recorded in the unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Employment
Contracts&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Oncocyte
has entered into employment and severance benefit contracts with certain executive officers. Under the provisions of the contracts, Oncocyte
may be required to incur severance obligations for matters relating to changes in control, as defined, and certain terminations of executives.
As of June 30, 2023, Oncocyte accrued approximately $&lt;span id="xdx_90E_eus-gaap--SeveranceCosts1_pn5n6_c20230101__20230630__srt--TitleOfIndividualAxis__custom--ExecutiveOfficersMember_zgDoVsDPXsuh" title="Severance costs"&gt;3.1&lt;/span&gt; million in severance obligations for certain executive officers, in accordance
with the severance benefit provisions of their respective employment and severance benefit agreements, primarily related to Oncocyte&#x2019;s
acquisition of Chronix in 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Indemnification&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
the normal course of business, Oncocyte may provide indemnification of varying scope under Oncocyte&#x2019;s agreements with other
companies or consultants, typically Oncocyte&#x2019;s clinical research organizations, investigators, clinical sites, suppliers and
others. Pursuant to these agreements, Oncocyte will generally agree to indemnify, hold harmless, and reimburse the indemnified
parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection
with the use or testing of Oncocyte&#x2019;s diagnostic tests. Indemnification provisions could also cover third party infringement
claims with respect to patent rights, copyrights, or other intellectual property pertaining to Oncocyte&#x2019;s diagnostic tests.
Oncocyte&#x2019;s office and laboratory facility leases also will generally contain indemnification obligations, including
obligations for indemnification of the lessor for environmental law matters and injuries to persons or property of others, arising
from Oncocyte&#x2019;s use or occupancy of the leased property. The term of these indemnification agreements will generally continue
in effect after the termination or expiration of the particular research, development, services, lease, or license agreement to
which they relate. The Razor Stock Purchase Agreement also contains provisions under which Oncocyte has agreed to indemnify Razor
and Encore from losses and expenses resulting from breaches or inaccuracy of Oncocyte&#x2019;s representations and warranties and
breaches or nonfulfillment of Oncocyte&#x2019;s covenants, agreements, and obligations under the Razor Stock Purchase Agreement.
Oncocyte periodically enters into underwriting and securities sales agreements with broker-dealers in connection with the offer and
sale of Oncocyte securities. The terms of those underwriting and securities sales agreements include indemnification provisions
pursuant to which Oncocyte agrees to indemnify the broker-dealers from certain liabilities, including liabilities arising under the
Securities Act, in connection with the offer and sale of Oncocyte securities. The potential future payments Oncocyte could be
required to make under these indemnification agreements will generally not be subject to any specified maximum amounts.
Historically, Oncocyte has not been subject to any claims or demands for indemnification. Oncocyte also maintains various liability
insurance policies that limit Oncocyte&#x2019;s financial exposure. As a result, Oncocyte management believes that the fair value of
these indemnification agreements is minimal. Accordingly, Oncocyte has not recorded any liabilities for these agreements as of June
30, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand
      contextRef="AsOf2019-12-23_custom_OfficeLeaseAgreementMember"
      decimals="INF"
      unitRef="sqft">26800</us-gaap:AreaOfLand>
    <us-gaap:PaymentsForRent
      contextRef="From2019-12-222019-12-23_custom_OfficeLeaseAgreementMember"
      decimals="0"
      unitRef="USD">61640</us-gaap:PaymentsForRent>
    <OCX:CapitalLeaseAgreementImputedAnnualInterestRate
      contextRef="From2019-12-222019-12-23_custom_MonthlyRentMember_custom_OfficeLeaseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.035</OCX:CapitalLeaseAgreementImputedAnnualInterestRate>
    <OCX:CapitalLeaseAgreementImputedAnnualInterestRate
      contextRef="From2019-12-222019-12-23_custom_FirstTenCalendarMember_custom_OfficeLeaseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.50</OCX:CapitalLeaseAgreementImputedAnnualInterestRate>
    <OCX:ObligatedToPayExpensesAndTaxesPercentage
      contextRef="From2019-12-222019-12-23_custom_MonthlyRentMember_custom_OfficeLeaseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.437</OCX:ObligatedToPayExpensesAndTaxesPercentage>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="From2019-12-222019-12-23_custom_OfficeLeaseAgreementMember"
      decimals="-5"
      unitRef="USD">1300000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <OCX:PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment
      contextRef="From2019-12-222019-12-23_custom_OfficeLeaseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.015</OCX:PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="From2023-01-012023-06-30_custom_LandlordMember_custom_OfficeLeaseAgreementMember"
      decimals="-5"
      unitRef="USD">1300000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2019-12-23_custom_OfficeLeaseAgreementMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:SecurityDeposit>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2019-12-23_custom_OfficeLeaseAgreementMember"
      decimals="-5"
      unitRef="USD">1700000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:AreaOfLand
      contextRef="AsOf2021-08-27_custom_LeaseAgreementMember"
      decimals="INF"
      unitRef="sqft">1928</us-gaap:AreaOfLand>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2019-12-31_custom_DevelopmentAgreementMember_custom_OncocyteCorpMember"
      decimals="INF"
      unitRef="Pure">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <OCX:PaymentObligationAmount
      contextRef="AsOf2023-06-30_custom_LaboratoryEquipmentMember"
      decimals="0"
      unitRef="USD">62000</OCX:PaymentObligationAmount>
    <OCX:ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_890_ecustom--ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock_zoU8xW86RGY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table presents supplemental cash flow information related to operating and financing leases for the six months ended June 30,
2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_8BA_zyuipxi6fFNe" style="display: none"&gt;Schedule
of Supplemental Cash Flow Information Related to Operating and Financing Lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20230630_zrziQ1NGvGJ7" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20220630_z7DsbwjOiTcd" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="color: Black; font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; font-weight: bold; text-align: left"&gt;Cash paid for amounts included in the measurement of financing lease liabilities:&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeasePayments_pn3n3_zk6EhQKz8Lp1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 64%; color: Black; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;538&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; color: Black; text-align: right"&gt;564&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_pn3n3_zNUwHdSkQLlg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Operating cash flows from financing leases&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;5&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;12&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FinanceLeasePrincipalPayments_pn3n3_zp4CfHoNVK93" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Financing cash flows from financing leases&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;57&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;51&lt;/p&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OCX:ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">538000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">564000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">5000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">12000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">57000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">51000</us-gaap:FinanceLeasePrincipalPayments>
    <OCX:ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_894_ecustom--ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock_zRGLBGVydjE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;The
following table presents supplemental balance sheets information related to operating and financing leases as of June 30, 2023 and June
30, 2022 (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span id="xdx_8BD_zPcrYALQFgAk" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Schedule
of Supplemental Balance Sheet Information Related to Operating and Financing Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zC8bf6TbF4Uk" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zw782dUt37jf" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;June 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; font-weight: bold; text-align: left"&gt;Operating lease&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3_zdS95JagOMV5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Right-of-use assets, net&lt;/td&gt;&lt;td style="width: 2%; color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right"&gt;1,855&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; color: Black; text-align: right"&gt;2,343&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_iI_zWsyf8iLJFS7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Right-of-use lease liabilities, current&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;677&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;728&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zOPDzbD2GxH1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Right-of-use lease liabilities, noncurrent&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;2,398&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;3,075&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_z73ADENYoPJ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;3,075&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;3,803&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; font-weight: bold; text-align: left"&gt;Financing lease&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;536&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;537&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FinanceLeaseRightOfUseAssetAccumulatedAmortization_iNI_pn3n3_di_zNTJmeu4eYrf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;(391&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FinanceLeaseRightOfUseAsset_iTI_pn3n3_zE52rflxHsU5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Machinery and equipment, net&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;36&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;146&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityCurrent_iI_pn3n3_zvxSbovxTIBc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Current liabilities&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;60&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;110&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_zj1n66HYwRh8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Noncurrent liabilities&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1751"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_zkWZXDTZAsK3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Total financing lease liabilities&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;60&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;170&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; font-weight: bold"&gt;Weighted average remaining lease term&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Operating lease&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zgYHD3sS8Vi7" title="Weighted average remaining lease term, Operating lease"&gt;4.1&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zZ2Y4YZTjPs1" title="Weighted average remaining lease term, Operating lease"&gt;4.9 &lt;/span&gt;years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Financing lease&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_z2Dj1XQz6bNi" title="Weighted average remaining lease term, Financing lease"&gt;0.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630__us-gaap--LeaseContractualTermAxis__custom--OperatingAndFinancingLeasesMember_zAoDhPfBHfBd" title="Weighted average remaining lease term, Financing lease"&gt;1.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black"&gt;Weighted average discount rate&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_z8p3245Ffea1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Operating lease&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;11.28&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;11.20&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_z7JXatNuyIo2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; color: Black; text-align: left"&gt;Financing lease&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;11.55&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;11.55&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OCX:ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">1855000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">2343000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">677000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">728000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">2398000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">3075000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">3075000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">3803000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">536000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">537000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">500000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">391000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">36000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">146000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">60000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">110000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">60000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">60000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="-3"
      unitRef="USD">170000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember">P4Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember">P4Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember">P0Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember">P1Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="INF"
      unitRef="Pure">0.1128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="INF"
      unitRef="Pure">0.1120</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="INF"
      unitRef="Pure">0.1155</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2022-06-30_custom_OperatingAndFinancingLeasesMember"
      decimals="INF"
      unitRef="Pure">0.1155</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <OCX:ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_891_ecustom--ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock_zB3YPOSoONha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Future
minimum lease commitments are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zguNJzI8MRc2" style="display: none"&gt;Schedule of Future Minimum Lease Commitments for Operating and Financing Leases&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-right: auto; border-collapse: collapse; width: 75%; margin-left: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Operating&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="color: Black; font-weight: bold; text-align: center"&gt;Financing&lt;/td&gt;&lt;td style="color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="color: Black"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center"&gt;Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; font-weight: bold"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; color: Black; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zriheRiF3Ar7" style="width: 14%; color: Black; text-align: right" title="2023"&gt;510&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zk4J6fj1OAoe" style="width: 14%; color: Black; text-align: right" title="2023"&gt;62&lt;/td&gt;&lt;td style="width: 1%; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zLm8IT4JXrZ7" style="color: Black; text-align: right" title="2024"&gt;903&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zl6gGSFeX7Ff" style="color: Black; text-align: right" title="2024"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1779"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zZH0wxnUymN3" style="color: Black; text-align: right" title="2025"&gt;869&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zjb7BBgNdOG5" style="color: Black; text-align: right" title="2025"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1783"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zT3Liqw1f3Gl" style="color: Black; text-align: right" title="2026"&gt;899&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zgaX8I51rNqg" style="color: Black; text-align: right" title="2025"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1787"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zjYefaNdgpl7" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="2027"&gt;695&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pdn3_c20230630_zy7DLtobbh96" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="2026"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1791"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left"&gt;Total minimum lease payments&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zk776WVUaCAd" style="color: Black; text-align: right" title="Total minimum lease payments"&gt;3,876&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black"&gt;&#160;&lt;/td&gt;
    &lt;td style="color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTIP1us-gaap--FinanceLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zXrlp9B8YUU5" style="color: Black; text-align: right" title="Total minimum lease payments"&gt;62&lt;/td&gt;&lt;td style="color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 1.5pt"&gt;Less amounts representing interest&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_di_c20230630_z4N4SumEecal" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Less amounts representing interest"&gt;(801&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_c20230630_zqvhCVW531H3" style="border-bottom: Black 1.5pt solid; color: Black; text-align: right" title="Less amounts representing interest"&gt;(2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; color: Black; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: Black; text-align: left; padding-bottom: 2.5pt"&gt;Present value of net minimum lease payments&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--PresentValueOfNetMinimumLeasePayments_iTIP1us-gaap--OperatingLeaseLiabilitiesPaymentsDueAbstract_pn3n3_c20230630_zJHJcUKQCTb" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Present value of net minimum lease payments"&gt;3,075&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="color: Black; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; color: Black; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FinanceLeaseLiability_iTI_pn3n3_c20230630_z4EJo3AOkYn2" style="border-bottom: Black 2.5pt double; color: Black; text-align: right" title="Present value of net minimum lease payments"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; color: Black; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OCX:ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">510000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">62000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">903000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">869000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">899000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">695000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">3876000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">62000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">801000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">2000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <OCX:PresentValueOfNetMinimumLeasePayments contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">3075000</OCX:PresentValueOfNetMinimumLeasePayments>
    <us-gaap:FinanceLeaseLiability contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">60000</us-gaap:FinanceLeaseLiability>
    <us-gaap:SeveranceCosts1
      contextRef="From2023-01-012023-06-30_custom_ExecutiveOfficersMember"
      decimals="-5"
      unitRef="USD">3100000</us-gaap:SeveranceCosts1>
    <OCX:WorkforceReductionTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_805_ecustom--WorkforceReductionTextBlock_z0ZbrsvAieTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;11.
&lt;span id="xdx_826_zJtUJox1dgxl"&gt;Workforce Reduction&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
August 2022, the Company initiated a workforce reduction plan to strategically realign its operations and implement cost reduction programs
to prioritize near term revenue generators and to manage and preserve cash. In connection with the reduction, the Company eliminated
14 positions, implemented tighter expense controls, and ceased non-core activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Further,
on December 16, 2022, Oncocyte initiated an additional reduction in work force involving over 40% of its full-time employees. The transition
began on December 16, 2022 and was completed in February 2023. As of December 31, 2022, the Company incurred an aggregate of $&lt;span id="xdx_90D_eus-gaap--SeveranceCosts1_pn5n6_c20220101__20221231_zxqyAalFq5L6" title="Employee severance"&gt;1.9&lt;/span&gt; million
related to employee severance and benefits costs in connection with its reductions in force during fiscal year 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
April 12, 2023, Oncocyte announced a reduction in force involving approximately 20% of its workforce (the &#x201c;April 2023 Reduction&#x201d;),
which management believes will extend Oncocyte&#x2019;s cash runway into 2024. In connection with the April 2023 Reduction, we incurred
approximately $&lt;span id="xdx_90A_eus-gaap--SeveranceCosts1_pn5n6_c20230401__20230630_z2zdQJ5iBoj" title="Employee severance"&gt;0.3&lt;/span&gt; million related to employee severance and benefits costs during the second quarter of 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</OCX:WorkforceReductionTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="From2022-01-012022-12-31"
      decimals="-5"
      unitRef="USD">1900000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="From2023-04-012023-06-30"
      decimals="-5"
      unitRef="USD">300000</us-gaap:SeveranceCosts1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zHEsm1tJBM8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;12.
&lt;span id="xdx_820_zZjc3SqBJq3c"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Financing
Transactions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On April 13, 2022, Oncocyte entered into the Securities Purchase Agreement with the Investors, including Broadwood&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and John Peter Gutfreund, a former director of Oncocyte, for
the Series A Preferred Stock Offering. Each of Broadwood and Mr. Gutfreund has a direct material interest in the Series A Preferred Stock
Offering and agreed to purchase &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp2d_c20220412__20220412__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zlqiyxSHG4Ve" title="Offering shares"&gt;5,882.35&lt;/span&gt; and &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp2d_c20220413__20220413__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zALKRSt9jAKb" title="Offering shares"&gt;1,176.48&lt;/span&gt; shares, respectively, in the Series A Preferred Stock Offering and on the same terms
as other investors. Additionally, Halle Capital Management, L.P. received $&lt;span id="xdx_900_eus-gaap--LegalFees_c20220413__20220413__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zbLpeAvh8qQd" title="Legal fees"&gt;85,000&lt;/span&gt; from the Company as reimbursement for its legal fees
and expenses. Mr. Gutfreund is the Managing Partner of Halle Capital Management, L.P. See Note 15 for additional information about the
Series A Preferred Stock Offering.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Further, on April 13, 2022, Oncocyte
entered into the Underwriting Agreement with the Underwriters for the Underwritten Offering. Pursuant to the Underwritten Offering, Broadwood
acquired from us (i) &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zOEM9YizVJd6" title="Sale of stock, shares"&gt;261,032&lt;/span&gt; shares of common stock, and (ii) &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zC9ghIA6VO2e" title="Warrant to purchase common stock"&gt;300,187&lt;/span&gt; April 2022 Warrants to purchase up to &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember__srt--RangeAxis__srt--MaximumMember_zgqrkiRphIb4" title="Warrant to purchase common stock"&gt;150,093&lt;/span&gt; shares of common
stock at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zjWykj2AlOvd" title="Warrant exercise price"&gt;30.60&lt;/span&gt; per share. However, the total number of shares of common stock that Broadwood purchased in the Underwritten
Offering was &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zHA37fRuHzQj" title="Warrant to purchase common stock"&gt;300,187&lt;/span&gt;, of which &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember_zYXTQjNAtji4" title="Warrant to purchase common stock"&gt;39,154&lt;/span&gt; existing shares were acquired by the underwriters in the open market and re-sold to Broadwood.
Pura Vida acquired from us (i) &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember_zx8ZVGI7wsMi" title="Sale of stock, shares"&gt;249,204&lt;/span&gt; shares of common stock, and (ii) &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember_zoEaPeiKT1z9" title="Warrant to purchase common stock"&gt;286,585&lt;/span&gt; April 2022 Warrants to purchase up to &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--BroadwoodCapitalLPMember__srt--RangeAxis__srt--MaximumMember_z5Nc6XXf05Ya" title="Sale of stock, shares"&gt;143,292&lt;/span&gt; shares
of common stock. However, the total number of shares of common stock that Pura Vida purchased in the Underwritten Offering was &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember_zNHEvch00Twa" title="Issuance of shares"&gt;286,585&lt;/span&gt;,
of which &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--PuraVidaInvestmentsLLCMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z9H4CxzjYARe" title="Issuance of shares"&gt;37,380&lt;/span&gt; existing shares were acquired by the underwriters in the open market and re-sold to Pura Vida. Halle Special Situations
Fund LLC purchased from us (i) &lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember_z3D1sO3EcSw" title="Sale of stock, shares"&gt;309,976&lt;/span&gt; shares of common stock, and (ii) &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember_z588Go5psBv3" title="Warrant to purchase common stock"&gt;356,472&lt;/span&gt; 2022 Warrants to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember__srt--RangeAxis__srt--MaximumMember_zP95YY1jNjOb" title="Warrant to purchase common stock"&gt;178,236&lt;/span&gt; shares of
common stock. Mr. Gutfreund is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of Halle
Special Situations Fund LLC. However, the total number of shares of common stock that Halle Special Situations Fund LLC purchased in the
Underwritten was &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember_zEGKj0A7JJT7" title="Warrant to purchase common stock"&gt;356,472&lt;/span&gt;, of which &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenOfferingMember__dei--LegalEntityAxis__custom--HalleSpecialSituationsFundLLCMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zOcZ21AOdKS8" title="Issuance of shares"&gt;46,496&lt;/span&gt; existing shares were acquired by the underwriters in the open market and re-sold to Halle
Special Situations Fund LLC. See Note 15 for additional information about the Underwritten Offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On April 3, 2023, Oncocyte entered
into a securities purchase agreement (the &#x201c;2023 Securities Purchase Agreement&#x201d;) with certain investors, including Broadwood,
Pura Vida and entities affiliated with AWM, and certain individuals, including our Chairman Andrew Arno and former director John Peter
Gutfreund (and certain of their affiliated parties), which provides for the sale and issuance by the Company of an aggregate of &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zMsTlEQa9qA3" title="Offering shares"&gt;2,274,709&lt;/span&gt;
shares of common stock at an offering price of: &lt;span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zix9qv3MCfH2" title="Related party transaction, description"&gt;(i) $6.03 to investors who are not considered to be &#x201c;insiders&#x201d; of the Company
pursuant to Nasdaq Listing Rules (&#x201c;Insiders&#x201d;), which amount reflects the average closing price of the Common Stock on Nasdaq
during the five trading day period immediately prior to pricing, and (ii) $7.08 to Insiders, which amount reflects the final closing
price of the Common Stock on Nasdaq on the last trading day immediately prior to pricing (the &#x201c;2023 Registered Direct Offering&#x201d;)&lt;/span&gt;.
Broadwood purchased &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember_z5XIG6KjyRhk" title="Offering shares"&gt;1,341,381&lt;/span&gt; shares of common stock for $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--BroadwoodPartnersLPMember_zgi7nOooYcxl" title="Proceeds from issuance of stock"&gt;8,093,361.84&lt;/span&gt;, Pura Vida purchased &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PuraVidaMember_zOWvY25l0Uf5" title="Offering shares"&gt;33,150&lt;/span&gt; shares of common stock for $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--PuraVidaMember_zyA3gb8xWtM9" title="Proceeds from issuance of stock"&gt;200,013.84&lt;/span&gt;
and entities affiliated with AVM purchased &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--AVMMember_zVPxGawD1iRe" title="Offering shares"&gt;472,354&lt;/span&gt; shares of common stock for $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--AVMMember_zLrBrFqzNs9j" title="Proceeds from issuance of stock"&gt;2,849,999.92&lt;/span&gt;. Mr. Arno and his affiliated parties purchased
&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--ArnoMember_z1sFbNXKb87h" title="Offering shares"&gt;21,162&lt;/span&gt; shares of common stock for $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--ArnoMember_zrqVnimk2ZQe" title="Proceeds from issuance of stock"&gt;150,000.51&lt;/span&gt;, and Mr. Gutfreund and his affiliated parties purchased &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--MrGutfreundMember_zweVaocFJeN3" title="Offering shares"&gt;85,250&lt;/span&gt; for $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp2d_c20230403__20230403__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--MrGutfreundMember_zShhhQIXlpCi" title="Proceeds from issuance of stock"&gt;604,252.00&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On April 5, 2023, Oncocyte redeemed
all of the &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pp5d_c20220405__20220405__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zffpYiREbyQ2" title="Stock issued during period, shares, conversion of units"&gt;588.23529&lt;/span&gt; shares of Series A Preferred Stock held by Mr. Gutfreund for $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pp2d_c20220405__20220405__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z8r7Yh5acMoh" title="Stock issued during period, value conversion of units"&gt;618,672.34&lt;/span&gt;. Mr. Gutfreund is no longer a related party
as of June 23, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Company Employee(s)&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;As of June 30, 2023, the
Company employed the son of Andrew Arno, Chairman of the Board as its Senior Manager, Investor Relations, Corporate Planning &amp;amp;
Development. As of June 30, 2023, the total compensation paid by the Company to Mr. Arno&#x2019;s son since January 1, 2022 is
approximately $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20230630__us-gaap--RelatedPartyTransactionAxis__custom--ArnoMember_zUQI2BjgQCmf" title="Total compensation paid"&gt;0.2&lt;/span&gt;
million. Mr. Arno&#x2019;s son is no longer an employee of the Company as of July 28, 2023.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-122022-04-12_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_BroadwoodCapitalLPMember"
      decimals="2"
      unitRef="Shares">5882.35</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-132022-04-13_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_BroadwoodCapitalLPMember"
      decimals="2"
      unitRef="Shares">1176.48</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LegalFees
      contextRef="From2022-04-132022-04-13_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_BroadwoodCapitalLPMember"
      decimals="0"
      unitRef="USD">85000</us-gaap:LegalFees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_BroadwoodCapitalLPMember"
      decimals="INF"
      unitRef="Shares">261032</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_BroadwoodCapitalLPMember"
      decimals="INF"
      unitRef="Shares">300187</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_PuraVidaInvestmentsLLCMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">150093</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_BroadwoodCapitalLPMember"
      decimals="INF"
      unitRef="USDPShares">30.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_BroadwoodCapitalLPMember"
      decimals="INF"
      unitRef="Shares">300187</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_UnderwritersMember_custom_BroadwoodCapitalLPMember"
      decimals="INF"
      unitRef="Shares">39154</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_PuraVidaInvestmentsLLCMember"
      decimals="INF"
      unitRef="Shares">249204</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_PuraVidaInvestmentsLLCMember"
      decimals="INF"
      unitRef="Shares">286585</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_custom_BroadwoodCapitalLPMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">143292</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_PuraVidaInvestmentsLLCMember"
      decimals="INF"
      unitRef="Shares">286585</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_custom_PuraVidaInvestmentsLLCMember_custom_UnderwritersMember"
      decimals="INF"
      unitRef="Shares">37380</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_us-gaap_CommonStockMember_custom_HalleSpecialSituationsFundLLCMember"
      decimals="INF"
      unitRef="Shares">309976</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember"
      decimals="INF"
      unitRef="Shares">356472</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">178236</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember"
      decimals="INF"
      unitRef="Shares">356472</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-04-122022-04-13_custom_UnderwrittenOfferingMember_custom_HalleSpecialSituationsFundLLCMember_custom_UnderwritersMember"
      decimals="INF"
      unitRef="Shares">46496</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Shares">2274709</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember">(i) $6.03 to investors who are not considered to be &#x201c;insiders&#x201d; of the Company
pursuant to Nasdaq Listing Rules (&#x201c;Insiders&#x201d;), which amount reflects the average closing price of the Common Stock on Nasdaq
during the five trading day period immediately prior to pricing, and (ii) $7.08 to Insiders, which amount reflects the final closing
price of the Common Stock on Nasdaq on the last trading day immediately prior to pricing (the &#x201c;2023 Registered Direct Offering&#x201d;)</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_BroadwoodPartnersLPMember"
      decimals="INF"
      unitRef="Shares">1341381</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_BroadwoodPartnersLPMember"
      decimals="2"
      unitRef="USD">8093361.84</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_PuraVidaMember"
      decimals="INF"
      unitRef="Shares">33150</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_PuraVidaMember"
      decimals="2"
      unitRef="USD">200013.84</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_AVMMember"
      decimals="INF"
      unitRef="Shares">472354</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_AVMMember"
      decimals="2"
      unitRef="USD">2849999.92</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_ArnoMember"
      decimals="INF"
      unitRef="Shares">21162</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_ArnoMember"
      decimals="2"
      unitRef="USD">150000.51</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_MrGutfreundMember"
      decimals="INF"
      unitRef="Shares">85250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-032023-04-03_us-gaap_CommonStockMember_custom_SecuritiesPurchaseAgreementMember_custom_MrGutfreundMember"
      decimals="2"
      unitRef="USD">604252.00</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-04-052022-04-05_us-gaap_SeriesAPreferredStockMember"
      decimals="5"
      unitRef="Shares">588.23529</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2022-04-052022-04-05_us-gaap_SeriesAPreferredStockMember"
      decimals="2"
      unitRef="USD">618672.34</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-06-30_custom_ArnoMember"
      decimals="-5"
      unitRef="USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:LongTermDebtTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_805_eus-gaap--LongTermDebtTextBlock_zdqR29ID3GN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;13.
&lt;span id="xdx_828_zrMTYXD6zsN1"&gt;Loan Payable to Silicon Valley Bank&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Amended
Loan Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
October 17, 2019, Oncocyte entered into a First Amendment to Loan and Security Agreement (the &#x201c;Amended Loan Agreement&#x201d;) with
Silicon Valley Bank (&#x201c;the Bank&#x201d;) pursuant to which Oncocyte obtained a new $&lt;span id="xdx_905_eus-gaap--LinesOfCreditCurrent_iI_pn6n6_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zkwh5lsbnqO6" title="Line of credit, current"&gt;3&lt;/span&gt; million secured credit facility (&#x201c;Tranche
1&#x201d;), a portion of which was used to repay the remaining balance of approximately $&lt;span id="xdx_903_eus-gaap--RepaymentsOfLinesOfCredit_c20191016__20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zSbNPVsuVGk3" title="Repayments of lines of credit"&gt;400,000&lt;/span&gt; on outstanding loans from the Bank, plus
a final payment of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zkkDswSjbCF" title="Debt instrument, final payment"&gt;116,000&lt;/span&gt;, under the February 21, 2017 Loan Agreement. The credit line under the Amended Loan Agreement may be increased
by an additional $&lt;span id="xdx_908_eus-gaap--LinesOfCreditCurrent_iI_pn6n6_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zXb5yFwe35" title="Line of credit, current"&gt;2&lt;/span&gt; million (&#x201c;Tranche 2&#x201d;) if Oncocyte obtains at least $&lt;span id="xdx_909_eus-gaap--AdditionalPaidInCapital_iI_pn6n6_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zuJoOEOQblx9" title="Additional paid in capital"&gt;20&lt;/span&gt; million of additional equity capital, as was the
case with the original Loan Agreement, and a positive final coverage determination is received from CMS for DetermaRx at a specified
minimum price point per test (the &#x201c;Tranche 2 Milestone&#x201d;), and Oncocyte is not in default under the Amended Loan Agreement.
As of June 30, 2023, Oncocyte had satisfied the Tranche 2 Milestone and was eligible to borrow the $&lt;span id="xdx_90A_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_do_c20230630__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zMVCgLpOOy61" title="Line of credit facility, maximum borrowing capacity"&gt;2&lt;/span&gt; million Tranche 2 funds. However,
Oncocyte has not yet borrowed any funds under Tranche 2.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;Payments
of interest only on the principal balance were due monthly from the draw date through March 31, 2020, followed by 24 monthly payments
of principal and interest, but the Bank has agreed to a deferral of principal payments, as discussed below. The outstanding principal
balance of the loan will bear interest at a stated floating annual interest equal to the greater of (a) the prime rate or (b) &lt;span id="xdx_90C_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20191017__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zzHOBuJr9S8b" title="Interest rate"&gt;5&lt;/span&gt;% per
annum. During August 2022, period in which the loan was paid off, the published prime rate was &lt;span id="xdx_90E_eus-gaap--LineOfCreditFacilityInterestRateAtPeriodEnd_iI_pid_dp_uPure_c20230630_zzUrc3mk0Gj8" title="Interest rate"&gt;5.5&lt;/span&gt;% per annum.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
April 2, 2020, as part of the Bank&#x2019;s COVID-19 pandemic relief program, Oncocyte and the Bank entered into a Loan Deferral Agreement
(&#x201c;Loan Deferral&#x201d;) with respect to the Amended Loan Agreement. &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20200401__20200402__us-gaap--TypeOfArrangementAxis__custom--LoanDeferralAgreementMember_zazUK3crrSD4" title="Debt instrument maturity date description"&gt;Under the Loan Deferral Agreement, the Bank agreed to (i) extend
the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal
payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May
1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided
at no additional fees to Oncocyte&lt;/span&gt;. No other terms of the Amended Loan Agreement were changed or modified. The Loan Deferral was accounted
for as a modification of debt in accordance with ASC 470-50, &lt;i&gt;Debt &#x2013; Modifications and Extinguishments&lt;/i&gt;, thus there was no
gain or loss recognized on the transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;At
maturity of the loan, Oncocyte agreed to pay the Bank an additional final payment fee of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_c20191031__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zLE3svKM2k21" title="Debt instrument, final payment"&gt;200,000&lt;/span&gt;, which was recorded as a deferred financing
charge in October 2019 and is being amortized to interest expense over the term of the loan using the effective interest method. As of
June 30, 2023, there is no remaining unamortized deferred financing cost and the full principal balance of the loan in addition to the
final payment fee have been paid off.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Bank
Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;In
2017, in connection with the Loan Agreement, Oncocyte issued common stock purchase warrants to the Bank (the &#x201c;2017 Bank Warrants&#x201d;)
entitling the Bank to purchase shares of Oncocyte common stock in tranches related to the loan tranches under the Loan Agreement. In
conjunction with the availability of the loan, the Bank was issued warrants to purchase &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z0BAs5j803Wf" title="Warrants to purchase, shares"&gt;412&lt;/span&gt; shares of Oncocyte common stock at an exercise
price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20171231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z09BO9ImYD2j" title="Warrant exercise price, per share"&gt;97.00&lt;/span&gt; per share, through February 21, 2027. On March 23, 2017, the Bank was issued warrants to purchase an additional &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20170323__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zTAL024Hgzea" title="Warrants to purchase, shares"&gt;366&lt;/span&gt; shares
at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20170323__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zsWZL0Dh2Ci2" title="Warrant exercise price, per share"&gt;109.20&lt;/span&gt; per share, through March 23, 2027. The Bank may elect to exercise the 2017 Bank Warrants on a &#x201c;cashless
exercise&#x201d; basis and receive a number of shares determined by multiplying the number of shares for which the applicable tranche
is being exercised by (A) the excess of the fair market value of the common stock over the applicable exercise price, divided by (B)
the fair market value of the common stock. The fair market value of the common stock will be the last closing or sale price on a national
securities exchange, inter-dealer quotation system, or over-the-counter market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
October 17, 2019, in conjunction with Tranche 1 becoming available under the Amended Loan Agreement, Oncocyte issued a common stock purchase
warrant to the Bank (the &#x201c;2019 Bank Warrant&#x201d;) entitling the Bank to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zEFZgzEkwh0k" title="Warrants to purchase, shares"&gt;4,928&lt;/span&gt; shares of Oncocyte common stock at the
initial &#x201c;Warrant Price&#x201d; of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_z9pnCFgayZb9" title="Warrant exercise price, per share"&gt;33.80&lt;/span&gt; per share through October 17, 2029. The number of shares of common stock issuable upon
the exercise of the 2019 Bank Warrant will increase on the date of each draw, if any, on Tranche 2. The number of additional shares of
common stock issuable upon the exercise of the 2019 Bank Warrant will be equal to &lt;span id="xdx_906_ecustom--PercentageForWarrantExercisePricePerShare_pid_dp_uPure_c20191016__20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zSlgxVF4OsTh" title="Percentage for warrant exercise price per share"&gt;0.02&lt;/span&gt;% of Oncocyte&#x2019;s fully diluted equity outstanding
for each $&lt;span id="xdx_908_ecustom--DilutedEquityOutstanding_pn6n6_c20191016__20191017__us-gaap--StatementEquityComponentsAxis__custom--BankWarrantMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zBM5N48O83U3" title="Diluted equity outstanding"&gt;1&lt;/span&gt; million draw under Tranche 2. The Warrant Price for Tranche 2 warrant shares will be determined upon each draw of Tranche
2 funds and will be closing price of Oncocyte common stock on the date immediately before
the applicable date on which Oncocyte borrows funds under Tranche 2. The Bank may elect to exercise the 2019 Bank Warrant on a &#x201c;cashless
exercise&#x201d; basis and receive a number of shares determined by multiplying the number of shares for which the 2019 Bank Warrant is
being exercised by (A) the excess of the fair market value of the common stock over the applicable Warrant Price, divided by (B) the
fair market value of the common stock. The fair market value of the common stock will be last closing or sale price on a national securities
exchange, interdealer quotation system, or over-the-counter market. As of June 30, 2023, Oncocyte has not borrowed any funds under Tranche
2.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;ONCOCYTE
CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="-6"
      unitRef="USD">3000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="From2019-10-162019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="0"
      unitRef="USD">400000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="AsOf2019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="0"
      unitRef="USD">116000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:LinesOfCreditCurrent
      contextRef="AsOf2019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="-6"
      unitRef="USD">2000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2019-10-17_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="-6"
      unitRef="USD">20000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2023-06-30_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="0"
      unitRef="USD">2</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="AsOf2019-10-17_custom_AmendedLoanAgreementMember"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="AsOf2023-06-30" decimals="INF" unitRef="Pure">0.055</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2020-04-012020-04-02_custom_LoanDeferralAgreementMember">Under the Loan Deferral Agreement, the Bank agreed to (i) extend
the scheduled maturity date of the Amended Loan Agreement from March 31, 2022 to September 30, 2022, and (ii) deferred the principal
payments by an additional 6 months whereby payments of interest only on the Bank loan principal balance will be due monthly from May
1, 2020 through October 1, 2020, followed by 23 monthly payments of principal and interest beginning on November 1, 2020, all provided
at no additional fees to Oncocyte</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="AsOf2019-10-31_custom_BankWarrantMember_custom_AmendedLoanAgreementMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2017-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">412</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2017-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">97.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2017-03-23_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">366</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2017-03-23_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">109.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2019-10-17_custom_BankWarrantMember_custom_AmendedLoanAgreementMember"
      decimals="INF"
      unitRef="Shares">4928</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-10-17_custom_BankWarrantMember_custom_AmendedLoanAgreementMember"
      decimals="INF"
      unitRef="USDPShares">33.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <OCX:PercentageForWarrantExercisePricePerShare
      contextRef="From2019-10-162019-10-17_custom_BankWarrantMember_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="INF"
      unitRef="Pure">0.0002</OCX:PercentageForWarrantExercisePricePerShare>
    <OCX:DilutedEquityOutstanding
      contextRef="From2019-10-162019-10-17_custom_BankWarrantMember_custom_AmendedLoanAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="-6"
      unitRef="USD">1000000</OCX:DilutedEquityOutstanding>
    <OCX:CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_80F_ecustom--CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock_zobTcfDT6Tqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;14.
&lt;span id="xdx_828_zZwTbgUjSyeb"&gt;Co-Development Agreement with Life Technologies Corporation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
January 13, 2022, Oncocyte entered into a Collaboration Agreement (the &#x201c;LTC Agreement&#x201d;) with Life Technologies Corporation,
a Delaware corporation and subsidiary of Thermo Fisher Scientific (&#x201c;LTC&#x201d; and together with Oncocyte, the &#x201c;Parties&#x201d;
or individually, a &#x201c;Party&#x201d;), in order to partner in the development and collaborate in the commercialization of Thermo Fisher
Scientific&#x2019;s existing Oncomine Comprehensive Assay Plus (&#x201c;OCA Plus&#x201d;) and Oncocyte&#x2019;s DetermaIO assay for use with
LTC&#x2019;s Ion Torrent&lt;sup&gt;TM&lt;/sup&gt; Genexus&lt;sup&gt;TM&lt;/sup&gt; Integrated Sequencer and LTC&#x2019;s Ion Torrent&lt;sup&gt;TM&lt;/sup&gt; Genexus&lt;sup&gt;TM
&lt;/sup&gt;Purification System (&#x201c;Genexus system&#x201d;) in order to obtain &lt;i&gt;in vitro &lt;/i&gt;diagnostic (&#x201c;IVD&#x201d;) regulatory
approval. On February 7, 2023, Oncocyte entered into a Termination Agreement (the &#x201c;Termination Agreement&#x201d;) with LTC, pursuant
to which the parties terminated the LTC Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;As
of June 30, 2023, Oncocyte was responsible for reimbursing LTC for $&lt;span id="xdx_901_eus-gaap--DevelopmentCosts_c20230101__20230630__dei--LegalEntityAxis__custom--LifeTechnologiesCorporationMember_zfCvAuebcka4" title="Development costs"&gt;749,000&lt;/span&gt; of certain development costs under the terms of the LTC Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</OCX:CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock>
    <us-gaap:DevelopmentCosts
      contextRef="From2023-01-012023-06-30_custom_LifeTechnologiesCorporationMember"
      decimals="0"
      unitRef="USD">749000</us-gaap:DevelopmentCosts>
    <OCX:AprilTwentyTwentyTwoOfferingsTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_809_ecustom--AprilTwentyTwentyTwoOfferingsTextBlock_z7bMY3Mjbwdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;b&gt;15.
&lt;span id="xdx_822_z1Lt1DpVWOP2"&gt;Equity Offerings&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&lt;i&gt;Series
A Preferred Stock Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;On
April 13, 2022, Oncocyte entered into the Securities Purchase Agreement with Investors, including Broadwood, in a registered direct offering
of &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHkNo2g6D8C8" title="Stock issued during period, shares, conversion of units"&gt;11,765
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;shares of our Series A Preferred
Stock, which shares of Series A Preferred Stock are convertible into a total of &lt;span id="xdx_906_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKLvE8EwmGTd" title="Preferred stock, convertible, shares issuable"&gt;384,477
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;shares of our common stock, at
a conversion price of $&lt;span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMQHkgXeJKv9" title="Preferred stock, convertible, conversion price"&gt;30.60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;.
The purchase price of each share of Series A Preferred Stock was $&lt;span id="xdx_901_ecustom--PurchasePrice_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpePk84Xj6pg" title="Purchase price"&gt;850&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;,
which included an original issue discount to the stated value of $&lt;span id="xdx_907_ecustom--StatedValue_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHCuAznQ42Mb" title="Stated value"&gt;1,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;per share. The rights, preferences
and privileges of the Series A Convertible Preferred Stock are set forth in the Company&#x2019;s Certificate of Determination, which the
Company filed with the Secretary of State of the State of California. The Securities Purchase Agreement provides that the closing of
the Series A Preferred Stock Offering will occur, subject to the satisfaction of certain closing conditions, in two equal tranches of
$&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--AwardTypeAxis__custom--TwoEqualTranchesMember_zp2vVD2j2rV6" title="Proceeds from issuance of preferred stock and preference stock"&gt;5,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;each for aggregate gross proceeds
from both closings of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20220412__20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHmN7jFCvz52" title="Proceeds from issuance of preferred stock and preference stock"&gt;10,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;.
The first closing occurred on June 1, 2022, and Oncocyte received net proceeds of approximately $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220601__20220601__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z5u8wT87iHX7" title="Net proceeds"&gt;4.9
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;million from the Series A Preferred
Stock issued from the first tranche. The second closing would occur, subject to the satisfaction of certain closing conditions (including
but not limited to a requirement that the Company has not received, in the 12 months preceding the second closing, a notice from Nasdaq
that the Company is not in compliance with the listing and maintenance and listing requirements of Nasdaq), on the earlier of (a) the
second trading day following the date that Oncocyte receives notice from an Investor to accelerate the second closing and (b) a date
selected by Oncocyte on or after October 8, 2022 and on or prior to March 8, 2023. On August 9, 2022, Oncocyte received a letter from
Nasdaq indicating that the Company no longer met the minimum bid price requirement of the Nasdaq continued
listing requirements. Accordingly&lt;/span&gt;, the second closing did not occur and no additional proceeds were received under the Securities
Purchase Agreement. On August 8, 2023, the Company received a letter from Nasdaq indicating that the Company had regained compliance
with the minimum bid price requirement of the Nasdaq continued listing requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ONCOCYTE
CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A Preferred Stock is convertible into shares of common stock at any time at the holder&#x2019;s option. The conversion price will
be subject to customary anti-dilution adjustments for matters such as stock splits, stock dividends and other distributions on common
stock, and recapitalizations. &lt;span id="xdx_902_eus-gaap--ConversionOfStockDescription_c20220412__20220413_zpQT5S2YFPoj" title="Conversion of stock description"&gt;The holder will be prohibited from converting shares of Series A Preferred Stock into shares of common
stock if, as a result of such conversion, the holder, together with its affiliates, would own more than &lt;span id="xdx_905_ecustom--PercentageOfIssuedAndOutstandingShares_pid_dp_uPure_c20220412__20220413_zdiZERYD99zc" title="Percentage of issued and outstanding shares"&gt;4.99&lt;/span&gt;% of the shares of common
stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation
solely as to itself up to 19.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion,
provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance
of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the
holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)&lt;/span&gt;. On July 15, 2022, the
Company received such shareholder approval to remove the beneficial ownership limitation with respect to the Series A Preferred Stock
held by Broadwood. Oncocyte may force the conversion of up to one-third of the shares of Series A Preferred Stock originally
issued, subject to customary equity conditions, &lt;span id="xdx_904_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20220714__20220715__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zNNjsrs7T0Uf" title="Equity method investment description"&gt;if the daily volume weighted average price of our common stock for 20 out of 30 trading
days exceeds &lt;span id="xdx_90C_ecustom--ConversionPricePercentage_dp_uPure_c20220714__20220715_zBcnfG6qw7q3"&gt;140&lt;/span&gt;% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000
shares of our common stock&lt;/span&gt;. Oncocyte may only effect one forced conversion during any 30-trading day period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the event of the Company&#x2019;s liquidation, dissolution, or winding up, holders of Series A Preferred Stock will receive a payment
equal to the stated value of the Series A Preferred Stock plus accrued but unpaid dividends and any other amounts that may have become
payable on the Series A Preferred Stock due to any failure or delay that may have occurred in issuing shares of common stock upon conversion
of a portion of the Series A Preferred Stock, before any distribution or payment to the holders of common stock or any of Oncocyte&#x2019;s
other junior equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares
of Series A Preferred Stock generally has no voting rights, except as required by law and except that the consent of holders of a majority
of the outstanding Series A Preferred Stock will be required to amend any provision of our certificate of incorporation that would have
a materially adverse effect on the rights of the holders of the Series A Preferred Stock. Additionally, as long as any shares of Series
A Preferred Stock remain outstanding, unless the holders of at least &lt;span id="xdx_908_ecustom--PreferredStockRemainsOutstandingPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWtuwefAG66c" title="Preferred stock outstanding percentage"&gt;51&lt;/span&gt;% of the then outstanding shares of Series A Preferred Stock shall
have otherwise given prior written consent, the Company, on a consolidated basis with its subsidiaries, is not permitted to (1) have
less than $&lt;span id="xdx_90F_eus-gaap--Cash_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrGbCIpHHeG9" title="Cash in hand"&gt;8&lt;/span&gt; million of unrestricted, unencumbered cash on hand (&#x201c;Cash Minimum Requirement&#x201d;); (2) other than certain permitted
indebtedness, incur indebtedness to the extent that our aggregate indebtedness exceeds $&lt;span id="xdx_901_ecustom--IndebtednessExpenses_iI_pn6n6_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zXrh9NtXVYUl" title="Indebtedness expenses"&gt;15&lt;/span&gt; million; (3) enter into any agreement (including
any indenture, credit agreement or other debt instrument) that by its terms prohibits, prevents, or otherwise limits our ability to pay
dividends on, or redeem, the Series A Preferred Stock in accordance with the terms of the Certificate of Determination; or (4) authorize
or issue any class or series of preferred stock or other capital stock of the Company that ranks senior or pari passu with the Series
A Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shares
of Series A Preferred Stock will be entitled to receive cumulative dividends at a rate per share (as a percentage of stated value) of
6% per annum, payable quarterly in cash or, at our option, by accreting such dividends to the stated value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is required to redeem, for cash, the shares of Series A Preferred Stock on the earlier to occur of (1) April 8, 2024, (2) the
commencement of certain a voluntary or involuntary bankruptcy, receivership, or similar proceedings against us or our assets, (3) a Change
of Control Transaction (as defined herein) and (4) at the election and upon notice of 51% in interest of the holders, if the Company
fails to meet the Cash Minimum Requirement. A &#x201c;Change of Control Transaction&#x201d; means the occurrence of any of (a) an acquisition
by an individual or legal entity or &#x201c;group&#x201d; (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective
control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess of &lt;span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--OncocyteCorpMember_zt3FhiR5dqwf" title="Ownership percentage"&gt;50&lt;/span&gt;%
of the voting securities of the Company (other than by means of conversion of Series A Preferred Stock), (b) the Company merges into
or consolidates with any other person, or any person merges into or consolidates with the Company and, after giving effect to such transaction,
the stockholders of the Company immediately prior to such transaction own less than &lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220413__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SecurityMember_zc8URNam80lb" title="Ownership percentage"&gt;50&lt;/span&gt;% of the aggregate voting power of the Company
or the successor entity of such transaction, or (c) the Company sells or transfers all or substantially all of its assets to another
person. Additionally, the Company has the right to redeem the Series A Preferred Stock for cash upon 30 days prior notice to the holders;
provided if the Company undertakes a capital raise in connection with such redemption, the Investors will have the right to participate
in such financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
issuance and sale of the Series A Preferred Stock was completed pursuant to the Company&#x2019;s effective shelf registration statement
on Form S-3 (Registration No. 333-256650), filed with the SEC on May 28, 2021 and declared effective by
the SEC on June 8, 2021, and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13,
2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ONCOCYTE
CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the registered direct offering in April 2023, the Company used approximately $&lt;span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zuPcvV2JzAvj" title="Net proceeds to immediately redeem"&gt;1.1&lt;/span&gt; million of the net proceeds to immediately
redeem an aggregate of &lt;span id="xdx_901_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjccM0IMidKg" title="Number of stock redeem"&gt;1,064&lt;/span&gt; shares of its Series A Preferred Stock and may thereafter elect to redeem additional shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Series A Preferred Stock dividend for all issued and outstanding shares is set at &lt;span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBVX0IP0j7I5" title="Preferred stock, dividend rate, percentage"&gt;6&lt;/span&gt;% per annum per share. As of June 30, 2023, the Company
elected to accrete dividends of $&lt;span id="xdx_905_eus-gaap--DividendsPreferredStock_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2vPxXQiYTYg" title="Dividends, preferred stock"&gt;321,000&lt;/span&gt;, net of the April 2023 redemption, with respect to shares of Series A Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, Oncocyte had &lt;span id="xdx_908_eus-gaap--TemporaryEquitySharesIssued_iI_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zancJFOFUNh2" title="Number of shares issued"&gt;&lt;span id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKtCuCVF48kj" title="Number of shares outstanding"&gt;4,818&lt;/span&gt;&lt;/span&gt; shares issued and outstanding. The future right or obligation associated with the Series A Preferred
Stock to be issued in the second closing was written off since the second closing was not received as of June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Underwritten
Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 13, 2022, Oncocyte entered into the Underwriting Agreement with the Underwriters, pursuant to which the Company agreed to issue
and sell to the Underwriters an aggregate of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_z5cvbXFKqjM5" title="Stock issued during period, shares, new issues"&gt;1,313,320&lt;/span&gt; shares of common stock and &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_zJ2JaG4Z3Fcc" title="Number of warrants"&gt;1,313,320&lt;/span&gt; April 2022 Warrants to purchase up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlzplsDO1AX" title="Number of warrants"&gt;656,660&lt;/span&gt;
shares of common stock. Each share of common stock and the accompanying April 2022 Warrant was sold at a combined offering price of $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_zArsGT6Feauj" title="Sale of stock, price per share"&gt;26.65&lt;/span&gt;,
representing an offering price of $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBKsZLYRlKXf" title="Sale of stock, price per share"&gt;26.45&lt;/span&gt; per share of common stock and $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuauwKKWFnae" title="Exercise price"&gt;0.20&lt;/span&gt; per accompanying April 2022 Warrant, before underwriting
discounts and commissions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms of the Underwriting Agreement, the Company also granted to the Underwriters an over-allotment option, exercisable in whole
or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase up to an additional &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyTwoWarrantsMember_zVBDxM5BxTpf" title="Stock issued during period, shares, new issues"&gt;196,998&lt;/span&gt; shares
of common stock and &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsU71sbHzO2h" title="Number of warrants"&gt;196,998&lt;/span&gt; April 2022 Warrants to purchase &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbGV7DgeWKlj" title="Number of warrants"&gt;98,499&lt;/span&gt; shares of common stock to cover over-allotments, if any. The over-allotment
option may be exercised separately for shares of common stock at a price to the underwriters of $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_z0A5bI6Lc27h" title="Shares issued, price per share"&gt;24.85&lt;/span&gt; per share, and April 2022 Warrants
at a price of $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220413__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaUkRKySMzTb" title="Shares issued, price per share"&gt;0.20&lt;/span&gt; per April 2022 Warrant. On April 14, 2022, the Underwriters exercised their option to purchase the &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zqZ8aHbKM2T7" title="Stock issued during period, shares, new issues"&gt;196,998&lt;/span&gt; April
2022 Warrants pursuant to the over-allotment option but did not exercise their option to purchase the additional &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220412__20220413__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zNPFOf32TESf" title="Stock issued during period, shares, new issues"&gt;196,998&lt;/span&gt; shares of common
stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company received net proceeds of approximately $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220418__20220419__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z8RSGCj7oAMd" title="Proceeds from issuance initial public offering"&gt;32.8&lt;/span&gt; million from the Underwritten Offering, which includes the April 2022 Warrants sold
upon the exercise of the Underwriters&#x2019; overallotment option. The Underwritten Offering closed on April 19, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Underwritten Offering was made pursuant to the Company&#x2019;s effective &#x201c;shelf&#x201d; registration statement on Form S-3 (Registration
No. 333-256650) filed with the SEC Commission on May 28, 2021 and declared effective by the SEC on June 8, 2021,
and an accompanying prospectus dated June 8, 2021 as supplemented by a prospectus supplement dated April 13, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Registered
Direct Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 3, 2023, Oncocyte entered into an agreement with certain members of the Company&#x2019;s board of directors, and several institutional
and accredited investors, including Broadwood, the Company&#x2019;s largest shareholder, and certain members of the Company&#x2019;s board
of directors (and certain of their affiliated parties), relating to their purchase of an aggregate of up to &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--RangeAxis__srt--MaximumMember_zPrVMZICxex3" title="Number of shares issued"&gt;2,278,121&lt;/span&gt; shares of its common
stock at an offering price of $&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--BoardMembersMember_z6ErrnuHCXza" title="Shares issued price per share"&gt;7.08&lt;/span&gt; per share to board members and $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__srt--TitleOfIndividualAxis__custom--OtherInvestorsMember_zaI3G4Mx9rE2" title="Shares issued price per share"&gt;6.03&lt;/span&gt; per share to the other investors participating in the offering.
The offering was intended to be priced at-the-market for purposes of complying with applicable Nasdaq Listing Rules. The aggregate gross
proceeds from the offering were approximately $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember_zTATHj93Nwf7" title="Proceeds from issuance of common stock"&gt;13.9&lt;/span&gt; million. The Company used approximately $&lt;span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn5n6_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9lzrGVuCRZe" title="Net proceeds to immediately redeem"&gt;1.1&lt;/span&gt; million of the net proceeds to immediately
redeem an aggregate of &lt;span id="xdx_901_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pid_c20230403__20230403__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBG8ioUQcEXf" title="Number of stock redeem"&gt;1,064&lt;/span&gt; shares of its Series A Preferred Stock and may thereafter elect to redeem additional shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</OCX:AprilTwentyTwentyTwoOfferingsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">11765</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">384477</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">30.60</us-gaap:PreferredStockConvertibleConversionPrice>
    <OCX:PurchasePrice
      contextRef="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">850</OCX:PurchasePrice>
    <OCX:StatedValue
      contextRef="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">1000</OCX:StatedValue>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember_custom_TwoEqualTranchesMember"
      decimals="0"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2022-04-122022-04-13_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="USD">10000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-06-012022-06-01_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="-5"
      unitRef="USD">4900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ConversionOfStockDescription contextRef="From2022-04-122022-04-13">The holder will be prohibited from converting shares of Series A Preferred Stock into shares of common
stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of common
stock then issued and outstanding (provided a holder may elect, at the first closing, to increase such beneficial ownership limitation
solely as to itself up to 19.99% of the number of shares of common stock outstanding immediately after giving effect to the conversion,
provided further that following the receipt of shareholder approval required by applicable Nasdaq rules with respect to the issuance
of common stock that would exceed the beneficial ownership limitation, such beneficial ownership limitation will no longer apply to the
holder if the holder notified the Company that the holder wishes the Company to seek such shareholder approval)</us-gaap:ConversionOfStockDescription>
    <OCX:PercentageOfIssuedAndOutstandingShares
      contextRef="From2022-04-122022-04-13"
      decimals="INF"
      unitRef="Pure">0.0499</OCX:PercentageOfIssuedAndOutstandingShares>
    <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="From2022-07-142022-07-15_us-gaap_SeriesAPreferredStockMember_custom_OncocyteCorpMember">if the daily volume weighted average price of our common stock for 20 out of 30 trading
days exceeds 140% of the conversion price and on 20 out of the same 30 trading days the daily trading volume equals or exceeds 20,000
shares of our common stock</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
    <OCX:ConversionPricePercentage
      contextRef="From2022-07-142022-07-15"
      decimals="INF"
      unitRef="Pure">1.40</OCX:ConversionPricePercentage>
    <OCX:PreferredStockRemainsOutstandingPercentage
      contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.51</OCX:PreferredStockRemainsOutstandingPercentage>
    <us-gaap:Cash
      contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember"
      decimals="-6"
      unitRef="USD">8000000</us-gaap:Cash>
    <OCX:IndebtednessExpenses
      contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember"
      decimals="-6"
      unitRef="USD">15000000</OCX:IndebtednessExpenses>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember_custom_OncocyteCorpMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-04-13_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember_custom_SecurityMember"
      decimals="INF"
      unitRef="Pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-5"
      unitRef="USD">1100000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1064</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2023-01-012023-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DividendsPreferredStock
      contextRef="From2023-01-012023-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      unitRef="USD">321000</us-gaap:DividendsPreferredStock>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2023-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">4818</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="Shares">4818</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-122022-04-13_us-gaap_OverAllotmentOptionMember_custom_AprilTwoThousandTwentyTwoWarrantsMember"
      decimals="INF"
      unitRef="Shares">1313320</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-13_us-gaap_IPOMember_custom_AprilTwoThousandTwentyTwoWarrantsMember"
      decimals="INF"
      unitRef="Shares">1313320</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-13_us-gaap_IPOMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">656660</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-04-13_us-gaap_IPOMember_custom_AprilTwoThousandTwentyTwoWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">26.65</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-04-13_us-gaap_IPOMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">26.45</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-13_us-gaap_IPOMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-122022-04-13_custom_UnderwritingAgreementMember_custom_AprilTwoThousandTwentyTwoWarrantsMember"
      decimals="INF"
      unitRef="Shares">196998</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-13_custom_UnderwritingAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">196998</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-13_custom_UnderwritingAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">98499</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-04-13_custom_UnderwritingAgreementMember"
      decimals="INF"
      unitRef="USDPShares">24.85</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-04-13_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">0.20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-122022-04-13_custom_UnderwritingAgreementMember"
      decimals="INF"
      unitRef="Shares">196998</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-122022-04-13_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      unitRef="Shares">196998</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-04-182022-04-19_us-gaap_OverAllotmentOptionMember"
      decimals="-5"
      unitRef="USD">32800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">2278121</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-04-03_custom_RegisteredDirectOfferingMember_custom_BoardMembersMember"
      decimals="INF"
      unitRef="USDPShares">7.08</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-04-03_custom_RegisteredDirectOfferingMember_custom_OtherInvestorsMember"
      decimals="INF"
      unitRef="USDPShares">6.03</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember"
      decimals="-5"
      unitRef="USD">13900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-5"
      unitRef="USD">1100000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2023-04-032023-04-03_custom_RegisteredDirectOfferingMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1064</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_800_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zmtyUnKr1rF1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;16.
&lt;span id="xdx_828_zjDs3QD2cCw4"&gt;Assets Held for Sale and Discontinued Operations&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Razor
Disposal &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 15, 2022, the Company entered into the Razor Stock Purchase Agreement with Dragon and Razor. Pursuant to the Razor Stock Purchase
Agreement, Oncocyte agreed to sell, and Dragon agreed to purchase, &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221214__20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--DragonMember_zhnzNri45yRb" title="Number of shares issued"&gt;3,188,181&lt;/span&gt; shares of common stock of Razor, which constitutes approximately
&lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221215__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_z6WarqAjJeZd" title="Equity method investment ownership percentage"&gt;70&lt;/span&gt;% of the issued and outstanding equity interests of Razor on a fully-diluted basis. On February 16, 2023, Oncocyte completed the Razor
Sale Transaction. In connection with the Razor Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx.
While &lt;span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_dp_c20230216__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_zmqFraAOBuE5" title="Cash received on stock transaction"&gt;no&lt;/span&gt; monetary consideration was received for the sale of &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_zh4YBVstOJJ6" title="Equity method investment ownership percentage"&gt;70&lt;/span&gt;% of the equity interests of Razor, the transaction allows the Company
to eliminate all development and commercialization costs with respect to DetermaRx. Following the Razor Closing, Oncocyte continues to
own &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230216__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zZnX60kItHAi" title="Number of shares issued"&gt;1,366,364&lt;/span&gt; shares of common stock of Razor, which constitutes approximately &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zlp8TfKYFJv4" title="Equity method investment ownership percentage"&gt;30&lt;/span&gt;% of the issued and outstanding equity interests of
Razor on a fully-diluted basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the transfer of &lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember__srt--TitleOfIndividualAxis__custom--DragonMember_zPTA9Kgah2kh" title="Equity method investment ownership percentage"&gt;70&lt;/span&gt;% of the equity interests of Razor, the Razor Stock Purchase Agreement provided that Dragon would purchase
furniture, fixtures, and equipment from the Company for a cash consideration of $&lt;span id="xdx_90A_eus-gaap--BusinessCombinationConsiderationTransferred1_c20230216__20230216__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--BusinessAcquisitionAxis__custom--RazorMember_zKYXIdHUoHrb" title="Consideration transferred"&gt;115,660&lt;/span&gt;. Upon the Razor Closing, the Company deconsolidated
the assets and liabilities of Razor as control of Razor has transferred to Dragon.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded the final adjustment related to the disposal, including final working capital adjustments, and recognized a loss of
$&lt;span id="xdx_90A_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_iN_pn5n6_di_c20230101__20230331__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zHN3nfvUWC82" title="Loss on disposal"&gt;1.3&lt;/span&gt; million during the first quarter of 2023. Including the impairment losses we recognized as of December 31, 2022 related to this
transaction, we recorded an overall loss of $&lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentRealizedGainLossOnDisposal_iN_pn5n6_di_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--RazorStockPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--RazorMember_zosQd1370lpe" title="Loss on disposal"&gt;27.2&lt;/span&gt; million. The operating results for Razor have been recorded in discontinued operations
of the accompanying unaudited condensed consolidated statements of operations for all periods presented, and we have reclassified their
assets and liabilities as held for sale for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Laboratory
equipment sold and held for sale&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 31, 2023, the Company entered into an agreement to sell laboratory equipment for $&lt;span id="xdx_908_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_pn5n6_c20230131__20230131__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_z18Xsr3O9IRb" title="Proceeds from sale of equipment"&gt;0.2&lt;/span&gt; million. As of June 30, 2023, the Company
classified the equipment not yet sold as held for sale in current assets in the unaudited condensed consolidated balance sheet, as all
the criteria of ASC subtopic 360-10, Property, Plant, and Equipment (&#x201c;ASC 360-10&#x201d;) have been met and the transaction was
qualified as assets held for sale. The balance included in current assets held for sale related to this transaction was $&lt;span id="xdx_906_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroupCurrent_iI_pn5n6_c20230630__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_zcw9dyVgiJhf" title="Assets held for sale"&gt;0.2&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2023, the Company entered into an agreement to auction equipment for $&lt;span id="xdx_909_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_pn5n6_c20230301__20230331__us-gaap--TypeOfArrangementAxis__custom--AuctionEquipmentAgreementMember_zw0lFlDJCEYl" title="Proceeds from sale of equipment"&gt;0.1&lt;/span&gt; million net proceeds. The auction was finalized on March
21, 2023, and the Company recorded a loss of $&lt;span id="xdx_90C_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pn5n6_c20230301__20230331__us-gaap--TypeOfArrangementAxis__custom--AuctionEquipmentAgreementMember_z5flXigqZRc3" title="Loss on disposal and held-for-sale assets"&gt;0.3&lt;/span&gt; million which is included in the loss on disposal and held-for-sale assets, on the
unaudited condensed consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 31, 2023, the Company entered into an agreement to sell laboratory equipment for $&lt;span id="xdx_90C_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_pn5n6_c20230331__20230331__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_zcV0ZQdbK0ad" title="Proceeds from sale of equipment"&gt;0.2&lt;/span&gt; million. As a result, the Company classified
the equipment as held for sale as current assets, in the unaudited condensed consolidated balance sheet, as all the criteria of ASC subtopic
360-10, Property, Plant, and Equipment (&#x201c;ASC 360-10&#x201d;) have been met and the transaction was qualified as assets held for
sale. This equipment was written down to its fair value, less cost to sell, to $&lt;span id="xdx_90E_eus-gaap--DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_pn5n6_c20230331__20230331__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_zqPlOSOvvYOe" title="Proceeds from sale of equipment"&gt;0.2&lt;/span&gt; million in the unaudited condensed consolidated balance
sheet. As a result of the expected sale, the Company recorded an impairment loss and loss on disposal of $&lt;span id="xdx_909_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn5n6_c20230331__20230331__us-gaap--TypeOfArrangementAxis__custom--LaboratoryEquipmentAgreementMember_zV3plvjPvVcg" title="Impairment loss"&gt;1.0&lt;/span&gt; million on held-for-sale
assets, in the unaudited condensed consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company classified its results of operations as discontinued operations for all periods presented in the accompanying unaudited condensed
consolidated statements of operations. We have retrospectively adjusted the amounts reported for the period ended June 30, 2022, in the
following table to give effect to such reporting of discontinued operations. For the period ended June 30, 2023, discontinued operations
reflect operating results of Razor up to the closing of the sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s unaudited condensed consolidated balance sheets and consolidated statements of operations report discontinued operations
separate from continuing operations. Our unaudited condensed consolidated statements of comprehensive loss, statements of shareholders&#x2019;
equity and statements of cash flows combined continuing and discontinued operations. A summary of financial information related to the
Company&#x2019;s discontinued operations is as follows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ONCOCYTE
CORPORATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zGdZMxHT2XY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents the results of the discontinued operation of Razor (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zxGaizYTg6zc"&gt;Schedule
of Discontinued Operations&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230401__20230630_z0gyMZVfHy8h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220401__20220630_zdqYEtBar4F8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20230630_zuBpcQRtcPfg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20220630_zYCwMq5QzTl3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_maILFDOz7EG_zskB8uCAfHda" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold; text-align: left; padding-left: 0pt"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2050"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,830&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;421&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,874&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_pn3n3_msILFDOz7EG_zXMm03wbM6zg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2055"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;507&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_pn3n3_msILFDOz7EG_zoOVqv17lnm4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2060"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;702&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_pn3n3_msILFDOz7EG_ztcBHCsHHzIf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Sales and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2065"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_pn3n3_msILFDOz7EG_zK53DyhlaqE2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2070"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax_pn3n3_msILFDOz7EG_zSQ2ie5pvEHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Loss from impairment of held for sale assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2075"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2076"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,311&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2078"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pn3n3_maNILziQi_mtILFDOz7EG_z5leA6WS1ql3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Net loss from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2080"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(6,936&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,926&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(13,814&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AE_zmJnvLI4Imul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hus-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zOQtzHOB0hf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents the carrying amounts of the held for sale related assets and liabilities as of June 30, 2023 and carrying
amounts of the held for sale related assets and liabilities of discontinued operations as of December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z5eSjrfdTnxh" style="display: none"&gt;Schedule
of Assets and Liabilities of Disposal Group Held for Sale&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230630__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zOzjMJC91CUk" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zDPDc331bJjh" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zo0L4cJtyTE7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_iB_zLWgqZ0u2nTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;CURRENT ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_z4rcUtCfq877" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2093"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,510&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_znknJj3nFopb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2096"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_iI_z03BhLjQQiia" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Machinery and equipment, net, and construction in progress&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2099"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_iI_zJJS9apEFwda" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2102"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_iI_ztiYQ2fmOHCe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Impairment of held for sale assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2105"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25,866&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--Assets_iTI_zjuNc9dwbuNg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;TOTAL ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,121&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zxlqfIG4mWg7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;LIABILITIES &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_zBjMqrQ9nRXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_iI_pn3n3_zpnkOBYVPVti" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2117"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_iI_zdWefBMn5567" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2120"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,265&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_iI_zibFh2pWp4lf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,005&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--Liabilities_iTI_zIjraUnT43Od" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;TOTAL LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;135&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,005&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes cash used related to Razor as of and for the six months ended June 30, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230630_zPeD0kFUQLb4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20220630_zFYgXi0vnvqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInDiscontinuedOperationsAbstract_iB_zQ4AOA5Y2PY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_i01_zbwC2PUjf0r1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Net cash used in operating activities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;(4,357&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;(10,549&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zIpX1ulQNjo2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;CASH FLOWS FROM INVESTING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_i01_zfXsAZWSjqc4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Net cash used in investing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2138"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(96&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zIiql2e3Nr1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-12-142022-12-15_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_DragonMember"
      decimals="INF"
      unitRef="Shares">3188181</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-12-15_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember_custom_DragonMember"
      decimals="INF"
      unitRef="Pure">0.70</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_custom_RazorMember_us-gaap_CommonStockMember_custom_DragonMember"
      decimals="INF"
      unitRef="Pure">0.70</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-162023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember"
      decimals="INF"
      unitRef="Shares">1366364</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember"
      decimals="INF"
      unitRef="Pure">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2023-02-16_custom_RazorStockPurchaseAgreementMember_custom_RazorMember_us-gaap_CommonStockMember_custom_DragonMember"
      decimals="INF"
      unitRef="Pure">0.70</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2023-02-162023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember26469671"
      decimals="0"
      unitRef="USD">115660</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="From2023-01-012023-03-31_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember"
      decimals="-5"
      unitRef="USD">-1300000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="From2022-01-012022-12-31_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember"
      decimals="-5"
      unitRef="USD">-27200000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-01-312023-01-31_custom_LaboratoryEquipmentAgreementMember"
      decimals="-5"
      unitRef="USD">200000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="AsOf2023-06-30_custom_LaboratoryEquipmentAgreementMember"
      decimals="-5"
      unitRef="USD">200000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-03-012023-03-31_custom_AuctionEquipmentAgreementMember"
      decimals="-5"
      unitRef="USD">100000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-03-012023-03-31_custom_AuctionEquipmentAgreementMember"
      decimals="-5"
      unitRef="USD">300000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-03-312023-03-31_custom_LaboratoryEquipmentAgreementMember"
      decimals="-5"
      unitRef="USD">200000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
      contextRef="From2023-03-312023-03-31_custom_LaboratoryEquipmentAgreementMember"
      decimals="-5"
      unitRef="USD">200000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2023-03-312023-03-31_custom_LaboratoryEquipmentAgreementMember"
      decimals="-5"
      unitRef="USD">1000000.0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_897_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zGdZMxHT2XY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents the results of the discontinued operation of Razor (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zxGaizYTg6zc"&gt;Schedule
of Discontinued Operations&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230401__20230630_z0gyMZVfHy8h" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220401__20220630_zdqYEtBar4F8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20230630_zuBpcQRtcPfg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20220630_zYCwMq5QzTl3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_pn3n3_maILFDOz7EG_zskB8uCAfHda" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold; text-align: left; padding-left: 0pt"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2050"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,830&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;421&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2,874&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_pn3n3_msILFDOz7EG_zXMm03wbM6zg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2055"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;507&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_pn3n3_msILFDOz7EG_zoOVqv17lnm4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2060"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;702&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing_pn3n3_msILFDOz7EG_ztcBHCsHHzIf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Sales and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2065"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_pn3n3_msILFDOz7EG_zK53DyhlaqE2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2070"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax_pn3n3_msILFDOz7EG_zSQ2ie5pvEHg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Loss from impairment of held for sale assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2075"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2076"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,311&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2078"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pn3n3_maNILziQi_mtILFDOz7EG_z5leA6WS1ql3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Net loss from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2080"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(6,936&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,926&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(13,814&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">1830000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">421000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">2874000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">2175000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">507000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">3999000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <OCX:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">3130000</OCX:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment>
    <OCX:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">702000</OCX:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment>
    <OCX:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">6251000</OCX:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment>
    <OCX:DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">3395000</OCX:DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing>
    <OCX:DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">498000</OCX:DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing>
    <OCX:DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">6366000</OCX:DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">66000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">329000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">72000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">1311000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2022-04-012022-06-30"
      decimals="-3"
      unitRef="USD">-6936000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-2926000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-13814000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="From2023-01-012023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember">&lt;p id="xdx_899_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hus-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zOQtzHOB0hf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table represents the carrying amounts of the held for sale related assets and liabilities as of June 30, 2023 and carrying
amounts of the held for sale related assets and liabilities of discontinued operations as of December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_z5eSjrfdTnxh" style="display: none"&gt;Schedule
of Assets and Liabilities of Disposal Group Held for Sale&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230630__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zOzjMJC91CUk" style="font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldforsaleMember_zDPDc331bJjh" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zo0L4cJtyTE7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_iB_zLWgqZ0u2nTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;CURRENT ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_z4rcUtCfq877" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 10pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2093"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,510&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_znknJj3nFopb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2096"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment_iI_z03BhLjQQiia" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Machinery and equipment, net, and construction in progress&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2099"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent_iI_zJJS9apEFwda" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Intangible assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2102"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales_iI_ztiYQ2fmOHCe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Impairment of held for sale assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2105"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25,866&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--Assets_iTI_zjuNc9dwbuNg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;TOTAL ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,121&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zxlqfIG4mWg7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;LIABILITIES &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_zBjMqrQ9nRXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedCompensation_iI_pn3n3_zpnkOBYVPVti" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Accrued compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2117"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities_iI_zdWefBMn5567" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2120"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,265&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_iI_zibFh2pWp4lf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,005&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--Liabilities_iTI_zIjraUnT43Od" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;TOTAL LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;135&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,005&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes cash used related to Razor as of and for the six months ended June 30, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230630_zPeD0kFUQLb4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20220630_zFYgXi0vnvqb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Six Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInDiscontinuedOperationsAbstract_iB_zQ4AOA5Y2PY9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_i01_zbwC2PUjf0r1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Net cash used in operating activities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;(4,357&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;(10,549&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zIpX1ulQNjo2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;CASH FLOWS FROM INVESTING ACTIVITIES:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_i01_zfXsAZWSjqc4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Net cash used in investing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2138"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(96&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">1510000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">346000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <OCX:DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment
      contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">211000</OCX:DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent
      contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">25920000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent>
    <OCX:DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales
      contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">-25866000</OCX:DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">2121000</us-gaap:Assets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">135000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">492000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <OCX:DisposalGroupIncludingDiscontinuedOperationAccruedCompensation
      contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">248000</OCX:DisposalGroupIncludingDiscontinuedOperationAccruedCompensation>
    <OCX:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities
      contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">1265000</OCX:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">135000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">2005000</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-06-30_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">135000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31_us-gaap_DiscontinuedOperationsHeldforsaleMember"
      decimals="-3"
      unitRef="USD">2005000</us-gaap:Liabilities>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="From2023-01-01to2023-06-30"
      decimals="-3"
      unitRef="USD">-4357000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-10549000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="From2022-01-012022-06-30"
      decimals="-3"
      unitRef="USD">-96000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-06-30">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_z3jEItIc8Rw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;17.
&lt;span id="xdx_82F_zBr8zJmCDqQa"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 24, 2023, the Company implemented a &lt;span id="xdx_90B_eus-gaap--StockholdersEquityReverseStockSplit_c20230723__20230724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlXf9FZENefa" title="Reverse stock split"&gt;1-for-20 reverse stock split&lt;/span&gt; of the outstanding shares of its common stock. The par value per
share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split.
All common stock share and per-share amounts for all periods presented in these condensed financial statements have been adjusted to
reflect the reverse stock split. The number of authorized shares of common stock remains at &lt;span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pn6n6_c20230724__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlNOOzxLrOdg" title="Common stock, shares authorized"&gt;230&lt;/span&gt; million shares.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-07-232023-07-24_us-gaap_SubsequentEventMember">1-for-20 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-07-24_us-gaap_SubsequentEventMember"
      decimals="-6"
      unitRef="Shares">230000000</us-gaap:CommonStockSharesAuthorized>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001176"
          xlink:label="Fact001176"
          xlink:type="locator"/>
        <link:footnote id="Footnote001187" xlink:label="Footnote001187" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indicates
    the maximum payable if the Milestone is achieved.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001176"
          xlink:to="Footnote001187"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001178"
          xlink:label="Fact001178"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001178"
          xlink:to="Footnote001187"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001180"
          xlink:label="Fact001180"
          xlink:type="locator"/>
        <link:footnote id="Footnote001188" xlink:label="Footnote001188" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As
    defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Pharma Services over their respective useful
    life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001180"
          xlink:to="Footnote001188"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001182"
          xlink:label="Fact001182"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001182"
          xlink:to="Footnote001188"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001252"
          xlink:label="Fact001252"
          xlink:type="locator"/>
        <link:footnote id="Footnote001275" xlink:label="Footnote001275" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See
    Note 3 for information on the Insight Merger.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001252"
          xlink:to="Footnote001275"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001254"
          xlink:label="Fact001254"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001254"
          xlink:to="Footnote001275"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001256"
          xlink:label="Fact001256"
          xlink:type="locator"/>
        <link:footnote id="Footnote001276" xlink:label="Footnote001276" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See
    Note 3 for information on the Chronix Merger.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001256"
          xlink:to="Footnote001276"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001258"
          xlink:label="Fact001258"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001258"
          xlink:to="Footnote001276"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001268"
          xlink:label="Fact001268"
          xlink:type="locator"/>
        <link:footnote id="Footnote001277" xlink:label="Footnote001277" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amortization
    of intangible assets is included in &#x201c;Cost of revenues &#x2013; amortization of acquired intangibles&#x201d; on the condensed
    consolidated statements of operations because the intangible assets pertain directly to the revenues generated from the acquired
    intangibles.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001268"
          xlink:to="Footnote001277"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001270"
          xlink:label="Fact001270"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001270"
          xlink:to="Footnote001277"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001556"
          xlink:label="Fact001556"
          xlink:type="locator"/>
        <link:footnote id="Footnote001577" xlink:label="Footnote001577" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Less
    than 10%</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001556"
          xlink:to="Footnote001577"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001560"
          xlink:label="Fact001560"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001560"
          xlink:to="Footnote001577"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001562"
          xlink:label="Fact001562"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001562"
          xlink:to="Footnote001577"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1564"
          xlink:label="xdx2ixbrl1564"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1564"
          xlink:to="Footnote001577"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1568"
          xlink:label="xdx2ixbrl1568"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1568"
          xlink:to="Footnote001577"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001570"
          xlink:label="Fact001570"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001570"
          xlink:to="Footnote001577"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001651"
          xlink:label="Fact001651"
          xlink:type="locator"/>
        <link:footnote id="Footnote001676" xlink:label="Footnote001676" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Oncocyte
    recorded certain right-of-use assets and liabilities for operating leases in accordance with ASC 842 (see Note 10).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001651"
          xlink:to="Footnote001676"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001652"
          xlink:label="Fact001652"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001652"
          xlink:to="Footnote001676"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M%SP2REX YZ=2FNV._8%JB7KX'U!+ P04    " !+A@I7LM8@O(@'  #T(
M&    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;+5::W/;MA+]*QC5TVEGE(@
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M<>!#,$>#!1 ,>TZO(0N2VHB2;QC18#J]0O[H\\@/'OPI&CSX:# <3H+9:/R
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M8/?5ZEFJ$CK*<1TU0P.HKD55VPO%PK1AMX/6II>:3>]1,IC&A.XO(2& 8P6
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M:&5E=#8N>&ULS5UM<]LV$OXK'+73:V>B2 1?)*:V9Q*)F.;F<I>QF]Z'F_M
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M?'=RI/(NM*Z*@R%!96OYJS]%.WS)@%D<,&.Y92&6\CO=ZI?/O5LK3V]C-OK
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M4D<NS7&WG3"^/?!]3@0+X[TX:K0JHB!Z2M3SOM5ZHU*L]* Z5K^N;$E829E
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MEY6N7E)-;>1)96M;=8A:6T0$';I=Q*$X\Y9U']HPE$%YCO()OR,*-6_@/6Z
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M^QFKQMFZP^[P?AU>:29V[NJ6A/K.7I95U995ZQAH1=5T!%%38@A@0*<MNH6
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M T:0F!-TOMLZ8W',(7J2E?:FV[HZT6H^ ZB!.TUBK#<%N=GB;(Y#(8%ZCC
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M>+'*: \I'>],-IJ:3,:6^$FQ,,SH-4V'Q4-D%-^MY8/Z2'9TG_LF^\S]0#<
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MY?[.K'Z6C3]3UA>;W(7_M*K73L<=BBOG3=$( T&A='T5#PT/&P+'@R<$1HW
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M"QH/0S(@)=CRO+0JI^$TO,,7^%'*4.+Y8S?@O(02H1\I@]6 SP*%TE1:$S,
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M6?<UELR&W>/7[$M<H=)"LFV:?E+]P?@0O\&0<!E-C^APUYUZ=K]D2[/Q:]S
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MOSP%6]2P@IMFHO"W"YS:=[L[#Y%,ZI:L%<BCY'A (]T$#5+ ;().W>B"/6'
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M965T,3,N>&ULM5EM<]LV$O[.7X%1ZXXS(\LB]>J\>,8O:9O,M?7$2?OAYCY
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ME&/)S;.+=HDT)F:G7!).'ZR#<1SYDXSU+[TL"@Z(D,8 5= .X:+AN/@%G-Q
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M6;<-Z D%A5[8U]+AU5A\7:FZKY*H9KTE1^0I,,M!@XPUBK>:!XS\"@PV878
MH;BHU]>JU"MC"D)S*ME+ VMAJ[I;\[4!3]<T-_VH8N><M[C5D'XI-QHP5ULV
M<?30-T)\!BW+45+/22&2A@QSM,6P.Q?BQ2AMZ<HR\X4QT0\HLHE%#Y%BAB)=
M[8=]D;6P\'X.0HOR#28*?V6"0**]7I=Z,5"75W2OWXZ9A#;TYR=* [7H^L:4
M-]0Z\9AI3C-&V!14QM2[ Y!H2IG<1]#\8A%>DHT3SY5MUZ').T:,%HYG/?#"
M:7]#A^ *'>8A?HR*]7!N&I+TGLLM"R51(N>XG0LF!9%DV,1.TK=??D#DO<'S
MY9!DL)!GBLY+V3<T"6^I;Y:;6,*SPA%;#3CZ0(,V7_NAB=+J9GA%(PL<QIU<
MWS1WC2=89[M&W(E,L@DWI+L@(1=N32+^"_3-MSC.CCBOE:D"1N0).&#DC9<1
MCNAEK=%O2A:[T(N%XE3)<Z"'&CYZW]9\'CL"ZN3:^4]0FRXX_!D>=:PJJ=]M
MPBP(^GG+:,'7)W2/11=[ P5M==0J+F=_="0@5VMSX./".T4@PA;K1V J;VEN
M%;IJPIY?X_"'%>_8NT*L13*C'<2U5(%8#X<\RDNX2(=:9,2 <QY!&5"-0!,)
M1':AYVRL*4>4> NP7_,4DW [L.VG]8$@6(MBN'%VL5L;I]/O/+<M51/IK("R
M#,J0]Q"\\M;F<NM]S1A14Z%;)EFASPB1+.F@&P/H 1GL0 K:D)BH7-;=L&&G
MD8[3D& C3@D97YW4(:K(@>#5DGVUV:QQ! 78#JD<<$+?412@7,A!S"Y!Y0\9
MDA%0BL!Q26TSE<C=>@>/Q3-W+)HL!*UGS @<XQ,4T,JZN\5(!SAN /-BZ?,R
MF.,UWBF\7A!>/+I:25N5K$8_*-;5G#7L;\Z"#M%@KJ5E5"''(2!6V_<18):#
MLA!\N[!]Z9#0$1T=E ..C,'0$(H"=F]M^T4/C&VH7: D1,H#";/8U7VAY;(V
M^#[G9931!@Z1A)5/$K)TW1BOYX(N9!8T O*7J(%1Y@1678<4L9:$L\)2D4R&
M-.M-]QE\^JJ"D*:DGY6TR?R?;@2ZP1DU;M\4(]L=,/E!'!DCF<$L9.[3>M>K
MDG #GPA#N]U0Z7$B*;>R(7S<$V')')=6J/I&6U.'UK64MQ%RB%M=4^I4?L#.
M%R,^9W6J 3WO\Z/.63)VEAT-!'<P:-@0I/FFYX0O#3J"8688+MU]Z QEV(K^
M'67INE59?]TK%TV Z 0)0UVG[992V*%S=),V@L$(H'JC2A/:1?H)!>P(89EM
M=IP2+^K!A#:+]TR;4/IZN3[+/[#CJC'Y-4&$'P;V/VT(SLT&=ZGO>QCT1+=_
M%!!O*"-D^$-X.O<62^ENF0QR'QSXQ!\#?&[INM'#)Q0%2R%_;>Z-W-B]!%<C
MLBB[D<(\;@ *4VJUJ1=MB=*M[$98NSB,F*X]6J=0R05_XM/]=<OCNNQC,/PJ
M(N _EP+.5P),ZY8*L=!BAOL,DL!)&EH/\\S<FFMEGQ4*W]H!\B5W? 2RK .B
MDDJ;G- [>H!4T\W6_RQ'84BX$QZ]WV3K) T-O(<)N6W/X4N3;1$]\G?CXW3N
MT[=XZ9"CRQC13ME5+\)%WMP[*-]2FOBFTOIF8^''"+$%CENZCB)+2ZU*7JN>
ML;\$+*%A2AL.%->46GS"K-!U4$L>2MQQ]I-V@'CO=(,AOJ>EZB&U+K]:8$Y%
M,Y/[ #SY41"C17??[V+O'IM%@"#Z5BXJURBEN7_GZK_4E6YV(["OKON6%Q6B
M##"Q5<+M=B3QUFU!E]C=O"+[IJ+1*O(\@YJ^BSSGR<+R7IW%MH&[\\3G0E.\
M560E<]]L:^X[N+J9S<;BOA_N'22_NZR47?*O2[D(J1O_$\SX-OZ ]<+_;K-?
M[G_]^D':)1FH5 MLG8Q/C_=\$=(]-&;-O^*<FZ8Q%7]<*31UEA;@>_IM4/=
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M;F%$JTH&'*@\X5PI#<I=&]"+G@ZCCX..AB$*,YBC](4ABG=.%]_@\P*'Z"R
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M<4T"N+]4RE8/9*!^=QO^ U!+ P04    " !+A@I7?3F J50#  #D!P  &0
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M+'4%/\RI#:-V!K2_5<H>)BY U]CG/P%02P,$%     @ 2X8*5X2:A5TF#
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M3!CU($9<UDOP*W'^K,VUR2U%IAS))PLB[RWX/R78\O;OA*@P(C/%$BMRY4>
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MWSN;'/E36O/@3,E?:^?&.9/SSY5"M58T >,+8USS0!NTG^\O_@M02P,$%
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M7$$$N+\60F\?2$!]R77]-U!+ P04    " !+A@I7K%IGH#L"   "!0  &0
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M*0/(VWC:,5FW91 >CO?TS[%V7\N".[PQ\J<HJ9JP2P8E+GDCZ<%LON"NGO/
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M5K6&51P._1<A(RYW,&FE#?+(8QCR-7P^$:H1(I3[ FYJ/#?5P%K@5 "7P $
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M!Z#B+3D?D\60")MQJ">Q=AM;?E%%B&,TXCBH0-7P?M>![?CA2<=)BAPF01@
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ML-HJM.5$$ M)S3/4"BO%@J6TUHS\7J8RO8?BIE@E%2I,20DJ"U09/CX(%8)
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M=R=#OW-W'*,)SY+V) EGK)3PP=D0YXO]NL6D!(_ QWJ3*YI YF98_E++?<S
M+F?7&?5<AR2N-_8([)%10$:N%V+;#R/GY$$*;PE=P5O9:%'?&[6V]8=)T_+Z
M24OKL&^M;3!_'&<&M>UU5]PJ.!U!!QZE-L T87>IJ#&E[89DJ]1V\?A7PR9.
M4W1DU>Q=0]!C%/HD&HY)'(V<B_DG34:XI7G S2]PD*-8?I/ (\DP6OT[3Z5]
M1&+\M4<:WPW]"#?-),!V,L2VE_QO3GA,@9W;ZV#CD@0*XI6]"M+$?MXW]R5=
M;W?;-&LN6=;3FZLJ.&=><7"Z8$M8ZO5'<&)2S?5/\V)D9:]<%M(86=AFSB@0
M'2? ^%*"3]H7%-#=P4W_ 5!+ P04    " !+A@I7+9@3Y^D$  #U#P  &0
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M)(&45<+<R?6OL#5H9/%B*;3[)>OZ;(0:XTH;F6^%<9[SHOYGCUM'M 0F](!
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MO%>XS+,"3NG.J*VP50%>/6G9[]UPK!0C,7\"\I8$_HA2]S\8TM9>2 8^Q9W
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M@Z]$-\SP70[*'L#]5$JSFU@%S4M_^A=02P,$%     @ 2X8*5WMM_I(6!
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MHME5^NK@6ZT:J+@A \MER^4.W/'WR3-P 5GZ^C%[06F43++ E?]G6:KRR6)
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M4!"8\;61V>M4(N/VNI7^UO@.OJRH8A<B^\03G9[U1CV2L#6M,KT0#^]9XT^
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M[>N>/X?]<^/<UO;</*UI%%TN(^OBXV)Q>;TD[9:JM$$"%NQKQ>]!&"+1MM7
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M&AXL9IG""Y%))(#[M1"ZW:""[LTY^1-02P,$%     @ 2X8*5VB3Q__)&P
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MU7Q4"U M1+4(U6)42U M1;6,TII959<3F"#E!,1*[[Q!RPE,NI830+O54<U
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MQ24V/I'OA>4GBJ^SW:$Y5XK'V>$*: A"/X#W%YRKMQ/MH-R1'/\'4$L#!!0
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MH7(#8YGDY2>YJ]8]/.Z1>)UKF=;!9@M2D57?[+X^$!L!WO") +\.\'<-".J
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MF*8B.^C('A1?F:W_C"LL^<WM$F@(0AM@_YRC OF#'J X;AK]#U!+ P04
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MGR3Y\R]E@<<D_6V[.S?_#U!+ P04    " !+A@I7ZQ:@'[T#  "X#0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6S%5VV/VC@0_BNC7%6UTBUY <*R
MA4C MKV>NNIJ5]W[4-T'0P:P<.*<[<#R[\]V0C;0;-KN(=T7B)V9Q\\SSHS'
MHQT7&[E&5/"8L%2.G;52V97KRL4:$R([/,-4OUERD1"EAV+ERDP@B:U3PMS
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M0!_%HK@F% /%,]MIS[G2?;M]7.NK%0ICH-\O.5>'@5F@NJQ%_P)02P,$%
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MB-1'*YK^4)1O$:U*)$JT%#_G4NV-5%P^^IRGXZ^G-ZHP)^0V72B%9[S0R-M
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M?M>S<H^L/!'TH#>!-E0(FNG#/> $F#*0U[>4BO.)FJ#>J0S^ U!+ P04
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MTB$/W2YBSR<NP )/QXSN$5/6DJ:^Y+.?>\OY(IDJE(5@\BF1?F*ZD)47[Q)
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M)3R5YA?M*EG/04DA%<\J,##(*"O_XY?*$4< ,-0.""I < ;H#BX P@H0_EM
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M$DV45Y#R1?'<#.5+KF#$-X];N+81H07@^YJ#==6+WJ"^"([_!E!+ P04
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MQ14HYZ[O>8&;LTPXX:@:NU7A2):&9P)O%>@RSYGZ,T$NUV.GYVP&[K)E:NR
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M!!UUU=]G(T/3ZO=K:]<*=ZHRHV8'] ._0*PP'A>,Q\<S;G2L,VD2&9.MVR3
MN-FZAL,:?ROXJ?R;@$-O9*:/W=*ANO])@)2F%@WRY/W*/1G7GDIS>PFGRF#
M]-UAOT6( ZN.CWA\T:)''_7XRG.VUI+SMR*?S-^ .7);U@$NO3*V.L<VTV)D
M[34JZ#=<FAWN9-(FR&$+Y]+.8KL+?1V&NV27O7 M0=811OHMS$C:;U1PWG?K
M9L4.>#)K Z9_X RKM$M[BKOUI[AI4)NWNR/KF1,W6.)@T,*[-*C8[E!G62-[
M<E$?84KM2"?3;2)B[+;0+>TFMOO-#T7K?I+Q,UP<,FX/=.HM\VPM-Z*J2ND9
ML=5!/>\U)<\YL$Z)3FV@ 1$/V\B7_@[;#=Y7O;4GNQUYD,^Y-2 &:K^SU$$
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MQR'+/M!D!X)N]1>(>RH$3?3/#9 E,'6!/+^BDEU^H "*SV33?P%02P,$%
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M62N[KI3%'<H^EOP"#:,!BJ-XB+X\WJ+7K]Z\#!.:9)N,XR;CV,4==L2]!Z4
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M.%034$VB-#W/NNJZ9ZZN#Z[_F9W1>6'WKTU9L]ED?\Z ]AI!-0K5&%3C4$U
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MM !*"VO:_EV.Y^A_YB0;05N-4313$*TIZ]I=V1--$3NEMPI&QW[!E7=Y6,Q
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M%$TZ+/HV@1\$9A:3EL5DD,5;R#&5LXH&C?$VD>K,K6]J)B2#6F<@F?1G$G2
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M/NO!WLN)^W"]$?F)_G22XC59$O$UO6/RJ%^K!&%,$A[2!##R>-:;P5,/.7E
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MRHZQ<D>S/! T+?;X'J@0-"Y^;@@.",MOD-<?*14O!WD#];[R]#]02P,$%
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M=9R_RQY<5F_0I/!F62S*G^2A7E<;D-E:Y%E2!\L>)%%:_::?ZG_$5H ^?B;
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MJ.9!-1^J!5 M1&GMC#2:C#3^^P%8V86]$QFIF5#-@FHV5'.@F@O5/*CF0[4
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !+A@I73>^WB:$%  "W+
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M?=&4Y2G<NZPAWA1/YVZ?S@P?_P=02P,$%     @ 2X8*5\A<P5(@ @  T"<
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M[01Z.^KM!'H[ZNT$>OMDLYM ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0.]
MO8- [T"]@T#O0+V#0.] O8- [T"]@T#OF'RL)- [4.\@T#M0[R#0.U#O(- [
M4.\@T#NCWIE [XQZ9P*],^J="?3.J'<FT#NCWIE [XQZ9P*]\^1G$P*],^J=
MOU/O.GX>2KWV?*WQ^=])]7B^MUP??UE^G9RP<\$YW5;4Y[]02P,$%     @
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $N&"E?>E MY[0   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $N&
M"E>97)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 2X8*5VV**66T!0  KAX  !@
M ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $N&
M"E>RUB"\B <  /0@   8              " @?8-  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !+A@I7\RFI(L,#  !%#@  &
M        @(&T%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ 2X8*5RRW_,-V"   8BH  !@              ("!K1D  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( $N&"E<,.VK]#P,  +\)   8
M              " @5DB  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !+A@I7(RB;,)P+  " 9P  &               @(&>)0  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 2X8*5XZ$(1',"
M=B@  !@              ("!<#$  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( $N&"E?A(SCPK1$  +DO   8              " @7(Z
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !+A@I7C! 3
M5 4I  #6@P  &               @(%53   >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ 2X8*5^ZS49;P"@  A2   !D
M ("!D'4  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !+
MA@I7,-RWDEL&   U#P  &0              @(&W@   >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( $N&"E<1K62$OPH  )@;   9
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M970Q-BYX;6Q02P$"% ,4    " !+A@I7Z$I_<_T/  #B*P  &0
M    @('LJ   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M $N&"E>R<TYIL@,  &((   9              " @2"Y  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ 2X8*5X%]0Z7/!0  0@T  !D
M             ("!";T  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !+A@I7"DCV1+4%  #'#0  &0              @($/PP  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $N&"E=].8"I5 ,
M .0'   9              " @?O(  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ 2X8*5X2:A5TF#   RA\  !D              ("!
MALP  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !+A@I7
MVMW9SF\'  #P$@  &0              @('CV   >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( $N&"E>L6F>@.P(   (%   9
M      " @8G@  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ 2X8*5V^;_<>)*@  -Y   !D              ("!^^(  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !+A@I7&_5$4T4&  "/$P
M&0              @(&[#0$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( $N&"E<MF!/GZ00  /4/   9              " @3<4 0!X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 2X8*5WMM_I(6
M!   3 H  !D              ("!5QD! 'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !+A@I7K*\9]CP&  #,$@  &0
M@(&D'0$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( $N&
M"E>CB=T(^ ,  ( ,   9              " @1<D 0!X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ 2X8*5\U<POME P  TP@  !D
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M=#,U+GAM;%!+ 0(4 Q0    ( $N&"E>#"2#JN@(  'D'   9
M  " @?]7 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M2X8*5\B,6IY?!@  JB8  !D              ("!\%H! 'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " !+A@I7=>%\92\%  "='   &0
M            @(&&80$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( $N&"E>>4M457P0  )T2   9              " @>QF 0!X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 2X8*5RHA34^= P
M"@X  !D              ("!@FL! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " !+A@I7414-!N@&  ":0@  &0              @(%6
M;P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $N&"E>Q
MJ>LSH@0  'H2   9              " @75V 0!X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ 2X8*5^HR@TU0 @  A 4  !D
M     ("!3GL! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $N&"E=1"6[_S@0  *<?   9              "
M@0.B 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ 2X8*
M5Q:K!GR?"@  _&H  !D              ("!"*<! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " !+A@I7L-)FJD\$   @&   &0
M        @('>L0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( $N&"E>8BAI8S@,  +44   9              " @62V 0!X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ 2X8*5ZZJU5Z/!   OAP
M !D              ("!:;H! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " !+A@I7:MB8<R<$   4#@  &0              @($OOP$
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( $N&"E?54[>U
MO (   @(   9              " @8W# 0!X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ 2X8*5WL(V,K+ @  =0<  !D
M ("!@,8! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !+
MA@I7>(9X96\%   R&P  &0              @(&"R0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( $N&"E=A[;W(?P,  .\,   9
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M970V,2YX;6Q02P$"% ,4    " !+A@I7F,.CPS,"  #1!   &0
M    @($S] $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (
M $N&"E=U\I&EQ10  .HA 0 9              " @9WV 0!X;"]W;W)K<VAE
M971S+W-H965T-C,N>&UL4$L! A0#%     @ 2X8*5]JTB.33 P  RPX  !D
M             ("!F0L" 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"
M% ,4    " !+A@I7L(GT:IX%  !C'@  &0              @(&C#P( >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( $N&"E</NP[ .P@
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( $N&"E=-[[>)H04  +<L   /
M      "  3<E @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !+A@I7R%S!
M4B "  #0)P  &@              @ $%*P( >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !+A@I7XB$R0O$!   9)P  $P
M    @ %=+0( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     2P!+ (04  !_
%+P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>339</ContextCount>
  <ElementCount>400</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>125</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/StatementsOfShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization, Description of the Business and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity</Role>
      <ShortName>Organization, Description of the Business and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Intangible Assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Disaggregation of Revenues and Concentration Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk</Role>
      <ShortName>Disaggregation of Revenues and Concentration Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress</Role>
      <ShortName>Right-of-use assets, machinery and equipment, net, and construction in progress</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Workforce Reduction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/WorkforceReduction</Role>
      <ShortName>Workforce Reduction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Loan Payable to Silicon Valley Bank</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/LoanPayableToSiliconValleyBank</Role>
      <ShortName>Loan Payable to Silicon Valley Bank</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Co-Development Agreement with Life Technologies Corporation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation</Role>
      <ShortName>Co-Development Agreement with Life Technologies Corporation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Equity Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/EquityOfferings</Role>
      <ShortName>Equity Offerings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Assets Held for Sale and Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperations</Role>
      <ShortName>Assets Held for Sale and Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/BusinessCombinations</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Intangible Assets, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/IntangibleAssetsNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/Stock-basedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Disaggregation of Revenues and Concentration Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables</Role>
      <ShortName>Disaggregation of Revenues and Concentration Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables</Role>
      <ShortName>Right-of-use assets, machinery and equipment, net, and construction in progress (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Assets Held for Sale and Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables</Role>
      <ShortName>Assets Held for Sale and Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperations</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Organization, Description of the Business and Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative</Role>
      <ShortName>Organization, Description of the Business and Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails</Role>
      <ShortName>Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Fair Value of Contingent Consideration Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails</Role>
      <ShortName>Schedule of Fair Value of Contingent Consideration Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Schedule of Contingent Consideration, Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails</Role>
      <ShortName>Schedule of Contingent Consideration, Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Business Combinations (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/BusinessCombinationsDetailsNarrative</Role>
      <ShortName>Business Combinations (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/BusinessCombinationsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails</Role>
      <ShortName>Schedule of Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Intangible Assets Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails</Role>
      <ShortName>Schedule of Intangible Assets Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Intangible Assets, net (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative</Role>
      <ShortName>Intangible Assets, net (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Shareholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ShareholdersEquityDetailsNarrative</Role>
      <ShortName>Shareholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/ShareholdersEquity</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails</Role>
      <ShortName>Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SummaryOfStockOptionActivityDetails</Role>
      <ShortName>Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails</Role>
      <ShortName>Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Schedule of Consolidated Revenues Attributable to Products or Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails</Role>
      <ShortName>Schedule of Consolidated Revenues Attributable to Products or Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails</Role>
      <ShortName>Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails</Role>
      <ShortName>Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative</Role>
      <ShortName>Right-of-use assets, machinery and equipment, net, and construction in progress (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails</Role>
      <ShortName>Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails</Role>
      <ShortName>Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails</Role>
      <ShortName>Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Workforce Reduction (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/WorkforceReductionDetailsNarrative</Role>
      <ShortName>Workforce Reduction (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/WorkforceReduction</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/RelatedPartyTransactions</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Loan Payable to Silicon Valley Bank (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative</Role>
      <ShortName>Loan Payable to Silicon Valley Bank (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/LoanPayableToSiliconValleyBank</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Co-Development Agreement with Life Technologies Corporation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative</Role>
      <ShortName>Co-Development Agreement with Life Technologies Corporation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Equity Offerings (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/EquityOfferingsDetailsNarrative</Role>
      <ShortName>Equity Offerings (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/EquityOfferings</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - Schedule of Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails</Role>
      <ShortName>Schedule of Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - Schedule of Assets and Liabilities of Disposal Group Held for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails</Role>
      <ShortName>Schedule of Assets and Liabilities of Disposal Group Held for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - Assets Held for Sale and Discontinued Operations (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative</Role>
      <ShortName>Assets Held for Sale and Discontinued Operations (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oncocyte.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://oncocyte.com/role/SubsequentEvents</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="form10-q.htm">form10-q.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ocx-20230630.xsd</File>
    <File>ocx-20230630_cal.xml</File>
    <File>ocx-20230630_def.xml</File>
    <File>ocx-20230630_lab.xml</File>
    <File>ocx-20230630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1100">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1100,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "contextCount": 339,
   "dts": {
    "calculationLink": {
     "local": [
      "ocx-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ocx-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ocx-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ocx-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ocx-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 665,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 169,
    "http://oncocyte.com/20230630": 43,
    "http://xbrl.sec.gov/dei/2023": 4,
    "total": 216
   },
   "keyCustom": 81,
   "keyStandard": 319,
   "memberCustom": 85,
   "memberStandard": 29,
   "nsprefix": "OCX",
   "nsuri": "http://oncocyte.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://oncocyte.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Business Combinations",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://oncocyte.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Intangible Assets, net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://oncocyte.com/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Shareholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://oncocyte.com/role/ShareholdersEquity",
     "shortName": "Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://oncocyte.com/role/Stock-basedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Disaggregation of Revenues and Concentration Risk",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk",
     "shortName": "Disaggregation of Revenues and Concentration Risk",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://oncocyte.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress",
     "shortName": "Right-of-use assets, machinery and equipment, net, and construction in progress",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://oncocyte.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OCX:WorkforceReductionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Workforce Reduction",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://oncocyte.com/role/WorkforceReduction",
     "shortName": "Workforce Reduction",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OCX:WorkforceReductionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://oncocyte.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://oncocyte.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Loan Payable to Silicon Valley Bank",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://oncocyte.com/role/LoanPayableToSiliconValleyBank",
     "shortName": "Loan Payable to Silicon Valley Bank",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OCX:CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Co-Development Agreement with Life Technologies Corporation",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation",
     "shortName": "Co-Development Agreement with Life Technologies Corporation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OCX:CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OCX:AprilTwentyTwentyTwoOfferingsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Equity Offerings",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://oncocyte.com/role/EquityOfferings",
     "shortName": "Equity Offerings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OCX:AprilTwentyTwentyTwoOfferingsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Assets Held for Sale and Discontinued Operations",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperations",
     "shortName": "Assets Held for Sale and Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://oncocyte.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "25",
     "role": "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "OCX:BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "OCX:BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Business Combinations (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://oncocyte.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Intangible Assets, net (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://oncocyte.com/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://oncocyte.com/role/Stock-basedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://oncocyte.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Disaggregation of Revenues and Concentration Risk (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables",
     "shortName": "Disaggregation of Revenues and Concentration Risk (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables",
     "shortName": "Right-of-use assets, machinery and equipment, net, and construction in progress (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OCX:ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://oncocyte.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OCX:ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Assets Held for Sale and Discontinued Operations (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables",
     "shortName": "Assets Held for Sale and Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Organization, Description of the Business and Liquidity (Details Narrative)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
     "shortName": "Organization, Description of the Business and Liquidity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012023-06-30_custom_BTIGLLCMember",
      "decimals": "-4",
      "lang": null,
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "OCX:BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails",
     "shortName": "Schedule of Fair Value Measurement of Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "OCX:BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Schedule of Cash and Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails",
     "shortName": "Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInAssetsHeldForSale",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DiscontinuedOperationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "OCX:ContingentConsiderationLiabilityContractualValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Schedule of Fair Value of Contingent Consideration Liability (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails",
     "shortName": "Schedule of Fair Value of Contingent Consideration Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "OCX:ContingentConsiderationLiabilityContractualValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://oncocyte.com/role/StatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Schedule of Contingent Consideration, Measured at Fair Value (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails",
     "shortName": "Schedule of Contingent Consideration, Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OCX:ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_custom_InsightMergerMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "OCX:FairValueOfContingentConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Business Combinations (Details Narrative)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
     "shortName": "Business Combinations (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "OCX:FairValueOfContingentConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Schedule of Goodwill and Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails",
     "shortName": "Schedule of Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Schedule of Intangible Assets Future Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails",
     "shortName": "Schedule of Intangible Assets Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Intangible Assets, net (Details Narrative)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative",
     "shortName": "Intangible Assets, net (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Shareholders\u2019 Equity (Details Narrative)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
     "shortName": "Shareholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockNoParValue",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails",
     "shortName": "Schedule of Assumptions Used to Calculate Fair Value of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-06-30_custom_MarketBasedAwardsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_custom_TwoThousandTenPlanActivityMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails",
     "shortName": "Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-12-31_custom_TwoThousandTenPlanActivityMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - Summary of Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails",
     "shortName": "Summary of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30_us-gaap_EmployeeStockOptionMember_custom_CostOfRevenuesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-07-012022-07-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://oncocyte.com/role/StatementsOfComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OCX:ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails",
     "shortName": "Schedule of Consolidated Revenues Generated by Unaffiliated Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30_custom_PharmaServicesCompanyAMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OCX:ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - Schedule of Consolidated Revenues Attributable to Products or Services (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
     "shortName": "Schedule of Consolidated Revenues Attributable to Products or Services (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OCX:ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30_custom_PharmaServicesMember_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OCX:ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails",
     "shortName": "Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30_country_US_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails",
     "shortName": "Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - Right-of-use assets, machinery and equipment, net, and construction in progress (Details Narrative)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative",
     "shortName": "Right-of-use assets, machinery and equipment, net, and construction in progress (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OCX:ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails",
     "shortName": "Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OCX:ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails",
     "shortName": "Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OCX:ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30_custom_OperatingAndFinancingLeasesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OCX:ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails",
     "shortName": "Schedule of Future Minimum Lease Commitments for Operating and Financing Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OCX:ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "OCX:WorkforceReductionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-06-30_custom_ExecutiveOfficersMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "OCX:WorkforceReductionTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-04-012023-06-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - Workforce Reduction (Details Narrative)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://oncocyte.com/role/WorkforceReductionDetailsNarrative",
     "shortName": "Workforce Reduction (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://oncocyte.com/role/StatementsOfShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - Related Party Transactions (Details Narrative)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "Related Party Transactions (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-06-30_custom_ArnoMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - Loan Payable to Silicon Valley Bank (Details Narrative)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
     "shortName": "Loan Payable to Silicon Valley Bank (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "OCX:CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-06-30_custom_LifeTechnologiesCorporationMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - Co-Development Agreement with Life Technologies Corporation (Details Narrative)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative",
     "shortName": "Co-Development Agreement with Life Technologies Corporation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "OCX:CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-012023-06-30_custom_LifeTechnologiesCorporationMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - Equity Offerings (Details Narrative)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
     "shortName": "Equity Offerings (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:ConversionOfStockDescription",
       "span",
       "span",
       "p",
       "OCX:AprilTwentyTwentyTwoOfferingsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-122022-04-13",
      "decimals": "INF",
      "lang": null,
      "name": "OCX:PercentageOfIssuedAndOutstandingShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - Schedule of Discontinued Operations (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails",
     "shortName": "Schedule of Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-04-012022-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - Schedule of Assets and Liabilities of Disposal Group Held for Sale (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails",
     "shortName": "Schedule of Assets and Liabilities of Disposal Group Held for Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000066 - Disclosure - Assets Held for Sale and Discontinued Operations (Details Narrative)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
     "shortName": "Assets Held for Sale and Discontinued Operations (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-02-162023-02-16_custom_RazorStockPurchaseAgreementMember_us-gaap_CommonStockMember_custom_RazorMember26469671",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000067 - Disclosure - Subsequent Events (Details Narrative)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://oncocyte.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "Subsequent Events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://oncocyte.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Organization, Description of the Business and Liquidity",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity",
     "shortName": "Organization, Description of the Business and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2023-01-01to2023-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 125,
   "tag": {
    "OCX_AVMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVM [Member]",
        "label": "AVM [Member]"
       }
      }
     },
     "localname": "AVMMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_AccountingForSharesOfCommonStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting For Shares OfCommon Stock [PolicyTextBlock]",
        "label": "Accounting for Lineage and AgeX shares of common stock"
       }
      }
     },
     "localname": "AccountingForSharesOfCommonStockPolicyTextBlock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OCX_AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Severance And Liabilities From Chronix Biomedical Acquisition.",
        "label": "Accrued severance and liabilities from Chronix Biomedical acquisition"
       }
      }
     },
     "localname": "AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_AccruedSeveranceFromAcquisitionCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued severance from acquisition current.",
        "label": "Accrued severance from acquisition"
       }
      }
     },
     "localname": "AccruedSeveranceFromAcquisitionCurrent",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_AmendedLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Loan Agreement [Member]",
        "label": "Amended Loan Agreement [Member]"
       }
      }
     },
     "localname": "AmendedLoanAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_AprilTwentyTwentyTwoOfferingsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "April twenty twenty two offerings[TextBlock]",
        "label": "AprilTwentyTwentyTwoOfferingsTextBlock",
        "verboseLabel": "Equity Offerings"
       }
      }
     },
     "localname": "AprilTwentyTwentyTwoOfferingsTextBlock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OCX_AprilTwoThousandTwentyTwoWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "April 2022 Warrants [Member]",
        "label": "April 2022 Warrants [Member]"
       }
      }
     },
     "localname": "AprilTwoThousandTwentyTwoWarrantsMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_ArnoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arno [Member]",
        "label": "Arno [Member]"
       }
      }
     },
     "localname": "ArnoMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_AtTheMarketSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Sales Agreement [Member]",
        "label": "At The Market Sales Agreement [Member]"
       }
      }
     },
     "localname": "AtTheMarketSalesAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_AuctionEquipmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auction Equipment Agreement [Member]",
        "label": "Auction Equipment Agreement [Member]"
       }
      }
     },
     "localname": "AuctionEquipmentAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_BTIGLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BTIG, LLC [Member]",
        "label": "BTIG, LLC [Member]"
       }
      }
     },
     "localname": "BTIGLLCMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_BankWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank Warrant [Member]",
        "label": "Bank Warrant [Member]"
       }
      }
     },
     "localname": "BankWarrantMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_BoardMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board Members [Member]",
        "label": "Board Members [Member]"
       }
      }
     },
     "localname": "BoardMembersMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_BroadwoodCapitalLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broadwood Capital LP [Member]",
        "label": "Broadwood Capital LP [Member]"
       }
      }
     },
     "localname": "BroadwoodCapitalLPMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_BroadwoodPartnersLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broadwood Partners LP [Member]",
        "label": "Broadwood Partners LP [Member]"
       }
      }
     },
     "localname": "BroadwoodPartnersLPMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in estimated fair value.",
        "label": "Change in estimated fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAsset",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations and Fair Value Measurements [Policy Text Block]",
        "label": "Business combinations and fair value measurements"
       }
      }
     },
     "localname": "BusinessCombinationsAndFairValueMeasurementsPolicyTextBlock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OCX_CapitalLeaseAgreementImputedAnnualInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to annual interest rate on capital lease agreement.",
        "label": "Interest rate on lease agreement"
       }
      }
     },
     "localname": "CapitalLeaseAgreementImputedAnnualInterestRate",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OCX_ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of Series A redeemable convertible preferred stock second tranche obligation.",
        "label": "Change in fair value of Series A redeemable convertible preferred stock second tranche obligation"
       }
      }
     },
     "localname": "ChangeInFairValueOfSeriesRedeemableConvertiblePreferredStockSecondTrancheObligation",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_ChronixBiomedicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chronix Biomedical Inc [Member]",
        "label": "Chronix Biomedical Inc [Member]"
       }
      }
     },
     "localname": "ChronixBiomedicalIncMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_ChronixEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chronix Equity [Member]",
        "label": "Chronix Equity [Member]"
       }
      }
     },
     "localname": "ChronixEquityMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_ChronixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chronix [Member]",
        "label": "Chronix [Member]"
       }
      }
     },
     "localname": "ChronixMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_ChronixMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chronix Merger [Member]",
        "label": "Chronix Merger [Member]"
       }
      }
     },
     "localname": "ChronixMergerMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsTables",
      "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_ChronixMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chronix Milestone [Member]",
        "label": "Chronix Milestone [Member]"
       }
      }
     },
     "localname": "ChronixMilestoneMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_ClinicalTrialExpenseReserveAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial expense reserve amount.",
        "label": "Clinical trial expense reserve amount"
       }
      }
     },
     "localname": "ClinicalTrialExpenseReserveAmount",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co development agreementwith life technologies corporation [TextBlock]",
        "label": "Co-Development Agreement with Life Technologies Corporation"
       }
      }
     },
     "localname": "CoDevelopmentAgreementwithLifeTechnologiesCorporationTextBlock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OCX_CommonStockSharesHeldAsAvailableForSaleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury) held by the entity as available for sale securities.",
        "label": "Common stock, shares held as available for sale securities"
       }
      }
     },
     "localname": "CommonStockSharesHeldAsAvailableForSaleSecurities",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability.",
        "label": "Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability"
       }
      }
     },
     "localname": "ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_ContingentConsiderationLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Liabilities [Member]",
        "label": "Contingent Consideration Liabilities [Member]"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilitiesMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_ContingentConsiderationLiabilityContractualValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability Contractual value.",
        "label": "Contractual Value"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityContractualValue",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_ConversionPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion price percentage.",
        "label": "Conversion price percentage"
       }
      }
     },
     "localname": "ConversionPricePercentage",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OCX_CostOfRevenuesAmortizationOfAcquiredIntangibles": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of revenues &amp;#8211; amortization of acquired intangibles.",
        "label": "Cost of revenues \u2013 amortization of acquired intangibles"
       }
      }
     },
     "localname": "CostOfRevenuesAmortizationOfAcquiredIntangibles",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_CostOfRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Of Revenues [Member]"
       }
      }
     },
     "localname": "CostOfRevenuesMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_DeemedDividendOnPreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend on preferred stock.",
        "label": "DeemedDividendOnPreferredStock",
        "negatedLabel": "Deemed dividend on Series A redeemable convertible preferred stock"
       }
      }
     },
     "localname": "DeemedDividendOnPreferredStock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_DeemedDividendOnSeriesRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend on Series A redeemable convertible preferred stock.",
        "label": "Deemed dividend on Series A redeemable convertible preferred stock"
       }
      }
     },
     "localname": "DeemedDividendOnSeriesRedeemableConvertiblePreferredStock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_DetermaCNIAndVitaGraftMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DetermaCNI and VitaGraft [Member]",
        "label": "DetermaCNI and VitaGraft [Member]"
       }
      }
     },
     "localname": "DetermaCNIAndVitaGraftMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_DetermaCNIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Determa CNI [Member]",
        "label": "Determa CNI [Member]"
       }
      }
     },
     "localname": "DetermaCNIMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_DetermaIOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DetermaI O [Member]",
        "label": "DetermaIO [Member]"
       }
      }
     },
     "localname": "DetermaIOMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_DetermaRxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Determa Rx [Member]",
        "label": "DetermaRx [Member]"
       }
      }
     },
     "localname": "DetermaRxMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_DetermalOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Determal O [Member]",
        "label": "Determal O [Member]"
       }
      }
     },
     "localname": "DetermalOMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_DevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Agreement [Member]",
        "label": "Development Agreement [Member]"
       }
      }
     },
     "localname": "DevelopmentAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_DilutedEquityOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diluted equity outstanding.",
        "label": "Diluted equity outstanding"
       }
      }
     },
     "localname": "DilutedEquityOutstanding",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Co-development Agreement With Life Technologies Corporation"
       }
      }
     },
     "localname": "DisclosureCodevelopmentAgreementWithLifeTechnologiesCorporationAbstract",
     "nsuri": "http://oncocyte.com/20230630",
     "xbrltype": "stringItemType"
    },
    "OCX_DisclosureEquityOfferingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offerings"
       }
      }
     },
     "localname": "DisclosureEquityOfferingsAbstract",
     "nsuri": "http://oncocyte.com/20230630",
     "xbrltype": "stringItemType"
    },
    "OCX_DisclosureWorkforceReductionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Workforce Reduction"
       }
      }
     },
     "localname": "DisclosureWorkforceReductionAbstract",
     "nsuri": "http://oncocyte.com/20230630",
     "xbrltype": "stringItemType"
    },
    "OCX_DiscontinuedOperationsDetermaRxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued Operations Determa Rx [Member]",
        "label": "Discontinued Operations Determa Rx [Member]"
       }
      }
     },
     "localname": "DiscontinuedOperationsDetermaRxMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails",
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_DiscontinuedOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued Operations [Member]",
        "label": "Discontinued Operations [Member]"
       }
      }
     },
     "localname": "DiscontinuedOperationsMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_DiscontinuedOperationsOutsideUnitedStatesLicensingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations Outside United States Licensing [Member]"
       }
      }
     },
     "localname": "DiscontinuedOperationsOutsideUnitedStatesLicensingMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_DisposalGroupIncludingDiscontinuedOperationAccruedCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation accrued compensation.",
        "label": "DisposalGroupIncludingDiscontinuedOperationAccruedCompensation",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedCompensation",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation accrued expenses other current liabilities.",
        "label": "DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedExpensesOtherCurrentLiabilities",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation impairment of held for sale assets.",
        "label": "Impairment of held for sale assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationImpairmentOfHeldForSales",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation machinery and equipment.",
        "label": "DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment",
        "verboseLabel": "Machinery and equipment, net, and construction in progress"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationMachineryAndEquipment",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation research and development.",
        "label": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation sales and marketing.",
        "label": "DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing",
        "verboseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationSalesAndMarketing",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_DividendOnPreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend on Series A redeemable convertible preferred stock.",
        "label": "Dividend on Series A redeemable convertible preferred stock"
       }
      }
     },
     "localname": "DividendOnPreferredStock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends and Accretion of Series A Redeemable Convertible Preferred Stock.",
        "label": "LESS: DIVIDENDS AND ACCRETION OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK"
       }
      }
     },
     "localname": "DividendsAndAccretionOfSeriesARedeemableConvertiblePreferredStock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_DividendsRatePerPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends rate per percentage.",
        "label": "Dividends rate"
       }
      }
     },
     "localname": "DividendsRatePerPercentage",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OCX_DragonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dragon [Member]",
        "label": "Dragon [Member]"
       }
      }
     },
     "localname": "DragonMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_DragonScientificLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dragon Scientific LLC [Member]",
        "label": "Dragon Scientific LLC [Member]"
       }
      }
     },
     "localname": "DragonScientificLLCMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_EarnoutPercentageOnCollectionsForSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout percentage on collections for sale.",
        "label": "Gross proceeds percentage"
       }
      }
     },
     "localname": "EarnoutPercentageOnCollectionsForSale",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OCX_EarnoutPercentageOnCollectionsForSaleOrLicense": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout percentage on collections for sale or license.",
        "label": "Earnout percentage on collections for sale or license"
       }
      }
     },
     "localname": "EarnoutPercentageOnCollectionsForSaleOrLicense",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OCX_EarnoutPercentageOnCollectionsForSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout percentage on collections for sales.",
        "label": "Earnout percentage on collections for sales"
       }
      }
     },
     "localname": "EarnoutPercentageOnCollectionsForSales",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OCX_ExecutiveOfficersAndEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Officers and Employees [Member]",
        "label": "Executive Officers and Employees [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficersAndEmployeesMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_ExecutiveOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Officers [Member]",
        "label": "Executive Officers [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficersMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_FairValueOfContingentConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of contingent consideration.",
        "label": "Fair value"
       }
      }
     },
     "localname": "FairValueOfContingentConsideration",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of Series A redeemable convertible preferred stock second tranche obligation.",
        "label": "FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares",
        "negatedLabel": "Financing costs to issue redeemable convertible Series A preferred shares"
       }
      }
     },
     "localname": "FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_FirstTenCalendarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Ten Calendar [Member]",
        "label": "First Ten Calendar [Member]"
       }
      }
     },
     "localname": "FirstTenCalendarMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_HalleSpecialSituationsFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Halle Special Situations Fund L L C [Member]"
       }
      }
     },
     "localname": "HalleSpecialSituationsFundLLCMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_IndebtednessExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indebtedness expenses.",
        "label": "Indebtedness expenses"
       }
      }
     },
     "localname": "IndebtednessExpenses",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_InsightMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insight Merger [Member]",
        "label": "Insight Merger [Member]"
       }
      }
     },
     "localname": "InsightMergerMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsTables",
      "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_InterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest [Member]",
        "label": "Interest [Member]"
       }
      }
     },
     "localname": "InterestMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_InvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investors [Member]",
        "label": "Investors [Member]"
       }
      }
     },
     "localname": "InvestorsMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_LaboratoryEquipmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment Agreement [Member]",
        "label": "Laboratory Equipment Agreement [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_LandlordMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Landlord [Member]",
        "label": "Landlord [Member]"
       }
      }
     },
     "localname": "LandlordMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_LeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Agreement [Member]",
        "label": "Lease Agreement [Member]"
       }
      }
     },
     "localname": "LeaseAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_LifeTechnologiesCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Life Technologies Corporation [Member]",
        "label": "Life Technologies Corporation [Member]"
       }
      }
     },
     "localname": "LifeTechnologiesCorporationMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_LineageAndAgeXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lineage and AgeX [Member]",
        "label": "Lineage and AgeX [Member]"
       }
      }
     },
     "localname": "LineageAndAgeXMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_LoanDeferralAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Deferral Agreement [Member]",
        "label": "Loan Deferral Agreement [Member]"
       }
      }
     },
     "localname": "LoanDeferralAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_MachineryAndEquipmentNetAndConstructionInProgress": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Machinery and equipment net and construction in progress.",
        "label": "Machinery and equipment, net, and construction in progress"
       }
      }
     },
     "localname": "MachineryAndEquipmentNetAndConstructionInProgress",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_MarketBasedAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market Based Awards [Member]",
        "label": "Market Based Awards [Member]"
       }
      }
     },
     "localname": "MarketBasedAwardsMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_MarketableEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Equity Securities [Member]",
        "label": "Marketable Equity Securities [Member]"
       }
      }
     },
     "localname": "MarketableEquitySecuritiesMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare for DetermaRx and Medicare Advantage for DetermaRx [Member]",
        "label": "Medicare for DetermaRx and Medicare Advantage for DetermaRx [Member]"
       }
      }
     },
     "localname": "MedicareforDetermaRxandMedicareAdvantageforDetermaRxMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_MergerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger Agreement [Member]",
        "label": "Merger Agreement [Member]"
       }
      }
     },
     "localname": "MergerAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone 1 [Member]",
        "label": "Milestone 1 [Member]"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone 3 [Member]",
        "label": "Milestone 3 [Member]"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone 2 [Member]",
        "label": "Milestone 2 [Member]"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_MonteCarloValuationTechniqueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monte Carlo Valuation Technique [Member]",
        "label": "Monte Carlo Valuation Technique [Member]"
       }
      }
     },
     "localname": "MonteCarloValuationTechniqueMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_MonthlyRentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly Rent [Member]",
        "label": "Monthly Rent [Member]"
       }
      }
     },
     "localname": "MonthlyRentMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_MrGutfreundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Gutfreund [Member]"
       }
      }
     },
     "localname": "MrGutfreundMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_ObligatedToPayExpensesAndTaxesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligated to pay expenses and taxes percentage.",
        "label": "Obligated to pay expenses and taxes percentage"
       }
      }
     },
     "localname": "ObligatedToPayExpensesAndTaxesPercentage",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OCX_OfficeLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Lease Agreement [Member]",
        "label": "Office Lease Agreement [Member]"
       }
      }
     },
     "localname": "OfficeLeaseAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_OncocyteCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncocyte Corp [Member]",
        "label": "Oncocyte Corp [Member]"
       }
      }
     },
     "localname": "OncocyteCorpMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_OperatingAndFinancingLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and Financing Leases [Member]",
        "label": "Operating and Financing Leases [Member]"
       }
      }
     },
     "localname": "OperatingAndFinancingLeasesMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_OtherInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Investors [Member]",
        "label": "Other Investors [Member]"
       }
      }
     },
     "localname": "OtherInvestorsMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_OutsideUnitedStatesPharmaServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outside United States Pharma Services [Member]"
       }
      }
     },
     "localname": "OutsideUnitedStatesPharmaServicesMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_PaymentForFinancingCostsForAtthemarketSales": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Financing Costs For Atthemarket Sales.",
        "label": "PaymentForFinancingCostsForAtthemarketSales",
        "negatedLabel": "Financing costs for at-the-market sales"
       }
      }
     },
     "localname": "PaymentForFinancingCostsForAtthemarketSales",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_PaymentObligationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment obligation amount.",
        "label": "Payment obligation amount."
       }
      }
     },
     "localname": "PaymentObligationAmount",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_PercentageForWarrantExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage for warrant exercise price per share.",
        "label": "Percentage for warrant exercise price per share"
       }
      }
     },
     "localname": "PercentageForWarrantExercisePricePerShare",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OCX_PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of administrative fee paid on original cost of equipment.",
        "label": "Percentage of administrative fee paid on original cost of equipment"
       }
      }
     },
     "localname": "PercentageOfAdiministrativeFeePaidOnOriginalCostOfEquipment",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OCX_PercentageOfIssuedAndOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Issued and Outstanding Shares.",
        "label": "Percentage of issued and outstanding shares"
       }
      }
     },
     "localname": "PercentageOfIssuedAndOutstandingShares",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OCX_PerformanceBasedOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Options [Member]",
        "label": "Performance-Based Options [Member]"
       }
      }
     },
     "localname": "PerformanceBasedOptionsMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_PharmaServicesCompanyAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharma Services Company A [Member]",
        "label": "Pharma Services Company A [Member]"
       }
      }
     },
     "localname": "PharmaServicesCompanyAMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_PharmaServicesCompanyBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharma Services Company B [Member]",
        "label": "Pharma Services Company B [Member]"
       }
      }
     },
     "localname": "PharmaServicesCompanyBMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_PharmaServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharma Services [Member]",
        "label": "Pharma Services [Member]"
       }
      }
     },
     "localname": "PharmaServicesMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_PreferredStockRemainsOutstandingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock remains outstanding percentage.",
        "label": "Preferred stock outstanding percentage"
       }
      }
     },
     "localname": "PreferredStockRemainsOutstandingPercentage",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OCX_PresentValueOfNetMinimumLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of net minimum lease payments.",
        "label": "Present value of net minimum lease payments",
        "totalLabel": "Present value of net minimum lease payments"
       }
      }
     },
     "localname": "PresentValueOfNetMinimumLeasePayments",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of common shares under At the market transactions.",
        "label": "Proceeds from sale of common shares under at-the-market transactions"
       }
      }
     },
     "localname": "ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_PuraVidaInvestmentsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pura Vida Investments LLC [Member]",
        "label": "Pura Vida Investments LLC [Member]"
       }
      }
     },
     "localname": "PuraVidaInvestmentsLLCMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_PuraVidaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pura Vida [Member]",
        "label": "Pura Vida [Member]"
       }
      }
     },
     "localname": "PuraVidaMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_PurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Price.",
        "label": "Purchase price"
       }
      }
     },
     "localname": "PurchasePrice",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "OCX_RazorGenomicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Razor Genomics, Inc. [Member]",
        "label": "Razor Genomics, Inc. [Member]"
       }
      }
     },
     "localname": "RazorGenomicsIncMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_RazorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Razor [Member]",
        "label": "Razor [Member]"
       }
      }
     },
     "localname": "RazorMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_RazorStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Razor Stock Purchase Agreement [Member]",
        "label": "Razor Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "RazorStockPurchaseAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered Direct Offering [Member]",
        "label": "Registered Direct Offering [Member]"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_RepaymentOfFinancingLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment Of Financing Lease Obligations.",
        "label": "RepaymentOfFinancingLeaseObligations",
        "negatedLabel": "Repayment of financing lease obligations"
       }
      }
     },
     "localname": "RepaymentOfFinancingLeaseObligations",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_RightOfUseAndFinancingLeaseLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use and financing lease liabilities, current.",
        "label": "Right-of-use and financing lease liabilities, current"
       }
      }
     },
     "localname": "RightOfUseAndFinancingLeaseLiabilitiesCurrent",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_RightOfUseAndFinancingLeaseLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use and financing lease liabilities, noncurrent.",
        "label": "Right-of-use and financing lease liabilities, noncurrent"
       }
      }
     },
     "localname": "RightOfUseAndFinancingLeaseLiabilitiesNoncurrent",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_RightofuseAssetsMachineryAndEquipmentContinuingOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use assets machinery and equipment continuing operations.",
        "label": "RightofuseAssetsMachineryAndEquipmentContinuingOperations",
        "verboseLabel": "Right-of-use assets, machinery and equipment, net, and construction in progress"
       }
      }
     },
     "localname": "RightofuseAssetsMachineryAndEquipmentContinuingOperations",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use Assets Machinery And Equipment Discontinuing Operations.",
        "label": "Right-of-use assets, machinery and equipment, net, and construction in progress from discontinuing operations"
       }
      }
     },
     "localname": "RightofuseAssetsMachineryAndEquipmentDiscontinuingOperations",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_RightofuseAssetsMachineryAndEquipmentNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets, machinery and equipment, net.",
        "label": "Right-of-use assets, machinery and equipment, net, and construction in progress [Default Label]",
        "verboseLabel": "Right-of-use assets, machinery and equipment, net, and construction in progress"
       }
      }
     },
     "localname": "RightofuseAssetsMachineryAndEquipmentNet",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_RoyaltyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty 1 [Member]",
        "label": "Royalty 1 [Member]"
       }
      }
     },
     "localname": "RoyaltyOneMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_RoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payments percentage.",
        "label": "Royalty payments"
       }
      }
     },
     "localname": "RoyaltyPaymentsPercentage",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OCX_RoyaltyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty 2 [Member]",
        "label": "Royalty 2 [Member]"
       }
      }
     },
     "localname": "RoyaltyTwoMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_SalesAndMarketingExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and Marketing Expenses [Policy Text Block]",
        "label": "Sales and marketing expenses"
       }
      }
     },
     "localname": "SalesAndMarketingExpensesPolicyTextBlock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OCX_ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of consolidated revenues attributable to products or services [TableTextBlock]",
        "label": "Schedule of Consolidated Revenues Attributable to Products or Services"
       }
      }
     },
     "localname": "ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesTableTextBlock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OCX_ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of contingent consideration measured at fair value [Table Text Block]",
        "label": "Schedule of Contingent Consideration, Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfContingentConsiderationMeasuredAtFairValueTableTextBlock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OCX_ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of future minimum lease commitments for operating and financing leases [Table Text Block]",
        "label": "Schedule of Future Minimum Lease Commitments for Operating and Financing Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesTableTextBlock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OCX_ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of operating and finance lease balance sheet [TableTextBlock]",
        "label": "Schedule of Supplemental Balance Sheet Information Related to Operating and Financing Leases"
       }
      }
     },
     "localname": "ScheduleOfOperatingAndFinanceLeaseBalanceSheetTableTextBlock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OCX_ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of operating and finance lease cash flow [TableTextBlock]",
        "label": "Schedule of Supplemental Cash Flow Information Related to Operating and Financing Lease"
       }
      }
     },
     "localname": "ScheduleOfOperatingAndFinanceLeaseCashFlowTableTextBlock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OCX_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_SecurityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security [Member]",
        "label": "Security [Member]"
       }
      }
     },
     "localname": "SecurityMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Redeemable Convertible Preferred Stock [Member]",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of RSUs Outstanding, option RSUs granted.",
        "label": "Number of RSUs Outstanding, option RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRSUs",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options performance restricted stock options forfeited.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited",
        "negatedLabel": "Number of Performance RSUs Outstanding, options forfeited, canceled and expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceRestrictedStockOptionsForfeited",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options restricted stock options forfeited.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited",
        "negatedLabel": "Number of RSUs Outstanding, options forfeited, canceled and expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockOptionsForfeited",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of RSUs Outstanding, option RSUs vested.",
        "label": "Number of RSUs Outstanding, option RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRSUs",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share based Payment Award Options Available Grants In Period Gross.",
        "label": "Shares available for grant options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableGrantsInPeriodGross",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options available restricted stock options grants in period gross.",
        "label": "Shares available for grant options RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsGrantsInPeriodGross",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options available restricted stock options vested in period.",
        "label": "Shares available for grant options RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAvailableRestrictedStockOptionsVestedInPeriod",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value.",
        "label": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award performance restricted stock units options forfeitures in period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod",
        "negatedLabel": "Number of options outstanding, options forfeited, performance RSUs cancelled and expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriod",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Options Outstanding, Option RSUs Granted.",
        "label": "Number of options outstanding, option RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsGrantsInPeriodGross",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based CompensationArrangement By Share Based Payment Award Restricted Stock Options Vested In Period",
        "label": "Number of options outstanding, option RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockOptionsVestedInPeriod",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award restricted stock units options forfeitures in period.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod",
        "negatedLabel": "Number of options outstanding, options forfeited, RSUs cancelled and expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriod",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Vesting Price.",
        "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice",
        "verboseLabel": "Weighted average exercise price, options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageVestingPrice",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award performance restricted stock units options forfeitures in period weighted average exercise price.",
        "label": "Weighted average exercise price, options forfeited, performance RSUs cancelled and expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardPerformanceRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award restricted stock grants in period weighted average exercise price.",
        "label": "Weighted average exercise price, option RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "OCX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangements by sharebased payment award restricted stock units options forfeitures in period weighted average exercise price.",
        "label": "Weighted average exercise price, options forfeited, RSUs cancelled and expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardRestrictedStockUnitsOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options nonvested performance restricted stock options forfeited number of shares.",
        "label": "Shares available for grant performance RSUs, cancelled and expired"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedPerformanceRestrictedStockOptionsForfeitedNumberOfShares",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award options nonvested restricted stock options forfeited number of shares.",
        "label": "Shares available for grant RSUs, cancelled and expired"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedRestrictedStockOptionsForfeitedNumberOfShares",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_StatedValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated Value.",
        "label": "Stated value"
       }
      }
     },
     "localname": "StatedValue",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "OCX_StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares stock options nonvested options forfeited.",
        "label": "StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited",
        "verboseLabel": "Shares available for grant options forfeited, cancelled and expired"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsNonvestedOptionsForfeited",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OCX_StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of Series A convertible preferred stock to redemption value.",
        "label": "Accretion of Series A convertible preferred stock to redemption value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_StockIssuedDuringPeriodValueVestingOfBonusAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value vesting of bonus awards.",
        "label": "Vesting of bonus awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueVestingOfBonusAwards",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OCX_SublicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense Agreement [Member]",
        "label": "Sublicense Agreement [Member]"
       }
      }
     },
     "localname": "SublicenseAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_TemporaryEquityNoParValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity no par value.",
        "label": "Temporary equity, no par value"
       }
      }
     },
     "localname": "TemporaryEquityNoParValue",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "OCX_TwoEqualTranchesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Equal Tranches [Member]",
        "label": "Two Equal Tranches [Member]"
       }
      }
     },
     "localname": "TwoEqualTranchesMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_TwoThousandEighteenIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Incentive Plan [Member]",
        "label": "2018 Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenIncentivePlanMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_TwoThousandEighteenPalnActivityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Paln Activity [Member]",
        "label": "2018 Paln Activity [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenPalnActivityMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_TwoThousandTenPlanActivityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2010 Plan Activity [Member]",
        "label": "2010 Plan Activity [Member]"
       }
      }
     },
     "localname": "TwoThousandTenPlanActivityMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationTables",
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_TwoThousandTenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2010 Stock Option Plan [Member]",
        "label": "2010 Stock Option Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTenStockOptionPlanMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_UnderwriterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriter [Member]",
        "label": "Underwriter [Member]"
       }
      }
     },
     "localname": "UnderwriterMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_UnderwritersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters [Member]",
        "label": "Underwriters [Member]"
       }
      }
     },
     "localname": "UnderwritersMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_UnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting Agreement [Member]",
        "label": "Underwriting Agreement [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_UnderwrittenOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Offering [Member]",
        "label": "Underwritten Offering [Member]"
       }
      }
     },
     "localname": "UnderwrittenOfferingMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_VariousAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various Agreements [Member]",
        "label": "Various Agreements [Member]"
       }
      }
     },
     "localname": "VariousAgreementsMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_VitaGraftMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vita Graft [Member]",
        "label": "Vita Graft [Member]"
       }
      }
     },
     "localname": "VitaGraftMember",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OCX_WorkforceReductionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workforce reduction [Text Block]",
        "label": "WorkforceReductionTextBlock",
        "verboseLabel": "Workforce Reduction"
       }
      }
     },
     "localname": "WorkforceReductionTextBlock",
     "nsuri": "http://oncocyte.com/20230630",
     "presentation": [
      "http://oncocyte.com/role/WorkforceReduction"
     ],
     "xbrltype": "textBlockItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r710",
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://oncocyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r240",
      "r434",
      "r435",
      "r436",
      "r437",
      "r482",
      "r651",
      "r764",
      "r767",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r240",
      "r434",
      "r435",
      "r436",
      "r437",
      "r482",
      "r651",
      "r764",
      "r767",
      "r768"
     ],
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [
      "r292",
      "r293",
      "r294"
     ],
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r375",
      "r490",
      "r525",
      "r561",
      "r562",
      "r620",
      "r623",
      "r627",
      "r628",
      "r630",
      "r652",
      "r653",
      "r664",
      "r668",
      "r681",
      "r687",
      "r769",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r375",
      "r490",
      "r525",
      "r561",
      "r562",
      "r620",
      "r623",
      "r627",
      "r628",
      "r630",
      "r652",
      "r653",
      "r664",
      "r668",
      "r681",
      "r687",
      "r769",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r285",
      "r494",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r655",
      "r669",
      "r686",
      "r729",
      "r762",
      "r763",
      "r772",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r285",
      "r494",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r655",
      "r669",
      "r686",
      "r729",
      "r762",
      "r763",
      "r772",
      "r819"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r368",
      "r375",
      "r403",
      "r404",
      "r405",
      "r489",
      "r490",
      "r525",
      "r561",
      "r562",
      "r620",
      "r623",
      "r627",
      "r628",
      "r630",
      "r652",
      "r653",
      "r664",
      "r668",
      "r681",
      "r687",
      "r690",
      "r760",
      "r769",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r368",
      "r375",
      "r403",
      "r404",
      "r405",
      "r489",
      "r490",
      "r525",
      "r561",
      "r562",
      "r620",
      "r623",
      "r627",
      "r628",
      "r630",
      "r652",
      "r653",
      "r664",
      "r668",
      "r681",
      "r687",
      "r690",
      "r760",
      "r769",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r254",
      "r376",
      "r720",
      "r751"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r292",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r286",
      "r287",
      "r558",
      "r559",
      "r560",
      "r622",
      "r625",
      "r629",
      "r632",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r656",
      "r670",
      "r690",
      "r772",
      "r819"
     ],
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r286",
      "r287",
      "r558",
      "r559",
      "r560",
      "r622",
      "r625",
      "r629",
      "r632",
      "r639",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r656",
      "r670",
      "r690",
      "r772",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r254",
      "r376",
      "r720",
      "r721",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r754",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r685"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net of allowance of $178 and $154, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableSale": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease from sale of accounts receivable.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableSale",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r74",
      "r207",
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r40",
      "r41",
      "r131",
      "r217",
      "r509",
      "r530",
      "r531"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r8",
      "r24",
      "r41",
      "r439",
      "r442",
      "r475",
      "r526",
      "r527",
      "r736",
      "r737",
      "r738",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expected value at the end of their useful life of a major finite-lived intangible asset class acquired during the period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Acquired intangible assets"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetResidualValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r126",
      "r685",
      "r821"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r407",
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total stock-based compensation expense",
        "verboseLabel": "Total compensation paid"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r218",
      "r291",
      "r298",
      "r300",
      "r302",
      "r817"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts receivable, allowance for credit loss"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r138",
      "r329",
      "r459",
      "r743"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r17",
      "r66",
      "r71"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r17",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r181",
      "r211",
      "r238",
      "r274",
      "r279",
      "r283",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r434",
      "r436",
      "r451",
      "r503",
      "r584",
      "r685",
      "r698",
      "r765",
      "r766",
      "r805"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets",
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets",
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r204",
      "r219",
      "r238",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r434",
      "r436",
      "r451",
      "r685",
      "r765",
      "r766",
      "r805"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "auth_ref": [
      "r158",
      "r685"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.",
        "label": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NONCURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r7",
      "r104",
      "r117",
      "r160",
      "r163",
      "r202",
      "r203"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Current assets of discontinuing operations"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r429",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/BusinessCombinationsTables",
      "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails",
      "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r91",
      "r92",
      "r429",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/BusinessCombinationsTables",
      "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails",
      "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/BusinessCombinationsTables",
      "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails",
      "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r2",
      "r3",
      "r23"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business combination consideration transferred",
        "verboseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r432",
      "r742"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows",
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r4",
      "r94",
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Fair Value on the Merger Date",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails",
      "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r5",
      "r94"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Accrued liabilities from acquisition"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r5",
      "r94"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r174",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r190",
      "r505",
      "r556",
      "r579",
      "r685",
      "r698",
      "r731"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash in hand"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r47",
      "r206",
      "r657"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r48",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r47",
      "r150",
      "r235"
     ],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Cash, cash equivalents and restricted cash shown in the statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {
     "auth_ref": [
      "r47",
      "r150",
      "r235"
     ],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash from discontinuing operations"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r47",
      "r150",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING",
        "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r6",
      "r150"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r116",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net cash used in investing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r116",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net cash used in operating activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r200",
      "r214",
      "r215",
      "r216",
      "r238",
      "r258",
      "r259",
      "r266",
      "r268",
      "r272",
      "r273",
      "r295",
      "r319",
      "r321",
      "r322",
      "r323",
      "r326",
      "r327",
      "r331",
      "r332",
      "r336",
      "r339",
      "r346",
      "r451",
      "r536",
      "r537",
      "r538",
      "r539",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r557",
      "r571",
      "r593",
      "r613",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r719",
      "r745",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r272",
      "r331",
      "r332",
      "r334",
      "r336",
      "r339",
      "r344",
      "r346",
      "r536",
      "r537",
      "r538",
      "r539",
      "r668",
      "r719",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrant exercise price per share",
        "terseLabel": "Warrant exercise price, per share",
        "verboseLabel": "Warrant exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Purchase of warrant",
        "terseLabel": "Warrant to purchase common stock",
        "verboseLabel": "Number of common stock purchase warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r100",
      "r504",
      "r570"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r313",
      "r314",
      "r641",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r688",
      "r689",
      "r690",
      "r692",
      "r693",
      "r694",
      "r695",
      "r748",
      "r749",
      "r800",
      "r820",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common stock, no par value"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r125",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r125",
      "r571",
      "r590",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r125",
      "r507",
      "r685"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, no par value, 230,000 shares authorized; 8,241 and 5,932 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r42",
      "r221",
      "r223",
      "r227",
      "r499",
      "r517"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r57",
      "r59",
      "r97",
      "r98",
      "r288",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails",
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r57",
      "r59",
      "r97",
      "r98",
      "r288",
      "r532",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails",
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r57",
      "r59",
      "r97",
      "r98",
      "r288",
      "r640",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails",
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r57",
      "r59",
      "r97",
      "r98",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration risk, percentage",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails",
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r57",
      "r59",
      "r97",
      "r98",
      "r288",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails",
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentLiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.",
        "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]",
        "verboseLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "ContingentLiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockDescription": {
     "auth_ref": [
      "r49",
      "r50",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of stock, description",
        "verboseLabel": "Conversion of stock description"
       }
      }
     },
     "localname": "ConversionOfStockDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r142",
      "r238",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r451",
      "r765"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "verboseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.",
        "label": "Debt instrument maturity date description"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt instrument, final payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r90",
      "r799"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r17",
      "r73"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r17",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopmentCosts": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas.",
        "label": "Development costs"
       }
      }
     },
     "localname": "DevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [
      "r366",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails",
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r366",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails",
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Schedule of Consolidated Revenues Generated by Unaffiliated Customers"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r377",
      "r380",
      "r408",
      "r409",
      "r410",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "auth_ref": [
      "r11",
      "r12",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations, Held-for-Sale [Member]"
       }
      }
     },
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables",
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "auth_ref": [
      "r20",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "verboseLabel": "Assets Held for Sale and Discontinued Operations"
       }
      }
     },
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables",
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables",
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "auth_ref": [
      "r7",
      "r104",
      "r117",
      "r160",
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r7",
      "r104",
      "r117",
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r115",
      "r203"
     ],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "verboseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r104",
      "r117",
      "r160",
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r104",
      "r117",
      "r160",
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r115",
      "r203"
     ],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "verboseLabel": "Net revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r310",
      "r743",
      "r759"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "negatedLabel": "Loss on disposal of discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": {
     "auth_ref": [
      "r17",
      "r18",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down",
        "verboseLabel": "Proceeds from sale of equipment"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Assets Held for Sale and Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r13",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, preferred stock"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r228",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r255",
      "r258",
      "r266",
      "r267",
      "r268",
      "r270",
      "r446",
      "r447",
      "r500",
      "r518",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share: basic",
        "verboseLabel": "Basic net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails",
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r228",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r258",
      "r266",
      "r267",
      "r268",
      "r270",
      "r446",
      "r447",
      "r500",
      "r518",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share: diluted",
        "verboseLabel": "Earnings Per Share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails",
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net loss per common share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r25",
      "r201",
      "r224",
      "r225",
      "r226",
      "r241",
      "r242",
      "r243",
      "r245",
      "r251",
      "r253",
      "r271",
      "r296",
      "r297",
      "r348",
      "r411",
      "r412",
      "r413",
      "r422",
      "r423",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r475",
      "r526",
      "r527",
      "r528",
      "r545",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the principal activities of an investee accounted for under the equity method.",
        "label": "Equity method investment, description of principal activities",
        "verboseLabel": "Equity method investment description"
       }
      }
     },
     "localname": "EquityMethodInvestmentDescriptionOfPrincipalActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity interest",
        "terseLabel": "Ownership percentage",
        "verboseLabel": "Outstanding equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [
      "r739",
      "r740",
      "r743"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "negatedLabel": "Loss on disposal"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r14",
      "r99",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Investments in capital stock of privately held companies"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r212",
      "r450",
      "r658"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Marketable equity securities",
        "terseLabel": "Fair value of equity securities",
        "verboseLabel": "Marketable equity securities fair value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets",
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r328",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r449",
      "r486",
      "r487",
      "r488",
      "r666",
      "r667",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails",
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r328",
      "r369",
      "r374",
      "r449",
      "r486",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r328",
      "r369",
      "r374",
      "r449",
      "r487",
      "r666",
      "r667",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r328",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r449",
      "r488",
      "r666",
      "r667",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails",
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r328",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r486",
      "r487",
      "r488",
      "r666",
      "r667",
      "r676",
      "r677",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails",
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r464",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Operating cash flows from financing leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r461",
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total financing lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails",
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Current liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Noncurrent liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r802"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less amounts representing interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r463",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Financing cash flows from financing leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Right-of-use and financing lease assets, net",
        "totalLabel": "Machinery and equipment, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets",
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r723",
      "r727"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r722"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "verboseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r470",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Financing lease"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r469",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term, Financing lease"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-lived intangible assets, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r209",
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r67",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r155",
      "r495"
     ],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfIntangibleAssetsFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r743"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on disposal and held for sale assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r743"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "negatedLabel": "Loss on disposal and held for sale assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Loss on disposal and held-for-sale assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r144",
      "r595"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r208",
      "r304",
      "r498",
      "r665",
      "r685",
      "r756",
      "r757"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r21",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r140",
      "r238",
      "r274",
      "r278",
      "r282",
      "r284",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r451",
      "r663",
      "r765"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r743",
      "r758"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment loss from intangible assets",
        "verboseLabel": "Impairment of intangible"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/IntangibleAssetsNetDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfCashFlows",
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r17",
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment loss"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r0",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r1",
      "r133",
      "r185",
      "r274",
      "r278",
      "r282",
      "r284",
      "r501",
      "r514",
      "r663"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "LOSS BEFORE INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r176",
      "r238",
      "r244",
      "r274",
      "r278",
      "r282",
      "r284",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r447",
      "r451",
      "r514",
      "r663",
      "r765"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r132",
      "r184",
      "r186",
      "r228",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r258",
      "r266",
      "r267",
      "r447",
      "r500",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss from continuing operations per share: basic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r132",
      "r228",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r258",
      "r266",
      "r267",
      "r268",
      "r447",
      "r500",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss from continuing operations per share: diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r119",
      "r203",
      "r426",
      "r515"
     ],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Loss from discontinuing operations",
        "totalLabel": "Net loss from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails",
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r134",
      "r228",
      "r259",
      "r266",
      "r267",
      "r815",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Net loss from discontinuing operations per share: basic"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r177",
      "r259",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Net loss from discontinuing operations per share: diluted"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale attributable to noncontrolling interest. Excludes discontinued operations.",
        "label": "Loss from impairment of held for sale assets"
       }
      }
     },
     "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsAttributableToNoncontrollingInterestBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r141",
      "r738"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Net loss attributable to Oncocyte Corporation"
       }
      }
     },
     "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables",
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r20",
      "r28",
      "r30",
      "r104",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r118",
      "r120",
      "r121",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables",
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r311",
      "r312",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r312",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r239",
      "r418",
      "r419",
      "r420",
      "r421",
      "r424",
      "r425",
      "r427",
      "r428",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAssetsHeldForSale": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in book value of long-lived assets that the reporting entity plans to sell within one year (or one business cycle).",
        "label": "Increase (decrease) in asset, held-for-sale",
        "negatedLabel": "Assets held for sale"
       }
      }
     },
     "localname": "IncreaseDecreaseInAssetsHeldForSale",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks).",
        "label": "Increase in fair value"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r728",
      "r742"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Intangible assets acquired IPR&amp;D"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r70",
      "r491",
      "r492",
      "r493",
      "r495",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Long-lived intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r65",
      "r69"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets",
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income (expenses), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r231",
      "r233",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory write down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r802"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less amounts representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r238",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r435",
      "r436",
      "r437",
      "r451",
      "r569",
      "r662",
      "r698",
      "r765",
      "r805",
      "r806"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets",
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r130",
      "r183",
      "r511",
      "r685",
      "r747",
      "r755",
      "r801"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY",
        "verboseLabel": "LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets",
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r205",
      "r238",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r435",
      "r436",
      "r437",
      "r451",
      "r685",
      "r765",
      "r805",
      "r806"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Total current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets",
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NONCURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r7",
      "r104",
      "r117",
      "r160",
      "r163",
      "r202",
      "r203"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Current liabilities of discontinuing operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r122",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of Credit, Current",
        "verboseLabel": "Line of credit, current"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Loan Payable to Silicon Valley Bank"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBank"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Unrealized gain (loss) on marketable equity securities",
        "negatedLabel": "Unrealized (gain) loss on marketable equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows",
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssetsAndLiabilitiesOfDisposalGroupHeldForSaleDetails",
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r150",
      "r151",
      "r152"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r135",
      "r152",
      "r187",
      "r203",
      "r220",
      "r222",
      "r226",
      "r238",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r252",
      "r253",
      "r264",
      "r274",
      "r278",
      "r282",
      "r284",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r447",
      "r451",
      "r516",
      "r592",
      "r611",
      "r612",
      "r663",
      "r696",
      "r765"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://oncocyte.com/role/StatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "NET LOSS",
        "terseLabel": "Net loss",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows",
      "http://oncocyte.com/role/StatementsOfComprehensiveLoss",
      "http://oncocyte.com/role/StatementsOfOperations",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r230",
      "r246",
      "r247",
      "r248",
      "r249",
      "r255",
      "r256",
      "r265",
      "r268",
      "r274",
      "r278",
      "r282",
      "r284",
      "r663"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS: BASIC",
        "verboseLabel": "Net loss attributable to common stockholders - Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails",
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r230",
      "r257",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS DILUTED",
        "verboseLabel": "Net income (loss) attributable to common stockholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails",
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expenses), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME (EXPENSES), NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r274",
      "r278",
      "r282",
      "r284",
      "r663"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfFutureMinimumLeaseCommitmentsForOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Right-of-use lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Right-of-use lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r465",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingAndFinancingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right-of-use assets",
        "verboseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails",
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r470",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r469",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term, Operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfSupplementalBalanceSheetInformationRelatedToOperatingAndFinancingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r102",
      "r175",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Description of the Business and Liquidity"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfComprehensiveLoss",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other income (expenses), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r43",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Total tenant improvement allowance"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for rent"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security.",
        "label": "Payments for Repurchase of Redeemable Convertible Preferred Stock",
        "negatedLabel": "Redemption of redeemable convertible Series A preferred shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Financing costs to issue common shares"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Construction in progress and purchases of furniture and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://oncocyte.com/role/Stock-basedCompensationTables",
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://oncocyte.com/role/Stock-basedCompensationTables",
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Conversion price",
        "verboseLabel": "Preferred stock, convertible, conversion price"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of preferred stock.",
        "label": "Preferred stock, convertible, shares issuable"
       }
      }
     },
     "localname": "PreferredStockConvertibleSharesIssuable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r332",
      "r621",
      "r624",
      "r626",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred stock, dividend rate, percentage"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [
      "r688",
      "r689",
      "r692",
      "r693",
      "r694",
      "r695",
      "r820",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNoParValue": {
     "auth_ref": [
      "r124",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, no par value",
        "verboseLabel": "Preferred stock no par value"
       }
      }
     },
     "localname": "PreferredStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r124",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock stated value per share",
        "verboseLabel": "Stated value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r124",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r124",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r124",
      "r571",
      "r590",
      "r822",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r124",
      "r506",
      "r685"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r735"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from issuance initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from sale of common shares",
        "terseLabel": "Net proceeds",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Gross proceeds, closing",
        "verboseLabel": "Proceeds from issuance of preferred stock and preference stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from sale of redeemable convertible Series A preferred shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of machinery and equipment.",
        "label": "Proceeds from sale of equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "verboseLabel": "Proceeds from sale of equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails",
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r157",
      "r194",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Right-of-use assets, machinery and equipment, net, and construction in progress"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgress"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r19",
      "r502",
      "r513",
      "r685"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Right-of-use assets, machinery and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfRight-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Right-of-use Assets, Machinery and Equipment, Net, and Construction in Progress"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Right-of-useAssetsMachineryAndEquipmentNetAndConstructionInProgressTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r229",
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemablePreferredStockDividends": {
     "auth_ref": [
      "r25",
      "r52",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.",
        "label": "Redeemable Preferred Stock Dividends",
        "negatedLabel": "Accretion of Series A redeemable convertible preferred stock"
       }
      }
     },
     "localname": "RedeemablePreferredStockDividends",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r479",
      "r480",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "auth_ref": [
      "r189",
      "r213",
      "r472",
      "r473",
      "r474",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.",
        "label": "Related party transaction, description"
       }
      }
     },
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r542",
      "r543",
      "r544",
      "r596",
      "r597",
      "r598",
      "r617",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of loan payable"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r46",
      "r746"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r101",
      "r417",
      "r813"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r731",
      "r744",
      "r814",
      "r816"
     ],
     "calculation": {
      "http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r191",
      "r732",
      "r744"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r127",
      "r171",
      "r510",
      "r529",
      "r531",
      "r540",
      "r572",
      "r685"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r201",
      "r241",
      "r242",
      "r243",
      "r245",
      "r251",
      "r253",
      "r296",
      "r297",
      "r411",
      "r412",
      "r413",
      "r422",
      "r423",
      "r438",
      "r440",
      "r441",
      "r443",
      "r445",
      "r526",
      "r528",
      "r545",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r285",
      "r286",
      "r288",
      "r365",
      "r366",
      "r494"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r199",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r199",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Disaggregation of Revenues and Concentration Risk"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRisk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Gross proceeds from offering",
        "verboseLabel": "Cash received on stock transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Fair value of common stock sold",
        "verboseLabel": "Sale of stock, shares"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r288",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesAttributableToProductsOrServicesDetails",
      "http://oncocyte.com/role/ScheduleOfConsolidatedRevenuesGeneratedByUnaffiliatedCustomersDetails",
      "http://oncocyte.com/role/ScheduleOfPercentageOfConsolidatedRevenuesAttributableToGeographicalLocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Fair Value of Contingent Consideration Liability"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r91",
      "r92",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/BusinessCombinationsTables",
      "http://oncocyte.com/role/ScheduleOfContingentConsiderationMeasuredAtFairValueDetails",
      "http://oncocyte.com/role/ScheduleOfFairValueOfContingentConsiderationLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r20",
      "r28",
      "r30",
      "r104",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r118",
      "r120",
      "r121",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Schedule of Assets and Liabilities of Disposal Group Held for Sale"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "auth_ref": [
      "r53",
      "r56",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.",
        "label": "Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value Measurement of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r67",
      "r70",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r63",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/DisaggregationOfRevenuesAndConcentrationRiskTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://oncocyte.com/role/Stock-basedCompensationTables",
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails",
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r26",
      "r27",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Assumptions Used to Calculate Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Assumptions Used to Calculate Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r169",
      "r170",
      "r171",
      "r214",
      "r215",
      "r216",
      "r272",
      "r331",
      "r332",
      "r334",
      "r336",
      "r339",
      "r344",
      "r346",
      "r536",
      "r537",
      "r538",
      "r539",
      "r668",
      "r719",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Intangible Assets Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r732"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "General and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r733",
      "r734",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r733",
      "r734",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance costs",
        "verboseLabel": "Employee severance"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://oncocyte.com/role/WorkforceReductionDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://oncocyte.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share based payment award vesting rights description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share based payment award description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Number of RSUs Outstanding, options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of RSUs Outstanding, option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of RSUs Outstanding, end of period",
        "periodStartLabel": "Number of RSUs Outstanding, beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility",
        "verboseLabel": "Expected Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rates"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://oncocyte.com/role/Stock-basedCompensationTables",
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails",
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options outstanding, options forfeited, cancelled and expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of options outstanding, option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Grant date fair value of awards granted during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options outstanding, end of period",
        "periodStartLabel": "Number of options outstanding, beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, outstanding end of period",
        "periodStartLabel": "Weighted average exercise price, options outstanding, beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative",
      "http://oncocyte.com/role/SummaryOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted average exercise price, options forfeited, cancelled and expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "periodEndLabel": "Number of options outstanding, exercisable, end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Vested percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfAssumptionsUsedToCalculateFairValueOfStockOptionsDetails",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Shares available for grant outstanding, end of period",
        "periodStartLabel": "Shares available for grant options, beginning of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Shares available for grant options forfeited, cancelled and expired"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Shares available for grant options exercised"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, exercisable, end of period"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r153",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r200",
      "r214",
      "r215",
      "r216",
      "r238",
      "r258",
      "r259",
      "r266",
      "r268",
      "r272",
      "r273",
      "r295",
      "r319",
      "r321",
      "r322",
      "r323",
      "r326",
      "r327",
      "r331",
      "r332",
      "r336",
      "r339",
      "r346",
      "r451",
      "r536",
      "r537",
      "r538",
      "r539",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r557",
      "r571",
      "r593",
      "r613",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r719",
      "r745",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r25",
      "r39",
      "r201",
      "r224",
      "r225",
      "r226",
      "r241",
      "r242",
      "r243",
      "r245",
      "r251",
      "r253",
      "r271",
      "r296",
      "r297",
      "r348",
      "r411",
      "r412",
      "r413",
      "r422",
      "r423",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r475",
      "r526",
      "r527",
      "r528",
      "r545",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r271",
      "r494",
      "r535",
      "r557",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r571",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r591",
      "r594",
      "r595",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r613",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BalanceSheetsParenthetical",
      "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative",
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r271",
      "r494",
      "r535",
      "r557",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r571",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r591",
      "r594",
      "r595",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r613",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BalanceSheetsParenthetical",
      "http://oncocyte.com/role/Co-developmentAgreementWithLifeTechnologiesCorporationDetailsNarrative",
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r25",
      "r79",
      "r124",
      "r125",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Issuance of Series A redeemable convertible preferred stock, net of financing costs, shares",
        "terseLabel": "Stock issued during period, shares, conversion of units",
        "verboseLabel": "Convertible preferred shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r25",
      "r124",
      "r125",
      "r171",
      "r536",
      "r613",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts, shares",
        "terseLabel": "Offering shares",
        "verboseLabel": "Purchase of warrant"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Sale of common shares, net of financing costs, shares",
        "verboseLabel": "Issuance of shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r25",
      "r124",
      "r125",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Shares issued upon vesting of RSU, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r124",
      "r125",
      "r171",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Number of options outstanding, option exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r25",
      "r39",
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Issuance of Series A redeemable convertible preferred stock, net of financing costs",
        "verboseLabel": "Stock issued during period, value conversion of units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r25",
      "r124",
      "r125",
      "r171",
      "r545",
      "r613",
      "r634",
      "r697"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts",
        "terseLabel": "Preferred stock offering",
        "verboseLabel": "Net proceeds"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Sale of common shares, net of financing costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r25",
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Shares issued upon vesting of RSU, net of shares retired to pay employees\u2019 taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Redemption of SeriesA redeemable convertible preferred stock, shares",
        "verboseLabel": "Number of stock redeem"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Redemption of Series A redeemable convertible preferred stock",
        "terseLabel": "Number of stock redeem value",
        "verboseLabel": "Net proceeds to immediately redeem"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r125",
      "r128",
      "r129",
      "r154",
      "r573",
      "r590",
      "r614",
      "r615",
      "r685",
      "r698",
      "r747",
      "r755",
      "r801",
      "r822"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets",
      "http://oncocyte.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r237",
      "r330",
      "r332",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r348",
      "r444",
      "r616",
      "r618",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [
      "r458",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r458",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r458",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r458",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r458",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r483",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r319",
      "r321",
      "r322",
      "r323",
      "r326",
      "r327",
      "r414",
      "r508"
     ],
     "calculation": {
      "http://oncocyte.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 and 6 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $5,140 and $6,091 as of June 30, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary equity, liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r29",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary equity, stated par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary equity, shares issued",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary equity, shares outstanding",
        "verboseLabel": "Number of shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BalanceSheetsParenthetical",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/AssetsHeldForSaleAndDiscontinuedOperationsDetailsNarrative",
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://oncocyte.com/role/BusinessCombinationsDetailsNarrative",
      "http://oncocyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfFairValueMeasurementOfFinancialAssetsAndLiabilitiesDetails",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative",
      "http://oncocyte.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r192",
      "r193",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/OrganizationDescriptionOfBusinessAndLiquidityDetailsNarrative",
      "http://oncocyte.com/role/ShareholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r688",
      "r689",
      "r692",
      "r693",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/EquityOfferingsDetailsNarrative",
      "http://oncocyte.com/role/LoanPayableToSiliconValleyBankDetailsNarrative",
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r257",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average shares outstanding: diluted",
        "verboseLabel": "Weighted average number of shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails",
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r255",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average shares outstanding: basic",
        "verboseLabel": "Weighted average number of shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://oncocyte.com/role/ScheduleOfCommonStockComputationOfDilutedNetLossPerShareOfCommonStockDetails",
      "http://oncocyte.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205-20/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.18)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org//360/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482309/360-10-15-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org//805/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(13)(b))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org//606/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.B)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350-30/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r699": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r701": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r702": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r703": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r704": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r705": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r706": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r707": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r708": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r709": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r711": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r712": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r713": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r714": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r715": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r716": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r717": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r718": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org//705/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001493152-23-027603-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-027603-xbrl.zip
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MDZO^]?6GN^[5X.;7][73FKN^Z_9ZQ?6+39SQR$ZPZ>F/+3)2.F*Z'BHA:&I
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M9TRS7 A:D7 C&$6W L?:"5AI4A8Z+5%N"OJI'%Q#!8L:?#2:EQU2O3,5<%;
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M]5AQ,D*MR^?'T@?*Y'-G?P-02P,$%     @ 2X8*5ZOLIF<R1P( ^U\:  P
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M>PKHR L'&&Y!%PX<-\6R<$#T@.A!@OZ1 ]!QI07A.RJ! 8TO-+_RC+Z=Z">
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MT C\?,//P;%C6[^L^88$;MF%6P9]/P*W[,(M@[X=@5MVX98AWRWD*;P$D#L
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M.=-H>9HNK3Z5[R$C[V_9A3#39TZT&NE8#RB;*=M+09[A-F-BYJTK M0 P=A
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MS%]_A1T:M[K$FR_1P3H/G18R$QA5C08-QJ?RT2 <C9FI!MZ_;](=]UK_(8Y
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M*&#2"F@E5(G6Y5[KG*(FJI:TJC6^WQ(MR[V6K:1,%"QQ!5,DF6A87C3,&LD
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MAO282(6WH42QC3I^S%T[,#=B%VVSA-FH+=[EO3Q5?W=_?;E[_'I9B6P2\AC
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M'V.")X*G8 &S,)NS1A7I!"V^2'CN1-6B9@0RL2;@C^@+ B\"KT#F"M5\ DW
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M6=L<R][\\QXRWDT&"F ?+QX M)[PV7,L.#O7*^Y8<ST4QS[SS)UOM \4$6
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MWNB*F]#W$X()P;DGV+,,D]-5^)2+BROA6>"!Q*OHI%&.4P"R:[TQJI(':F,
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MHWYU>5J&[X5&$_ZYKM::#:%^ACWZ;VZK%W#=Y7V5MO'?<P!\OE0/#\R>-C1
M43+^VN?=>!.>/YYO60N99/XQE<H\#M2,FGD<RY?=XNW-3ZEB8E>E81_V-:(7
M N^UA+1P)%1LR5YQ2W;[$@/5@0KH#3KIP77R"Q&PQ$'X?&<I!W]]6AW(_@34
MI^EPGZ^,'Q\S+U(SK="77>PQ(&-.*W78"9[B?S^EG:/)ELJ/7H&FTC.YS!L%
M\[3^/"V[%R@,2T9U6-B)KPED;V'#IO#HY3O_G?GVLY"I5MJ=8BBP2>\%;$X>
MO=R!XNBTG1Z\I7I_Y ^,-Z>/7MX-22]DDC^R/T@E'66\\9E<,S^'9D+NK +#
M_*>YMWIONMG3"1&NX>*>(51!7$BKK6&KBVW(;YLLU7>.252D3#YX)/\V5(F0
M22:BR@0BO^6]0Z)P.&64I4AT!<.^;#<^W6VQ!E\!.8_M+TV[C!_L_6#O2I7J
MO(F/CWVQ<EFK-\=W]<+C^%FZ.WUX?6FW;]KA%+ES SF;_<]2_)V<VCB-P?Q!
MZ?\L'@IF&>3_\34(S#;?_[/Q]*]=C$',9)8GS"\$R,P8MKV$<M@3"Y->:0L?
M#LJA#QB,X;R5>8"YTO(YCG[ ["UWW EE=;-'] EOK*OKC*:#(% K0UTG:GO4
MU$758(LIJQ+]2Z%-:,H21H[0MVMUHYD48./3RYMK8IZJ9B; -L9SU"7K:X0#
M<QU[P8=O36CSO0FFLQU!M/=C^-+1%F/N<IW1;\[3:D_RA^OAG/_V!>WJ VM3
M:\\]C0_=_Z&'*O>75PQ_I$./S)D'I86$1N$KN LB?>*1(O/P%*)\X&2^O+NH
M!]ALY49N/O9-EW[S=%X].VGH%^?I<.SS.9.??9GJ7CD:BV'G8ZJW)[+2^P1)
M&[84XDM)7_$I_G!^P;GMQOKWRH+U<0!A#61_1T<7NDMA=?4B/CK?5!>NGR)=
M6MX6)3Z\M>DN9.='\(07%PO$Q0+[ [(UB@7R<;% &,4"^;A8("X66+-8H! 7
M"[B*!1H79;!#ZU>GU=O&__V_8CI5^")4?]Q=-G_M.2"V6#00O0*!S&,JE;4*
M! I*7C^1\N?Y;^F-"P1H(6E/4T"0&/\G#C0#L.7/4#9'^U$GX#=;U8E7^?$Z
MAIF1Q"IW@T[!"G##MI_NI/AHN^ELI&'(@:8,'!#@4/E--IS+;G32(;I.I(:I
MM9^O"=9'>SRD@E7H]0Z]B#Z@#4).Z\,5@#S$*-\2B9 ^D@A@+L4!^.CY[/&O
MEY^57+)^<7&O!']6Y;XV5,V@SXHOCP5._2TN1MZ5D;>T,O+"]WU-G<"N/Z.A
M^"853\S?J7W!KE" 65T9F.5V>]@?*BAQYH5'+"#WJO>W;\9E]_MY"+54DP5P
M[,5[ ?*3E4%^2TQ15HED-;"UX-O/I-_R775P,0X!B4])1V[+^X'%H#H5KR]?
M^W]."V?)$.JOV/%$O<IH74B&4+PQ6Y\D6/4<0G")Z@%D;@<-S!!@R50GH2PX
MRI/@TIX$6WT2J(3;5Z5F%<AY>:H\-L3D?CA@"5Z7\[NB.3J'(Y8%*I??SX8G
M-O=^MC6'<VJFJ/S;TH6_OTZ:\,SC\VX9YT>T:?;#[HBMVH^. 1'>\)Y9@1_/
M2(N^*3:5Q)@I>$X@("ZC'=1)+I79:A[EQN/X.OGK(MDUSG]E0TIBY-[U3,&K
MR/#3UQ-1$3&R*IK"M:BW>T(FY6UKV?5"_@MY9PMF?*5.3B&7,PG/W=E]MDLJ
M0-/K!/RZ398XK?UXK3=P6YO=9+E5:DL/*;N1*S^9!&_@^FD*G+GEX/25G[ZD
M2VD9=LB2Q3)'F90%A4?/7;#M/ZZZ^\URU)W.I\7B\E3U#7%QZ[0PK\(NL-.?
MX4I[=OP\[S"7V=;9+]-K(\ GL]OADQ[Q$=%0GO_<->]K^\'%9G80%"LJY;,Q
M*]H.*PKX#%G)4PDYRDK] ^(C7/\(?<<& SC:;'RJ*R>JKWFLWO''0(N/<X5$
M/H03G=\L80\.,\BS#(#@,H5$*616ZEU5>#*WR\]XF.NI;S_/[A\>>@$V1O#H
MUT-,VF/7VNQ"3/'+6#R._&C1-=L?!<-_/S)(^TA^.^K)DD3@&CB6M/S6TI5D
M-I>DBUYKC(T_17PQ57XH6*?6A_7.UYZ.WMJ#;WRU18GIKR_6 HFX/U"-$-B\
M!50Q_'9 XTKNK/"]5[[Z693#<2^OW>(GEHG3O"X?R\2MP;JP=W)EEPVCMF2I
MK]UB:@?RRC>FE6),BVQKLA4%=FHZG'MI&$,BG0YU4-9NB"YKTKVH# GU Y^(
M!I$0B@!""I)SG=J>9?7WY;URI1='W5!M3[K HY;(JK>=9<1R=XI"\QO8&+'<
M]>US6IU65I1-800"BIGE<9S(XW<V>A+(]]IS$5S[[G ]$A@]UYBULU\6@.">
M&"9\4^^<:.K0*+^*N@0R\?SB3=2S<K)8VY:1RM>!%<\M7(D@TJ7$PG&: (NQ
M< R'8=0K/Q<R"R]*B8!$S"WO[Q5UG"YL$'S8^=JCZ,S?,GY' 8N]A6#>IX%(
M+>S',5PR;!;>3GZ56N&:@@ $E'1M5MC&,K$2@DIHTR_>Q0N$85LSS%@$SI#<
M!OKS5D2@D_A778Y_/%&.(F!H:8 /%V;NF_%;:30E.Q%P)22<21<,2@]W;7^W
MPM3*%4PGTOGE?9:CQ=K]V#H1 #'K:YE)9-/+AWI$G@EM$!S:^=HC&&S9"F)'
M!7WG3J.Q+/93 HQ>.I5?9#@[J:ZR%'X?&?R/X^=4IW'_.JSGGM9Q9Z]EN[/5
M"A)?KH"U^E:S ]UI=M!V-3L8V,T.#'=5?ZSC<!(MQC[PL*)J: >M35\[$:#S
M.D2GUC&:(A.(+>ZQ&[P803?X[M ],DCM+5=GBG[9QHE4URNBHGBH%(_CI'$G
M_M1.;XN%=:J _7L"<"G] 3TN[/6Y"ZGI6*LK 8K92WM<X5L5OY=Z+P_]_HUC
M$WL=A]_3\&,B^ZGK6 [T%870SFM#9TG=,K93B:2/PKP="+%-#XJRD?T_)\:2
M$TD?PTX7'%*LD*ZH740P1<WOVDM[',LI13&6XW?M:QN,RT? +?*^W!+#U.6V
MR;D/#1O1#,,S3>\0V1RBDC"6:Y?G/T[*+P_*\[:<$DS$"#)=MC $O4-X<7(,
M;AMWL<]A&H6BGN_N:*IG?N,JOM SM+!+MIAI7SR\DI?KG!-V68:7(8=:_$ D
M&I&85'2C!,LOC"2!;Y [M/.U[Z].E$NNK1-YR^:RO]2^<KNM$R0;,)BI^3#7
M9FAJCN'+'2!_Q%97JO]^:Z7"K,B>VX_.7ON$6V2!]2V8&K73N?7^@KN8AO7^
MS36>T2$^W&3G]7*9-D#]?3/:IVSUTO*JV UQ:%F_K?W#L9C*%L0.HD%FX0;2
M@B2:I3-RHX\-OO6:!0;CAR,AWT!;D'SSX8 65;X3=>[BW?$XMT;'X^KC>%"X
M?\C=]\USD@W'.>>C#34?'.YJ?KQPSHS_)ZZ,_)-#Q#?K^UE>W/>SNL?1T^RO
M*[UR)GY/EY9V%MT<S,%V'(VH_FZYO;*)HH\<B#ESWS?HCQ@MFIIIN[<M+/+=
MCB^B:,2::B8*Z=P.<"B &2-1X-NI[?!MCXC!5:U0_/7[I/?2[NTW7PTI)@ Z
M1G9Y6"!FCI%BCF&4D622I40NLPL>%Z/"!JBPU<[2,:,(#SL"ZU"]Y7Z;Z7PN
M42HL+_#;!#-F7( ?!2F"Q(E 6LLG\CXR%X-B K93YF\3M7SX?'CP[\"- _\(
MJ20 M2GWB2'4R*MPJ_5%-<&^2- X9^>+T!?UK@QOP$OM_Z8<C'1Q';$O*Z-_
MECV/7FO(8\)>#T]JV>MN?;5=D0.V8)/E.1-%X7#Y[R<X"_P;KFM;?Z^\*8YC
M;4U1Q($!2[$^V0-:4LGD?SY%;ISE]H<JIWTZ!_=O-F@\5#E"D(N'*K^+#<=#
ME>.ARO%(W7BH<HP!\5!E#Q$?#U7^2 <>_E#E4QKZ2-NAC[2_H<JCSMWSX.5W
MX31:,Y5G3*T(S K-^YD5.GT ^Y$S\"H/^IEQIY7\(X8PCM1G_E5Z0=+:QQLT
MZ!MJ"TH8/LP8WY/MD*9'6/B5/+7$U.WMZ]E3- ?YIK<SR#>;R*?BF>(A.=Y#
M/D,^(#2;*)7B6<Q;.L)MAELSRY/6/MZI!A,FG3[6\,.DJ5(QD<PO3Z^(!_FN
M>99!],S.)TKY0K0&^8Y;Y]^O+RO7ST_Q'-]=E!IGXCF^VX/U_K:+R67>XQS?
MM%W&D][%'-_-FF3M#U0C!+;=S?&]N[G+C\^U/P5=BN?X1IS71;VOT7N"=01;
MRT=GNNI\ ;63.;[+;8<=R"O?F!;!AD 1QK2(X$V(<WS[Y8MD-ET8]<[SH=J>
M\1Q?GQ2:C6<8; [KK<TVG2^;0HD#@.J[SCCPB&%X-GHRR/?:(SC"8(?8'A&<
M]I:/!9_RL49>Z2\@#0<-M?.KTLYEB^M(P[7L4WPU3;.9'2HGJVUEB,%C032/
M0 LZZHOZ,S&9!<L -7?TG""J$D :Q,"K+M,^J9)LM#&5+W;_SA!UU*<#.\D4
M%;\M?!VD#BV]HG6;+F4Z9O>M0^STBNUC<\B-?VTX[E;\.Z,?,JGEC9'V3Q)%
M!,PL))].9-,1!K)/KI;;WYD"N5P4@T3;0NZHH/!FPZ']C3BX&YWGU6X^>?VD
MA.M^6-X_GDL>)DT$[)2'!9"F)@S$D4#Z T4;$6(530FF^$9B36J&;J,>-' T
M*1_6P8K#$$)1LB[OOO_N7_9'/TA[_X<A;%U=6IZ*%7F*BF!HR/?:]W=R0BX7
MP4")W[7G YZ<D/,I\EDIBT$[S-X!*8)\+Y>5ZV]:.U5O[,*?LN)DR'G69S#G
MZHB>M%_1,PO0_2UCNFL8ORY_GC>N"Z*GMR"@LPI9],V<R(IR+CH=+YUY08F"
MCY3E_;.ZWL]16<U)BYO'?N((X8JB-(KQ'K]KW\ 8V_G:]UCMS:^M]NYN<-7/
M,W'TLU;Y]JV;BP=7Q2-U/OC@JKU1"@K+-8)X;E5,9&L*LD(F'KJS.M 69#=]
M.*!%9%+1+DN<@F31[V!*6E0Q(N)'[MU7*K-&7ZGJX[AP]2M3NZG_?KI>1]G?
MQNBJF193T>H%/M>SF_,S F4__;=E\[Q:;;[*U^/\?LU8B:X*OZ(+-AZ[L-,.
M^]'%(^X?+N:6=PCZZ,.K/'AV<3L\VR.WXT?[_L]9IMKK7[?WFZ6&E;V1*&6V
M-X@B9HN!L,50ZIZ*I40^6XI18;]08:M]U.*Q55$?6[5]WPO(ZD0VL[SP.AY;
MM6.6$0 #*&82Z>SJ,\,_]MBJB"[8:ZG_<W0DG,E$D?X1;L0N8&F#_!D24)7_
M$0K"T9%%09+\XM\_R?9R9&H#NA_["^N6/%W/2K.]_$WL\MKV_,$IL#Y/6\8[
MT,[:VD\-"'.#SP+<%Z$Y&L#[R[K8DMM?A!H0, -N34.(%MPW_6W=A;\X)&"A
M_[]_ ^"]SD GXO-1BP!YP[,'].#<4,][0)V!PT9-%\(Y)#B8?*-[H;@!AA#1
M1?#Y%!D/DC-#'B37D-_FCY'+^'34[]\TI'B,7(0@%X^1>Q<;CL?(Q6/DXB%B
M\1BY& /B,7(>(CX>(_>1#CS\,7(I&HK,)%,\%)GQ-T:NV.C<JUJ_.3[)['J.
MW"EI4R=OE$?)I?W,JYH^A/W(X;E\2'9'_9HY[LE1'8B52KM'MD0GQ\*)21=]
ME.%]O)$] 44#HGK\;'1,(I/<UMGOP6"_TG88I4?BS*#R_36;4A[D]/-^\+$0
M$V1B9K0E9A1*8DLIFRBEER>VQ$<8R!%N-2$E/M7P$DDFCW4+B23Y9")?R,>#
M_<(BT2 (#FS44KC2<.7!?F<MY49ZZ8]+M7BPWRY:,92BWMGY/<%Z?SNFY9,1
M[)6[\0BZS%$RQ6H<,UO/O,R]V\%^'*JFYL U0H#;W6B_3K[XYRYS=STH=>+1
M?A'G=@M:%,12,6!81[&!6%3FK<V74-NTU/=^HE(^&<5N:1%#LHT%=K!($^)(
MOZI6><F>9Y^J:PW9C4?Z!4Z>J7B\?,CL),@A9_.%4A@1@%0BGR_NO0!*;3"T
M<N=K7]#E[,-@>\#2,0BLGBLA_31#O6?S,.J=$TT=&G1"!4A&Y?;^Q]W][:M>
MRV[+1KUW!G.T<"F"2-<2R\AI*HSZY)A]@/5:K=6\2"4"@C'W#J3B_LX_R:>B
MZ,W?"GX'+ HWQN/-QK!10_MQ?&>F[I)&J7&J%L*U"0$('K,_PYRKL@^,V2?1
MI:,^^WU.I\-%$U,8 H:6"OCK)'5CD+>A?M5UYJ.M@H0A#XRAV]^M.+6R!=.)
M='YY"DNTF+L?DR<"(&9&3R:132]O0Q1Y)K1!=&CG:]^[:,M&B!VTU1X$ L\=
M(6>9[:<$6+UT*K_(<'I2766)_#[R^!_'?R2S_"S]U$[.MF:_L]4*$E^N@%7[
MJTTJB[6<*2+-Q.[PL-)8T!9:F[YV(D+GI,&D4NN83:%G#_E&\3WVAV<BZ _?
M-KJ'E=VU$5I[2]9,H//857,T^J:FJ^.[XF[GL<=2<YHLH^X@=WP#/E!RQ='J
MH;@.RL5GDKH\R[T,I?T?K;YU;X*/7IN1)ZDHIDWY7?L>QQ8R48PM^%Q[-N#9
MZC.SP)GF0J2Z7A$5Q4.0/XY[Q7[#$,\;5X5UA/1:9K S4VF-6=W!G)TC7V9Z
MGBR"&>-7>]RTXZ)TENZW?_;'16?PCM=Q^)^<OER"^:G37 [T%075SKL]S"KM
M]H2>!%!^% W230]J_H2TO3HGGG24W*SF*'8NK2@+H^AM][OV_1V.GL_NL=Z:
MW</AZ)GN6&W^*N>&-1(/1X_G-G_PX>@15@RF)N*E5Q\'$D]'__!4%I$)Q3L*
MO 5*-.]@7K5?O2:W(&OFPY&0;Z M," ^'-"BQ7?"BH"&P5^\NR6?K-$M&8>C
MW[1OBJ^_E>OB.LK^-H:CS\RHB=;$N;ENVU,_@W;WTT=[UZO>Y8QA]ZU5V*])
MOM%5X>TX8Z+H(VDBGNVYTS&.T44C/AN]D,[%L]'79=R9[3!NCQ2-K/ZM5_H]
MSM^\=?>;KX:4A %*1C8>?+QGS#&,VI-,LI3(97;!XV)4V  5MMGF*F84D9^0
MOOT^G>E\+E'RT=@ZGI"^8Y81! /()/(^$B3B">GQ/.8IBMO=/.:9 6'O9JQH
M/(\Y0I"+YS&_BPW'\YCC><SQ--YX'G., ?$\9@\1'\]C_D@''OX\YC(-?*3M
MP$?:WSSFER?SM/ TT'-GN:C-8TY-@RL"8T;S?L:,3A_"?J0-#)ZET:!F/MT-
M6B',,?69A%58D+GV\284^H5:?D$=PX>9 .QK5/KFI.D1&'ZM%F]__RD7!THO
MFA. 4]N9 )Q-Y%/Q!."07.\AGR$+P.32B5)N>6UI?(2!'.%6)P 7XE,-*5 Z
M?:SA!TI3Q4*B4 B>3N,)P*G )@#G<XET*ERB6Y1JOK(A2(J_'TI/R5\_SYU4
M<TDV!HHX^D> '9 O0KB9Y[8MN-2L7XQYP2:(^*E*"_*- >QMAI0"-M$6&!O;
M3$_=,19P9?==8L)[TU?C8]D7'?1]G-1[URL#RK1['Z2T/5UQ305QLD?)B4L5
MG!@P_CC^+7:[^5SULG_1"[7?*KQ6P#=:^XM[&''5JKC ^QV,'A7WB[)AO<?]
MHHH1[!>U1.9-L!K/6N^TW6,BO?7,\U0QD2NM,VQBUSWUU@!KE.#FW4:KZ!)1
MX<SF?AR?GM1/FZ<_KS+I=6:0K=6VE"]7://U"J:S1$&TUQA+Q2EN5XI'=&P/
MUJF]DRSA<(@5152X9O0<[KO._+3(3"4I[<]DCRA@6D3P9NX<;%]C/Q;, W\<
M%WN#']G"BU'OASP5%!=XU,)5X%!&>QFQW)VFT*@/^=@'6*\];V\!K:PHF\+P
MO(/JFUV>ZA-Y#-_CN16E*,ZMV!VV1P2GY_:%]B4?:^25_@+2L/O]AWY_^O2S
M?Y?>EGV*KZ:YV+/3BF6UK0PQO5 0S2/0@H[ZHOY,3&;!,D#-G6DLB*H$D 8Q
M\*K+='B1)!MM+/B('<!31%U([L_,[5._<[4<I XM ;?U[;Q5O^TK)]=I.P%W
M^]@<\C0N&XZ[%?_.%)),:ITI)%&71!$!,PN8IQ/9W-Z/-BLD-PAK[7SM40P3
M;0NYHX+"WEI5/M!AHUKQ].:B?/'[9+3...\ AXW:DH=)$P$;*F.;#%,3!N)(
M(/V!HHT(L4KK!5-\([$F-4VWJ:@'#1Q-JAKXA-)0E"PQE?_^]/UI7""I_9]0
MNG5U*<*JDE^*BF!HR/?:]W<$>B$5P4")[[6OK?EYB_R<3Y'/BIT-.HC@#D@1
MY'NI]Z1(]PWMHMG9A4-EQ2FE\\S/8 [6D3T^/%.,@\U"='\KW37SZ;[VDDE*
MYWE/=T% 9Q6R[)LYD14%773:HMLNA52BD%_>-GC_S*[W<U16!_OBYL&?.$2X
MHBR-8L#'Y]K3&UAC.U_['NN]Z;7UWMT-.&V^&69%[=7D>SD><!J/7OS@ T[W
M1BDH+-<(XOFF,9&M*\@63!F/@38/: O2FSX<T"(RT7*754Y!LNAW,$TWJA@1
M\2/W[CJ36J/K3/5Q7+]2^J/&=^-<7D?9W\: 4S\]/J(X)^_$SYR\_?3?G@V*
MW=3)V>C"R._7(+[HJO KNF#CV5P['<,473SB_N&BCZ8\\833.9R[LAW.[9'B
MT3%^9A^RZ5>YN6<33K>4Q)%+E#+;FUD6,\= F&,HC<>*I40^6XI18;]08:O-
MSN()IU&?<+I]#PS(ZD361QN\>,+ICEE&  R@F$FDL\LSWP.?<#KAEJFLYY9Y
M>% >,MK%@R&)NVD&O,Q+$VT<7\%)N0ZB6T;ZQY(F(0,U-LQCPWPKB,:-R)AX
MHTZ\L>'XT;7 V'!\E]PBMA[WUGK<(SFRKR8D_(/:*'R"SP,W&OPCI)( TJ;<
M)X90(Z_"K=87U03[(D&393M?A+ZH=V5X/EYJ_S?Y:FR!)W=&4YE,=+T=L2\K
M8&0N>0F]UI#'A*T)GM2RM]+Z:N<\#<+<A37;-<!-R%^;/7)X(+:Q,9VHCK"6
M2-5,>(BH$P'>(L,KN[JH  WJM.8(I)%! &W$H22;M*.=*H%88I^H>HU"B]ZG
MRWVK1 D>8%AA(N,8$&R?06:=^\PF8!O_<W0DG,E$D?X1;L0N\($&^3,D:AON
M+PI'1Q:CDN07_ZE$;)]'IC:@>[6_L&[)TW69K&R,* HGS_]^ I: ?\,:V];?
MDR]M:XHB#@Q8G/7)GJR92B;_X[5]4Y^7-@/K\R+X.3GQ[&0F7@?7NL!G >Z+
MT!P-X/UE76S)[2]"#5@D VY-0X@6W3?];=V%OSA,QF(Q__X-@/<Z YV(ST<M
M @P4GCV@!^>&>MX#Z@P<-MJZD-%A<H/)-[H7BAM@"+%/7,_:V)[2;HL_#/V5
MQF,R6?QDD7"]5JE7?C6KAP>5^NU-_;;<O*S7]IJUM[[>U<IWIY?-ZBENJG9:
MK36JIP)\:M2O+D_+\+W0:,(_U]5:LR'4SX1*N7$AG%W5'QI[OO'/E^KA@=G3
MAH:H2L9?>[V;!>+&)\NWG/.99/$QE4H_#M2,FGD<O_6S]<RUFA^=22 6AGW8
MWHA>"*S7$M7"D5"QY7O%+=_M2PQ4"BJBT1/.%.W5$#[?6:K!7Y]6A[$_N?3)
M#CRL$BIPA0'6-TH791G#6O%\_OLI[0 ]6\IC&"1C!T0R-" R?NNU7M.7SWJ-
M0M^O)K!$P[;0#U_C,^MV\8RDL&%S^N@1+!H/OS<NR451>LAV0X'-3(;M>K!Q
MAATMS"-> ^V6P3#_:<&I>&VZ(;\)UW!ISQ"J0,[2:BN8"/4%O=<UT2@?/&98
M2=A!8D>D8);^<)PFZLQC(_18NOT%UV]ZNW>U=FERU!MJ!3>Z]B(#QSD9W8$.
M<:G6!T07L5]7N6W*+[*)$<F68:*GZ5$^>1Q_>S7/?MSW,N0EM;7ZC%F;U=&$
MA;/;^K50OZFB15 [%\J5YN7]9?.RVOAG73:^RD)\4XB';W&M>U=Z[?O8X/*9
M4)-C"V705I@.W1=KE9N3NW&UD7L<BZTKI=4NETMZ*\ V A9W8:'L%'7_<$TX
MCPZ:V:WAL$/%->S0>I(]6GWQJ;GF@_N(HEE7Y_^S3N!C^3"Q#*M5,S7V.>AJ
MM5PBDUR>7[T0)/-'V.\3G*,PM,T/F)=W:7/FW1A8#@E[;<L*F8! 4UM9,B53
M()M.KZ^O3/E"ZIQUPY%-7L0^"PK7#EDK$+Y'VA4,*1^_Q<]MM,J'!O7&"YJU
M/4&T]_?/8EW PVN[8MN8Y1=NLXG-.JM9W@GXE S@"&0Z/P(0)>TE&]*UJTKZ
MX6F4ZH<F&M)SL,6]/(&\X:@+$C:@%W,C]XI"9?I3L<WBOG9Z6PJP,/IHYPOK
MC-E<K:-FN:\!$8Q%5MQ^J9JBVL5LQ+)A$-.81TQWW]J-^]MB+F6$5,+MC[#<
MBT<?J&PO7Q#I^G>+-(MANT6ZRT:X$W'0$ R#$%.)4G)3$'J38GJZ[G-F'M(\
M$FPVY%3ZN5"\J(M;%VB[&J?GHVQT!GY;)+-4(I\O[BFEK0"\_9K#Y7:(7=.9
M/QBQ:Y#V4*<*^)VJ$WCDF$CGHJQR[T*ZQDE.DA_[AHOJ3ENW?WJ-N^?7=$B^
M,7\$Z"Q:^-R%9?_%C XXU;Z]18'0=#7!L+<:-H8M,8']07^+]%I:GE:YP-FP
M&SK= (BA.A@RZ4U5>V_R/9VKJYY9G;<KV'A[GI@4T[]'9NW[P[?OI:V+R6GU
M5"(MD\[-H#V' NSMO@"9?+:-RT>QT? *JN$D,FQ/,0S'0'-/ASD9&K)*# /$
M<@LVB>^HP.9@J]AA25,-6:)>)4TMZSJHQRPCI-+#CY<J0&FHFO7.G%NN9+$E
M*R E4O/HYZ>6JHW;G;/72F^7 H_M!YUH'5'66<-=-N7/VA?-?;4WMF-1MZ5#
MVX6_/I5/Y%+KJ&JA"\X(GTFXOOU4(IE:1_HN=.B7G+;?%@S.@/1H3T.K"Z*/
M.M8&NL:E)@"TW2/U%KQ^H55[7Z^_/-^E_GPSUO'O;R:NY_&8%4>#H,(-6Z:3
M16'/@F9O.BK"OA#!^88+&G.&@'X[T(^3@5-HUJ4E7/8' !WD6+-N,M"-@"P4
M^85(\P+GQH^G;_*OPH6\5N \,"GO[(+9LQTXF*@Y=7U">IO>W40IMSR"OC,M
MWB]36ML"\::.C#L^*!L#S1"5<T#;04TS3W%\,\KQ(9%XS%E3+=NYKEJ7([7,
M<P3U?UV,WZ0[[=;8OOOUBOMZ)+Y.:ENZMF0%FD%!V7'4;#VX[T2M]5&@'W42
M*@8\^<4=G)@^)9G9W8SOI191BM9_ZW9DX\?/UCI#=@.3+3-$@T/=>T21$(D$
M^"(:XF4QG'="&8ET<?_GD1?7UGE]IPG[8?013K.)UFKFSJ)R5%ZUK1/1(*>$
M_>M*'ZN( ]D4%5?N6/ID6P- F;5B3.5[4?*E+$?AGH(X]VM]-"@N1(-RNXV^
M&C /VT1^0?,0$" S3SP5LR_GK=[MMY\_I>T'"/A*,8&0+W7'QHT/8.Y"!J5+
M^<A*H"5NQ[5!&D:\(K/6J-6%7HC,0EJ\T0F8R](I]\E46?)C664ME>PDL[G4
MF=;KZ9O3'UI#?]ZE\LBW825O,DZNX18BH32N!_==$'*F\(X(>6T@AT':A<(Z
M2OI"TC[S)69OQ!'R,-@V3DD"R_[*T7"0M+W\C=)]^S8[[.4+_<SNA.Z +9S2
MLLB6[M;.(H=N?@"^"YK.)C*I=9PG.\ZD"1# 8=!S.K.I0VJN[FS%]?CN&@1(
M#U-28,.NG>+>*CU=4^6W$UGK$PF)L]S^,Y294V(>;8]*?]3&:^OV8IC>I<CF
MFQ,,:W?3UA>++O ="LX6@1?8>XR*]Z(4P?2<!1&[S1!K^\&Y8FJ#3,!UU&+;
M4W&%?]O) _-(*CMZZ7TK)E]+9!T7ZH;!!EQAI.7B'&#NQ%>:6B?_>]>9,9N!
M-%3*7"NPN2RO99%22Y7V"Z)(9YK>$!>[CI+%YO?"P]O5@[K#9/#Y0^V9SW$B
MQ#$-N_T;X+JR3C=]H#MA"SY*KS_<<&:?ND\QF0]XHO7RT(+_QBD8^&S:(KM2
MJ=Y6QM\'#X]]T\4G7MMD>%913]7OZVC$\\2W;T90\U.'OO_XM+P!@\\SW556
MK8\2PWA4=U#G&:K6DLXF<NG@3W.C2/0"=2/"\;]HK69YM<8<K+Q47X@QM^56
M@$)AK=9:E[7[:F->:ZTHP3]:J_'&!O<,=D"#-B$2]7B@[EGO7(OMGJP2?516
M)1PG,,!$4H^LW*N'N\=QXT(]T3N*?-G<2I>%><UNK%TPAQG-E-(ZM+J4KGZW
M7ER?(-YF%7AZ[[.EBJE LJ4<HBBXB4(<\=90U.>G$SA"$-KFZ$8157.:+CQL
M;TH;6B99S^7&Q9.[=6SO55J]^=:SL2#(U(<,2T'-'NA:5R<&"Q8/AGJ[)V+H
M&&BG,]0!988Z\TG/4-+^ZFR^\:L0L$VWST!;HNCZIY?MQ:82^<+J\\Q646]7
M:FCJH5U-V.6FPS?<-OKX5AD.?_\R6NW4.E'H-;(#EYOH [XUH342/G-[_2_X
MCV_P71GL:]EW'F<=,=D>\Z] #S)<0SUT1A9GC._6'$LM%Q]V[X@Y_;#?"A?#
MNX?*;_/A*4+]L,\N:^5:)3;: \&2]!RC_9(W:\&Z?WLPK(>Y;N1.'\>YW]E[
M^;S]^UKL;-DDF6>CM^FB!0-[>^TX174I5+<IQ3.)8G9?&[6M!\A0DLG3B>):
MG4!6=*)Q^Z?>H=NS]FQU??+R$%!RK'72QL6WW)^+HK)+[YDM75C#)VP,C2V@
MR':)TZ>-Z07C;5:RIR/9D2UHX(5"C,4-4G"]B;"R5"CZ:, Q3UA*O[__UO)7
M)S>%L$<U^!66<[J[V-U?7&U>MB-/??K2,FM7?4=+A/E IBVV(RT6PNEGF/&0
M;&>:?DLL![%OJIHG]Y0?W^_._A1.?M2WTK%M'I'A+OH#J_5AU(C+)TM?_62V
MVFXXHNFFOCG7@LRN-6U]J[1ALA]D4T,V0SR/CZ&@<X@4_1;1UU/KX?1ZW!\V
MS/ ZOZRL3$:-OGRC0#%ZPFM!8<.&:+4U^54*O!:PZM#6;,B=6Y]TCW>J1/2R
M:?8(:T6-O=<,M@:ON5U,9(VRW8<[+7]#UJG!#SG18<). SA+6/1K'L$&C]@.
M::<_:XM1(:QL*GJ$-9^NUD>I[1E8X;3Z/7'1%5,Z0.>89#/PA6OS")Z%\NF$
MW"7+K_G4-RW(;./UY!/6'4S2"E)5=(@D&STB62!]5D"0[77 #EK0N(<3@>YM
M^U9.26M>0A!%^^=OA4KGHOCVT HIF._7[.%+1M&A:("&O,P\,CB_(/4F8CAO
M66/3:+"]G@K!EY^YRJ_M;;G:U]-Z.Z=/[4)&G^]<?E/2E=[-12$J*7 3V-^Q
MA8%":TB=1LCO('EE 9OV<ZY;=!/DEOO4X[*2S0XN#-Z3"[!D<-,$.X\,":\$
M.^1*$PEV9S]^WYM#J?.C%E((;K,$.X=!??BT.H\3WFI:72*=7=X8ZL-EUH5Z
ME.'TETMD,P$6OLVSG^.LNNCD2R$.XG^8AOX":$$[&QJF+K=-(N$/956:_,)U
MY0W194V:+=MO*T/$D.I;F[93O15-4NUT"&;D.5+')6G:C;>7=O%/[FP84JF4
MKQR]6K4I5"[*M?.J<%D3,&,O0?]?J/ZXN[PO7U5KS890KIT*M]5&\_:RTJR>
MTM]W;%]M]P1WTZ(LE=F@\^6N N41.)A0HA- :$%Z4P.S?6>(/,J<.5JK69Y]
MO1$RVV@[,5("[O <*0'628-)B9T)@_E5@KZE0D(XJ9Y?UFJ7M?/WKLIN$S<F
MV5S9J'<H<TNECS*I0/HV)M+)N$IHWQ @%1@"9 H)/\.^ FQ=%)@VOC*7K:[-
M93=H8#'+6M.KL]9J[=0'7TVO25;T/D'2ABV%>)WI__HBJ?E/V0^:"M!!5$HD
M\\MSW3R/;WVF&I_^9B(UL&S<?"*76=T]Z.OTXYY*D30<\BZ1UA@.!@J=QBLJ
MB*=GBO9ZJ3*LPFF][EK-PD7Q0AGJ!:,09'+F[ X:=S<W5]5KD"_E*^'TLE&Y
MJC?N;JM"_4RP"S6%R]I9_?:ZW+RLUZ((^6BM9GDAV"6P&!TXUHTH2S7"NB:-
MF]UBYUI_T-6S]B[3/BHTMH0C0C#E2>8K71/.,_)A@W2/_/82;'TM>TG[UHD3
MWEX_DTAYHR),I-%:C3?+.'7'LS45H[Y.KPE5LL-CER;I3Q;Z-]\J/][N<^G&
M16E;T^(FY$BC<E$]O;NB4J16KS%!XI3Y@QGCU:DOBB<3K=7,'9]M#[AW=>["
ML3ZL;Y=G([D;JX\74Y$QX#H]-H0-/W!US,?Q!Z(J 99([E;_(+U^?=-^F3]+
MY]^2X0V?FRNRYK0K2PA]:^.3[<E</<QDOGF\3YR:IY/P&J;#AF]P(-@_C+8N
M:>@\^>V?]C9S*;8^8.M]G$8HR=&)3'"!KK]-W"%\/CSX=^!VES$2%YIR'^BL
M1EZ%6ZTOJ@GV18+6@'6^ %'K71G>@)?:_TWRA39!_6M*MZ0.N8[8EY71/\O>
M0:\UY#%A2\)CM_<B?[6UT,'>;:+9(X<'R.CZ\- 19HRIFHE<C;9PI/I^5Q<5
M8($Z37TU>\0@@ SB4 (6+2&^23@;CGZB/G+1I-P3EBKWK40T>(!AP@\TU?EX
M>R![ C$H=T9!PLPZ]8GEPP;^Y^A(.).)(OTCW(A=\@4>\&=(U#;<6!*.CBQV
M(\DO_H,-;(='IC:@N[2_L&[)TT,T67$D410N'O_["4@<_X8UMJV_)U\*<E81
M!P8LSOKT17B5);.'VTS^QPM7YAL L#XO,3R'$3 TGG@=7.L"GP6X+T)S-(#W
MEW7@;NTO0@TX*P-N34.(EMPW_6W=A;\X_,7B+?_^#8#W.@.=B,]'+0(,$9X]
MH ?GAGK> ^H,'#;"NM#0P8[!Y!O="\4-,(38>[3?'T;7X@]#)=EX3"9+GRP.
M!-9(O?*K63T\J-1O;^JWW*G5VE^FWOI:JS>KC<.#9EVHU&NGU5H#@T/U6J-^
M=7E:QDC19:U9O;VT6ZVAA=:$']!::^SYWC_?U<IWIY>PR[_V>2?>],;TK=JP
M#W>U?6O>!+2X 7)AT" _33FFZGI75.4Q]3=7; F.SF=5N@%]%7W3^*==." J
M#5N28\Q$T8RA3IJPCA,%NT0@9[1,T>)$"G[0KWH<]W\4C*I<*#PY7HVH\U'
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M**0S"0&3TQ*"!5@VSU$4)D5C::)L'AUFYNB:F#W,_\;0!RUJ?%6);O3DP0T
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MY2L(HBM>SBWEY[2W3N?SQ\NEO4A5-2MH=GB :SEV?(#D#=V'!@_C4G<@+0_
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M"?BZP,.""U1+:5:]!Y8'"DJGPUYN>8<]7X9MG,H0^3T%N9L5DC'.AKI))WD
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MR-3G&9_BD,6UYLQ/IX,.Y;[W]"^[-)[N!QCC+1EHNLF@P#RHZ'.!'SB\$-#
M9'!KP)LEC14'""9R3QK4FYS]3,>S:R9AL.C#?5W>-@YL,=I3BP*%LWW<$YU'
MAH]LT?ZL=!SCY)@].RPH644'6X#!0X^H'N=*P%J&1]"T6W9SGT[6U!2M.YK
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MDI,W!E2 M!$ H+SIX61*RBWS<TU^X;KR%.P*S1"5<Z""P:6*GDM@'!A=HQE
M0R+5!SSYQY@A-:4H&LEO@_;E13H<2>D_OYNZ!<#F%21[Z1A@T>S%[R@7SAMM
M0TT@+*U0[Q3-!,(@@;94@&Z%=$)G-+G4%AKP._PG&13_>92;P%1,%U,9&MKX
MO/)+*W>4$.7WW#P]ZB.?T;T]W:83?LQY;LK=)Y"$F)FQT=&'K:64$DD?AL#>
MY0/MU7$&Q^+2F40Z&5+A_4XZ=,\+L;IS><X>QZD;,YGI--*#M+)/H4@+O+/1
MP_!#RMXBF,5VYX0NLNY"%E_W/X[S3S_N?]UT+EI_\OMT,M-!XLKC^&?A0AF9
MF1^=UM,GWIKT\.""*!*2K=  @J3RSPT7H>[2K*<CQ4[&Q'L-O.WUELH&#0M9
M\05LXYU)N/O>NWK3"XH(DD8T-7U$]:$!JCB8K/8B:T-#&5E]\^%*4(3Z8KLG
MJP2NI;VM[>M%0^A9Z&2(M%VOE9B&$5R6UN8W(#P1=T[@LT5%H;>V=;A/ET74
MP,J-BF ,6Z8V *Z2R2>/4K#3&QT-0G,$G^ 9)HN&5ZUE'AY\QIAZ.OD%;V;W
MT"]27_X2>N(+$5J$P":)2>^C06Y=5 TN2U]A)7^&<)04;J(]-6!BY]M-F8N)
M8^4MG0YQ2,/A =7IY3>A#Q?T#(' ^Z1%)$/#&Y0*3$UX$74D#T'LZH0;!?"M
M00!//>D)L0/6+W;A^BZ.?F"I$H#'AP?_.\FP2TEWFA.8G3H1#7)*V+^7*F/?
MR+S/-!U9]^- S:EY/DPFE4P].M%)WU5P]VP_97L[5@IX2\P\_[R36B.C^TDP
M91/!;ZU)^"SQ5?U%.[OCPA*4&HY@OT=(#<L44A_;^[1 99@=,3MG(W[UTYRM
MG^:G]=/D<=Y#.:6$(0 F*O#WL5 VZ"008ZB8<QDN?KV <\(7T_G ZV7L!,DY
MA548)Z.MU3FGT)R #-[T"LLVX<D2&N) 83+<Y.0S)T#5-P!<FF%:Y)? #S,4
M59F@J!=X.I#G X+D%!Z\@(#&_5)VF#TOJ36CZ,)__@2Z/$(7MQS1I]^Z"*\G
M5>$ 4->K=F$"=0\/UI+.$QCOY()ARKH;^S&!39?H&!U!AJ]DG9ZPHAG4F3)S
M7C/MK"[MFRH]D"3$6'1F@U^5UJ]:\OYI7+#/C#[%_>XV>XZO/G4S;]_BV:6.
MO6SBJ;.#94^PW54YA^/<PN-P?.JQ,A/Q+5FVW-3@*D'4B5ODS B9UQXP590-
MUO I>UB6+2BHRB(,@-CQ(GK7!*?_1_B<^@M H8I,H4@<'L#O=-X6CKD:FCU-
MQT$!P(]I.0K<2G^@*)P ].OW9:8V\;=8"A2]BN[KB_ Y_9?K;[HM\464%9J>
MABN4^WTBT6%:C.O(*I4^("&XW4(Q7F;O!*'W1-J XZI"UX6%+SRO%9\\-$!$
ML<P,JDR(P.$MB%$^90S;/6=IF;^H2L?FV< &N[I(<V,5K4WK;D2A-1P1W56J
MP_:.^;P@Y%"7A*L!#@.%F PX<^#@ KP,S &W*\$"LG_9[-8Z1WZ];.""6@@E
MAAOP!98.4=<V/+]%[/?:.<$::+XC(NKPX-P,T%N$5C/1O0+LV/0>(EE(@M-]
M&!QEW)UH:"H?V@)_*927P+'0M&'9J5AR!/D7"J3/^;]\@@CH248@\W?2UPY5
M17[&Q;$\9=F9)0.L'I1>@^<M'Q[01[P"[T0X]$4)H*<[S[9^0+!(NO@*6MW#
M)+48+G5J@B02$V!;2)(TKWG&9%Y/ -/7+:)V?+6= @[ P=< N1.=N@GXH5@E
M:WRDG>X>2&>K6;:9<RR<$J"P-D])Q\V"2:.;\MC.4>=P:*->#\<S@&\E@N?"
M;W%6>7@06\Y[L"6W>Q PQ]82*('JLL&8^PM#=TJ%F,&/ ?N!AEB,JH7NBM\[
MR$A4R>)@\%19DQ*(KYR!BX!P U%'<N^+3_ $158IPVL-#?AD&,CQX4% ZY2Q
M*<#$@ W >[##R5 &.F&T8*^8<_F.K (AR? 7(P[$_L%0Q\5:\4#7&DQ<01<L
M)NNU0(!RQQ2XT!,/#]CJ2*?#9(SGH$D7U*:7@"JT06L_=8F*44THLT)0_*MA
MPO6B+L$3)<K8*!&YS#++'CL\:%+#+IW,)81_Y:\W; LV69[9KVS8$4UT[>Z4
M_-(!I]:_0^HK2TR-$97# XF8H 0!!H(DQ>"XI77Y&VLZ+1W@UPFB=..HCG*)
MECM2_V]- RI,Y3\"JPX_C'6N:1)J&V55N@0"5;LRZ$Q,G"^.9>5=YK'_ASR.
MI?_/WILVM:ULC<+?J>(_Z.9]SJVDRO!XPL#>YZ;*3 D)4X",7URRU<8*LN1H
M .Q?_ZZU>I0L&P,VV,0?SMD!I%;WZC6/]:/.MOO]/&Y7%CF@56X,MJ^K?ZJ;
MK8NMV]]OWDL0"%5704&@_[,7.BZ'-$]RI$,P";BP(VT6U6WR3%8VBB2W-#9'
M%C&TTK^6O&GB6:=H4^&MHM6W!O9."X4R2COL=L+9&K8!"=(>S,.S\_]K=WO_
M[FF!">^B78C"5U@=Z,[6@A[TFZ8KU%9E+?I!K"T3/J>9V[>P1$2<VG+(TX]Z
MO]US8P#O0$R2%@T>I &%@U$=UD;;CJUY8&(YZ([+H+&%BH G/TG"'%YMPG*!
M+STWN $RN)@S&A"@H("R$ZU;7U$E!YL6X=9.TDNWA:G$(<,-F]0I>/P"["ZA
M]J/<N $;%VUZ/?,VB1BN[+EMMFX=MLE6I!7I3;YY!MH>&E<AZ]H  O1!#'T(
M71P 1^D.#MIM;?E[_77KU&\%K7[,5//?2(5HVJ"4!J%0Z-SH.B*8]T"0 3Q!
M"S)\@G!JA1V&"TTD_G&(J'8;[$JHD2&[2CP1\/%OW%!<AXP@(E0!J.0E\+!P
M%04"F&T.0 LM2=!F,?/-BD-##2RD#%@'KK0?X7T#%I(4[Y,Y'31!#?#)X>#!
M0^C.D&C:PLO I@42[8]V%<+S/%K2%RBHQ2%RS-"F#KD^P']P':3>&QK=*]?9
M/;[0ZZ#IIMX+F=MM)G F'?$"O<*^\L%N!(D9 U9P/%*'(%<$C4P?>A+_Q+T,
M"I! $6'@)"V%^\X-<@X>V,64/ %HN&RA &4714I./$>ZJP%T8%<0$J"YFWA9
M9##):8@>URWLG$@-+&*O7^#8P=#+G] ]"OP5YC1?3&.7)(.NW4=,[?,[28<W
MI'5$; 0-:LU:>'A&+S?LV$9SI&\%+<!7/&@[H?8NW+J"O?,HJ&%Q@>D4WZ(?
M8R2#*62.(-@2\6-DADUF\()F$EM<)L.O$?:"UYD ]LE_YOL(KZ8=N9Q&Y3[$
M'_B]N6U-XDT&6T0+[=;F#6LH.GO#,S/QO'0R^);T^Z!/L.6&K:0;Q8@QTC@E
M7%"N)(QB2.P2KACC*D9=(+;4\8);X40!Q$(G&Y+Z4 N@MQ$#!$$%.K(J=-+J
MN[^WOTYMV5]G)OUU:LO^.O-$$8NMHFO#2GG"(NZONR-=6[KL$E S,1^$QP%(
M#1QFGS[&7W&CH-78AEJ;<4ZL*R4?=2#8MQVB+J 8;P%4XXCD35K8P"_SQ8R-
MNIH=Q4*@H*C&!T!?2(D$)0=0!O--HP#U,9X#4B1$\89A;%2K8/?KJRM?,*$!
M_6HW3"F94OWD)D3<<;D/)HIH*\*3@M^""Q1)=$++46$JN _Z"$A5[1T$&4V1
M9-AJP0@H@7+"0 F*A>(A?(I2X25')(H@*3J57TA:-NO6CDV>62[O_A@GTMLN
M(+!XC$7JF)3%(K03?<NDA5U)$PT>APL"G5=%97RZ-AY^HH@"_0[AG1&6A1ST
ML0TG+4;(59P&F&XKX3H:A>[0!1:B!4469<[JW +SAW4FM23>,VC? X%,9-;Q
M5]6I,^$2) CF1)E]:[L$%!#A7J,("O>P4<@'PVX1NU(F@X%!'%(4X@L\ECT_
M/$QP"HE/%U* 'T4)/#.'A UWV'MH%[ZP-Z^ZC+S<=R2-1D[ ./>CP..PDX C
MO?(F: /\!D/8Q#2(ZJY,3XKR6R#6:147G<))%&G/KU!<5U>JE/<SG&*L5@5Q
MP*.B:%7U!1(JY\?0E]3CPAXS7GEE*O(SN)6S;N #PH0C="OE=M7;3"7'W?-N
M8U"M');V-K]]C/_,MH_3C)W(I<:@][E>/-T;V%YW^\W[HP#;_(_PO2U=R'/)
M%L?>68&+THB'=4,7M@T?47X49$ \S8?K43S@U7%[V$(O%.6>%*#6CP?HP2+-
MQ6Z!ZBBU#B/O =3"NID&(?KUHDQ&Q23A/E'I><&8,I;MK5%$N\OB3N!H]3G7
MBXK[SV9+FJ5-!L%F:/DK+7($:V"9OQ/_%,F3E#)Y]:'Z_<^OD]*G3DNE3&KH
M#LN9@KFG-^.XV)BR3RQQ_\=)0LPZRC*Q2<[QYOW&$#L5F9&X)'>Y6*_:X_(<
M_5L#.2E&MFGOGX,I&-ZP?8&@N5+%1,I)EV@,PB^]#X?>X9?/G>M%%B[5QN#G
M[V"W>7ZY5?U:,Z<3DB$P:CSARPB9I4+^\"/MLA!#+V3Q#EG7Q"*Y+UM&$ W7
M/;H:;@)/I,/J.%2;8A#<2V_W90@BC2V4P>B&SAKIR2)+"3DJIO)A6AY*E@B,
M6=8)/(J"82!3.* -XQTK,-"G@'Y']+S!A\2GT4L3HC,!+55 6+)3'7*94 :?
M'>.YY>[$DYB(#M(*3-FHL+I"D8PSV$37UN$C3-O2A5'DU.?U*;T>4#YO<D\U
M4N3TAUVZW:1KA4'?]G@Z66"U.,R!9&#;41#R!3"SV'6DOX49"ZZNZ.HL7EN2
M]BA0-J^9%I-V<' QG?A!$SF52&?%V1*T5B1_4DZ=M,C6K@:PN=TN123:,F@@
M^TOP-K?2 L/@Y)KM( 8SD9&#2Y"C((FX/T#FH_%#<$>$6BA/W(F]!DT@#Z[B
M\$AJR-HL%$X&F_Q6N>-3EZZ!>>=$]8O=U96MXH;,F!;!K5$7BAXE TLI?"UK
M<^)4['%,1D-$=KK\.^\#G?H*X#Q6?W$4HT!I_F8HY&<@9^J3(2//KUS)LE4"
MG'1V8+8E/!CW44%E(1/YR:1:<V8(7#'##<E#QWD=^H %3Q&_,:.(%$%43EFR
M"2C%6Q0!\'VFN&&/AZ=3R1::,ZYC7^\1<+"]*)",)#(/FA8(*OMZB,TWI1L7
MZ[/A\UI\=(%KRZ8UH!1C?@4R:7D*$=7'OZP%22Q"^YRK1G1P3);(DQ122I@9
M$II?TZB3]%WD[)@JE[*22-[)L!A:<J-YYT;4OCXM9D=R(KL="TMWB,.(*A*,
M0&!XIZ^#_RBK5%@_$\(1[G-!L8!;2,8%[A(E/$R:(E]#K$&)$7JSBA,*-C%1
MOWJC6,[:U3N[9GWD4DFW)S:#V>G(=$/NWN3!F8S2,"'@4E4E& 50.>,B#T4D
MN"#-72$EH?(5\'@+&" *EOR\M%V7\LON*3PA)NMVC;"4!L4ZH$1&^1 I0)17
M(US)FL5'@"=FU.]UF>4/2(387"9"S"018G.9"/%W-H?:)XWPF)RI6'4?Q<2@
M<IU49E^ L>\U!K\VH^VR<U+IWKF+[)G:; QV-F[O*G;2_]1GF(6M3DHM $3J
M+7P^ (9#2JU[0TFVO&J$PNO^"WJKE@K8A)%BAHJ$C?+XML,H\.OJN^:7Z5*V
M9Q>SP.5UBYF"\I:E56DH H:9UA+M'1(X#2A:;3>4*;Z8?,U],-(RPZP#M-1D
M'O&WPWV51]P-'.85I"/$Y^OQ=0+28M0B]"0YM3*5 [:NE+M*7/Z'-K?@]+X!
MQ?G2.75UT;V%==96"?N>4!Y[+CC$"45ZDJI@YI]DK@B^,PN.OKK"3Q*,.69!
M:[W*+:4O4W:1@0_*P%';A$+4H?36IO"(B9J&--165ZC@ B/W5'"AT4,67'"F
M:'&N2!?T*8!=6M\PS3EDO'!0]6W1>^'?)'O5Q+HAA$.D7$.]G%1X=(X;?S63
M?MD=V(@N%F::B?&NW_:X7,>H68$2P52&! J3,/ *QMT4$'P8W,M= Q-G^CU4
M7KR^D?+&+9#@%HQ0C \BG,O%_^#>NY1X@Q_5Z4Q4!(J04"\4)'YD;CGB:4V"
MB%Z9!OQ:N"COMX 6F[26THAN8G?:@29RZF3R?M;.):YE6*3<\:N\/+S@0:ZM
M.SLI1\]0U*$7!N@KMKF;Q73W2/L/0* J/_3:2Z?*O&,C:L*K*P>L&298*5*N
M4KI5J9#"K^$HE(%LJI9%5EAI'@0L^=P>!"&N%@;)5<=2'RK5>%Z7^1V@" PE
M44F_J$2AUP6#55_/\Q$8S3)2?@4B!;G_E".A8%6Y6E"J<6^"40,-?)M2"9X]
M2O$:@OJZH]5I*-O<G[8QXX-2+B8I0CXPT\8>L5QC$'RY_-F)?K*S'[\7V:3:
M;0PVG*M*/?K\:_/*!9-* 8/"PYY.HUDFD\TQE]4R7SB>>8@G71$X=)G428MA
MRI:,'86C'=3IMD5&-RFKBVE@J*S+M%=>RYZ3:<Z+$N)L.<(P_Q_>JLB'2R?#
MY:1V42OYM:"]ED1,=N\U&ZC 7CQJZE,8G4%'A0VYO8+)?GHHL'CB>C:1GVK_
M1+I%/EQ4<%UUO\)N&9&JON:A+#,8'\>A"QH]O2ST,)'/@<-HM9X_8C_J^4).
MK\,"0@%K&H.<*IIL R9C+5U9C?KEZHIH?NE&*F0QH=2T#*')Q:ZH6"1#36TV
MRD5U_0VQ\.H*@A(.EG!]<U1S:+WP4E _5%"?\R HOH[18^P ^1WN;5?0W>0]
M[Q^V4&,076\FS8V?>_XA6W#A_/.N<@7&4>>/_QN'NA$8T+RG&A^DA*5 GDN!
M?):$44+%;=@)ZV+7JA5K!9T5P+.85*$6=;04+A_*[I*99Z)TCE$31",MA5+*
M!/;S3JFVGRKS"EG;HPIO$0LVTUL,OU2//T.U6F0$>7QM%[._19R95Y$%$5/;
M6I<GD@ELD0R7 L==BV+6$[Y.WN%0I(;,;.0YWMT21Q]^I+?N.[!$>55K7Z;U
MMP1_%9YIA66%5W;TO+,;A:IFTJ&14D&@>76@0%A(+[V$A=D!G4JC7]NI;^#0
MMD?];D>>62J[(Q"#%-77!1:$BA1,E!0GDJ110O$D9SJU#!=% (BH3;D\(X T
M,ZUYR?6?7(ZK W-#F&]D91H5Y$,Y_;=2B4!* ;QAU$\ %0:IJRC>"KJ[BRMB
MF2T9SU*;4-W[)7_ES8GT1] Z!OVD[=YA,K^,SG)L3+4WP[:J0=SA,3TUO$(U
MU9(_8>$:V8E^)MR;2?&C?GPBK55L<9A#R+?SBAT0.#$9D:(! 4--3C:W%MW8
M4O$\)+<PXA[B+.!YS1X"6!*EJ4'*1D8\_9<42MZ0662DQI32%[1<[;4V#S^<
MVZS#.SR@&&'9QVNK:'Y KMO6,M=M)KEN6\M<MWFBB,46;LJ)8J*L@WY&XFO_
M\'P6K%A^\WZ/Q)]]?@<V.N.5UH*Q+GTJ<WFY9Z&+?ELA6GGDEL8_7FJI;.0=
MJ<H+)2\I@4"HJ7C="@-$HSYL/2D[6D8V=A*,5&"9.&XD=1Q'5 KV.OW(!9F*
MMD GB"C],#*;''68[<4=:C$I?"5AM&X=^I9I;\FT*#GO*B/?>4],.;0!K':U
M*5+7[2:.)Q$E/D..\<P9"Q:S6QW>I5)VDDQU?D)]Q+_R1MD\EAC(P8&+J27Z
M7<J XBUEE?Z1^9##T"F/W\$,))Q>H2>B2%L+GH;#-JGS@02OQ=";%08^3W J
MB-*!B.)0HI.0:&R+55-NKR?:*';@0:K?:3/2XJ@#:KHJ YYJ@O:4<:JM6W6X
M.(*R>I(ZO?!';<L3T2B1JT=WQ[$H%-"0'9T\/6T$'NK9.%<E!J$8%?):OX[1
M4+/*-P(YSUC#3ZE[7U]=V6$M.XF8@0M8NP:PNF%\TS+2I("HQIRD^Z+:>@1?
M)'5(6=';YR=+->J1[55%@]%A[=EHS99_2+@&7A.;3MV4(**CCM9AT2D*JH%T
MB?(:0T 00^/^G3A7/+)W8%[0B&.H^^H"GJCOT:8(FG%?%1:JCK&F"DYEQ\A!
MJ+Q/5,:1)<.'U,@A/XB)GNUVI6,U9.T$,9XS';Y!@O]MASJO6NG62D#$21L.
MZ.*ER8)LU!$9!WX'<!=+F7F.*1E=B4V=\E*W;50@U\TJ'>T1YELII$G$,$LD
M1E+YM=Q(4Z"C&]/C'1OM++WAU16Y/;(IL= &V(PL-%*K].P8L)G7^,EEC,.,
MP5P.;[A?<ISW0&-_Z?$MRSRR1XX%-O!.-2:70II80MZ OJHYH$^\<ZY>N6\J
M:13&:VMGO%KV-!0] M(#226_ #I1+!<XK/QU'7L_8\&H^7<UL_1R[_JN>E%E
M^]=Z_M_PP>X=_9=[KH>-(WW\,:8R.O#>B:6<&^:T_H8?U.9X,W%@15EE3[<T
MMC:?N;/.<GS3@X_TG6%/<,SW$;%.'/FG"B54@DP+;MJ-9<(PNM=46/16%ZN*
M@*<A(ZD[!:GG%BBE?Q(2-"'@!J<M&RM1([DN><-$B2JA('GY'#Z D+Z/73*3
MT%0FO_/L9]%556Y>S;A4LY4+EA+/9(880AL/&;J,=U&]X@U+-4/@%<1"+;=
M OM!EZ=QB)+B=>L4MM2T<9Y"4^:S\J0CIJM[:16=ZBK&Z^E!B0+4MEC2G$=-
M%338AC7$TF@J-,B.H;:=H(?7E%O"\K5':;JZ>.6K*EXY"=9AM5)MK<2K/?08
MJ$/4!!,2ZVN[!/S5E2-^^V_Y**E*N?;N'V ,-F;ZR%0X_J@EG@3@YJZ(#@ "
MB)GJ#G]Q,IGNE&6O2W?(QX#E*5]QTUMKI>V")7[87BM6S1\V:'GU,\XRONVX
MF%J'GQ'1>SE0&0=1DO$6:$Q.(SS:B;(IA#R0.<)>#8,(R?0R6O$J-,+A#D%/
M:]OH"9;3NQS7,75,A3.8(S5Z:EAZRG-N;C5OY<$[TNFTK"BW42<]O <;1D%C
M54KTVW(!Z9N4 !,D-$<DO,E7 \P<X#/9,@*,@+T@:<;MQ),B=-RTWL\;E:L?
M[9V[2N@J::W6(M;DB-64=O+F_3A]9,*-E-5&RJ5RI=08_/Q1_/ M2?YL[[0?
ML)&Q*L2XK3SC#.$I;[*LM)WR6JF\5BG-;$1UOO*2G;J^-#SF7/-XB$N9-P[#
M;F8B?^N%'<K+^W[XD4229:3S()B* P]UAM/Y>89'44D^4"4H-1XEUFX'O9=W
MI$JXCFN'KLB:P\SH'BW;8DG,E3XSLT_(;!VD:)/#,J#6^V(B*5@XZ!.-(KLO
MQM1F!V<5LK.:HJ2''=FYK]JVFJ!:@)Z#NATH/Q1)5Y\@>TDT8UM=R8( K2WM
M#=8 X97#F @/:C4Z9&"?/9+$MT%XK=2\B]/O2LU+N1=I5FJ+&M!J1Y3U-@ZN
MR%DN6N3#ZZ1TB-6RFZNK-]5'>.TB'!0]@-(AS35H:CS.[Y(K7OP:UH>NW0Z9
M/JGH T5^>4 M43[ 5:-(S :"PV#*&;[$':[:+TP/B'EF0T/,9)*$U#55R4)>
M/;0]M$]U_(R'CG?L0]1$2\@580>UN)H;@*\[PGE'_MJWHA)<=K[BA^%=MDQ8
M8LTG'.N=:M)&=!1E-JC<@[8<3@#P6U=D(P=NP'L4M)"SPI%B,@L%[3;CL[BB
MW @&W)'.2%*T:'Q I*A@38-H=T@GDU$@OJR<Y#LB-/(V'49!8RUZ)TTH@<MF
M7T>.BMI(7,8:YT<*["I*E&/&%2F204AY;T(CU<.?\[#"+,RW&+H8X 'B,38-
M+Y2DS2=D4%,%ZJ*0#8Z)*B))H]1OM"_L-_PN_4;U#T63W>=FN"#+OF)OPN<P
MFE>N6Q^#6T9-":@-A3 I@=>J)A3<2B5.[IIBL"?RWK,,2\G$#I V1@WI]R1;
M)2^6.95#G(IAW4^+T;$DUP(&D\NV:$>*N1:PJ%R%<9)\%@O'XL$?'M+ 4QJ;
M,)B7Y%94T&2+T7.K*PZ?1L<A@@L.0X6W8[7IGA)/Q*.4NUIZL'QLWR8&7!8,
MF=KEO@NZ..I#:W6"1'20-?L/<DREAI:Z+9M83_'T$>>O1R.SGZFAO,CS=(SV
M)J/QIX"QS[[JW8NE_+QOK^+WV%Y8Q5Q3EY@=VISCU(?=^GU=2R&6QTX6Z)SH
MLUBLK5(%].*J8&UDY?F(]G'Y;HO0Z+LG&M%2[KPQ'8HJ[\P#]8#0;=>)#/>+
M\O"(U]0N<[Y*.P<(=!545-N_H<_S[7GP(PHY#H^\((F;TY'A(7!0T7ZMGO!&
MT2YRNM10>(H#X_50M+/584["-Y!* 'U=DO !28;;RR3#F209;B^3#.>)(A9;
M-S3:E$6(,FX$EG&NVUDQVU0RO6ANEDIHH2B/G"R<:^-$>:P[XHUH=>HZUS,P
M(X;QA<1 O<PH:* [_PJ,#_P^VJRI%:EG,ZB@#M9IF[DRHO"=M!=,RN>UT;EZ
M'J:EJ3')/;NO6T_;  S_.DQZ<:L/XL03B5J4#^<&,G?'S]<>=1&_F#5-PX_U
MI$'5UP4[\ :^Z*1/$1QR=Q#_0P)NX0&Y&J:;V0Y?@U;,55M\[C$Q0G0Z+L>[
MJZ4: <BH!FJLRM(3?0,*2DV+]+=$];_:@7DSM[(K6CL)><*@:+B?GB&.H_J"
M)$+-$<Q<,=I1AA$C#@_5E)L"F'IGW'G!XZP1GWANQ!"T6ID)M/JH&,J/4.L"
M@:LT?Q&4P8(@ =+!7>S7F M!,=ZPKQTT2J4P(J%N%-$L0KP^':M4UKRCU2-S
MYB/%?#.[1.7,G,LN [V$#6,(>L0(N93IPOOH2>T0SB2#=&'>TG MDKPYA.2W
M4AB0-Y[BE6E+BRT;'IFFE#MV1%-E7OBR]/0LIDN,$YZV#Y6/-IW&Q/<CMR,3
ME'Y_J';;9UN5J[O:2R<HY6UP*N&\RGVI1P5N[O%IK<A:AJZG_I#KR89SGW ]
MQ?*'G]]OVE^Z<?F9KF<HHOKRU\--Z-65H30!/68&D[X>G%X@,F8$RQZ5;("2
M,D/+!G<W<RV6G'M^./=#XKQ'Y,RGJ-RR9&B>+W5L,->3MZC\DFA (5V3.!X9
MJ!$.6U@DHFI<=$F3&U],0\_K;MI#@\P.^SJ,&[-6QP^\X*J_;GU53E7]4;.2
M*;3)CYKS2>F;IXPN_+X8R:46-YV<R@G<2T(PE;C#F&\Z=](Z3Y05 2Q;Q0^N
M6  [ZG5 .X^QPAMS]8&7#H=KR4CDFGQ?#Q-*QURQHFMD>P7RZ)-??9P_GMR/
MJ#&+#9 1U';#;I3C\1Z^G%%1PKJ!(.DCF1./0%N_"LB9:>-QA)W),4@/?L$K
M44$@550.$FR-5W:0$NAIKD+52F2GL7"-XD%9Y5"YO_6@:RH$RP5:#.:PZ 6D
MSZ0*522J% PL*O#I;^IPXE@CPJMFO$N'"D08O8=Y"7PZ$OD:U(Q8-,U4JS@)
MX-<F$Y]CQFD4G[91/;NGZ>E^:JKIJ)<:@[MV]&LC2JYN_FPO<O>T[<;@JNY>
MEUO'X9_/#H9THU@D37/26<KLN9390_>4+385W>=QHC7OW"AR;0K "T/TY?$@
MJ79X-N']MHLBM1GX"6>LU*5_C3NE4$( 4[2YZU#W?B06Z/KMT,:4\!:?LL>'
M8D>%;*FP<O7AOJ*A9AMCRHYQ.QGV7A#E"/BX*2ZY':&B:5ADD".DX'4IBTF0
M. E3TU<M,7U5)'Z9\[[-Z>)#G57-T8&K*[SX6L^*S6VE.KP(YO;D0E-)4P<+
M0A%N8D/&W%5U+P5+]&W"D&;(2QNIM)D:N^*,/O1, _PD,.BD\I54&U%#3^+7
M9G2*I=AWCC:W>W18U_NBV:O^ZLHN$ F\[+LV?>Z2^3@[ES%L9I.'#Z(Z7?KC
MASH#RIBRK"5-M<Q))Z!96#H2.MC>E>A&EI,K_2A5D[D.9"@''0;Z(=YX7[N%
M=?I=2IL$?&_)T?'#<WA#I6[KXGL],=X @;%B]L *)6SNAB6=@8/(,ZOYLTT4
M_XI,ZN?HV1HQ.VQUZKZSI]-']_FEY,ZAJJ<:M=[[=F.P_>WGX+)S\>OS=6O!
M]8MN_<M1_<?/K<&O:[0U^=EY@,6<HRI1>JEPS*7"<?_%$:M!+2&D%F9"^3#Z
M28!T%>^E["ENADG9!A8B3_NF]">ADUAOM9YBZ"2\EX942MX54H)0[LIX%0R\
M*U5*A=8:33"BR=LTC9:?,)L5;JZ*66OO,$QL"NC5E;R/:5G:MELB4MEJ)7 ?
M+2%'WQ7D0%.>D:0%ETIZ"I(8(];\>50,A/(V:J_&5JC:5^U!=X174?8.LYV6
M"-:FQ[0;3=VL4.AX5A*+29X%.>&)ND90')3YO% SQ@XD\,?$5YF*JROHV&'8
M^B*V[Z1*A:T,0INBP>>CP"Y41*T D>23V+0T@2<56J>[/_XA&Q;DS;'T8PEI
M<X\QO-M@,I RZ0J-P<6OP>=/[@_G^F:AAWX4&X/.V>E/=G+A?-OMO'E/ .#<
M3WL#7UIH+8OD'WRDL?>8/T$#V%<4@*GB29YD5.)JLSE71&7,9EY3''6"6VTC
MKZXT@15RF8'.3)&>8VY+"0I54<^P\)>.8HTX2<K_ZDK!H?[<3F?"H[\1!8)J
M]\N+;H8EA2$:])/:+'RJN+"DM%A=R147KXOK3Y[T6BXNDUYGD?1:+BZ37O_.
M*=(7C/+K/W"W*6@V=0<[#6+/-.P?/)F"9.87/6Y!L/2]O>CZX_6WCWO>(NM+
M>XU!96NSV*H.]@^2S3?O!1RXI+53H'AQM6FI(HT]TB17EZ\IF=I.KIHTPI)/
MO?A.Y Z [8&?E#TBPUX@"TNY-D;*0AN+46GR58Z*5%CJ(_-BA4JVNR]&UIZQ
M\ *]Z9./H+SGS<:@>[/WJ=^ZWKHX7NB0[$9C4/O,=MCAQ9?HKO;F_0F+5U<H
M=Z['![?3_&R$P))]SB7[W+$CMV5<&8\:N3P7-A'3QBE=509]?":R(PV+#/.6
MC%GI&+&CV@,L9;$<AIT5J9F:GGB0^%@SR5>FQE@4FK5;K3!5RMH+F9B/10L7
M9 K*+<.$*?2R82 5U$L_H?1.'+6%)Q#Q9'.X>Q)3VRL*P"9JBD6?V>&ZM>=Z
M=%8\%V4OO2@<+ 4&5:K^"#B8Q!>ECM_S$AZ&U \;0QG3[_%QE[Q.15=FF*MA
M.8CGP0D\DH!6+\ )&>[02I@IS\LZL-C#*1AQ1,QF B'5%U<EAIF+U#:W#<:;
MCR88.M'YWPKRC_%ML$;UL/(EE,84$&^Y/1Z,C4 TAT*:DON>YJ/"S7;! E+;
M7K?.1NR;.W5%N:^<6,Z]^0EOFX<@@-^Y(=9FH^."&A7'KEK[57&,?"8X YM'
MU!*?MK/"E'C63G^7KFD7;W^$2-[>,DV>QZS7&/3.>YWXR$].#FHS%=0SKV/Q
M/$):S1$Q_>+&]E3ANXFRJJ6SD:8IB^8TYU,=T*EQ0F2)UM^8DH #>]H!ML4D
M(B?N*#N#R_&Y//% SOG!2^!Q%8,9&S(IR]#?4DEAD$3P3O1N9K,('WM9.)3>
ML^&B@"R8N(]'*UYIK6NGU!A\Z?W::.ZPK8MO[3?O)6J3N.!H;%T0D'8-+@5_
MDW(.U#1JE6D!"5@7$KSFF^GF=K/F'@_RZ$U^H9/Y_MZ0S\IP]V6N+NO]XUZQ
M-]+3%3OJ4.B#TSY .CL7T/B2Y_QKB=,IQQHY/]^8[ZM%<:\(I/_WIOQ&77UU
M>Y.7?%7372O=VK?.UXOS3NNHG75\CO&VYFQPV&_YYCU^)GNVW(/DK/CF.6%3
MIGHK!9LRATUYHUC?_K;3_XR=(6< F_)"P&:OD=?M]-=1NWUW'#7/3ME?C#>5
M1KIBC\/FP\=F4O[6W?QR6YMGO$&?/W+0D<&*(78U$I83 _T^Z*8UI0G <=D)
M&;..X>%.9.UCVZ2'[>%9-WOAWCUEJ_S"4@+G&:[LD70R ]27Q9GSRAKF_LB/
M0:#9L]._3'K,KT!8E.,N;W>FQ _6#^SV*@P2WT$+* C_L<*KYEO0CPOERE:A
MO+'Q;C()0TX=3"G]1QXA'X YJ0\\+R+_NLSGJ/QUD@?S%ESN9C%V8Z*N4KY3
MLQ(._5;09>B8.)2!US,L9PK\>AR';C,A/\%E<!+XE(@<4!+#(=(8B^+&X/?O
MF]L_5^4P;CMO'DX=WSMNS')(0K@*JM7_Y"7]G*@P@+%%# 0HS]FNB ;#,;(
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MXM\"DW,JSJ:H5)^&UE?8AW>&7"VTB1MXP*AI+,@(K,K@.4=F<59BSRFF(@@
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ML@IAGTD0;O[\<3SX\]O[&7DO)0A+VR*\)43=&&C,6!B61U9T_H<* %!0Y4A
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M"EZ>-&!O0K8IN.76QMG@XW%[^X+5<J;QS6[BWG!M2FIC4R@X*4U2<?*"0_B
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M:?Y5(EFU)'@ M!XKQC>0M[TH?R,=E48X7P$8KI U7&%K)3Y,F3G WJA2I!D
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MF!W%0Q;QGK:(TXX WNXI.M5K&R:RR)W.6,JS3R,9V-M?>L4OFZQTO3TZI]!
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M")2IL@-E2@24J;(#9=J!,NU F5(+RI3T?K?60[9]83"SR+@ 0Y8(? 9<H!T
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MPZW^@:D=D('67I+8[&#XIU#9 X+H>IP E4-KAL#+AI0)PO[>Q$7"5UL,[WI
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M(\G>)]29I*FX98SGUU1Z]8\#9FIG6:87NW@!T=B&.; .["J2C!?#X)BB#L"
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M?VG:[>O\]W2"C,%/<7C2BG407,O$6)A]7SG%>1FN!1Z_HK#:$#+&?E;N9)Y
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MY[=3O!:[O99M#TB_>/5:^:/'Z_<K[6KN,J@-:*9/G7@59V>3-U*\Y@68BJ=
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M=KP8@8K91HB#->H6*F;YQ\^KZJ"]J;Q(K?<UX1ZM'2DN&89;,P+<'X!\M38
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M#C;%X(?XK"1TX/ND37[01"IJRZ:!OZV0$\(KMO +=-@H^49?,\@O\%/E-M[
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MSX."<M[D1X*R8>;*O\WO?#8$/>"D,?K]?BNB\EN_U"Q#>8-#$;O=U:7)JK$
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M4P9PXX#]A&Q(A*XW2@Y,&WILC*ED&F(E?S>PH4CM7N?KGL.]%K%J!76\OT?
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ME,J"]&3F2J_M51[)GY+MJ/N#P5L8WM^JS81'$OB)N8I[>'&]_62@*C1,4/Q
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MB0>64(HGPH$MG^?Y:YJ^R4>S5R-IF]+E+]&\L887VKK[FU/O=4?./&Z:@HF
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MKDH[A*M5B0 VI.R=;;Q3BO>"[R?4HTX!J*<MV-3V>MH7*@V'J7 3*YX@J!L
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M6,/?U1&5XC"U0 -YCJ"#R=7J4D6*284/"_M%PU !=FK &+O!8S]$';LF5'^
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M5NT!W'@ :LIOXM)P%XBP$1B@PL\U,JA6S[KJ1D8/?P;@X<_8:]MA1JTO\VY
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MNO ,A_*P*:K#IY\_SGH?OEH?;-\O'P)$T.\TBW@6 >HV]6*U4JK4*U5EV<E
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MA? C7>*21Q*1 9NT%>.A&BL;EDX[73VD4'SVQBEI/83M">A2?3-5WN6EC'4
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M'877$I)_;H)X?LE?WV!!72"0,[5[=15$A?['4$GQPE;Z2WO$4]&]>G*?\S:
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MR/?QYA(%L0VY!<9$5.<5MX5 ZL18G9 Z,5Y'(78$YEYFNF7HV ,+VZ=R/1_
MDBW]\E](N+PC<SS%[C*@/EW "C&D;$U9;O_6L:Z1C"NN$&CL*FO,25MSGJ$Y
M1[3GY!MT<BWVLJ^7O7)=C.9SS, ,B&?1\D<C:54\)?$Y7(JF%T&]")1I_QOV
MO1O*)LC'8.J)CI26603MED(?6L ;":[B15$-.*(%!ZP21[0AC<5\*[F B%ZP
M&L=7-..P30)6KY^$P1U[O,I?C814\9)D:!R%IY?"_D_1]G>:UNI4[;SB=]G'
MJ9KS0_*K/U<_@*Y,A>6Y!TV)\1CI2<5QLQ\]423T6M+B&+8@?7VYD50K3IO:
M(]E>3.W/9O-2TA<;":GBPZD_I^VEU.UT,"^I9A C:54\.[J3PEY>>SPRS NQ
M0ST3R5Y4'$&MCP][D1_^0"NO"?M#9Z0@%2_2G@^W>O7I?LJ55XOM8$;BKKBA
M&D^\>N'MS3F5EV7K6D:BW=E1U4M[GW'E5SA$Q.</B(GN?<(=XLPK*(STH.(+
MZQAW[OP0M^^D!/2:H3/3W27V(A^/YC>(,'G)_AXCT?]B9H6OL"V%&17Y:DQ*
M(:,9\8%&S.-NCJWY?6 RTI.*%RUI6JB%:%PE"W!RS<N2A(!D?E%*D]*0JDVO
M+%N515SK$:LY_$\8=D\P0:OU_1&#,47<$,LRC8*TK&VD%!6765XIY"TD:22(
M'[DVY<>L557>ZX&Y'H 11@.YZ1:[[2B,=X%7Q(^@/\'6%Q<QQYC)\.H"O$XW
M=L=HI"\59UQ!7R12Y4QP<F2(LI@0!RA1MTR!%A4]7JG9*](!_?+U9LI>,1HI
M4L5AN!]??6_"[&#"B&DAW@V&PM- O'BKD"SWFVVFBSD&(R6I^BGK318Y@R3M
M.H6&4U-ET\\K;1:H6BG&IJ$W"%.):]>CM@A,%.*GBGNSN/S4J\"/B4GK.2C,
MJTVO$!V.]C0+B FDD8@K#DK-<5\_T[<?UA\I]9Z)[\/:7C[OTXQC@QI&4JU>
M',P-W*01N=I7#@[[86HNX+*,;J(0NGNPHBR,'4+7+^)P3S=MMZYO)/SJQ<2<
M\*OR5HTZ^5:=N-E>%SH<\]?/V": 1M*M^!]U1__]C-W]VG:]# W@C$18=0UJ
MKW7W8NPR+\,XB%;2!\\_08-3.HS9P+FMD_1^C-9YVZD\/W?&8Z0&C<[ 7-..
M:%O<*DE;+VW&E!\G)J&?L[='1B=^EDQR Q>&5F7';0!H).FJ&R_G8\D)STFP
M]T)L)\1J?%:MX=6NCI%H*XZULFA5,\4PK]Z\VBT^3[,\&P(;R;5%S%Z_0G?R
M>*7)^)((N3A5//8N-Y\"-)\3GXB_AA$/Z0HL([WOJS,J$U5XO<T+EF453&/]
MTO:=V<;)4^"D)/2#?S=M&80A([,H5!=YQXR*J^M\Q":8/1%7>^R_"RHC;:DX
MU+9K2[Y]8><E%#@BJBBFH5<7<W498R:B;-'"2-X?,5TPM%Z*;-AWU"TX4\O:
MLT?,1LK4Z,?+B#%7K3Q)3DI3KUSFRK6' &*-<NT1LY%R-?H)"W'*B5_IOA"G
M?)W%*3\D<<IYLD2<\CB-4^XU[.!Q[O5F\2$0&^E7Q5.Y]]CWWO)N/W]-HO5:
M/1R#_"2WMGC(B*W4#1B5=&9*X\#E8 %:$0<E!HL[C+2'&?M#;*1=C?&5>5JR
M[-Y.CIPTNPXLBBE%4MU2FAQ)5#]S==.M_.,F[=1 MS[N&;N1EC7Z: M:5GAE
MI9.F]8MDFR@J>6IY#\VOHI7LOMQ5FQO*VJO7'C :J51C3&=\&!M3$<] ^4M$
MXJ9)KT4'NQ-6;T*UJ6"D Q6O\99[8KVATSU;8KU(#>",)%GQ$]=D4^SEUV(;
MI,FAJ-G;F$*;R/)-Q=&KS\#8B]1<I,T9%^L%V[*.D7@KGEF#K(V]G-LLJUVR
M,>I6W+W@,M*+FDO;G3,]]OIBKB^E1(_UBK -R$C"%4]G.3MD+[8N>[#Z2_6:
M[54SL)$8JVD(<SLG[:W[?C?4(FRN<N=9"FY-.?(_,AJM<UD5]#%S'9 8R;_1
MY:>Y+JTT0[;MR,9+"1MZ]=A;#H[Z"7R'^D9*4?'0M<_+T<_]79/*:@*QMD$9
M";8F:+*4=/9?7G+B/R+>[1'/G1?Y)02P#T><K-8^"$-]6S(\_W!$W9?C\]/S
M"["&3O\!7+]Z6?D)A&@@E?KS\_.KEQGS7U&V.#D_/;U0HB]W5-QN@@(QMX+E
M^4+B.'O[]NV)A (D%,:=F)A/$MH3!"$)1?7"=631#BPP)_MCW$>SMHQ#%>P?
MD.,[@?\ K()VMF6UI- '8GB8M7( MF%DM66[.!@/Q/55VDB5Z?<G:+TFP9S&
M7^#O(*!J$"2?@&_*0B= *\S7R&UBB@0\%&=11PX' VF%DCB?ABKBK^.DWK'X
M='QV?GQQ]NJ%>QFE;8C(NJ$=$4F]#D1(;!R[KQ;T"81*3H12U+?/=>#BAU0F
MTT;GB,\D"Q$_7B"T-FFTMLX)]D.>?.E,@A@E?'<:))I61!3$Z87L1* 02,^/
M08X79WIRMM64?_-.2B!35K!-&T7(5TG^Z"8-SL)6@DC@E1#@K\[-=M"":N-:
M%<#JS%LE7!O^_H\)9C#O#1ZQAZ&AF8^'-'@2DR'\A.5\CAG#G@R?O\>K&69'
MDGHP$]O7([XO #\<A2P2$RRP0-[!Q$NH-Y7+@Q<E[\.HY0+423'RSJ,K1(+;
M$*\$)'0+6),P-4<"6FX,/QPI= 1 &KA]1']2]A$'=$5<?ANX19ZTI;90+OMS
M'#%W"7-LZMFL86(+H 7\7#&TH,'$)?!19*FYNQL6^6@"L(!^V<TU/6\3C:H+
MZ[K5)BH'X72)[Q'[BD.QV^<:O=X.9@$OE]/;CQ5-+G^T@,X)=B,F?6Q;9A,3
M0 OX^11XF#T+0H.%AI-F$)MXP$Q#.;9J=GG$"\*!)NQ=$8;=,#F/*4V*VZ L
MX.22(N8I@GAIZ-:56$#Q*%QB=@L&%P]IF69-F054J]E;4*&.\++)I<B! 9P%
MW&S)WE;AJ@6\!=Q]1M!:E*VR)6;TQ1;0?H\]XB+8A%!VA6'N6:''%Q1XR>>!
M]X3DS:M\>4D#=\%@00^,EPAH2JX?%GG3E%E ]1T),'3J(/ &"_Q[D6I-F054
MW\)@7BS!E&"+\LI=7V0!S<,EHP%YJ:.YOL@"FN^)+Y:T (\"7!JM=24V43Q]
MIAJ*\R564;R$B5U'<Z', JH?Z0;YX::B%S7?[:&VHA,UWRV@=A0?(XLPN9*=
M65=B <57-:&')1]($X0%'$RBF0]K<Z#?E3< 6$"_6CLTM.L*+: [7OHN"5U)
M0\^O>(@;(>SA0&V;:DDO%=E#<[J\U)LCE5*+**^WG^RA,]ZBW([*TV#YLSVT
M#A]NP=3_3$+TD:%Y9?YNA+& "XUKQDJOS&T@W',\+)-:^FH!I;$?J#2Q5;Y:
M0"D8<=,EC3@*O"D.<AD(QSXJ'<B8@5K TST%E1@BYE.1NU(V)B]2D#^B\D[!
M!-("CL:8R8O>@8ME:K@X"6?)7;(%R (^KE]@"(@ RM%\#F8A$P'<UZNU3S>X
M[/PQ [6 )^4#ECT^>$;,JW41UQ5;0+MFV;)RI8K74K_>-O MM0UT]H!-U.8F
M]FOA!<0XN)4/",/H:UP&FJ'MX@R6+$%=DOJV:6FKA;.+FZ3GQ\C?SE(CL 5\
M#2D/L\>RRV=1M6464%U_NZ0TWIMA+."B>,8B,LZB8#-H.H>IP-C*Q:4!%Y<V
M<:&]KU1W\&<*; -?&@YLI'44A>+$^U, <-XD1"'F34>4YN 6\%:O,C4LW$F7
M;25"9H?Z%G"O]A$R>9'&X=L(80$'8K>Z]#>/54]U38$%]-X0QD.PIX;B?5D/
ME8YOM:464'X'5I-/DX"J]&2__-4&2AOTV5Y-OD,SD<F"LDV:&+3<U7H "^BO
M.">V^"YLHKTAP5QI.C0 M("?2T:1]TRI-T1K$B+_;ER*C-276T!]&C(;XJ ^
M+K41P@(.QM#"9^(A=60@0^PJ@>5;8"S@(A>ZS#7];]DX_DVDCYJLL4N0/X'Z
MRAJ[B0*OTOUFH!;PE(Y5D0HM@ [7#N8:  OH3_2\7OMMHG3P^;Y(9/Z##?2Q
MH!1U5/AB 87W[&,4SAF.@I*96%=@ ;T#^,O#GLA&I[NXU 1A 0>"L"MY81/Y
M.I.W$<0"'D2VOR\BC4B9\KH""^AM2(-7#GO>#F@!/]-G"CL*Y(LLF^ZR;/)J
M2RV@?+!FQ,\?5#Q#J0C"C+6FQ(HYN 6\U6SW= /<!-("C@8J)^\V=K:#6<!+
MZX<\LK/O]A6W\JO2AX1)T4PEQ >^\8R$22>HLA4-<(C89@_B=%T@QYO@)RRF
M!GS#Z&K@ DM<YEH91HQA05,L55/HSLRZ#'N'XU:^H#*:?^*XLO7/70(K,=VV
MTG?-^P,-W"[L%^I9V@-3+))_(#7#AIL'"GLM^0APNDHV )CS5)ZM $@^4+WO
M\^3\B_.CN1R&T'W9<^;I;-6^6HNY^5M.5E?DB7A@RHN0*3$58<6#>2*4[,!G
M=T3=^^BP6B[IN^4<YNFK2/C4QI(FJ<>?,1=^S]'\D@815V%;:1!G^WJV=L&5
M,#6\1,BC0,FUC7[L@,#63FF2;V4,:!F<4M$+ZF7UPMQY./2V=NAP"3,FO@WR
M;]F;ZLD$NQ2V+FHW-IKY9!%SD-Q@. 1J2V?ULE%9S'TL3,S*G9^<S:DS35MC
ML;1W4HM+K.)\2N40JU4#I2&9,@B;(YW==T=CZS"$+9:+L2=%+-(2B9=E5X!>
M$2X/.09A*'*XB7CE_",DJ1M[%PR6JLT8;<3?-Y05)0\?<KS(-$YI-[2J8JLZ
M/.*UXF,T+VY6LJDPY=@0UE96ZUT-M;Z))'64R*GG1YZP]V'"%-D9>?R 2SQ_
M^MF<*6;0.# DF4DWV9;BKVC:TK&69=FNOHHU )0,9HM\J-EV6!3_2CAM[RQ3
M$( %5'IW#JNT3O%+>.GG3.9FD!V<?6&"9I^"&M(.S^/H9;DC.MO$/:1U]_.?
MF]FI:,3.6&Q3FM);.GIUT +:)NCX+$4=H,3'*"G9%8$:0]LAN,N(PV+$143\
M#%9WN9H+%V:RI[J'E1Z$)8-VQM0G[J;"\6XH[.@&E:HS\-1]/1#5]<M:Y*W0
M\=P"W@X&8VL"*!4OI$B;/;7@91+>>C[;5[.#W>RI($TZNU@IO4&8ZNE4/@18
MD?0^,%G8*1PDYXF')U.7=PCSY2R2^0RG%*Q58:'P$4ON,AATS^XX;>NH:A2L
MNB&0O#V_K5-:U_]>.B#_-GK73FC$85M'[/!R][;^V2=J.[HM.Q1H/EJJ*;=U
M^UHZ[# [$OE>N,NMZ&J1%P^;#?C@"1%);_RJ6I;@-MN^M*_8]I XMN8E^KWX
M@YK2VVY$N=A]1,@O'-UTJ&=G,$N-N:[A;2!"Q1;*<$\.6P8K80]JC:&T.^0#
M>0T[A ,V:>D8RQU3:3A)CR%,("WE<NC#,N:*&$J"_'A3](@YV'M8R3$=3P:
MEH;(7",6T"@<8R827Z %'H$Z^SY6QQWQE)=.D<;0.RS=:X7\&[$V8NJ*+V[%
M8K[6=\-J*PXM82Q.T!J?5/&,YO1$IP' !@;4.2N'6F,&*E-EH G !@:*9M\C
M%H&X\J8\3%:>BOHH<=2JQDY1=OOA\#: 500V^F)53UQ?"2^:,CNMH33([1&%
M0I&JHFF$L$ 4TNZ6&<9$5A/H[;(A=;G)0.(Q+X/3X@QQJ:T.JV\(PRF,E3 N
M%E%MXCA212JEF]=OW&C7(X ];1HZL_M-^O2?O _50=&M/$N7"Y9\.68*NX-:
M3A\GG_C.7=JM3=M[F&\9E=<O,"D1&86@^/J"9?(P;R#BQ19)A*M<=(V[>,^-
M[K:^[RG&_,#3WT=Y12OI#R",[Z[1N[1LNUZWFQ@/T;O_"KVY=4XLLOMMYN':
M-FWO8>V46%*C(G.E>3&9-_<T&^_2]#_7G/PM9E\[9X;ZVPG*L9^?UQZHS.22
M)IF^H6R. 7EFRNX#TU_=&P+/;+NL9QI9IZS5KPTIIP^1N.L[FA=#T?^RUFWH
M]3VLP"(A(2\R&[',QMSW@K^]N>^U7[>NP%L4[/ FP'8";.][TT5YBY9]4P-A
M-UKLL1CV,<>.L[<7_MK)?@=";!\C.K74LWSH)6"7EK_7WMXZ&9MKX.$7AE:T
MV"X1[;S<60T/NUP<BBQ[5HX=]H'E[1_\=85"G 9^[&N_:=".I7$D,J$*G4<<
MR[">^EMS*CHF$DD7UDE"\D)&EHX([#RJ-.(HR]+>O5?T.+[CCGG(PM%:P-O)
M\!BF2_@[CA$#2O.QPTE81RZTP C8TF"K)&]S(9OY[6H=B24B""+QMJEZ E"<
MSZ<1(FUKV1 V$E^HQMZ4@ER2T E0RBEZP35Q/"W@;6 O%SPU'WAD!6HH+OJ)
M3.DW&#21>*-@Q,B"!,A7V9C2P9CJ\DXHK.B$^"Y]>G>^&!6I+[9T>&82 5,N
M3BY9,-G&L=%5%>'V"C8([(KX8M*(;ZMF$5E9>)"VW%+3*LDU4##TRQ_M,+/%
M>S)>*8-2_I,55.8G)77F 5-P3A.*OAYC:#N4GZ\I1[ZLHU)3 (FU+P&)V&T$
M.@3<Y&ZTYZY][XS(TN'4@K7*K>$.W5.'X_OOF5H3O$/OZ/#8:<>W8 QL5]BT
M2]M@+NY8E6\9[ ?5=]]-<9:<O+>D0P_58['4 FO/5[)3D/[2."5O+@U<]P[;
MCMC2/H1=\1WEI>OJN;N-2^I[F/%+Q(DKUB5E\R4=U;FV!3FSWI]P5V0M@Y__
M#U!+ P04    " !+A@I7"QG.8>@8  "T+P$ %    &]C>"TR,#(S,#8S,%]C
M86PN>&UL[3UK;^0VDM\/N/_ \P*'+) >CSV/9":97;1?LP8\;L/M2?8^!;3$
M[N:.6NRE)-N]OWZ+E-0MM22*U)-SV !)9FRQ6"\6JXI5Y*]_?5E[Z(GP@#+_
MT]')J]='B/@.<ZF__'3T=3Z9SL^OKX]0$&+?Q1[SR:<CGQW]]2___5\(_OGU
M?R83=$6)YWY$%\R97/L+]@NZQ6OR$7TF/N$X9/P7]!OV(O$3=D4]PM$Y6V\\
M$A+X13SQ1_3NU<F'1S29:,#]C?@NXU_OKW=P5V&X"3X>'S\_/[_RV1-^9OQ;
M\,IA:SV \Q"'4;"#]OKE=?)///Q7C_K?/HK_/.* (."7'WQ\">BG(S%O,NWS
MFU>,+X]/7[\^.?[[EYNYLR)K/*&^X)M#CM)1 DK9N),/'SX<R]^FGQ:^?'GD
M7CK'F^,4G1UD^"U5?)_!)* ? XG>#7-P*,5>.PVJ_$+\;9)^-A$_FIR<3MZ<
MO'H)W*.4^9*#G'GDGBR0^#](;S<K W5SMB$1 CL6OSP^9Z"0@*D<MN)D\>F(
M.2\ _/3-Z_=O7@O0?\I]$VXWH)<!%6IUA(X;3GN&/<&B^8J0,*B9OO3;'M"X
MPYSXX8J$U,&>"4ZE [M!4*P7L@;HP6PQVX@U#DI4QS#UH.X1$S:&DQ7Q _I$
M;EA@@E_EV.[1G*] 3BOFN6 (+_\9T7!K@&?UX![XB8/5E<>>C?AX.*8;M&9\
MB7WZ+ZE!%R1P.-V(/\X69U% ?1($4]^]H< /MYZ=C6!UM<X#"DRZXR0 =DD,
M8+)YM%YCO@7ATJ5/%[!Z_7#J."SR0]B2[YA''4KJK5-[T!T1F; 1EM0C];4L
MA6I(-TA= T_\)7WTR#0(P%;>DK &)\6(CI::L1WH?>TSY]M$;.JN,(=@"Z4D
M:E>_<E0WJ%W0 "^7G"QQO%3OR1/Q(R*6ZCE\#1H?[R[W-/A6@V\34%WI(/R1
M/."7VL5<\F4W*-S3Y2J<L,4D"A*U_H*=%:P]O@7ZA5)MA"$'78_9$80\<@0W
MKOT[SH!KM9MJAS-T0S(HY9J&<GN*9Q26#^*=>I.J,;(;%'^'X&7!N .?NS$S
M:C"K'M"1FA /MG07',IP^\ Q+&E'QXS7#>L&N1N&_3N\Q6"9']B<PA;&?(CC
M/+(]PW[=ZM<;W)7F35PP+AZ3&C\%W99>TN\T7-W0!7D@SLIG'EN"/ITSOF%<
MQ]RV ]H-8?'F,ULL"(<54:<5%5]W@TIL8OX&0?X5XW,,F[7O@H5WY&*-B*L=
MK)@#ZFC3C1X#\L\(1'CY)"Q-W6Y;\?GX_ND ?FI/_FH+C!Z$(>F3Y/P$_3GH
M>H34#NS-6=?"KW9<KWZR%HI:8X?WF;5P;P[0&N=5B\[.Y^G=D=4B2WO\T#NS
M%O9-P8V0?[H@(:9><(NYP.B)=)F/JH+=D65S5A!0>&2VN,*4R\.1+P0'$9<^
M)OP4K#XH#/9B:4C$\"-XT2$H48):G0'L<(JNB1;)2[$TX']BE3^!EL6+Y9[
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M_KGBS*<O9Y2MB2LN%,N\$E,>\[6%J2ES&Q.+'5!OGY-?U. =)W(7Z2MN0C4
MH2E]B].0QORR6]B%)].-K'QQL*: +4X&&O#(JDV]@O!K_XD$+2LU2F&,]=X
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M388C.1Z5YS,[Q_F&83\IN'U@<PJ[./-_PYY'MF?8+S=)IX7]50!!"104,I3
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MZ^5="H<$YEWFP^9E#J[,T:.RI*CEX J=:C(291?_$:49\)-_ U!+ P04
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M?I)E@]$>R9E\,2IP[AOD&LK-^=PR'';$[UO!#O9>MS;%!JLQ!B+I$F;LG_0
M*7N J=#5SMM8F?3E6'$EX-)#V39A<_D9K6%H.WQ3>TD%,%^D7Q"9(R)Z-LMI
M:"O;B?K4P%+RP96OZ=+'E?+9@N X_"&7,J>AK=PD3:0,D0^N5/:B)]5WU(V1
M+F5FSC H[\GW=($XC?CA[/K;MNPCDS?.:('!@Z02UY#RF,TML"$:H.D+\MGU
M+1BE%WY89,W.CUHB-6"19 >/VP?DS3&J<!+MTL7/<4&*KOHU SK?$=F!D0)P
M\HF(KUG4(5>?95,%_U'HB! JZ?R\=KK:-KGQ5[EAFT7L*A@T3(QM>T.3\I!
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M5T]NSH?O<M@1!_""'1PPR6MB@]48<^[*SJ.4_9,@:48_A:YVXG9ETI=CQ96
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M'.=&>+4H.WZW/IRSU#B!(&N:P<Y0LN,-F;(K*]#<<LR=4-:\),8 OR[9$$P
MX^1!R31XCEH;]**ZN"%176_T2E,$J]$-[O;6(H8H0TL<*Z%1:SHYL63+T<$"
MH!H\)?S>J9.Z5Y745*PJ"D73S.9('8JFN2I.)_?9?A9-HR*3%4VK-IF<O'>N
M:EJ=/G )?M_I$JQ=D>[$@JE!IR3=B>BD<?+!7F _VSXNDR1#P7G&@L9N$ EQ
MD#M=DFOTG/])>!U6Z3]YW;7AHLFS00U6("3M>0Q%Q!<O3M@:/9Y]I1)OBF=M
MG/[C"K $SE0W[FB5)T1;!FY(.!6\\U4=H1>8ZC$#'M,<FZUYJIWFB^YN]U[@
MJ,$)>.IS8TK>^&1,<DM103UE)%]A5"<DU+\7,.JP N%H+>+LAN I0D%R027
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M0U95%A*QS$^B[#2HE$X5;M_;/*IBEDPOM?P"F_3;YWDF/3]2@D'0H?/JT<:
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MT)1-?_?QT^$#1-%V^;'R%>R8W(;S17J=,=&,9]O,O\5QZG2U?CA>-A3 >^#
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M*,L\?MJ5+/(J,W07Y&0.A /5>UP&<8JCRR!/XW1=:'&I(G8)0KW";<3)*<'
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M"C:[N0(%"!@HU1+V=2DAJBC]3OY?@C?]G-#]W=F<(%.KF1/:/WKO>95&PIS
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M5<=^2FJ7\#"HW :*@A0,9/3Z"5<<*FK4(I]S"7J=%O'ZF0 Z7VMNLTJI7"U
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MV1HN*CH0*#$HUP='0XXJ>G1S!V>N>M@]%7$4!_D[S4I?KECM#\UDI:%W>A/
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MC<7^B@63QPM.IMT6(X=W> Q2T^KNDZ,MF,6.'><,P)*1P]ET9*=Z,PWIR4%
MR$Y'8=KA7+."Y^#IYR(NMED1))_S;+=EVP7Q*C:^T&CD<CE569K0GL ,+-Y!
M-TQ/2:TIQH48&^KR0:DT+J^O]1-.HE66$^7U[Z59<SL&XA"3>H"T884$S 'Z
M6A9#.T%4P"F1<,KN6LSB).M:H!&..4S)'_;H)'_YZWE&EZ]/!;N7V+-?\KL+
MA"G5HA@2?O2.$I5&XF,(A(8XI(K*=4=?9.&.SL:T/(+$@N[/KKI9IE3=R^W?
M0'2R1"%AK%<D[)D+QQW,3MCIQZ^28"U1O_>[JRZ6JE7W<>='$)TLTTB:R\"Z
MF1+YZN8+7(1YS'8/=79TR)QWND1)H>];-+ @("JF1D*+UI-CO\?KZFW++&W*
M*&K<F(+>M>O7JMV?"Z3$($!CHZ%RMF@S[=^>]X2C19KN@N0>;[-<!Y\NF6O4
MR)3L@Z5- PHC$L64T."TB!-[0L1_[H*\Q#DMV&D A4#I&A<*5?O0Z)&!0H=<
M-R5 &G*_&&%I^3%[I\L$$I'4^7)#H:RP].C1@<*)0CGUDJ2A]XN4AV><)-5S
M6T:LR(A=HT6M<!\O(B4HQ"C54V*&<31OHX&!S>4+C<Y)F&1I;(O>)W@$M77X
M:8C!0JBOH26*&!NB?)Z0=(?S.*/O6>0F# F4KM&C4+6/FQX9*,3(=5-BA9,C
M1N\?))=I9 61ALX/0'IJRN%1$0$$1U<S$S0(M4]@7,5%&"1<EROR;_U38P.M
M:X HU>V#1" $!125=DJP<(8:,XS%*V#^"P>Y'5Q:E'[ (J@JATI#!A H?=U,
M,*'T7D!ROLOSCM;J&4=-ZNQ0UJ!L<SZKH ,!%(-RPJDM)^\ Q=,,=)F6<?E^
M%2?X=B?)%I&3N,*&2KD:$_W?06!!H910"9R1(4J'.*&7GJ]/"=+R-MC(/(2<
MS"T"Y$IV4="E 80$J6(*-.QI$27V@HAS3.N))]=IA-_^ [\K[1+HW&)"H687
M%#TB0*B0:Z: 146,&#4BY%Z <9?'&UKJ-PX-4X5(Z!8:*D6[V.A3 0*'0C4%
M.BIJ]'!][G,F>0S>KB,"U"9/UH 2);U;L!C4[F)&00P(.GH-%0@B3*C+Y1-(
MUVFXOQ_-$A?.^6OIYUFDCE ,7&Y!965"%UI:%D  L]%3 ;,.ZPG/2:'U%"H!
MB$KP@KA%%)&&*JK_N8E3_$%IOY36+;HTZG8Q)2$$A"2U=@K\5)0G]1\0Y4'+
M% IH/@XP]:-_T'RT!<U'T*#Y. 8TCZ\9$-!\&F#J)_^@^60+FD^@0?-I%&A(
MQWOU->?DC\O\,7N5)6<K*;U 1E15"I@]&3RX"+J9P$(9:#Q#67S"A 56R_PN
MSU[B-%2'S"IR+X!1*"U%38\6'G3D"IKPTP3$-9]77\.#<N,@J<G\>)FNDG(7
MPVG@@:2KF-&Y<&J?D+C+BC)(_M]XJUV(RXF]P$.JL!0D'4IX4)&I9P(,YT&$
MR<?"NH(K/="07B7K_>[N"K!$K?T5X-:/($ @TTB\ LQW3SB1ZVZF&,UQH/ (
MW9^==;)$J::/6[_!Z&)1(:&'V;@F-#X&\DU&<Z2>LU2=(""2N.IIE7)U;_=_
M!]'C"J7$PM4LUXS2>=J-?RMQ6LC==^LW9S-[7YUF(J]_ -&[?6W$%^"KWQWW
MYL_\B<WS;+/9I=4ICRQO4$'GJI>U:M8]+B4"T?LZS?I(J&A1E]@Q+!ZR) YC
M^@CX%[+XS.- 9I6,R!4@U K6:! I0$!!J9;P*G)#B&I*QR"XRS$%(28=P2X!
MTE<U<O86K\0N';$K4)@5KL&AI@0!$J-ZP@MV.3X-6QR(L_"7D_W"YKHH=C@?
M!!X)BR<(*957 $F@AP@GE9)&4'%&G]AZP.&.S(_O'SX^/<9E(EM<BB3.YB2%
M<LV,U/L=!#842@FUZ>EO],&+#Q]_\_1;5',Y[O[;[#$/(C(E/KQOGK)$47U*
M2N4*!!H5:QQ(2$! 0:U7'PVW&:I($:?U49VJHZS$G-[OK@ @5:ON^LZ/(#I=
MII$P^#M][<GE7[Z%ST0IK+B0("=S[?IE2O;=?YL&! 0TB@F+DHH4U;0^+B3L
MIZRU.0A8>PL"UH8@8 TQ"%C;!@%K;T% _5E>(H3XI>53$J\#17%"+;5K4&A4
M[N-#0@H**FK]E#ZC84%['M<5+5F)L^MTE>4;]OTK\@>)E0HZ9S4M=6HV12UE
M1" PHM-,*&O)B\ZUB!&E=HV+7127..+*7,5ID(9QD#3E$64[XF869VBQ5+X!
MCH$>!H;LE!3?AF!L=2W#AG%?ZM+U5CI/P/@9)\E_I-EK^H"#(DMQQ/=29"=%
M>GJW&3,&M;M),PIB$'"RT5"1.D.93G^A7*AFJW;"O"#I6Y;LTC+(V5WR7.:9
M%'1ND:-0LXN8'A$@I,@U4R"D(4:<VL\%;5X]H@FRJ,.3EH#1DSN^KJU5NG=K
M6TH+"#-:!55WN*N:'_O8F'-YNF)98OI>1/R"+X(RJ'13VJLB=WVI4J=T_S:E
MC!80A+0**N]/-CRT5$Q08\I;R9C\G(1:ZTR3)=ZC<E\X1E!1K!W3D ""ATPO
M3069'-6T7K#PL F2Y&Q7Q"DNU!-1C\HM%J0J=K'0(0&$!9E>"BPP4E33>L'"
MY0;G:S*]?<ZSU_*YJL^JM$U![18;6I6[&)&2 L**3C\%9FH6Q'GJDKI^P/.V
M+RC.JRRJ+960.H:-4MD>9@0Z2(!1*2>@)<$AW6^YS4KTF*&O!4;E,T8LG34B
M_]ZJ!,_E^'II) SIA0@>E:=1D,L@I"-V_NJ(4F'A[1&!$@20C.JIWR%I.%#-
MXA@U2X+AO+V.8TI<EWBCO.U@9G&%(%OE:QR9Z$&@R5+)/J886W=QS1@1Y?19
MS:A=W%X=XG6('$?&$@5[@7&+ @1&E&JIPN+V6P%^:N?MGI(XO$JR0+W+TJ%Q
M7#%/5*]7+&]/  @!HE:J$GF,$#%*+_U_%J2_Y+MM&;[?Y5F(,<VR*AIO9=I_
ML^1VBYE!)G719,4*"&=#]%4@<"\"M62<M&8LGYMY-&F<5G/+PE\>G@/2@,M=
M6= 9E"BFW@77,CD^7K PH'?(H.$ !#T+-54'#HP3,=83Q)E1B]O3^JS85P'$
MT=G[/5[AG-X[>,1OY1GYT"^:%88%K^O5F[4Y_<6<D1$$"(=JJUKJ%:@M #W1
M'+%*!/H+%8*8E&G?+U\%Q1.S<U><KH-@RY&)D[*H_V4/T>H?_MIDCRQ734K)
M7<8W-A0OV@]C=0'0,<90? [A\P[/$<H*"8LU*TUUW6<0U=SH+S6_?UPNB@*7
MA0&!?2*76),KV$95EP(,?J1J"=EF#P^7CP] 4%!%BE9@$&C=8T*AK@B-'B$P
MA,BU$VJU?+V_O[Q]1$  <QX4SXLTHO]S^;==_!(D=#)>E.=!GK^3(/!;D.SZ
MURH&\KH$U"!SV@"S8@0#N"':"@ D3(A$^"BD?\![=N]8K';[R<(YQ$2IIP3?
MXE*^]6''XM2562C?\6@:>C XLU!2F @K%I0W/"<HQ2R""I(D>PUH2$_^\H\?
M_N5?&0[_\<,??G]"R(LM9JE+R;0[L&.02 =5^5Y=5XEQ<?5R&RN:2$[J$GDZ
M9=N(D]&!09I&N3["O@3Y+[BDP&+>JWQ'1</F'3EW.=X&<73YML5I@8F/9N=.
MG0!!T0)6G"YQ-<"4-LPLV,"@SEY7244,RHDP9RV8)\O8&6-8)?(&3(QW1')K
M?L))=)7E#V2JO\W*NR GJ^&+N-AF19!\SK/=UC#/#A3B?A$QU$!Q=6$K 0QZ
M1ZDMS-=,"'HF4M JRQ'AFO86]WC,]NRX3L-D1S>FR;\26)1QNL/1<HOY<S$V
M^!TGT#V6#S%<Q/48:< P?H )JJ=5N7>F@6C4"*&G;%DM!HKGM@&V1ZP:X><#
M4656!LF-[8Z-JL8!%0)S-K\EO3-@CT]&[AXI:J5%T(BTP#R24D&A0-+R%MB6
M'S_'P#<X*/!]O'XF\<)7$OQ2LQ0F:SE< LE"]3:6-.1@X&36L8\H1G6:K4YW
M!6;+CA4_F"*35T*E5*Z*[;H<"K8L?&, ^N&?/_W 0+0\__-?OP3A<YSB_)TL
MF.BZ?4M/R&YQ27<DR;Q9YKN03J#7Z5V>K7/QQL](&2Z =I!Y%'JC!'@'XR%:
MB]LSE1R&35Q+8G \X1O/+7$H3M&V$NC=,UZG);$D?DIPY>1Q>?E6A9J?LRQZ
MC1/5,+9C=>DKAQC3=IHV?-X!.T+9/D[WK%,ZS(,Q>(_)V(CI31IZ4+,/,Q0-
MH"9WB363TFU\J6C!8,J@H# =-^3L1,T[@%I;F$;T*&A=0D>K;ALW4D(PH-%I
M)[^*DC9DL-:6VF6/CW6C>I4(<4]!M9FP?%S<0%D!WL3!4YRP S,2W;$$X.<L
MB7!>\&,XPZ:"/;M+L PUJ@TG6UXP[F:@PL+30=>+L^N;Z\?KRP>TN+U #S\M
M[B]_6MY<7-X__-,__.O'#__R)W3YGU^O'_\+$E;MTMIT#)[P:)'@IJ:&B+EA
MJ6XMM'F'4YV><A>\TPP"N^RB/K&/O"*YPK*,HBXE&/AHU5-F$6TY-03<Y#L<
MB6- ;:V*WC%Z]&KW "0GAH0AK882&%%Z%&8;FJ8Q?9WA"5Q0DW4R'&$#Q7AT
M6]9&:AR:408DF(Y17(5>38Y1LI<URU9_I<(#?L$Y/::X(IV\"$F(R2_ R!$Z
MA-'5IOXP0^J=?#LN[[@;K*H*:47-C6C+H6#/[]UKUC7+SK/-4YSR1 ^6M;$F
M9M$#BCBJ$C?J\?6N]Y^'"'3I20\WO.U3QTOSCO+)3%"AO^5,)\>_U+NVSGO3
MZ*H^Q65'P<8P8 2_*U\[RJS:Y0YB]H[)L1H//M-O8?.DGOV]^^26>1/F:AXL
MU=,NSU19FP>*]#XFIK5#E;_9=M:0DSBMUW.^5VQV:S+//MAX"&/M<;O9G1.N
MHZ9$C'6>IX''$X[L,CZU#!"]V9C<SPGWP \()94) >-$P HHY>D#8_B]@^X
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M:%S#,K[HBR(Y?L9I0?2C!:XW^"8KZ"W%Y>HQ>%.GCPV3XCBQ;XR)O;R^(2+
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MLGH6IS?_+93OW/?7T(.!I(62R@N+'811+L38_,-LP#C;Y_B>MU-\[8..";X
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MQ,YCW/"(N1FX $:BKK8(^W%9+]PKE76YE0,%.1U%HPVU+B CE0)G!(Q5?6
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M&11,A-[E,=%M&R0&UV?@\85'I?HJ& H,(-&GTK(/NJL&6N!!=T,B2<RM:]W
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MRTT:=%HQ1(#O!#+[DPI[;C"QZ&"5Y4=I^,C/)J3)=F/.),8(\@WPX6<0PZ5
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ML9->_BC?E[NR*(,T(M&AQ%PUJ2M<F92M8:2B X$:@W+"9,3)V24:,@5E>P8
MD=$+3C)VLX<EBRJGXCZ9VWA'KF0WM.G2>,>)03$Q8&G(S/G/;JZZ$C$X)VL
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M_+Q(HU;.A33)YV"9[I*J)C)_GWUUH$ HN)[2&/%&)B=FV[#1GMPWPFEE,%J
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M0+IR:ZQ0"H_D@*C?^))4HI) X/I8J"HE;&8O*15KLWVJN"%12:B53:.2;(E
M"@RO#D9A1+5(PPJ$2A!-'!H^1FDWHAC^JW7*DOC;9<RV-((YZ]R^W9"H!-'*
MIFE."0128L!.[E,FUT&:L%U>%AM?<!-SLZ'BYCIS95/KAH5*5KU8KLM-(5=*
MJD/(;UCB%ZG2O-SP=^K;(KV-PWKEH?[8YR?4.NO#A4OX_S>2EI<@ +EZZ'<_
M#0MG%025P-S\N99*"8I^B1PTJ5")I@_'PZ>0%Y>!O*1X"/;"/U+VT'$C8P*B
M$E0;EZX[FE>%4)&2QU6LN/QN7,AJ4*CDT,BB:SDK[_S]&^+-(X]WP+N,L\_1
M95F^6*E2Y-ELR](\_D/T:;$2X8@II(_0^:0-V[HG.BX)#>*]K6@U^;=@^_KW
M?_W;QY]__CLX= JB !0HLB0NZ?I<UAINI2P@N*3GY,^YFGF_E?J%I;]SVR*D
MCS22X=;."^(&4%1B:.>S+HX"@T\9A4)^]7M)^XGF--T&\X7+Y7GP&=7XVWDS
MG9L2BBQ\JK_BXNI^/DNBKW$>?$Z#E=/-[(;%*( F1AW2X"CB^46!Y#>N,MRE
M(HO3 Q^A=9#1%L]S*P(J*77EU@R5U'A$(R)Q3XMXS2R&FE)Q2-W'1"<@*OFT
M<6G):*3@R2L@>#XF'@;?/M)M$"?98I=GW,J#-,%N\73'1"6OWFQ;RIJI&&.9
M9RR5) @K:7B6Z3R)Z'-.(XAIT:F<Z]*SP:"24P.#9O!6"5IDG_9R%PU%KVD2
M98]!#BN!>_*X(5$)H95-PT#0""3E&# /O,\%61?<%<!8_8IJZ*VL6>IE"2 $
M]I?CIN3P*ZH1MK+F,*.\WHP\TI<X T%'G^*4AOEBQ3<@OLTX8O(:H5%)H!.K
MAI^]0"(2BV@TGS):OK/EFNTR;@ L:2)LB\4K=!NR6]D%U0$%E;2Z\UL7V<>?
M?OY)O<B2& 10O(8H,;YR7@7IAD%$O\Q'2L-U$O]SYWH1V8J!2EB=V34BF0"1
M"$Q2H)("U^M.LPY2>LD/L@>U>RHQV9?[$D3=V\W>@S222I=]YH!Y-D^X%1.S
M2/SK$[=2BG<=QMYUY/90*<R).FOLKT"3"**DVC"IM$PN]Z0*IUHGHGFUHF1$
M,D#F?'$1+,@?"#!!Q .MK[YBZ3D_*Y9N(=N%Z(#BV+[.- *CTI@NG!J'YQ+G
M@Q2F%I_/R)-OW,C+XS?*#8DXI"E4@KS>OF[8GE*'E#J@H))5=WZ-F!.-232J
M</T6R%YW\2#]G>9"C\1:X!"6 PR5@)IY-/,B ;1:#B6\3SFTW(A@O@3I=N\!
M4,3[38>Z?=DT7_9M$%_V;3I=]FVP7/:U7?#A'>@Z<XZ1)G"3YW&H9[PK$8UN
M69"T7-JY(5$-?RN;1CXTB4   \?]W.$Q'P[JJO*.P\/7!H]*/AV9M3HPA,]"
M@_M=H+B21-K5ODAD5IP.N77,E6P@(50R'=L+<VT$>B12!"'$NL@[E)9YA\)*
MWJ'7PSM!'X=,6$ ^"2Z"3<M:V@"*2K#M?)I5 O@4U2@XEM/+(/G]EP"<&0YI
M& "H9.#BSLCZR.&( D2R>UU#1@]*DWD"]X_\!-O)%=^ A4HPO5BV[&=_(P6X
M=V]\>:U\PU*E1-??^(]Q1G54C7  6IQEW1!1B:XOUQ8GFG[^ ^]]WM6LHXI$
M&5=$,J#B)Q)BL\MI)%^55:)KS#@(.QPJ>;4P:<9 "'"1KIH;BI6X("\9P, @
MF6?9CIM(NU0&.,4L$LYP2,9,Y;,!:>$X3:4E WMJ*WRU]KN2XS2#2@^.VT=;
MIFRJGU\4!FB#U4ER)NQ32=I?ZB#+SO00;+J?(MU(J+2A#\?6_1>@49PGQU[]
MS=Z"> -GHD>:Y7SOR96FJ\]?^:_P'DG.EJDO67LUCDJ!?/3<?OWZ+.X1PNKU
M:U"Y?GW>2T-"P:D'KB00UZ],W=\%FAO(":384>N2!GD3'(DZ#8(G+]OA<0>]
M?@O.S,H>I^?@SZ3U[NY[5?T7&9Q0J#[_@?DI4S+9^)]2U?\T2MU7?;L&SCPW
M!,X4C=M":#QIZ16SI4%[C_/U;;RB(AJ-;=B+L+/35Z8JBKN>I(ZCADK3)NF*
M^2:)1)4D<D&5+-EPNB2O$.:K94%9OG_U]OQU]IK&F^4[9W6O_V0Z&CASJD,W
M+%1B[\6R<9($9)(+O/)_C)\K%0&_0G0<J\7"E57W]GN62!-2_?N&I2L:\W]W
M=$;TH(A*^)-UQ]A#A(T2"\HD$J2U?2*LGJQFQ22:?O'+2K?@S91Y;M]UGQV[
M;C%<=E.R&+W['9S,%RLYX%8CY^1<X%)0GT-@-8PZFO5-5GVI[$ZKOM!^D@C.
MP%,G)XZ7,&/US%M<(1@W)=6/J)3'QIEQXZ%?L N@LSHVG=0G]N?Q@8WV>9DG
MI\XO#LJV#QXU940V7YZ?SE]/CWG(_Y/YK\;ZJ^Z++4:K6^4J\D(_K'M\^J*>
MPGBRR7(H7N&X(BP^X9*HP9=I)XN*'-X>$/'#WO4_=Y"T/TC"M>M-BAT*U5 W
MLE@?=0Y,!#31X&=Y25:;]U^2.,\.#=L='^ICFP(MS:+2DM/V>>KS@W%:V $;
M]3,#,'*F-V$R#F8N*J_#C]DB7]-TN0X2JQ4&.])D6CV@[>]#M8=WW&U'"%OA
MP(A@%2-"'GZ_+\T\M+9.JYEFVW\2S71V?*AFOG@T;X\V2BVNK]/I:0LC?Q*E
M[38*T\<4J*#1N.2,,&"-Y)RWPHAH]TBBG!Q9RS6X#H(N%HM?J(BLBV9O- U>
M*.QQ</UA<W">M/'SF@1'Z/F0:(2L6QZ/@IM*'()FB"B.B&()L3_8.>BUE>5P
M=ZR-_,&K@.DT?C +WXG>C^W_D&4_:U[WC17=B!A[UW,@4'/@\+W'64^"EI.Z
MEUDQ@J?O<YJ,'Y !KI9L<E\+QHE4J0:UDH$>LR2JG'_LD0?=L% I8R^6&]Z]
M\3.B1!?)B"H$I('AY?Y=Q6B5"09TH)9ZXN=PVW=$0R7&?CS;X]$^_O3QHWXQ
M[-6S_R6):/H.N?*3EY:7\PV@J.33SF==)E4,' _GK]:P!\R3(H.@?EG7(;/#
M$^7$(W5MM'C>Q"\'(U56"IJ\"51J<+S^F96*H"789%>0:E&\/3QXM]@M<0;)
M1*LDE\T25K3K95?F6\DVX%UXXV9!!M93D.QGCK2-#;"H=*(#H\:^*U"(QB$*
MB4O59^JH,$SY_O]$P8CCD-R.N(V#YW@C:I[<<#BC;+0HC9;%MI5@'#54 IZD
M*[;'R&!M%50))TLJ= D0)I;"VQ7:/N;P)>/G!*FE#OO+A$ E3B=[1@86 "0*
MTN?,%*[TN0B>9:Y!M\&@&O8&!NL#+T!) >LUD8H\'?/3^4V<\&G*C3FH\@C'
M]5G.V=R*O*'66O,]4%$)JC_?QO:F7 H<@Q0TB" B?JN0(4^^:L\_4N7Y6*P*
M'F]ID%5,,T.D77!0R;('PV95".T96JPJ4A38I(+NI\86"RF-Q-X+"K18<0MJ
MRQ+IJA GKXJ.@<F=!:%5HL,IH9+SZ&Z8-;DD00*#+@J@P^$C%$3U4Z8=D.63
MF7#"1$WGO$+:RZP._F"I.&YUK%W8BH!*SEVY-28SX*G8>ES%"P5G#:+!*H0.
MP^TSH6D:O#!':K[J-U3C:F',R 0F0'R.[*%-M&3":6[U_DA/3>D#LMXXC"2'
M2G[3].5/X0CC8P'A2&*?G"=\L^5+<9;=!>$Z3FBZAUH2_) OD@?HY3J;)^%F
M%T%$ZBP,V2[),VYG0[>5*V%3^@[ 0Q$DT8:EA:=B;[AJ3\\"*FWUUW]+ =N"
M$W&KJGBYX$:5XD9<RE'-#WG5#'%PR1'@!8HGN-(%IB[@%^%DJO E*&T49\6'
MO9>4EF(Q?PICWJ5X%8>WMU=-.Y8%$)5"M7'IV,M*!,(Q?&YMM\$S)"%AZ;[0
M_+:\UZT8J"34F5TC"W:!2 I,'.;S3"X;7076 HY*6MUX-?SJ:AW%)J=\N:9W
MI>>L34[-X+CDU(E70TXYX6CDKN(%Q"&IR^7\LW,G.OB(2@HVSHP+#0YSX7N7
ML5Z77O:X [Y$./H=&.UZ!WSIU6\09QPBCY,=I#RB,B59IFH;/7YSF&==D%")
MJP_'9C+R$I>4R$07@'K\YEF KRP+-I]3MGN5QQ5^(+?V]Y%FE%-=\Y-*)0.>
M1;CC"&(3_"2]L2B%H M92'>OZE0&UR5155N8I@UAMH*X.(U5,@7ZJ2S0>4SD
M_IY$<M>V5A\83NM<%<75D;$ZD@F;"!1DJRE[>9(0KFFTDU=*2<8V<12(O&)O
ME/.;S?(\C9]W.?@;ENPA91&WO[-%JK>UI?C@RALY)6U4ZG.$CAFA_JH)>2]7
M-L+7%MD*"2K-0"F#5]4082G)M-GQZV%C_BW"+I8@0I.B@<$VRP^=O=?'S$,H
MB@Z,=C7J_!=-=1K=F,WK;H8T"H/Y<I?%"<W@S/8<)U+L?#,O KSO:)#M4OER
MZH&OL>'>N9N-((5*?./[83@>%$52)2E,&R JTX"1*EGRJR1,@#+QMC-)DPXV
M2)G>X(F&NU1<HS3517?#HQ)S1V;ME=*%32'Q2(GH]76+6+]?>(?!Y(HCM897
M(JKM,NN*ATIV/9FVW#@J='* ?Q!_[E&67X,T9KO2D^P0G0,,E:2:>:P+1D&7
MGG"O8GB$9[ULM<OH+,MH;K\<E[JTX^I4VDU&)-=00JA$.;871I08T(/C&Z=(
M D'2>>,?%F1+#X&? ,LN@U":T^/5PD'K_#2CN2.-RB&IDH*L>"M4WG >4*X<
M7]#JQSTU_,Q=\<Y/[B735AE_8*L/Y0+@C/FY( G%[AZV=G^$B]A*#Y4"3-29
ML:YBA\X@5Y?Y]I6?_N3KE'_0373#4NM#J@E(GJO2M/1GK-[$!7G8:=:\ 5'_
M6CSWD.L1<A52<9?5/#PCM,="[5P5Q]V5L3JC8TJK^87.0TNNOP'#5&:FO-JE
M*1_JRH%WO.*T-'#FNM2M=U.I%U6MJ62=H6RO&LGL0^D6JU4<4O$&LB6"SPV)
M2@U:V33>9@L$]0P41<#>5? :Y\'FL ]\X]Q!ZK0DV06;>9)32&SV&.1&=KM^
MV*AD-XAU\YGO"K(;Y(R;CH#"9ZC$(7Q"4L)G9"B;(1LA\J*4I8_I=\<7C/5F
M_^B<=08 *H&YN#-<[!*./'J>63=QFN5+FEQQ>S") L<S33L4JH%O9+$^^@*8
M<&BBP;WF_I#OU&BT9 _!7N_!_ RY#+[1K$S@9^P_'?%0R:DGT\;>I-%%M$NP
M+XT(.!;G0 -25BHBOM-2SJ)X&R=QEH/E\T9O*'T(XFB1+-+X)4Z"#;RB7*R<
M?I01I%#)?'P_FK-:!E&5)%E1RE4CCF!G8XHL/\MDX@3LU7.BGPNZGEI5OZ*2
MH)4U\PF5>G+H\X%;![L=O<7>PU9'9*2KE$!EWIC9%MZJ&HN:'0R5 )IY=.5"
M*M^;DT# ^UEBC >0G1]V8IP*+5QV>L;ILP)>$26L?"W)"\19B30*\DQ^%63K
MFPU[[QI&W8\.*F&.[$13>#33!(4=N)(DU7DVY$3)BE/%$ EM/"70)G!+Y&%7
M/%P"[\>T(>#B>41!@&@*2,('VU7Z,MC WY_6E.9CY[B;%BZQC^_(T+G^+ F3
M#"ACF._F".C\?*XLGVT(J$3=E5OC''\@PUKN0;\U:POEO=E!%8P[?K3<[K9R
M>V+;;9R+H+T;EC;TO>M$GZP)5$IQO/XU+0LKT1;9RL;TWE\V)^Z];6L'_&NC
M]$ZTZGE/>8"GHTFNDL_?T[PZ?NJP8<ERV0$)E9;TX=C,72EPRU1A"5_M#R6O
M4IMZN4.\_D;#'?BBY%6:*Z&S PR5E)IYK,NE@"8:W'.Z>SB&\_D-034B UV1
M-54DV&PVN7NBHQ+;,-XM&>P5%9'46=(AFI!*-OIKC9:?ER%%SR23$$DURV9O
M0;R!%5T%597/6(P[XKX$4$E[*/=U>2\9W (G14GAPV3 X&E/"&<#7@3EZR G
MZX#/]&=*.0C;1/#H6)49AML9@;7FO\,J\(/*8I?5: HR[Y3OV[$H375!4JI3
MW\DZ52G=!K%(F@<YB/-4/"';_RA#V9[WXE?%4\ /B[K+991;5O3:BS\N3FCP
M @4E9B_T?QRN. L,*OUJ8-!PP$E0(3H ]OOT^2V.:!(MDL,R/688F!T.E0Q:
MF#2#LB0X7(+US*/JK2KF<WM1ZF='.=Y[)DI)\&\TY3-_"TZ EG+4LG+Z8F7/
MVNN=(53*AV4TIJ\=KLM>)II#"!_0+':H&5[9+3-O510'EW1WBZ.E<*EUNIR4
M WSSPT?WIY\0C>K?H53L6>F_?-X^%\F9A;= 1#XOUT&B1K[[>C79C)B0I^]C
MCDP_(-//&BKS),0EDRJJG1]PDF+"]-M:4,XD9^'KP2O9:0J5'X6]\YI?7L9F
MR%3+CKM#82QF_@GBMZ+.!]9&:%1:V8E5,V\4()&H<H9%<$:]C5=T2<-UPC;L
M)88<P.DK4R]_'7Z=%@14DNK*K>GQ6<&-68E(*IC><YLL5E\R:MPN5AZUJ6=N
M==GU0D8EQR&<-Z<M,&]*JX_T+O3+/6^Y*%H[>\^)C!%SB7^&DC:8'R?LI"#G
M0]Y+NH6E18:#YOM[]A#(C'5UP3H!44FPC4OC@D;#ZP-' J]@5,DL+^<%V(Q%
M%;#HTR[E*B,-0]&'K]PV@SPXJTN6[#)A:9INUI[XJ*0WD'G#)!:&J[S_(I$@
MI"U5&=_P)FF!C_$9J$D[V(NG4=09?4_Y\=3Q5-  0"4Q%W=UD53@?%HP=Z(>
M/+=\65HD7.4+M/YY%KT%XA%4];OCU>Q@2JCD-[H;QCM<A2FNBPL4&7.L/Q54
M:T ^@Q1WSQM^4DU:WSHY 5&)M8U+8\4LX'$\?9JE"7-4>2J^H!IP@RTC\H<#
M^!S1N;B-8Z[(N=IG5&-KYZT^P 44A@ )>*,!*6 H=&FQDO$",VM=UVZ1%(,)
MHI+D5+UQQ6;(MRT%Y8.2MR5U4B%/"OHR^*[1!&3AP0CQ?\/#.-W/-:?TW__"
MPF\?/O[T\:\__<=??_K+MRSZ5^CW/<UO65:K85&),5-!79=!%H=0.R?>["H7
M8)4!'$K(*NXCZ/^XCFJE'T8%E::/ZD)=O3DQLN'4C.HD.O2O0A$<_'$H:R1)
MHCY.-9<I"Z)WQB*=;^?!41O0 8=*EBU,&HG[-3A1\.3VP>>>5!R]<LK76K[8
M\9-ORU'3@$0ECU8VG8=/CD TAM>7_;LT^!I'@;19Q V=LWQF$RPJL71@U'AU
MPE$(X) *DN]BFQ57A<-8-B%0"<+)7H-3QJO57*R8#T&:)YR9UNVB#HAJ_-NX
M=&\8&L'SCJ%G<O."A'#DK:RY%QV?#HZO=P[_AOZ :F#K7!G>C:]WOD9SEWUX
M"8+7WV0V><OELQ7@MX^_;9XW)QO? [[5N#;S98RP2G6OX+P.LGMTT0UKRWAZ
M&D9'!F7+9T0#:N/*#%TI8#P-;?5T+>^ ;2-L0OWV[V@&NH$YXWFP^'Q!9C7'
M #<D_"T2%268)5$W@;3AX)P'S:PV3 [AGY'@GH3T.659]I"R56S=+"N?$0V]
MC:OZ* L8(H%\C6T0)^#]6X@ZUXN5"*]W;YT-X)C&O@.7ABS@H?$/@/4CA)S*
MO/:Q=LT+"L3K1ERD2]%9L&SR,8 02<7-FSM!D ;U/>;S)&1;"MK1..HE&,9Q
MMW#G'GD)K&:$I^&_9PD[9%[I@TT(3F!$HFCGT;A/J6 4,E%(OL12ZM$-_]U6
M$?$2@G"HA!.YO:^_Y6G TBA.@G0_S^E61*9R3-[F1@R&K$I@$^P1FT.D&J?H
MI1F'4)GC!(1,KFR%!LFS:%KKGVC\@APV1G1K:)6RJ(+SP%+Q.NK@PG-*?1S2
MTEFIXJ@.#M5"KG%4I''G^G=!"A:(XL$X6.+23WB7E](U7[?C-S6)>7<6*]X9
MFY(U@"/2E"Y<FL6I*SB'9L:AA%$Y"E0:K5V>Y?P\S/7)ZJJI _WV5S2B<O-F
M?:7)9UL%UN>@&Z]:G2-O0"*:*2T,6F7P0< 3G6*^\II7;KZ0VEJ9@IX$=%!E
M[I[EUOIRY6E<@]LD.) 4(A&/[8&SM)X@""*OEH+FBE$0O2!6[T6P\>Y4JKA1
M%BOI/OFYV:]DPT DY(Z,]O,N>?4K\1T8\NK13U3^?YZHS(_9(PUI_ ;;K\,,
M;L5#)+A>[%I,5(%$?M#H/T)* 4V!E"30"/$AI5 'Z9,*&5;[Q"R)6CR\PRBA
M%G2O#G04O:*I]U]Q28+ 2<SM9RBC\9 RB#*/+O=?N 4Q3\I4VV$>OSDO<[MC
M(Y+W *9M0<M @V@BD(/D!Z##1?TC*9VB)2U/\M6IL9=L%OYS%Z>4<\RYR_</
MO$-YM?2\3;[=L1')=P#3CB)-H@RJ(D(TE0LBZ%P4UYR"%*[I*R-.ATY?"S8B
M\0Y@NN?T+4CAF;Z+5?%\'#(90=U#JT2;X!')L!.;SDD)+Y_$*WB-1P2B9Q'=
ML/2QR$:]6/5\#S>>&D+QCNB$4_CPJKHD"KK0[?&;EW+)*C.*4,\E$\D?K(,@
M'_*50V%-,CR2' +7XI2],*LTCZ+KKP0FGR2'O/,?9CD_&6Q%&3-1UJRN"CU0
MD8A]",>.-: +#4][ 5^8BIWM$WVVVM1U&$3KMI,U(PE4 0@+,(#ZR.:EF5BL
M#M-9E958C8G3!0?)C.G%JE- #<BXCBP%FX..+!9L1/-J -,]CRQE33SO1Q;@
M$OZ#H_$;7XN%PU3G784/_ 1^^$,%4N;$,CURZNK^^ANW^I(7^ACD]'JUHJ%U
MA3TM!XCTS%/'C0M[3OA":FN%_@4IFR82!#PHM1\/,21/Q.)2K<9S:-8(\$8D
M<^>H_$6/#BX&108%R\6@=7D\9?L(]DFOW3Z>VI>J?7BE*S#M-[H^#C"_L/1W
M?AR'/.#1+@0NG-7Q&D 1J%%7#NL2;\#Q\>SV-8TWRW>N0GO])],)(3)WW<).
M6$B$U)-9XUUD)W1_H3&6U::AZF0O1$162C]^+4$NMN6/VPJRPKO_2N]EK*,H
MALGU3#^.V_-5GZ9O]#K+XRVW522KUGV\(RXBL?9FV8SSU 1(08$H$D330"GG
MC!^SA=NIPVQU0Z.292N3IO0R$8G[F3&5JNZ)"RX.*2))E:7&[:5-JE6 ("^S
MK(F29;NM_,U=J/TX+2#2B"-UK*E$NS6D%=JZ4-=_JKD+4C1(*BWZ+\]>NE6K
M)P^[3[@*@4CL#L9,=^/!:>8<#]^3GZ8127&:?ASKO.MM5NJ[P<,KZ"+?JGVB
MMB ADGIW7LWI7-RHUV[128%\[F6O<!QH.S)I+WGE0O,TH6[B),[I;?P&=QLY
M9Q<NVV5PZSVU.NJ;,1!-I8Z,6F(2.-H'@4=*1*+S77%<GP^EIBC1[*Z+?>2F
M$$S@4_6PZ:U7M<7J@R^X'FPPH O3N6B;_[6H3>TE)*;YX5N'RJ^J3Y57B+)'
M3J6<LA%LZGB4OAU3$2NM:E4\?P7L6JWVQ$U_G\K:J<<G4V'-#5'L$,T/$0R=
MJ6Y;ROH>0X]M)>SQ6(/'[-TQ]?/FL+ZQ;!F5(DK#8[;+URR-_Z"12.)=<2W"
MRYOL8&(_PB!HNTE]@8.KZG1WY9R\:?0*>[P>]TY.( E<U-9((MJ[4.8HJ32(
MZM0T<!S-\6O:P*R/X'WR@TV]?0_#Q#I?8>.[LR5D;MAYDN7I3D:;PSOHY3I(
M[ ?B22V,OHU_#[;RX#X?P1J1O) *,^H9?,[9:?!+^*B;V3;>68NAIZ=I8>;5
MEA)5]M<X#IZ\<01*[J_/5B4_%1=XJG#+_;)ZCU_,P<-SBUG3;CQ%+ HX74>L
M=;M'D<:X KIF0GG=*[KV)8GYIM/)A7#"9K$HW8E[VWN]FZ;]<U+?5H.IUO76
M!=(7(^>NXI/U?S*E'\O1.4T#/G%7+-U"B@U/"_I@#LY=\<=W?#*-'\S*.:EZ
MZ[1VCX*_Q;\[3^<^'8XQ%*?;$KHS=VZNO,.(E=+9.JG+SM4(-A?T4?IV!!=<
M/="'E,WZ*KT8AKOM;A/P&?")OJ8TC$6?^-\W5 QD$LVVD+7_#_%[KQR&4]%&
MI&V3=\EX*%DV0*HM7)"B#1'576WE E>&1)%"!=QN;+7+5*SF71"NXX2F^^H@
MV,I5U+?PP820[+OC^3="Q(=2Q*H&M1#E/GCG).0JNU:9?F"K#SO(3ZQBE+>:
MBIC-5-.Y( E5,YR//E@^XOT[Q)6\INR%]RLCOWZBJV"WR<DM,.GK]55U_:HM
MC+;MH@$<T0[0A4OST4#7A?R>)5R(*J6![TIZ(FU5\2#8)C('*")QM7'HKJHG
M$"[*!]'^WG; Z45P(Y:)Q>J+6F=DE;&*Q= VPX;20B3/T5VP9Z^D6MS%2LRI
MRM<B%[JD6M4TJY+&IQC3J,19*\,1U "Q_!L7:2L@4BFV+] U0?E>GF^YN46I
M8Y?1J9,?Z3:((0@.<D)F8;#Y7QI88ZN&4T,DSPDZ8=0X%R0OB'MWOH"" <^4
M/ 1Q! ^A%75PM4CZ!!K K"2?=O2>?LN7[W3S1N_X^6UMC:$>2NO<%*2I"V/5
M U2!+!)?X9M=^P]L+M_9&"U0),Y0^'7.)Y$Y)XA<YF.$?892GDB\&(7Z)8D@
M8=HNR:&.5<A!N=&XLWO*!Q$Z%W&W\C]$]E6B1%(EDJR/>@)\/+E"0S(DNEC=
MT_PN3N+M;BO8UMI>]W%V0D+BX.S'JU$]0&*3-T 'BRRA.=E*"F0CT@OKI/:8
MSE*]K??^5!!-X1',=SVBH;;1&_O?T3;O2^-<Q-_'%N\F?,\6>%MO&RSOCJAG
M)-HV2[N'1/W9UYTZN4ZIU<#NC'QN4CW@>8Q<@1!BR=[PH1TJ6, ],[D>L#Q"
MK$ 'J52'2/.,I#A*>IA$UN>4VXL =F'V/M6Z)8OF+%O)$U^6XZ@6Z3"SQS_2
M-YK8IVM_*HAD/H)Y2][\2B616HT12T9].!H)BOBE+XH +E8B\_@3VUB#CT>0
M.T]]</9BO&((TF6N=Z#N(QMLG[F1<4,CA#3'G[A2;Y@1+#P)021NLNGZX5*5
MP91QJXFH=\ 9OA-U1#G4" TQ:)V?<KB[,$(O#*+XMY?/-.%_VT"8903^XBR'
MW]_H]3=X?#'6Z&BA?IZ;3]=.C=^+5$LRB/6@+:(:PZ]@*@-_AX($HXF>ISJU
M]&4"BP9*$H *(:E-T&-L'E+ZRD_C?'C$JT,9^G^U2U/'<ZB)2)^G(G7JT7AU
M4LT(C9+)K73&=]46;CO(^G!DA"UDI7=^]E!S-T;81%;"^%>>>B6$:18=!]7S
M7&_:.C-^J;%4E?"SQ@P8G5DHW(W90["'/)?3Z(^=Z'FJ3TM?QFN/;H"H%LYD
M@^)LI[O#I_8CMB<+M?/;G)HZ,6)KLI ]"]509S^9B4/IM+[KB*D1!3=Y V>K
M0%W[-5ZG6EKRM'W)7"YW-%^S:"X2,8(Q]DB##:3'^!S$R2W+LD6B^VO;K?K2
M0+0Y#6:]K@\JS:^D1$I2<*TDB1&@1GX >C\2EA2E[CT)_B%E(:51=L-_!2?E
M8M4KRT@/=$3B'L*U&5<K:1 83P)4X&H(52X0J^EUSW+K\@0*":JY2'Y)XYQ^
M8N_V/ $#:2&2_N@NM!F@G*;3] 2ZY >@+&:_(/XAXM0MNE']Z9;_C?^L?^)_
M0.9__LO_ U!+ P04    " !+A@I7]WO[?;UQ  !UF@< %    &]C>"TR,#(S
M,#8S,%]P<F4N>&UL[;UM<^,XDB[Z_4;<_Z S&W%B3\34]%3U=,_T[.X](;_5
M.([+\K55W;OW2P<M0A*W*5(#DK;5O_X"("51)%X2)*&$7-HX9]IE R#RR40"
MR$QD_OO_?EO%HQ="LRA-_N,/'__TYS^,2#)+PRA9_,<?OCY]&#]=WM[^893E
M01(&<9J0__A#DO[A?_\___?_-6+_]^__X\.'T4U$XO#OHZMT]N$VF:?_-KH/
M5N3OH\\D(33(4_IOHY^#N."_26^BF-#19;I:QR0G[ _EA_\^^N%/'W]Z'GWX
M !CW9Y*$*?WZ>+L;=YGGZ^SOWWWW^OKZIR1]"5Y3^EOVIUFZ@@WXE =YD>U&
M^_/;GZO_*[O_>QPEO_V=_\]SD)$1PRO)_OZ61?_Q!_[=ZK.OW_\II8OO/OWY
MSQ^_^\\O=T^S)5D%'Z*$XS8C?]CVXJ/(^GW\Z:>?OA-_W39MM7Q[IO'V&]]_
MMYW.;F3VUTC3OC:3+/I[)J9WE\Z"7+#=^)F1L@7_UX=MLP_\5Q\^?OKP_<<_
MO67A'[;@"P1I&I-',A_Q_S+N[;Z:,G&;;7+"&?8=_^-WERD32#93T6U)R?P_
M_I#.WMC@G[[_\X_?_YD/_2\';?+-FLEE%G&Q^L/HNXZ?O0AB#M'3DI \,WQ>
MVM;!-!X"2I)\2?)H%L0V<Y)V'&:"?+V0%1L]F\PG:[[&F1"9 --W&GYB7,=0
MLB1)%KV0NS2SF9^R[_#3?%HR/BW3.&2*\/J?191O+.:I[NP SR!;WL3IJQ6.
MS3[#3&M"%T$2_2XDZ(ID,QJM^8^3^46110G)LG$2WD4,C] ,9Z>QAEKG6<1
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MC3N;^YRP/X9W)=7*&8KIY6D>Q*(E+L?NTV1F=X>3]4!+]6M_C5,3C+Z&2LL
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M;GD:!D/TE5^_R$'O2>HN4/[AFZ>,=.-SANN;,DJ=A!-:2E+K(&$X3P'ZHT>
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MDM4ZI0'=E%JOE.O2/J]FN;83E,]>F#$ Y*-OU=(YUFX@EGPZZ(D7!#,4LR1
MH'.L9NHL)SDNV&&"1K_K%I6V$UY432?;H)%\=!8=7NOOTX> &O8Y=0^P"]T'
MYI@(/^FS3$OR0&I2WPO*73\L)0  T-=>1= O(N](/J&/T6*9WQ<\*H^1N<OX
M4AZZ+C95NZQJ:,XVV7U@**^]B(89",;37O R#*[?V!4]RHBPG>_^N"/\HZ4
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M?W!4^^)@+WD4 KV=Y67: 0[-<YZ#6O(]!T<.[#BMHN%# J^/U?#F<<VYKOB
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M>JC05>J[RB$$4;'Z_#]X#U#/^7].+/_//K+IH:"S)5,2H 0T@&[84<;]T]"
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MTSJ.=(<72&=L=Z=A_Y0Y/6%XH/.N%E-=.F7'1;Y,*;?PJGFF[>39VC(Q"P"
MU;6G^@O_G^<@(^PW_S]02P$"% ,4    " !+A@I786>R["D(   24@  "@
M            @ $     97@S,2TQ+FAT;5!+ 0(4 Q0    ( $N&"E=T?3H$
M# @  .50   *              "  5$(  !E>#,Q+3(N:'1M4$L! A0#%
M  @ 2X8*5RS.Q_/6!   ?B8   H              ( !A1   &5X,S(M,2YH
M=&U02P$"% ,4    " !+A@I7J^RF9S)' @#[7QH #               @ &#
M%0  9F]R;3$P+7$N:'1M4$L! A0#%     @ 2X8*5[G]9?8A&0  DB<! !
M             ( !WUP" &]C>"TR,#(S,#8S,"YX<V102P$"% ,4    " !+
MA@I7"QG.8>@8  "T+P$ %               @ $N=@( ;V-X+3(P,C,P-C,P
M7V-A;"YX;6Q02P$"% ,4    " !+A@I7[==3*KI5   *WP4 %
M    @ %(CP( ;V-X+3(P,C,P-C,P7V1E9BYX;6Q02P$"% ,4    " !+A@I7
M@0JE0 R=  !ZX @ %               @ $TY0( ;V-X+3(P,C,P-C,P7VQA
M8BYX;6Q02P$"% ,4    " !+A@I7]WO[?;UQ  !UF@< %
M@ %R@@, ;V-X+3(P,C,P-C,P7W!R92YX;6Q02P4&      D "0 H @  8?0#
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
